Torsade O
de O
pointes O
ventricular O
tachycardia O
during O
low O
dose O
intermittent O
dobutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
in O
a O
patient O
with O
dilated O
cardiomyopathy O
and O
congestive O
heart O
failure O
. O

The O
authors O
describe O
the O
case O
of O
a O
56 O
- O
year O
- O
old O
woman O
with O
chronic O
, O
severe O
heart O
failure O
secondary O
to O
dilated O
cardiomyopathy O
and O
absence O
of O
significant O
ventricular O
arrhythmias O
who O
developed O
QT O
prolongation O
and O
torsade O
de O
pointes O
ventricular O
tachycardia O
during O
one O
cycle O
of O
intermittent O
low O
dose O
( O
2 O
. O
5 O
mcg O
/ O
kg O
per O
min O
) O
dobutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
report O
of O
torsade O
de O
pointes O
ventricular O
tachycardia O
during O
intermittent O
dobutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
supports O
the O
hypothesis O
that O
unpredictable O
fatal O
arrhythmias O
may O
occur O
even O
with O
low O
doses O
and O
in O
patients O
with O
no O
history O
of O
significant O
rhythm O
disturbances O
. O

The O
mechanisms O
of O
proarrhythmic O
effects O
of O
Dubutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O
discussed O
. O

positive O
skin O
tests O
in O
late O
reactions O
to O
radiographic O
contrast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
media I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
the O
last O
few O
years O
delayed O
reactions O
several O
hours O
after O
the O
injection O
of O
radiographic O
and O
contrast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
materials I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PRC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
have O
been O
described O
with O
increasing O
frequency O
. O

The O
authors O
report O
two O
observations O
on O
patients O
with O
delayed O
reactions O
in O
whom O
intradermoreactions O
( O
IDR O
) O
and O
patch O
tests O
to O
a O
series O
of O
ionic O
and O
non O
ionic O
PRC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
studied O
. O

After O
angiography B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
the O
venous B_PERSON/B_LOCATION
route I_PERSON/I_LOCATION
in O
patient B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
n O
degree B_MEASURE
1 I_MEASURE
a O
biphasic B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
an O
immediate B_DISEASE_ADJECTIVE[DISEASE]
reaction I_DISEASE_ADJECTIVE[DISEASE]
( O
dyspnea B_DISEASE
, O
loss B_DISEASE_ADJECTIVE[DISEASE]
of O
consciousness B_DISEASE/B_MEASURE
) O
and O
delayed B_DISEASE_ADJECTIVE[DISEASE]
macro I_DISEASE_ADJECTIVE[DISEASE]
- O
papular B_DISEASE
rash I_DISEASE
appeared O
, O
whilst O
patient B_PERSON
n O
degree B_MEASURE
2 I_MEASURE
developed O
a O
generalised B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
heat B_DISEASE/B_BIO
, O
persistent B_DISEASE
pain I_DISEASE
at O
the O
site B_LOCATION
of O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
immediately O
and O
a O
generalised B_DISEASE
macro I_DISEASE
- O
papular B_DISEASE
reaction I_DISEASE
after O
24 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
hours I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O

The O
skin O
tests O
revealed O
positive O
delayed O
reactions O
of O
24 O
hours O
and O
48 O
hours O
by O
IDR O
and O
patch O
tests O
to O
only O
some O
PRC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
common O
chains O
in O
their O
structures O
. O

The O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
skin I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
tests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
in O
favour B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
immunological B_DISEASE
reactions I_DISEASE
and O
may O
help O
in O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
allergy B_DISEASE
in O
the O
patients B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Risk O
of O
transient O
hyperammonemic O
encephalopathy O
in O
cancer O
patients O
who O
received O
continuous O
infusion O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
fluorouracil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
with O
the O
complication O
of O
dehydration O
and O
infection O
. O

From O
1986 O
to O
1998 O
, O
29 O
cancer O
patients O
who O
had O
32 O
episodes O
of O
transient O
hyperammonemic O
encephalopathy O
related O
to O
continuous O
infusion O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
were O
identified O
. O

None B_PERSON/B_NUMBER[MEASURE]
of O
the O
patients B_PERSON
had O
decompensated O
liver B_DISEASE/B_GENE
disease I_DISEASE/I_GENE
. O

onset B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
hyperammonemic B_DISEASE
encephalopathy I_DISEASE
varied O
from O
0 B_NUMBER[MEASURE]
. O
5 B_MEASURE
to O
5 B_MEASURE/B_ENT
days I_MEASURE/I_ENT
( O
mean B_MEASURE/B_LOCATION
: O
2 B_MEASURE
. O
6 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
. O
3 B_MEASURE/B_ENT
days I_MEASURE/I_ENT
) O
after O
the O
initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
chemotherapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

plasma O
ammonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O
ranged O
from O
248 O
to O
2387 O
microg O
% O
( O
mean O
: O
626 O
+ O
/ O
- O
431 O
microg O
% O
) O
. O

Among O
the O
32 B_PERSON/B_TIME[MEASURE]
episodes I_PERSON/I_TIME[MEASURE]
, O
26 B_MEASURE
( O
81 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
had O
various B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
degrees B_TIME[MEASURE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
azotemia B_DISEASE
, O
18 B_MEASURE
( O
56 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
occurred O
during O
bacterial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infections I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
14 B_MEASURE
( O
44 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
without O
infection B_DISEASE/B_PERSON
occurred O
during O
periods B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
dehydration B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Higher O
plasma O
ammonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
and O
more O
rapid O
onset O
of O
hyperammonemia O
were O
seen O
in O
18 O
patients O
with O
bacterial O
infections O
( O
p O
= O
0 O
. O
003 O
and O
0 O
. O
0006 O
, O
respectively O
) O
and O
in O
nine O
patients O
receiving O
high O
daily O
doses O
( O
2600 O
or O
1800 O
mg O
/ O
m2 O
) O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p O
= O
0 O
. O
0001 O
and O
< O
0 O
. O
0001 O
, O
respectively O
) O
. O

In O
25 O
out O
of O
32 O
episodes O
( O
78 O
% O
) O
, O
plasma O
ammonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
and O
mental O
status O
returned O
to O
normal O
within O
2 O
days O
after O
adequate O
management O
. O

In O
conclusion O
, O
hyperammonemic O
encephalopathy O
can O
occur O
in O
patients O
receiving O
continuous O
infusion O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Azotemia B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
, O
body B_DISEASE/B_SPECIES[BIO]
fluid B_DISEASE/I_SPECIES[BIO]
insufficiency B_DISEASE/I_SPECIES[BIO]
and O
bacterial B_DISEASE
infections I_DISEASE
were O
frequently O
found O
in O
these O
patients B_PERSON/B_BIO
. O

It O
is O
therefore O
important O
to O
recognize O
this O
condition O
in O
patients O
receiving O
continuous O
infusion O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
effects O
of O
quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminopyridine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
conditioned O
place O
preference O
and O
changes O
in O
motor O
activity O
induced O
by O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
rats O
. O

1 B_NUMBER[MEASURE]
. O

The O
effects O
of O
two O
unselective O
potassium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
K B_PROTEIN[GENE]/B_LOCATION
( O
+ O
) O
- O
) O
channel O
blockers O
, O
quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
12 O
. O
5 O
, O
25 O
and O
50 O
mg O
/ O
kg O
) O
and O
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminopyridine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 O
and O
2 O
mg O
/ O
kg O
) O
, O
on O
conditioned O
place O
preference O
and O
biphasic O
changes O
in O
motor O
activity O
induced O
by O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 O
mg O
/ O
kg O
) O
were O
tested O
in O
Wistar O
rats O
. O

Quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
to O
block O
voltage O
- O
, O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
and O
ATP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
sensitive O
K B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
+ O
) O
- O
channels O
while O
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminopyridine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
known O
to O
block O
voltage O
- O
sensitive O
K B_OTHER/B_LOCATION
( O
+ O
) O
- O
channels O
. O

2 B_NUMBER[MEASURE]
. O

In O
the O
counterbalanced O
method O
, O
quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
attenuated O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
place O
preference O
, O
whereas O
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminopyridine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
ineffective O
. O

In O
the O
motor O
activity O
test O
measured O
with O
an O
Animex O
- O
activity O
meter O
neither O
of O
the O
K B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
+ O
) O
- O
channel O
blockers O
affected O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hypoactivity O
, O
but O
both O
K B_OTHER/B_LOCATION
( O
+ O
) O
- O
channel O
blockers O
prevented O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
secondary O
hyperactivity O
. O

3 B_NUMBER[MEASURE]
. O

These O
results O
suggest O
the O
involvement O
of O
quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
sensitive O
but O
not O
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminopyridine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
sensitive O
K B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
+ O
) O
- O
channels O
in O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reward O
. O

It O
is O
also O
suggested O
that O
the O
blockade O
of O
K B_OTHER/B_LOCATION
( O
+ O
) O
- O
channels O
sensitive O
to O
these O
blockers O
is O
not O
sufficient O
to O
prevent O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hypoactivity O
whereas O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hyperactivity O
seems O
to O
be O
connected O
to O
both O
quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
and O
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminopyridine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
sensitive O
K B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
+ O
) O
- O
channels O
. O

Nociceptin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
orphanin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
FQ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
nocistatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
learning O
and O
memory O
impairment O
induced O
by O
scopolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
mice O
. O

1 B_NUMBER[MEASURE]
. O

Nociceptin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
also O
known O
as O
orphanin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
FQ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
is O
an O
endogenous O
ligand O
for O
the O
orphan O
opioid O
receptor O
- O
like O
receptor O
1 O
( O
ORL1 O
) O
and O
involves O
in O
various O
functions O
in O
the O
central O
nervous O
system O
( O
CNS O
) O
. O

On O
the O
other O
hand O
, O
nocistatin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
recently O
isolated O
from O
the O
same O
precursor O
as O
nociceptin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
blocks O
nociceptin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
allodynia O
and O
hyperalgesia O
. O

2 B_NUMBER[MEASURE]
. O

Although O
ORL1 B_GENE
receptors I_GENE
which O
display O
a O
high B_MEASURE/B_LOCATION
degree I_MEASURE/I_LOCATION
of O
sequence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
homology I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
with O
classical B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
opioid I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
are O
abundant B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
, O
little B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
regarding O
their O
role B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
learning B_DISEASE
and O
memory B_DISEASE
. O

3 B_NUMBER[MEASURE]
. O

The O
present O
study O
was O
designed O
to O
investigate O
whether O
nociceptin B_GENE/B_PERSON
/ O
orphanin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FQ I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
nocistatin B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
modulate O
impairment O
of O
learning O
and O
memory O
induced O
by O
scopolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
muscarinic O
cholinergic O
receptor O
antagonist O
, O
using O
spontaneous O
alternation O
of O
Y O
- O
maze O
and O
step O
- O
down O
type O
passive O
avoidance O
tasks O
in O
mice O
. O

4 B_NUMBER[MEASURE]
. O

While O
nocistatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
0 O
. O
5 O
- O
5 O
. O
0 O
nmol O
mouse O
- O
1 O
, O
i O
. O
c O
. O
v O
. O
) O
administered O
30 O
min O
before O
spontaneous O
alternation O
performance O
or O
the O
training O
session O
of O
the O
passive O
avoidance O
task O
, O
had O
no O
effect O
on O
spontaneous O
alternation O
or O
passive O
avoidance O
behaviours O
, O
a O
lower O
per O
cent O
alternation O
and O
shorter O
median O
step O
- O
down O
latency O
in O
the O
retention O
test O
were O
obtained O
in O
nociceptin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 O
. O
5 O
and O
/ O
or O
5 O
. O
0 O
nmol O
mouse O
- O
1 O
, O
i O
. O
c O
. O
v O
. O
) O
- O
treated O
normal O
mice O
. O

5 B_NUMBER[MEASURE]
. O

Administration O
of O
nocistatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
1 O
. O
5 O
and O
/ O
or O
5 O
. O
0 O
nmol O
mouse O
- O
1 O
, O
i O
. O
c O
. O
v O
. O
) O
30 O
min O
before O
spontaneous O
alternation O
performance O
or O
the O
training O
session O
of O
the O
passive O
avoidance O
task O
, O
attenuated O
the O
scopolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
impairment O
of O
spontaneous O
alternation O
and O
passive O
avoidance O
behaviours O
. O

6 B_NUMBER[MEASURE]
. O

These O
results O
indicated O
that O
nocistatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
new O
biologically O
active O
peptide O
, O
ameliorates O
impairments O
of O
spontaneous O
alternation O
and O
passive O
avoidance O
induced O
by O
scopolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
suggested O
that O
these O
peptides O
play O
opposite O
roles O
in O
learning O
and O
memory O
. O

Meloxicam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
liver O
toxicity O
. O

We O
report O
the O
case O
of O
a O
female O
patient O
with O
rheumatoid O
arthritis O
who O
developed O
acute O
cytolytic O
hepatitis O
due O
to O
meloxicam B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Recently O
introduced O
in O
Belgium O
, O
meloxicam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
first O
nonsteroidal O
antiinflammatory O
drug O
with O
selective O
action O
on O
the O
inducible O
form O
of O
cyclooxygenase O
2 O
. O

The O
acute O
cytolytic O
hepatitis O
occurred O
rapidly O
after O
meloxicam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
and O
was O
associated O
with O
the O
development O
of O
antinuclear O
antibodies O
suggesting O
a O
hypersensitivity O
mechanism O
. O

This O
first O
case O
of O
meloxicam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related O
liver O
toxicity O
demonstrates O
the O
potential O
of O
this O
drug O
to O
induce O
hepatic O
damage O
. O

induction O
of O
apoptosis O
by O
remoxipride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
metabolites O
in O
HL60 O
and O
CD34 O
+ O
/ O
CD19 O
- O
human O
bone O
marrow O
progenitor O
cells O
: O
potential O
relevance O
to O
remoxipride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
aplastic O
anemia O
. O

The O
antipsychotic O
agent O
, O
remoxipride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
[ O
( B_TIME[MEASURE]/B_LOCATION
S I_TIME[MEASURE]/I_LOCATION
) I_TIME[MEASURE]/I_LOCATION
- I_TIME[MEASURE]/I_LOCATION
( I_TIME[MEASURE]/I_LOCATION
- I_TIME[MEASURE]/I_LOCATION
) I_TIME[MEASURE]/I_LOCATION
- I_TIME[MEASURE]/I_LOCATION
3 I_TIME[MEASURE]/I_LOCATION
- I_TIME[MEASURE]/I_LOCATION
bromo I_TIME[MEASURE]/I_LOCATION
- I_TIME[MEASURE]/I_LOCATION
N I_TIME[MEASURE]/I_LOCATION
- I_TIME[MEASURE]/I_LOCATION
[ I_TIME[MEASURE]/I_LOCATION
( I_TIME[MEASURE]/I_LOCATION
1 I_TIME[MEASURE]/I_LOCATION
- I_TIME[MEASURE]/I_LOCATION
ethyl I_TIME[MEASURE]/I_LOCATION
- I_TIME[MEASURE]/I_LOCATION
2 I_TIME[MEASURE]/I_LOCATION
- I_TIME[MEASURE]/I_LOCATION
pyrrolidinyl I_TIME[MEASURE]/I_LOCATION
) I_TIME[MEASURE]/I_LOCATION
methyl I_TIME[MEASURE]/I_LOCATION
] I_TIME[MEASURE]/I_LOCATION
- I_TIME[MEASURE]/I_LOCATION
2 I_TIME[MEASURE]/I_LOCATION
, I_TIME[MEASURE]/I_LOCATION
6 I_TIME[MEASURE]/I_LOCATION
- I_TIME[MEASURE]/I_LOCATION
dimethoxybenz I_TIME[MEASURE]/I_LOCATION
amide I_TIME[MEASURE]/I_LOCATION
] O
has O
been O
associated O
with O
acquired O
aplastic O
anemia O
. O

We O
have O
examined O
the O
ability O
of O
remoxipride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
three O
pyrrolidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
ring O
metabolites O
and O
five O
aromatic O
ring O
metabolites O
of O
the O
parent O
compound O
to O
induce O
apoptosis O
in O
HL60 O
cells O
and O
human O
bone O
marrow O
progenitor O
( O
HBMP O
) O
cells O
. O

cells B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
treated O
for O
0 B_MEASURE
- O
24 B_MEASURE
h I_MEASURE
with O
each O
compound B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 B_MEASURE
- O
200 B_MEASURE
microM I_MEASURE
) O
. O

Apoptosis O
was O
assessed O
by O
fluorescence O
microscopy O
in O
Hoechst B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
33342 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
propidium B_TIME[MEASURE]/B_COLOR
iodide I_TIME[MEASURE]/I_COLOR
stained O
cell O
samples O
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
confirmed O
by O
determination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
internucleosomal B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
DNA I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
fragmentation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
using O
gel B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrophoresis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
HL60 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
cell B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
samples B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
terminal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
deoxynucleotidyl I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
transferase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
HBMP B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
catechol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hydroquinone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
metabolites O
, O
NCQ436 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
NCQ344 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
induced O
apoptosis O
in O
HL60 O
and O
HBMP O
cells O
in O
a O
time O
- O
and O
concentration O
dependent O
manner O
, O
while O
the O
phenols B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
NCR181 O
, O
FLA873 O
, O
and O
FLA797 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
and O
the O
derivatives O
formed O
by O
oxidation O
of O
the O
pyrrolidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
ring O
, O
FLA838 O
, O
NCM001 O
, O
and O
NCL118 O
, O
had O
no O
effect O
. O

No O
necrosis O
was O
observed O
in O
cells O
treated O
with O
NCQ436 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
but O
NCQ344 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
a O
biphasic O
effect O
in O
both O
cell O
types O
, O
inducing O
apoptosis O
at O
lower O
concentrations O
and O
necrosis O
at O
higher O
concentrations O
. O

These O
data O
show O
that O
the O
catechol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hydroquinone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
metabolites O
of O
remoxipride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
direct O
toxic O
effects O
in O
HL60 O
and O
HBMP O
cells O
, O
leading O
to O
apoptosis O
, O
while O
the O
phenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolites O
were O
inactive O
. O

Similarly O
, O
benzene B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
derived O
catechol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hydroquinone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
but O
not O
phenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
induce O
apoptosis O
in O
HBMP O
cells O
[ O
Moran O
et O
al O
. O
, O
Mol O
. O
Pharmacol O
. O
, O
50 O
( O
1996 O
) O
610 O
- O
615 O
] O
. O

We O
propose O
that O
remoxipride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
benzene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
induce O
aplastic O
anemia O
via O
production O
of O
similar O
reactive O
metabolites O
and O
that O
the O
ability O
of O
NCQ436 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
NCQ344 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
induce O
apoptosis O
in O
HBMP O
cells O
may O
contribute O
to O
the O
mechanism O
underlying O
acquired O
aplastic O
anemia O
that O
has O
been O
associated O
with O
remoxipride B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

synthesis O
and O
preliminary O
pharmacological O
investigations O
of O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dihydro I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acenaphthylenyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
piperazine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derivatives O
as O
potential O
atypical O
antipsychotic O
agents O
in O
mice O
. O

In O
research B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
towards O
the O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
new B_DISEASE
atypical I_DISEASE
antipsychotic I_DISEASE
agents I_DISEASE
, O
one B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
strategy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
is O
that O
the O
dopaminergic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
system I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
can O
be O
modulated O
through O
manipulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
serotonergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
system B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
synthesis O
and O
preliminary O
pharmacological O
evaluation O
of O
a O
series O
of O
potential O
atypical O
antipsychotic O
agents O
based O
on O
the O
structure O
of O
1 B_LOCATION/B_ORGANIZATION
- I_LOCATION/I_ORGANIZATION
( I_LOCATION/I_ORGANIZATION
1 I_LOCATION/I_ORGANIZATION
, I_LOCATION/I_ORGANIZATION
2 I_LOCATION/I_ORGANIZATION
- I_LOCATION/I_ORGANIZATION
dihydro I_LOCATION/I_ORGANIZATION
- I_LOCATION/I_ORGANIZATION
2 I_LOCATION/I_ORGANIZATION
- I_LOCATION/I_ORGANIZATION
acenaphthylenyl I_LOCATION/I_ORGANIZATION
) I_LOCATION/I_ORGANIZATION
piperazine I_LOCATION/I_ORGANIZATION
( O
7 O
) O
is O
described O
. O

compound O
7e O
, O
5 B_MEASURE/B_LOCATION
- I_MEASURE/I_LOCATION
{ I_MEASURE/I_LOCATION
2 I_MEASURE/I_LOCATION
- I_MEASURE/I_LOCATION
[ I_MEASURE/I_LOCATION
4 I_MEASURE/I_LOCATION
- I_MEASURE/I_LOCATION
( I_MEASURE/I_LOCATION
1 I_MEASURE/I_LOCATION
, I_MEASURE/I_LOCATION
2 I_MEASURE/I_LOCATION
- I_MEASURE/I_LOCATION
dihydro I_MEASURE/I_LOCATION
- I_MEASURE/I_LOCATION
2 I_MEASURE/I_LOCATION
- I_MEASURE/I_LOCATION
acenaphthylenyl I_MEASURE/I_LOCATION
) I_MEASURE/I_LOCATION
piperazinyl I_MEASURE/I_LOCATION
] I_MEASURE/I_LOCATION
ethyl I_MEASURE/I_LOCATION
} I_MEASURE/I_LOCATION
- I_MEASURE/I_LOCATION
2 I_MEASURE/I_LOCATION
, I_MEASURE/I_LOCATION
3 I_MEASURE/I_LOCATION
- I_MEASURE/I_LOCATION
dihy I_MEASURE/I_LOCATION
dro I_MEASURE/I_LOCATION
- I_MEASURE/I_LOCATION
1H I_MEASURE/I_LOCATION
- I_MEASURE/I_LOCATION
indol I_MEASURE/I_LOCATION
- I_MEASURE/I_LOCATION
2 I_MEASURE/I_LOCATION
- I_MEASURE/I_LOCATION
one I_MEASURE/I_LOCATION
, O
from O
this O
series O
showed O
significant O
affinities O
at O
the O
5 O
- O
HT1A O
and O
5 O
- O
HT2A O
receptors O
and O
moderate O
affinity O
at O
the O
D2 O
receptor O
. O

7e O
exhibits O
a O
high O
reversal O
of O
catalepsy O
induced O
by O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicating O
its O
atypical O
antipsychotic O
nature O
. O

Sub O
- O
chronic O
inhibition O
of O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
synthesis O
modifies O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
catalepsy O
and O
the O
number O
of O
NADPH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
diaphorase O
neurons O
in O
mice O
. O

RATIONALE O
: O
NG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
nitro I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
L I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
arginine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
NOARG I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
) O
, O
an O
inhibitor O
of O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
synthase O
( O
NOS O
) O
, O
induces O
catalepsy O
in O
mice O
. O

This O
effect O
undergoes O
rapid O
tolerance O
, O
showing O
a O
significant O
decrease O
after O
2 O
days O
of O
sub O
- O
chronic O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
NOARG I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
treatment O
. O

Nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
NO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
has O
been O
shown O
to O
influence O
dopaminergic O
neurotransmission O
in O
the O
striatum O
. O

Neuroleptic O
drugs O
such O
as O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
block O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O
, O
also O
cause O
catalepsy O
in O
rodents O
. O

objectives O
: O
To O
investigate O
the O
effects O
of O
subchronic O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NOARG I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
in O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
catalepsy O
and O
the O
number O
of O
NOS O
neurons O
in O
areas O
related O
to O
motor O
control O
. O

methods O
: O
Male O
albino O
Swiss O
mice O
were O
treated O
sub O
- O
chronically O
( O
twice O
a O
day O
for O
4 O
days O
) O
with O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NOARG I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
40 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
or O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
. O

Catalepsy B_DISEASE_ADJECTIVE[DISEASE]
was O
evaluated O
at O
the O
beginning B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_SEQUENCE[MEASURE]
and O
the O
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
treatments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

reduced O
nicotinamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
adenine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dinucleotide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phosphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
diaphorase O
( O
NADPH B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
d O
) O
histochemistry O
was O
also O
employed O
to O
visualize O
NOS O
as O
an O
index O
of O
enzyme O
expression O
in O
mice O
brain O
regions O
related O
to O
motor O
control O
. O

Results O
: O
L B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NOARG I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sub O
- O
chronic O
administration O
produced O
tolerance O
of O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
NOARG I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
of O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
catalepsy O
. O

It O
also O
induced O
an O
increase O
in O
the O
number O
of O
NADPH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
d O
- O
positive O
cells O
in O
the O
dorsal O
part O
of O
the O
caudate O
and O
accumbens O
nuclei O
compared O
with O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
in O
the O
pedunculopontine O
tegmental O
nucleus O
compared O
with O
saline O
. O

In O
contrast O
, O
there O
was O
a O
decrease O
in O
NADPH B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
d O
neuron O
number O
in O
the O
substantia O
nigra O
, O
pars O
compacta O
in O
both O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
and O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NOARG I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
animals O
. O

conclusions O
: O
The O
results O
give O
further O
support O
to O
the O
hypothesis O
that O
NO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plays O
a O
role O
in O
motor O
behavior O
control O
and O
suggest O
that O
it O
may O
take O
part O
in O
the O
synaptic O
changes O
produced O
by O
antipsychotic O
treatment O
. O

prolonged O
left O
ventricular O
dysfunction O
occurs O
in O
patients O
with O
coronary O
artery O
disease O
after O
both O
dobutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
exercise O
induced O
myocardial O
ischaemia O
. O

Objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
To O
determine O
whether O
pharmacological B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stress I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
leads O
to O
prolonged O
but O
reversible B_DISEASE_ADJECTIVE[DISEASE]
left O
ventricular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
patients B_PERSON
with O
coronary B_DISEASE
artery I_DISEASE
disease I_DISEASE
, O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
that O
seen O
after O
exercise B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Design O
: O
A O
randomised O
crossover O
study O
of O
recovery O
time O
of O
systolic O
and O
diastolic O
left O
ventricular O
function O
after O
exercise O
and O
dobutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O
ischaemia O
. O

subjects B_PERSON/B_MEASURE
: O
10 B_PERSON
patients I_PERSON
with O
stable B_DISEASE_ADJECTIVE[DISEASE]
angina I_DISEASE_ADJECTIVE[DISEASE]
, O
angiographically O
proven O
coronary B_DISEASE/B_LOCATION
artery I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
, O
and O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
left O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

interventions O
: O
Treadmill O
exercise O
and O
dobutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stress O
were O
performed O
on O
different O
days O
. O

Quantitative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
systolic B_BODY_PART_OR_ORGAN_COMPONENT
and O
diastolic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
left O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
using O
transthoracic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
echocardiography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
at O
regular B_TIME[MEASURE]/B_LOCATION
intervals I_TIME[MEASURE]/I_LOCATION
after O
each O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Both O
forms B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
stress B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
led O
to O
prolonged O
but O
reversible B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
systolic B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
diastolic B_DISEASE
dysfunction I_DISEASE
. O

There O
was O
no O
difference B_MEASURE
in O
the O
maximum B_MEASURE/B_DISEASE
double B_MEASURE/I_DISEASE
product B_MEASURE/I_DISEASE
( O
p B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
53 B_MEASURE
) O
or O
ST B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
depression B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
p B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
63 B_MEASURE
) O
with O
either O
form B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
stress B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

After O
exercise O
, O
ejection O
fraction O
was O
reduced O
at O
15 O
and O
30 O
minutes O
compared O
with O
baseline O
( O
mean O
( O
SEM O
) O
, O
- O
5 O
. O
6 O
( O
1 O
. O
5 O
) O
% O
, O
p O
< O
0 O
. O
05 O
; O
and O
- O
6 O
. O
1 O
( O
2 O
. O
2 O
) O
% O
, O
p O
< O
0 O
. O
01 O
) O
, O
and O
at O
30 O
and O
45 O
minutes O
after O
dobutamine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
- O
10 O
. O
8 O
( O
1 O
. O
8 O
) O
% O
and O
- O
5 O
. O
5 O
( O
1 O
. O
8 O
) O
% O
, O
both O
p O
< O
0 O
. O
01 O
) O
. O

Regional O
analysis O
showed O
a O
reduction O
in O
the O
worst O
affected O
segment O
15 O
and O
30 O
minutes O
after O
exercise O
( O
- O
27 O
. O
9 O
( O
7 O
. O
2 O
) O
% O
and O
- O
28 O
. O
6 O
( O
5 O
. O
7 O
) O
% O
, O
both O
p O
< O
0 O
. O
01 O
) O
, O
and O
at O
30 O
minutes O
after O
dobutamine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
- O
32 O
( O
5 O
. O
3 O
) O
% O
, O
p O
< O
0 O
. O
01 O
) O
. O

The O
isovolumic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
relaxation B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
period B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O
prolonged O
45 B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
after O
each O
form B_TIME[MEASURE]/B_LOCATION
of O
stress B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
p B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

conclusions O
: O
In O
patients O
with O
coronary O
artery O
disease O
, O
dobutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O
ischaemia O
results O
in O
prolonged O
reversible O
left O
ventricular O
dysfunction O
, O
presumed O
to O
be O
myocardial O
stunning O
, O
similar O
to O
that O
seen O
after O
exercise O
. O

Dobutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
ischaemia O
could O
therefore O
be O
used O
to O
study O
the O
pathophysiology O
of O
this O
phenomenon O
further O
in O
patients O
with O
coronary O
artery O
disease O
. O

Anorexigens B_DISEASE/B_BIO
and O
pulmonary B_DISEASE/B_PERSON
hypertension I_DISEASE/I_PERSON
in O
the O
United B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
States B_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
: O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
surveillance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
North B_DISEASE
American I_DISEASE
pulmonary I_DISEASE
hypertension I_DISEASE
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
The O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
appetite B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suppressants I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Europe B_LOCATION/B_PERSON
has O
been O
associated O
with O
the O
development B_DISEASE_ADJECTIVE[DISEASE]
of O
primary B_DISEASE
pulmonary I_DISEASE
hypertension I_DISEASE
( O
PPH B_DISEASE/B_GENE
) O
. O

Recently O
, O
fenfluramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
appetite O
suppressants O
became O
widely O
used O
in O
the O
United O
States O
but O
were O
withdrawn O
in O
September O
1997 O
because O
of O
concerns O
over O
adverse O
effects O
. O

materials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
AND O
METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
We O
conducted O
a O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surveillance I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
patients B_PERSON
diagnosed O
with O
pulmonary B_DISEASE
hypertension I_DISEASE
at O
12 B_LOCATION
large I_LOCATION
referral I_LOCATION
centers I_LOCATION
in O
North B_LOCATION
America I_LOCATION
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
collected O
on O
patients B_PERSON/B_ENT
seen O
from O
September B_TIME[MEASURE]
1 I_TIME[MEASURE]
, O
1996 B_MEASURE
, O
to O
December B_TIME[MEASURE]
31 I_TIME[MEASURE]
, O
1997 B_MEASURE
, O
included O
the O
cause B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
pulmonary B_DISEASE_ADJECTIVE[DISEASE]
hypertension I_DISEASE_ADJECTIVE[DISEASE]
and O
its O
severity B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

patients B_PERSON/B_BIO
with O
no O
identifiable B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cause B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pulmonary B_DISEASE/B_GENE
hypertension I_DISEASE/I_GENE
were O
classed O
as O
PPH B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
. O

A O
history O
of O
drug O
exposure O
also O
was O
taken O
with O
special O
attention O
on O
the O
use O
of O
antidepressants O
, O
anorexigens O
, O
and O
amphetamines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Results B_MEASURE
: O
Five B_NUMBER[MEASURE]
hundred I_NUMBER[MEASURE]
seventy I_NUMBER[MEASURE]
- O
nine B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
were O
studied O
, O
205 B_MEASURE
with O
PPH B_DISEASE/B_GENE
and O
374 B_NUMBER[MEASURE]
with O
pulmonary B_DISEASE
hypertension I_DISEASE
from O
other B_DISEASE/B_LOCATION
causes I_DISEASE/I_LOCATION
( O
secondary B_DISEASE/B_LOCATION
pulmonary I_DISEASE/I_LOCATION
hypertension I_DISEASE/I_LOCATION
[ O
SPH B_MEASURE/B_DISEASE
] I_MEASURE/I_DISEASE
) O
. O

The O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
anorexigens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O
common B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
both O
groups B_ORGANIZATION/B_LOCATION
. O

However O
, O
of O
the O
medications O
surveyed O
, O
only O
the O
fenfluramines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
had O
a O
significant O
preferential O
association O
with O
PPH O
as O
compared O
with O
SPH O
( O
adjusted O
odds O
ratio O
for O
use O
> O
6 O
months O
, O
7 O
. O
5 O
; O
95 O
% O
confidence O
interval O
, O
1 O
. O
7 O
to O
32 O
. O
4 O
) O
. O

The O
association B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
stronger B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
longer B_TIME[MEASURE]
duration I_TIME[MEASURE]
of O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
when O
compared O
to O
shorter B_TIME[MEASURE]
duration I_TIME[MEASURE]
of O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
was O
more O
pronounced B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
recent B_PERSON/B_LOCATION
users I_PERSON/I_LOCATION
than O
in O
remote B_PERSON/B_ORGANIZATION
users I_PERSON/I_ORGANIZATION
. O

An O
unexpectedly O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
( O
11 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
number B_MEASURE/B_PERSON
of O
patients B_PERSON
with O
Sph B_DISEASE/B_GENE
had O
used O
anorexigens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

conclusion O
: O
The O
magnitude O
of O
the O
association O
with O
PPH O
, O
the O
increase O
of O
association O
with O
increasing O
duration O
of O
use O
, O
and O
the O
specificity O
for O
fenfluramines B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O
consistent O
with O
previous O
studies O
indicating O
that O
fenfluramines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
are O
causally O
related O
to O
PPH O
. O

The O
high B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevalence B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
anorexigen B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients B_PERSON/B_LOCATION
with O
Sph B_DISEASE/B_GENE
also O
raises O
the O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
that O
these O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
precipitate O
pulmonary B_DISEASE
hypertension I_DISEASE
in O
patients B_PERSON/B_ORGANIZATION
with O
underlying B_DISEASE/B_GENE
conditions I_DISEASE
associated O
with O
Sph B_DISEASE/B_GENE
. O

Clinical O
aspects O
of O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
thrombocytopenia O
and O
thrombosis O
and O
other O
side O
effects O
of O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O
. O

Heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
first O
used O
to O
prevent O
the O
clotting O
of O
blood O
in O
vitro O
, O
has O
been O
clinically O
used O
to O
treat O
thrombosis O
for O
more O
than O
50 O
years O
. O

Although O
several O
new O
anticoagulant O
drugs O
are O
in O
development O
, O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remains O
the O
anticoagulant O
of O
choice O
to O
treat O
acute O
thrombotic O
episodes O
. O

The O
clinical O
effects O
of O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
meritorious O
, O
but O
side O
effects O
do O
exist O
. O

bleeding O
is O
the O
primary O
untoward O
effect O
of O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Major O
bleeding O
is O
of O
primary O
concern O
in O
patients O
receiving O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

However O
, O
additional O
important O
untoward O
effects O
of O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O
include O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
thrombocytopenia O
, O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
osteoporosis O
, O
eosinophilia O
, O
skin O
reactions O
, O
allergic O
reactions O
other O
than O
thrombocytopenia O
, O
alopecia O
, O
transaminasemia O
, O
hyperkalemia O
, O
hypoaldosteronism O
, O
and O
priapism O
. O

These O
side O
effects O
are O
relatively O
rare O
in O
a O
given O
individual O
, O
but O
given O
the O
extremely O
widespread O
use O
of O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
some O
are O
quite O
common O
, O
particularly O
HITT O
and O
osteoporosis O
. O

Although O
reasonable O
incidences O
of O
many O
of O
these O
side O
effects O
can O
be O
' O
softly O
' O
deduced O
from O
current O
reports O
dealing O
with O
unfractionated O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
at O
present O
the O
incidences O
of O
these O
side O
effects O
with O
newer O
low O
molecular O
weight O
heparins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
appear O
to O
be O
much O
less O
common O
. O

However O
, O
only O
longer B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experience I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
more O
clearly O
define O
the O
incidence B_DISEASE_ADJECTIVE[DISEASE]
of O
each O
side B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
low B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecular I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weight I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
case O
of O
bilateral O
optic O
neuropathy O
in O
a O
patient O
on O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
FK506 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
therapy O
after O
liver O
transplantation O
. O

purpose O
: O
To O
report O
a O
case O
of O
bilateral O
optic O
neuropathy O
in O
a O
patient O
receiving O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
FK B_PERSON/B_LOCATION
506 B_PERSON/I_LOCATION
, O
Prograf O
; O
Fujisawa O
USA O
, O
Inc O
, O
Deerfield O
, O
Illinois O
) O
for O
immunosuppression O
after O
orthotropic O
liver O
transplantation O
. O

Method B_MEASURE/B_LOCATION
: O
Case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
a O
58 O
- O
year O
- O
old O
man O
receiving O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
orthotropic O
liver O
transplantation O
, O
serial O
neuro O
- O
ophthalmologic O
examinations O
and O
laboratory O
studies O
were O
performed O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
The O
patient B_PERSON
had O
episodic B_DISEASE_ADJECTIVE[DISEASE]
deterioration I_DISEASE_ADJECTIVE[DISEASE]
of O
vision B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O
both O
eyes B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
with O
clinical B_DISEASE_ADJECTIVE[DISEASE]
features I_DISEASE_ADJECTIVE[DISEASE]
resembling O
ischemic B_DISEASE
optic I_DISEASE
neuropathies I_DISEASE
. O

Deterioration O
of O
vision O
occurred O
despite O
discontinuation O
of O
the O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusion O
: O
Tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
other O
immunosuppressive O
agents O
may O
be O
associated O
with O
optic O
nerve O
toxicity O
. O

hypercalcemia B_DISEASE
, O
arrhythmia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
mood B_DISEASE
stabilizers I_DISEASE
. O

Recent O
findings O
in O
a O
bipolar O
patient O
receiving O
maintenance O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
who O
developed O
hypercalcemia O
and O
severe O
bradyarrhythmia O
prompted O
the O
authors O
to O
conduct O
a O
retrospective O
study O
of O
bipolar O
patients O
with O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
hypercalcemia O
. O

A O
printout B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
all O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hypercalcemia B_DISEASE
that O
presented O
during O
a O
1 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
period I_TIME[MEASURE]
was O
generated O
. O

After O
eliminating O
spurious O
hypercalcemias O
or O
those O
associated O
with O
intravenous O
fluids O
, O
the O
authors O
identified O
18 O
non O
- O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
patients O
with O
hypercalcemias O
related O
to O
malignancies O
and O
other O
medical O
conditions O
( O
group O
A O
) O
and O
12 O
patients O
with O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
hypercalcemia O
( O
group O
B O
) O
. O

patients B_PERSON
in O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
B I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
not O
comparable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
those O
in O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
A I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
as O
the O
latter B_NUMBER[MEASURE]/B_PERSON
were O
medically O
compromised O
and O
were O
receiving O
multiple B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pharmacotherapies I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thus O
, O
two O
control O
groups O
were O
generated O
: O
group O
C1 O
, O
which O
included O
age O
- O
and O
sex O
- O
comparable O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
bipolar O
normocalcemic O
patients O
, O
and O
group O
C2 O
, O
which O
included O
bipolar O
normocalcemic O
patients O
treated O
with O
anticonvulsant O
mood O
stabilizers O
. O

The O
electrocardiographic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
ECG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
patients B_PERSON/B_DISEASE
in O
group B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
compared O
with O
those O
of O
patients B_PERSON
in O
groups B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C1 I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
C2 B_PROTEIN[GENE]
. O

It O
was O
found O
that O
these O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
differ O
in O
their O
overall B_MEASURE
frequency I_MEASURE
of O
ECG B_DISEASE_ADJECTIVE[DISEASE]
abnormalities I_DISEASE_ADJECTIVE[DISEASE]
; O
however O
, O
there O
were O
significant B_DISEASE_ADJECTIVE[DISEASE]
differences I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
frequency B_MEASURE
of O
conduction B_DISEASE/B_LOCATION
defects I_DISEASE/I_LOCATION
. O

patients O
with O
hypercalcemia O
resulting O
from O
medical O
diseases O
and O
bipolar O
patients O
with O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
hypercalcemia O
had O
significantly O
higher O
frequencies O
of O
conduction O
defects O
. O

patients B_PERSON
in O
group B_NUMBER[MEASURE]/B_LOCATION
A I_NUMBER[MEASURE]/I_LOCATION
had O
significant B_DISEASE/B_MEASURE
mortality I_DISEASE/I_MEASURE
at O
2 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]/B_LOCATION
follow I_TIME[MEASURE]/I_LOCATION
- O
up B_TIME[MEASURE]/B_LOCATION
( O
28 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
in O
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
zero B_PERSON/B_DISEASE
mortality I_PERSON/I_DISEASE
in O
the O
other B_MEASURE/B_LOCATION
three B_MEASURE/I_LOCATION
groups B_MEASURE/I_LOCATION
. O

The O
clinical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
implications I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
these O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
discussed O
. O

Attenuation O
of O
nephrotoxicity O
by O
a O
novel O
lipid O
nanosphere O
( O
NS O
- O
718 O
) O
incorporating O
amphotericin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

NS O
- O
718 O
, O
a O
lipid O
nanosphere O
incorporating O
amphotericin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
effective O
against O
pathogenic O
fungi O
and O
has O
low O
toxicity O
. O

We O
compared O
the O
toxicity O
of O
NS O
- O
718 O
with O
that O
of O
Fungizone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
amphotericin B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
deoxycholate I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
AmB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
in O
vitro O
using O
renal O
cell O
cultures O
and O
in O
vivo O
by O
biochemical O
analysis O
, O
histopathological O
study O
of O
the O
kidney O
and O
pharmacokinetic O
study O
of O
amphotericin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
following O
intravenous O
infusion O
of O
the O
formulation O
in O
rats O
. O

Incubation O
with O
NS O
- O
718 O
resulted O
in O
significantly O
less O
damage O
of O
cultured O
human O
renal O
proximal O
tubular O
epithelial O
cells O
compared O
with O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
AmB I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

serum O
blood O
urea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentrations O
increased O
significantly O
in O
rats O
given O
an O
IV O
infusion O
of O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AmB I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O
mg O
/ O
kg O
but O
not O
in O
those O
given O
the O
same O
dose O
of O
NS O
- O
718 O
. O

Histopathological O
examination O
of O
the O
kidney O
showed O
tubular O
necrosis O
in O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
AmB I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
treated O
rats O
but O
no O
change O
in O
NS O
- O
718 O
- O
treated O
rats O
. O

Amphotericin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
concentrations O
in O
the O
kidney O
in O
NS O
- O
718 O
- O
treated O
rats O
were O
higher O
than O
those O
in O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
AmB I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
treated O
rats O
. O

Our O
in O
vitro O
and O
in O
vivo O
results O
suggest O
that O
incorporation O
of O
amphotericin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
into O
lipid O
nanospheres O
of O
NS O
- O
718 O
attenuates O
the O
nephrotoxicity O
of O
amphotericin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

patterns O
of O
sulfadiazine B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
acute O
nephrotoxicity O
. O

Sulfadiazine B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
acute O
nephrotoxicity O
is O
reviving O
specially O
because O
of O
its O
use O
in O
toxoplasmosis O
in O
HIV O
- O
positive O
patients O
. O

We O
report O
4 B_NUMBER[MEASURE]/B_PERSON
cases I_NUMBER[MEASURE]/I_PERSON
, O
one B_NUMBER[MEASURE]
of O
them O
in O
a O
previously O
healthy B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
person I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
. O

Under O
treatment O
with O
sulfadiazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
they O
developed O
oliguria O
, O
abdominal O
pain O
, O
renal O
failure O
and O
showed O
multiple O
radiolucent O
renal O
calculi O
in O
echography O
. O

All O
patients B_PERSON
recovered O
their O
previous B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
normal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
renal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O
adequate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
hydration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
alcalinization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

A O
nephrostomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
tube B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEDICAL_DEVICE[OBJECT]
had O
to O
be O
placed O
in O
one B_NUMBER[MEASURE]/B_LOCATION
of O
the O
patients B_PERSON/B_LOCATION
for O
ureteral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
lithiasis I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
single B_TIME[MEASURE]/B_LOCATION
functional B_TIME[MEASURE]/I_LOCATION
kidney B_TIME[MEASURE]/I_LOCATION
. O

None B_PERSON/B_NUMBER[MEASURE]
of O
them O
needed O
dialysis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
a O
renal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
biopsy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O
of O
a O
typical B_DISEASE
benign I_DISEASE
course I_DISEASE
. O

Treatment O
with O
sulfadiazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
requires O
exquisite O
control O
of O
renal O
function O
, O
an O
increase O
in O
water O
ingestion O
and O
possibly O
the O
alcalinization O
of O
the O
urine O
. O

We O
communicate O
a O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
previously O
healthy B_PERSON/B_TIME[MEASURE]
person B_PERSON/I_TIME[MEASURE]
, O
a O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
not O
found O
in O
the O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
literature I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Probably O
many B_PERSON
more I_PERSON
cases I_PERSON
are O
not O
detected O
. O

We O
think O
that O
a O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
would O
be O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Downbeat O
nystagmus O
associated O
with O
intravenous O
patient O
- O
controlled O
administration O
of O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

implications O
: O
This O
case O
documents O
a O
patient O
who O
developed O
dizziness O
with O
downbeating O
nystagmus O
while O
receiving O
a O
relatively O
large O
dose O
of O
IV O
patient O
- O
controlled O
analgesia O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Although O
there O
have O
been O
case O
reports O
of O
epidural O
morphine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
these O
symptoms O
and O
signs O
, O
this O
has O
not O
been O
previously O
documented O
with O
IV O
or O
patient O
- O
controlled O
analgesia O
morphine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
. O

Hemodynamic O
and O
antiadrenergic O
effects O
of O
dronedarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
animals O
with O
a O
healed O
myocardial O
infarction O
. O

The O
hemodynamic O
and O
antiadrenergic O
effects O
of O
dronedarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
noniodinated O
compound O
structurally O
related O
to O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
were O
compared O
with O
those O
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
prolonged O
oral O
administration O
, O
both O
at O
rest O
and O
during O
sympathetic O
stimulation O
in O
conscious O
dogs O
with O
a O
healed O
myocardial O
infarction O
. O

All O
dogs O
( O
n O
= O
6 O
) O
randomly O
received O
orally O
dronedarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 O
and O
30 O
mg O
/ O
kg O
) O
, O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 O
and O
30 O
mg O
/ O
kg O
) O
, O
and O
placebo O
twice O
daily O
for O
7 O
days O
, O
with O
a O
3 O
- O
week O
washout O
between O
consecutive O
treatments O
. O

Heart O
rate O
( O
HR O
) O
, O
mean O
arterial O
pressure O
( O
MBP O
) O
, O
positive O
rate O
of O
increase O
of O
left O
ventricular O
pressure O
( O
+ O
LVdP O
/ O
dt O
) O
, O
echocardiographically O
assessed O
left O
ventricular O
ejection O
fraction O
( O
LVEF O
) O
, O
and O
fractional O
shortening O
( O
FS O
) O
, O
as O
well O
as O
chronotropic O
response O
to O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
exercise O
- O
induced O
sympathetic O
stimulation O
were O
evaluated O
under O
baseline O
and O
posttreatment O
conditions O
. O

resting O
values O
of O
LVEF O
, O
FS O
, O
+ O
LVdP O
/ O
dt O
, O
and O
MBP O
remained O
unchanged O
whatever O
the O
drug O
and O
the O
dosing O
regimen O
, O
whereas O
resting O
HR O
was O
significantly O
and O
dose O
- O
dependently O
lowered O
after O
dronedarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
to O
a O
lesser O
extent O
after O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Both O
dronedarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O
reduced O
the O
exercise O
- O
induced O
tachycardia O
and O
, O
at O
the O
highest O
dose O
, O
decreased O
the O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
tachycardia O
. O

Thus O
, O
dronedarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
displayed O
a O
similar O
level O
of O
antiadrenergic O
effect O
and O
did O
not O
impair O
the O
resting O
left O
ventricular O
function O
. O

Consequently O
, O
dronedarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
might O
be O
particularly O
suitable O
for O
the O
treatment O
and O
prevention O
of O
various O
clinical O
arrhythmias O
, O
without O
compromising O
the O
left O
ventricular O
function O
. O

Phase O
2 O
trial O
of O
liposomal O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
40 O
mg O
/ O
m O
( O
2 O
) O
) O
in O
platinum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
refractory O
ovarian O
and O
fallopian O
tube O
cancers O
and O
primary O
carcinoma O
of O
the O
peritoneum O
. O

Background O
: O
Several O
studies O
have O
demonstrated O
liposomal O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Doxil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
to O
be O
an O
active O
antineoplastic O
agent O
in O
platinum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
resistant O
ovarian O
cancer O
, O
with O
dose O
limiting O
toxicity O
of O
the O
standard O
dosing O
regimen O
( O
50 O
mg O
/ O
m O
( O
2 O
) O
q O
4 O
weeks O
) O
being O
severe O
erythrodysesthesia O
( O
' O
hand O
- O
foot O
syndrome O
' O
) O
and O
stomatitis O
. O

We O
wished O
to O
develop O
a O
more O
tolerable O
liposomal O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
regimen O
and O
document O
its O
level O
of O
activity O
in O
a O
well O
- O
defined O
patient O
population O
with O
platinum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
refractory O
disease O
. O

methods O
AND O
Materials O
: O
patients O
with O
ovarian O
or O
fallopian O
tube O
cancers O
or O
primary O
peritoneal O
carcinoma O
with O
platinum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
refractory O
disease O
( O
stable O
or O
progressive O
disease O
following O
treatment O
with O
these O
agents O
or O
previous O
objective O
response O
< O
3 O
months O
in O
duration O
) O
were O
treated O
with O
liposomal O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
dose O
of O
40 O
mg O
/ O
m O
( O
2 O
) O
q O
4 O
weeks O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
A O
total B_MEASURE
of O
49 B_TIME[MEASURE]
patients I_TIME[MEASURE]
( O
median B_MEASURE/B_PERSON
age I_MEASURE/I_PERSON
: O
60 B_MEASURE
; O
range B_MEASURE/B_LOCATION
41 I_MEASURE/I_LOCATION
- O
81 B_MEASURE
) O
entered O
this O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
median B_MEASURE/B_LOCATION
number I_MEASURE/I_LOCATION
of O
prior B_PERSON/B_ORGANIZATION
regimens I_PERSON/I_ORGANIZATION
was O
2 B_MEASURE
( O
range B_MEASURE/B_LOCATION
: O
1 B_NUMBER[MEASURE]
- O
6 B_MEASURE
) O
. O

Six B_NUMBER[MEASURE]
( O
12 B_MEASURE
% I_MEASURE
) O
and O
4 B_NUMBER[MEASURE]
( O
8 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
) O
patients B_PERSON/B_LOCATION
experienced O
grade B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
2 I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
hand I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
- O
foot B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
syndrome I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
stomatitis B_DISEASE
, O
respectively O
( O
no O
episodes B_DISEASE/B_ENT
of O
grade B_DISEASE
3 I_DISEASE
) O
. O

One B_PERSON
patient I_PERSON
developed O
grade B_DISEASE
3 I_DISEASE
diarrhea I_DISEASE
requiring O
hospitalization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
hydration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Six B_NUMBER[MEASURE]
( O
12 B_NUMBER[MEASURE]
% I_NUMBER[MEASURE]
) O
individuals B_PERSON/B_LOCATION
required O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
reductions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
median O
number O
of O
courses O
of O
liposomal O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administered O
on O
this O
protocol O
was O
2 O
( O
range O
: O
1 O
- O
12 O
) O
. O

Four B_NUMBER[MEASURE]
of O
44 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
( O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
evaluable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exhibited O
objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
subjective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
an O
antineoplastic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
therapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusion O
: O
This O
modified O
liposomal O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimen O
results O
in O
less O
toxicity O
( O
stomatitis O
, O
hand O
- O
foot O
syndrome O
) O
than O
the O
standard O
FDA O
- O
approved O
dose O
schedule O
. O

definite O
, O
although O
limited O
, O
antineoplastic O
activity O
is O
observed O
in O
patients O
with O
well O
- O
defined O
platinum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
refractory O
ovarian O
cancer O
. O

efficacy O
of O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
acute O
bipolar O
mania O
: O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
. O

The O
Olanzipine B_LOCATION
HGGW O
Study O
Group O
. O

Background O
: O
We O
compared O
the O
efficacy O
and O
safety O
of O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vs O
placebo O
for O
the O
treatment O
of O
acute O
bipolar O
mania O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Four B_NUMBER[MEASURE]
- O
week B_TIME[MEASURE]/B_PERSON
, O
randomized O
, O
double B_MEASURE/B_COLOR
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
parallel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

A O
total O
of O
115 O
patients O
with O
a O
DSM O
- O
IV O
diagnosis O
of O
bipolar O
disorder O
, O
manic O
or O
mixed O
, O
were O
randomized O
to O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5 O
to O
20 O
mg O
/ O
d O
( O
n O
= O
55 O
) O
, O
or O
placebo O
( O
n O
= O
60 O
) O
. O

The O
primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
efficacy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
measure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
the O
Young B_PERSON/B_NUMBER[MEASURE]
- O
Mania B_MEASURE/B_PERSON
rating B_MEASURE/I_PERSON
Scale B_MEASURE/I_PERSON
( O
Y B_OTHER/B_PERSON
- O
Mrs B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
total B_MEASURE
score I_MEASURE
. O

Response B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
euthymia B_DISEASE_ADJECTIVE[DISEASE]
were O
defined O
, O
a O
priori B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
as O
at O
least O
a O
50 B_MEASURE
% I_MEASURE
improvement I_MEASURE
from O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
point B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
as O
a O
score B_MEASURE
of O
no O
less B_MEASURE
than O
12 B_NUMBER[MEASURE]
at O
end B_LOCATION/B_MEASURE
point I_LOCATION/I_MEASURE
in O
the O
Y B_OTHER/B_LOCATION
- O
Mrs B_MEASURE/B_LOCATION
total I_MEASURE/I_LOCATION
score I_MEASURE/I_LOCATION
, O
respectively O
. O

Safety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
assessed O
using O
adverse B_DISEASE
events I_DISEASE
, O
Extrapyramidal B_DISEASE
Symptom I_DISEASE
( O
EPS B_LOCATION
) O
rating B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scales I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
laboratory B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
values I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
electrocardiograms B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
vital B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
signs I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
and O
weight B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
change I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Results O
: O
Olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
patients O
demonstrated O
a O
statistically O
significant O
greater O
mean O
( O
+ O
/ O
- O
SD O
) O
improvement O
in O
Y O
- O
Mrs O
total O
score O
than O
placebo O
- O
treated O
patients O
( O
- O
14 O
. O
8 O
+ O
/ O
- O
12 O
. O
5 O
and O
- O
8 O
. O
1 O
+ O
/ O
- O
12 O
. O
7 O
, O
respectively O
; O
P O
< O
. O
001 O
) O
, O
which O
was O
evident O
at O
the O
first O
postbaseline O
observation O
1 O
week O
after O
randomization O
and O
was O
maintained O
throughout O
the O
study O
( O
last O
observation O
carried O
forward O
) O
. O

Olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
patients O
demonstrated O
a O
higher O
rate O
of O
response O
( O
65 O
% O
vs O
43 O
% O
, O
respectively O
; O
P O
= O
. O
02 O
) O
and O
euthymia O
( O
61 O
% O
vs O
36 O
% O
, O
respectively O
; O
P O
= O
. O
01 O
) O
than O
placebo O
- O
treated O
patients O
. O

There O
were O
no O
statistically O
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
EPSs B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

However O
, O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
patients O
had O
a O
statistically O
significant O
greater O
mean O
( O
+ O
/ O
- O
SD O
) O
weight O
gain O
than O
placebo O
- O
treated O
patients O
( O
2 O
. O
1 O
+ O
/ O
- O
2 O
. O
8 O
vs O
0 O
. O
45 O
+ O
/ O
- O
2 O
. O
3 O
kg O
, O
respectively O
) O
and O
also O
experienced O
more O
treatment O
- O
emergent O
somnolence O
( O
21 O
patients O
[ O
38 O
. O
2 O
% O
] O
vs O
5 O
[ O
8 O
. O
3 O
% O
] O
, O
respectively O
) O
. O

conclusion O
: O
Olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O
greater O
efficacy O
than O
placebo O
in O
the O
treatment O
of O
acute O
bipolar O
mania O
and O
was O
generally O
well O
tolerated O
. O

The O
effect O
of O
pupil O
dilation O
with O
tropicamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
vision O
and O
driving O
simulator O
performance O
. O

Purpose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
To O
assess O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pupil B_DISEASE
dilation I_DISEASE
on O
vision B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
driving O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

methods O
: O
A O
series O
of O
tests O
on O
various O
parameters O
of O
visual O
function O
and O
driving O
simulator O
performance O
were O
performed O
on O
12 O
healthy O
drivers O
, O
before O
and O
after O
pupil O
dilation O
using O
guttae O
tropicamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_COLOR
1 O
% O
. O

A O
driving O
simulator B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Transport B_LOCATION/B_ORGANIZATION
Research I_LOCATION/I_ORGANIZATION
Laboratory I_LOCATION/I_ORGANIZATION
) O
was O
used O
to O
measure O
reaction B_MEASURE
time I_MEASURE
( O
RT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
) O
, O
speed B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
maintenance B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
steering B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
accuracy B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
basic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
visual I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
included O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
- O
and O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
contrast B_MEASURE
visual I_MEASURE
acuity I_MEASURE
( O
HCVA B_LOCATION/B_ORGANIZATION
and O
LCVA B_LOCATION/B_ORGANIZATION
) O
, O
Pelli B_PERSON
- O
Robson B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
threshold B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
CT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
and O
Goldmann B_MEASURE
perimetry I_MEASURE
( O
Fields B_LOCATION/B_ORGANIZATION
) O
. O

useful B_LOCATION/B_PERSON
Field I_LOCATION/I_PERSON
of O
view B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
UFOV B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
- O
a O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
visual B_DISEASE/B_ORGANISM_FUNCTION
attention I_DISEASE/I_ORGANISM_FUNCTION
) O
was O
also O
undertaken O
. O

The O
mean B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
the O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
and O
post B_LOCATION/B_DISEASE
- O
dilatation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
tested O
for O
statistical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
at O
the O
95 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
level I_MEASURE/I_LOCATION
using O
one B_NUMBER[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
tail B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
paired O
t B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Pupillary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dilation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
resulted O
in O
a O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]
deterioration I_DISEASE_ADJECTIVE[DISEASE]
in O
CT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
HCVA B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
only O
. O

Five B_NUMBER[MEASURE]/B_LOCATION
of O
12 B_PERSON
drivers I_PERSON
also O
exhibited O
deterioration B_DISEASE_ADJECTIVE[DISEASE]
in O
LCVA B_LOCATION/B_ORGANIZATION
, O
CT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
RT B_LOCATION
. O

Little B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
emerged O
for O
deterioration B_DISEASE_ADJECTIVE[DISEASE]
in O
fields B_DISEASE/B_PROTEIN[GENE]
and O
UFOV B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Also O
, O
7 B_NUMBER[MEASURE]/B_ORGANIZATION
of O
12 B_MEASURE/B_PERSON
drivers B_MEASURE/I_PERSON
appeared O
to O
adjust O
their O
driving O
behaviour B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
by O
reducing O
their O
speed B_MEASURE/B_SPORT[ENT]
on O
the O
driving O
simulator B_LOCATION/B_PERSON
, O
leading O
to O
improved B_DISEASE/B_LOCATION
steering I_DISEASE/I_LOCATION
accuracy I_DISEASE/I_LOCATION
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Pupillary B_DISEASE/B_PERSON
dilation I_DISEASE/I_PERSON
may O
lead O
to O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]
in O
vision B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
daylight B_DISEASE/B_MEASURE
driving I_DISEASE/I_MEASURE
performance I_DISEASE/I_MEASURE
in O
young B_PERSON/B_DISEASE
people I_PERSON/I_DISEASE
. O

A O
larger B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
a O
broader B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
spectrum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
subjects B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
warranted O
before O
guidelines B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
can O
be O
recommended O
. O

A O
case B_PERSON/B_MEASURE
of O
isotretinoin B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
embryopathy B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
with O
bilateral B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
anotia I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
Taussig B_PERSON
- O
Bing B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
malformation I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

We O
report O
a O
newborn O
infant O
with O
multiple O
congenital O
anomalies O
( O
anotia O
and O
Taussig O
- O
Bing O
malformation O
) O
due O
to O
exposure O
to O
isotretinoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O
the O
first O
trimester O
. O

In O
this O
paper O
we O
aim O
to O
draw O
to O
the O
fact O
that O
caution O
is O
needed O
when O
prescribing O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
containing O
drugs O
to O
women O
of O
childbearing O
years O
. O

Effect O
of O
methoxamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
maximum O
urethral O
pressure O
in O
women O
with O
genuine O
stress O
incontinence O
: O
a O
placebo O
- O
controlled O
, O
double O
- O
blind O
crossover O
study O
. O

The O
aim B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
to O
evaluate O
the O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
a O
selective B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha1 I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
adrenoceptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
urinary B_DISEASE/B_LOCATION
stress I_DISEASE/I_LOCATION
incontinence I_DISEASE/I_LOCATION
. O

A O
randomised B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
double B_MEASURE/B_COLOR
- O
blind B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
placebo B_LOCATION/B_PERSON
- O
controlled O
, O
crossover B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
design I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
employed O
. O

Half O
log O
incremental O
doses O
of O
intravenous O
methoxamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
placebo O
( O
saline O
) O
were O
administered O
to O
a O
group O
of O
women O
with O
genuine O
stress O
incontinence O
while O
measuring O
maximum O
urethral O
pressure O
( O
MUP O
) O
, O
blood O
pressure O
, O
heart O
rate O
, O
and O
symptomatic O
side O
effects O
. O

Methoxamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
evoked O
non O
- O
significant O
increases O
in O
MUP O
and O
diastolic O
blood O
pressure O
but O
caused O
a O
significant O
rise O
in O
systolic O
blood O
pressure O
and O
significant O
fall O
in O
heart O
rate O
at O
maximum O
dosage O
. O

Systemic B_DISEASE_ADJECTIVE[DISEASE]
side I_DISEASE_ADJECTIVE[DISEASE]
effects I_DISEASE_ADJECTIVE[DISEASE]
including O
piloerection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
headache B_DISEASE
, O
and O
cold B_DISEASE
extremities I_DISEASE
were O
experienced O
in O
all O
subjects B_PERSON
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O
that O
the O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
usefulness I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
peripherally O
acting O
sub B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
type B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
selective B_PROTEIN[GENE]/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alpha1 I_PROTEIN[GENE]/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
adrenoceptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agonists I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
medical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
stress B_DISEASE/B_LOCATION
incontinence I_DISEASE/I_LOCATION
may O
be O
limited O
by O
associated O
piloerection B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
cardiovascular B_DISEASE
side I_DISEASE
effects I_DISEASE
. O

Hyperglycemic O
effect O
of O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
compounds O
structurally O
related O
to O
caproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
rats O
. O

The O
chronic O
feeding O
of O
small O
amounts O
( O
0 O
. O
3 O
- O
3 O
% O
of O
diet O
weight O
) O
of O
certain O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivatives O
of O
caproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O
in O
hyperglycemia O
, O
an O
elevated O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
tolerance O
curve O
and O
, O
occasionally O
, O
glucosuria O
. O

effective O
compounds O
included O
norleucine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
norvaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
epsilon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminocaproate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
methionine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
leucine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Toleration O
of O
high O
doses O
of O
angiotensin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
converting I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
patients O
with O
chronic O
heart O
failure O
: O
results O
from O
the O
Atlas O
trial O
. O

The O
Assessment O
of O
Treatment O
with O
Lisinopril B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Survival O
. O

Background O
: O
Treatment O
with O
angiotensin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
converting I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ACE I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reduces O
mortality O
and O
morbidity O
in O
patients O
with O
chronic O
heart O
failure O
( O
CHF O
) O
, O
but O
most O
affected O
patients O
are O
not O
receiving O
these O
agents O
or O
are O
being O
treated O
with O
doses O
lower O
than O
those O
found O
to O
be O
efficacious O
in O
trials O
, O
primarily O
because O
of O
concerns O
about O
the O
safety O
and O
tolerability O
of O
these O
agents O
, O
especially O
at O
the O
recommended O
doses O
. O

The O
present O
study O
examines O
the O
safety O
and O
tolerability O
of O
high O
- O
compared O
with O
low O
- O
dose O
lisinopril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
CHF O
. O

methods O
: O
The O
Assessment O
of O
Lisinopril B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
Survival O
study O
was O
a O
multicenter O
, O
randomized O
, O
double O
- O
blind O
trial O
in O
which O
patients O
with O
or O
without O
previous O
ACE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
treatment O
were O
stabilized O
receiving O
medium O
- O
dose O
lisinopril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
12 O
. O
5 O
or O
15 O
. O
0 O
mg O
once O
daily O
[ O
OD O
] O
) O
for O
2 O
to O
4 O
weeks O
and O
then O
randomized O
to O
high O
- O
( O
35 O
. O
0 O
or O
32 O
. O
5 O
mg O
OD O
) O
or O
low O
- O
dose O
( O
5 O
. O
0 O
or O
2 O
. O
5 O
mg O
OD O
) O
groups O
. O

patients B_PERSON
with O
New B_DISEASE_ADJECTIVE[DISEASE]
York I_DISEASE_ADJECTIVE[DISEASE]
Heart I_DISEASE_ADJECTIVE[DISEASE]
Association I_DISEASE_ADJECTIVE[DISEASE]
classes I_DISEASE_ADJECTIVE[DISEASE]
II I_DISEASE_ADJECTIVE[DISEASE]
to O
IV B_SEQUENCE[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
CHF I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
left O
ventricular B_MEASURE/B_DISEASE
ejection I_MEASURE/I_DISEASE
fractions I_MEASURE/I_DISEASE
of O
no O
greater B_MEASURE
than O
0 B_MEASURE
. O
30 B_MEASURE
( O
n B_OTHER/B_LOCATION
= O
3164 B_MEASURE
) O
were O
randomized O
and O
followed O
up O
for O
a O
median B_MEASURE
of O
46 B_NUMBER[MEASURE]
months I_NUMBER[MEASURE]
. O

We O
examined O
the O
occurrence B_DISEASE/B_MEASURE
of O
adverse B_DISEASE
events I_DISEASE
and O
the O
need B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
discontinuation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
with O
a O
focus B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
hypotension B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
renal B_DISEASE
dysfunction I_DISEASE
. O

Results O
: O
Of O
405 O
patients O
not O
previously O
receiving O
an O
ACE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
doses O
in O
only O
4 O
. O
2 O
% O
could O
not O
be O
titrated O
to O
the O
medium O
doses O
required O
for O
randomization O
because O
of O
symptoms O
possibly O
related O
to O
hypotension O
( O
2 O
. O
0 O
% O
) O
or O
because O
of O
renal O
dysfunction O
or O
hyperkalemia O
( O
2 O
. O
3 O
% O
) O
. O

doses B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
more B_MEASURE
than O
90 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
of O
randomized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patients B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
the O
high B_MEASURE/B_LOCATION
- O
and O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
dose B_MEASURE/B_LOCATION
groups B_MEASURE/I_LOCATION
were O
titrated O
to O
their O
assigned O
target B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
and O
the O
mean B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
blinded B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medication I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remained O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
throughout O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Withdrawals B_DISEASE
occurred O
in O
27 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
of O
the O
high B_MEASURE/B_LOCATION
- O
and O
30 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
dose B_MEASURE/B_LOCATION
groups B_MEASURE/I_LOCATION
. O

Subgroups O
presumed O
to O
be O
at O
higher O
risk O
for O
ACE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intolerance O
( O
blood O
pressure O
, O
< O
120 O
mm O
Hg O
; O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
> O
or O
= O
132 O
. O
6 O
micromol O
/ O
L O
[ O
> O
or O
= O
1 O
. O
5 O
mg O
/ O
DL O
] O
; O
age O
, O
> O
or O
= O
70 O
years O
; O
and O
patients O
with O
diabetes O
) O
generally O
tolerated O
the O
high O
- O
dose O
strategy O
. O

conclusions O
: O
These O
findings O
demonstrate O
that O
ACE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
in O
most O
patients O
with O
CHF O
can O
be O
successfully O
titrated O
to O
and O
maintained O
at O
high O
doses O
, O
and O
that O
more O
aggressive O
use O
of O
these O
agents O
is O
warranted O
. O

Cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
cocaethylene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiotoxity O
in O
an O
animal O
model O
of O
cocaine O
and O
ethanol O
abuse O
. O

objectives B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Simultaneous B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
abuse B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
affects O
12 B_PERSON/B_ENT
million I_PERSON/I_ENT
Americans I_PERSON/I_ENT
annually O
. O

In O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
these O
substances B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
substantially O
more O
toxic B_DISEASE_ADJECTIVE[DISEASE]
than O
either O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
alone O
. O

Their O
combined O
cardiac O
toxicity O
may O
be O
due O
to O
independent O
effects O
of O
each O
drug O
; O
however O
, O
they O
may O
also O
be O
due O
to O
cocaethylene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
, O
a O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolite O
formed O
only O
in O
the O
presence O
of O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
purpose O
of O
this O
study O
was O
to O
delineate O
the O
role O
of O
CE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
combined O
cardiotoxicity O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
model O
simulating O
their O
abuse O
. O

methods O
: O
Twenty O
- O
three O
dogs O
were O
randomized O
to O
receive O
either O
1 O
) O
three O
intravenous O
( O
IV O
) O
boluses O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 O
. O
5 O
mg O
/ O
kg O
with O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 O
g O
/ O
kg O
) O
as O
an O
IV O
infusion O
( O
C O
+ O
E O
, O
n O
= O
8 O
) O
, O
2 O
) O
three O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
boluses O
only O
( O
C O
, O
n O
= O
6 O
) O
, O
3 O
) O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
only O
( O
E O
, O
n O
= O
5 O
) O
, O
or O
4 O
) O
placebo O
boluses O
and O
infusion O
( O
n O
= O
4 O
) O
. O

hemodynamic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
electrocardiograms B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
serum B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
obtained O
at O
baseline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
and O
then O
at O
fixed O
time B_MEASURE/B_LOCATION
intervals I_MEASURE/I_LOCATION
after O
each O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Two B_NUMBER[MEASURE]
of O
eight B_PERSON/B_ENT
dogs I_PERSON/I_ENT
in O
the O
C B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
E I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
experienced O
cardiovascular B_DISEASE
collapse I_DISEASE
. O

The O
most O
dramatic O
hemodynamic O
changes O
occurred O
after O
each O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bolus O
in O
the O
C O
+ O
E O
and O
C O
only O
groups O
; O
however O
, O
persistent O
hemodynamic O
changes O
occurred O
in O
the O
C O
+ O
E O
group O
. O

Peak O
CE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
were O
associated O
with O
a O
45 O
% O
( O
SD O
+ O
/ O
- O
22 O
% O
, O
95 O
% O
CI O
= O
22 O
% O
to O
69 O
% O
) O
decrease O
in O
cardiac O
output O
( O
p O
< O
0 O
. O
05 O
) O
, O
a O
56 O
% O
( O
SD O
+ O
/ O
- O
23 O
% O
, O
95 O
% O
CI O
= O
32 O
% O
to O
80 O
% O
) O
decrease O
in O
dP O
/ O
dt O
( O
Max O
) O
( O
p O
< O
. O
006 O
) O
, O
and O
a O
23 O
% O
( O
SD O
+ O
/ O
- O
15 O
% O
, O
95 O
% O
CI O
= O
7 O
% O
to O
49 O
% O
) O
decrease O
in O
SVO O
( O
2 O
) O
( O
p O
< O
0 O
. O
025 O
) O
. O

ventricular B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
arrhythmias I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
primarily O
observed O
in O
the O
C B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
+ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
E B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
in O
which O
four B_NUMBER[MEASURE]/B_LOCATION
of O
eight B_PERSON/B_ENT
dogs I_PERSON/I_ENT
experienced O
ventricular B_DISEASE
tachycardia I_DISEASE
. O

conclusions O
: O
Cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
combination O
were O
more O
toxic O
than O
either O
substance O
alone O
. O

Co B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
resulted O
in O
prolonged B_DISEASE
cardiac I_DISEASE
toxicity I_DISEASE
and O
was O
dysrhythmogenic B_DISEASE_ADJECTIVE[DISEASE]
. O

Peak O
serum O
cocaethylene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentrations O
were O
associated O
with O
prolonged O
myocardial O
depression O
. O

Worsening O
of O
Parkinsonism O
after O
the O
use O
of O
veralipride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
treatment O
of O
menopause O
: O
case O
report O
. O

We O
describe O
a O
female O
patient O
with O
stable O
Parkinson O
' O
s O
disease O
who O
has O
shown O
a O
marked O
worsening O
of O
her O
motor O
functions O
following O
therapy O
of O
menopause O
related O
symptoms O
with O
veralipride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
well O
as O
the O
improvement O
of O
her O
symptoms O
back O
to O
baseline O
after O
discontinuation O
of O
the O
drug O
. O

We O
emphasize O
the O
anti O
- O
dopaminergic O
effect O
of O
veralipride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Viracept B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
and O
irregular O
heartbeat O
warning O
. O

A O
group O
of O
doctors O
in O
Boston O
warn O
that O
the O
protease O
inhibitor O
Viracept B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
may O
cause O
an O
irregular O
heart O
beat O
, O
known O
as O
bradycardia O
, O
in O
people O
with O
HIV O
. O

Bradycardia O
occurred O
in O
a O
45 O
- O
year O
- O
old O
male O
patient O
who O
was O
Viracept B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BACTERIUM[BIO]
in O
combination O
with O
other O
anti O
- O
HIV O
drugs O
. O

The O
symptoms B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ceased O
after O
switching O
to O
another O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combination I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

frequency O
of O
appearance O
of O
myeloperoxidase O
- O
antineutrophil O
cytoplasmic O
antibody O
( O
MPO O
- O
ANCA O
) O
in O
Graves O
' O
disease O
patients O
treated O
with O
propylthiouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
relationship O
between O
MPO O
- O
ANCA O
and O
clinical O
manifestations O
. O

objective O
: O
Myeloperoxidase O
antineutrophil O
cytoplasmic O
antibody O
( O
MPO O
- O
ANCA O
) O
- O
positive O
vasculitis O
has O
been O
reported O
in O
patients O
with O
Graves O
' O
disease O
who O
were O
treated O
with O
propylthiouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
. O

The O
appearance O
of O
MPO O
- O
ANCA O
in O
these O
cases O
was O
suspected O
of O
being O
related O
to O
PTU B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O
the O
titres O
of O
MPO O
- O
ANCA O
decreased O
when O
PTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
stopped O
. O

Nevertheless O
, O
there O
have O
been O
no O
studies O
on O
the O
temporal O
relationship O
between O
the O
appearance O
of O
MPO O
- O
ANCA O
and O
vasculitis O
during O
PTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
, O
or O
on O
the O
incidence O
of O
MPO O
- O
ANCA O
in O
untreated O
Graves O
' O
disease O
patients O
. O

Therefore O
, O
we O
sought O
to O
address O
these O
parameters B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients B_PERSON
with O
Graves B_DISEASE/B_LOCATION
' I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
. O

patients O
: O
We O
investigated O
102 O
untreated O
patients O
with O
hyperthyroidism O
due O
to O
Graves O
' O
disease O
for O
the O
presence O
of O
MPO O
- O
ANCA O
, O
and O
for O
the O
development O
vasculitis O
after O
starting O
PTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
therapy O
. O

Twenty O
- O
nine O
of O
them O
were O
later O
excluded O
because O
of O
adverse O
effects O
of O
PTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
because O
the O
observation O
period O
was O
less O
than O
3 O
months O
. O

The O
remaining O
73 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
( O
55 B_MEASURE/B_SPORT[ENT]
women I_MEASURE/I_SPORT[ENT]
and O
18 B_PERSON
men I_PERSON
) O
, O
all O
of O
whom O
were O
examined O
for O
more B_TIME[MEASURE]
than O
3 B_TIME[MEASURE]
months I_TIME[MEASURE]
, O
were O
adopted O
as O
the O
subjects B_PERSON
of O
the O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
median B_TIME[MEASURE]/B_LOCATION
observation I_TIME[MEASURE]/I_LOCATION
period I_TIME[MEASURE]/I_LOCATION
was O
23 B_MEASURE
. O
6 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
range B_LOCATION/B_MEASURE
: O
3 B_MEASURE
- O
37 B_TIME[MEASURE]
months I_TIME[MEASURE]
) O
. O

Measurements B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
MPO B_MEASURE/B_PROTEIN[GENE]
- O
ANCA B_MEASURE/B_DISEASE
was O
measured O
at O
intervals B_MEASURE/B_LOCATION
of O
2 B_NUMBER[MEASURE]
- O
6 B_TIME[MEASURE]
months I_TIME[MEASURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Before O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
the O
MPO B_PROTEIN[GENE]/B_MEASURE
- O
ANCA B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
titres B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
all O
102 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
untreated B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Graves B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
' B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
disease B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
patients B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
within O
the O
reference B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
range B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
below O
10 B_MEASURE
U I_MEASURE
/ O
ml B_MEASURE/B_PERSON
) O
. O

Three O
( O
4 O
. O
1 O
% O
) O
of O
the O
73 O
patients O
were O
positive O
for O
MPO O
- O
ANCA O
at O
13 O
, O
16 O
and O
17 O
months O
, O
respectively O
, O
after O
the O
start O
of O
PTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O
. O

In O
two O
of O
them O
, O
the O
MPO O
- O
ANCA O
titres O
transiently O
increased O
to O
12 O
. O
8 O
and O
15 O
. O
0 O
U O
/ O
ml O
, O
respectively O
, O
despite O
continued O
PTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
, O
but O
no O
vasculitic O
disorders O
developed O
. O

In O
the O
third O
patient O
, O
the O
MPO O
- O
ANCA O
titre O
increased O
to O
204 O
U O
/ O
ml O
and O
she O
developed O
a O
higher O
fever O
, O
oral O
ulcers O
and O
polyarthralgia O
, O
but O
the O
symptoms O
resolved O
2 O
weeks O
after O
stopping O
PTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O
, O
and O
the O
MPO O
- O
ANCA O
titre O
decreased O
to O
20 O
. O
7 O
U O
/ O
ml O
by O
4 O
months O
after O
discontinuing O
PTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusions O
: O
PTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O
may O
be O
related O
to O
the O
appearance O
of O
MPO O
- O
ANCA O
, O
but O
MPO O
- O
ANCA O
does O
not O
appear O
to O
be O
closely O
related O
to O
vasculitis O
. O

prevalence O
of O
heart O
disease O
in O
asymptomatic O
chronic O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
. O

To O
determine O
the O
prevalence O
of O
heart O
disease O
in O
outpatient O
young O
asymptomatic O
chronic O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
users O
, O
35 O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
and O
32 O
age O
- O
matched O
controls O
underwent O
resting O
and O
exercise O
electrocardiography O
( O
ECG O
) O
and O
Doppler O
echocardiography O
. O

findings B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consistent I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
coronary B_DISEASE/B_LOCATION
artery I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
were O
detected O
in O
12 B_MEASURE
( O
34 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
patients B_PERSON
and O
3 B_MEASURE
( O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
controls B_PERSON
( O
p B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

decreased O
left O
ventricular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systolic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
demonstrated O
in O
5 B_NUMBER[MEASURE]
( O
14 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
) O
patients B_PERSON
, O
but O
in O
none B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
controls B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
055 B_MEASURE
) O
. O

Finally O
, O
resting B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
peak B_MEASURE
exercise O
abnormal B_DISEASE
left I_DISEASE
ventricular I_DISEASE
filling I_DISEASE
was O
detected O
in O
38 B_MEASURE
and O
35 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
patients B_PERSON/B_BIO
as O
compared O
to O
19 B_MEASURE
and O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
controls B_PERSON/B_BIO
, O
respectively O
( O
p B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
11 B_MEASURE
and O
0 B_MEASURE
. O
02 B_MEASURE
, O
respectively O
) O
. O

We O
conclude O
that O
coronary O
artery O
or O
myocardial O
disease O
is O
common O
( O
38 O
% O
) O
in O
young O
asymptomatic O
chronic O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
. O

Therefore O
, O
screening O
ECG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
echocardiography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O
be O
warranted O
in O
these O
patients B_PERSON/B_LOCATION
. O

Cardioprotective O
effects O
of O
Picrorrhiza O
kurroa O
against O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
myocardial O
stress O
in O
rats O
. O

The O
cardioprotective O
effect O
of O
the O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
extract O
of O
Picrorrhiza O
kurroa O
rhizomes O
and O
roots O
( O
PK O
) O
on O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
myocardial O
infarction O
in O
rats O
with O
respect O
to O
lipid O
metabolism O
in O
serum O
and O
heart O
tissue O
has O
been O
investigated O
. O

Oral O
pre O
- O
treatment O
with O
PK O
( O
80 O
mg O
kg O
( O
- O
1 O
) O
day O
( O
- O
1 O
) O
for O
15 O
days O
) O
significantly O
prevented O
the O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
myocardial O
infarction O
and O
maintained O
the O
rats O
at O
near O
normal O
status O
. O

Phase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
early I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
afterdepolarization I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
as O
a O
trigger B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
polymorphic B_DISEASE
ventricular I_DISEASE
tachycardia I_DISEASE
in O
acquired O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
QT B_DISEASE/B_LOCATION
syndrome I_DISEASE/I_LOCATION
: O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
from O
intracellular B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recordings B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
intact B_BODY_PART_OR_ORGAN_COMPONENT
left O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT
wall I_BODY_PART_OR_ORGAN_COMPONENT
. O

Background O
: O
This O
study O
examined O
the O
role O
of O
phase O
2 O
early O
afterdepolarization O
( O
EAD O
) O
in O
producing O
a O
trigger O
to O
initiate O
torsade O
de O
pointes O
( O
TdP O
) O
with O
QT O
prolongation O
induced O
by O
DL O
- O
sotalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
azimilide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
contribution B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
transmural B_MEASURE
dispersion I_MEASURE
of O
repolarization B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
TDR B_LOCATION/B_DISEASE
) O
to O
transmural B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
propagation I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
EAD B_DISEASE
and O
the O
maintenance B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
TDP B_PROTEIN[GENE]/B_DISEASE
was O
also O
evaluated O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O
RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
transmembrane B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
action I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
potentials I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
from O
epicardium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
midmyocardium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
endocardium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
were O
recorded O
simultaneously O
, O
together O
with O
a O
transmural B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ECG I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
arterially O
perfused O
canine B_SPECIES[BIO]
and O
rabbit B_SPECIES[BIO]
left O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
preparations I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

DL O
- O
Sotalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preferentially O
prolonged O
action O
potential O
duration O
( O
APD O
) O
in O
M O
cells O
dose O
- O
dependently O
( O
1 O
to O
100 O
micromol O
/ O
L O
) O
, O
leading O
to O
QT O
prolongation O
and O
an O
increase O
in O
TDR O
. O

Azimilide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
however O
, O
significantly O
prolonged O
APD O
and O
QT O
interval O
at O
concentrations O
from O
0 O
. O
1 O
to O
10 O
micromol O
/ O
L O
but O
shortened O
them O
at O
30 O
micromol O
/ O
L O
. O

Unlike O
DL O
- O
sotalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
azimilide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
> O
3 O
micromol O
/ O
L O
) O
increased O
epicardial O
APD O
markedly O
, O
causing O
a O
diminished O
TDR O
. O

Although O
both O
DL O
- O
sotalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
azimilide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rarely O
induced O
EADs O
in O
canine O
left O
ventricles O
, O
they O
produced O
frequent O
EADs O
in O
rabbits O
, O
in O
which O
more O
pronounced O
QT O
prolongation O
was O
seen O
. O

An O
increase O
in O
TDR O
by O
DL O
- O
sotalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
facilitated O
transmural O
propagation O
of O
EADs O
that O
initiated O
multiple O
episodes O
of O
spontaneous O
TdP O
in O
3 O
of O
6 O
rabbit O
left O
ventricles O
. O

Of O
note O
, O
although O
azimilide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3 O
to O
10 O
micromol O
/ O
L O
) O
increased O
APD O
more O
than O
DL O
- O
sotalol B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
its O
EADs O
often O
failed O
to O
propagate O
transmurally O
, O
probably O
because O
of O
a O
diminished O
TDR O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
direct I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O
intracellular B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
action I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
potential I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
recordings I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
that O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
EAD B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
can O
be O
generated O
from O
intact B_BODY_PART_OR_ORGAN_COMPONENT
ventricular I_BODY_PART_OR_ORGAN_COMPONENT
wall I_BODY_PART_OR_ORGAN_COMPONENT
and O
produce O
a O
trigger B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
initiate O
the O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
TDP B_PROTEIN[GENE]/B_DISEASE
under O
QT B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prolongation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

A O
pilot O
study O
to O
assess O
the O
safety O
of O
dobutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress O
echocardiography O
in O
the O
emergency O
department O
evaluation O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
chest O
pain O
. O

Study O
objective O
: O
chest O
pain O
in O
the O
setting O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
poses O
a O
diagnostic O
dilemma O
. O

Dobutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
stress O
echocardiography O
( O
DSE O
) O
is O
a O
widely O
available O
and O
sensitive O
test O
for O
evaluating O
cardiac O
ischemia O
. O

Because O
of O
the O
theoretical O
concern O
regarding O
administration O
of O
dobutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
setting O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
, O
we O
conducted O
a O
pilot O
study O
to O
assess O
the O
safety O
of O
DSE O
in O
emergency O
department O
patients O
with O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
chest O
pain O
. O

methods B_MEASURE
: O
A O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
case I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
series I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
conducted O
in O
the O
intensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
diagnostic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
unit I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
in O
the O
Ed B_PERSON/B_LOCATION
of O
an O
urban B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
tertiary I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- O
care B_LOCATION/B_ORGANIZATION
teaching I_LOCATION/I_ORGANIZATION
hospital I_LOCATION/I_ORGANIZATION
. O

patients O
were O
eligible O
for O
DSE O
if O
they O
had O
used O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O
24 O
hours O
preceding O
the O
onset O
of O
chest O
pain O
and O
had O
a O
normal O
ECG O
and O
tropinin O
I O
level O
. O

patients O
exhibiting O
signs O
of O
continuing O
cocaine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
toxicity O
were O
excluded O
from O
the O
study O
. O

All O
patients B_PERSON
were O
admitted O
to O
the O
hospital B_LOCATION/B_ORGANIZATION
for O
serial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
testing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O
the O
DSE B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
testing I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
in O
the O
intensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
diagnostic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
unit I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Twenty B_NUMBER[MEASURE]
- O
four B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
were O
enrolled O
. O

Two B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
had O
inadequate B_DISEASE/B_LOCATION
resting I_DISEASE/I_LOCATION
images I_DISEASE/I_LOCATION
, O
one B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
DSE I_NUMBER[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
terminated O
because O
of O
inferior B_DISEASE
hypokinesis I_DISEASE
, O
another O
DSE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
terminated O
because O
of O
a O
rate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O
related O
atrial B_DISEASE
conduction I_DISEASE
deficit I_DISEASE
, O
and O
1 B_PERSON/B_NUMBER[MEASURE]
patient B_PERSON/I_NUMBER[MEASURE]
did O
not O
reach O
the O
target B_MEASURE/B_LOCATION
heart B_MEASURE/I_LOCATION
rate B_MEASURE/I_LOCATION
. O

Thus O
, O
19 B_PERSON
patients I_PERSON
completed O
a O
DSE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
reached O
their O
target B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
heart I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
rates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

None B_PERSON/B_NUMBER[MEASURE]
of O
the O
patients B_PERSON
experienced O
signs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
exaggerated B_DISEASE
adrenergic I_DISEASE
response I_DISEASE
, O
which O
was O
defined O
as O
a O
systolic B_DISEASE/B_MEASURE
blood B_DISEASE/I_MEASURE
pressure B_DISEASE/I_MEASURE
of O
greater B_MEASURE
than O
200 B_NUMBER[MEASURE]
mm I_NUMBER[MEASURE]
Hg I_NUMBER[MEASURE]
or O
the O
occurrence B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tachydysrhythmias B_DISEASE
( O
excluding O
sinus B_DISEASE
tachycardia I_DISEASE
) O
. O

Further O
suggesting O
lack O
of O
exaggerated O
adrenergic O
response O
, O
13 O
( O
65 O
% O
) O
of O
20 O
patients O
required O
supplemental O
atropine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
reach O
their O
target O
heart O
rates O
. O

conclusion O
: O
No O
exaggerated O
adrenergic O
response O
was O
detected O
when O
dobutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
to O
patients O
with O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
related O
chest O
pain O
. O

Prenatal O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O
and O
cranial O
sonographic O
findings O
in O
preterm O
infants O
. O

purpose O
: O
Prenatal O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O
has O
been O
linked O
with O
subependymal O
hemorrhage O
and O
the O
formation O
of O
cysts O
that O
are O
detectable O
on O
cranial O
sonography O
in O
neonates O
born O
at O
term O
. O

We O
sought O
to O
determine O
if O
prenatal O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O
increases O
the O
incidence O
of O
subependymal O
cysts O
in O
preterm O
infants O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
retrospectively O
reviewed O
the O
medical B_BODY_PART_OR_ORGAN_COMPONENT/B_ORGANIZATION
records I_BODY_PART_OR_ORGAN_COMPONENT/I_ORGANIZATION
and O
cranial B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sonograms I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O
during O
a O
1 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
period I_TIME[MEASURE]
on O
122 B_NUMBER[MEASURE]/B_PERSON
premature I_NUMBER[MEASURE]/I_PERSON
( O
< B_TIME[MEASURE]/B_LOCATION
36 I_TIME[MEASURE]/I_LOCATION
weeks I_TIME[MEASURE]/I_LOCATION
of O
gestation B_ORGANISM_FUNCTION
) O
infants B_PERSON/B_BIO
. O

infants O
were O
categorized O
into O
1 O
of O
2 O
groups O
: O
those O
exposed O
to O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
those O
not O
exposed O
to O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

infants O
were O
assigned O
to O
the O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
exposed O
group O
if O
there O
was O
a O
maternal O
history O
of O
cocaine O
abuse O
during O
pregnancy O
or O
if O
maternal O
or O
neonatal O
urine O
toxicology O
results O
were O
positive O
at O
the O
time O
of O
delivery O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Five B_NUMBER[MEASURE]
of O
the O
122 B_PERSON
infants I_PERSON
were O
excluded O
from O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O
of O
insufficient B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
medical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O
drug B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
histories I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
incidence B_MEASURE
of O
subependymal B_DISEASE
cysts I_DISEASE
in O
the O
117 B_NUMBER[MEASURE]
remaining O
infants B_PERSON/B_DISEASE
was O
14 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
( O
16 B_MEASURE/B_LOCATION
of O
117 B_MEASURE/B_PERSON
) O
. O

The O
incidence O
of O
subependymal O
cysts O
in O
infants O
exposed O
to O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prenatally O
was O
44 O
% O
( O
8 O
of O
18 O
) O
compared O
with O
8 O
% O
( O
8 O
of O
99 O
) O
in O
the O
unexposed O
group O
( O
p O
< O
0 O
. O
01 O
) O
. O

conclusions O
: O
We O
found O
an O
increased O
incidence O
of O
subependymal O
cyst O
formation O
in O
preterm O
infants O
who O
were O
exposed O
to O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prenatally O
. O

This O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
term B_LOCATION
infants I_LOCATION
. O

Thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
neuropathy O
in O
patients O
treated O
for O
metastatic O
prostate O
cancer O
. O

We O
prospectively O
evaluated O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
neuropathy O
using O
electrodiagnostic O
studies O
. O

sixty O
- O
seven O
men O
with O
metastatic O
androgen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
independent O
prostate O
cancer O
in O
an O
open O
- O
label O
trial O
of O
oral O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
underwent O
neurologic O
examinations O
and O
nerve O
conduction O
studies O
( O
NCS O
) O
prior O
to O
and O
at O
3 O
- O
month O
intervals O
during O
treatment O
. O

NCS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
included O
recording B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
sensory B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nerve B_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action B_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentials B_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
snaps B_DISEASE
) O
from O
median B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
, O
radial B_BODY_PART_OR_ORGAN_COMPONENT
, O
ulnar B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
sural B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nerves I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

SNAP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
amplitudes B_MEASURE/B_ENT
for O
each O
nerve B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
were O
expressed O
as O
the O
percentage B_MEASURE
of O
its O
baseline B_MEASURE/B_LOCATION
, O
and O
the O
mean B_MEASURE
of O
the O
four B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
was O
termed O
the O
snap B_MEASURE/B_LOCATION
index I_MEASURE/I_LOCATION
. O

A O
40 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
decline I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
SNAP B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
index I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
considered O
clinically O
significant B_DISEASE_ADJECTIVE[DISEASE]
. O

Thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
discontinued O
in O
55 O
patients O
for O
lack O
of O
therapeutic O
response O
. O

Of O
67 O
patients O
initially O
enrolled O
, O
24 O
remained O
on O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
3 O
months O
, O
8 O
remained O
at O
6 O
months O
, O
and O
3 O
remained O
at O
9 O
months O
. O

Six B_PERSON/B_LOCATION
patients I_PERSON/I_LOCATION
developed O
neuropathy B_DISEASE
. O

Clinical B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
symptoms I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
a O
decline B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
SNAP B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
index I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
occurred O
concurrently O
. O

Older B_MEASURE
age I_MEASURE
and O
cumulative B_MEASURE/B_PERSON
dose B_MEASURE/I_PERSON
were O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contributing O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

Neuropathy O
may O
thus O
be O
a O
common O
complication O
of O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
older O
patients O
. O

The O
SNAP B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
index I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
can O
be O
used O
to O
monitor O
peripheral B_DISEASE_ADJECTIVE[DISEASE]
neuropathy I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
not O
for O
early B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
detection I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Overexpression O
of O
copper B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ O
zinc B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
dismutase O
protects O
from O
kanamycin B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hearing O
loss O
. O

The O
participation O
of O
reactive O
oxygen B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species O
in O
aminoglycoside B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
ototoxicity O
has O
been O
deduced O
from O
observations O
that O
aminoglycoside B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
iron B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complexes O
catalyze O
the O
formation O
of O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radicals O
in O
vitro O
and O
that O
antioxidants O
attenuate O
ototoxicity O
in O
vivo O
. O

We O
therefore O
hypothesized O
that O
overexpression O
of O
Cu B_LOCATION
/ O
Zn B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dismutase O
( O
h O
- O
SOD1 O
) O
should O
protect O
transgenic O
mice O
from O
ototoxicity O
. O

immunocytochemistry B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
confirmed O
expression B_GENE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
h O
- O
SOD1 B_GENE
in O
inner B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ear I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
tissues I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
transgenic B_GENE/B_MEASURE
C57BL I_GENE/I_MEASURE
/ O
6 B_MEASURE
- O
TgN B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SOD1 I_GENE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O
3Cje B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
mice I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Transgenic O
and O
nontransgenic O
littermates O
received O
kanamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O
400 O
mg O
/ O
kg O
body O
weight O
/ O
day O
) O
for O
10 O
days O
beginning O
on O
day O
10 O
after O
birth O
. O

Auditory B_PERSON/B_ORGANIZATION
thresholds I_PERSON/I_ORGANIZATION
were O
tested O
by O
evoked B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
auditory I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
brain I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
stem O
responses B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O
1 B_TIME[MEASURE]/B_LOCATION
month I_TIME[MEASURE]/I_LOCATION
after O
birth B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

In O
nontransgenic O
animals O
, O
the O
threshold O
in O
the O
kanamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
treated O
group O
was O
45 O
- O
50 O
DB O
higher O
than O
in O
saline O
- O
injected O
controls O
. O

In O
the O
transgenic O
group O
, O
kanamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
increased O
the O
threshold O
by O
only O
15 O
DB O
over O
the O
respective O
controls O
. O

The O
effects B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O
12 B_MEASURE
and O
24 B_MEASURE/B_LOCATION
kHz I_MEASURE/I_LOCATION
. O

The O
protection O
by O
overexpression O
of O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dismutase O
supports O
the O
hypothesis O
that O
oxidant O
stress O
plays O
a O
significant O
role O
in O
aminoglycoside B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
ototoxicity O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
also O
suggest O
transgenic B_SPECIES[BIO]/B_PERSON
animals I_SPECIES[BIO]/I_PERSON
as O
suitable B_PERSON/B_LOCATION
models I_PERSON/I_LOCATION
to O
investigate O
the O
underlying O
mechanisms B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
possible B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
strategies I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
for O
prevention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

fatty O
liver O
induced O
by O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
the O
rat O
. O

dose B_TIME[MEASURE]/B_PERSON
- O
response B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
relationships I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
effect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
sex B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

dose O
- O
response O
relationships O
, O
biochemical O
mechanisms O
, O
and O
sex O
differences O
in O
the O
experimental O
fatty O
liver O
induced O
by O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
studied O
in O
the O
intact O
rat O
and O
with O
the O
isolated O
perfused O
rat O
liver O
in O
vitro O
. O

In O
the O
intact O
male O
and O
female O
rat O
, O
no O
direct O
relationship O
was O
observed O
between O
dose O
of O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
hepatic O
accumulation O
of O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

With O
provision O
of O
adequate O
oleic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
substrate O
for O
the O
isolated O
perfused O
liver O
, O
a O
direct O
relationship O
was O
observed O
between O
dose O
of O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
both O
accumulation O
of O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
liver O
and O
depression O
of O
output O
of O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
livers O
from O
male O
and O
female O
rats O
. O

marked O
differences O
were O
observed O
between O
female O
and O
male O
rats O
with O
regard O
to O
base O
line O
( O
control O
) O
hepatic O
concentration O
of O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
output O
of O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

accumulation O
of O
hepatic O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
as O
a O
per O
cent O
of O
control O
values O
, O
in O
response O
to O
graded O
doses O
of O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
did O
not O
differ O
significantly O
between O
male O
, O
female O
and O
pregnant O
rat O
livers O
. O

However O
, O
livers O
from O
female O
, O
and O
especially O
pregnant O
female O
rats O
, O
were O
strikingly O
resistant O
to O
the O
effects O
of O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
depression O
of O
output O
of O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
under O
these O
experimental O
conditions O
. O

These O
differences O
between O
the O
sexes O
could O
not O
be O
related O
to O
altered O
disposition O
of O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
altered O
uptake O
of O
oleic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

depressed O
hepatic O
secretion O
of O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
accounted O
only O
for O
30 O
to O
50 O
% O
of O
accumulated O
hepatic O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
indicating O
that O
additional O
mechanisms O
must O
be O
involved O
in O
the O
production O
of O
the O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
rich O
fatty O
liver O
in O
response O
to O
tetracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Prednisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induces O
anxiety O
and O
glial O
cerebral O
changes O
in O
rats O
. O

objective O
: O
To O
assess O
whether O
prednisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PDN B_DISEASE/B_PROTEIN[GENE]
) O
produces O
anxiety O
and O
/ O
or O
cerebral O
glial O
changes O
in O
rats O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Male B_BIO/B_GENE
Wistar I_BIO/I_GENE
rats I_BIO/I_GENE
were O
studied O
and O
3 B_ORGANIZATION/B_PERSON
groups I_ORGANIZATION/I_PERSON
were O
formed O
( O
8 B_NUMBER[MEASURE]
rats I_NUMBER[MEASURE]
per O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
moderate O
- O
dose O
group O
received O
5 O
mg O
/ O
kg O
/ O
day O
PDN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
released O
from O
a O
subcutaneous O
implant O
. O

In O
the O
high O
- O
dose O
group O
, O
implants O
containing O
PDN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
equivalent O
to O
60 O
mg O
/ O
kg O
/ O
day O
were O
applied O
. O

In O
the O
control O
group O
implants O
contained O
no O
PDN B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Anxiety B_DISEASE
was O
assessed O
using O
an O
open B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
field I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
elevated O
plus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
maze B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
devices I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
number B_MEASURE/B_LOCATION
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
and O
cytoplasmic B_MEASURE/B_LOCATION
transformation I_MEASURE/I_LOCATION
of O
astrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
microglia B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
assessed O
by O
immunohistochemical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
anxiety O
was O
documented O
in O
both O
groups O
of O
PDN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
treated O
rats O
compared O
with O
controls O
. O

The O
magnitude O
of O
transformation O
of O
the O
microglia O
assessed O
by O
the O
number O
of O
intersections O
was O
significantly O
higher O
in O
the O
PDN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
groups O
than O
in O
controls O
in O
the O
prefrontal O
cortex O
( O
moderate O
- O
dose O
, O
24 O
. O
1 O
; O
high O
- O
dose O
, O
23 O
. O
6 O
; O
controls O
18 O
. O
7 O
; O
p O
< O
0 O
. O
01 O
) O
and O
striatum O
( O
moderate O
- O
dose O
25 O
. O
6 O
; O
high O
- O
dose O
26 O
. O
3 O
; O
controls O
18 O
. O
9 O
; O
p O
< O
0 O
. O
01 O
) O
, O
but O
not O
in O
hippocampus O
. O

The O
number O
of O
stained O
microglia O
cells O
was O
significantly O
higher O
in O
the O
PDN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
treated O
groups O
in O
the O
prefrontal O
cortex O
than O
in O
controls O
( O
moderate O
- O
dose O
, O
29 O
. O
1 O
; O
high O
- O
dose O
, O
28 O
. O
4 O
; O
control O
, O
17 O
. O
7 O
cells O
per O
field O
; O
p O
< O
0 O
. O
01 O
) O
. O

stained O
microglia B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
cells I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
were O
significantly O
more O
numerous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
striatum I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
high B_MEASURE/B_LOCATION
- O
dose B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O
to O
controls B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

conclusion O
: O
Subacute O
exposure O
to O
PDN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induced O
anxiety O
and O
reactivity O
of O
microglia O
. O

The O
relevance O
of O
these O
features O
for O
patients O
using O
PDN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
remains O
to O
be O
elucidated O
. O

Phase O
II O
study O
of O
carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
liposomal O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients O
with O
recurrent O
squamous O
cell O
carcinoma O
of O
the O
cervix O
. O

Background O
: O
The O
activity O
of O
the O
combination O
of O
carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
liposomal O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
tested O
in O
a O
Phase O
II O
study O
of O
patients O
with O
recurrent O
cervical O
carcinoma O
. O

methods O
: O
The O
combination O
of O
carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
area O
under O
the O
concentration O
curve O
[ O
AUC O
] O
, O
5 O
) O
and O
liposomal O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Doxil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
; O
starting O
dose O
, O
40 O
mg O
/ O
m O
( O
2 O
) O
) O
was O
administered O
intravenously O
every O
28 O
days O
to O
37 O
patients O
with O
recurrent O
squamous O
cell O
cervical O
carcinoma O
to O
determine O
antitumor O
activity O
and O
toxicity O
profile O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Twenty B_NUMBER[MEASURE]
- O
nine B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
were O
assessable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
35 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
were O
assessable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
overall B_MEASURE
response I_MEASURE
rate I_MEASURE
was O
38 B_MEASURE
% I_MEASURE
, O
the O
median B_MEASURE/B_LOCATION
time I_MEASURE/I_LOCATION
to O
response O
was O
10 B_MEASURE/B_ENT
weeks I_MEASURE/I_ENT
, O
the O
median B_MEASURE/B_LOCATION
duration I_MEASURE/I_LOCATION
of O
response B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
26 B_MEASURE/B_ENT
weeks I_MEASURE/I_ENT
, O
and O
the O
median B_MEASURE
survival I_MEASURE
was O
37 B_MEASURE/B_ENT
weeks I_MEASURE/I_ENT
. O

The O
main B_DISEASE_ADJECTIVE[DISEASE]
toxic I_DISEASE_ADJECTIVE[DISEASE]
effect I_DISEASE_ADJECTIVE[DISEASE]
was O
myelosuppression B_DISEASE
, O
with O
Grade B_MEASURE/B_DISEASE
3 I_MEASURE/I_DISEASE
and O
4 B_DISEASE/B_MEASURE
neutropenia I_DISEASE/I_MEASURE
in O
16 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
, O
anemia B_DISEASE
in O
12 B_TIME[MEASURE]
patients I_TIME[MEASURE]
, O
thrombocytopenia B_DISEASE
in O
11 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
, O
and O
neutropenic B_DISEASE
fever I_DISEASE
in O
3 B_NUMBER[MEASURE]/B_PERSON
patients B_NUMBER[MEASURE]/I_PERSON
. O

Four O
patients O
had O
five O
infusion O
- O
related O
reactions O
during O
the O
infusion O
of O
liposomal O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
leading O
to O
treatment O
discontinuation O
in O
three O
patients O
. O

Grade B_MEASURE/B_PERSON
> I_MEASURE/I_PERSON
or O
= O
2 B_MEASURE
nonhematologic I_MEASURE
toxicity I_MEASURE
included O
nausea B_DISEASE
in O
17 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
, O
emesis B_DISEASE
in O
14 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
, O
fatigue B_DISEASE
in O
9 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
, O
mucositis B_DISEASE
and O
/ O
or O
stomatitis B_DISEASE
in O
8 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
, O
constipation B_DISEASE
in O
6 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
, O
weight B_DISEASE
loss I_DISEASE
in O
5 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
, O
hand B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
- O
foot B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
syndrome B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
2 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
, O
and O
skin B_DISEASE
reactions I_DISEASE
in O
3 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
. O

conclusions O
: O
The O
combination O
of O
carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
liposomal O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
modest O
activity O
in O
patients O
with O
recurrent O
cervical O
carcinoma O
. O

Antimicrobial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
mania B_DISEASE
( O
antibiomania B_DISEASE/B_MEASURE
) O
: O
a O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
spontaneous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
authors B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reviewed O
reported O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
antibiotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
manic I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
episodes I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
by O
means B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
MEDLINE B_ORGANIZATION
and O
PsychLit B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
search B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
for O
reports B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
antibiotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
mania B_DISEASE
. O

Unpublished B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
requested O
from O
the O
World B_ORGANIZATION/B_PERSON
Health I_ORGANIZATION/I_PERSON
Organization I_ORGANIZATION/I_PERSON
( O
WHO B_ORGANIZATION/B_LOCATION
) O
and O
the O
Food B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Drug B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Administration I_ORGANIZATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
FDA B_ORGANIZATION/B_LOCATION
) O
. O

Twenty B_NUMBER[MEASURE]/B_LOCATION
- O
one B_NUMBER[MEASURE]/B_ORGANIZATION
reports I_NUMBER[MEASURE]/I_ORGANIZATION
of O
antimicrobial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
mania B_DISEASE
were O
found O
in O
the O
literature B_PERSON/B_LOCATION
. O

There O
were O
6 O
cases O
implicating O
clarithromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
13 O
implicating O
isoniazid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
1 O
case O
each O
implicating O
erythromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
amoxicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
WHO O
reported O
82 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Of O
these O
, O
clarithromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
implicated O
in O
23 O
( O
27 O
. O
6 O
% O
) O
cases O
, O
ciprofloxacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
12 O
( O
14 O
. O
4 O
% O
) O
cases O
, O
and O
ofloxacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
10 O
( O
12 O
% O
) O
cases O
. O

Cotrimoxazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
metronidazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
erythromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
involved O
in O
15 O
reported O
manic O
episodes O
. O

cases O
reported O
by O
the O
FDA O
showed O
clarithromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ciprofloxacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
be O
the O
most O
frequently O
associated O
with O
the O
development O
of O
mania O
. O

Statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
would O
not O
have O
demonstrated O
a O
significant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
statistical I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
correlative I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
risk I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
was O
therefore O
not O
undertaken O
. O

patients B_PERSON/B_BIO
have O
an O
increased O
risk B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
developing O
mania B_DISEASE
while O
being O
treated O
with O
antimicrobials B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Although O
this O
is O
not O
a O
statistically O
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
risk I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
physicians B_PERSON
must O
be O
aware B_PERSON
of O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
reversibility B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clearly O
is O
required O
to O
determine O
the O
incidence B_MEASURE
of O
antimicrobial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
mania B_DISEASE
, O
the O
relative B_MEASURE
risk I_MEASURE
factors I_MEASURE
of O
developing O
an O
antimicrobial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
manic B_DISEASE
episode I_DISEASE
among O
various B_PERSON
demographic I_PERSON
populations I_PERSON
, O
and O
the O
incidence B_MEASURE
of O
patients B_PERSON
who O
continue O
to O
have O
persistent B_DISEASE
affective I_DISEASE
disorders I_DISEASE
once O
the O
initial B_DISEASE
episode I_DISEASE
, O
which O
occurs O
while O
the O
patient B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
is O
taking O
antibiotics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
subsides B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O

The O
authors B_PERSON/B_ORGANIZATION
elected O
to O
name O
this O
syndrome B_DISEASE/B_BIO
' O
antibiomania B_BACTERIUM[BIO]/B_GENE
. O
' O
. O

Levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
ocular O
dyskinesias O
in O
Parkinson O
' O
s O
disease O
. O

Levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
ocular O
dyskinesias O
are O
very O
uncommon O
. O

Usually O
they O
occur O
simultaneously O
with O
limb B_MEASURE/B_LOCATION
peak I_MEASURE/I_LOCATION
- O
dose B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
choreatic B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
dyskinesias B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

We O
report O
on O
a O
patient O
with O
leftward O
and O
upward O
deviations O
of O
gaze O
during O
the O
peak O
effect O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
hypothesize O
that O
a O
severe O
dopaminergic O
denervation O
in O
the O
caudate O
nucleus O
is O
needed O
for O
the O
appearance O
of O
these O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induce O
ocular O
dyskinesias O
. O

A O
comparison O
of O
glyceryl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trinitrate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
diclofenac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
treatment O
of O
primary O
dysmenorrhea O
: O
an O
open O
, O
randomized O
, O
cross O
- O
over O
trial O
. O

Primary O
dysmenorrhea O
is O
a O
syndrome O
characterized O
by O
painful O
uterine O
contractility O
caused O
by O
a O
hypersecretion O
of O
endometrial O
prostaglandins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
; O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
are O
the O
first O
choice O
for O
its O
treatment O
. O

However O
, O
in O
vivo O
and O
in O
vitro O
studies O
have O
demonstrated O
that O
myometrial O
cells O
are O
also O
targets O
of O
the O
relaxant O
effects O
of O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
NO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
. O

The O
aim O
of O
the O
present O
study O
was O
to O
determine O
the O
efficacy O
of O
glyceryl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trinitrate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GTN B_ORGANIZATION/B_LOCATION
) O
, O
an O
NO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
donor O
, O
in O
the O
resolution O
of O
primary O
dysmenorrhea O
in O
comparison O
with O
diclofenac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DCF B_LOCATION/B_ORGANIZATION
) O
. O

A O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
24 B_PERSON
patients I_PERSON
with O
the O
diagnosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
severe B_DISEASE
primary I_DISEASE
dysmenorrhea I_DISEASE
were O
studied O
during O
two B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
consecutive I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
menstrual I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
cycles I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
an O
open O
, O
cross O
- O
over O
, O
controlled O
design O
, O
patients O
were O
randomized O
to O
receive O
either O
DCF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
per O
OS O
or O
GTN B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patches O
the O
first O
days O
of O
menses O
, O
when O
menstrual O
cramps O
became O
unendurable O
. O

In O
the O
subsequent B_TIME[MEASURE]/B_LOCATION
cycle I_TIME[MEASURE]/I_LOCATION
the O
other B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
used O
. O

patients O
received O
up O
to O
3 O
doses O
/ O
day O
of O
50 O
mg O
DCF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
or O
2 O
. O
5 O
mg O
/ O
24 O
h O
transdermal O
GTN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
first O
3 O
days O
of O
the O
cycle O
, O
according O
to O
their O
needs O
. O

The O
participants B_PERSON
recorded O
menstrual B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
symptoms I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
possible B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
at O
different B_MEASURE/B_ENT
times I_MEASURE/I_ENT
( O
0 B_MEASURE
, O
30 B_MEASURE
, O
60 B_MEASURE
, O
120 B_MEASURE/B_ENT
minutes I_MEASURE/I_ENT
) O
after O
the O
first B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
medication B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
the O
first B_SEQUENCE[MEASURE]/B_LOCATION
day I_SEQUENCE[MEASURE]/I_LOCATION
of O
the O
cycle B_TIME[MEASURE]
, O
with O
both O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
difference B_MEASURE
in O
pain B_DISEASE
intensity I_DISEASE
score I_DISEASE
( O
DPI B_DISEASE/B_LOCATION
) O
was O
the O
main B_MEASURE
outcome I_MEASURE
variable I_MEASURE
. O

Both O
treatments O
significantly O
reduced O
DPI O
by O
the O
30th O
minute O
( O
GTN B_LOCATION
, O
- O
12 O
. O
8 O
+ O
/ O
- O
17 O
. O
9 O
; O
DCF B_LOCATION/B_ORGANIZATION
, O
- O
18 O
. O
9 O
+ O
/ O
- O
16 O
. O
6 O
) O
. O

However O
, O
DCF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
continued O
to O
be O
effective O
in O
reducing O
pelvic O
pain O
for O
two O
hours O
, O
whereas O
GTN B_DISEASE/B_MEASURE
scores O
remained O
more O
or O
less O
stable O
after O
30 O
min O
and O
significantly O
higher O
than O
those O
for O
DFC O
( O
after O
one O
hour O
: O
GTN B_LOCATION/B_PROTEIN[GENE]
, O
- O
12 O
. O
8 O
+ O
/ O
- O
17 O
. O
9 O
; O
DFC O
, O
- O
18 O
. O
9 O
+ O
/ O
- O
16 O
. O
6 O
and O
after O
two O
hours O
: O
GTN B_LOCATION/B_PROTEIN[GENE]
, O
- O
23 O
. O
7 O
+ O
/ O
- O
20 O
. O
5 O
; O
DFC O
, O
- O
59 O
. O
7 O
+ O
/ O
- O
17 O
. O
9 O
, O
p O
= O
0 O
. O
0001 O
) O
. O

Low B_DISEASE/B_PERSON
back I_DISEASE/I_PERSON
pain I_DISEASE/I_PERSON
was O
also O
relieved O
by O
both O
drugs B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

headache O
was O
significantly O
increased O
by O
GTN B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
but O
not O
by O
DCF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Eight O
patients O
stopped O
using O
GTN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
because O
headache O
- O
- O
attributed O
to O
its O
use O
- O
- O
became O
intolerable O
. O

These O
findings O
indicate O
that O
GTN B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
has O
a O
reduced O
efficacy O
and O
tolerability O
by O
comparison O
with O
DCF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
treatment O
of O
primary O
dysmenorrhea O
. O

Temocapril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
long O
- O
acting O
non O
- O
SH O
group O
angiotensin B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
converting O
enzyme O
inhibitor O
, O
modulates O
glomerular O
injury O
in O
chronic O
puromycin B_DISEASE_ADJECTIVE[DISEASE]
aminonucleoside I_DISEASE_ADJECTIVE[DISEASE]
nephrosis O
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
determine O
whether O
chronic O
administration O
of O
temocapril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
long O
- O
acting O
non O
- O
SH O
group O
angiotensin B_GENE
converting O
enzyme O
( O
ace O
) O
inhibitor O
, O
reduced O
proteinuria O
, O
inhibited O
glomerular O
hypertrophy O
and O
prevented O
glomerulosclerosis O
in O
chronic O
puromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aminonucleoside I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
PAN B_DISEASE
) O
- O
induced O
nephrotic O
rats O
. O

Nephrosis O
was O
induced O
by O
injection O
of O
PAN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
15mg O
/ O
100g O
body O
weight O
) O
in O
male O
Sprague O
- O
Dawley O
( O
SD O
) O
rats O
. O

Four O
groups O
were O
used O
, O
i O
) O
the O
PAN B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O
( O
14 O
) O
, O
ii O
) O
PAN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O
temocapril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
13 O
) O
, O
III O
) O
temocapril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
14 O
) O
and O
IV O
) O
untreated O
controls O
( O
15 O
) O
. O

Temocapril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
8 O
mg O
/ O
kg O
/ O
day O
) O
was O
administered O
to O
the O
rats O
which O
were O
killed O
at O
weeks O
4 O
, O
14 O
or O
20 O
. O

At O
each O
time B_MEASURE/B_LOCATION
point B_MEASURE/I_LOCATION
, O
systolic B_DISEASE/B_GENE
blood I_DISEASE/I_GENE
pressure I_DISEASE/I_GENE
( O
BP B_DISEASE/B_GENE
) O
, O
urinary B_BODY_PART_OR_ORGAN_COMPONENT
protein I_BODY_PART_OR_ORGAN_COMPONENT
excretion I_BODY_PART_OR_ORGAN_COMPONENT
and O
renal B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
histopathological B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
evaluated O
, O
and O
morphometric B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
image I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
done O
. O

Systolic O
BP O
in O
the O
PAN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O
was O
significantly O
high O
at O
4 O
, O
14 O
and O
20 O
weeks O
, O
but O
was O
normal O
in O
the O
PAN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O
temocapril B_LOCATION
group O
. O

Urinary O
protein O
excretion O
in O
the O
PAN B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O
increased O
significantly O
, O
peaking O
at O
8 O
days O
, O
then O
decreased O
at O
4 O
weeks O
, O
but O
rose O
again O
significantly O
at O
14 O
and O
20 O
weeks O
. O

Temocapril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
did O
not O
attenuate O
proteinuria O
at O
8 O
days O
, O
but O
it O
did O
markedly O
lower O
it O
from O
weeks O
4 O
to O
20 O
. O

The O
glomerulosclerosis O
index O
( O
GSI O
) O
was O
6 O
. O
21 O
% O
at O
4 O
weeks O
and O
respectively O
25 O
. O
35 O
% O
and O
30 O
. O
49 O
% O
at O
14 O
and O
20 O
weeks O
in O
the O
PAN B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O
. O

There O
was O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlation B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
urinary B_LOCATION/B_ORGANIZATION
protein I_LOCATION/I_ORGANIZATION
excretion I_LOCATION/I_ORGANIZATION
and O
GSI B_DISEASE/B_GENE
( O
r B_OTHER/B_MEASURE
= O
0 B_MEASURE/B_LOCATION
. O
808 B_MEASURE
, O
p O
< O
0 B_MEASURE
. O
0001 B_MEASURE
) O
. O

The O
ratio O
of O
glomerular O
tuft O
area O
to O
the O
area O
of O
Bowman O
' O
s O
capsules O
( O
GT O
/ O
BC O
) O
in O
the O
PAN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O
was O
significantly O
increased O
, O
but O
it O
was O
significantly O
lower O
in O
the O
PAN B_LOCATION/B_ORGANIZATION
/ O
temocapril B_LOCATION/B_ORGANIZATION
group O
. O

It O
appears O
that O
temocapril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
effective O
in O
retarding O
renal O
progression O
and O
protected O
renal O
function O
in O
PAN B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
neprotic O
rats O
. O

pulmonary O
hypertension O
after O
ibuprofen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prophylaxis O
in O
very O
preterm O
infants O
. O

We O
report O
three O
cases O
of O
severe O
hypoxaemia O
after O
ibuprofen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
during O
a O
randomised O
controlled O
trial O
of O
prophylactic O
treatment O
of O
patent O
ductus O
arteriosus O
with O
ibuprofen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
premature O
infants O
born O
at O
less O
than O
28 O
weeks O
of O
gestation O
. O

echocardiography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
showed O
severely O
decreased O
pulmonary B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Hypoxaemia O
resolved O
quickly O
on O
inhaled O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
therapy O
. O

We O
suggest O
that O
investigators O
involved O
in O
similar O
trials O
pay O
close O
attention O
to O
pulmonary O
pressure O
if O
hypoxaemia O
occurs O
after O
prophylactic O
administration O
of O
ibuprofen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Hyponatremia O
and O
syndrome O
of O
inappropriate O
anti O
- O
diuretic O
hormone O
reported O
with O
the O
use O
of O
Vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O
an O
over O
- O
representation O
of O
Asians O
. O

purpose O
: O
This O
retrospective O
study O
used O
a O
pharmaceutical O
company O
' O
s O
global O
safety O
database O
to O
determine O
the O
reporting O
rate O
of O
hyponatremia O
and O
/ O
or O
syndrome O
of O
inappropriate O
secretion O
of O
anti O
- O
diuretic O
hormone O
( O
SIADH O
) O
among O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
patients O
and O
to O
explore O
the O
possibility O
of O
at O
- O
risk O
population O
subgroups O
. O

Method O
: O
We O
searched O
the O
Eli O
Lilly O
and O
Company O
' O
s O
computerized O
adverse O
event O
database O
for O
all O
reported O
cases O
of O
hyponatremia O
and O
/ O
or O
SIADH O
as O
of O
1 O
November O
1999 O
that O
had O
been O
reported O
during O
the O
use O
of O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
A O
total O
of O
76 O
cases O
of O
hyponatremia O
and O
/ O
or O
SIADH O
associated O
with O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
were O
identified O
. O

The O
overall B_MEASURE/B_PERSON
reporting I_MEASURE/I_PERSON
rate I_MEASURE/I_PERSON
was O
estimated O
to O
be O
1 B_MEASURE
. O
3 B_MEASURE
/ O
100 B_MEASURE
, O
000 B_MEASURE
treated O
patients B_PERSON/B_LOCATION
. O

The O
average B_MEASURE/B_PERSON
age I_MEASURE/I_PERSON
of O
patients B_PERSON/B_LOCATION
was O
35 B_MEASURE
. O
6 B_MEASURE
+ I_MEASURE
/ O
- O
28 B_MEASURE
. O
3 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
, O
and O
62 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
were O
males B_PERSON
. O

Approximately O
75 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
the O
patients B_PERSON
were O
receiving O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
leukemia B_DISEASE
or O
lymphoma B_DISEASE
. O

Among O
the O
39 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
included O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
race B_SPORT[ENT]/B_PERSON
, O
the O
racial B_MEASURE/B_PERSON
distribution I_MEASURE/I_PERSON
was O
: O
1 B_PERSON/B_NUMBER[MEASURE]
Black B_PERSON/I_NUMBER[MEASURE]
, O
3 B_PERSON/B_COLOR
Caucasian I_PERSON/I_COLOR
, O
and O
35 B_NUMBER[MEASURE]/B_PERSON
Asian I_NUMBER[MEASURE]/I_PERSON
. O

conclusion O
: O
Our O
data O
suggest O
that O
Asian O
patients O
may O
be O
at O
increased O
risk O
of O
hyponatremia O
and O
/ O
or O
SIADH O
associated O
with O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
. O

Although O
the O
overall O
reported O
rate O
of O
SIADH O
associated O
with O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
very O
low O
, O
physicians O
caring O
for O
Asian O
oncology O
patients O
should O
be O
aware O
of O
this O
potential O
serious O
but O
reversible O
adverse O
event O
. O

delayed O
toxicity O
of O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
bladder O
of O
DBA O
/ O
2 O
and O
C57BL O
/ O
6 O
female O
mouse O
. O

The O
present O
study O
describes O
the O
delayed O
development O
of O
a O
severe O
bladder O
pathology O
in O
a O
susceptible O
strain O
of O
mice O
( O
DBA O
/ O
2 O
) O
but O
not O
in O
a O
resistant O
strain O
( O
C57BL O
/ O
6 O
) O
when O
both O
were O
treated O
with O
a O
single O
300 O
mg O
/ O
kg O
dose O
of O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CY B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
. O

Inbred O
DBA O
/ O
2 O
and O
C57BL O
/ O
6 O
female O
mice O
were O
injected O
with O
CY B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
the O
effect O
of O
the O
drug O
on O
the O
bladder O
was O
assessed O
during O
100 O
days O
by O
light O
microscopy O
using O
different O
staining O
procedures O
, O
and O
after O
30 O
days O
by O
conventional O
electron O
microscopy O
. O

Early O
CY B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
toxicity O
caused O
a O
typical O
haemorrhagic O
cystitis O
in O
both O
strains O
that O
was O
completely O
repaired O
in O
about O
7 O
- O
10 O
days O
. O

After O
30 O
days O
of O
CY B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection O
ulcerous O
and O
non O
- O
ulcerous O
forms O
of O
chronic O
cystitis O
appeared O
in O
86 O
% O
of O
DBA O
/ O
2 O
mice O
but O
only O
in O
4 O
% O
of O
C57BL O
/ O
6 O
mice O
. O

Delayed B_DISEASE
cystitis I_DISEASE
was O
characterized O
by O
infiltration B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
transepithelial B_DISEASE_ADJECTIVE[DISEASE]
passage I_DISEASE_ADJECTIVE[DISEASE]
into O
the O
lumen B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
of O
inflammatory B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
by O
frequent B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exfoliation I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
urothelium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

mast B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
appeared O
in O
the O
connective B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
muscular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
layers I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
bladder B_BODY_PART_OR_ORGAN_COMPONENT
at O
a O
much O
higher B_MEASURE
number I_MEASURE
in O
DBA B_PROTEIN[GENE]/B_DISEASE
/ O
2 B_MEASURE/B_PROTEIN[GENE]
mice I_MEASURE/I_PROTEIN[GENE]
than O
in O
C57BL B_PROTEIN[GENE]/B_BIO
/ O
6 B_MEASURE
mice I_MEASURE
or O
untreated B_PERSON/B_MEASURE
controls I_PERSON/I_MEASURE
. O

Electron B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
microscopy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
disclosed O
the O
absence B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
typical B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
discoidal I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
vesicles I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
normally O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
of O
surface B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Instead O
, O
numerous B_DISEASE_ADJECTIVE[DISEASE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
abnormal B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
vesicles B_DISEASE_ADJECTIVE[DISEASE]/I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
containing O
one B_NUMBER[MEASURE]
or O
several B_NUMBER[MEASURE]/B_PERSON
dark I_NUMBER[MEASURE]/I_PERSON
granules I_NUMBER[MEASURE]/I_PERSON
were O
observed O
in O
the O
cytoplasm B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
of O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
from O
all O
the O
epithelial B_LOCATION/B_DISEASE
layers I_LOCATION/I_DISEASE
. O

Delayed B_DISEASE_ADJECTIVE[DISEASE]
cystitis I_DISEASE_ADJECTIVE[DISEASE]
still O
persisted O
in O
DBA B_MEASURE/B_PROTEIN[GENE]
/ O
2 B_PROTEIN[GENE]/B_DISEASE
mice I_PROTEIN[GENE]/I_DISEASE
100 I_PROTEIN[GENE]/I_DISEASE
days I_PROTEIN[GENE]/I_DISEASE
after O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

These O
results O
indicate O
that O
delayed O
toxicity O
of O
CY B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
female O
DBA O
/ O
2 O
mice O
causes O
a O
bladder O
pathology O
that O
is O
not O
observed O
in O
C57BL O
/ O
6 O
mice O
. O

This O
pathology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resembles O
interstitial B_DISEASE/B_LOCATION
cystitis I_DISEASE/I_LOCATION
in O
humans B_PERSON/B_SPECIES[BIO]
and O
could O
perhaps O
be O
used O
as O
an O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
the O
disease B_DISEASE
. O

High O
- O
dose O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
folinic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
combination O
with O
three O
- O
weekly O
mitomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
treatment O
of O
advanced O
gastric O
cancer O
. O

A O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
II I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Background O
: O
The O
24 O
- O
hour O
continuous O
infusion O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 B_LOCATION/B_PROTEIN[GENE]
- I_LOCATION/I_PROTEIN[GENE]
FU I_LOCATION/I_PROTEIN[GENE]
) O
and O
folinic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
FA B_LOCATION
) O
as O
part O
of O
several O
new O
multidrug O
chemotherapy O
regimens O
in O
advanced O
gastric O
cancer O
( O
AGC O
) O
has O
shown O
to O
be O
effective O
, O
with O
low O
toxicity O
. O

In O
a O
previous O
phase O
II O
study O
with O
3 O
- O
weekly O
bolus O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
FA B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
mitomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MMC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
we O
found O
a O
low O
toxicity O
rate O
and O
response O
rates O
comparable O
to O
those O
of O
regimens O
such O
as O
ELF O
, O
FAM O
or O
FAMTX O
, O
and O
a O
promising O
median O
overall O
survival O
. O

In O
order O
to O
improve O
this O
MMC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
dependent O
schedule O
we O
initiated O
a O
phase O
II O
study O
with O
high O
- O
dose O
5 B_LOCATION/B_PERSON
- I_LOCATION/I_PERSON
FU I_LOCATION/I_PERSON
/ O
FA B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
3 O
- O
weekly O
bolus O
MMC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

patients O
AND O
methods O
: O
From O
February O
, O
1998 O
to O
September O
, O
2000 O
we O
recruited O
33 O
patients O
with O
AGC O
to O
receive O
weekly O
24 O
- O
hour O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
2 O
, O
600 O
mg O
/ O
m O
( O
2 O
) O
preceded O
by O
2 O
- O
hour O
FA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
500 O
mg O
/ O
m O
( O
2 O
) O
for O
6 O
weeks O
, O
followed O
by O
a O
2 O
- O
week O
rest O
period O
. O

Bolus O
MMC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
10 O
mg O
/ O
m O
( O
2 O
) O
was O
added O
in O
3 O
- O
weekly O
intervals O
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
given O
on O
an O
outpatient B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
basis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O
using O
portable B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pump I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
repeated O
on O
day B_TIME[MEASURE]/B_LOCATION
57 I_TIME[MEASURE]/I_LOCATION
. O

Patients B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
characteristics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
: O
male B_PERSON
/ O
female B_MEASURE/B_PERSON
ratio I_MEASURE/I_PERSON
20 I_MEASURE/I_PERSON
/ O
13 B_MEASURE
; O
median B_MEASURE/B_PERSON
age I_MEASURE/I_PERSON
57 I_MEASURE/I_PERSON
( O
27 B_MEASURE
- O
75 B_MEASURE
) O
years B_TIME[MEASURE]/B_ORGANIZATION
; O
median B_LOCATION/B_MEASURE
WHO O
status B_MEASURE
1 I_MEASURE
( O
0 B_MEASURE
- O
2 B_MEASURE
) O
. O

18 B_TIME[MEASURE]
patients I_TIME[MEASURE]
had O
a O
primary B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
AGC I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
and O
15 B_NUMBER[MEASURE]
showed O
a O
relapsed B_DISEASE/B_LOCATION
AGC I_DISEASE/I_LOCATION
. O

median B_TIME[MEASURE]/B_PERSON
follow I_TIME[MEASURE]/I_PERSON
- O
up B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
11 B_MEASURE
. O
8 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
range B_MEASURE/B_LOCATION
of O
those O
surviving O
: O
2 B_MEASURE
. O
7 B_MEASURE
- O
11 B_MEASURE
. O
8 B_TIME[MEASURE]
months I_TIME[MEASURE]
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
32 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
were O
evaluable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
complete B_MEASURE
remission I_MEASURE
9 I_MEASURE
. O
1 B_MEASURE
% I_MEASURE
( O
n B_MEASURE/B_PROTEIN[GENE]
= O
3 B_MEASURE
) O
, O
partial B_TIME[MEASURE]
remission I_TIME[MEASURE]
45 I_TIME[MEASURE]
. O
5 B_MEASURE
% I_MEASURE
( O
n B_OTHER/B_MEASURE
= O
15 B_MEASURE
) O
, O
no O
change B_TIME[MEASURE]
27 I_TIME[MEASURE]
. O
3 B_MEASURE
% I_MEASURE
( O
n B_OTHER/B_MEASURE
= O
9 B_MEASURE
) O
, O
progressive B_MEASURE
disease I_MEASURE
15 I_MEASURE
. O
1 B_MEASURE
% I_MEASURE
( O
n B_OTHER/B_MEASURE
= O
5 B_MEASURE
) O
. O

median B_TIME[MEASURE]/B_PERSON
overall I_TIME[MEASURE]/I_PERSON
survival I_TIME[MEASURE]/I_PERSON
time I_TIME[MEASURE]/I_PERSON
was O
10 B_MEASURE
. O
2 B_MEASURE
months I_MEASURE
[ I_MEASURE
95 I_MEASURE
% I_MEASURE
confidence I_MEASURE
interval I_MEASURE
( O
CI B_LOCATION
) O
: O
8 B_MEASURE
. O
7 B_MEASURE
- O
11 B_MEASURE
. O
6 B_MEASURE
] I_MEASURE
, O
and O
median B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
progression I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
free B_TIME[MEASURE]/B_LOCATION
survival I_TIME[MEASURE]/I_LOCATION
time I_TIME[MEASURE]/I_LOCATION
was O
7 B_MEASURE
. O
6 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
95 B_TIME[MEASURE]/B_LOCATION
% I_TIME[MEASURE]/I_LOCATION
CI I_TIME[MEASURE]/I_LOCATION
: O
4 B_MEASURE
. O
4 B_MEASURE
- O
10 B_MEASURE
. O
9 B_MEASURE
) O
. O

The O
worst B_DISEASE/B_MEASURE
toxicities I_DISEASE/I_MEASURE
( O
% B_PROTEIN[GENE]/B_DISEASE
) O
observed O
were O
( O
CTC B_MEASURE/B_LOCATION
- O
NCI B_MEASURE
1 I_MEASURE
/ O
2 B_MEASURE
/ O
3 B_MEASURE
) O
: O
leukopenia B_MEASURE
45 I_MEASURE
. O
5 B_MEASURE
/ O
18 B_MEASURE
. O
2 B_MEASURE
/ O
6 B_MEASURE
. O
1 B_MEASURE
, O
thrombocytopenia B_MEASURE
33 I_MEASURE
. O
3 B_MEASURE
/ O
9 B_MEASURE
. O
1 B_MEASURE
/ O
6 B_MEASURE
. O
1 B_MEASURE
, O
vomitus B_TIME[MEASURE]
24 I_TIME[MEASURE]
. O
2 B_MEASURE
/ O
9 B_MEASURE
. O
1 B_MEASURE
/ O
0 B_MEASURE
, O
diarrhea B_TIME[MEASURE]
36 I_TIME[MEASURE]
. O
4 B_MEASURE
/ O
6 B_MEASURE
. O
1 B_MEASURE
/ O
3 B_MEASURE
. O
0 B_NUMBER[MEASURE]
, O
stomatitis B_MEASURE
18 I_MEASURE
. O
2 B_MEASURE
/ O
9 B_MEASURE
. O
1 B_MEASURE
/ O
0 B_MEASURE
, O
hand B_BODY_PART_OR_ORGAN_COMPONENT
- O
foot B_MEASURE
syndrome I_MEASURE
12 I_MEASURE
. O
1 B_MEASURE
/ O
0 B_MEASURE
/ O
0 B_MEASURE
. O

Two B_PERSON/B_LOCATION
patients I_PERSON/I_LOCATION
developed O
hemolytic B_DISEASE
- O
uremic B_DISEASE
syndrome I_DISEASE
( O
HUS B_MEASURE/B_DISEASE
) O
. O

conclusions O
: O
High O
- O
dose O
5 B_LOCATION/B_PERSON
- I_LOCATION/I_PERSON
FU I_LOCATION/I_PERSON
/ O
FA B_LOCATION
/ O
MMC B_LOCATION/B_ORGANIZATION
is O
an O
effective O
and O
well O
- O
tolerated O
outpatient O
regimen O
for O
AGC O
( O
objective O
response O
rate O
54 O
. O
6 O
% O
) O
. O

It O
may O
serve O
as O
an O
alternative O
to O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
containing O
regimens O
; O
however O
, O
it O
has O
to O
be O
considered O
that O
possibly O
HUS O
may O
occur O
. O

persistent O
sterile O
leukocyturia O
is O
associated O
with O
impaired O
renal O
function O
in O
human O
immunodeficiency O
virus O
type O
1 O
- O
infected O
children O
treated O
with O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Background O
: O
prolonged O
administration O
of O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
associated O
with O
the O
occurrence O
of O
a O
variety O
of O
renal O
complications O
in O
adults O
. O

These O
well O
- O
documented O
side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
have O
restricted O
the O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
this O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protease I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
children B_PERSON/B_DISEASE
. O

Design O
: O
A O
prospective O
study O
to O
monitor O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
related O
nephrotoxicity O
in O
a O
cohort O
of O
30 O
human O
immunodeficiency O
virus O
type O
1 O
- O
infected O
children O
treated O
with O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

methods O
: O
Urinary O
pH O
, O
albumin O
, O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
the O
presence O
of O
erythrocytes O
, O
leukocytes O
, O
bacteria O
and O
crystals O
, O
and O
culture O
were O
analyzed O
every O
3 O
months O
for O
96 O
weeks O
. O

serum O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
were O
routinely O
determined O
at O
the O
same O
time O
points O
. O

steady O
- O
state O
pharmacokinetics O
of O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
done O
at O
week O
4 O
after O
the O
initiation O
of O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
cumulative B_MEASURE
incidence I_MEASURE
of O
persistent B_DISEASE
sterile I_DISEASE
leukocyturia I_DISEASE
( O
> B_MEASURE/B_OTHER
or O
= O
75 B_MEASURE
cells I_MEASURE
/ O
micro B_TIME[MEASURE]/B_LOCATION
L I_TIME[MEASURE]/I_LOCATION
in O
at O
least O
2 B_NUMBER[MEASURE]/B_PERSON
consecutive I_NUMBER[MEASURE]/I_PERSON
visits I_NUMBER[MEASURE]/I_PERSON
) O
after O
96 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O
53 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
% I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

persistent O
sterile O
leukocyturia O
was O
frequently O
associated O
with O
a O
mild O
increase O
in O
the O
urine O
albumin O
/ O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ratio O
and O
by O
microscopic O
hematuria O
. O

The O
cumulative O
incidence O
of O
serum O
creatinine B_MEASURE/B_GENE
levels O
> O
50 O
% O
above O
normal O
was O
33 O
% O
after O
96 O
weeks O
. O

Children O
with O
persistent O
sterile O
leukocyturia O
more O
frequently O
had O
serum O
creatinine B_MEASURE/B_GENE
levels O
of O
50 O
% O
above O
normal O
than O
those O
children O
without O
persistent O
sterile O
leukocyturia O
. O

In O
children B_MEASURE/B_PERSON
younger I_MEASURE/I_PERSON
than O
5 B_MEASURE
. O
6 B_TIME[MEASURE]
years I_TIME[MEASURE]
, O
persistent B_DISEASE
sterile I_DISEASE
leukocyturia I_DISEASE
was O
significantly O
more O
frequent B_DISEASE_ADJECTIVE[DISEASE]
than O
in O
older B_PERSON/B_ORGANIZATION
children I_PERSON/I_ORGANIZATION
. O

A O
higher O
cumulative O
incidence O
of O
persistent O
leukocyturia O
was O
found O
in O
children O
with O
an O
area O
under O
the O
curve O
> O
19 O
mg O
/ O
L O
x O
h O
or O
a O
peak O
serum O
level O
of O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
> O
12 O
mg O
/ O
L O
. O

In O
4 O
children O
, O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
discontinued O
because O
of O
nephrotoxicity O
. O

Subsequently O
, O
the O
serum O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
decreased O
, O
the O
urine O
albumin O
/ O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
ratios O
returned O
to O
zero O
, O
and O
the O
leukocyturia O
disappeared O
within O
3 O
months O
. O

conclusions O
: O
Children O
treated O
with O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
have O
a O
high O
cumulative O
incidence O
of O
persistent O
sterile O
leukocyturia O
. O

Children O
with O
persistent O
sterile O
leukocyturia O
more O
frequently O
had O
an O
increase O
in O
serum O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
of O
> O
50 O
% O
above O
normal O
. O

Younger B_PERSON/B_ENT
children I_PERSON/I_ENT
have O
an O
additional B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
risk I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O
renal B_DISEASE
complications I_DISEASE
. O

The O
impairment B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
renal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
function B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O
these O
children B_PERSON/B_BIO
occurred O
in O
the O
absence B_DISEASE/B_MEASURE
of O
clinical B_DISEASE_ADJECTIVE[DISEASE]
symptoms I_DISEASE_ADJECTIVE[DISEASE]
of O
nephrolithiasis B_DISEASE/B_GENE
. O

Indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
associated O
nephrotoxicity O
must O
be O
monitored O
closely O
, O
especially O
in O
children O
with O
risk O
factors O
such O
as O
persistent O
sterile O
leukocyturia O
, O
age O
< O
5 O
. O
6 O
years O
, O
an O
area O
under O
the O
curve O
of O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
> O
19 O
mg O
/ O
L O
x O
h O
, O
and O
a O
C O
( O
Max O
) O
> O
12 O
mg O
/ O
L O
. O

utility O
of O
troponin O
I O
in O
patients O
with O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
chest O
pain O
. O

Baseline O
electrocardiogram O
abnormalities O
and O
market O
elevations O
not O
associated O
with O
myocardial O
necrosis O
make O
accurate O
diagnosis O
of O
myocardial O
infarction O
( O
MI O
) O
difficult O
in O
patients O
with O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
chest O
pain O
. O

troponin B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sampling I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
may O
offer O
greater B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnostic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
utility I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
these O
patients B_PERSON/B_LOCATION
. O

objective O
: O
To O
assess O
outcomes O
based O
on O
troponin O
positivity O
in O
patients O
with O
cocaine B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chest O
pain O
admitted O
for O
exclusion O
of O
MI O
. O

methods O
: O
outcomes O
were O
examined O
in O
patients O
admitted O
for O
possible O
MI O
after O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O
. O

All O
patients O
underwent O
a O
rapid O
rule O
- O
in O
protocol O
that O
included O
serial O
sampling O
of O
creatine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kinase O
( O
CK O
) O
, O
CK O
- O
MB O
, O
and O
cardiac O
troponin O
I O
( O
cTnI O
) O
over O
eight O
hours O
. O

outcomes B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O
CK B_MEASURE/B_GENE
- O
MB B_DISEASE/B_PROTEIN[GENE]
MI B_DISEASE/I_PROTEIN[GENE]
( O
CK B_GENE/B_LOCATION
- O
MB B_LOCATION/B_MEASURE
> I_LOCATION/I_MEASURE
or O
= O
8 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
mL B_MEASURE/B_LOCATION
with O
a O
relative B_MEASURE/B_LOCATION
index I_MEASURE/I_LOCATION
[ I_MEASURE/I_LOCATION
( O
CK B_GENE/B_LOCATION
- O
MB B_LOCATION/B_PROTEIN[GENE]
x O
100 B_MEASURE
) O
/ O
total B_MEASURE
CK I_MEASURE
] O
> B_MEASURE/B_OTHER
or O
= O
4 B_MEASURE
, O
cardiac B_DISEASE
death I_DISEASE
, O
and O
significant B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
coronary I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
> B_MEASURE
or O
= O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Of O
the O
246 B_MEASURE
admitted O
patients B_PERSON
, O
34 B_MEASURE
( O
14 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
met O
CK B_PROTEIN[GENE]/B_DISEASE
- O
MB B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
criteria I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
MI B_DISEASE/B_LOCATION
and O
38 B_MEASURE
( O
16 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
had O
cTnI B_DISEASE/B_LOCATION
elevations I_DISEASE/I_LOCATION
. O

angiography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
performed O
in O
29 B_NUMBER[MEASURE]
of O
38 B_TIME[MEASURE]/B_PERSON
patients B_TIME[MEASURE]/I_PERSON
who O
were O
cTnI B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
with O
significant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
disease I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
present I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
25 B_NUMBER[MEASURE]/B_PERSON
( O
86 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

Three B_NUMBER[MEASURE]/B_PERSON
of O
the O
four B_PERSON
patients I_PERSON
without O
significant B_DISEASE/B_LOCATION
disease I_DISEASE/I_LOCATION
who O
had O
cTnI B_DISEASE/B_LOCATION
elevations I_DISEASE/I_LOCATION
met O
CK B_PROTEIN[GENE]/B_LOCATION
- O
MB B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
criteria B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
for O
MI B_DISEASE/B_LOCATION
, O
and O
the O
other B_SEQUENCE[MEASURE]/B_LOCATION
had O
a O
peak B_LOCATION
CK I_LOCATION
- O
MB B_MEASURE/B_LOCATION
level B_MEASURE/I_LOCATION
of O
13 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
mL B_MEASURE/B_LOCATION
. O

sensitivities B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
specificities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
and O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
negative B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
likelihood B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
ratios B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
for O
predicting O
cardiac B_DISEASE_ADJECTIVE[DISEASE]
death I_DISEASE_ADJECTIVE[DISEASE]
or O
significant B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
for O
both O
CK B_PROTEIN[GENE]/B_MEASURE
- O
MB B_MEASURE/B_DISEASE
MI I_MEASURE/I_DISEASE
and O
cTnI B_LOCATION
and O
were O
not O
significantly O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Most B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
cTnI B_DISEASE/B_LOCATION
elevations I_DISEASE/I_LOCATION
meet O
CK B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
MB B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
criteria B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
for O
MI B_DISEASE/B_LOCATION
, O
as O
well O
as O
have O
a O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
incidence B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
underlying B_DISEASE/B_GENE
significant I_DISEASE/I_GENE
disease I_DISEASE/I_GENE
. O

Troponin O
appears O
to O
have O
an O
equivalent O
diagnostic O
accuracy O
compared O
with O
CK O
- O
MB O
for O
diagnosing O
necrosis O
in O
patients O
with O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
chest O
pain O
and O
suspected O
MI O
. O

acute O
interstitial O
nephritis O
due O
to O
nicergoline B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Sermion B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

We O
report O
a O
case O
of O
acute O
interstitial O
nephritis O
( O
Ain O
) O
due O
to O
nicergoline B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Sermion B_PROTEIN[GENE]/B_BACTERIUM[BIO]
) O
. O

A O
50 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
- O
old B_PERSON
patient I_PERSON
admitted O
to O
our O
hospital B_LOCATION
for O
fever B_DISEASE
and O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
. O

Before O
admission O
, O
he O
had O
been O
taking O
nicergoline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
bendazac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lysine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O
to O
retinal O
vein O
occlusion O
at O
ophthalmologic O
department O
. O

Thereafter O
, O
he O
experienced O
intermittent B_DISEASE
fever I_DISEASE
and O
skin B_DISEASE
rash I_DISEASE
. O

On O
admission B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
clinical B_DISEASE_ADJECTIVE[DISEASE]
symptoms I_DISEASE_ADJECTIVE[DISEASE]
( O
i O
. O
e B_DISEASE/B_PROTEIN[GENE]
. O
arthralgia B_DISEASE
and O
fever B_DISEASE
) O
and O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
i O
. O
e O
. O
eosinophilia B_DISEASE
and O
renal B_DISEASE/B_GENE
failure I_DISEASE/I_GENE
) O
suggested O
AIN B_DISEASE
, O
and O
which O
was O
confirmed O
by O
pathologic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
findings I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
renal B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biopsy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
lymphocyte O
transformation O
test O
demonstrated O
a O
positive O
result O
against O
nicergoline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Treatment O
was O
consisted O
of O
withdrawal O
of O
nicergoline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
intravenous O
methylprednisolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
his O
renal O
function O
was O
completely O
recovered O
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
nicergoline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
Ain O
. O

neuroleptic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
malignant I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
syndrome I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
complicated O
by O
massive B_DISEASE
intestinal I_DISEASE
bleeding I_DISEASE
in O
a O
patient B_PERSON/B_BIO
with O
chronic B_DISEASE
renal I_DISEASE
failure I_DISEASE
. O

A O
patient O
with O
chronic O
renal O
failure O
( O
CRF O
) O
developed O
neuroleptic O
malignant O
syndrome O
( O
NMS O
) O
after O
administration O
of O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
levomepromazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
addition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
typical B_DISEASE
symptoms I_DISEASE
of O
NMS B_DISEASE/B_GENE
, O
massive B_DISEASE
intestinal I_DISEASE
bleeding I_DISEASE
was O
observed O
during O
the O
episode B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggests O
that O
NMS B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
a O
patient B_PERSON/B_BIO
with O
CRF B_DISEASE
may O
be O
complicated O
by O
intestinal B_DISEASE
bleeding I_DISEASE
and O
needs O
special B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caution I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
this O
complication B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Blood B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
brain B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
barrier B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
right B_SEQUENCE[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
and O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_SEQUENCE[MEASURE]
- O
pawed O
female B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
rats B_BIO/I_BODY_PART_OR_ORGAN_COMPONENT
assessed O
by O
a O
new B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
staining I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
asymmetrical B_DISEASE_ADJECTIVE[DISEASE]
breakdown I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
blood B_BODY_PART_OR_ORGAN_COMPONENT
- O
brain B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
barrier B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
BBB B_LOCATION/B_ORGANIZATION
) O
was O
studied O
in O
female B_SPECIES[BIO]/B_DISEASE
rats I_SPECIES[BIO]/I_DISEASE
. O

Paw B_PERSON/B_DISEASE
preference I_PERSON/I_DISEASE
was O
assessed O
by O
a O
food B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reaching O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Adrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hypertension O
was O
used O
to O
destroy O
the O
BBB O
, O
which O
was O
evaluated O
using O
triphenyltetrazolium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O
TTC B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
staining O
of O
the O
brain O
slices O
just O
after O
giving O
adrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
30 O
s O
. O

In O
normal O
rats O
, O
the O
whole O
brain O
sections O
exhibited O
complete O
staining O
with O
TTC B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

After O
adrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
for O
30 O
s O
, O
there O
were O
large O
unstained O
areas O
in O
the O
left O
brain O
in O
right O
- O
pawed O
animals O
, O
and O
vice O
versa O
in O
left O
- O
pawed O
animals O
. O

Similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
obtained O
in O
seizure B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
breakdown B_DISEASE
of O
BBB B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
explained O
by O
an O
asymmetric B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cerebral I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depending O
upon O
the O
paw B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
preference I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
was O
suggested O
that O
this O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
contralateral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
motor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
that O
may O
be O
important B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
determining O
the O
dominant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cerebral I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
hemisphere I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
animals B_BIO/B_DISEASE
. O

Carvedilol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
protects O
against O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
mitochondrial O
cardiomyopathy O
. O

Several O
cytopathic O
mechanisms O
have O
been O
suggested O
to O
mediate O
the O
dose O
- O
limiting O
cumulative O
and O
irreversible O
cardiomyopathy O
caused O
by O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicates O
that O
oxidative B_DISEASE/B_GENE
stress I_DISEASE/I_GENE
and O
mitochondrial B_DISEASE/B_GENE
dysfunction I_DISEASE/I_GENE
are O
key B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
pathogenic B_DISEASE_ADJECTIVE[DISEASE]
process I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
objective O
of O
this O
investigation O
was O
to O
test O
the O
hypothesis O
that O
carvedilol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
nonselective O
beta O
- O
adrenergic O
receptor O
antagonist O
with O
potent O
antioxidant O
properties O
, O
protects O
against O
the O
cardiac O
and O
hepatic O
mitochondrial O
bioenergetic O
dysfunction O
associated O
with O
subchronic O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
toxicity O
. O

Heart O
and O
liver O
mitochondria O
were O
isolated O
from O
rats O
treated O
for O
7 O
weeks O
with O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 O
mg O
/ O
kg O
Sc O
/ O
week O
) O
, O
carvedilol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 O
mg O
/ O
kg O
IP O
/ O
week O
) O
, O
or O
the O
combination O
of O
the O
two O
drugs O
. O

Heart O
mitochondria O
isolated O
from O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
rats O
exhibited O
depressed O
rates O
for O
state O
3 O
respiration O
( O
336 O
+ O
/ O
- O
26 O
versus O
425 O
+ O
/ O
- O
53 O
natom O
O O
/ O
min O
/ O
mg O
protein O
) O
and O
a O
lower O
respiratory O
control O
ratio O
( O
RCR O
) O
( O
4 O
. O
3 O
+ O
/ O
- O
0 O
. O
6 O
versus O
5 O
. O
8 O
+ O
/ O
- O
0 O
. O
4 O
) O
compared O
with O
cardiac O
mitochondria O
isolated O
from O
saline O
- O
treated O
rats O
. O

mitochondrial O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
loading O
capacity O
and O
the O
activity O
of O
NADH O
- O
dehydrogenase O
were O
also O
suppressed O
in O
cardiac O
mitochondria O
from O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
treated O
rats O
. O

Doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment O
also O
caused O
a O
decrease O
in O
RCR O
for O
liver O
mitochondria O
( O
3 O
. O
9 O
+ O
/ O
- O
0 O
. O
9 O
versus O
5 O
. O
6 O
+ O
/ O
- O
0 O
. O
7 O
for O
control O
rats O
) O
and O
inhibition O
of O
hepatic O
cytochrome O
oxidase O
activity O
. O

Coadministration O
of O
carvedilol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O
the O
extent O
of O
cellular O
vacuolization O
in O
cardiac O
myocytes O
and O
prevented O
the O
inhibitory O
effect O
of O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
mitochondrial O
respiration O
in O
both O
heart O
and O
liver O
. O

Carvedilol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
also O
prevented O
the O
decrease O
in O
mitochondrial O
Ca B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
2 O
+ O
) O
loading O
capacity O
and O
the O
inhibition O
of O
the O
respiratory O
complexes O
of O
heart O
mitochondria O
caused O
by O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Carvedilol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O
itself O
did O
not O
affect O
any O
of O
the O
parameters O
measured O
for O
heart O
or O
liver O
mitochondria O
. O

It O
is O
concluded O
that O
this O
protection O
by O
carvedilol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
both O
the O
structural O
and O
functional O
cardiac O
tissue O
damage O
may O
afford O
significant O
clinical O
advantage O
in O
minimizing O
the O
dose O
- O
limiting O
mitochondrial O
dysfunction O
and O
cardiomyopathy O
that O
accompanies O
long O
- O
term O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
in O
cancer O
patients O
. O

Cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
hyperactivity O
is O
more O
influenced O
by O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O
agonists O
than O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hyperactivity O
. O

The O
influence O
of O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O
agonists O
and O
antagonists O
on O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
and O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hyperactivity O
was O
examined O
in O
mice O
. O

All O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O
agonists O
significantly O
decreased O
the O
locomotor O
activity O
in O
mice O
, O
and O
the O
effects O
were O
dose O
- O
dependent O
. O

It O
seems O
that O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A1 O
and O
A2 O
receptors O
might O
be O
involved O
in O
this O
reaction O
. O

Moreover O
, O
all O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O
agonists O
: O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
p I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboxyethyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenethylamino I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ethylcarboxamidoadenosine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CGS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
21680 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O
, O
A2A O
receptor O
agonist O
, O
N6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cyclopentyladenosine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
) O
, O
A1 O
receptor O
agonist O
, O
and O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
N I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ethylcarboxamidoadenosine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NECA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
A2 O
/ O
A1 O
receptor O
agonist O
significantly O
and O
dose O
- O
dependently O
decreased O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
locomotor O
activity O
. O

CPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
reduced O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action O
at O
the O
doses O
which O
, O
given O
alone O
, O
did O
not O
influence O
motility O
, O
while O
CGS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
21680 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
NECA B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O
the O
action O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
at O
the O
doses O
which O
, O
given O
alone O
, O
decreased O
locomotor O
activity O
in O
animals O
. O

These O
results O
suggest O
the O
involvement O
of O
both O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O
in O
the O
action O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
although O
agonists O
of O
A1 O
receptors O
seem O
to O
have O
stronger O
influence O
on O
it O
. O

The O
selective O
blockade O
of O
A2 O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptor O
by O
DMPX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
3 B_TIME[MEASURE]/B_LOCATION
, B_TIME[MEASURE]/I_LOCATION
7 B_TIME[MEASURE]/I_LOCATION
- B_TIME[MEASURE]/I_LOCATION
dimethyl B_TIME[MEASURE]/I_LOCATION
- B_TIME[MEASURE]/I_LOCATION
1 B_TIME[MEASURE]/I_LOCATION
- B_TIME[MEASURE]/I_LOCATION
propargylxanthine B_TIME[MEASURE]/I_LOCATION
) O
significantly O
enhanced O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
locomotor O
activity O
of O
animals O
. O

Caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O
similar O
action O
but O
the O
effect O
was O
not O
significant O
. O

CPT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
8 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cyclopentyltheophylline I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
- O
A1 O
receptor O
antagonist O
, O
did O
not O
show O
any O
influence O
in O
this O
test O
. O

Similarly O
, O
all O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O
agonists O
decreased O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hyperactivity O
, O
but O
at O
the O
higher O
doses O
than O
those O
which O
were O
active O
in O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hyperactivity O
. O

The O
selective O
blockade O
of O
A2 O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O
( O
DMPX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
non O
- O
selective O
blockade O
of O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
receptors O
( O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
significantly O
increased O
the O
action O
of O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
the O
locomotor O
activity O
test O
. O

Our O
results O
have O
shown O
that O
all O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O
agonists O
( O
A1 O
and O
A2 O
) O
reduce O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
locomotor O
activity O
and O
indicate O
that O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
induced O
hyperactivity O
is O
more O
influenced O
by O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O
agonists O
( O
particularly O
A1 O
receptors O
) O
than O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hyperactivity O
. O

Amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
the O
risk O
of O
bradyarrhythmia O
requiring O
permanent O
pacemaker O
in O
elderly O
patients O
with O
atrial O
fibrillation O
and O
prior O
myocardial O
infarction O
. O

objectives O
: O
The O
aim O
of O
this O
study O
was O
to O
determine O
whether O
the O
use O
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients O
with O
atrial O
fibrillation O
( O
AF O
) O
increases O
the O
risk O
of O
bradyarrhythmia O
requiring O
a O
permanent O
pacemaker O
. O

Background O
: O
Reports O
of O
severe O
bradyarrhythmia O
during O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O
are O
infrequent O
and O
limited O
to O
studies O
assessing O
the O
therapy O
' O
s O
use O
in O
the O
management O
of O
patients O
with O
ventricular O
arrhythmias O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
A O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cohort I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
8 B_MEASURE
, O
770 B_MEASURE
patients I_MEASURE
age I_MEASURE
> I_MEASURE
or O
= O
65 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
with O
a O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
AF B_DISEASE
was O
identified O
from O
a O
provincewide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
Quebec B_PERSON/B_ORGANIZATION
residents I_PERSON/I_ORGANIZATION
with O
a O
myocardial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
MI B_LOCATION
) O
between O
1991 B_MEASURE
and O
1999 B_MEASURE
. O

Using O
a O
nested B_PERSON/B_MEASURE
case I_PERSON/I_MEASURE
- O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
design I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
477 B_PERSON/B_MEASURE
cases I_PERSON/I_MEASURE
of O
bradyarrhythmia B_DISEASE
requiring O
a O
permanent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pacemaker I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
matched O
( O
1 B_MEASURE
: O
4 B_MEASURE
) O
to O
1 B_MEASURE
, O
908 B_MEASURE/B_PERSON
controls I_MEASURE/I_PERSON
. O

Multivariable O
logistic O
regression O
was O
used O
to O
estimate O
the O
odds O
ratio O
( O
OR O
) O
of O
pacemaker O
insertion O
associated O
with O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
, O
controlling O
for O
baseline O
risk O
factors O
and O
exposure O
to O
sotalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
Class O
I O
antiarrhythmic O
agents O
, O
beta O
- O
blockers O
, O
calcium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
channel O
blockers O
, O
and O
digoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Results O
: O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O
was O
associated O
with O
an O
increased O
risk O
of O
pacemaker O
insertion O
( O
OR O
: O
2 O
. O
14 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
: O
1 O
. O
30 O
to O
3 O
. O
54 O
) O
. O

This O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
modified O
by O
gender B_PERSON/B_DISEASE
, O
with O
a O
greater B_MEASURE
risk I_MEASURE
in O
women B_PERSON/B_BIO
versus O
men B_PERSON
( O
OR O
: O
3 B_MEASURE
. O
86 B_MEASURE
, O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
: O
1 B_MEASURE
. O
70 B_MEASURE
to O
8 B_NUMBER[MEASURE]
. O
75 B_MEASURE/B_SPORT[ENT]
vs I_MEASURE/I_SPORT[ENT]
. O
OR O
: O
1 B_MEASURE
. O
52 B_MEASURE
, O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
: O
0 B_MEASURE
. O
80 B_MEASURE
to O
2 B_MEASURE
. O
89 B_MEASURE
) O
. O

Digoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
the O
only O
other O
medication O
associated O
with O
an O
increased O
risk O
of O
pacemaker O
insertion O
( O
OR O
: O
1 O
. O
78 O
, O
95 O
% O
CI O
: O
1 O
. O
37 O
to O
2 O
. O
31 O
) O
. O

conclusions O
: O
This O
study O
suggests O
that O
the O
use O
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
elderly O
patients O
with O
AF O
and O
a O
previous O
MI O
increases O
the O
risk O
of O
bradyarrhythmia O
requiring O
a O
permanent O
pacemaker O
. O

The O
finding O
of O
an O
augmented O
risk O
of O
pacemaker O
insertion O
in O
elderly O
women O
receiving O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
requires O
further O
investigation O
. O

Indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
morphologic O
changes O
in O
the O
rat O
urinary O
bladder O
epithelium O
. O

objectives O
: O
To O
evaluate O
the O
morphologic O
changes O
in O
rat O
urothelium O
induced O
by O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

nonsteroidal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
inflammatory B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drug I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
induced O
cystitis B_DISEASE
is O
a O
poorly O
recognized O
and O
under O
- O
reported O
condition B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
addition O
to O
tiaprofenic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
reported O
to O
be O
associated O
with O
this O
condition O
. O

methods O
: O
Three O
groups O
were O
established O
: O
a O
control O
group O
( O
n O
= O
10 O
) O
, O
a O
high O
- O
dose O
group O
( O
n O
= O
10 O
) O
, O
treated O
with O
one O
intraperitoneal O
injection O
of O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
20 O
mg O
/ O
kg O
, O
and O
a O
therapeutic O
dose O
group O
( O
n O
= O
10 O
) O
in O
which O
oral O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
3 O
. O
25 O
mg O
/ O
kg O
body O
weight O
daily O
for O
3 O
weeks O
. O

The O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
then O
killed O
and O
the O
bladders B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
removed O
for O
light B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
electron B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
light B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O
some O
focal B_DISEASE
epithelial I_DISEASE
degeneration I_DISEASE
that O
was O
more O
prominent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
high B_MEASURE/B_PERSON
- O
dose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

When O
compared O
with O
the O
control O
group O
, O
both O
indomethacin B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
groups O
revealed O
statistically O
increased O
numbers O
of O
mast O
cells O
in O
the O
mucosa O
( O
P O
< O
0 O
. O
0001 O
) O
and O
penetration O
of O
lanthanum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
intercellular O
areas O
of O
the O
epithelium O
. O

Furthermore O
, O
the O
difference B_MEASURE
in O
mast B_MEASURE/B_DISEASE
cell B_MEASURE/I_DISEASE
counts B_MEASURE/I_DISEASE
between O
the O
high B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
therapeutic B_MEASURE
dose I_MEASURE
groups I_MEASURE
was O
also O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
0001 B_MEASURE
) O
. O

conclusions O
: O
Indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resulted O
in O
histopathologic O
findings O
typical O
of O
interstitial O
cystitis O
, O
such O
as O
leaky O
bladder O
epithelium O
and O
mucosal O
mastocytosis O
. O

The O
true B_MEASURE/B_LOCATION
incidence B_MEASURE/I_LOCATION
of O
nonsteroidal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
inflammatory B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drug I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
induced O
cystitis B_DISEASE
in O
humans B_PERSON/B_BIO
must O
be O
clarified O
by O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
clinical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

An O
open O
- O
label O
phase O
II O
study O
of O
low O
- O
dose O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
androgen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
independent O
prostate O
cancer O
. O

The O
antiangiogenic O
effects O
of O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
assessed O
in O
clinical O
trials O
in O
patients O
with O
various O
solid O
and O
haematological O
malignancies O
. O

Thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blocks O
the O
activity O
of O
angiogenic O
agents O
including O
bFGF O
, O
VEGF O
and O
IL O
- O
6 O
. O

We O
undertook O
an O
open O
- O
label O
study O
using O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100 O
mg O
once O
daily O
for O
up O
to O
6 O
months O
in O
20 O
men O
with O
androgen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
independent O
prostate O
cancer O
. O

The O
mean B_TIME[MEASURE]/B_LOCATION
time I_TIME[MEASURE]/I_LOCATION
of O
study B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
109 B_MEASURE/B_ENT
days I_MEASURE/I_ENT
( O
median B_TIME[MEASURE]/B_LOCATION
107 I_TIME[MEASURE]/I_LOCATION
, O
range B_MEASURE/B_LOCATION
4 I_MEASURE/I_LOCATION
- O
184 B_TIME[MEASURE]
days I_TIME[MEASURE]
) O
. O

patients O
underwent O
regular O
measurement O
of O
prostate O
- O
specific O
antigen O
( O
PSA O
) O
, O
urea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
electrolytes O
, O
serum O
bFGF O
and O
VEGF O
. O

Three B_NUMBER[MEASURE]/B_PERSON
men I_NUMBER[MEASURE]/I_PERSON
( O
15 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
showed O
a O
decline B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
serum B_DISEASE
PSA I_DISEASE
of O
at O
least O
50 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
, O
sustained O
throughout O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Of O
16 B_PERSON/B_BIO
men I_PERSON/I_BIO
treated O
for O
at O
least O
2 B_TIME[MEASURE]/B_DISEASE
months I_TIME[MEASURE]/I_DISEASE
, O
six B_NUMBER[MEASURE]
( O
37 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
) O
showed O
a O
fall B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
absolute B_MEASURE/B_DISEASE
PSA I_MEASURE/I_DISEASE
by O
a O
median B_MEASURE/B_LOCATION
of O
48 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
. O

increasing O
levels B_MEASURE/B_GENE
of O
serum B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
bFGF I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
VEGF B_GENE/B_DISEASE
were O
associated O
with O
progressive B_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
; O
five B_NUMBER[MEASURE]/B_PERSON
of O
six B_NUMBER[MEASURE]/B_PERSON
men I_NUMBER[MEASURE]/I_PERSON
who O
demonstrated O
a O
fall B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
PSA B_GENE
also O
showed O
a O
decline B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
bFGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
VEGF B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
three B_NUMBER[MEASURE]/B_PERSON
of O
four B_NUMBER[MEASURE]/B_ENT
men I_NUMBER[MEASURE]/I_ENT
with O
a O
rising O
PSA B_MEASURE/B_DISEASE
showed O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
both O
growth B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Adverse B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
included O
constipation B_DISEASE
, O
morning B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drowsiness I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
dizziness B_DISEASE
and O
rash B_DISEASE
, O
and O
resulted O
in O
withdrawal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
from O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
three B_PERSON/B_ENT
men I_PERSON/I_ENT
. O

Evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
peripheral B_DISEASE
sensory I_DISEASE
neuropathy I_DISEASE
was O
found O
in O
nine B_NUMBER[MEASURE]
of O
13 B_PERSON
men I_PERSON
before O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
the O
seven O
men O
who O
completed O
six O
months O
on O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
subclinical O
evidence O
of O
peripheral O
neuropathy O
was O
found O
in O
four O
before O
treatment O
, O
but O
in O
all O
seven O
at O
repeat O
testing O
. O

The O
findings O
indicate O
that O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
may O
be O
an O
option O
for O
patients O
who O
have O
failed O
other O
forms O
of O
therapy O
, O
provided O
close O
follow O
- O
up O
is O
maintained O
for O
development O
of O
peripheral O
neuropathy O
. O

Central O
nervous O
system O
toxicity O
following O
the O
administration O
of O
levobupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
lumbar O
plexus O
block O
: O
A O
report O
of O
two O
cases O
. O

Background B_TIME[MEASURE]/B_LOCATION
AND O
objectives B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Central B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nervous I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
cardiac B_DISEASE
toxicity I_DISEASE
following O
the O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
local B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthetics I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
a O
recognized O
complication B_DISEASE
of O
regional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Levobupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
, O
the O
pure O
S O
( O
- O
) O
enantiomer O
of O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
developed O
to O
improve O
the O
cardiac O
safety O
profile O
of O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
describe O
2 O
cases O
of O
grand O
Mal O
seizures O
following O
accidental O
intravascular O
injection O
of O
levobupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Case B_MEASURE
Report I_MEASURE
: O
Two B_PERSON
patients I_PERSON
presenting O
for O
elective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
orthopedic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
limb I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
underwent O
blockade B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
lumbar B_BODY_PART_OR_ORGAN_COMPONENT
plexus I_BODY_PART_OR_ORGAN_COMPONENT
via O
the O
posterior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
approach I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Immediately O
after O
the O
administration O
of O
levobupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O
. O
5 O
% O
with O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O
. O
5 O
microgram O
/ O
mL O
, O
the O
patients O
developed O
grand O
Mal O
seizures O
, O
despite O
negative O
aspiration O
for O
blood O
and O
no O
clinical O
signs O
of O
intravenous O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
. O

The O
seizures O
were O
successfully O
treated O
with O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thiopental I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
addition O
to O
succinylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
1 O
patient O
. O

Neither O
patient B_PERSON/B_BIO
developed O
signs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
cardiovascular B_DISEASE
toxicity I_DISEASE
. O

Both O
patients O
were O
treated O
preoperatively O
with O
beta O
- O
adrenergic O
antagonist O
medications O
, O
which O
may O
have O
masked O
the O
cardiovascular O
signs O
of O
the O
unintentional O
intravascular O
administration O
of O
levobupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusions O
: O
Although O
levobupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O
have O
a O
safer O
cardiac O
toxicity O
profile O
than O
racemic O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
if O
adequate O
amounts O
of O
levobupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reach O
the O
circulation O
, O
it O
will O
result O
in O
convulsions O
. O

Plasma B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
concentrations I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
sufficient I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
to O
result O
in O
central B_DISEASE
nervous I_DISEASE
system I_DISEASE
toxicity I_DISEASE
did O
not O
produce O
manifestations B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cardiac B_DISEASE
toxicity I_DISEASE
in O
these O
2 B_PERSON/B_BIO
patients B_PERSON/I_BIO
. O

Amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
torsade O
de O
pointes O
during O
bladder O
irrigation O
: O
an O
unusual O
presentation O
- O
- O
a O
case O
report O
. O

The O
authors O
present O
a O
case O
of O
early O
( O
within O
4 O
days O
) O
development O
of O
torsade O
de O
pointes O
( O
TdP O
) O
associated O
with O
oral O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

consistent O
with O
other O
reports O
this O
case O
of O
TdP O
occurred O
in O
the O
context O
of O
multiple O
exacerbating O
factors O
including O
hypokalemia O
and O
digoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
excess O
. O

Transient B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prolongation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
QT B_DISEASE/B_PROTEIN[GENE]
during O
bladder B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
irrigation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
prompted O
the O
episode B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
TDP B_DISEASE/B_GENE
. O

It O
is O
well O
known O
that O
bradycardia B_DISEASE
exacerbates O
acquired O
TDP B_DISEASE/B_GENE
. O

The O
authors O
speculate O
that O
the O
increased O
vagal O
tone O
during O
bladder O
irrigation O
, O
a O
vagal O
maneuver O
, O
in O
the O
context O
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O
resulted O
in O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
proarrhythmia O
. O

In O
the O
absence O
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
, O
a O
second O
bladder O
irrigation O
did O
not O
induce O
TdP O
despite O
hypokalemia O
and O
hypomagnesemia O
. O

anaesthetic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complications I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O
with O
myotonia B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
congenita B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
myotonic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
disorders B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Myotonia O
congenita O
( O
MC O
) O
is O
caused O
by O
a O
defect O
in O
the O
skeletal O
muscle O
chloride B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
channel O
function O
, O
which O
may O
cause O
sustained O
membrane O
depolarisation O
. O

We O
describe O
a O
previously O
healthy O
32 O
- O
year O
- O
old O
woman O
who O
developed O
a O
life O
- O
threatening O
muscle O
spasm O
and O
secondary O
ventilation O
difficulties O
following O
a O
preoperative O
injection O
of O
suxamethonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
muscle B_DISEASE
spasms I_DISEASE
disappeared O
spontaneously O
and O
the O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
proceeded O
without O
further B_DISEASE_ADJECTIVE[DISEASE]
problems I_DISEASE_ADJECTIVE[DISEASE]
. O

When O
subsequently O
questioned O
, O
she O
reported O
minor B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
symptoms B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggesting O
a O
myotonic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
condition I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Myotonia B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
was O
found O
on O
clinical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
examination I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
EMG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
diagnosis B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
MC B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
confirmed O
genetically O
. O

Neither O
the O
patient B_PERSON
nor O
the O
anaesthetist B_PERSON/B_LOCATION
were O
aware B_PERSON
of O
the O
diagnosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
this O
potentially O
lethal B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
complication I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O
. O

We O
give O
a O
brief B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
overview I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
ion B_DISEASE_ADJECTIVE[DISEASE]
channel I_DISEASE_ADJECTIVE[DISEASE]
disorders I_DISEASE_ADJECTIVE[DISEASE]
including O
malignant B_DISEASE/B_PERSON
hyperthermia I_DISEASE/I_PERSON
and O
their O
anaesthetic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
considerations I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Respiratory B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pattern B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
a O
rat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
epilepsy B_DISEASE/B_LOCATION
. O

Purpose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
apnea B_DISEASE
is O
known O
to O
occur O
during O
seizures B_DISEASE/B_LOCATION
, O
but O
systematic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
ictal B_DISEASE
respiratory I_DISEASE
changes I_DISEASE
in O
adults B_PERSON/B_BIO
are O
few B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regarding O
respiratory B_DISEASE_ADJECTIVE[DISEASE]
pattern I_DISEASE_ADJECTIVE[DISEASE]
defects I_DISEASE_ADJECTIVE[DISEASE]
during O
interictal B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
periods I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
also O
are O
scarce B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Here O
we O
sought O
to O
generate O
information O
with O
regard O
to O
the O
interictal O
period O
in O
animals O
with O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
epilepsy O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Twelve B_PERSON/B_BIO
rats I_PERSON/I_BIO
( O
six B_NUMBER[MEASURE]
chronically O
epileptic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
animals I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
six B_NUMBER[MEASURE]/B_PERSON
controls I_NUMBER[MEASURE]/I_PERSON
) O
were O
anesthetized O
, O
given O
tracheotomies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
subjected O
to O
hyperventilation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
hypoventilation B_DISEASE
conditions I_DISEASE
. O

breathing B_PERSON/B_LOCATION
movements I_PERSON/I_LOCATION
caused O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
thoracic B_MEASURE/B_LOCATION
volume I_MEASURE/I_LOCATION
and O
forced O
air B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
to O
flow O
tidally O
through O
a O
pneumotachograph B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

This O
flow B_MEASURE/B_SPORT[ENT]
was O
measured O
by O
using O
a O
differential B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
pressure I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
transducer I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
passed O
through O
a O
polygraph B_MEDICAL_DEVICE[OBJECT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
from O
this O
to O
a O
computer B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
with O
custom B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
software I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
derived O
ventilation B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
ve B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
tidal B_MEASURE/B_LOCATION
volume I_MEASURE/I_LOCATION
( O
VT B_PROTEIN[GENE]/B_DISEASE
) O
, O
inspiratory B_MEASURE/B_LOCATION
time I_MEASURE/I_LOCATION
( O
TI B_PROTEIN[GENE]/B_DISEASE
) O
, O
expiratory B_MEASURE/B_LOCATION
time I_MEASURE/I_LOCATION
( O
TE B_PROTEIN[GENE]/B_DISEASE
) O
, O
breathing B_MEASURE/B_LOCATION
frequency I_MEASURE/I_LOCATION
( O
f B_PROTEIN[GENE]/B_LOCATION
) O
, O
and O
mean B_MEASURE/B_LOCATION
inspiratory I_MEASURE/I_LOCATION
flow I_MEASURE/I_LOCATION
( O
VT B_PROTEIN[GENE]/B_DISEASE
/ O
TI B_PROTEIN[GENE]/B_DISEASE
) O
on O
a O
breath B_BODY_PART_OR_ORGAN_COMPONENT
- O
by O
- O
breath B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
basis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

Results O
: O
The O
hyperventilation O
maneuver O
caused O
a O
decrease O
in O
spontaneous O
ventilation O
in O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
and O
control O
rats O
. O

Although O
VE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
had O
a O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decrease B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
both O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
the O
epileptic B_TIME[MEASURE]/B_ORGANIZATION
group I_TIME[MEASURE]/I_ORGANIZATION
, O
the O
decrease B_DISEASE_ADJECTIVE[DISEASE]
in O
VE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
was O
due O
to O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
p O
< B_MEASURE
0 B_MEASURE
. O
05 B_MEASURE
) O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
te B_MEASURE/B_LOCATION
peak I_MEASURE/I_LOCATION
in O
relation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
that O
of O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

The O
hypoventilation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
maneuver I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
led O
to O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
arterial B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
Paco2 I_PROTEIN[GENE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
followed O
by O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
VE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

In O
the O
epileptic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
increase B_DISEASE_ADJECTIVE[DISEASE]
in O
VE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
was O
mediated O
by O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
p B_OTHER/B_MEASURE
< B_MEASURE
0 B_MEASURE
. O
05 B_MEASURE
) O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
te B_MEASURE/B_LOCATION
peak I_MEASURE/I_LOCATION
compared O
with O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

Systemic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
application I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
KCN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
to O
evaluate O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
peripheral B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemoreception B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activation B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
ventilation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
, O
led O
to O
a O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
VE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
both O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

conclusions O
: O
The O
data O
indicate O
that O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
animals O
have O
an O
altered O
ability O
to O
react O
to O
( O
or O
compensate O
for O
) O
blood O
gas O
changes O
with O
changes O
in O
ventilation O
and O
suggest O
that O
it O
is O
centrally O
determined O
. O

We O
speculate O
on O
the O
possible B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
relation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
treating O
different B_DISEASE
epilepsy I_DISEASE
- O
associated O
conditions B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

fatal O
myeloencephalopathy O
due O
to O
intrathecal O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
. O

Vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
accidentally O
given O
intrathecally O
to O
a O
child O
with O
leukaemia O
, O
producing O
sensory O
and O
motor O
dysfunction O
followed O
by O
encephalopathy O
and O
death O
. O

separate O
times O
for O
administering O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
intrathecal O
therapy O
is O
recommended O
. O

Progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
potentiation O
of O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
arrhythmogenicity O
in O
pentobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
anesthetized O
rats O
and O
beating O
rat O
heart O
cell O
cultures O
. O

The O
effects O
of O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
on O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
arrhythmogenicity O
in O
beating O
rat O
heart O
myocyte O
cultures O
and O
on O
anesthetized O
rats O
were O
determined O
. O

After O
determining O
the O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
AD50 O
( O
the O
concentration O
of O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
caused O
50 O
% O
of O
all O
beating O
rat O
heart O
myocyte O
cultures O
to O
become O
arrhythmic O
) O
, O
we O
determined O
the O
effect O
of O
1 O
- O
hour O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
HCl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
exposure O
on O
myocyte O
contractile O
rhythm O
. O

Each O
concentration O
of O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
6 O
. O
25 O
, O
12 O
. O
5 O
, O
25 O
, O
and O
50 O
micrograms O
/ O
ml O
) O
caused O
a O
significant O
and O
concentration O
- O
dependent O
reduction O
in O
the O
AD50 O
for O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Estradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment O
also O
increased O
the O
arrhythmogenicity O
of O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
myocyte O
cultures O
, O
but O
was O
only O
one O
fourth O
as O
potent O
as O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Neither O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O
estradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O
on O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
arrhythmogenicity O
were O
potentiated O
by O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

chronic O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreatment O
( O
5 O
mg O
/ O
kg O
/ O
day O
for O
21 O
days O
) O
caused O
a O
significant O
increase O
in O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
arrhythmogenicity O
in O
intact O
pentobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
anesthetized O
rats O
. O

There O
was O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decrease I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
time B_TIME[MEASURE]/B_DISEASE
to O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
arrhythmia B_DISEASE
as O
compared O
with O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nonprogesterone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
6 B_MEASURE
. O
2 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
1 B_MEASURE
. O
3 B_MEASURE/B_SPORT[ENT]
vs I_MEASURE/I_SPORT[ENT]
. O
30 B_MEASURE
. O
8 B_MEASURE
+ I_MEASURE
/ O
- O
2 B_MEASURE
. O
5 B_TIME[MEASURE]
min I_TIME[MEASURE]
, O
mean O
+ B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
- O
SE B_DISEASE/B_PROTEIN[GENE]
) O
. O

The O
results O
of O
this O
study O
indicate O
that O
progesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
potentiate O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
arrhythmogenicity O
both O
in O
vivo O
and O
in O
vitro O
. O

Potentiation O
of O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
arrhythmia O
in O
myocyte O
cultures O
suggests O
that O
this O
effect O
is O
at O
least O
partly O
mediated O
at O
the O
myocyte O
level O
. O

increased O
serum O
soluble O
Fas O
in O
patients O
with O
acute O
liver O
failure O
due O
to O
paracetamol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
overdose O
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
/ O
aims B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
suggested O
that O
apoptosis B_DISEASE/B_GENE
via O
the O
Fas B_GENE/B_DISEASE
/ O
Fas B_GENE/B_PERSON
ligand I_GENE/I_PERSON
signaling O
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O
play O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
development B_DISEASE_ADJECTIVE[DISEASE]
of O
acute B_DISEASE
liver I_DISEASE
failure I_DISEASE
. O

The O
aim B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
to O
investigate O
the O
soluble B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
form I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
Fas B_GENE
in O
patients B_PERSON/B_BIO
with O
acute B_DISEASE/B_LOCATION
liver I_DISEASE/I_LOCATION
failure I_DISEASE/I_LOCATION
. O

methodology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
: O
Serum B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
sFas B_GENE/B_DISEASE
( O
soluble B_PROTEIN[GENE]/B_LOCATION
Fas I_PROTEIN[GENE]/I_LOCATION
) O
were O
measured O
by O
ELISA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
24 B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
acute B_DISEASE/B_LOCATION
liver I_DISEASE/I_LOCATION
failure I_DISEASE/I_LOCATION
and O
10 B_DISEASE
normal I_DISEASE
control I_DISEASE
subjects I_DISEASE
. O

Serum B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
alpha B_PROTEIN[GENE]
and O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
gamma B_PROTEIN[GENE]/B_MEASURE
were O
also O
determined O
by O
ELISA B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Serum B_GENE
sFas I_GENE
was O
significantly O
increased O
in O
patients B_PERSON/B_BIO
with O
acute B_DISEASE/B_LOCATION
liver I_DISEASE/I_LOCATION
failure I_DISEASE/I_LOCATION
( O
median B_MEASURE
, O
26 B_MEASURE
. O
8 B_MEASURE/B_LOCATION
U I_MEASURE/I_LOCATION
/ O
mL B_MEASURE/B_LOCATION
; O
range B_LOCATION/B_MEASURE
, O
6 B_MEASURE
. O
9 B_MEASURE
- O
52 B_MEASURE
. O
7 B_MEASURE/B_LOCATION
U I_MEASURE/I_LOCATION
/ O
mL B_MEASURE/B_LOCATION
) O
compared O
to O
the O
normal B_PERSON/B_MEASURE
controls I_PERSON/I_MEASURE
( O
median B_MEASURE/B_GENE
, O
8 B_MEASURE
. O
6 B_MEASURE
U I_MEASURE
/ O
mL B_MEASURE/B_LOCATION
; O
range B_LOCATION/B_MEASURE
, O
6 B_MEASURE
. O
5 B_MEASURE
- O
12 B_MEASURE
. O
0 B_MEASURE/B_LOCATION
U I_MEASURE/I_LOCATION
/ O
mL B_MEASURE/B_LOCATION
, O
P B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
0001 B_MEASURE
) O
. O

levels O
were O
significantly O
greater O
in O
patients O
with O
acute O
liver O
failure O
due O
to O
paracetamol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
overdose O
( O
median O
, O
28 O
. O
7 O
U O
/ O
mL O
; O
range O
, O
12 O
. O
8 O
- O
52 O
. O
7 O
U O
/ O
mL O
, O
n O
= O
17 O
) O
than O
those O
due O
to O
non O
- O
A O
to O
E O
hepatitis O
( O
median O
, O
12 O
. O
5 O
U O
/ O
mL O
; O
range O
, O
6 O
. O
9 O
- O
46 O
. O
0 O
U O
/ O
mL O
, O
n O
= O
7 O
, O
P O
< O
0 O
. O
01 O
) O
. O

There O
was O
no O
relationship B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
sFas B_GENE/B_DISEASE
to O
eventual B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
patients B_PERSON/B_LOCATION
. O

A O
significant O
correlation O
was O
observed O
between O
serum O
sFas O
levels O
and O
aspartate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminotransferase O
( O
r O
= O
0 O
. O
613 O
, O
P O
< O
0 O
. O
01 O
) O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
increased O
concentration B_MEASURE/B_LOCATION
of O
sFas B_GENE
in O
serum B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON/B_BIO
with O
acute B_DISEASE/B_LOCATION
liver I_DISEASE/I_LOCATION
failure I_DISEASE/I_LOCATION
may O
reflect O
activation B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
of O
Fas B_GENE
- O
mediated O
apoptosis B_DISEASE/B_GENE
in O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
this O
together O
with O
increased O
tumor B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
necrosis I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
alpha B_PROTEIN[GENE]
may O
be O
an O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
liver B_DISEASE
cell I_DISEASE
loss I_DISEASE
. O

Bilateral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
subthalamic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nucleus I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
Parkinson B_DISEASE/B_PERSON
' I_DISEASE
s B_DISEASE
disease I_DISEASE
. O

High B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
frequency I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
stimulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
the O
subthalamic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
nucleus I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
( O
STN B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
known O
to O
ameliorate O
the O
signs B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
symptoms B_DISEASE
of O
advanced B_DISEASE
Parkinson I_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
. O

Aim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
studied O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
high B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
frequency I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
STN I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
23 B_PERSON/B_BIO
patients I_PERSON/I_BIO
. O

Method O
: O
Twenty O
- O
three O
patients O
suffering O
from O
severe O
Parkinson O
' O
s O
disease O
( O
stages O
III O
- O
V O
on O
Hoehn O
and O
Yahr O
scale O
) O
and O
, O
particularly O
bradykinesia O
, O
rigidity O
, O
and O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
dyskinesias O
underwent O
bilateral O
implantation O
of O
electrodes O
in O
the O
STN O
. O

Preoperative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
postoperative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assessments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
these O
patients B_PERSON
at O
1 B_SEQUENCE[MEASURE]
, O
3 B_SEQUENCE[MEASURE]
, O
6 B_NUMBER[MEASURE]
and O
12 B_NUMBER[MEASURE]/B_PERSON
months I_NUMBER[MEASURE]/I_PERSON
follow O
- O
up O
, O
in O
' O
on O
' O
and O
' O
off O
' O
drug B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
conditions B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
was O
carried O
out O
using O
Unified B_PERSON
Parkinson I_PERSON
' I_PERSON
s I_PERSON
Disease I_PERSON
rating I_PERSON
Scale I_PERSON
, O
Hoehn B_DISEASE/B_LOCATION
and O
Yahr B_LOCATION/B_ENT
staging I_LOCATION/I_ENT
, O
England B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
daily B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
living B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
score B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
video B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
recordings I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
After O
one B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
year I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
electrical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
STN B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
the O
patients B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
scores B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
activities B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
daily B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
living I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
and O
motor B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scores I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Unified B_MEASURE/B_LOCATION
Parkinson B_MEASURE/I_LOCATION
' B_MEASURE/I_LOCATION
s B_MEASURE/I_LOCATION
Disease B_MEASURE/I_LOCATION
rating B_MEASURE/I_LOCATION
Scale B_MEASURE/I_LOCATION
parts O
II B_NUMBER[MEASURE]/B_PROTEIN[GENE]
and O
III B_TIME[MEASURE]
) O
off O
medication B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
improved O
by O
62 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
61 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
respectively O
( O
p B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
0005 B_MEASURE
) O
. O

The O
subscores B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
akinesia B_DISEASE/B_MEASURE
, O
rigidity B_DISEASE
, O
tremor B_DISEASE
and O
gait B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
also O
improved O
. O

( O
p O
< O
0 B_MEASURE
. O
0005 B_MEASURE
) O
. O

The O
average O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O
decreased O
from O
813 O
mg O
to O
359 O
mg O
. O

The O
cognitive B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
functions I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
remained O
unchanged B_DISEASE_ADJECTIVE[DISEASE]
. O

Two B_PERSON
patients I_PERSON
developed O
device B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
related O
complications B_DISEASE
and O
two B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
experienced O
abnormal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weight I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
gain I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Bilateral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
subthalamic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
nucleus I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
an O
effective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
advanced B_DISEASE/B_LOCATION
Parkinson I_DISEASE/I_LOCATION
' I_DISEASE/I_LOCATION
s I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
. O

It O
reduces O
the O
severity O
of O
' O
off O
' O
phase O
symptoms O
, O
improves O
the O
axial O
symptoms O
and O
reduces O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
requirements O
. O

The O
reduction O
in O
the O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O
is O
useful O
in O
controlling O
drug O
- O
induced O
dyskinesias O
. O

acute O
renal O
failure O
occurring O
during O
intravenous O
desferrioxamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
: O
recovery O
after O
haemodialysis O
. O

A O
patient O
with O
transfusion O
- O
dependent O
thalassemia O
was O
undergoing O
home O
intravenous O
desferrioxamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
DFX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
treatment O
by O
means O
of O
a O
totally O
implanted O
system O
because O
of O
his O
poor O
compliance O
with O
the O
nightly O
subcutaneous O
therapy O
. O

Due O
to O
an O
accidental B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
malfunctioning I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
infusion B_PRODUCT[OBJECT]/B_LOCATION
pump I_PRODUCT[OBJECT]/I_LOCATION
, O
the O
patient B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
was O
inadvertently O
administered O
a O
toxic B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dosage B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
caused O
renal B_DISEASE
insufficiency I_DISEASE
. O

Given O
the O
progressive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
deterioration I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
the O
symptoms B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
of O
the O
laboratory B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
despite O
adequate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
medical I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
a O
decision B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
made O
to O
introduce O
haemodialytical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
order B_MEASURE/B_PERSON
to O
remove O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
reduce O
the O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

From O
the O
results O
obtained O
, O
haemodialysis O
can O
therefore O
be O
suggested O
as O
a O
useful O
therapy O
in O
rare O
cases O
of O
progressive O
acute O
renal O
failure O
caused O
by O
desferrioxamine B_DISEASE
. O

Ocular O
motility O
changes O
after O
subtenon O
carboplatin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
chemotherapy O
for O
retinoblastoma O
. O

Background O
: O
focal O
subtenon O
carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
injections O
have O
recently O
been O
used O
as O
a O
presumably O
toxicity O
- O
free O
adjunct O
to O
systemic O
chemotherapy O
for O
intraocular O
retinoblastoma O
. O

objective O
: O
To O
report O
our O
clinical O
experience O
with O
abnormal O
ocular O
motility O
in O
patients O
treated O
with O
subtenon O
carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
chemotherapy O
. O

methods O
: O
We O
noted O
abnormal O
ocular O
motility O
in O
10 O
consecutive O
patients O
with O
retinoblastoma O
who O
had O
received O
subtenon O
carboplatin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

During O
ocular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
manipulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
under O
general B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
we O
assessed O
their O
eyes B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
forced B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
duction I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
testing I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
comparing O
ocular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motility B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
tumor B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
control I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
ocular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motility B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
diagnosis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Eyes B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
subsequently O
enucleated O
because O
of O
treatment B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
n B_PROTEIN[GENE]/B_LOCATION
= I_PROTEIN[GENE]/I_LOCATION
4 I_PROTEIN[GENE]/I_LOCATION
) O
were O
examined O
histologically O
. O

Results O
: O
limitation O
of O
ocular O
motility O
was O
detected O
in O
all O
12 O
eyes O
of O
10 O
patients O
treated O
for O
intraocular O
retinoblastoma O
with O
1 O
to O
6 O
injections O
of O
subtenon O
carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
part O
of O
multimodality O
therapy O
. O

Histopathological B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
examination I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O
many B_DISEASE
lipophages I_DISEASE
in O
the O
periorbital B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
fat B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
surrounding O
the O
optic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
nerve I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
1 B_PERSON/B_BIO
eye I_PERSON/I_BIO
, O
indicative B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
phagocytosis B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
of O
previously O
existing O
fat B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
and O
suggesting O
prior B_DISEASE
fat I_DISEASE
necrosis I_DISEASE
. O

The O
enucleations B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
were O
technically O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hazardous B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
globe B_DISEASE/B_PERSON
rupture I_DISEASE/I_PERSON
because O
of O
extensive B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
orbital I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
soft I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tissue I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
adhesions I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

conclusions O
: O
Subtenon O
carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
chemotherapy O
is O
associated O
with O
significant O
fibrosis O
of O
orbital O
soft O
tissues O
, O
leading O
to O
mechanical O
restriction O
of O
eye O
movements O
and O
making O
subsequent O
enucleation O
difficult O
. O

Subtenon O
carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
free O
of O
toxicity O
, O
and O
its O
use O
is O
best O
restricted O
to O
specific O
indications O
. O

Ethambutol B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
optic O
neuropathy O
. O

purpose O
: O
To O
demonstrate O
the O
association O
between O
ethambutol B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
optic O
neuropathy O
. O

Method O
: O
Thirteen O
patients O
who O
developed O
optic O
neuropathy O
after O
being O
treated O
with O
ethambutol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
tuberculosis O
of O
the O
lung O
or O
lymph O
node O
at O
Siriraj O
Hospital O
between O
1997 O
and O
2001 O
were O
retrospectively O
reviewed O
. O

The O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
characteristics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
initial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
final B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visual B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acuity B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
analyzed O
to O
determine O
visual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Results O
: O
All O
patients O
had O
optic O
neuropathy O
between O
1 O
to O
6 O
months O
( O
mean O
= O
2 O
. O
9 O
months O
) O
after O
starting O
ethambutol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O
at O
a O
dosage O
ranging O
from O
13 O
to O
20 O
mg O
/ O
kg O
/ O
day O
( O
mean O
= O
17 O
mg O
/ O
kg O
/ O
day O
) O
. O

Seven B_NUMBER[MEASURE]
( O
54 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
) O
of O
the O
13 B_PERSON
patients I_PERSON
experienced O
visual B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
stopping O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Of O
6 B_PERSON
patients I_PERSON
with O
irreversible B_DISEASE
visual I_DISEASE
impairment I_DISEASE
, O
4 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
had O
diabetes B_DISEASE
mellitus I_DISEASE
, O
glaucoma B_DISEASE
and O
a O
history B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
heavy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
smoking I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

conclusion O
: O
Early O
recognition O
of O
optic O
neuropathy O
should O
be O
considered O
in O
patients O
with O
ethambutol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

A O
low B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
dose I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
and O
prompt B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
discontinuation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
recommended O
particularly O
in O
individuals B_PERSON/B_LOCATION
with O
diabetes B_DISEASE
mellitus I_DISEASE
, O
glaucoma B_DISEASE
or O
who O
are O
heavy B_DISEASE/B_PERSON
smokers I_DISEASE/I_PERSON
. O

Treatment O
of O
compensatory O
gustatory O
hyperhidrosis O
with O
topical O
glycopyrrolate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Gustatory B_DISEASE
hyperhidrosis I_DISEASE
is O
facial B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
sweating B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
usually O
associated O
with O
the O
eating B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
hot B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
spicy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
food I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
or O
even O
smelling O
this O
food B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

Current O
options O
of O
treatment O
include O
oral O
anticholinergic O
drugs O
, O
the O
topical O
application O
of O
anticholinergics O
or O
aluminum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
injection O
of O
botulinum O
toxin O
. O

Thirteen O
patients O
have O
been O
treated O
to O
date O
with O
1 O
. O
5 O
% O
or O
2 O
% O
topical O
glycopyrrolate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

All O
patients B_PERSON
had O
gustatory B_DISEASE
hyperhidrosis I_DISEASE
, O
which O
interfered O
with O
their O
social B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
activities I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
after O
transthroacic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
endoscopic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
sympathectomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
, O
and O
which O
was O
associated O
with O
compensatory B_DISEASE
focal I_DISEASE
hyperhidrosis I_DISEASE
. O

After O
applying O
topical O
glycopyrrolate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
subjective O
effect O
was O
excellent O
( O
no O
sweating O
after O
eating O
hot O
spicy O
food O
) O
in O
10 O
patients O
( O
77 O
% O
) O
, O
and O
fair O
( O
clearly O
reduced O
sweating O
) O
in O
3 O
patients O
( O
23 O
% O
) O
. O

All O
had O
reported O
incidents B_PERSON/B_DISEASE
of O
being O
very O
embarrassed B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
whilst B_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
eating O
hot B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
spicy I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
foods I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

adverse O
effects O
included O
a O
mildly O
dry O
mouth O
and O
a O
sore O
throat O
in O
2 O
patients O
( O
2 O
% O
glycopyrrolate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
a O
light O
headache O
in O
1 O
patient O
( O
1 O
. O
5 O
% O
glycopyrrolate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
. O

The O
topical O
application O
of O
a O
glycopyrrolate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pad O
appeared O
to O
be O
safe O
, O
efficacious O
, O
well O
tolerated O
, O
and O
a O
convenient O
method O
of O
treatment O
for O
moderate O
to O
severe O
symptoms O
of O
gustatory O
hyperhidrosis O
in O
post O
transthoracic O
endoscopic O
sympathectomy O
or O
sympathicotomy O
patients O
, O
with O
few O
side O
effects O
. O

Neuroleptic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
hyperprolactinemia O
. O

Can O
it O
be O
treated O
with O
bromocriptine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]

Six O
stable O
psychiatric O
outpatients O
with O
hyperprolactinemia O
and O
amenorrhea O
/ O
oligomenorrhea O
associated O
with O
their O
neuroleptic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
medications B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
treated O
with O
bromocriptine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Daily B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
dosages I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
5 B_NUMBER[MEASURE]
- O
10 B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
corrected O
the O
hyperprolactinemia B_DISEASE_ADJECTIVE[DISEASE]
and O
restored O
menstruation B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
in O
four B_NUMBER[MEASURE]/B_PERSON
of O
the O
six B_PERSON
patients I_PERSON
. O

One O
woman O
, O
however O
, O
developed O
worsened O
psychiatric O
symptoms O
while O
taking O
bromocriptine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
it O
was O
discontinued O
. O

Thus O
, O
three O
of O
six O
patients O
had O
their O
menstrual O
irregularity O
successfully O
corrected O
with O
bromocriptine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

This O
suggests O
that O
bromocriptine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
further O
evaluated O
as O
potential O
therapy O
for O
neuroleptic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
hyperprolactinemia O
and O
amenorrhea O
/ O
galactorrhea O
. O

Ethacrynic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
induced O
convulsions O
and O
brain O
neurotransmitters O
in O
mice O
. O

Intracerebroventricular O
injection O
of O
ethacrynic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
50 O
% O
convulsive O
dose O
; O
50 O
micrograms O
/ O
mouse O
) O
accelerated O
the O
synthesis O
/ O
turnover O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
hydroxytryptamine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
5 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HT I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
but O
suppressed O
the O
synthesis O
of O
gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminobutyric I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
acetylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
mouse O
brain O
. O

These O
effects O
were O
completely O
antagonized O
by O
pretreatment O
with O
a O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspartate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonist O
, O
aminophosphonovaleric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
ethacrynic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
convulsions O
, O
these O
neurotransmitter O
systems O
may O
be O
differentially O
modulated O
, O
probably O
through O
activation O
of O
glutaminergic O
neurons O
in O
the O
brain O
. O

Pharmacology O
of O
gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminobutyric I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acidA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptor O
complex O
after O
the O
in O
vivo O
administration O
of O
the O
anxioselective O
and O
anticonvulsant O
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
carboline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derivative O
abecarnil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
rodents O
, O
the O
effect O
of O
the O
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
carboline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
derivative O
isopropyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benzyloxy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methoxymethyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboxylate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
abecarrnil B_LOCATION/B_PROTEIN[GENE]
) O
, O
a O
new O
ligand O
for O
benzodiazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors O
possessing O
anxiolytic O
and O
anticonvulsant O
properties O
, O
was O
evaluated O
on O
the O
function O
of O
central O
gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminobutyric I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
GABA B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
A O
receptor O
complex O
, O
both O
in O
vitro O
and O
in O
vivo O
. O

added O
in O
vitro O
to O
rat O
cortical O
membrane O
preparation O
, O
abecarnil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
increased O
[ O
3H O
] O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O
, O
enhanced O
muscimol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stimulated O
36Cl O
- O
uptake O
and O
reduced O
the O
binding O
of O
t B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
[ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
35S I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
butylbicyclophosphorothionate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
35S I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
TBPS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O
. O

These O
effects O
were O
similar O
to O
those O
induced O
by O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whereas O
the O
partial O
agonist O
Ro B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
16 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6028 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
tert B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
butyl I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
S I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
8 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bromo I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
11 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
13 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
13a I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tetrahydro I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxo I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9H I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imidazo I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pyrrolo I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
c I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
[ I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benzodiazepine I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
carboxylate I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
showed O
very O
weak O
efficacy O
in O
these O
biochemical O
tests O
. O

After O
i O
. O
p O
. O
injection O
to O
rats O
, O
abecarnil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O
in O
a O
time O
- O
dependent O
and O
dose O
- O
related O
( O
0 O
. O
25 O
- O
20 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
manner O
[ B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
35S I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TBPS I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
binding O
measured O
ex O
vivo O
in O
the O
cerebral O
cortex O
. O

Moreover O
, O
both O
drugs O
at O
the O
dose O
of O
0 O
. O
5 O
mg O
/ O
kg O
antagonized O
completely O
the O
convulsant O
activity O
and O
the O
increase O
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
35S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
TBPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding O
induced O
by O
isoniazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
350 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
as O
well O
as O
the O
increase O
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
35S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
TBPS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding O
induced O
by O
foot O
- O
shock O
stress O
. O

To O
better O
correlate O
the O
biochemical O
and O
the O
pharmacological O
effects O
, O
we O
studied O
the O
action O
of O
abecarnil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
35S I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
TBPS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding O
, O
exploratory O
motility O
and O
on O
isoniazid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
biochemical O
and O
pharmacological O
effects O
in O
mice O
. O

In O
these O
animals O
, O
abecarnil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O
a O
paralleled O
dose O
- O
dependent O
( O
0 O
. O
05 O
- O
1 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
reduction O
of O
both O
motor O
behavior O
and O
cortical O
[ O
35S O
] O
TBPS O
binding O
. O

Moreover O
, O
0 O
. O
05 O
mg O
/ O
kg O
of O
this O
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
carboline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reduced O
markedly O
the O
increase O
of O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
35S I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
TBPS I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding O
and O
the O
convulsions O
induced O
by O
isoniazid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
200 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
. O
( O
abstract O
TRUNCATED O
AT O
250 O
Words O
) O
. O

Recurrent O
myocardial O
infarction O
in O
a O
postpartum O
patient O
receiving O
bromocriptine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Myocardial B_DISEASE
infarction I_DISEASE
in O
puerperium B_BIO/B_DISEASE
is O
infrequently O
reported O
. O

spasm B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
coronary B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dissection I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
or O
atheromatous B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
etiology I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O
been O
described O
. O

Bromocriptine B_PERSON
has O
been O
implicated O
in O
several O
previous O
case O
reports O
of O
myocardial O
infarction O
in O
the O
puerperium O
. O

Our O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
including O
an O
inadvertent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rechallenge I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O
suggests O
such O
a O
relationship B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Although O
generally O
regarded O
as O
' O
safe O
, O
' O
possible O
serious O
cardiac O
effects O
of O
bromocriptine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
acknowledged O
. O

Asterixis O
induced O
by O
carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

There O
are O
very O
few B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
about O
asterixis B_DISEASE/B_BIO
as O
a O
side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
psychopharmacologic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
this O
report O
we O
present O
four O
patients O
treated O
with O
a O
combination O
of O
different O
psychotropic O
drugs O
, O
in O
whom O
asterixis O
was O
triggered O
either O
by O
adding O
carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CBZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
to O
a O
treatment O
regimen O
, O
or O
by O
increasing O
its O
dosage O
. O

Neither O
dosage O
nor O
serum O
levels O
of O
CBZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
in O
a O
higher O
range O
. O

We O
consider O
asterixis O
to O
be O
an O
easily O
overlooked O
sign O
of O
neurotoxicity O
, O
which O
may O
occur O
even O
at O
low O
or O
moderate O
dosage O
levels O
, O
if O
certain O
drugs O
as O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
used O
in O
combination O
with O
CBZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pharmacodynamics O
of O
the O
hypotensive O
effect O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
parkinsonian O
patients O
. O

Blood O
pressure O
effects O
of O
i O
. O
v O
. O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
examined O
in O
parkinsonian O
patients O
with O
stable O
and O
fluctuating O
responses O
to O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

The O
magnitude O
of O
the O
hypotensive O
effect O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
concentration O
dependent O
and O
was O
fit O
to O
an O
Emax O
model O
in O
fluctuating O
responders O
. O

stable B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responders I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O
a O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
hypotensive I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
response I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Baseline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
blood I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
pressures I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
fluctuating O
patients B_PERSON/B_LOCATION
; O
a O
higher B_MEASURE
baseline I_MEASURE
blood I_MEASURE
pressure I_MEASURE
correlated O
with O
greater B_DISEASE
hypotensive I_DISEASE
effects I_DISEASE
. O

Antiparkinsonian O
effects O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
temporally O
correlated O
with O
blood O
pressure O
changes O
. O

Phenylalanine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
a O
large O
neutral O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
LNAA O
) O
competing O
with O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
transport O
across O
the O
blood O
- O
brain O
barrier O
, O
reduced O
the O
hypotensive O
and O
antiparkinsonian O
effects O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
conclude O
that O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
a O
central O
hypotensive O
action O
that O
parallels O
the O
motor O
effects O
in O
fluctuating O
patients O
. O

The O
hypotensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
appears O
to O
be O
related O
to O
the O
higher B_DISEASE_ADJECTIVE[DISEASE]
baseline I_DISEASE_ADJECTIVE[DISEASE]
blood I_DISEASE_ADJECTIVE[DISEASE]
pressure I_DISEASE_ADJECTIVE[DISEASE]
we O
observed O
in O
fluctuating O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relative I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
stable B_PERSON
patients I_PERSON
. O

syndrome O
of O
inappropriate O
secretion O
of O
antidiuretic O
hormone O
after O
infusional O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

A O
77 O
- O
year O
- O
old O
woman O
with O
refractory O
multiple O
myeloma O
was O
treated O
with O
a O
4 O
- O
day O
continuous O
intravenous O
infusion O
of O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
4 O
days O
of O
oral O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Nine B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
after O
her O
second B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
cycle I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
she O
presented O
with O
lethargy B_DISEASE
and O
weakness B_DISEASE
associated O
with O
hyponatremia B_DISEASE
. O

Evaluation O
revealed O
the O
syndrome O
of O
inappropriate O
secretion O
of O
antidiuretic O
hormone O
, O
which O
was O
attributed O
to O
the O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
infusion O
. O

After O
normal O
serum O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
returned O
, O
further O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O
without O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
did O
not O
produce O
this O
complication O
. O

Heart B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failure B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
to O
digitalise O
or O
not O
. O

The O
view B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
against O
. O

Despite O
extensive O
clinical O
experience O
the O
role O
of O
digoxin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
still O
not O
well O
defined O
. O

In O
patients O
with O
atrial O
fibrillation O
digoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
beneficial O
for O
ventricular O
rate O
control O
. O

For O
patients B_PERSON
in O
sinus B_DISEASE
rhythm I_DISEASE
and O
heart B_DISEASE
failure I_DISEASE
the O
situation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
less O
clear B_DISEASE_ADJECTIVE[DISEASE]
. O

Digoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
a O
narrow O
therapeutic O
: O
toxic O
ratio O
and O
concentrations O
are O
affected O
by O
a O
number O
of O
drugs O
. O

Also O
, O
digoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
has O
undesirable O
effects O
such O
as O
increasing O
peripheral O
resistance O
and O
myocardial O
demands O
, O
and O
causing O
arrhythmias O
. O

There O
is O
a O
paucity B_DISEASE/B_MEASURE
of O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
from O
well O
- O
designed O
trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
are O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
generally O
small B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
with O
limitations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
these O
show B_MEASURE
variation I_MEASURE
in O
patient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benefit I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

More O
convincing O
evidence O
is O
required O
showing O
that O
digoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improves O
symptoms O
or O
exercise O
capacity O
. O

Furthermore O
, O
no O
trial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
has O
had O
sufficient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
power I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
evaluate O
mortality B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pooled O
analysis O
of O
the O
effects O
of O
other O
inotropic O
drugs O
shows O
an O
excess O
mortality O
and O
there O
is O
a O
possibility O
that O
digoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
may O
increase O
mortality O
after O
myocardial O
infarction O
( O
MI O
) O
. O

Angiotensin B_GENE
- O
converting O
enzyme O
( O
ace O
) O
inhibitors O
should O
be O
used O
first O
as O
they O
are O
safer O
, O
do O
not O
require O
blood O
level O
monitoring O
, O
modify O
progression O
of O
disease O
, O
relieve O
symptoms O
, O
improve O
exercise O
tolerance O
and O
reduce O
mortality O
. O

caution O
should O
be O
exercised O
in O
using O
digoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
until O
large O
mortality O
trials O
are O
completed O
showing O
either O
benefit O
or O
harm O
. O

Until O
then O
digoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
considered O
a O
third O
- O
line O
therapy O
. O

Isradipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment O
for O
hypertension O
in O
general O
practice O
in O
Hong O
Kong O
. O

A O
6 O
- O
week O
open O
study O
of O
the O
introduction O
of O
isradipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
was O
conducted O
in O
general O
practice O
in O
Hong O
Kong O
. O

303 B_PERSON/B_BIO
Chinese I_PERSON/I_BIO
patients I_PERSON/I_BIO
with O
mild B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
moderate B_DISEASE
hypertension I_DISEASE
entered O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
reported O
in O
21 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
patients B_PERSON
and O
caused O
withdrawal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
from O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
3 B_TIME[MEASURE]/B_PERSON
patients I_TIME[MEASURE]/I_PERSON
. O

The O
main O
side O
- O
effects O
were O
headache O
, O
dizziness O
, O
palpitation O
and O
flushing O
and O
these O
were O
not O
more O
frequent O
than O
reported O
in O
other O
studies O
with O
isradipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
with O
placebo O
. O

supine B_DISEASE/B_GENE
blood I_DISEASE/I_GENE
pressure I_DISEASE/I_GENE
was O
reduced O
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
01 B_MEASURE
) O
from O
170 B_MEASURE
+ I_MEASURE
/ O
- O
20 B_MEASURE
/ O
102 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
mmHg I_MEASURE
to O
153 B_MEASURE
+ I_MEASURE
/ O
- O
19 B_MEASURE
/ O
92 B_MEASURE
+ O
/ O
- O
8 B_MEASURE
, O
147 B_MEASURE
+ I_MEASURE
/ O
- O
18 B_MEASURE
/ O
88 B_MEASURE
+ O
/ O
- O
7 B_MEASURE
and O
144 B_MEASURE
+ I_MEASURE
/ O
- O
14 B_MEASURE
/ O
87 B_MEASURE
+ O
/ O
- O
6 B_MEASURE
mmHg I_MEASURE
at O
2 B_NUMBER[MEASURE]
, O
4 B_MEASURE
and O
6 B_MEASURE/B_ENT
weeks I_MEASURE/I_ENT
respectively O
in O
evaluable B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
. O

Similar B_DISEASE_ADJECTIVE[DISEASE]
reductions I_DISEASE_ADJECTIVE[DISEASE]
occurred O
in O
standing O
blood B_MEASURE/B_DISEASE
pressure I_MEASURE/I_DISEASE
and O
there O
was O
no O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
postural B_DISEASE
hypotension I_DISEASE
. O

normalization B_DISEASE/B_PERSON
and O
responder B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
6 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
weeks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
were O
86 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
69 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
respectively O
. O

dosage B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
increased O
from O
2 B_MEASURE
. O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
mg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
b B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O
d B_TIME[MEASURE]/B_DISEASE
. O
to O
5 B_MEASURE
mg I_MEASURE
b O
. O
d B_TIME[MEASURE]/B_DISEASE
. O
at O
4 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
patients B_PERSON/B_BIO
with O
diastolic B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
blood B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
pressure B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
greater B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
90 B_MEASURE/B_LOCATION
mmHg I_MEASURE/I_LOCATION
and O
their O
further B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
greater B_MEASURE
than O
those O
remaining O
on O
2 B_NUMBER[MEASURE]
. O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
mg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
b B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O
d B_TIME[MEASURE]/B_DISEASE
. O

Pharmacological O
characteristics O
and O
side O
effects O
of O
a O
new O
galenic O
formulation O
of O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
without O
soyabean O
oil O
. O

We O
compared O
the O
pharmacokinetics O
, O
pharmacodynamics O
and O
safety O
profile O
of O
a O
new O
galenic O
formulation O
of O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
AM149 O
1 O
% O
) O
, O
which O
does O
not O
contain O
soyabean O
oil O
, O
with O
a O
standard O
formulation O
of O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Disoprivan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1 O
% O
) O
. O

In O
a O
randomised O
, O
double O
- O
blind O
, O
cross O
- O
over O
study O
, O
30 O
healthy O
volunteers O
received O
a O
single O
intravenous O
bolus O
injection O
of O
2 O
. O
5 O
mg O
. O
kg O
- O
1 O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

plasma O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
were O
measured O
for O
48 O
h O
following O
drug O
administration O
and O
evaluated O
according O
to O
a O
three O
- O
compartment O
model O
. O

The O
pharmacodynamic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
parameters I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
assessed O
included O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
emergence B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
times I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
respiratory B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
cardiovascular B_DISEASE_ADJECTIVE[DISEASE]
effects I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
pain B_DISEASE/B_MEASURE
on O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

patients B_PERSON/B_BIO
were O
monitored O
for O
side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
over O
48 B_MEASURE
h O
. O

owing O
to O
a O
high B_DISEASE_ADJECTIVE[DISEASE]
incidence I_DISEASE_ADJECTIVE[DISEASE]
of O
thrombophlebitis B_DISEASE
, O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
terminated O
prematurely O
and O
only O
the O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
parallel I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
15 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
in O
each O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
were O
analysed O
. O

Plasma B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
concentrations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
did O
not O
differ O
significantly O
between O
the O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
formulations I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

anaesthesia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
induction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
and O
emergence B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
times B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
respiratory B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cardiovascular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
variables I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
showed O
no O
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pain O
on O
injection O
( O
80 O
vs O
. O
20 O
% O
, O
p O
< O
0 O
. O
01 O
) O
and O
thrombophlebitis O
( O
93 O
. O
3 O
vs O
. O
6 O
. O
6 O
% O
, O
p O
< O
0 O
. O
001 O
) O
occurred O
more O
frequently O
with O
AM149 O
than O
with O
Disoprivan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Although O
both O
formulations B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
similar B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pharmacokinetic I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
pharmacodynamic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
profiles I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
the O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
formulation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
not O
suitable B_DISEASE_ADJECTIVE[DISEASE]
for O
clinical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
use I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
due O
to O
the O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
incidence B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
thrombophlebitis B_DISEASE
produced O
. O

Pure O
red O
cell O
aplasia O
, O
toxic O
dermatitis O
and O
lymphadenopathy O
in O
a O
patient O
taking O
diphenylhydantoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
patient O
taking O
diphenylhydantoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
3 O
weeks O
developed O
a O
generalized O
skin O
rash O
, O
lymphadenopathy O
and O
pure O
red O
cell O
aplasia O
. O

After O
withdrawal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
pharmacon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
all O
symptoms B_DISEASE
disappeared O
spontaneously O
. O

Skin O
rash O
is O
a O
well O
- O
known O
complication O
of O
diphenylhydantoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
as O
is O
benign O
and O
malignant O
lymphadenopathy O
. O

Pure O
red O
cell O
aplasia O
associated O
with O
diphenylhydantoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medication O
has O
been O
reported O
in O
3 O
patients O
. O

The O
exact O
mechanism O
by O
which O
diphenylhydantoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exerts O
its O
toxic O
effects O
is O
not O
known O
. O

In O
this O
patient O
the O
time O
relation O
between O
the O
ingestion O
of O
diphenylhydantoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
the O
occurrence O
of O
the O
skin O
rash O
, O
lymphadenopathy O
and O
pure O
red O
cell O
aplasia O
is O
very O
suggestive O
of O
a O
direct O
connection O
. O

Vinorelbine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O
related O
cardiac O
events O
: O
a O
meta O
- O
analysis O
of O
randomized O
clinical O
trials O
. O

Several O
cases O
of O
cardiac O
adverse O
reactions O
related O
to O
vinorelbine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
VNR B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
have O
been O
reported O
in O
the O
literature O
. O

In O
order O
to O
quantify O
the O
incidence O
of O
these O
cardiac O
events O
, O
we O
performed O
a O
meta O
- O
analysis O
of O
clinical O
trials O
comparing O
VNR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O
other O
chemotherapeutic O
agents O
in O
the O
treatment O
of O
various O
malignancies O
. O

Randomized O
clinical O
trials O
comparing O
VNR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O
other O
drugs O
in O
the O
treatment O
of O
cancer O
were O
searched O
in O
Medline O
, O
Embase O
, O
Evidence O
- O
based O
Medicine O
Reviews O
databases O
and O
the O
Cochrane O
library O
from O
1987 O
to O
2002 O
. O

outcomes B_PERSON/B_LOCATION
of O
interest B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
severe B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cardiac I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
events I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
toxic B_DISEASE
deaths I_DISEASE
and O
cardiac B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
event B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
related O
deaths B_DISEASE
reported O
in O
each O
publication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

We O
found O
19 O
trials O
, O
involving O
2441 O
patients O
treated O
by O
VNR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
2050 O
control O
patients O
. O

The O
incidence O
of O
cardiac O
events O
with O
VNR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
1 O
. O
19 O
% O
[ O
95 O
% O
confidence O
interval O
( O
CI O
) O
( O
0 O
. O
75 O
; O
1 O
. O
67 O
) O
] O
. O

There O
was O
no O
difference O
in O
the O
risk O
of O
cardiac O
events O
between O
VNR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
other O
drugs O
[ O
odds O
ratio O
: O
0 O
. O
92 O
, O
95 O
% O
CI O
( O
0 O
. O
54 O
; O
1 O
. O
55 O
) O
] O
. O

The O
risk O
of O
VNR B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cardiac O
events O
was O
similar O
to O
vindesine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
VDS B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
other O
cardiotoxic O
drugs O
[ O
fluorouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
anthracyclines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
gemcitabine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GEM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
em O
leader O
] O
. O

Even O
if O
it O
did O
not O
reach O
statistical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
significance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
because O
of O
a O
few B_MEASURE/B_PERSON
number I_MEASURE/I_PERSON
of O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
risk B_DISEASE/B_MEASURE
was O
lower B_MEASURE
in O
trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
excluding O
patients B_PERSON
with O
cardiac B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
history I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
seemed O
to O
be O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
including O
patients B_PERSON
with O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
existing O
cardiac B_DISEASE
diseases I_DISEASE
. O

Vinorelbine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
related O
cardiac O
events O
concern O
about O
1 O
% O
of O
treated O
patients O
in O
clinical O
trials O
. O

However O
, O
the O
risk O
associated O
with O
VNR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
seems O
to O
be O
similar O
to O
that O
of O
other O
chemotherapeutic O
agents O
in O
the O
same O
indications O
. O

MRI B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
findings I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
hypoxic B_DISEASE/B_LOCATION
cortical I_DISEASE/I_LOCATION
laminar I_DISEASE/I_LOCATION
necrosis I_DISEASE/I_LOCATION
in O
a O
child B_PERSON/B_LOCATION
with O
hemolytic B_DISEASE/B_GENE
anemia I_DISEASE/I_GENE
crisis I_DISEASE/I_GENE
. O

We O
present O
magnetic O
resonance O
imaging O
findings O
of O
a O
5 O
- O
year O
- O
old O
girl O
who O
had O
a O
rapidly O
installing O
hemolytic O
anemia O
crisis O
induced O
by O
trimethoprim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
sulfomethoxazole I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
resulting O
in O
cerebral O
anoxia O
leading O
to O
permanent O
damage O
. O

Magnetic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Resonance I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
cortical B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
laminar I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
necrosis I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
arterial B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
border B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
zones B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O
both O
cerebral B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hemispheres I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
ischemic B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
in O
subcortical B_LOCATION/B_BIO
white I_LOCATION/I_BIO
matter I_LOCATION/I_BIO
of O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cerebral I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
hemisphere I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
in O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
putamen I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Although O
cortical B_DISEASE
laminar I_DISEASE
necrosis I_DISEASE
is O
a O
classic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
entity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
adulthood B_PERSON/B_DISEASE
related O
to O
conditions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
energy B_DISEASE
depletions I_DISEASE
, O
there O
are O
few B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
available I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
children B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
. O

A O
wide B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
review I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
also O
presented O
. O

The O
natural O
history O
of O
Vigabatrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
associated O
visual O
field O
defects O
in O
patients O
electing O
to O
continue O
their O
medication O
. O

purpose O
: O
To O
determine O
the O
natural O
history O
of O
visual O
field O
defects O
in O
a O
group O
of O
patients O
known O
to O
have O
Vigabatrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
changes O
who O
elected O
to O
continue O
the O
medication O
because O
of O
good O
seizure O
control O
. O

methods O
: O
All O
patients O
taking O
Vigabatrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
or O
in O
combination O
with O
other O
antiepileptic O
drugs O
for O
at O
least O
5 O
years O
( O
range O
5 O
- O
12 O
years O
) O
were O
entered O
into O
a O
visual O
surveillance O
programme O
. O

patients B_PERSON
were O
followed O
up O
at O
6 B_NUMBER[MEASURE]/B_LOCATION
- O
monthly B_TIME[MEASURE]
intervals I_TIME[MEASURE]
for O
not O
less B_TIME[MEASURE]
than O
18 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
range B_MEASURE/B_LOCATION
18 I_MEASURE/I_LOCATION
- O
43 B_TIME[MEASURE]
months I_TIME[MEASURE]
) O
. O

In O
all O
, O
16 B_PERSON
patients I_PERSON
with O
unequivocal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
defects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
continued O
the O
medication B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Following O
already O
published O
methodology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O
Eye B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2002 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
16 B_MEASURE
; O
567 B_MEASURE
- O
571 B_MEASURE
) O
monocular B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mean B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radial B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
degrees B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MRDs B_MEASURE/B_PROTEIN[GENE]
) O
to O
the O
I B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O
4e B_MEASURE/B_PROTEIN[GENE]
isopter I_MEASURE/I_PROTEIN[GENE]
on O
Goldmann B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
perimetry I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
calculated O
for O
the O
right B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
eye I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
at O
the O
time B_MEASURE/B_LOCATION
of O
discovery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
visual B_DISEASE
field I_DISEASE
defect I_DISEASE
and O
again O
after O
not O
less B_TIME[MEASURE]
than O
18 B_TIME[MEASURE]
months I_TIME[MEASURE]
follow I_TIME[MEASURE]
- O
up B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Mean O
right B_DISEASE/B_MEASURE
eye I_DISEASE/I_MEASURE
MRD I_DISEASE/I_MEASURE
at O
presentation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
36 B_MEASURE
. O
98 B_MEASURE
degrees I_MEASURE
( O
range B_MEASURE/B_LOCATION
22 I_MEASURE/I_LOCATION
. O
25 B_MEASURE
- O
51 B_MEASURE
. O
0 B_MEASURE
) O
, O
compared O
to O
38 B_MEASURE
. O
40 B_MEASURE
degrees I_MEASURE
( O
range B_MEASURE/B_LOCATION
22 I_MEASURE/I_LOCATION
. O
5 B_MEASURE
- O
49 B_MEASURE
. O
75 B_MEASURE
) O
after O
follow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
up B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
; O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
338 B_MEASURE
unpaired I_MEASURE
t I_MEASURE
- O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Only O
one B_PERSON
patient I_PERSON
demonstrated O
a O
deterioration B_DISEASE_ADJECTIVE[DISEASE]
in O
visual B_DISEASE
field I_DISEASE
during O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
discontinued O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

conclusion O
: O
Established O
visual O
field O
defects O
presumed O
to O
be O
due O
to O
Vigabatrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O
did O
not O
usually O
progress O
in O
spite O
of O
continuing O
use O
of O
the O
medication O
. O

These O
data O
give O
support O
to O
the O
hypothesis O
that O
the O
pathogenesis O
of O
Vigabatrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
visual O
field O
defects O
may O
be O
an O
idiosyncratic O
adverse O
drug O
reaction O
rather O
than O
dose O
- O
dependent O
toxicity O
. O

induction O
of O
rosaceiform O
dermatitis O
during O
treatment O
of O
facial O
inflammatory O
dermatoses O
with O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ointment O
. O

Background O
: O
Tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
ointment O
is O
increasingly O
used O
for O
anti O
- O
inflammatory O
treatment O
of O
sensitive O
areas O
such O
as O
the O
face O
, O
and O
recent O
observations O
indicate O
that O
the O
treatment O
is O
effective O
in O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
aggravated O
rosacea O
and O
perioral O
dermatitis O
. O

We O
report O
on O
rosaceiform O
dermatitis O
as O
a O
complication O
of O
treatment O
with O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ointment O
. O

observations O
: O
Six O
adult O
patients O
with O
inflammatory O
facial O
dermatoses O
were O
treated O
with O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ointment O
because O
of O
the O
ineffectiveness O
of O
standard O
treatments O
. O

Within O
2 B_NUMBER[MEASURE]/B_LOCATION
to O
3 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
of O
initially O
effective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
and O
well O
- O
tolerated O
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
3 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
with O
a O
history B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
of O
rosacea B_DISEASE
and O
1 B_NUMBER[MEASURE]/B_PERSON
with O
a O
history B_ORGANIZATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
acne B_DISEASE
experienced O
sudden B_DISEASE_ADJECTIVE[DISEASE]
worsening O
with O
pustular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rosaceiform I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lesions I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Biopsy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
an O
abundance B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
Demodex B_DISEASE
mites I_DISEASE
in O
2 B_NUMBER[MEASURE]
of O
these O
patients B_PERSON/B_LOCATION
. O

In O
1 B_PERSON/B_BIO
patient I_PERSON/I_BIO
with O
eyelid B_DISEASE
eczema I_DISEASE
, O
rosaceiform B_DISEASE
periocular I_DISEASE
dermatitis I_DISEASE
gradually O
appeared O
after O
3 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
weeks B_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

In O
1 B_PERSON/B_BIO
patient I_PERSON/I_BIO
with O
atopic B_DISEASE/B_LOCATION
dermatitis I_DISEASE/I_LOCATION
, O
telangiectatic B_DISEASE
and O
papular B_DISEASE
rosacea I_DISEASE
insidiously O
appeared O
after O
5 B_TIME[MEASURE]/B_LOCATION
months I_TIME[MEASURE]/I_LOCATION
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

conclusions O
: O
Our O
observations O
suggest O
that O
the O
spectrum O
of O
rosaceiform O
dermatitis O
as O
a O
complication O
of O
treatment O
with O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ointment O
is O
heterogeneous O
. O

A O
variety O
of O
factors O
, O
such O
as O
vasoactive O
properties O
of O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
proliferation O
of O
Demodex O
due O
to O
local O
immunosuppression O
, O
and O
the O
occlusive O
properties O
of O
the O
ointment O
, O
may O
be O
involved O
in O
the O
observed O
phenomena O
. O

Future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
needed O
to O
identify O
individual B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
risk I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
factors I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Intravascular O
hemolysis O
and O
acute O
renal O
failure O
following O
intermittent O
rifampin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

Renal O
failure O
is O
a O
rare O
complication O
associated O
with O
the O
use O
of O
rifampin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Intravascular O
hemolysis O
leading O
to O
acute O
renal O
failure O
following O
rifampin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
is O
extremely O
rare O
. O

Two O
patients O
with O
leprosy O
who O
developed O
hemolysis O
and O
acute O
renal O
failure O
following O
rifampin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
are O
reported O
. O

structural O
abnormalities O
in O
the O
brains O
of O
human O
subjects O
who O
use O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

We O
visualize O
, O
for O
the O
first O
time O
, O
the O
profile O
of O
structural O
deficits O
in O
the O
human O
brain O
associated O
with O
chronic O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
abuse O
. O

Studies O
of O
human O
subjects O
who O
have O
used O
MA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chronically O
have O
revealed O
deficits O
in O
dopaminergic O
and O
serotonergic O
systems O
and O
cerebral O
metabolic O
abnormalities O
. O

Using O
magnetic O
resonance O
imaging O
( O
MRI O
) O
and O
new O
computational O
brain O
- O
mapping O
techniques O
, O
we O
determined O
the O
pattern O
of O
structural O
brain O
alterations O
associated O
with O
chronic O
MA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abuse O
in O
human O
subjects O
and O
related O
these O
deficits O
to O
cognitive O
impairment O
. O

We O
used O
high O
- O
resolution O
MRI O
and O
surface O
- O
based O
computational O
image O
analyses O
to O
map O
regional O
abnormalities O
in O
the O
cortex O
, O
hippocampus O
, O
white O
matter O
, O
and O
ventricles O
in O
22 O
human O
subjects O
who O
used O
MA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
21 O
age O
- O
matched O
, O
healthy O
controls O
. O

Cortical O
maps O
revealed O
severe O
gray O
- O
matter O
deficits O
in O
the O
cingulate O
, O
limbic O
, O
and O
paralimbic O
cortices O
of O
MA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abusers O
( O
averaging O
11 O
. O
3 O
% O
below O
control O
; O
p O
< O
0 O
. O
05 O
) O
. O

On O
average O
, O
MA B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abusers O
had O
7 O
. O
8 O
% O
smaller O
hippocampal O
volumes O
than O
control O
subjects O
( O
p O
< O
0 O
. O
01 O
; O
left O
, O
p O
= O
0 O
. O
01 O
; O
right O
, O
p O
< O
0 O
. O
05 O
) O
and O
significant O
white O
- O
matter O
hypertrophy O
( O
7 O
. O
0 O
% O
; O
p O
< O
0 O
. O
01 O
) O
. O

hippocampal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
deficits I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
mapped O
and O
correlated O
with O
memory B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performance I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
a O
word B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
recall B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
p B_PROTEIN[GENE]/B_DISEASE
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

MRI O
- O
based O
maps O
suggest O
that O
chronic O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abuse O
causes O
a O
selective O
pattern O
of O
cerebral O
deterioration O
that O
contributes O
to O
impaired O
memory O
performance O
. O

MA B_LOCATION/B_DISEASE
may O
selectively O
damage O
the O
medial O
temporal O
lobe O
and O
, O
consistent O
with O
metabolic O
studies O
, O
the O
cingulate O
- O
limbic O
cortex O
, O
inducing O
neuroadaptation O
, O
neuropil O
reduction O
, O
or O
cell O
death O
. O

prominent B_PERSON/B_COLOR
white B_PERSON/I_COLOR
- O
matter B_DISEASE
hypertrophy I_DISEASE
may O
result O
from O
altered B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myelination I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
adaptive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glial I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
gliosis B_DISEASE_ADJECTIVE[DISEASE]
secondary I_DISEASE_ADJECTIVE[DISEASE]
to O
neuronal B_DISEASE
damage I_DISEASE
. O

These O
brain O
substrates O
may O
help O
account O
for O
the O
symptoms O
of O
MA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abuse O
, O
providing O
therapeutic O
targets O
for O
drug O
- O
induced O
brain O
injury O
. O

disruption O
of O
hepatic O
lipid O
homeostasis O
in O
mice O
after O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
is O
associated O
with O
peroxisome O
proliferator O
- O
activated O
receptor O
- O
alpha O
target O
gene O
activation O
. O

Amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
an O
efficacious O
and O
widely O
used O
antiarrhythmic O
agent O
, O
has O
been O
reported O
to O
cause O
hepatotoxicity O
in O
some O
patients O
. O

To O
gain O
insight O
into O
the O
mechanism O
of O
this O
unwanted O
effect O
, O
mice O
were O
administered O
various O
doses O
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
examined O
for O
changes O
in O
hepatic O
histology O
and O
gene O
regulation O
. O

Amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O
hepatomegaly O
, O
hepatocyte O
microvesicular O
lipid O
accumulation O
, O
and O
a O
significant O
decrease O
in O
serum O
triglycerides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
glucose B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Northern O
blot O
analysis O
of O
hepatic O
RNA O
revealed O
a O
dose O
- O
dependent O
increase O
in O
the O
expression O
of O
a O
number O
of O
genes O
critical O
for O
fatty B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxidation O
, O
lipoprotein O
assembly O
, O
and O
lipid O
transport O
. O

Many B_NUMBER[MEASURE]/B_PERSON
of O
these O
genes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
are O
regulated O
by O
the O
peroxisome B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proliferator I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
activated O
receptor B_GENE
- O
alpha B_PROTEIN[GENE]
( O
PPARalpha B_GENE
) O
, O
a O
ligand B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
activated O
nuclear B_GENE
hormone I_GENE
receptor I_GENE
transcription I_GENE
factor I_GENE
. O

The O
absence O
of O
induction O
of O
these O
genes O
as O
well O
as O
hepatomegaly O
in O
PPARalpha O
knockout O
[ O
PPARalpha O
- O
/ O
- O
] O
mice O
indicated O
that O
the O
effects O
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
dependent O
upon O
the O
presence O
of O
a O
functional O
PPARalpha O
gene O
. O

Compared O
to O
wild O
- O
type O
mice O
, O
treatment O
of O
PPARalpha O
- O
/ O
- O
mice O
with O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
resulted O
in O
an O
increased O
rate O
and O
extent O
of O
total O
body O
weight O
loss O
. O

The O
inability O
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
directly O
activate O
either O
human O
or O
mouse O
PPARalpha O
transiently O
expressed O
in O
human O
HepG2 O
hepatoma O
cells O
indicates O
that O
the O
effects O
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
the O
function O
of O
this O
receptor O
were O
indirect O
. O

Based O
upon O
these O
results O
, O
we O
conclude O
that O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disrupts O
hepatic O
lipid O
homeostasis O
and O
that O
the O
increased O
expression O
of O
PPARalpha O
target O
genes O
is O
secondary O
to O
this O
toxic O
effect O
. O

These O
results O
provide O
important O
new O
mechanistic O
information O
regarding O
the O
hepatotoxic O
effects O
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
indicate O
that O
PPARalpha O
protects O
against O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hepatotoxicity O
. O

Safety O
and O
compliance O
with O
once O
- O
daily O
niacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extended I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lovastatin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
initial O
therapy O
in O
the O
Impact O
of O
Medical O
Subspecialty O
on O
patient O
compliance O
to O
Treatment O
( O
Impact O
) O
study O
. O

Niacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extended I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lovastatin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
new O
combination O
product O
approved O
for O
treatment O
of O
primary O
hypercholesterolemia O
and O
mixed O
dyslipidemia O
. O

This O
open O
- O
labeled O
, O
multicenter O
study O
evaluated O
the O
safety O
of O
bedtime O
niacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extended I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lovastatin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
dosed O
as O
initial O
therapy O
and O
patient O
compliance O
to O
treatment O
in O
various O
clinical O
practice O
settings O
. O

A O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
4 B_MEASURE
, O
499 B_TIME[MEASURE]
patients I_TIME[MEASURE]
with O
dyslipidemia B_DISEASE
requiring O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intervention I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
enrolled O
at O
1 B_MEASURE
, O
081 B_MEASURE/B_ORGANIZATION
sites I_MEASURE/I_ORGANIZATION
. O

patients O
were O
treated O
with O
1 O
tablet O
( O
500 O
mg O
of O
niacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extended O
- O
release O
/ O
20 O
mg O
of O
lovastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
once O
nightly O
for O
4 O
weeks O
and O
then O
2 O
tablets O
for O
8 O
weeks O
. O

patients O
also O
received O
dietary O
counseling O
, O
educational O
materials O
, O
and O
reminders O
to O
call O
a O
toll O
- O
free O
number O
that O
provided O
further O
education O
about O
dyslipidemia O
and O
niacin B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extended I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lovastatin I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
points I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
study B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compliance I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
increases B_DISEASE_ADJECTIVE[DISEASE]
in O
liver B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transaminases I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
> O
3 B_MEASURE/B_LOCATION
times I_MEASURE/I_LOCATION
the O
upper B_MEASURE/B_LOCATION
limit I_MEASURE/I_LOCATION
of O
normal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
and O
clinical B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
myopathy I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Final B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
status I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
4 B_MEASURE
, O
217 B_MEASURE
patients I_MEASURE
( O
94 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

compliance O
to O
niacin B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
extended I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
- I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
release I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
/ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
lovastatin I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
77 O
% O
, O
with O
3 O
, O
245 O
patients O
completing O
the O
study O
. O

patients B_PERSON/B_LOCATION
in O
the O
southeast B_LOCATION/B_ORGANIZATION
and O
those O
enrolled O
by O
endocrinologists B_LOCATION/B_ORGANIZATION
had O
the O
lowest B_MEASURE
compliance I_MEASURE
and O
highest B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adverse B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
event B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rates B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Flushing B_DISEASE
was O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
adverse I_DISEASE_ADJECTIVE[DISEASE]
event I_DISEASE_ADJECTIVE[DISEASE]
, O
reported O
by O
18 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
patients B_PERSON/B_LOCATION
and O
leading O
to O
discontinuation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
by O
6 B_PERSON
% I_PERSON
. O

incidence O
of O
increased O
aspartate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminotransferase O
and O
/ O
or O
alanine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminotransferase O
> O
3 O
times O
the O
upper O
limit O
of O
normal O
was O
< O
0 O
. O
3 O
% O
. O

An O
increase O
of O
creatine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
phosphokinase O
to O
> O
5 O
times O
the O
upper O
limit O
of O
normal O
occurred O
in O
0 O
. O
24 O
% O
of O
patients O
, O
and O
no O
cases O
of O
drug O
- O
induced O
myopathy O
were O
observed O
. O

Niacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
extended I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
release I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
/ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
lovastatin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
1 O
, O
000 O
/ O
40 O
mg O
, O
dosed O
as O
initial O
therapy O
, O
was O
associated O
with O
good O
compliance O
and O
safety O
and O
had O
very O
low O
incidences O
of O
increased O
liver O
and O
muscle O
enzymes O
. O

protective O
effect O
of O
Terminalia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
chebula I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
against O
experimental O
myocardial O
injury O
induced O
by O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Cardioprotective O
effect O
of O
ethanolic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
extract I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Terminalia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chebula I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
fruits I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
500 O
mg O
/ O
kg O
body O
wt O
) O
was O
examined O
in O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
200 O
mg O
/ O
kg O
body O
wt O
) O
induced O
myocardial O
damage O
in O
rats O
. O

In O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
administered O
rats O
, O
the O
level O
of O
lipid O
peroxides B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
increased O
significantly O
in O
the O
serum O
and O
heart O
. O

A O
significant B_MEASURE
decrease I_MEASURE
was O
observed O
in O
the O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
myocardial B_ENZYME[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
marker I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
enzymes I_ENZYME[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
a O
concomitant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
their O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Histopathological B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
carried O
out O
to O
confirm O
the O
myocardial B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
necrosis B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

T B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
chebula I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
extract I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
pretreatment O
was O
found O
to O
ameliorate O
the O
effect O
of O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
lipid O
peroxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
formation O
and O
retained O
the O
activities O
of O
the O
diagnostic O
marker O
enzymes O
. O

A O
case O
of O
postoperative O
anxiety O
due O
to O
low O
dose O
droperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
with O
patient O
- O
controlled O
analgesia O
. O

A O
multiparous B_PERSON
woman I_PERSON
in O
good B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
psychological I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
health I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
underwent I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
urgent I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
caesarean I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
section I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
in O
labour B_PERSON/B_LOCATION
. O

Postoperatively O
, O
she O
was O
given O
a O
patient O
- O
controlled O
analgesia O
device O
delivering O
boluses O
of O
diamorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
0 O
. O
5 O
mg O
and O
droperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O
. O
025 O
mg O
. O

whilst B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
the O
device B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
she O
gradually O
became O
anxious B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
feeling B_PERSON/B_DISEASE
worsening O
after O
each O
bolus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

The O
diagnosis O
of O
droperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
psychological O
disturbance O
was O
not O
made O
straight O
away O
although O
on O
subsequent O
close O
questioning O
the O
patient O
gave O
a O
very O
clear O
history O
. O

After O
she O
had O
received O
a O
total O
of O
only O
0 O
. O
9 O
mg O
droperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
syringe O
containing O
diamorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
only O
was O
substituted O
and O
her O
unease O
resolved O
completely O
. O

We O
feel O
that O
, O
although O
the O
dramatic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
extrapyramidal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
side I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
dopaminergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiemetics I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
well O
known O
, O
more O
subtle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
manifestations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
easily O
be O
overlooked O
. O

Accurate B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patient I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
history I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
contributes O
to O
differentiating O
diabetes B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
insipidus B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
a O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

This O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
highlights O
the O
important B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contribution I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
nursing B_PERSON
in O
obtaining O
an O
accurate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
history I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
case B_PERSON/B_DISEASE
discussed O
herein B_LOCATION/B_TIME[MEASURE]
initially O
appeared O
to O
be O
neurogenic B_DISEASE
diabetes I_DISEASE
insipidus O
( O
DI B_DISEASE/B_PROTEIN[GENE]
) O
secondary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
a O
traumatic B_DISEASE
brain I_DISEASE
injury I_DISEASE
. O

The O
nursing O
staff O
, O
by O
reviewing O
the O
patient O
' O
s O
health O
history O
with O
his O
family O
, O
discovered O
a O
history O
of O
polydipsia O
and O
long O
- O
standing O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
. O

Lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
implicated O
in O
drug O
- O
induced O
nephrogenic O
Di O
, O
and O
because O
the O
patient O
had O
not O
received O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
since O
being O
admitted O
to O
the O
hospital O
, O
his O
treatment O
changed O
to O
focus O
on O
nephrogenic O
Di O
. O

By O
combining O
information O
from O
the O
patient O
history O
, O
the O
physical O
examination O
, O
and O
radiologic O
and O
laboratory O
studies O
, O
the O
critical O
care O
team O
demonstrated O
that O
the O
patient O
had O
been O
self O
- O
treating O
his O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
nephrogenic O
Di O
and O
developed O
neurogenic O
Di O
secondary O
to O
brain O
trauma O
. O

Thus O
successful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
required O
that O
nephrogenic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
neurogenic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
DI I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
be O
treated O
concomitantly O
. O

factors O
contributing O
to O
ribavirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
anemia O
. O

Background O
AND O
aim O
: O
Interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
ribavirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
combination O
therapy O
for O
chronic O
hepatitis O
C O
produces O
hemolytic O
anemia O
. O

This O
study O
was O
conducted O
to O
identify O
the O
factors O
contributing O
to O
ribavirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
anemia O
. O

methods O
: O
eighty O
- O
eight O
patients O
with O
chronic O
hepatitis O
C O
who O
received O
interferon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
alpha I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2b I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
at O
a O
dose O
of O
6 O
Mu O
administered O
intramuscularly O
for O
24 O
weeks O
in O
combination O
with O
ribavirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administered O
orally O
at O
a O
dose O
of O
600 O
mg O
or O
800 O
mg O
participated O
in O
the O
study O
. O

A O
hemoglobin O
concentration O
of O
< O
10 O
g O
/ O
DL O
was O
defined O
as O
ribavirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
anemia O
. O

Results O
: O
Ribavirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
anemia O
occurred O
in O
18 O
( O
20 O
. O
5 O
% O
) O
patients O
during O
treatment O
. O

A O
2 B_MEASURE/B_PROTEIN[GENE]
g I_MEASURE/I_PROTEIN[GENE]
/ O
DL B_MEASURE
decrease I_MEASURE
in O
hemoglobin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentrations B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
patients B_PERSON/B_BIO
with O
anemia B_DISEASE
was O
observed O
at O
week B_TIME[MEASURE]/B_LOCATION
2 I_TIME[MEASURE]/I_LOCATION
after O
the O
start B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
hemoglobin B_MEASURE
concentration I_MEASURE
in O
patients B_PERSON/B_BIO
with O
> B_MEASURE
or O
= O
2 B_MEASURE/B_PROTEIN[GENE]
g I_MEASURE/I_PROTEIN[GENE]
/ O
dL B_MEASURE
decrease I_MEASURE
at O
week B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
2 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
was O
observed O
to O
be O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
even O
after O
week B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
2 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
than O
in O
patients B_PERSON
with O
< B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
g I_MEASURE/I_LOCATION
/ O
DL B_MEASURE/B_LOCATION
decrease B_MEASURE/I_LOCATION
( O
P B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

A O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationship B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
between O
the O
rate B_MEASURE
of O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
hemoglobin B_DISEASE/B_GENE
concentrations B_DISEASE/I_GENE
at O
week B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
2 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
the O
severity B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
anemia B_DISEASE
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

Such O
factors O
as O
sex O
( O
female O
) O
, O
age O
( O
> O
or O
= O
60 O
years O
old O
) O
, O
and O
the O
ribavirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O
by O
body O
weight O
( O
12 O
mg O
/ O
kg O
or O
more O
) O
were O
significant O
by O
univariate O
analysis O
. O

conclusions O
: O
careful O
administration O
is O
necessary O
in O
patients O
> O
or O
= O
60 O
years O
old O
, O
in O
female O
patients O
, O
and O
in O
patients O
receiving O
a O
ribavirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O
of O
12 O
mg O
/ O
kg O
or O
more O
. O

patients B_PERSON
who O
experience O
a O
fall B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
hemoglobin B_MEASURE/B_DISEASE
concentrations I_MEASURE/I_DISEASE
of O
2 B_MEASURE/B_PROTEIN[GENE]
g I_MEASURE/I_PROTEIN[GENE]
/ O
dL B_TIME[MEASURE]/B_PROTEIN[GENE]
or O
more B_MEASURE
at O
week B_TIME[MEASURE]/B_LOCATION
2 I_TIME[MEASURE]/I_LOCATION
after O
the O
start B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
should O
be O
monitored O
with O
particular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
care I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
. O

Zidovudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
hepatitis O
. O

A O
case O
of O
acute O
hepatitis O
induced O
by O
zidovudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
a O
38 O
- O
year O
- O
old O
patient O
with O
AIDS O
is O
presented O
. O

The O
mechanism B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
whereby O
the O
hepatitis B_DISEASE
was O
induced O
is O
not O
known O
. O

However O
, O
the O
patient O
tolerated O
well O
an O
alternative O
reverse O
transcriptase O
inhibitor O
, O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dideoxyinosine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Physicians B_PERSON/B_ORGANIZATION
caring O
for O
patients B_PERSON
with O
AIDS B_DISEASE
should O
be O
aware B_PERSON/B_TIME[MEASURE]
of O
this O
hitherto B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
rarely O
reported O
complication B_DISEASE
. O

Oxidative O
damage O
precedes O
nitrative O
damage O
in O
adriamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cardiac O
mitochondrial O
injury O
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
determine O
if O
elevated O
reactive O
oxygen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
ROS O
) O
/ O
nitrogen B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species O
( O
RNS O
) O
reported O
to O
be O
present O
in O
adriamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ADR B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
induced O
cardiotoxicity O
actually O
resulted O
in O
cardiomyocyte O
oxidative O
/ O
nitrative O
damage O
, O
and O
to O
quantitatively O
determine O
the O
time O
course O
and O
subcellular O
localization O
of O
these O
postulated O
damage O
products O
using O
an O
in O
vivo O
approach O
. O

B6C3 O
mice O
were O
treated O
with O
a O
single O
dose O
of O
20 O
mg O
/ O
kg O
ADR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Ultrastructural O
damage O
and O
levels O
of O
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
hydroxy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nonenal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
4HNE B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
protein O
adducts O
and O
3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrotyrosine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3NT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
were O
analyzed O
. O

Quantitative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ultrastructural I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
damage I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
using O
computerized B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
image I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
techniques I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
cardiomyocyte B_DISEASE_ADJECTIVE[DISEASE]
injury I_DISEASE_ADJECTIVE[DISEASE]
as O
early O
as O
3 B_MEASURE/B_ENT
hours I_MEASURE/I_ENT
, O
with O
mitochondria B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
being O
the O
most O
extensively O
and O
progressively O
injured B_DISEASE_ADJECTIVE[DISEASE]
subcellular I_DISEASE_ADJECTIVE[DISEASE]
organelle I_DISEASE_ADJECTIVE[DISEASE]
. O

Analysis O
of O
4HNE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
protein O
adducts O
by O
immunogold O
electron O
microscopy O
showed O
appearance O
of O
4HNE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
protein O
adducts O
in O
mitochondria O
as O
early O
as O
3 O
hours O
, O
with O
a O
peak O
at O
6 O
hours O
and O
subsequent O
decline O
at O
24 O
hours O
. O

3NT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
were O
significantly O
increased O
in O
all O
subcellular O
compartments O
at O
6 O
hours O
and O
subsequently O
declined O
at O
24 O
hours O
. O

Our O
data O
showed O
ADR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O
4HNE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
protein O
adducts O
in O
mitochondria O
at O
the O
same O
time O
point O
as O
when O
mitochondrial O
injury O
initially O
appeared O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
document O
for O
the O
first B_TIME[MEASURE]/B_PERSON
time I_TIME[MEASURE]/I_PERSON
in O
vivo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
that O
mitochondrial B_DISEASE/B_GENE
oxidative I_DISEASE/I_GENE
damage I_DISEASE/I_GENE
precedes O
nitrative B_DISEASE
damage I_DISEASE
. O

The O
progressive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nature B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
mitochondrial B_DISEASE_ADJECTIVE[DISEASE]
injury I_DISEASE_ADJECTIVE[DISEASE]
suggests O
that O
mitochondria B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
, O
not O
other B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
subcellular I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
organelles I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
are O
the O
major B_LOCATION
site I_LOCATION
of O
intracellular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Sotalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
coronary O
spasm O
in O
a O
patient O
with O
dilated O
cardiomyopathy O
associated O
with O
sustained O
ventricular O
tachycardia O
. O

A O
54 B_MEASURE
- O
year B_TIME[MEASURE]
- O
old B_PERSON
man I_PERSON
with O
severe B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
left O
ventricular B_DISEASE/B_LOCATION
dysfunction I_DISEASE/I_LOCATION
due O
to O
dilated O
cardiomyopathy B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
was O
referred O
to O
our O
hospital B_LOCATION/B_PERSON
for O
symptomatic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incessant I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sustained O
ventricular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tachycardia I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
VT B_DISEASE/B_PROTEIN[GENE]
) O
. O

After O
the O
administration O
of O
nifekalant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
sustained O
VT O
was O
terminated O
. O

An O
alternate O
class O
III O
agent O
, O
sotalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
also O
effective O
for O
the O
prevention O
of O
VT O
. O

However O
, O
one O
month O
after O
switching O
over O
nifekalant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
sotalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
short O
duration O
of O
ST O
elevation O
was O
documented O
in O
ECG O
monitoring O
at O
almost O
the O
same O
time O
for O
three O
consecutive O
days O
. O

ST O
elevation O
with O
chest O
discomfort O
disappeared O
since O
he O
began O
taking O
long O
- O
acting O
diltiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Coronary O
vasospasm O
may O
be O
induced O
by O
the O
non O
- O
selective O
beta O
- O
blocking O
properties O
of O
sotalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Effects O
of O
the O
antidepressant O
trazodone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HT I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2A O
/ O
2C O
receptor O
antagonist O
, O
on O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
dependent O
behaviors O
in O
rats O
. O

RATIONALE O
: O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
Hydroxytryptamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
via O
stimulation O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
HT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
2C O
receptors O
, O
exerts O
a O
tonic O
inhibitory O
influence O
on O
dopaminergic O
neurotransmission O
, O
whereas O
activation O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
HT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
2A O
receptors O
enhances O
stimulated O
DAergic O
neurotransmission O
. O

The O
antidepressant O
trazodone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
a O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HT I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2A O
/ O
2C O
receptor O
antagonist O
. O

objectives O
: O
To O
evaluate O
the O
effect O
of O
trazodone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
on O
behaviors O
dependent O
on O
the O
functional O
status O
of O
the O
nigrostriatal O
DAergic O
system O
. O

methods O
: O
The O
effect O
of O
pretreatment O
with O
trazodone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
dexamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
and O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
oral O
stereotypies O
, O
on O
catalepsy O
induced O
by O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 O
. O
05 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
, O
on O
ergometrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
wet O
dog O
shake O
( O
WDS O
) O
behavior O
and O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
penile O
erections O
was O
studied O
in O
rats O
. O

We O
also O
investigated O
whether O
trazodone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O
catalepsy O
in O
rats O
. O

Results O
: O
Trazodone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O
2 O
. O
5 O
- O
20 O
mg O
/ O
kg O
i O
. O
p O
. O
did O
not O
induce O
catalepsy O
, O
and O
did O
not O
antagonize O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 O
. O
5 O
and O
3 O
mg O
/ O
kg O
) O
stereotypy O
and O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 O
. O
05 O
mg O
/ O
kg O
) O
- O
induced O
catalepsy O
. O

However O
, O
pretreatment O
with O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
i O
. O
p O
. O
trazodone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhanced O
dexamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stereotypy O
, O
and O
antagonized O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
catalepsy O
, O
ergometrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
WDS O
behavior O
and O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
penile O
erections O
. O

Trazodone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O
30 O
, O
40 O
and O
50 O
mg O
/ O
kg O
i O
. O
p O
. O
induced O
catalepsy O
and O
antagonized O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dexamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stereotypies O
. O

conclusions O
: O
Our O
results O
indicate O
that O
trazodone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
2 O
. O
5 O
- O
20 O
mg O
/ O
kg O
does O
not O
block O
pre O
- O
and O
postsynaptic O
striatal O
D2 O
Da O
receptors O
, O
while O
at O
30 O
, O
40 O
and O
50 O
mg O
/ O
kg O
it O
blocks O
postsynaptic O
striatal O
D2 O
Da O
receptors O
. O

Furthermore O
, O
at O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
, O
trazodone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocks O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
HT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
2A O
and O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
HT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
2C O
receptors O
. O

We O
suggest O
that O
trazodone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 O
, O
10 O
and O
20 O
mg O
/ O
kg O
) O
, O
by O
blocking O
the O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
HT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
2C O
receptors O
, O
releases O
the O
nigrostriatal O
DAergic O
neurons O
from O
tonic O
inhibition O
caused O
by O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
HT I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
thereby O
potentiates O
dexamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stereotypy O
and O
antagonizes O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
catalepsy O
. O

swallowing O
abnormalities B_DISEASE_ADJECTIVE[DISEASE]
and O
dyskinesia B_DISEASE
in O
Parkinson B_PERSON/B_DISEASE
' O
s B_DISEASE
disease I_DISEASE
. O

Gastrointestinal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
abnormalities I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
in O
Parkinson B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
' O
s B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
PD B_DISEASE/B_PROTEIN[GENE]
) O
have O
been O
known O
for O
almost O
two B_TIME[MEASURE]/B_PERSON
centuries I_TIME[MEASURE]/I_PERSON
, O
but O
many B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
aspects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
concerning O
their O
pathophysiology B_DISEASE
have O
not O
been O
completely O
clarified O
. O

The O
aim O
of O
this O
study O
was O
to O
characterize O
the O
oropharyngeal O
dynamics O
in O
PD O
patients O
with O
and O
without O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
dyskinesia O
. O

Fifteen B_TIME[MEASURE]/B_ORGANIZATION
dyskinetic I_TIME[MEASURE]/I_ORGANIZATION
, O
12 B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
nondyskinetic I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
patients I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
and O
a O
control B_PERSON/B_ORGANIZATION
group I_PERSON/I_ORGANIZATION
were O
included O
. O

patients B_PERSON
were O
asked O
about O
dysphagia B_DISEASE
and O
evaluated O
with O
the O
Unified B_NUMBER[MEASURE]/B_DISEASE
Parkinson I_NUMBER[MEASURE]/I_DISEASE
' I_NUMBER[MEASURE]/I_DISEASE
s I_NUMBER[MEASURE]/I_DISEASE
Disease I_NUMBER[MEASURE]/I_DISEASE
rating I_NUMBER[MEASURE]/I_DISEASE
Scale I_NUMBER[MEASURE]/I_DISEASE
Parts I_NUMBER[MEASURE]/I_DISEASE
II I_NUMBER[MEASURE]/I_DISEASE
and O
III B_SEQUENCE[MEASURE]
and O
the O
Hoehn B_PERSON
and O
Yahr B_PERSON/B_LOCATION
scale I_PERSON/I_LOCATION
. O

Deglutition O
was O
assessed O
using O
modified O
barium B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
swallow O
with O
videofluoroscopy O
. O

Nondyskinetic B_PERSON/B_BIO
patients I_PERSON/I_BIO
, O
but O
not O
the O
dyskinetic B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
ones I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
, O
showed O
less O
oropharyngeal B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
swallowing O
efficiency B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
OPSE B_LOCATION/B_ORGANIZATION
) O
for O
liquid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
food I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
than O
controls B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Dunnett B_PERSON/B_DISEASE
, O
P B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
02 B_MEASURE
) O
. O

Dyskinetic B_PERSON/B_BIO
patients I_PERSON/I_BIO
tended O
to O
have O
a O
greater B_DISEASE/B_MEASURE
OPSE I_DISEASE/I_MEASURE
than O
nondyskinetic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
( O
Dunnett B_PERSON/B_PROTEIN[GENE]
, O
P B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
06 B_MEASURE
) O
. O

patients O
who O
were O
using O
a O
higher O
dose O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
a O
greater O
OPSE O
and O
a O
trend O
toward O
a O
smaller O
oral O
transit O
time O
( O
Pearson O
' O
s O
correlation O
, O
P O
= O
0 O
. O
01 O
and O
0 O
. O
08 O
, O
respectively O
) O
. O

Neither O
the O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
dysphagia B_DISEASE
nor O
any O
of O
the O
PD B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
severity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
correlated O
to O
the O
videofluoroscopic B_DISEASE_ADJECTIVE[DISEASE]
variables I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
the O
current O
study O
, O
dyskinetic O
patients O
performed O
better O
in O
swallowing O
function O
, O
which O
could O
be O
explained O
on O
the O
basis O
of O
a O
greater O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
dose O
. O

Our O
results O
suggest O
a O
role O
for O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
the O
oral O
phase O
of O
deglutition O
and O
confirm O
that O
dysphagia O
is O
not O
a O
good O
predictor O
of O
deglutition O
alterations O
in O
PD O
. O

Inhibition O
of O
nuclear O
factor O
- O
kappaB O
activation O
attenuates O
tubulointerstitial O
nephritis O
induced O
by O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Background O
: O
Animals O
treated O
with O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
show O
residual O
areas O
of O
interstitial O
fibrosis O
in O
the O
renal O
cortex O
. O

This O
study O
investigated O
the O
expression O
of O
nuclear O
factor O
- O
kappaB O
( O
NF O
- O
kappaB O
) O
, O
mitogen O
- O
activated O
protein O
( O
Map O
) O
kinases O
and O
macrophages O
in O
the O
renal O
cortex O
and O
structural O
and O
functional O
renal O
changes O
of O
rats O
treated O
with O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O
pyrrolidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dithiocarbamate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PDTC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
an O
NF O
- O
kappaB O
inhibitor O
. O

methods O
: O
38 O
female O
Wistar O
rats O
were O
injected O
with O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
40 O
mg O
/ O
kg O
, O
twice O
a O
day O
for O
9 O
days O
, O
38 O
with O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O
PDTC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
28 O
with O
0 O
. O
15 O
M O
NaCl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution O
. O

The O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
killed O
5 B_MEASURE
and O
30 B_MEASURE/B_ENT
days I_MEASURE/I_ENT
after O
these O
injections B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
the O
kidneys B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
were O
removed O
for O
histological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
immunohistochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
immunohistochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
scored O
according O
to O
the O
extent B_MEASURE
of O
staining O
. O

The O
fractional B_MEASURE/B_LOCATION
interstitial B_MEASURE/I_LOCATION
area B_MEASURE/I_LOCATION
was O
determined O
by O
morphometry B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
Gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
rats O
presented O
a O
transitory O
increase O
in O
plasma O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
. O

increased O
Ed O
- O
1 O
, O
Map O
kinases O
and O
NF O
- O
kappaB O
staining O
were O
also O
observed O
in O
the O
renal O
cortex O
from O
all O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
treated O
rats O
compared O
to O
control O
( O
p O
< O
0 O
. O
05 O
) O
. O

The O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
killed O
on O
day B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
30 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
presented O
fibrosis B_DISEASE
in O
the O
renal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cortex I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
despite O
the O
recovery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
renal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Treatment O
with O
PDTC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduced O
the O
functional O
and O
structural O
changes O
induced O
by O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

conclusions O
: O
These O
data O
show O
that O
inhibition O
of O
NF O
- O
kappaB O
activation O
attenuates O
tubulointerstitial O
nephritis O
induced O
by O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Glucose B_BODY_PART_OR_ORGAN_COMPONENT
metabolism O
in O
patients O
with O
schizophrenia O
treated O
with O
atypical O
antipsychotic O
agents O
: O
a O
frequently O
sampled O
intravenous O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
tolerance O
test O
and O
minimal O
model O
analysis O
. O

Background O
: O
While O
the O
incidence O
of O
new O
- O
onset O
diabetes O
mellitus O
may O
be O
increasing O
in O
patients O
with O
schizophrenia O
treated O
with O
certain O
atypical O
antipsychotic O
agents O
, O
it O
remains O
unclear O
whether O
atypical O
agents O
are O
directly O
affecting O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
metabolism O
or O
simply O
increasing O
known O
risk O
factors O
for O
diabetes O
. O

objective O
: O
To O
study O
the O
2 O
drugs O
most O
clearly O
implicated O
( O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
using O
a O
frequently O
sampled O
intravenous O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
tolerance O
test O
. O

Design O
: O
A O
cross O
- O
sectional O
design O
in O
stable O
, O
treated O
patients O
with O
schizophrenia O
evaluated O
using O
a O
frequently O
sampled O
intravenous O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
tolerance O
test O
and O
the O
Bergman O
minimal O
model O
analysis O
. O

setting B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
: O
subjects B_PERSON
were O
recruited O
from O
an O
urban B_LOCATION/B_ORGANIZATION
community B_LOCATION/I_ORGANIZATION
mental B_LOCATION/I_ORGANIZATION
health B_LOCATION/I_ORGANIZATION
clinic B_LOCATION/I_ORGANIZATION
and O
were O
studied O
at O
a O
general B_LOCATION/B_MEASURE
clinical I_LOCATION/I_MEASURE
research I_LOCATION/I_MEASURE
center I_LOCATION/I_MEASURE
. O

patients O
Fifty O
subjects O
signed O
informed O
consent O
and O
41 O
underwent O
the O
frequently O
sampled O
intravenous O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
tolerance O
test O
. O

Thirty O
- O
six O
nonobese O
subjects O
with O
schizophrenia O
or O
schizoaffective O
disorder O
, O
matched O
by O
body O
mass O
index O
and O
treated O
with O
either O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
were O
included O
in O
the O
analysis O
. O

Main O
outcome O
measures O
: O
Fasting O
plasma O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
fasting O
serum O
insulin O
levels O
, O
insulin O
sensitivity O
index O
, O
homeostasis O
model O
assessment O
of O
insulin O
resistance O
, O
and O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
effectiveness O
. O

Results O
: O
The O
mean O
+ O
/ O
- O
SD O
duration O
of O
treatment O
with O
the O
identified O
atypical O
antipsychotic O
agent O
was O
68 O
. O
3 O
+ O
/ O
- O
28 O
. O
9 O
months O
( O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
29 O
. O
5 O
+ O
/ O
- O
17 O
. O
5 O
months O
( O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
and O
40 O
. O
9 O
+ O
/ O
- O
33 O
. O
7 O
( O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Fasting O
serum O
insulin O
concentrations O
differed O
among O
groups O
( O
F O
( O
33 O
) O
= O
3 O
. O
35 O
; O
P O
= O
. O
047 O
) O
( O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
> O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
> O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
with O
significant O
differences O
between O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
t O
( O
33 O
) O
= O
2 O
. O
32 O
; O
P O
= O
. O
03 O
) O
and O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
t O
( O
33 O
) O
= O
2 O
. O
15 O
; O
P O
= O
. O
04 O
) O
. O

There O
was O
a O
significant O
difference O
in O
insulin O
sensitivity O
index O
among O
groups O
( O
F O
( O
33 O
) O
= O
10 O
. O
66 O
; O
P O
< O
. O
001 O
) O
( O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
< O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
< O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
, O
with O
subjects O
who O
received O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exhibiting O
significant O
insulin O
resistance O
compared O
with O
subjects O
who O
were O
treated O
with O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
vs O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
t O
( O
33 O
) O
= O
- O
4 O
. O
29 O
; O
P O
< O
. O
001 O
; O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vs O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
t O
( O
33 O
) O
= O
- O
3 O
. O
62 O
; O
P O
= O
. O
001 O
[ O
P O
< O
. O
001 O
] O
) O
. O

The O
homeostasis O
model O
assessment O
of O
insulin O
resistance O
also O
differed O
significantly O
among O
groups O
( O
F O
( O
33 O
) O
= O
4 O
. O
92 O
; O
P O
= O
. O
01 O
) O
( O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
> O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
> O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
( O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vs O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
t O
( O
33 O
) O
= O
2 O
. O
94 O
; O
P O
= O
. O
006 O
; O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vs O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
t O
( O
33 O
) O
= O
2 O
. O
42 O
; O
P O
= O
. O
02 O
) O
. O

There O
was O
a O
significant O
difference O
among O
groups O
in O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
effectiveness O
( O
F O
( O
30 O
) O
= O
4 O
. O
18 O
; O
P O
= O
. O
02 O
) O
( O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
< O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
< O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
with O
significant O
differences O
between O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
t O
( O
30 O
) O
= O
- O
2 O
. O
59 O
; O
P O
= O
. O
02 O
) O
and O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
t O
( O
30 O
) O
= O
- O
2 O
. O
34 O
, O
P O
= O
. O
03 O
) O
. O

conclusions O
: O
Both O
nonobese O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
and O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
groups O
displayed O
significant O
insulin O
resistance O
and O
impairment O
of O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
effectiveness O
compared O
with O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
subjects O
. O

patients O
taking O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
must O
be O
examined O
for O
insulin O
resistance O
and O
its O
consequences O
. O

Thoracic O
hematomyelia O
secondary O
to O
coumadin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anticoagulant O
therapy O
: O
a O
case O
report O
. O

A O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
thoracic B_DISEASE_ADJECTIVE[DISEASE]
hematomyelia I_DISEASE_ADJECTIVE[DISEASE]
secondary I_DISEASE_ADJECTIVE[DISEASE]
to O
anticoagulant B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
presented O
. O

Clinical B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
features I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
similar B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
2 B_NUMBER[MEASURE]/B_PERSON
other I_NUMBER[MEASURE]/I_PERSON
previously O
reported O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
are O
discussed O
. O

A O
high B_MEASURE/B_DISEASE
index I_MEASURE/I_DISEASE
of O
suspicion B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
lead O
to O
a O
quick B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnostic I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
procedure I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
successful B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decompressive I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Mania O
associated O
with O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
in O
adolescents O
. O

Fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
a O
selective O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reuptake O
inhibitor O
, O
is O
gaining O
increased O
acceptance O
in O
the O
treatment O
of O
adolescent O
depression O
. O

Generally O
safe O
and O
well O
tolerated O
by O
adults O
, O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
reported O
to O
induce O
mania O
. O

The O
cases O
of O
five O
depressed O
adolescents O
, O
14 O
- O
16 O
years O
of O
age O
, O
who O
developed O
mania O
during O
pharmacotherapy O
with O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
are O
reported O
here O
. O

apparent O
risk O
factors O
for O
the O
development O
of O
mania O
or O
hypomania O
during O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pharmacotherapy O
in O
this O
population O
were O
the O
combination O
of O
attention O
- O
deficit O
hyperactivity O
disorder O
and O
affective O
instability O
; O
major O
depression O
with O
psychotic O
features O
; O
a O
family O
history O
of O
affective O
disorder O
, O
especially O
bipolar O
disorder O
; O
and O
a O
diagnosis O
of O
bipolar O
disorder O
. O

Further O
study O
is O
needed O
to O
determine O
the O
optimal O
dosage O
and O
to O
identify O
risk O
factors O
that O
increase O
individual O
vulnerability O
to O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
mania O
in O
adolescents O
. O

acute O
renal O
insufficiency O
after O
high O
- O
dose O
melphalan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients O
with O
primary O
systemic O
amyloidosis O
during O
stem O
cell O
transplantation O
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
patients B_PERSON/B_BIO
with O
primary B_DISEASE
systemic I_DISEASE
amyloidosis I_DISEASE
( O
AL B_LOCATION/B_PERSON
) O
have O
a O
poor B_DISEASE_ADJECTIVE[DISEASE]
prognosis I_DISEASE_ADJECTIVE[DISEASE]
. O

median B_TIME[MEASURE]/B_PERSON
survival I_TIME[MEASURE]/I_PERSON
time I_TIME[MEASURE]/I_PERSON
from O
standard B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatments I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O
only O
17 B_TIME[MEASURE]
months I_TIME[MEASURE]
. O

High O
- O
dose O
intravenous O
melphalan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O
by O
peripheral O
blood O
stem O
cell O
transplant O
( O
PBSCT O
) O
appears O
to O
be O
the O
most O
promising O
therapy O
, O
but O
treatment O
mortality O
can O
be O
high O
. O

The O
authors O
have O
noted O
the O
development O
of O
acute O
renal O
insufficiency O
immediately O
after O
melphalan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
conditioning O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
undertaken O
to O
further O
examine O
its O
risk B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
impact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
posttransplant B_DISEASE
mortality I_DISEASE
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
consecutive B_PERSON
AL I_PERSON
patients I_PERSON
who O
underwent O
PBSCT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
studied O
retrospectively O
. O

acute O
renal O
insufficiency O
( O
Ari O
) O
after O
high O
- O
dose O
melphalan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
defined O
by O
a O
minimum O
increase O
of O
0 O
. O
5 O
mg O
/ O
DL O
( O
44 O
micromol O
/ O
L O
) O
in O
the O
serum O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O
that O
is O
greater O
than O
50 O
% O
of O
baseline O
immediately O
after O
conditioning O
. O

urine B_MEASURE/B_PERSON
sediment B_MEASURE/I_PERSON
score B_MEASURE/I_PERSON
was O
the O
sum B_MEASURE/B_PERSON
of O
the O
individual B_MEASURE
types I_MEASURE
of O
sediment B_BIO/B_DISEASE
identified O
on O
urine B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Results O
: O
Of O
the O
80 O
patients O
studied O
, O
Ari O
developed O
in O
18 O
. O
8 O
% O
of O
the O
patients O
after O
high O
- O
dose O
melphalan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Univariate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
identified O
age B_DISEASE/B_TIME[MEASURE]
, O
hypoalbuminemia B_DISEASE/B_PERSON
, O
heavy B_DISEASE
proteinuria I_DISEASE
, O
diuretic B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
urine B_DISEASE/B_GENE
sediment I_DISEASE/I_GENE
score I_DISEASE/I_GENE
( O
> B_LOCATION/B_DISEASE
3 I_LOCATION/I_DISEASE
) O
as O
risk B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Age B_DISEASE/B_GENE
and O
urine B_DISEASE/B_MEASURE
sediment I_DISEASE/I_MEASURE
score I_DISEASE/I_MEASURE
remained O
independently O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
risk I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
factors I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
multivariate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

patients O
who O
had O
Ari O
after O
high O
- O
dose O
melphalan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
underwent O
dialysis O
more O
often O
( O
P O
= O
0 O
. O
007 O
) O
, O
and O
had O
a O
worse O
1 O
- O
year O
survival O
( O
P O
= O
0 O
. O
03 O
) O
. O

conclusion O
: O
The O
timing O
of O
renal O
injury O
strongly O
suggests O
melphalan B_DISEASE/B_VIRUS[BIO]
as O
the O
causative O
agent O
. O

ongoing O
tubular O
injury O
may O
be O
a O
prerequisite O
for O
renal O
injury O
by O
melphalan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
as O
evidenced O
by O
the O
active O
urinary O
sediment O
. O

Development B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O
ari B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adversely O
affected O
the O
outcome B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
PBSCT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Effective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
preventive I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
measures I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
may O
help O
decrease O
the O
treatment B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mortality I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
PBSCT B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
AL B_LOCATION/B_PERSON
patients I_LOCATION/I_PERSON
. O

focal O
cerebral O
ischemia O
in O
rats O
: O
effect O
of O
phenylephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hypertension O
during O
reperfusion O
. O

After O
180 O
min O
of O
temporary O
middle O
cerebral O
artery O
occlusion O
in O
spontaneously O
hypertensive O
rats O
, O
the O
effect O
of O
phenylephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hypertension O
on O
ischemic O
brain O
injury O
and O
blood O
- O
brain O
barrier O
permeability O
was O
determined O
. O

Blood B_DISEASE
pressure I_DISEASE
was O
manipulated O
by O
one B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
following B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
schedules I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
during O
120 B_TIME[MEASURE]
min I_TIME[MEASURE]
of O
reperfusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
: O
Control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
normotensive B_DISEASE_ADJECTIVE[DISEASE]
reperfusion I_DISEASE_ADJECTIVE[DISEASE]
; O
90 B_MEASURE
/ O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
90 B_MEASURE
/ O
HTN B_LOCATION
) O
, O
blood B_DISEASE/B_MEASURE
pressure I_DISEASE/I_MEASURE
was O
increased O
by O
35 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mm I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Hg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
the O
initial B_TIME[MEASURE]/B_LOCATION
90 I_TIME[MEASURE]/I_LOCATION
min I_TIME[MEASURE]/I_LOCATION
of O
reperfusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
only O
; O
15 B_MEASURE
/ O
hypertension B_DISEASE/B_MEASURE
( O
15 B_MEASURE
/ O
HTN B_DISEASE/B_LOCATION
) O
, O
normotensive B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reperfusion B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
30 B_TIME[MEASURE]/B_PERSON
min B_TIME[MEASURE]/I_PERSON
followed O
by O
15 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
min I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
75 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
min I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
normotension B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Part O
A O
, O
for O
eight O
rats O
in O
each O
group O
brain O
injury O
was O
evaluated O
by O
staining O
tissue O
using O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
triphenyltetrazolium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
edema O
was O
evaluated O
by O
microgravimetry O
. O

Part B_MEASURE/B_LOCATION
B I_MEASURE/I_LOCATION
, O
for O
eight B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
different I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
rats I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
each O
group B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blood I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
brain B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
barrier I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
permeability I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
evaluated O
by O
measuring O
the O
amount B_MEASURE/B_LOCATION
and O
extent B_MEASURE/B_LOCATION
of O
extravasation B_DISEASE/B_PHYSIOLOGIC_FUNCTION[ORGANISM_FUNCTION]
of O
Evans B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Blue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dye I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Brain B_DISEASE/B_PERSON
injury I_DISEASE/I_PERSON
( O
percentage B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
ischemic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hemisphere I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
) O
was O
less B_MEASURE
in O
the O
15 B_MEASURE
/ O
HTN B_MEASURE/B_ORGANIZATION
group I_MEASURE/I_ORGANIZATION
( O
16 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
, O
mean O
+ B_OTHER/B_DISEASE
/ O
- O
SD B_MEASURE/B_DISEASE
) O
versus B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
90 B_MEASURE
/ O
HTN B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
30 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
) O
, O
which O
was O
in O
turn B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
the O
control B_MEASURE/B_ORGANIZATION
group I_MEASURE/I_ORGANIZATION
( O
42 B_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
) O
. O

specific B_MEASURE/B_PERSON
gravity B_MEASURE/I_PERSON
was O
greater B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
15 B_MEASURE
/ O
HTN B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 B_MEASURE
. O
043 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
002 B_MEASURE
) O
versus B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
the O
90 B_MEASURE
/ O
HTN B_MEASURE
( O
1 B_NUMBER[MEASURE]
. O
036 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
003 B_MEASURE
) O
and O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
1 B_NUMBER[MEASURE]
. O
037 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
003 B_MEASURE
) O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Evans B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Blue I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
mug O
g O
- O
1 O
of O
brain O
tissue O
) O
was O
greater O
in O
the O
90 O
/ O
HTN O
group O
( O
24 O
. O
4 O
+ O
/ O
- O
6 O
. O
0 O
) O
versus O
the O
control O
group O
( O
12 O
. O
3 O
+ O
/ O
- O
4 O
. O
1 O
) O
, O
which O
was O
in O
turn O
greater O
than O
the O
15 O
/ O
HTN O
group O
( O
7 O
. O
3 O
+ O
/ O
- O
3 O
. O
2 O
) O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supports O
a O
hypothesis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
during O
reperfusion B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
a O
short B_MEASURE
interval I_MEASURE
of O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decreases O
brain B_DISEASE/B_GENE
injury I_DISEASE/I_GENE
and O
edema B_DISEASE
; O
and O
that O
sustained O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
increases O
the O
risk B_MEASURE
of O
vasogenic B_DISEASE
edema I_DISEASE
. O

People O
aged O
over O
75 O
in O
atrial O
fibrillation O
on O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
the O
rate O
of O
major O
hemorrhage O
and O
stroke O
in O
more O
than O
500 O
patient O
- O
years O
of O
follow O
- O
up O
. O

objectives O
: O
To O
determine O
the O
incidence O
of O
major O
hemorrhage O
and O
stroke O
in O
people O
aged O
76 O
and O
older O
with O
atrial O
fibrillation O
on O
adjusted O
- O
dose O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
who O
had O
been O
recently O
been O
admitted O
to O
hospital O
. O

Design B_PERSON/B_MEASURE
: O
A O
retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observational I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cohort I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

setting B_LOCATION
: O
A O
major B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
healthcare I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
network I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
involving O
four B_PERSON/B_LOCATION
tertiary I_PERSON/I_LOCATION
hospitals I_PERSON/I_LOCATION
. O

participants O
: O
Two O
hundred O
thirty O
- O
five O
patients O
aged O
76 O
and O
older O
admitted O
to O
a O
major O
healthcare O
network O
between O
July O
1 O
, O
2001 O
, O
and O
June O
30 O
, O
2002 O
, O
with O
atrial O
fibrillation O
on O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
enrolled O
. O

measurements O
: O
Information O
regarding O
major O
bleeding O
episodes O
, O
strokes O
, O
and O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
was O
obtained O
from O
patients O
, O
relatives O
, O
primary O
physicians O
, O
and O
medical O
records O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Two B_NUMBER[MEASURE]
hundred I_NUMBER[MEASURE]
twenty I_NUMBER[MEASURE]
- O
eight B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
( O
42 B_PERSON/B_MEASURE
% I_PERSON/I_MEASURE
men I_PERSON/I_MEASURE
) O
with O
a O
mean B_MEASURE/B_DISEASE
age I_MEASURE/I_DISEASE
of O
81 B_MEASURE
. O
1 B_MEASURE
( O
range B_MEASURE/B_LOCATION
76 I_MEASURE/I_LOCATION
- O
94 B_MEASURE
) O
were O
included O
in O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Total O
follow O
- O
up O
on O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
530 O
years O
( O
mean O
28 O
months O
) O
. O

There O
were O
53 B_MEASURE/B_PERSON
major I_MEASURE/I_PERSON
hemorrhages I_MEASURE/I_PERSON
, O
for O
an O
annual B_MEASURE
rate I_MEASURE
of O
10 B_MEASURE
. O
0 B_MEASURE
% I_MEASURE
, O
including O
24 B_NUMBER[MEASURE]
( O
45 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
) O
life B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
threatening O
and O
five B_NUMBER[MEASURE]
( O
9 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
fatal B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
bleeds I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
annual O
stroke O
rate O
after O
initiation O
of O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
2 O
. O
6 O
% O
. O

conclusion O
: O
The O
rate O
of O
major O
hemorrhage O
was O
high O
in O
this O
old O
, O
frail O
group O
, O
but O
excluding O
fatalities O
, O
resulted O
in O
no O
long O
- O
term O
sequelae O
, O
and O
the O
stroke O
rate O
on O
warfarin B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
low O
, O
demonstrating O
how O
effective O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
is O
. O

Safety O
of O
celecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
patients O
with O
adverse O
skin O
reactions O
to O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
paracetamol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
nimesulide B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O
or O
not O
with O
common O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
. O

Background O
: O
Acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
paracetamol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
- O
P B_OTHER/B_LOCATION
) O
and O
Nimesulide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
N B_OTHER/B_LOCATION
) O
are O
widely O
used O
analgesic O
- O
antipyretic O
/ O
anti O
- O
inflammatory O
drugs O
. O

The O
rate B_MEASURE
of O
adverse B_DISEASE_ADJECTIVE[DISEASE]
hypersensitivity I_DISEASE_ADJECTIVE[DISEASE]
reactions I_DISEASE_ADJECTIVE[DISEASE]
to O
these O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
generally O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

On O
the O
contrary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
non B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
- O
steroidal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
anti I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O
inflammatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
NSAIDs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
are O
commonly O
involved O
in O
such B_DISEASE/B_LOCATION
reactions I_DISEASE/I_LOCATION
. O

Celecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
CE B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
a O
novel O
drug O
, O
with O
high O
selectivity O
and O
affinity O
for O
Cox O
- O
2 O
enzyme O
. O

objective O
: O
We O
evaluated O
the O
tolerability O
of O
CE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
a O
group O
of O
patients O
with O
documented O
history O
of O
adverse O
cutaneous O
reactions O
to O
P B_OTHER/B_LOCATION
and O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
associated O
or O
not O
to O
classic O
NSAIDs O
. O

methods O
: O
We O
studied O
9 O
patients O
with O
hypersensitivity O
to O
P B_OTHER/B_LOCATION
and O
N B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
or O
without O
associated O
reactions O
to O
classic O
NSAIDs O
. O

The O
diagnosis O
of O
P B_LOCATION
and O
N B_OTHER/B_LOCATION
- O
induced O
skin O
reactions O
was O
based O
in O
vivo O
challenge O
. O

The O
placebo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
was O
blindly O
administered O
at O
the O
beginning B_TIME[MEASURE]/B_LOCATION
of O
each O
challenge B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

After O
three O
days O
, O
a O
cumulative O
dosage O
of O
200 O
mg O
of O
CE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
refracted O
doses O
were O
given O
. O

After O
2 B_NUMBER[MEASURE]/B_LOCATION
- O
3 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
, O
a O
single B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
200 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
. O

All O
patients B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
observed O
for O
6 B_TIME[MEASURE]/B_SPORT[ENT]
hours I_TIME[MEASURE]/I_SPORT[ENT]
after O
each O
challenge B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
and O
controlled O
again O
after O
24 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
hours I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
to O
exclude O
delayed O
reactions B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
challenge B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
considered O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
if O
one B_NUMBER[MEASURE]
or O
more B_NUMBER[MEASURE]/B_PERSON
of O
the O
following B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
appeared O
: O
erythema B_DISEASE
, O
rush B_DISEASE
or O
urticaria B_DISEASE
- O
angioedema B_DISEASE_ADJECTIVE[DISEASE]
. O

Results O
: O
No O
reaction O
was O
observed O
with O
placebo O
and O
eight O
patients O
( O
88 O
. O
8 O
% O
) O
tolerated O
CE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Only O
one B_PERSON
patient I_PERSON
developed O
a O
moderate B_DISEASE
angioedema I_DISEASE
of O
the O
lips B_BODY_PART_OR_ORGAN_COMPONENT
. O

conclusion O
: O
Only O
one O
hypersensitivity O
reaction O
to O
CE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
documented O
among O
9 O
P B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
highly O
NSAIDs O
intolerant O
patients O
. O

Thus O
, O
we O
conclude O
that O
CE B_LOCATION/B_PERSON
is O
a O
reasonably O
safe O
alternative O
to O
be O
used O
in O
subjects O
who O
do O
not O
tolerate O
P B_OTHER/B_LOCATION
and O
N B_OTHER/B_LOCATION
. O

Case B_PERSON/B_TIME[MEASURE]
- O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
regular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
analgesic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
nonsteroidal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
inflammatory B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
end B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stage B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
renal I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
disease I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

Background O
: O
Studies O
on O
the O
association O
between O
the O
long O
- O
term O
use O
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
other O
analgesic O
and O
nonsteroidal O
anti O
- O
inflammatory O
drugs O
( O
NSAIDs O
) O
and O
end O
- O
stage O
renal O
disease O
( O
ESRD O
) O
have O
given O
conflicting O
results O
. O

In O
order B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
examine O
this O
association B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
a O
case B_PERSON/B_DISEASE
- O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
incident B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
ESRD B_DISEASE/B_LOCATION
was O
carried O
out O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
The O
cases B_PERSON/B_MEASURE
were O
all O
patients B_PERSON/B_LOCATION
entering O
the O
local B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
dialysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
program B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
because O
of O
ESRD B_DISEASE
in O
the O
study B_LOCATION
area I_LOCATION
between O
June B_TIME[MEASURE]
1 I_TIME[MEASURE]
, O
1995 B_MEASURE
and O
November B_TIME[MEASURE]
30 I_TIME[MEASURE]
, O
1997 B_MEASURE
. O

They O
were O
classified O
according O
to O
the O
underlying B_DISEASE
disease I_DISEASE
, O
which O
had O
presumably O
led O
them O
to O
ESRD B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

controls B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
were O
patients B_PERSON/B_TIME[MEASURE]
admitted O
to O
the O
same B_LOCATION/B_ORGANIZATION
hospitals I_LOCATION/I_ORGANIZATION
from O
where O
the O
cases B_PERSON/B_DISEASE
arose O
, O
also O
matched O
by O
age B_TIME[MEASURE]/B_DISEASE
and O
sex B_PERSON/B_LOCATION
. O

odds B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratios I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
calculated O
using O
a O
conditional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
logistic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
including O
potential B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confounding I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
both O
for O
the O
whole B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
population I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
for O
the O
various B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
underlying O
diseases B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Five B_NUMBER[MEASURE]/B_LOCATION
hundred I_NUMBER[MEASURE]/I_LOCATION
and O
eighty B_NUMBER[MEASURE]
- O
three B_NUMBER[MEASURE]
cases I_NUMBER[MEASURE]
and O
1190 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
controls I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
included O
in O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Long B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
any O
analgesic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
associated O
with O
an O
overall B_MEASURE
odds I_MEASURE
ratio I_MEASURE
of O
1 B_MEASURE
. O
22 B_MEASURE
( O
95 B_MEASURE
% I_MEASURE
CI I_MEASURE
, O
0 B_MEASURE
. O
89 B_MEASURE
- O
1 B_MEASURE
. O
66 B_MEASURE
) O
. O

For O
specific O
groups O
of O
drugs O
, O
the O
risks O
were O
1 O
. O
56 O
( O
1 O
. O
05 O
- O
2 O
. O
30 O
) O
for O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
1 O
. O
03 O
( O
0 O
. O
60 O
- O
1 O
. O
76 O
) O
for O
pyrazolones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
0 O
. O
80 O
( O
0 O
. O
39 O
- O
1 O
. O
63 O
) O
for O
paracetamol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
0 O
. O
94 O
( O
0 O
. O
57 O
- O
1 O
. O
56 O
) O
for O
nonaspirin O
NSAIDs O
. O

The O
risk O
of O
ESRD O
associated O
with O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
related O
to O
the O
cumulated O
dose O
and O
duration O
of O
use O
, O
and O
it O
was O
particularly O
high O
among O
the O
subset O
of O
patients O
with O
vascular O
nephropathy O
as O
underlying O
disease O
[ O
2 O
. O
35 O
( O
1 O
. O
17 O
- O
4 O
. O
72 O
) O
] O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
indicate O
that O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
nonaspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
analgesic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
NSAIDs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
associated O
with O
an O
increased O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
ESRD B_DISEASE
. O

However O
, O
the O
chronic O
use O
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
increase O
the O
risk O
of O
ESRD O
. O

Two O
cases O
of O
amisulpride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overdose O
: O
a O
cause O
for O
prolonged O
QT O
syndrome O
. O

Two O
cases O
of O
deliberate O
self O
- O
poisoning O
with O
5 O
g O
and O
3 O
. O
6 O
g O
of O
amisulpride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
, O
are O
reported O
. O

In O
both O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
QT B_DISEASE
prolongation I_DISEASE
and O
hypocalcaemia B_DISEASE
were O
noted O
. O

The O
QT O
prolongation O
appeared O
to O
respond O
to O
administration O
of O
i O
. O
v O
. O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gluconate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Growth O
- O
associated O
protein O
43 O
expression O
in O
hippocampal O
molecular O
layer O
of O
chronic O
epileptic O
rats O
treated O
with O
cycloheximide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Purpose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
: O
GAP43 B_GENE/B_DISEASE
has O
been O
thought O
to O
be O
linked O
with O
mossy B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
fiber I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
sprouting O
( O
MFS B_LOCATION/B_ORGANIZATION
) O
in O
various B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
experimental I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
epilepsy B_DISEASE
. O

To O
investigate O
how O
GAP43 O
expression O
( O
GAP43 O
- O
ir O
) O
correlates O
with O
MFS O
, O
we O
assessed O
the O
intensity O
( O
densitometry O
) O
and O
extension O
( O
width O
) O
of O
GAP43 O
- O
ir O
in O
the O
inner O
molecular O
layer O
of O
the O
dentate O
gyrus O
( O
IML O
) O
of O
rats O
subject O
to O
status O
epilepticus O
induced O
by O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Pilo B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
previously O
injected O
or O
not O
with O
cycloheximide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CHX B_LOCATION/B_ORGANIZATION
) O
, O
which O
has O
been O
shown O
to O
inhibit O
MFS O
. O

methods O
: O
CHX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
injected O
before O
the O
Pilo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
injection O
in O
adult O
Wistar O
rats O
. O

The O
Pilo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O
was O
injected O
with O
the O
same O
drugs O
, O
except O
for O
CHX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Animals B_BIO/B_PERSON
were O
killed O
between O
30 B_MEASURE
and O
60 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
later O
, O
and O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
sections I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
processed O
for O
GAP43 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunohistochemistry I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
Densitometry O
showed O
no O
significant O
difference O
regarding O
GAP43 O
- O
ir O
in O
the O
IML O
between O
Pilo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
CHX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
+ O
Pilo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
and O
control O
groups O
. O

However O
, O
the O
results O
of O
the O
width O
of O
the O
GAP43 O
- O
ir O
band O
in O
the O
IML O
showed O
that O
CHX B_DISEASE
+ O
Pilo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
control O
animals O
had O
a O
significantly O
larger O
band O
( O
p O
= O
0 O
. O
03 O
) O
as O
compared O
with O
that O
in O
the O
Pilo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O
. O

conclusions O
: O
Our O
current O
finding O
that O
animals O
in O
the O
CHX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
+ O
Pilo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O
have O
a O
GAP43 O
- O
ir O
band O
in O
the O
IML O
, O
similar O
to O
that O
of O
controls O
, O
reinforces O
prior O
data O
on O
the O
blockade O
of O
MFS O
in O
these O
animals O
. O

The O
change O
in O
GAP43 O
- O
ir O
present O
in O
Pilo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
animals O
was O
a O
thinning O
of O
the O
band O
to O
a O
very O
narrow O
layer O
just O
above O
the O
granule O
cell O
layer O
that O
is O
likely O
to O
be O
associated O
with O
the O
loss O
of O
hilar O
cell O
projections O
that O
express O
Gap O
- O
43 O
. O

Nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonizes O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
but O
not O
pentylenetetrazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
anxiogenic O
effect O
in O
mice O
. O

RATIONALE O
: O
Nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
widely O
consumed O
licit O
psychoactive O
drugs O
worldwide O
. O

Epidemiological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
that O
they O
were O
generally O
used O
concurrently O
. O

Although O
some O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
experimental B_LOCATION/B_ORGANIZATION
animals I_LOCATION/I_ORGANIZATION
indicate O
clear B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pharmacological I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interactions I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
them O
, O
no O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O
shown O
a O
specific B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
anxiety B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
responses I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

objectives O
: O
The O
present O
study O
investigates O
the O
effects O
of O
nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
anxiety O
induced O
by O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
another O
anxiogenic O
drug O
, O
pentylenetetrazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
mice O
. O

The O
elevated B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
plus I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- O
maze B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
EPM B_LOCATION/B_DISEASE
) O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
used O
to O
evaluate O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
anxiety B_DISEASE
. O

methods O
: O
Adult O
male O
Swiss O
Webster O
mice O
( O
25 O
- O
32 O
g O
) O
were O
given O
nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 O
. O
05 O
- O
0 O
. O
25 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
or O
saline O
10 O
min O
before O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
70 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
or O
pentylenetetrazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
15 O
and O
30 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
injections O
. O

After O
15 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
min I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
, O
mice B_BIO/B_PERSON
were O
evaluated O
for O
their O
open B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
and O
closed B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
arm B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
time I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
entries B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
EPM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
for O
a O
10 B_MEASURE
- O
min B_TIME[MEASURE]/B_LOCATION
session I_TIME[MEASURE]/I_LOCATION
. O

locomotor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
recorded O
for O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
using O
the O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protocol I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
EPM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
test I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Results O
: O
Nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 O
. O
05 O
- O
0 O
. O
25 O
mg O
/ O
kg O
) O
itself O
did O
not O
produce O
any O
significant O
effect O
in O
the O
EPM O
test O
, O
whereas O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
70 O
mg O
/ O
kg O
) O
and O
pentylenetetrazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
30 O
mg O
/ O
kg O
) O
produced O
an O
anxiogenic O
effect O
, O
apparent O
with O
decreases O
in O
open O
- O
arm O
time O
and O
entry O
. O

Nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
0 O
. O
25 O
mg O
/ O
kg O
) O
pretreatment O
blocked O
the O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
but O
not O
pentylenetetrazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
anxiety O
. O

Administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
each O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
their O
combinations B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
did O
not O
produce O
any O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
locomotor B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusions O
: O
Our O
results O
suggest O
that O
the O
antagonistic O
effect O
of O
nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
anxiety O
is O
specific O
to O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
instead O
of O
a O
non O
- O
specific O
anxiolytic O
effect O
. O

Thus O
, O
it O
may O
extend O
the O
current O
findings O
on O
the O
interaction O
between O
nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Long B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
term I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hormone I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
perimenopausal B_PERSON
and O
postmenopausal B_PERSON/B_DISEASE
women I_PERSON/I_DISEASE
. O

Background B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
HT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PROTEIN[GENE]
) O
is O
widely O
used O
for O
controlling O
menopausal B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
symptoms I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
has O
also O
been O
used O
for O
the O
management B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
prevention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cardiovascular B_DISEASE
disease I_DISEASE
, O
osteoporosis B_DISEASE
and O
dementia B_DISEASE
in O
older B_PERSON/B_BIO
women I_PERSON/I_BIO
but O
the O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supporting O
its O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
these O
indications B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
largely O
observational B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

objectives B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
To O
assess O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
long B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
HT I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O
mortality B_DISEASE
, O
heart B_DISEASE
disease I_DISEASE
, O
venous B_DISEASE
thromboembolism I_DISEASE
, O
stroke B_DISEASE
, O
transient B_DISEASE
ischaemic I_DISEASE
attacks I_DISEASE
, O
breast B_DISEASE
cancer I_DISEASE
, O
colorectal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
ovarian B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
cancer I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
endometrial B_DISEASE
cancer I_DISEASE
, O
gallbladder B_DISEASE
disease I_DISEASE
, O
cognitive B_DISEASE
function I_DISEASE
, O
dementia B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
fractures B_DISEASE
and O
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
life B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

search B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
strategy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
We O
searched O
the O
following B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
databases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
up O
to O
November B_TIME[MEASURE]
2004 I_TIME[MEASURE]
: O
the O
Cochrane B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
menstrual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Disorders B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
Subfertility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Register B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
Cochrane B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Central I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Register I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
Controlled B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
central B_LOCATION/B_TIME[MEASURE]
) O
, O
MEDLINE B_ORGANIZATION/B_PERSON
, O
EMBASE B_ORGANIZATION/B_LOCATION
, O
Biological B_ORGANIZATION/B_LOCATION
Abstracts I_ORGANIZATION/I_LOCATION
. O

relevant B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
non O
- O
indexed O
journals B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
conference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
abstracts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
were O
also O
searched O
. O

Selection O
criteria O
: O
Randomised O
double O
- O
blind O
trials O
of O
HT O
( O
oestrogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
or O
without O
progestogens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
versus O
placebo O
, O
taken O
for O
at O
least O
one O
year O
by O
perimenopausal O
or O
postmenopausal O
women O
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
collection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O
Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Fifteen B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
RCTs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
included O
. O

Trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
assessed O
for O
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
two B_PERSON/B_LOCATION
review I_PERSON/I_LOCATION
authors I_PERSON/I_LOCATION
extracted O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
independently O
. O

They O
calculated O
risk B_MEASURE
ratios I_MEASURE
for O
dichotomous B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
weighted B_MEASURE
mean O
differences B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
continuous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Clinical B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
heterogeneity I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
precluded O
meta B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
most B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Main B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
RESULTS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
All O
the O
statistically O
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
derived O
from O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
biggest I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
. O

In O
relatively O
healthy B_PERSON/B_TIME[MEASURE]
women I_PERSON/I_TIME[MEASURE]
, O
combined O
continuous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
HT I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
significantly O
increased O
the O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
venous B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
thromboembolism I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O
coronary B_DISEASE/B_LOCATION
event I_DISEASE/I_LOCATION
( O
after O
one B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
year I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
s O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
, O
stroke B_DISEASE
( O
after O
3 B_NUMBER[MEASURE]/B_ENT
years I_NUMBER[MEASURE]/I_ENT
) O
, O
breast B_DISEASE
cancer I_DISEASE
( O
after O
5 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
years I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
and O
gallbladder B_DISEASE
disease I_DISEASE
. O

Long O
- O
term O
oestrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
only O
HT O
also O
significantly O
increased O
the O
risk O
of O
stroke O
and O
gallbladder O
disease O
. O

Overall O
, O
the O
only B_NUMBER[MEASURE]/B_ORGANIZATION
statistically O
significant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
benefits I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
HT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
a O
decreased B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
incidence I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
fractures B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
colon B_DISEASE
cancer I_DISEASE
with O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

Among O
relatively O
healthy B_PERSON
women I_PERSON
over O
65 B_NUMBER[MEASURE]/B_ENT
years I_NUMBER[MEASURE]/I_ENT
taking O
continuous B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combined O
HT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
there O
was O
a O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
incidence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
dementia B_DISEASE
. O

Among O
women B_PERSON
with O
cardiovascular B_DISEASE
disease I_DISEASE
, O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
combined B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
continuous I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
HT I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
significantly O
increased O
the O
risk B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
venous B_DISEASE/B_LOCATION
thromboembolism I_DISEASE/I_LOCATION
. O

No O
trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
focussed O
specifically O
on O
younger B_PERSON/B_ENT
women I_PERSON/I_ENT
. O

However O
, O
one O
trial O
analysed O
subgroups O
of O
2839 O
relatively O
healthy O
50 O
to O
59 O
year O
- O
old O
women O
taking O
combined O
continuous O
HT O
and O
1637 O
taking O
oestrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
only O
HT O
, O
versus O
similar O
- O
sized O
placebo O
groups O
. O

The O
only B_SEQUENCE[MEASURE]/B_ORGANIZATION
significantly O
increased O
risk B_DISEASE_ADJECTIVE[DISEASE]
reported O
was O
for O
venous B_DISEASE
thromboembolism I_DISEASE
in O
women B_PERSON/B_BIO
taking O
combined O
continuous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
HT I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
; O
their O
absolute B_MEASURE/B_DISEASE
risk I_MEASURE/I_DISEASE
remained O
very O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Authors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
CONCLUSIONS I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
HT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
not O
indicated O
for O
the O
routine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
management I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
chronic B_DISEASE/B_PROTEIN[GENE]
disease B_DISEASE/I_PROTEIN[GENE]
. O

We O
need O
more B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
the O
safety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
HT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
menopausal B_PERSON/B_DISEASE
symptom I_PERSON/I_DISEASE
control I_PERSON/I_DISEASE
, O
though O
short B_MEASURE
- O
term B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O
to O
be O
relatively O
safe B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
for O
healthy B_PERSON
younger I_PERSON
women I_PERSON
. O

Drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
liver B_DISEASE
injury I_DISEASE
: O
an O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
461 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
incidences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
submitted O
to O
the O
Spanish B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
registry I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
over O
a O
10 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
period I_TIME[MEASURE]
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
& O
aims B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
progress B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
understanding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
susceptibility B_DISEASE_ADJECTIVE[DISEASE]
factors I_DISEASE_ADJECTIVE[DISEASE]
to O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
liver B_DISEASE
injury I_DISEASE
( O
DILI B_DISEASE
) O
and O
outcome B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predictability I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
hampered O
by O
the O
lack B_DISEASE_ADJECTIVE[DISEASE]
of O
systematic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
programs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
detect O
bona B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fide I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
A O
cooperative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
network I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
created O
in O
1994 B_MEASURE
in O
Spain B_LOCATION
to O
identify O
all O
suspicions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
DILI B_DISEASE
following O
a O
prospective B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structured O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
liver B_DISEASE
damage I_DISEASE
was O
characterized O
according O
to O
hepatocellular B_DISEASE
, O
cholestatic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
mixed B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
laboratory B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
criteria B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
to O
histologic O
criteria B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
causality B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
centrally O
performed O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Since O
April B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1994 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
August B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2004 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
461 B_MEASURE
out O
of O
570 B_MEASURE
submitted O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
involving O
505 B_PERSON/B_ORGANIZATION
drugs I_PERSON/I_ORGANIZATION
, O
were O
deemed O
to O
be O
related O
to O
DILI B_DISEASE
. O

The O
antiinfective O
group O
of O
drugs O
was O
the O
more O
frequently O
incriminated O
, O
amoxicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
clavulanate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
accounting O
for O
the O
12 O
. O
8 O
% O
of O
the O
whole O
series O
. O

The O
hepatocellular B_DISEASE/B_MEASURE
pattern B_DISEASE/I_MEASURE
of O
damage B_DISEASE
was O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
( O
58 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
) O
, O
was O
inversely O
correlated O
with O
age B_DISEASE/B_MEASURE
( O
P B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
. O
0001 B_MEASURE
) O
, O
and O
had O
the O
worst B_MEASURE/B_LOCATION
outcome I_MEASURE/I_LOCATION
( O
Cox B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
P B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
. O
034 B_MEASURE
) O
. O

Indeed O
, O
the O
incidence B_MEASURE/B_PERSON
of O
liver B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
death B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
this O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
11 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
if O
patients B_PERSON
had O
jaundice O
at O
presentation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
whereas O
the O
corresponding B_MEASURE/B_LOCATION
figure I_MEASURE/I_LOCATION
was O
3 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
in O
nonjaundiced B_MEASURE/B_PERSON
patients I_MEASURE/I_PERSON
( O
P B_MEASURE
< I_MEASURE
. O
04 B_MEASURE
) O
. O

factors O
associated O
with O
the O
development O
of O
fulminant O
hepatic O
failure O
were O
female O
sex O
( O
OR O
= O
25 O
; O
95 O
% O
CI O
: O
4 O
. O
1 O
- O
151 O
; O
P O
< O
. O
0001 O
) O
, O
hepatocellular O
damage O
( O
OR O
= O
7 O
. O
9 O
; O
95 O
% O
CI O
: O
1 O
. O
6 O
- O
37 O
; O
P O
< O
. O
009 O
) O
, O
and O
higher O
baseline O
plasma O
bilirubin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
value O
( O
OR O
= O
1 O
. O
15 O
; O
95 O
% O
CI O
: O
1 O
. O
09 O
- O
1 O
. O
22 O
; O
P O
< O
. O
0001 O
) O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
patients B_PERSON/B_BIO
with O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hepatocellular B_DISEASE
jaundice I_DISEASE
have O
11 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
chance I_MEASURE/I_PERSON
of O
progressing O
to O
death B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
transplantation B_DISEASE/B_SURGICAL_AND_MEDICAL_PROCEDURES[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Amoxicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clavulanate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stands O
out O
as O
the O
most O
common O
drug O
related O
to O
DILI O
. O

Morphological O
evaluation O
of O
the O
effect O
of O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ribose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
adriamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
evoked O
cardiotoxicity O
in O
rats O
. O

The O
influence O
of O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ribose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
adriamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
myocardiopathy O
in O
rats O
was O
studied O
. O

Adriamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
cumulative O
dose O
of O
25 O
mg O
/ O
kg O
evoked O
fully O
developed O
cardiac O
toxicity O
. O

D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ribose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
multiple O
doses O
of O
200 O
mg O
/ O
kg O
did O
not O
influence O
ADR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cardiotoxicity O
. O

In O
vivo O
evidences O
suggesting O
the O
role O
of O
oxidative O
stress O
in O
pathogenesis O
of O
vancomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
nephrotoxicity O
: O
protection O
by O
erdosteine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
aims O
of O
this O
study O
were O
to O
examine O
vancomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
VCM B_LOCATION/B_ORGANIZATION
) O
- O
induced O
oxidative O
stress O
that O
promotes O
production O
of O
reactive O
oxygen B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
species O
( O
ROS O
) O
and O
to O
investigate O
the O
role O
of O
erdosteine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
an O
expectorant O
agent O
, O
which O
has O
also O
antioxidant O
properties O
, O
on O
kidney O
tissue O
against O
the O
possible O
VCM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
induced O
renal O
impairment O
in O
rats O
. O

rats O
were O
divided O
into O
three O
groups O
: O
sham O
, O
VCM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
VCM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
plus O
erdosteine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

VCM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
administrated O
intraperitoneally O
( O
i O
. O
p O
. O
) O
with O
200mgkg O
( O
- O
1 O
) O
twice O
daily O
for O
7 O
days O
. O

Erdosteine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
orally O
. O

VCM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administration O
to O
control O
rats O
significantly O
increased O
renal O
malondialdehyde B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MDA B_LOCATION
) O
and O
urinary O
N O
- O
acetyl O
- O
beta O
- O
d O
- O
glucosaminidase O
( O
NAG O
, O
a O
marker O
of O
renal O
tubular O
injury O
) O
excretion O
but O
decreased O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dismutase O
( O
SOD O
) O
and O
catalase O
( O
Cat O
) O
activities O
. O

Erdosteine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration O
with O
VCM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
injections O
caused O
significantly O
decreased O
renal O
MDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
urinary O
NAG O
excretion O
, O
and O
increased O
SOD O
activity O
, O
but O
not O
Cat O
activity O
in O
renal O
tissue O
when O
compared O
with O
VCM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
alone O
. O

Erdosteine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
showed O
histopathological O
protection O
against O
VCM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
nephrotoxicity O
. O

There O
were O
a O
significant O
dilatation O
of O
tubular O
lumens O
, O
extensive O
epithelial O
cell O
vacuolization O
, O
atrophy O
, O
desquamation O
, O
and O
necrosis O
in O
VCM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
rats O
more O
than O
those O
of O
the O
control O
and O
the O
erdosteine B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O
. O

Erdosteine B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caused O
a O
marked O
reduction O
in O
the O
extent O
of O
tubular O
damage O
. O

It O
is O
concluded O
that O
oxidative O
tubular O
damage O
plays O
an O
important O
role O
in O
the O
VCM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
induced O
nephrotoxicity O
and O
the O
modulation O
of O
oxidative O
stress O
with O
erdosteine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduces O
the O
VCM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
induced O
kidney O
damage O
both O
at O
the O
biochemical O
and O
histological O
levels O
. O

Gemfibrozil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
lovastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
for O
primary O
hyperlipoproteinemias O
. O

The O
specific O
aim O
of O
this O
retrospective O
, O
observational O
study O
was O
to O
assess O
safety O
and O
efficacy O
of O
long O
- O
term O
( O
21 O
months O
/ O
patient O
) O
, O
open O
- O
label O
, O
gemfibrozil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
lovastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
in O
80 O
patients O
with O
primary O
mixed O
hyperlipidemia O
( O
68 O
% O
of O
whom O
had O
atherosclerotic O
vascular O
disease O
) O
. O

Because O
ideal O
lipid O
targets O
were O
not O
reached O
( O
low O
- O
density O
lipoprotein O
( O
LDL O
) O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
less O
than O
130 O
mg O
/ O
DL O
, O
high O
- O
density O
lipoprotein O
( O
HDL O
) O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
greater O
than O
35 O
mg O
/ O
DL O
, O
or O
total O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O
HDL O
cholesterol B_MEASURE/B_LOCATION
less O
than O
4 O
. O
5 O
mg O
/ O
DL O
) O
with O
diet O
plus O
a O
single O
drug O
, O
gemfibrozil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
1 O
. O
2 O
g O
/ O
day O
) O
- O
lovastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
primarily O
20 O
or O
40 O
mg O
) O
treatment O
was O
given O
. O

Follow O
- O
up O
visits O
were O
scheduled O
with O
2 O
- O
drug O
therapy O
every O
6 O
to O
8 O
weeks O
, O
an O
average O
of O
10 O
. O
3 O
visits O
per O
patient O
, O
with O
741 O
batteries O
of O
6 O
liver O
function O
tests O
and O
714 O
creatine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphokinase O
levels O
measured O
. O

Only O
1 B_NUMBER[MEASURE]
of O
the O
4 B_MEASURE
, O
446 B_MEASURE
liver I_MEASURE
function I_MEASURE
tests I_MEASURE
( O
0 B_MEASURE
. O
02 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
, O
a O
gamma B_MEASURE/B_PERSON
glutamyl I_MEASURE/I_PERSON
transferase I_MEASURE/I_PERSON
, O
was O
greater B_MEASURE
than O
or O
equal B_MEASURE
to O
3 B_TIME[MEASURE]/B_LOCATION
times B_TIME[MEASURE]/I_LOCATION
the O
upper B_MEASURE
normal I_MEASURE
limit I_MEASURE
. O

Of O
the O
714 O
creatine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phosphokinase O
levels O
, O
9 O
% O
were O
high O
; O
only O
1 O
( O
0 O
. O
1 O
% O
) O
was O
greater O
than O
or O
equal O
to O
3 O
times O
the O
upper O
normal O
limit O
. O

With O
2 O
- O
drug O
therapy O
, O
mean O
total O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O
22 O
% O
from O
255 O
to O
200 O
mg O
/ O
DL O
, O
triglyceride B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O
decreased O
35 O
% O
from O
236 O
to O
154 O
mg O
/ O
DL O
, O
LDL O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
decreased O
26 O
% O
from O
176 O
to O
131 O
mg O
/ O
DL O
, O
and O
the O
total O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
HDL O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ratio O
decreased O
24 O
% O
from O
7 O
. O
1 O
to O
5 O
. O
4 O
, O
all O
p O
less O
than O
or O
equal O
to O
0 O
. O
0001 O
. O

Myositis O
, O
attributable O
to O
the O
drug O
combination O
and O
symptomatic O
enough O
to O
discontinue O
it O
, O
occurred O
in O
3 O
% O
of O
patients O
, O
and O
in O
1 O
% O
with O
concurrent O
high O
creatine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
phosphokinase O
( O
769 O
U O
/ O
liter O
) O
; O
no O
patients O
had O
rhabdomyolysis O
or O
myoglobinuria O
. O
( O
abstract O
TRUNCATED O
AT O
250 O
Words O
) O
. O

Does O
domperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentiate O
mirtazapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
restless O
legs O
syndrome O
. O

There O
is O
now O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
suggest O
a O
central B_DISEASE_ADJECTIVE[DISEASE]
role I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
dopaminergic B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
system I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
restless B_DISEASE
legs I_DISEASE
syndrome I_DISEASE
( O
RLS B_DISEASE
) O
. O

For O
example O
, O
the O
symptoms O
of O
RLS O
can O
be O
dramatically O
improved O
by O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonists O
, O
whereas O
central O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D2 O
receptor O
antagonists O
can O
induce O
or O
aggravate O
RLS O
symptoms O
. O

To O
our O
knowledge O
, O
there O
is O
no O
previous O
report O
regarding O
whether O
domperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
peripheral O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D2 O
receptor O
antagonist O
, O
can O
also O
induce O
or O
aggravate O
symptoms O
of O
RLS O
. O

Mirtazapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
the O
first O
noradrenergic O
and O
specific O
serotonergic O
antidepressant O
( O
NaSSA O
) O
, O
has O
been O
associated O
with O
RLS O
in O
several O
recent O
publications O
. O

The O
authors O
report O
here O
a O
depressed O
patient O
comorbid O
with O
postprandial O
dyspepsia O
who O
developed O
RLS O
after O
mirtazapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
been O
added O
to O
his O
domperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
therapy O
. O

Our O
patient O
started O
to O
have O
symptoms O
of O
RLS O
only O
after O
he O
had O
been O
treated O
with O
mirtazapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
his O
RLS O
symptoms O
resolved O
completely O
upon O
discontinuation O
of O
his O
mirtazapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Such O
a O
temporal O
relationship O
between O
the O
use O
of O
mirtazapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
symptoms O
of O
RLS O
in O
our O
patient O
did O
not O
support O
a O
potentiating O
effect O
of O
domperione B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
mirtazapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
RLS O
. O

However O
, O
physicians O
should O
be O
aware O
of O
the O
possibility O
that O
mirtazapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
be O
associated O
with O
RLS O
in O
some O
individuals O
, O
especially O
those O
receiving O
concomitant O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D2 O
receptor O
antagonists O
. O

Antiandrogenic B_DISEASE/B_PERSON
therapy I_DISEASE/I_PERSON
can O
cause O
coronary B_DISEASE
arterial I_DISEASE
disease I_DISEASE
. O

aim B_MEASURE
: O
To O
study O
the O
change B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
lipid B_DISEASE/B_GENE
metabolism B_DISEASE/I_GENE
by O
antiandrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
patients B_PERSON/B_BIO
with O
prostate B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
. O

Materials O
AND O
methods O
: O
We O
studied O
with O
a O
2 O
. O
5 O
years O
follow O
- O
up O
the O
changes O
in O
plasma O
cholesterols B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
C B_OTHER/B_LOCATION
) O
, O
triglycerides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TG B_LOCATION
) O
, O
lipoproteins O
( O
LP O
) O
, O
and O
apolipoproteins O
( O
Apo O
) O
B O
- O
100 O
, O
A O
- O
I O
, O
and O
A O
- O
II O
pro O
fi O
les O
in O
24 O
patients O
of O
mean O
age O
60 O
years O
with O
low O
risk O
prostate O
cancer O
( O
stage O
: O
T1cN0M0 O
, O
Gleason O
score O
: O
2 O
- O
5 O
) O
during O
treatment O
with O
cyproterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CPA B_LOCATION/B_ORGANIZATION
) O
without O
surgical O
management O
or O
radiation O
therapy O
. O

Results O
: O
significant O
decreases O
of O
HDL O
- O
C O
, O
Apo O
A O
- O
I O
and O
Apo O
A O
- O
II O
and O
an O
increase O
of O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
levels O
in O
VLDL O
were O
induced O
by O
CPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

After O
a O
period O
of O
2 O
. O
5 O
years O
on O
CPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
, O
four O
patients O
out O
of O
twenty O
- O
four O
were O
found O
to O
be O
affected O
by O
coronary O
heart O
disease O
. O

conclusions O
: O
Ischaemic O
coronary O
arteriosclerosis O
with O
an O
incidence O
rate O
of O
16 O
. O
6 O
% O
as O
caused O
by O
prolonged O
CPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
is O
mediated O
through O
changes O
in O
HDL O
cholesterol B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
Apo O
A O
- O
I O
and O
Apo O
A O
- O
II O
pro O
fi O
les O
, O
other O
than O
the O
well O
- O
known O
hyperglyceridemic O
effect O
caused O
by O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

5 B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fluorouracil I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiotoxicity O
induced O
by O
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluoro I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alanine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Cardiotoxicity O
is O
a O
rare O
complication O
occurring O
during O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
treatment O
for O
malignancies O
. O

We O
herein O
report O
the O
case O
of O
a O
70 O
- O
year O
- O
old O
man O
with O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cardiotoxicity O
, O
in O
whom O
a O
high O
serum O
level O
of O
alpha B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluoro I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alanine I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
FBAL B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
was O
observed O
. O

The O
patient B_PERSON
, O
who O
had O
unresectable B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
colon I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cancer I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
metastases I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
lung B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
was O
referred O
to O
us O
for O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
from O
an O
affiliated B_LOCATION/B_PERSON
hospital B_LOCATION/I_PERSON
; O
he O
had O
no O
cardiac B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
history B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

After O
admission O
, O
the O
patient O
received O
a O
continuous O
intravenous O
infusion O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1000 O
mg O
/ O
day O
) O
, O
during O
which O
precordial O
pain O
with O
right O
bundle O
branch O
block O
occurred O
concomitantly O
with O
a O
high O
serum O
FBAL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O
of O
1955 O
ng O
/ O
ml O
. O

Both O
the O
precordial O
pain O
and O
the O
electrocardiographic O
changes O
disappeared O
spontaneously O
after O
the O
discontinuation O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

As O
the O
precordial O
pain O
in O
this O
patient O
was O
considered O
to O
have O
been O
due O
to O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cardiotoxicity O
, O
the O
administration O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
abandoned O
. O

Instead O
, O
oral O
administration O
of O
S O
- O
1 O
( O
a O
derivative O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
at O
200 O
mg O
/ O
day O
twice O
a O
week O
, O
was O
instituted O
, O
because O
S O
- O
1 O
has O
a O
strong O
inhibitory O
effect O
on O
dihydropyrimidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dehydrogenase O
, O
which O
catalyzes O
the O
degradative O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
into O
FBAL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
serum O
FBAL B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
concentration O
subsequently O
decreased O
to O
352 O
ng O
/ O
ml O
, O
the O
same O
as O
the O
value O
measured O
on O
the O
first O
day O
of O
S O
- O
1 O
administration O
. O

Thereafter O
, O
no O
cardiac B_DISEASE_ADJECTIVE[DISEASE]
symptoms I_DISEASE_ADJECTIVE[DISEASE]
were O
observed O
. O

The O
patient B_PERSON/B_BIO
achieved O
a O
partial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
response I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
6 I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
months I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O
the O
initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
S B_DISEASE/B_GENE
- O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
experience O
of O
this O
case O
, O
together O
with O
a O
review O
of O
the O
literature O
, O
suggests O
that O
FBAL B_DISEASE/B_GENE
is O
related O
to O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cardiotoxicity O
. O

S O
- O
1 O
may O
be O
administered O
safely O
to O
patients O
with O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cardiotoxicity O
. O

Hepatocellular O
carcinoma O
in O
Fanconi O
' O
s O
anemia O
treated O
with O
androgen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
corticosteroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
case O
of O
an O
11 O
- O
year O
- O
old O
boy O
is O
reported O
who O
was O
known O
to O
have O
Fanconi O
' O
s O
anemia O
for O
3 O
years O
and O
was O
treated O
with O
androgens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
corticosteroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
transfusions O
. O

Two B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
before O
his O
death B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
he O
was O
readmitted O
because O
of O
aplastic B_DISEASE
crisis I_DISEASE
with O
septicemia B_DISEASE
and O
marked B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abnormalities I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
liver B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
died O
of O
hemorrhagic B_DISEASE
bronchopneumonia I_DISEASE
. O

At O
autopsy B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
peliosis I_NUMBER[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
multiple B_DISEASE
hepatic I_DISEASE
tumors I_DISEASE
were O
found O
which O
histologically O
proved O
to O
be O
well O
- O
differentiated O
hepatocellular B_DISEASE
carcinoma I_DISEASE
. O

This O
case O
contributes O
to O
the O
previous O
observations O
that O
non O
- O
metastasizing O
hepatic O
neoplasms O
and O
peliosis O
can O
develop O
in O
patients O
with O
androgen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
corticosteroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
Fanconi O
' O
s O
anemia O
. O

The O
influence O
of O
the O
time O
interval O
between O
monoHER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
on O
the O
protection O
against O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cardiotoxicity O
in O
mice O
. O

purpose O
: O
Despite O
its O
well O
- O
known O
cardiotoxicity O
, O
the O
anthracyclin O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
continues O
to O
be O
an O
effective O
and O
widely O
used O
chemotherapeutic O
agent O
. O

DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cardiac O
damage O
presumably O
results O
from O
the O
formation O
of O
free O
radicals O
by O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

reactive O
oxygen B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
species O
particularly O
affect O
the O
cardiac O
myocytes O
because O
these O
cells O
seem O
to O
have O
a O
relatively O
poor O
antioxidant O
defense O
system O
. O

The O
semisynthetic O
flavonoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
monohydroxyethylrutoside I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
monoHER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
showed O
cardioprotection O
against O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cardiotoxicity O
through O
its O
radical O
scavenging O
and O
iron B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chelating O
properties O
. O

Because O
of O
the O
relatively O
short O
final O
half O
- O
life O
of O
monoHER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
about O
30 O
min O
) O
, O
it O
is O
expected O
that O
the O
time O
interval O
between O
monoHER B_LOCATION/B_ORGANIZATION
and O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
might O
be O
of O
influence O
on O
the O
cardioprotective O
effect O
of O
monoHER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Therefore O
, O
the O
aim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
to O
investigate O
this O
possible B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effect I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

methods O
: O
Six O
groups O
of O
6 O
BALB O
/ O
c O
mice O
were O
treated O
with O
saline O
, O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
or O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
4 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
preceded O
by O
monoHER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
500 O
mg O
/ O
kg O
i O
. O
p O
. O
) O
with O
an O
interval O
of O
10 O
, O
30 O
, O
60 O
or O
120 O
min O
. O

After O
a O
6 B_NUMBER[MEASURE]
- O
week B_TIME[MEASURE]
treatment I_TIME[MEASURE]
period I_TIME[MEASURE]
and O
additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
2 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
weeks I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
the O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
sacrificed O
. O

Their O
cardiac B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
were O
processed O
for O
light B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
after O
which O
cardiomyocyte B_DISEASE
damage I_DISEASE
was O
evaluated O
according O
to O
Billingham B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
in O
Cancer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Treat I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Rep B_MEASURE
62 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
6 B_NUMBER[MEASURE]
) O
: O
865 B_MEASURE
- O
872 B_MEASURE
, O
1978 B_MEASURE
) O
. O

Microscopic O
evaluation O
revealed O
that O
treatment O
with O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
induced O
significant O
cardiac O
damage O
in O
comparison O
to O
the O
saline O
control O
group O
( O
P O
< O
0 O
. O
001 O
) O
. O

Results O
: O
The O
number O
of O
damaged O
cardiomyocytes O
was O
9 O
. O
6 O
- O
fold O
( O
95 O
% O
CI O
4 O
. O
4 O
- O
21 O
. O
0 O
) O
higher O
in O
mice O
treated O
with O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
alone O
than O
that O
in O
animals O
of O
the O
control O
group O
. O

The O
ratio O
of O
aberrant O
cardiomyocytes O
in O
mice O
treated O
with O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
preceded O
by O
monoHER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
those O
in O
mice O
treated O
with O
saline O
ranged O
from O
1 O
. O
6 O
to O
2 O
. O
8 O
( O
mean O
2 O
. O
2 O
, O
95 O
% O
CI O
1 O
. O
2 O
- O
4 O
. O
1 O
, O
P O
= O
0 O
. O
019 O
) O
. O

The O
mean O
protective O
effect O
by O
adding O
monoHER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
before O
DOX B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
led O
to O
a O
significant O
4 O
. O
4 O
- O
fold O
reduction O
( O
P O
< O
0 O
. O
001 O
, O
95 O
% O
CI O
2 O
. O
3 O
- O
8 O
. O
2 O
) O
of O
abnormal O
cardiomyocytes O
. O

This O
protective O
effect O
did O
not O
depend O
on O
the O
time O
interval O
between O
monoHER B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
administration O
( O
P O
= O
0 O
. O
345 O
) O
. O

conclusion O
: O
The O
results O
indicate O
that O
in O
an O
outpatient O
clinical O
setting O
monoHER B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
administered O
shortly O
before O
DOX B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Clinical O
evaluation O
of O
adverse O
effects O
during O
bepridil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
for O
atrial O
fibrillation O
and O
flutter O
. O

Background O
: O
Bepridil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Bpd B_ORGANIZATION/B_LOCATION
) O
has O
attracted O
attention O
as O
an O
effective O
drug O
for O
atrial O
fibrillation O
( O
AF O
) O
and O
atrial O
flutter O
( O
AFL O
) O
. O

However O
, O
serious B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adverse I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
torsade B_DISEASE
de I_DISEASE
pointes I_DISEASE
( O
TDP B_PROTEIN[GENE]/B_LOCATION
) O
, O
have O
been O
reported O
. O

methods O
AND O
Results O
: O
adverse O
effects O
of O
Bpd B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
requiring O
discontinuation O
of O
treatment O
were O
evaluated O
. O

Bpd B_DISEASE/B_PROTEIN[GENE]
was O
administered O
to O
459 O
patients O
( O
361 O
males O
, O
63 O
+ O
/ O
- O
12 O
years O
old O
) O
comprising O
378 O
AF O
and O
81 O
AFL O
cases O
. O

Mean O
left O
ventricular B_MEASURE/B_LOCATION
ejection B_MEASURE/I_LOCATION
fraction B_MEASURE/I_LOCATION
and O
atrial B_MEASURE
dimension I_MEASURE
( O
lad B_PERSON/B_DISEASE
) O
were O
66 B_MEASURE
+ I_MEASURE
/ O
- O
11 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
40 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
mm I_MEASURE
, O
respectively O
. O

Adverse B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
observed O
in O
19 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
( O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
during O
an O
average B_MEASURE/B_LOCATION
follow B_MEASURE/I_LOCATION
- O
up B_LOCATION/B_LANGUAGE
of O
20 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
months B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
was O
marked O
QT B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
prolongation B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
greater B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE
. O
55 B_MEASURE
s I_MEASURE
in O
13 B_MEASURE/B_PERSON
patients B_MEASURE/I_PERSON
, O
bradycardia B_MEASURE
less I_MEASURE
than O
40 B_MEASURE
beats I_MEASURE
/ O
min B_TIME[MEASURE]/B_PERSON
in O
6 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
, O
dizziness B_DISEASE
and O
general B_DISEASE
fatigue I_DISEASE
in O
1 B_NUMBER[MEASURE]/B_PERSON
patient I_NUMBER[MEASURE]/I_PERSON
each O
. O

In O
4 B_NUMBER[MEASURE]
of O
13 B_TIME[MEASURE]/B_PERSON
patients B_TIME[MEASURE]/I_PERSON
with O
QT B_DISEASE
prolongation I_DISEASE
, O
TDP B_DISEASE/B_GENE
occurred O
. O

The O
major B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triggering B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
TDP B_DISEASE/B_GENE
were O
hypokalemia B_DISEASE
and O
sudden B_DISEASE_ADJECTIVE[DISEASE]
decrease I_DISEASE_ADJECTIVE[DISEASE]
in O
heart B_MEASURE/B_DISEASE
rate B_MEASURE/I_DISEASE
. O

There O
were O
no O
differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
clinical B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
backgrounds I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
patients B_PERSON
with O
and O
without O
TDP B_DISEASE/B_GENE
other I_DISEASE/I_GENE
than O
lad B_PERSON/B_DISEASE
and O
age B_DISEASE/B_LOCATION
, O
which O
were O
larger B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O
older B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
patients B_PERSON
with O
TDP B_DISEASE/B_GENE
. O

conclusion O
: O
careful O
observation O
of O
serum O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O
and O
the O
ECG O
should O
always O
be O
done O
during O
Bpd B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration O
, O
particularly O
in O
elderly O
patients O
. O

enhanced O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cardiac O
hypertrophy O
in O
transgenic O
rats O
with O
low O
brain O
angiotensinogen O
. O

We O
have O
previously O
shown O
that O
a O
permanent O
deficiency O
in O
the O
brain O
renin O
- O
angiotensin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
system O
( O
RAS O
) O
may O
increase O
the O
sensitivity O
of O
the O
baroreflex O
control O
of O
heart O
rate O
. O

In O
this O
study O
we O
aimed O
at O
studying O
the O
involvement O
of O
the O
brain O
RAS O
in O
the O
cardiac O
reactivity O
to O
the O
beta O
- O
adrenoceptor O
( O
beta O
- O
AR O
) O
agonist O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Iso B_ORGANIZATION/B_LOCATION
) O
. O

Transgenic B_PERSON/B_BIO
rats I_PERSON/I_BIO
with O
low B_DISEASE
brain I_DISEASE
angiotensinogen I_DISEASE
( O
TGR B_LOCATION/B_ORGANIZATION
) O
were O
used O
. O

In O
isolated O
hearts O
, O
Iso B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
induced O
a O
significantly O
greater O
increase O
in O
left O
ventricular O
( O
LV O
) O
pressure O
and O
maximal O
contraction O
( O
+ O
dP O
/ O
dt O
( O
Max O
) O
) O
in O
the O
TGR O
than O
in O
the O
Sprague O
- O
Dawley O
( O
SD O
) O
rats O
. O

LV O
hypertrophy O
induced O
by O
Iso B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
treatment O
was O
significantly O
higher O
in O
TGR O
than O
in O
SD O
rats O
( O
in O
g O
LV O
wt O
/ O
100 O
g O
body O
wt O
, O
0 O
. O
28 O
+ O
/ O
- O
0 O
. O
004 O
vs O
. O
0 O
. O
24 O
+ O
/ O
- O
0 O
. O
004 O
, O
respectively O
) O
. O

The O
greater B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
LV I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hypertrophy I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
TGR B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
was O
associated O
with O
more O
pronounced B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
downregulation I_GENE_EXPRESSION_ADJECTIVE[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
AR B_GENE/B_DISEASE
and O
upregulation B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
of O
LV B_PROTEIN[GENE]
beta I_PROTEIN[GENE]
- O
AR B_GENE/B_LOCATION
kinase I_GENE/I_LOCATION
- O
1 B_GENE
mRNA I_GENE
levels I_GENE
compared O
with O
those O
in O
SD B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O

The O
decrease O
in O
the O
heart O
rate O
( O
HR O
) O
induced O
by O
the O
beta O
- O
AR O
antagonist O
metoprolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
conscious O
rats O
was O
significantly O
attenuated O
in O
TGR O
compared O
with O
SD O
rats O
( O
- O
9 O
. O
9 O
+ O
/ O
- O
1 O
. O
7 O
% O
vs O
. O
- O
18 O
. O
1 O
+ O
/ O
- O
1 O
. O
5 O
% O
) O
, O
whereas O
the O
effect O
of O
parasympathetic O
blockade O
by O
atropine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
HR O
was O
similar O
in O
both O
strains O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
TGR B_PERSON/B_BIO
are O
more O
sensitive B_DISEASE_ADJECTIVE[DISEASE]
to O
beta O
- O
AR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cardiac B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inotropic I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
response I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
hypertrophy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
possibly O
due B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
to O
chronically O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
sympathetic I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
outflow I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
directed O
to O
the O
heart B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

Drug O
- O
induced O
long O
QT O
syndrome O
in O
injection O
drug O
users O
receiving O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
high O
frequency O
in O
hospitalized O
patients O
and O
risk O
factors O
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
long B_DISEASE
QT I_DISEASE
syndrome I_DISEASE
is O
a O
serious B_DISEASE_ADJECTIVE[DISEASE]
adverse I_DISEASE_ADJECTIVE[DISEASE]
drug I_DISEASE_ADJECTIVE[DISEASE]
reaction I_DISEASE_ADJECTIVE[DISEASE]
. O

Methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
prolongs O
the O
QT O
interval O
in O
vitro O
in O
a O
dose O
- O
dependent O
manner O
. O

In O
the O
inpatient O
setting O
, O
the O
frequency O
of O
QT O
interval O
prolongation O
with O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
, O
its O
dose O
dependence O
, O
and O
the O
importance O
of O
cofactors O
such O
as O
drug O
- O
drug O
interactions O
remain O
unknown O
. O

methods O
: O
We O
performed O
a O
systematic O
, O
retrospective O
study O
comparing O
active O
or O
former O
intravenous O
drug O
users O
receiving O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
those O
not O
receiving O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
among O
all O
patients O
hospitalized O
over O
a O
5 O
- O
year O
period O
in O
a O
tertiary O
care O
hospital O
. O

A O
total O
of O
167 O
patients O
receiving O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fulfilled O
the O
inclusion O
criteria O
and O
were O
compared O
with O
a O
control O
group O
of O
80 O
injection O
drug O
users O
not O
receiving O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
addition O
to O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O
, O
15 O
demographic O
, O
biological O
, O
and O
pharmacological O
variables O
were O
considered O
as O
potential O
risk O
factors O
for O
QT O
prolongation O
. O

Results O
: O
Among O
167 O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maintenance O
patients O
, O
the O
prevalence O
of O
QTc O
prolongation O
to O
0 O
. O
50 O
second O
( O
( O
1 O
/ O
2 O
) O
) O
or O
longer O
was O
16 O
. O
2 O
% O
compared O
with O
0 O
% O
in O
80 O
control O
subjects O
. O

Six O
patients O
( O
3 O
. O
6 O
% O
) O
in O
the O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group O
presented O
torsades O
de O
pointes O
. O

QTc O
length O
was O
weakly O
but O
significantly O
associated O
with O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O
dose O
( O
Spearman O
rank O
correlation O
coefficient O
, O
0 O
. O
20 O
; O
P O
< O
. O
01 O
) O
. O

Multivariate O
regression O
analysis O
allowed O
attribution O
of O
31 O
. O
8 O
% O
of O
QTc O
variability O
to O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O
, O
cytochrome O
P O
- O
450 O
3A4 O
drug O
- O
drug O
interactions O
, O
hypokalemia O
, O
and O
altered O
liver O
function O
. O

conclusions O
: O
QT O
interval O
prolongation O
in O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
maintenance O
patients O
hospitalized O
in O
a O
tertiary O
care O
center O
is O
a O
frequent O
finding O
. O

Methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O
, O
presence O
of O
cytochrome O
P O
- O
450 O
3A4 O
inhibitors O
, O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O
, O
and O
liver O
function O
contribute O
to O
QT O
prolongation O
. O

Long O
QT O
syndrome O
can O
occur O
with O
low O
doses O
of O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

mechanisms O
of O
hypertension O
induced O
by O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
NO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
deficiency O
: O
focus O
on O
venous O
function O
. O

Loss O
of O
endothelial O
cell O
- O
derived O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
NO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
in O
hypertension O
is O
a O
hallmark O
of O
arterial O
dysfunction O
. O

Experimental O
hypertension O
created O
by O
the O
removal O
of O
NO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
however O
, O
involves O
mechanisms O
in O
addition O
to O
decreased O
arterial O
vasodilator O
activity O
. O

These O
include O
augmented O
endothelin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
1 B_TIME[MEASURE]
( O
ET B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
1 B_NUMBER[MEASURE]
) O
release B_ENT/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
increased O
sympathetic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nervous I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
elevated O
tissue B_DISEASE
oxidative I_DISEASE
stress I_DISEASE
. O

We O
hypothesized O
that O
increased O
venous O
smooth O
muscle O
( O
venomotor O
) O
tone O
plays O
a O
role O
in O
Nomega B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitro I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
L I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arginine I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
LNNA B_LOCATION/B_DISEASE
) O
hypertension O
through O
these O
mechanisms O
. O

rats O
were O
treated O
with O
the O
NO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
synthase O
inhibitor O
LNNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
0 O
. O
5 O
g O
/ O
L O
in O
drinking O
water O
) O
for O
2 O
weeks O
. O

Mean O
arterial O
pressure O
of O
conscious O
rats O
was O
119 O
+ O
/ O
- O
2 O
mm O
Hg O
in O
control O
and O
194 O
+ O
/ O
- O
5 O
mm O
Hg O
in O
LNNA B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats O
( O
P O
< O
0 O
. O
05 O
) O
. O

carotid B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arteries I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
vena B_BODY_PART_OR_ORGAN_COMPONENT
cava I_BODY_PART_OR_ORGAN_COMPONENT
were O
removed O
for O
measurement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
isometric B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
contraction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Maximal O
contraction O
to O
norepinephrine B_LOCATION
was O
modestly O
reduced O
in O
arteries O
from O
LNNA B_DISEASE/B_GENE
compared O
with O
control O
rats O
whereas O
the O
maximum O
contraction O
to O
ET O
- O
1 O
was O
significantly O
reduced O
( O
54 O
% O
control O
) O
. O

Maximum O
contraction O
of O
vena O
cava O
to O
norepinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
37 O
% O
control O
) O
also O
was O
reduced O
but O
no O
change O
in O
response O
to O
ET O
- O
1 O
was O
observed O
. O

Mean O
circulatory O
filling O
pressure O
, O
an O
in O
vivo O
measure O
of O
venomotor O
tone O
, O
was O
not O
elevated O
in O
LNNA B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hypertension O
at O
1 O
or O
2 O
weeks O
after O
LNNA B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
scavenger O
tempol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
30 O
, O
100 O
, O
and O
300 O
micromol O
kg O
( O
- O
1 O
) O
, O
IV O
) O
did O
not O
change O
arterial O
pressure O
in O
control O
rats O
but O
caused O
a O
dose O
- O
dependent O
decrease O
in O
LNNA B_DISEASE
rats O
( O
- O
18 O
+ O
/ O
- O
8 O
, O
- O
26 O
+ O
/ O
- O
15 O
, O
and O
- O
54 O
+ O
/ O
- O
11 O
mm O
Hg O
) O
. O

Similarly O
, O
ganglionic O
blockade O
with O
hexamethonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
caused O
a O
significantly O
greater O
fall O
in O
LNNA B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hypertensive O
rats O
( O
76 O
+ O
/ O
- O
9 O
mm O
Hg O
) O
compared O
with O
control O
rats O
( O
35 O
+ O
/ O
- O
10 O
mm O
Hg O
) O
. O

Carotid O
arteries O
, O
vena O
cava O
, O
and O
sympathetic O
ganglia O
from O
LNNA B_DISEASE
rats O
had O
higher O
basal O
levels O
of O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O
with O
those O
from O
control O
rats O
. O

These O
data O
suggest O
that O
while O
NO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deficiency O
increases O
oxidative O
stress O
and O
sympathetic O
activity O
in O
both O
arterial O
and O
venous O
vessels O
, O
the O
impact O
on O
veins O
does O
not O
make O
a O
major O
contribution O
to O
this O
form O
of O
hypertension O
. O

Association O
of O
DRD2 O
polymorphisms O
and O
chlorpromazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
extrapyramidal O
syndrome O
in O
Chinese O
schizophrenic O
patients O
. O

Aim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Extrapyramidal B_DISEASE
syndrome I_DISEASE
( O
EPS B_DISEASE
) O
is O
most O
commonly O
affected O
by O
typical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antipsychotic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
have O
a O
high B_LOCATION/B_MEASURE
affinity I_LOCATION/I_MEASURE
with O
the O
D2 B_GENE
receptor I_GENE
. O

Recently O
, O
many B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
reported O
on O
the O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationship I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
genetic B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
variations B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
in O
the O
DRD2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
gene I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
therapeutic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
schizophrenia B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
role B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
variations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
in O
the O
receptor B_GENE/B_LOCATION
in O
modulating O
receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

In O
this O
study O
, O
we O
evaluate O
the O
role O
DRD2 O
plays O
in O
chlorpromazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
EPS O
in O
schizophrenic O
patients O
. O

methods O
: O
We O
identified O
seven O
SNP O
( O
single O
nucleotide O
polymorphism O
) O
( O
- O
141Cins O
> O
del O
, O
TaqIB O
, O
TaqID O
, O
Ser311Cys O
, O
rs6275 O
, O
rs6277 O
and O
TaqIA O
) O
in O
the O
DRD2 O
gene O
in O
146 O
schizophrenic O
inpatients O
( O
59 O
with O
EPS O
and O
87 O
without O
EPS O
according O
to O
the O
Simpson O
- O
Angus O
Scale O
) O
treated O
with O
chlorpromazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
after O
8 O
weeks O
. O

The O
alleles B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
all O
loci B_BIO/B_PERSON
were O
determined O
by O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
polymerase B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O
Polymorphisms B_MEASURE/B_GENE
TaqID I_MEASURE/I_GENE
, O
Ser311Cys B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
rs6277 B_GENE/B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]
were O
not O
polymorphic B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
population B_PERSON/B_LOCATION
recruited O
in O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

No O
statistical B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significance I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
in O
the O
allele B_MEASURE
distribution I_MEASURE
of O
- O
141Cins B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
> I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
del I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
TaqIB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
rs6275 B_GENE/B_DISEASE
and O
TaqIA B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
in O
the O
estimated O
haplotypes B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
constituted O
by O
TaqIB B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
, O
rs6275 B_GENE/B_LOCATION
and O
TaqIA B_GENE/B_LOCATION
) O
in O
linkage B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
disequilibrium I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
between O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

conclusion O
: O
Our O
results O
did O
not O
lend O
strong O
support O
to O
the O
view O
that O
the O
genetic O
variation O
of O
the O
DRD2 O
gene O
plays O
a O
major O
role O
in O
the O
individually O
variable O
adverse O
effect O
induced O
by O
chlorpromazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
at O
least O
in O
Chinese O
patients O
with O
schizophrenia O
. O

Our O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
confirmed O
a O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O
the O
relationship B_PERSON/B_MEASURE
between O
DRD2 B_DISEASE/B_GENE
and O
EPS B_DISEASE/B_LOCATION
in O
Caucasians B_DISEASE/B_PERSON
. O

Physical O
training O
decreases O
susceptibility O
to O
subsequent O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
seizures O
in O
the O
rat O
. O

Regular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
motor I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
activity I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
has O
many B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
benefits I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
mental B_DISEASE/B_PERSON
and O
physical B_DISEASE_ADJECTIVE[DISEASE]
condition I_DISEASE_ADJECTIVE[DISEASE]
but O
its O
implications B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
epilepsy B_DISEASE
are O
still O
controversial B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
order B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
elucidate O
this O
problem B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
have O
studied O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
long B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_TIME[MEASURE]/B_LOCATION
physical I_TIME[MEASURE]/I_LOCATION
activity I_TIME[MEASURE]/I_LOCATION
on O
susceptibility B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
subsequent B_DISEASE
seizures I_DISEASE
. O

Male B_PERSON
Wistar I_PERSON
rats I_PERSON
were O
subjected O
to O
repeated O
training B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sessions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
treadmill B_LOCATION/B_ORGANIZATION
and O
swimming B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pool I_LOCATION/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thereafter O
, O
seizures O
were O
induced O
by O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injections O
in O
trained O
and O
non O
- O
trained O
control O
groups O
. O

During O
the O
acute B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
status B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epilepticus B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
we O
measured O
: O
( O
1 O
) O
the O
latency B_MEASURE
of O
the O
first B_DISEASE
motor I_DISEASE
sign I_DISEASE
, O
( O
2 B_NUMBER[MEASURE]/B_PERSON
) O
the O
intensity B_MEASURE
of O
seizures B_DISEASE
, O
( O
3 B_SEQUENCE[MEASURE]/B_LOCATION
) O
the O
time B_TIME[MEASURE]
when O
it O
occurred O
within O
the O
6 B_MEASURE
- O
h B_TIME[MEASURE]/B_LOCATION
observation I_TIME[MEASURE]/I_LOCATION
period I_TIME[MEASURE]/I_LOCATION
, O
and O
( O
4 O
) O
the O
time B_TIME[MEASURE]
when O
the O
acute B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
period I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
ended O
. O

All O
these O
behavioral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O
statistically O
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggesting O
that O
regular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
physical I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
exercises I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
decrease O
susceptibility B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
subsequently O
induced O
seizures B_DISEASE
and O
ameliorate O
the O
course B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
experimentally O
induced O
status B_DISEASE
epilepticus I_DISEASE
. O

tonic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
dopaminergic I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
stimulation I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
impairs I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
associative I_DISEASE_ADJECTIVE[DISEASE]
learning O
in O
healthy B_PERSON/B_BIO
subjects I_PERSON/I_BIO
. O

Endogenous O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
plays O
a O
central O
role O
in O
salience O
coding O
during O
associative O
learning O
. O

Administration O
of O
the O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
precursor O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enhances O
learning O
in O
healthy O
subjects O
and O
stroke O
patients O
. O

Because O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increases O
both O
phasic O
and O
tonic O
dopaminergic O
neurotransmission O
, O
the O
critical O
mechanism O
mediating O
the O
enhancement O
of O
learning O
is O
unresolved O
. O

We O
here O
probed O
how O
selective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tonic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
dopaminergic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
affects O
associative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
learning B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Forty B_PERSON
healthy I_PERSON
subjects I_PERSON
were O
trained O
in O
a O
novel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
vocabulary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
45 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concrete I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
nouns I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
over O
the O
course B_LOCATION/B_TIME[MEASURE]
of O
5 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consecutive B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
training B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
randomized O
, O
double B_MEASURE/B_COLOR
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
controlled O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

subjects O
received O
the O
tonically O
stimulating O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
receptor O
agonist O
pergolide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
0 O
. O
1 O
mg O
) O
vs O
placebo O
120 O
min O
before O
training O
on O
each O
training O
day O
. O

The O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
agonist O
significantly O
impaired O
novel O
word O
learning O
compared O
to O
placebo O
. O

This O
learning B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
decrement I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
persisted O
up O
to O
the O
last B_MEASURE/B_PERSON
follow O
- O
up O
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
weeks B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
post B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
training B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

subjects O
treated O
with O
pergolide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
also O
showed O
restricted O
emotional O
responses O
compared O
to O
the O
PLACEBO O
group O
. O

The O
extent O
of O
' O
flattened O
' O
affect O
with O
pergolide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
related O
to O
the O
degree O
of O
learning O
inhibition O
. O

These O
findings O
suggest O
that O
tonic O
occupation O
of O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O
impairs O
learning O
by O
competition O
with O
phasic O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
signals O
. O

Thus O
, O
phasic O
signaling O
seems O
to O
be O
the O
critical O
mechanism O
by O
which O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
enhances O
associative O
learning O
in O
healthy O
subjects O
and O
stroke O
patients O
. O

Minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
vasculitis O
fulfilling O
the O
criteria O
of O
polyarteritis O
nodosa O
. O

A O
47 O
- O
year O
- O
old O
man O
who O
had O
been O
taking O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
palmoplantar O
pustulosis O
developed O
fever O
, O
myalgias O
, O
polyneuropathy O
, O
and O
testicular O
pain O
, O
with O
elevated O
C O
- O
reactive O
protein O
( O
CRP O
) O
. O

Neither O
myeloperoxidase B_GENE
- O
nor O
proteinase B_GENE
- O
3 B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
antineutrophil B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cytoplasmic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antibody I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
manifestations B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
met O
the O
American B_LOCATION/B_ORGANIZATION
College B_LOCATION/I_ORGANIZATION
of O
Rheumatology B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
1990 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
criteria I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
the O
classification B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
polyarteritis B_DISEASE/B_LOCATION
nodosa I_DISEASE/I_LOCATION
. O

stopping O
minocycline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
led O
to O
amelioration O
of O
symptoms O
and O
normalization O
of O
CRP O
level O
. O

To O
our O
knowledge O
, O
this O
is O
the O
second O
case O
of O
minocycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
vasculitis O
satisfying O
the O
criteria O
. O

Differential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
disease B_DISEASE
is O
invaluable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
even O
for O
patients B_PERSON/B_BIO
with O
classical B_DISEASE
polyarteritis I_DISEASE
nodosa I_DISEASE
. O

Intramuscular O
hepatitis O
B O
immune O
globulin O
combined O
with O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
prevention O
of O
hepatitis O
B O
recurrence O
after O
liver O
transplantation O
. O

Background O
: O
Combined O
hepatitis O
B O
immune O
globulin O
( O
HBIg O
) O
and O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
prophylaxis O
of O
the O
recurrence O
of O
hepatitis O
B O
after O
liver O
transplantation O
has O
significantly O
improved O
the O
survival O
of O
HBsAg B_DISEASE/B_GENE
positive O
patients O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
was O
undertaken O
to O
evaluate O
the O
outcomes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
liver B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
patients B_PERSON/B_DISEASE
with O
hepatitis B_DISEASE
B I_DISEASE
virus I_DISEASE
( O
HBV B_DISEASE
) O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
A O
retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
chart I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
a O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
organ B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
transplant I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
database I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
identified O
51 B_MEASURE
patients I_MEASURE
( O
43 B_MEASURE/B_PERSON
men I_MEASURE/I_PERSON
and O
8 B_PERSON/B_SPORT[ENT]
women I_PERSON/I_SPORT[ENT]
) O
transplanted O
for O
benign B_DISEASE
HBV I_DISEASE
- O
related O
cirrhotic B_DISEASE
diseases I_DISEASE
between O
June B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2002 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
December B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2004 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
who O
had O
survived O
more B_MEASURE
than O
3 B_TIME[MEASURE]
months I_TIME[MEASURE]
. O

HBIg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
administered O
intravenously O
during O
the O
first B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
week I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
intramuscularly O
thereafter O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
At O
a O
median B_MEASURE/B_LOCATION
follow B_MEASURE/I_LOCATION
- O
up B_LOCATION/B_LANGUAGE
of O
14 B_MEASURE
. O
1 B_TIME[MEASURE]
months I_TIME[MEASURE]
, O
the O
overall B_DISEASE
recurrence I_DISEASE
rate I_DISEASE
in O
the O
51 B_PERSON/B_DISEASE
patients I_PERSON/I_DISEASE
was O
3 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
2 B_MEASURE
/ O
51 B_MEASURE
) O
. O

The O
overall B_DISEASE
patient I_DISEASE
survival I_DISEASE
was O
88 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
, O
and O
82 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
after O
1 B_SEQUENCE[MEASURE]
and O
2 B_NUMBER[MEASURE]/B_ENT
years I_NUMBER[MEASURE]/I_ENT
, O
respectively O
. O

A O
daily O
oral O
dose O
of O
100 O
mg O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
2 O
weeks O
before O
transplantation O
for O
10 O
patients O
enabled O
57 O
. O
1 O
% O
( O
4 O
/ O
7 O
) O
and O
62 O
. O
5 O
% O
( O
5 O
/ O
8 O
) O
of O
HBV O
- O
DNA O
and O
HBeAg B_GENE/B_DISEASE
positive O
patients O
respectively O
to O
convert O
to O
be O
negative O
. O

intramuscular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
HBIg I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
was O
well O
tolerated O
in O
all O
patients B_PERSON/B_LOCATION
. O

conclusion O
: O
Lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
combined O
with O
intramuscular O
HBIg O
can O
effectively O
prevent O
allograft O
from O
the O
recurrence O
of O
HBV O
after O
liver O
transplantation O
. O

Anticonvulsant O
effect O
of O
eslicarbazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
BIA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
093 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
on O
seizures O
induced O
by O
microperfusion O
of O
picrotoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O
the O
hippocampus O
of O
freely O
moving O
rats O
. O

Eslicarbazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
BIA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
093 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
S B_MEASURE/B_PERSON
- I_MEASURE/I_PERSON
( I_MEASURE/I_PERSON
- I_MEASURE/I_PERSON
) I_MEASURE/I_PERSON
- I_MEASURE/I_PERSON
10 I_MEASURE/I_PERSON
- I_MEASURE/I_PERSON
acetoxy I_MEASURE/I_PERSON
- I_MEASURE/I_PERSON
10 I_MEASURE/I_PERSON
, I_MEASURE/I_PERSON
11 I_MEASURE/I_PERSON
- I_MEASURE/I_PERSON
dihydro I_MEASURE/I_PERSON
- I_MEASURE/I_PERSON
5H I_MEASURE/I_PERSON
- I_MEASURE/I_PERSON
dibenzo I_MEASURE/I_PERSON
/ I_MEASURE/I_PERSON
b I_MEASURE/I_PERSON
, I_MEASURE/I_PERSON
f I_MEASURE/I_PERSON
/ I_MEASURE/I_PERSON
azepine I_MEASURE/I_PERSON
- I_MEASURE/I_PERSON
5 I_MEASURE/I_PERSON
- I_MEASURE/I_PERSON
carboxamide I_MEASURE/I_PERSON
) O
is O
a O
novel O
antiepileptic O
drug O
, O
now O
in O
Phase O
III O
clinical O
trials O
, O
designed O
with O
the O
aim O
of O
improving O
efficacy O
and O
safety O
in O
comparison O
with O
the O
structurally O
related O
drugs O
carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CBZ B_LOCATION/B_ORGANIZATION
) O
and O
oxcarbazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
OXC B_LOCATION/B_ORGANIZATION
) O
. O

We O
have O
studied O
the O
effects O
of O
oral O
treatment O
with O
eslicarbazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
a O
whole O
- O
animal O
model O
in O
which O
partial O
seizures O
can O
be O
elicited O
repeatedly O
on O
different O
days O
without O
changes O
in O
threshold O
or O
seizure O
patterns O
. O

In O
the O
animals O
treated O
with O
threshold O
doses O
of O
picrotoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
the O
average O
number O
of O
seizures O
was O
2 O
. O
3 O
+ O
/ O
- O
1 O
. O
2 O
, O
and O
average O
seizure O
duration O
was O
39 O
. O
5 O
+ O
/ O
- O
8 O
. O
4s O
. O

Pre O
- O
treatment O
with O
a O
dose O
of O
30 O
mg O
/ O
kg O
2h O
before O
picrotoxin B_BIO/B_BODY_PART_OR_ORGAN_COMPONENT
microperfusion O
prevented O
seizures O
in O
the O
75 O
% O
of O
the O
rats O
. O

Lower B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
doses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
3 B_NUMBER[MEASURE]
and O
10mg B_MEASURE
/ O
kg B_MEASURE
) O
did O
not O
suppress O
seizures B_DISEASE
, O
however O
, O
after O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
10mg B_MEASURE
/ O
kg B_MEASURE
, O
significant B_DISEASE_ADJECTIVE[DISEASE]
reductions I_DISEASE_ADJECTIVE[DISEASE]
in O
seizures B_MEASURE/B_DISEASE
duration I_MEASURE/I_DISEASE
( O
24 B_MEASURE
. O
3 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
. O
8s B_MEASURE
) O
and O
seizure B_MEASURE/B_DISEASE
number I_MEASURE/I_DISEASE
( O
1 B_MEASURE
. O
6 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
34 B_MEASURE
) O
were O
found O
. O

No O
adverse O
effects O
of O
eslicarbazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
observed O
in O
the O
behavioral O
/ O
EEG O
patterns O
studied O
, O
including O
sleep O
/ O
wakefulness O
cycle O
, O
at O
the O
doses O
studied O
. O

acute O
renal O
failure O
associated O
with O
prolonged O
intake O
of O
slimming O
pills O
containing O
anthraquinones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Chinese B_PERSON/B_ORGANIZATION
herbal I_PERSON/I_ORGANIZATION
medicine O
preparations O
are O
widely O
available O
and O
often O
regarded O
by O
the O
public O
as O
natural O
and O
safe O
remedies O
for O
a O
variety O
of O
medical O
conditions O
. O

Nephropathy O
caused O
by O
Chinese B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
herbs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O
previously O
been O
reported O
, O
usually O
involving O
the O
use O
of O
aristolochic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
report O
a O
23 O
- O
year O
- O
old O
woman O
who O
developed O
acute O
renal O
failure O
following O
prolonged O
use O
of O
a O
proprietary O
Chinese B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
herbal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
slimming O
pill O
that O
contained O
anthraquinone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
derivatives O
, O
extracted O
from O
Rhizoma O
Rhei O
( O
rhubarb O
) O
. O

The O
renal O
injury O
was O
probably O
aggravated O
by O
the O
concomitant O
intake O
of O
a O
non O
- O
steroidal O
anti O
- O
inflammatory O
drug O
, O
diclofenac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Renal B_PERSON/B_ORGANIZATION
pathology I_PERSON/I_ORGANIZATION
was O
that O
of O
hypocellular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
interstitial I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
fibrosis I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Spontaneous B_DISEASE_ADJECTIVE[DISEASE]
renal I_DISEASE_ADJECTIVE[DISEASE]
recovery I_DISEASE_ADJECTIVE[DISEASE]
occurred O
upon O
cessation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
slimming B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
pills I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
but O
mild B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
interstitial B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
fibrosis B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
tubular B_DISEASE
atrophy I_DISEASE
was O
still O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
histologically O
4 B_TIME[MEASURE]/B_LOCATION
months I_TIME[MEASURE]/I_LOCATION
later O
. O

Although O
a O
causal O
relationship O
between O
the O
use O
of O
an O
anthraquinone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
containing O
herbal O
agent O
and O
renal O
injury O
remains O
to O
be O
proven O
, O
phytotherapy O
- O
associated O
interstitial O
nephropathy O
should O
be O
considered O
in O
patients O
who O
present O
with O
unexplained O
renal O
failure O
. O

Chloroacetaldehyde B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
as O
a O
sulfhydryl B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reagent O
: O
the O
role O
of O
critical O
thiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O
in O
ifosfamide B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephropathy O
. O

Chloroacetaldehyde B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
CAA B_LOCATION
) O
is O
a O
metabolite O
of O
the O
alkylating O
agent O
ifosfamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IFO B_DISEASE/B_PROTEIN[GENE]
) O
and O
putatively O
responsible O
for O
renal O
damage O
following O
anti O
- O
tumor O
therapy O
with O
IFO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Depletion O
of O
sulfhydryl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
groups O
has O
been O
reported O
from O
cell O
culture O
, O
animal O
and O
clinical O
studies O
. O

In O
this O
work O
the O
effect O
of O
CAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
human O
proximal O
tubule O
cells O
in O
primary O
culture O
( O
hRPTEC O
) O
was O
investigated O
. O

toxicity O
of O
CAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
determined O
by O
protein O
content O
, O
cell O
number O
, O
LDH O
release O
, O
trypan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blue I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
exclusion O
assay O
and O
caspase O
- O
3 O
activity O
. O

Free O
thiols B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
measured O
by O
the O
method O
of O
Ellman O
. O

CAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reduced O
hRPTEC O
cell O
number O
and O
protein O
, O
induced O
a O
loss O
in O
free O
intracellular O
thiols B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
an O
increase O
in O
necrosis O
markers O
. O

CAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
but O
not O
acrolein B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibited O
the O
cysteine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
proteases O
caspase O
- O
3 O
, O
caspase O
- O
8 O
and O
cathepsin O
B O
. O

Caspase O
activation O
by O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
inhibited O
by O
CAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

In O
cells O
stained O
with O
fluorescent O
dyes O
targeting O
lysosomes O
, O
CAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induced O
an O
increase O
in O
lysosomal O
size O
and O
lysosomal O
leakage O
. O

The O
effects O
of O
CAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
cysteine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
protease O
activities O
and O
thiols B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
could O
be O
reproduced O
in O
cell O
lysate O
. O

Acidification O
, O
which O
slowed O
the O
reaction O
of O
CAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O
thiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
donors O
, O
could O
also O
attenuate O
effects O
of O
CAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
necrosis O
markers O
, O
thiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
depletion O
and O
cysteine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
protease O
inhibition O
in O
living O
cells O
. O

Thus O
, O
CAA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
directly O
reacts O
with O
cellular O
protein O
and O
non O
- O
protein O
thiols B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
mediating O
its O
toxicity O
on O
hRPTEC O
. O

This O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
reduced O
by O
acidification B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Therefore O
, O
urinary O
acidification O
could O
be O
an O
option O
to O
prevent O
IFO B_DISEASE_ADJECTIVE[DISEASE]
nephropathy O
in O
patients O
. O

Stereological O
methods O
reveal O
the O
robust O
size O
and O
stability O
of O
ectopic O
hilar O
granule O
cells O
after O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
status O
epilepticus O
in O
the O
adult O
rat O
. O

Following O
status B_DISEASE
epilepticus I_DISEASE
in O
the O
rat B_SPECIES[BIO]/B_GENE
, O
dentate O
granule B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
neurogenesis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
increases I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
greatly O
, O
and O
many B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_NUMBER[MEASURE]
of O
the O
new B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
neurons B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
appear O
to O
develop O
ectopically O
, O
in O
the O
hilar B_LOCATION/B_MEASURE
region I_LOCATION/I_MEASURE
of O
the O
hippocampal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
formation I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

It O
has O
been O
suggested O
that O
the O
ectopic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
hilar B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
granule B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
cells B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
could O
contribute O
to O
the O
spontaneous B_DISEASE_ADJECTIVE[DISEASE]
seizures I_DISEASE_ADJECTIVE[DISEASE]
that O
ultimately O
develop O
after O
status B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epilepticus I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

However O
, O
the O
population B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
never O
been O
quantified O
, O
so O
it O
is O
unclear B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
whether O
it O
is O
substantial B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
enough O
to O
have O
a O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influence B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
epileptogenesis B_PERSON/B_ORGANIZATION
. O

To O
quantify O
this O
population O
, O
the O
total O
number O
of O
ectopic O
hilar O
granule O
cells O
was O
estimated O
using O
unbiased O
stereology O
at O
different O
times O
after O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
status O
epilepticus O
. O

The O
number B_MEASURE
of O
hilar B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunoreactive I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
Prox B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
1 B_NUMBER[MEASURE]
, O
a O
granule B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
- O
specific B_PROTEIN[GENE]/B_MEASURE
marker I_PROTEIN[GENE]/I_MEASURE
, O
was O
estimated O
using O
the O
optical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
fractionator I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
method I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
the O
size B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
the O
hilar B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
ectopic I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
granule I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cell I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
population I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
after O
status B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epilepticus I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
substantial B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
and O
stable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
over O
time B_TIME[MEASURE]
. O

Interestingly O
, O
the O
size B_MEASURE/B_PERSON
of O
the O
population B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
appears O
to O
be O
correlated O
with O
the O
frequency B_MEASURE/B_LOCATION
of O
behavioral B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
seizures I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
because O
animals B_BIO/B_PERSON
with O
more O
ectopic B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
granule B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
hilus B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
have O
more O
frequent B_DISEASE
behavioral I_DISEASE
seizures I_DISEASE
. O

The O
hilar B_MEASURE
ectopic I_MEASURE
granule I_MEASURE
cell I_MEASURE
population I_MEASURE
does O
not O
appear O
to O
vary O
systematically O
across O
the O
septotemporal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
axis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
although O
it O
is O
associated O
with O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
volume B_MEASURE
of O
the O
hilus B_BODY_PART_OR_ORGAN_COMPONENT/B_BACTERIUM[BIO]
. O

The O
results O
provide O
new O
insight O
into O
the O
potential O
role O
of O
ectopic O
hilar O
granule O
cells O
in O
the O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
model O
of O
temporal O
lobe O
epilepsy O
. O

A O
prospective O
, O
open O
- O
label O
trial O
of O
galantamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
autistic O
disorder O
. O

Objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Post B_LOCATION/B_DISEASE
- O
mortem B_PERSON
studies I_PERSON
have O
reported O
abnormalities B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
cholinergic B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
autism B_DISEASE/B_SPECIES[BIO]
. O

The O
purpose O
of O
this O
study O
was O
to O
assess O
the O
use O
of O
galantamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
an O
acetylcholinesterase O
inhibitor O
and O
nicotinic O
receptor O
modulator O
, O
in O
the O
treatment O
of O
interfering O
behaviors O
in O
children O
with O
autism O
. O

methods O
: O
Thirteen O
medication O
- O
free O
children O
with O
autism O
( O
mean O
age O
, O
8 O
. O
8 O
+ O
/ O
- O
3 O
. O
5 O
years O
) O
participated O
in O
a O
12 O
- O
week O
, O
open O
- O
label O
trial O
of O
galantamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

patients B_PERSON/B_BIO
were O
rated O
monthly O
by O
parents B_PERSON
on O
the O
Aberrant B_LOCATION/B_PERSON
behavior B_LOCATION/I_PERSON
Checklist B_LOCATION/I_PERSON
( O
ABC B_ORGANIZATION/B_DISEASE
) O
and O
the O
Conners B_TIME[MEASURE]/B_ORGANIZATION
' I_TIME[MEASURE]/I_ORGANIZATION
parent I_TIME[MEASURE]/I_ORGANIZATION
rating I_TIME[MEASURE]/I_ORGANIZATION
Scale I_TIME[MEASURE]/I_ORGANIZATION
- O
revised O
, O
and O
by O
a O
physician B_PERSON/B_ORGANIZATION
using O
the O
Children B_ORGANIZATION/B_LOCATION
' I_ORGANIZATION/I_LOCATION
s I_ORGANIZATION/I_LOCATION
psychiatric I_ORGANIZATION/I_LOCATION
rating I_ORGANIZATION/I_LOCATION
Scale I_ORGANIZATION/I_LOCATION
and O
the O
Clinical B_ORGANIZATION/B_MEASURE
Global I_ORGANIZATION/I_MEASURE
impressions I_ORGANIZATION/I_MEASURE
scale I_ORGANIZATION/I_MEASURE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
reduction I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
parent B_PERSON/B_LOCATION
- O
rated O
irritability B_DISEASE_ADJECTIVE[DISEASE]
and O
social B_DISEASE_ADJECTIVE[DISEASE]
withdrawal I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
ABC B_DISEASE
as O
well O
as O
significant B_DISEASE_ADJECTIVE[DISEASE]
improvements I_DISEASE_ADJECTIVE[DISEASE]
in O
emotional B_DISEASE_ADJECTIVE[DISEASE]
lability I_DISEASE_ADJECTIVE[DISEASE]
and O
inattention B_DISEASE_ADJECTIVE[DISEASE]
on O
the O
Conners B_MEASURE/B_DISEASE
' I_MEASURE/I_DISEASE
parent I_MEASURE/I_DISEASE
rating I_MEASURE/I_DISEASE
Scale I_MEASURE/I_DISEASE
- O
- O
revised O
. O

Similarly O
, O
clinician B_PERSON
ratings I_PERSON
showed O
reductions B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
anger B_MEASURE/B_ENT
subscale I_MEASURE/I_ENT
of O
the O
Children B_DISEASE
' I_DISEASE
s I_DISEASE
Psychiatric I_DISEASE
Rating I_DISEASE
Scale I_DISEASE
. O

Eight B_NUMBER[MEASURE]
of O
13 B_NUMBER[MEASURE]/B_PERSON
participants B_NUMBER[MEASURE]/I_PERSON
were O
rated O
as O
responders B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
on O
the O
basis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
their O
improvement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
scores I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O
the O
Clinical B_MEASURE/B_DISEASE
Global B_MEASURE/I_DISEASE
Impressions B_MEASURE/I_DISEASE
scale B_MEASURE/I_DISEASE
. O

Overall O
, O
galantamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
well O
- O
tolerated O
, O
with O
no O
significant O
adverse O
effects O
apart O
from O
headaches O
in O
one O
patient O
. O

conclusion O
: O
In O
this O
open O
trial O
, O
galantamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
well O
- O
tolerated O
and O
appeared O
to O
be O
beneficial O
for O
the O
treatment O
of O
interfering O
behaviors O
in O
children O
with O
autism O
, O
particularly O
aggression O
, O
behavioral O
dyscontrol O
, O
and O
inattention O
. O

Further B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controlled O
trials B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
warranted O
. O

Randomized O
comparison O
of O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
treatment O
of O
first O
- O
episode O
schizophrenia O
: O
4 O
- O
month O
outcomes O
. O

objective O
: O
The O
authors O
compared O
4 O
- O
month O
treatment O
outcomes O
for O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients O
with O
first O
- O
episode O
schizophrenia O
spectrum O
disorders O
. O

Method O
: O
One O
hundred O
twelve O
subjects O
( O
70 O
% O
male O
; O
mean O
age O
= O
23 O
. O
3 O
years O
[ O
SD O
= O
5 O
. O
1 O
] O
) O
with O
first O
- O
episode O
schizophrenia O
( O
75 O
% O
) O
, O
schizophreniform O
disorder O
( O
17 O
% O
) O
, O
or O
schizoaffective O
disorder O
( O
8 O
% O
) O
were O
randomly O
assigned O
to O
treatment O
with O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 O
. O
5 O
- O
20 O
mg O
/ O
day O
) O
or O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 O
- O
6 O
mg O
/ O
day O
) O
. O

Results O
: O
Response O
rates O
did O
not O
significantly O
differ O
between O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
43 O
. O
7 O
% O
, O
95 O
% O
CI O
= O
28 O
. O
8 O
% O
- O
58 O
. O
6 O
% O
) O
and O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
54 O
. O
3 O
% O
, O
95 O
% O
CI O
= O
39 O
. O
9 O
% O
- O
68 O
. O
7 O
% O
) O
. O

Among O
those O
responding O
to O
treatment O
, O
more O
subjects O
in O
the O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O
( O
40 O
. O
9 O
% O
, O
95 O
% O
CI O
= O
16 O
. O
8 O
% O
- O
65 O
. O
0 O
% O
) O
than O
in O
the O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O
( O
18 O
. O
9 O
% O
, O
95 O
% O
CI O
= O
0 O
% O
- O
39 O
. O
2 O
% O
) O
had O
subsequent O
ratings O
not O
meeting O
response O
criteria O
. O

Negative B_DISEASE_ADJECTIVE[DISEASE]
symptom I_DISEASE_ADJECTIVE[DISEASE]
outcomes I_DISEASE_ADJECTIVE[DISEASE]
and O
measures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
parkinsonism B_DISEASE
and O
akathisia B_DISEASE
did O
not O
differ O
between O
medications B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Extrapyramidal O
symptom O
severity O
scores O
were O
1 O
. O
4 O
( O
95 O
% O
CI O
= O
1 O
. O
2 O
- O
1 O
. O
6 O
) O
with O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
1 O
. O
2 O
( O
95 O
% O
CI O
= O
1 O
. O
0 O
- O
1 O
. O
4 O
) O
with O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

significantly O
more O
weight O
gain O
occurred O
with O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
than O
with O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
the O
increase O
in O
weight O
at O
4 O
months O
relative O
to O
baseline O
weight O
was O
17 O
. O
3 O
% O
( O
95 O
% O
CI O
= O
14 O
. O
2 O
% O
- O
20 O
. O
5 O
% O
) O
with O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
11 O
. O
3 O
% O
( O
95 O
% O
CI O
= O
8 O
. O
4 O
% O
- O
14 O
. O
3 O
% O
) O
with O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Body O
mass O
index O
at O
baseline O
and O
at O
4 O
months O
was O
24 O
. O
3 O
( O
95 O
% O
CI O
= O
22 O
. O
8 O
- O
25 O
. O
7 O
) O
versus O
28 O
. O
2 O
( O
95 O
% O
CI O
= O
26 O
. O
7 O
- O
29 O
. O
7 O
) O
with O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
23 O
. O
9 O
( O
95 O
% O
CI O
= O
22 O
. O
5 O
- O
25 O
. O
3 O
) O
versus O
26 O
. O
7 O
( O
95 O
% O
CI O
= O
25 O
. O
2 O
- O
28 O
. O
2 O
) O
with O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusions O
: O
Clinical O
outcomes O
with O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
equal O
to O
those O
with O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
response O
may O
be O
more O
stable O
. O

Olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
may O
have O
an O
advantage O
for O
motor O
side O
effects O
. O

Both O
medications O
caused O
substantial O
rapid O
weight O
gain O
, O
but O
weight O
gain O
was O
greater O
with O
olanzapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Early O
paracentral O
visual O
field O
loss O
in O
patients O
taking O
hydroxychloroquine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

objective O
: O
To O
review O
the O
natural O
history O
and O
ocular O
and O
systemic O
adverse O
effects O
of O
patients O
taking O
hydroxychloroquine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sulfate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
who O
attended O
an O
ophthalmic O
screening O
program O
. O

Design B_PERSON/B_NUMBER[MEASURE]
: O
Retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Results O
: O
Records O
of O
262 O
patients O
who O
were O
taking O
hydroxychloroquine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
screened O
in O
the O
Department O
of O
Ophthalmology O
were O
reviewed O
. O

Of O
the O
262 B_PERSON/B_DISEASE
patients I_PERSON/I_DISEASE
, O
14 B_MEASURE
( O
18 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
of O
76 B_NUMBER[MEASURE]/B_PERSON
who O
had O
stopped O
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
time B_TIME[MEASURE]/B_LOCATION
of O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experienced O
documented O
adverse B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Systemic B_DISEASE
adverse I_DISEASE
effects I_DISEASE
occurred O
in O
8 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
( O
10 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
) O
and O
ocular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
adverse I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
effects I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
in O
5 B_NUMBER[MEASURE]
( O
6 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
) O
. O

Thirty O
- O
five O
patients O
( O
13 O
. O
4 O
% O
) O
had O
visual O
field O
abnormalities O
, O
which O
were O
attributed O
to O
hydroxychloroquine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
treatment O
in O
4 O
patients O
( O
1 O
. O
5 O
% O
) O
. O

Three B_NUMBER[MEASURE]/B_PERSON
of O
the O
4 B_PERSON
patients I_PERSON
were O
taking O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
6 B_MEASURE
. O
5 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_MEASURE
per O
day B_TIME[MEASURE]/B_PERSON
and O
all O
patients B_PERSON/B_NUMBER[MEASURE]
had O
normal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
renal I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
liver B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
function I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
test I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
results I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
used O
a O
protocol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
visual B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acuity I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
color B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
vision I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
assessment I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
funduscopy B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
and O
Humphrey B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
2 B_MEASURE
visual I_MEASURE
field I_MEASURE
testing I_MEASURE
and O
shows O
that O
visual B_DISEASE_ADJECTIVE[DISEASE]
field I_DISEASE_ADJECTIVE[DISEASE]
defects I_DISEASE_ADJECTIVE[DISEASE]
appeared O
before O
any O
corresponding B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
any O
other B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
tested O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
; O
the O
defects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
reproducible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parameters I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
reliable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

patients O
taking O
hydroxychloroquine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
can O
demonstrate O
a O
toxic O
reaction O
in O
the O
retina O
despite O
the O
absence O
of O
known O
risk O
factors O
. O

Screening B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
Humphrey B_MEASURE/B_LOCATION
10 B_MEASURE/I_LOCATION
- O
2 B_MEASURE
visual I_MEASURE
field I_MEASURE
assessment I_MEASURE
, O
is O
recommended O
2 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
after O
the O
initial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
baseline I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O
yearly O
thereafter O
. O

Peri O
- O
operative O
atrioventricular O
block O
as O
a O
result O
of O
chemotherapy O
with O
epirubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
47 B_MEASURE
- O
year B_TIME[MEASURE]
- O
old B_PERSON
woman I_PERSON
presented O
for O
mastectomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
immediate B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
latissimus B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dorsi B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
flap B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reconstruction B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
having O
been O
diagnosed O
with O
carcinoma B_DISEASE/B_GENE
of O
the O
breast B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
6 I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
months I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
previously O
. O

In O
the O
preceding O
months O
she O
had O
received O
neo O
- O
adjuvant O
chemotherapy O
with O
epirubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Taxol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
had O
been O
apparently O
uncomplicated B_DISEASE_ADJECTIVE[DISEASE]
and O
she O
had O
maintained O
a O
remarkably O
high B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
of O
physical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
activity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

She O
was O
found O
to O
be O
bradycardic B_DISEASE_ADJECTIVE[DISEASE]
at O
pre B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
operative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
but O
had O
no O
cardiac B_DISEASE
symptoms I_DISEASE
. O

Second B_PERSON
degree I_PERSON
Mobitz I_PERSON
type I_PERSON
II I_PERSON
atrioventricular I_PERSON
block I_PERSON
was O
diagnosed O
on O
electrocardiogram B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
temporary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transvenous I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ventricular I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pacing I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
instituted O
in O
the O
peri B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
operative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
period I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O

We O
discuss O
how O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
based O
guidelines B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
would O
not O
have O
been O
helpful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
how O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
can O
exhibit O
substantial B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cardiotoxicity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
that O
may O
develop O
over O
many B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
. O

We O
suggest O
that O
patients B_PERSON
who O
have O
received O
chemotherapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
at O
any O
time B_MEASURE/B_LOCATION
should O
have O
a O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
operative B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
electrocardiogram I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
even O
if O
they O
are O
asymptomatic B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O

risks O
and O
benefits O
of O
COX B_DISEASE_ADJECTIVE[DISEASE]
- I_DISEASE_ADJECTIVE[DISEASE]
2 I_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DISEASE_ADJECTIVE[DISEASE]
vs O
non O
- O
selective O
NSAIDs O
: O
does O
their O
cardiovascular O
risk O
exceed O
their O
gastrointestinal O
benefit O
. O

A O
retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cohort I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

objectives O
: O
The O
risk O
of O
acute O
myocardial O
infarction O
( O
AMI O
) O
with O
COX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
may O
offset O
their O
gastrointestinal O
( O
GI O
) O
benefit O
compared O
with O
non O
- O
selective O
( O
NS O
) O
non B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
steroidal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inflammatory I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NSAIDs O
) O
. O

We O
aimed O
to O
compare O
the O
risks O
of O
hospitalization O
for O
AMI O
and O
GI O
bleeding O
among O
elderly O
patients O
using O
COX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
NS O
- O
NSAIDs O
and O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

methods O
: O
We O
conducted O
a O
retrospective O
cohort O
study O
using O
administrative O
data O
of O
patients O
> O
or O
= O
65 O
years O
of O
age O
who O
filled O
a O
prescription O
for O
NSAID O
or O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
1999 O
- O
2002 O
. O

outcomes B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
compared O
using O
Cox B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
regression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
with O
time B_MEASURE/B_LOCATION
- O
dependent B_MEASURE
exposures I_MEASURE
. O

Results O
: O
Person O
- O
years O
of O
exposure O
among O
non O
- O
users O
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
: O
75 O
, O
761 O
to O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
42 O
, O
671 O
to O
rofecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
65 O
, O
860 O
to O
celecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
37 O
, O
495 O
to O
NS O
- O
NSAIDs O
. O

Among O
users O
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
they O
were O
: O
14 O
, O
671 O
to O
rofecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
22 O
, O
875 O
to O
celecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
9 O
, O
832 O
to O
NS O
- O
NSAIDs O
and O
38 O
, O
048 O
to O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Among O
non O
- O
users O
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
adjusted O
hazard O
ratios O
( O
95 O
% O
confidence O
interval O
) O
of O
hospitalization O
for O
AMI O
/ O
GI O
vs O
the O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
with O
no O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
group O
were O
: O
rofecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
. O
27 O
( O
1 O
. O
13 O
, O
1 O
. O
42 O
) O
, O
celecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O
. O
93 O
( O
0 O
. O
83 O
, O
1 O
. O
03 O
) O
, O
naproxen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
. O
59 O
( O
1 O
. O
31 O
, O
1 O
. O
93 O
) O
, O
diclofenac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
. O
17 O
( O
0 O
. O
99 O
, O
1 O
. O
38 O
) O
and O
ibuprofen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
. O
05 O
( O
0 O
. O
74 O
, O
1 O
. O
51 O
) O
. O

Among O
users O
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
they O
were O
: O
rofecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
. O
73 O
( O
1 O
. O
52 O
, O
1 O
. O
98 O
) O
, O
celecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
. O
34 O
( O
1 O
. O
19 O
, O
1 O
. O
52 O
) O
, O
ibuprofen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
. O
51 O
( O
0 O
. O
95 O
, O
2 O
. O
41 O
) O
, O
diclofenac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
. O
69 O
( O
1 O
. O
35 O
, O
2 O
. O
10 O
) O
, O
naproxen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
. O
35 O
( O
0 O
. O
97 O
, O
1 O
. O
88 O
) O
and O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
. O
29 O
( O
1 O
. O
17 O
, O
1 O
. O
42 O
) O
. O

conclusion O
: O
Among O
non O
- O
users O
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
naproxen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
seemed O
to O
carry O
the O
highest O
risk O
for O
AMI O
/ O
GI O
bleeding O
. O

The O
AMI O
/ O
GI O
toxicity O
of O
celecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
similar O
to O
that O
of O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
seemed O
to O
be O
better O
than O
those O
of O
rofecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
NS O
- O
NSAIDs O
. O

Among O
users O
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
both O
celecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
naproxen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seemed O
to O
be O
the O
least O
toxic O
. O

Quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
arrhythmia O
in O
a O
patient O
with O
severe O
malaria O
. O

It O
was O
reported O
that O
there O
was O
a O
case O
of O
severe O
malaria O
patient O
with O
jaundice O
who O
presented O
with O
arrhythmia O
( O
premature O
ventricular O
contraction O
) O
while O
getting O
quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
infusion O
was O
reported O
. O

A O
man B_PERSON
, O
25 B_ENT/B_PERSON
years B_ENT/I_PERSON
old B_ENT/I_PERSON
, O
was O
admitted O
to O
hospital B_LOCATION
with O
high B_DISEASE
fever I_DISEASE
, O
chill B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
, O
vomiting B_DISEASE
, O
jaundice B_DISEASE
. O

The O
patient B_PERSON
was O
fully O
conscious B_PERSON
, O
blood B_MEASURE
pressure I_MEASURE
120 I_MEASURE
/ O
80 B_MEASURE
mmHg I_MEASURE
, O
pulse B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
rate I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
100 I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
x I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
/ O
minute B_MEASURE
, O
regular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

On O
admission O
, O
laboratory O
examination O
showed O
Plasmodium O
falciparum O
( O
+ O
+ O
+ O
+ O
) O
, O
total O
bilirubin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
8 O
. O
25 O
mg O
/ O
DL O
, O
conjugated O
bilirubin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
4 O
. O
36 O
mg O
/ O
DL O
, O
unconjugated O
bilirubin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3 O
. O
89 O
mg O
/ O
DL O
, O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
3 O
. O
52 O
meq O
/ O
L O
patient O
was O
diagnosed O
as O
severe O
malaria O
with O
jaundice O
and O
got O
quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
infusion O
in O
dextrose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
5 O
% O
500 O
mg O
/ O
8 O
hour O
. O

On O
the O
second B_TIME[MEASURE]/B_LOCATION
day B_TIME[MEASURE]/I_LOCATION
the O
patient B_PERSON
had O
vomitus O
, O
diarrhea B_DISEASE
, O
tinnitus B_DISEASE
, O
loss B_DISEASE_ADJECTIVE[DISEASE]
of O
hearing B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

After O
30 O
hours O
of O
quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
infusion O
the O
patient O
felt O
palpitation O
and O
electrocardiography O
( O
ECG O
) O
recording O
showed O
premature O
ventricular O
contraction O
( O
PVC O
) O
> O
5 O
x O
/ O
minute O
, O
trigemini O
, O
constant O
type O
- O
- O
sinoatrial O
block O
, O
positive O
U O
wave O
. O

He O
was O
treated O
with O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O
mg O
intravenously O
followed O
by O
infusion O
1500 O
mg O
in O
dextrose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
5 O
% O
/ O
24 O
hour O
and O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
aspartate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
tablet O
. O

Quinine B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
was O
discontinued O
and O
changed O
with O
sulfate O
quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tablets O
. O

Three O
hours O
later O
the O
patient O
felt O
better O
, O
the O
frequency O
of O
PVC O
reduced O
to O
4 O
- O
5 O
x O
/ O
minute O
and O
on O
the O
third O
day O
ECG O
was O
normal O
, O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O
was O
3 O
. O
34 O
meq O
/ O
L O
. O

He O
was O
discharged O
on O
7th B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
day I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
in O
good B_TIME[MEASURE]/B_PERSON
condition I_TIME[MEASURE]/I_PERSON
. O

Quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
like O
quinidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
a O
chincona O
alkaloid O
that O
has O
anti O
- O
arrhythmic O
property O
, O
although O
it O
also O
pro O
- O
arrhythmic O
that O
can O
cause O
various O
arrhythmias O
, O
including O
severe O
arrhythmia O
such O
as O
multiple O
PVC O
. O

Administration O
of O
parenteral O
quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
must O
be O
done O
carefully O
and O
with O
good O
observation O
because O
of O
its O
pro O
- O
arrhythmic O
effect O
, O
especially O
in O
older O
patients O
who O
have O
heart O
diseases O
or O
patients O
with O
electrolyte O
disorder O
( O
hypokalemia O
) O
which O
frequently O
occurs O
due O
to O
vomiting O
and O
or O
diarrhea O
in O
malaria O
cases O
. O

Penicillamine B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
related O
lichenoid O
dermatitis O
and O
utility O
of O
zinc B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
a O
Wilson O
disease O
patient O
with O
hepatic O
presentation O
, O
anxiety O
and O
SPECT O
abnormalities O
. O

Wilson O
' O
s O
disease O
is O
an O
autosomal O
recessive O
disorder O
of O
hepatic O
copper B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolism O
with O
consequent O
copper B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
accumulation O
and O
toxicity O
in O
many O
tissues O
and O
consequent O
hepatic O
, O
neurologic O
and O
psychiatric O
disorders O
. O

We O
report O
a O
case B_PERSON/B_MEASURE
of O
Wilson B_PERSON
' I_PERSON
s I_PERSON
disease I_PERSON
with O
chronic B_DISEASE
liver I_DISEASE
disease I_DISEASE
; O
Moreover O
, O
in O
our O
patient B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
presenting O
also O
with O
high B_DISEASE_ADJECTIVE[DISEASE]
levels I_DISEASE_ADJECTIVE[DISEASE]
of O
state B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anxiety B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O
depression B_DISEASE
, O
99mTc B_LOCATION
- O
ECD B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
SPECT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
showed O
cortical B_DISEASE_ADJECTIVE[DISEASE]
hypoperfusion I_DISEASE_ADJECTIVE[DISEASE]
in O
frontal B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lobes B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
more O
marked O
on O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
frontal I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
lobe I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

During O
the O
follow O
- O
up O
of O
our O
patient O
, O
penicillamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
interrupted O
after O
the O
appearance O
of O
a O
lichenoid O
dermatitis O
, O
and O
zinc B_LOCATION
acetate I_LOCATION
permitted O
to O
continue O
the O
successful O
treatment O
of O
the O
patient O
without O
side O
- O
effects O
. O

In O
our O
case O
the O
therapy O
with O
zinc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
represented O
an O
effective O
treatment O
for O
a O
Wilson O
' O
s O
disease O
patient O
in O
which O
penicillamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
related O
side O
effects O
appeared O
. O

The O
safety O
of O
the O
zinc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
allowed O
us O
to O
avoid O
other O
potentially O
toxic O
chelating O
drugs O
; O
this O
observation O
is O
in O
line O
with O
the O
growing O
evidence O
on O
the O
efficacy O
of O
the O
drug O
in O
the O
treatment O
of O
Wilson O
' O
s O
disease O
. O

Since O
most O
of O
Wilson O
' O
s O
disease O
penicillamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
treated O
patients O
do O
not O
seem O
to O
develop O
this O
skin O
lesion O
, O
it O
could O
be O
conceivable O
that O
a O
specific O
genetic O
factor O
is O
involved O
in O
drug O
response O
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
needed O
for O
a O
better B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clarification I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
Wilson B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
' B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
disease B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
therapy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
in O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
differentiate O
specific B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
therapies I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
for O
different B_DISEASE/B_PERSON
Wilson I_DISEASE/I_PERSON
' I_DISEASE/I_PERSON
s I_DISEASE/I_PERSON
disease I_DISEASE/I_PERSON
phenotypes I_DISEASE/I_PERSON
. O

A O
dramatic O
drop O
in O
blood O
pressure O
following O
prehospital O
GTN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration O
. O

A O
male B_PERSON
in O
his O
sixties B_TIME[MEASURE]/B_LOCATION
with O
no O
history B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cardiac B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chest I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pain I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
awoke I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
chest B_DISEASE
pain I_DISEASE
following O
an O
afternoon B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sleep I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
patient B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
did O
not O
self B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
medicate I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
patient O
' O
s O
observations O
were O
within O
normal O
limits O
, O
he O
was O
administered O
oxygen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
via O
a O
face O
mask O
and O
glyceryl B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
trinitrate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
GTN B_DISEASE/B_LOCATION
) O
. O

Several O
minutes O
after O
the O
GTN B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
the O
patient O
experienced O
a O
sudden O
drop O
in O
blood O
pressure O
and O
heart O
rate O
, O
this O
was O
rectified O
by O
atropine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
a O
fluid O
challenge O
. O

There O
was O
no O
further B_DISEASE_ADJECTIVE[DISEASE]
deterioration I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
patient B_PERSON
' O
s B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
condition I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
during O
transport B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
hospital B_LOCATION
. O

There O
are O
very O
few B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
documented I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
case I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
like O
this O
in O
the O
prehospital B_LOCATION
scientific I_LOCATION
literature I_LOCATION
. O

The O
cause B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appears O
to O
be O
the O
Bezold B_PERSON/B_LOCATION
- O
Jarish B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reflex B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
stimulation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
walls I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
which O
in O
turn B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreases O
sympathetic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outflow B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
vasomotor B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
centre I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Prehospital B_PERSON
care I_PERSON
providers I_PERSON
who O
are O
managing O
any O
patient B_PERSON/B_DISEASE
with O
a O
syncopal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
episode I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
that O
fails O
to O
recover O
within O
a O
reasonable B_TIME[MEASURE]
time I_TIME[MEASURE]
frame I_TIME[MEASURE]
should O
consider O
the O
Bezold B_PERSON
- O
Jarisch B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
reflex B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
as O
the O
cause B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
manage O
the O
patient B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accordingly O
. O

Chronic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lesion B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
rostral B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
ventrolateral I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
medulla I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
in O
spontaneously O
hypertensive B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
studied O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
chronic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
selective B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
neuronal B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lesion B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
rostral B_LOCATION/B_DISEASE
ventrolateral B_LOCATION/I_DISEASE
medulla B_LOCATION/I_DISEASE
on O
mean B_DISEASE/B_GENE
arterial I_DISEASE/I_GENE
pressure I_DISEASE/I_GENE
, O
heart B_DISEASE
rate I_DISEASE
, O
and O
neurogenic B_DISEASE
tone I_DISEASE
in O
conscious B_PERSON
, O
unrestrained O
spontaneously O
hypertensive B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
lesions O
were O
placed O
via O
bilateral O
microinjections O
of O
30 O
nmol O
/ O
200 O
NL O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspartic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
restimulation O
of O
this O
area O
with O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspartic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
15 O
days O
postlesion O
failed O
to O
produce O
a O
pressor O
response O
. O

One B_MEASURE/B_ENT
day I_MEASURE/I_ENT
postlesion I_MEASURE/I_ENT
, O
the O
resting B_DISEASE/B_GENE
mean B_DISEASE/I_GENE
arterial B_DISEASE/I_GENE
pressure B_DISEASE/I_GENE
was O
significantly O
decreased O
in O
lesioned B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
when O
compared O
with O
sham B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
rats I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O
100 B_MEASURE
+ I_MEASURE
/ O
- O
7 B_MEASURE
versus I_MEASURE
173 I_MEASURE
+ I_MEASURE
/ O
- O
4 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
, O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

Fifteen B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
later O
, O
the O
lesioned B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
still O
showed O
values B_MEASURE/B_DISEASE
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
sham B_PERSON/B_MEASURE
group B_PERSON/I_MEASURE
( O
150 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
versus I_MEASURE
167 I_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
, O
p B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

No O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heart B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
observed O
between O
the O
sham B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
lesioned B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
ganglionic O
blocker O
trimethaphan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 O
mg O
/ O
kg O
i O
. O
v O
. O
) O
caused O
similar O
reductions O
in O
mean O
arterial O
pressure O
in O
both O
lesioned O
and O
sham O
groups O
. O

The O
trimethaphan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hypotension O
was O
accompanied O
by O
a O
significant O
bradycardia O
in O
lesioned O
rats O
( O
- O
32 O
+ O
/ O
- O
13 O
beats O
per O
minute O
) O
but O
a O
tachycardia O
in O
sham O
rats O
( O
+ O
33 O
+ O
/ O
- O
12 O
beats O
per O
minute O
) O
1 O
day O
postlesion O
. O

Therefore O
, O
rostral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ventrolateral B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medulla B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appear O
to O
play O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
role I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
maintaining O
hypertension B_DISEASE/B_GENE
in O
conscious B_PERSON/B_NUMBER[MEASURE]
spontaneously O
hypertensive B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Spinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
or O
suprabulbar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
structures I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
could O
be O
responsible B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
gradual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recovery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
hypertension B_DISEASE
in O
the O
lesioned B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

acute O
encephalopathy O
and O
cerebral O
vasospasm O
after O
multiagent O
chemotherapy O
including O
PEG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
asparaginase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
intrathecal O
cytarabine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
treatment O
of O
acute O
lymphoblastic O
leukemia O
. O

A O
7 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
- O
old B_PERSON
girl I_PERSON
with O
an O
unusual B_DISEASE
reaction I_DISEASE
to O
induction B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
precursor B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
B I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
- O
cell B_DISEASE
acute I_DISEASE
lymphoblastic I_DISEASE
leukemia I_DISEASE
( O
ALL B_DISEASE
) O
is O
described O
. O

The O
patient O
developed O
acute O
encephalopathy O
evidenced O
by O
behavioral O
changes O
, O
aphasia O
, O
incontinence O
, O
visual O
hallucinations O
, O
and O
right O
- O
sided O
weakness O
with O
diffuse O
cerebral O
vasospasm O
on O
magnetic O
resonance O
angiography O
after O
the O
administration O
of O
intrathecal O
cytarabine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
polyethylene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glycol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
asparaginase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
also O
administered O
before O
the O
episode O
as O
part O
of O
induction O
therapy O
. O

neurologic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
status I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
returned O
to O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O
10 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
of O
the O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
event B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
magnetic B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
angiography I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
returned O
to O
normal B_TIME[MEASURE]
4 I_TIME[MEASURE]
months I_TIME[MEASURE]
later O
. O

comparison O
of O
valsartan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
hydrochlorothiazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combination O
therapy O
at O
doses O
up O
to O
320 O
/ O
25 O
mg O
versus O
monotherapy O
: O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
study O
followed O
by O
long O
- O
term O
combination O
therapy O
in O
hypertensive O
adults O
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
One B_MEASURE/B_PERSON
third I_MEASURE/I_PERSON
of O
patients B_PERSON/B_BIO
treated O
for O
hypertension B_DISEASE
attain O
adequate B_DISEASE
blood I_DISEASE
pressure I_DISEASE
( O
BP B_PROTEIN[GENE]/B_DISEASE
) O
control B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
and O
multidrug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimens I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
often O
required O
. O

Given O
the O
lifelong B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nature I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
there O
is O
a O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
to O
evaluate O
the O
long B_TIME[MEASURE]/B_LOCATION
- O
term B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
efficacy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
tolerability B_DISEASE_ADJECTIVE[DISEASE]
of O
higher B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
of O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
hypertensive B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapies I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

objective O
: O
This O
study O
investigated O
the O
efficacy O
and O
tolerability O
of O
valsartan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
VAL B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
or O
hydrochlorothiazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
HCTZ B_LOCATION/B_ORGANIZATION
) O
- O
monotherapy O
and O
higher O
- O
dose O
combinations O
in O
patients O
with O
essential O
hypertension O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
The O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
part I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
an O
8 B_NUMBER[MEASURE]
- O
week B_TIME[MEASURE]/B_PERSON
, O
multicenter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
randomized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
double B_MEASURE/B_COLOR
- O
blind B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
placebo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
controlled O
, O
parallel B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

patients O
with O
essential O
hypertension O
( O
mean O
sitting O
diastolic O
BP O
[ O
MSDBP O
] O
, O
> O
or O
= O
95 O
mm O
Hg O
and O
< O
110 O
mm O
Hg O
) O
were O
randomized O
to O
1 O
of O
8 O
treatment O
groups O
: O
VAL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
160 O
or O
320 O
mg O
; O
HCTZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12 O
. O
5 O
or O
25 O
mg O
; O
VAL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O
HCTZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
160 O
/ O
12 O
. O
5 O
, O
320 O
/ O
12 O
. O
5 O
, O
or O
320 O
/ O
25 O
mg O
; O
or O
placebo O
. O

Mean B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
MSDBP B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
mean O
sitting O
systolic B_MEASURE/B_LOCATION
BP I_MEASURE/I_LOCATION
( O
MSSBP B_DISEASE/B_LOCATION
) O
were O
analyzed O
at O
the O
8 B_NUMBER[MEASURE]
- O
week B_TIME[MEASURE]/B_LOCATION
core I_TIME[MEASURE]/I_LOCATION
study I_TIME[MEASURE]/I_LOCATION
end I_TIME[MEASURE]/I_LOCATION
point I_TIME[MEASURE]/I_LOCATION
. O

VAL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
HCTZ B_MEASURE/B_PROTEIN[GENE]
320 O
/ O
12 O
. O
5 O
and O
320 O
/ O
25 O
mg O
were O
further O
investigated O
in O
a O
54 O
- O
week O
, O
open O
- O
label O
extension O
. O

Response B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
defined O
as O
MSDBP B_DISEASE/B_LOCATION
< O
90 B_MEASURE/B_LOCATION
mm I_MEASURE/I_LOCATION
Hg I_MEASURE/I_LOCATION
or O
a O
> B_MEASURE
or O
= O
10 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
decrease I_MEASURE
compared O
to O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
defined O
as O
MSDBP B_DISEASE/B_MEASURE
< O
90 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
compared O
with O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Tolerability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
assessed O
by O
monitoring O
adverse B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
events I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
at O
randomization B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
all O
subsequent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visits I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
regular B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hematology B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
blood B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chemistry I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
A O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
1346 B_TIME[MEASURE]
patients I_TIME[MEASURE]
were O
randomized O
into O
the O
8 B_NUMBER[MEASURE]
- O
week B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
core I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
( O
734 B_MEASURE/B_PERSON
men I_MEASURE/I_PERSON
, O
612 B_MEASURE/B_PERSON
women I_MEASURE/I_PERSON
; O
924 B_MEASURE/B_PERSON
white I_MEASURE/I_PERSON
, O
291 B_PERSON/B_COLOR
black I_PERSON/I_COLOR
, O
23 B_MEASURE/B_PERSON
Asian I_MEASURE/I_PERSON
, O
108 B_MEASURE/B_PERSON
other I_MEASURE/I_PERSON
; O
mean O
age B_TIME[MEASURE]/B_PERSON
, O
52 B_MEASURE
. O
7 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
; O
mean B_MEASURE/B_PERSON
weight I_MEASURE/I_PERSON
, O
92 B_MEASURE
. O
6 B_MEASURE
kg I_MEASURE
) O
. O

All O
active O
treatments O
were O
associated O
with O
significantly O
reduced O
MSSBP O
and O
MSDBP O
during O
the O
core O
8 O
- O
week O
study O
, O
with O
each O
monotherapy O
significantly O
contributing O
to O
the O
overall O
effect O
of O
combination O
therapy O
( O
VAL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
HCTZ B_LOCATION
, O
P O
< O
0 O
. O
001 O
) O
. O

Each O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
was O
associated O
with O
significantly O
greater B_DISEASE_ADJECTIVE[DISEASE]
reductions I_DISEASE_ADJECTIVE[DISEASE]
in O
MSSBP B_DISEASE/B_GENE
and O
MSDBP B_DISEASE/B_GENE
compared O
with O
the O
monotherapies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
placebo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
all O
, O
P B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

The O
mean O
reduction O
in O
MSSBP O
/ O
MSDBP O
with O
VAL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
/ O
HCTZ B_MEASURE/B_PROTEIN[GENE]
320 O
/ O
25 O
mg O
was O
24 O
. O
7 O
/ O
16 O
. O
6 O
mm O
Hg O
, O
compared O
with O
5 O
. O
9 O
/ O
7 O
. O
0 O
mm O
Hg O
with O
placebo O
. O

The O
reduction O
in O
MSSBP O
was O
significantly O
greater O
with O
VAL B_LOCATION/B_ORGANIZATION
/ O
HCTZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
320 O
/ O
25 O
mg O
compared O
with O
VAL B_LOCATION/B_ORGANIZATION
/ O
HCTZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
160 O
/ O
12 O
. O
5 O
mg O
( O
P O
< O
0 O
. O
002 O
) O
. O

rates B_MEASURE
of O
response B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
BP B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
control I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
groups B_ORGANIZATION/B_PERSON
that O
received O
combination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
compared O
with O
those O
that O
received O
monotherapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

The O
incidence O
of O
hypokalemia O
was O
lower O
with O
VAL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O
HCTZ B_LOCATION
combinations O
( O
1 O
. O
8 O
% O
- O
6 O
. O
1 O
% O
) O
than O
with O
HCTZ B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monotherapies O
( O
7 O
. O
1 O
% O
- O
13 O
. O
3 O
% O
) O
. O

The O
majority B_MEASURE
of O
adverse B_DISEASE_ADJECTIVE[DISEASE]
events I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
core B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
of O
mild B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
moderate B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
severity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

The O
efficacy O
and O
tolerability O
of O
VAL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O
HCTZ B_LOCATION
combinations O
were O
maintained O
during O
the O
extension O
( O
797 O
patients O
) O
. O

conclusions O
: O
In O
this O
study O
population O
, O
combination O
therapies O
with O
VAL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ O
HCTZ B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
associated O
with O
significantly O
greater O
BP O
reductions O
compared O
with O
either O
monotherapy O
, O
were O
well O
tolerated O
, O
and O
were O
associated O
with O
less O
hypokalemia O
than O
HCTZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alone O
. O

Succimer B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
chelation O
improves O
learning O
, O
attention O
, O
and O
arousal O
regulation O
in O
lead B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
exposed O
rats O
but O
produces O
lasting O
cognitive O
impairment O
in O
the O
absence O
of O
lead B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O
. O

Background O
: O
There O
is O
growing O
pressure O
for O
clinicians O
to O
prescribe O
chelation O
therapy O
at O
only O
slightly O
elevated O
blood O
lead B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O
. O

However O
, O
very O
few O
studies O
have O
evaluated O
whether O
chelation O
improves O
cognitive O
outcomes O
in O
Pb B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
exposed O
children O
, O
or O
whether O
these O
agents O
have O
adverse O
effects O
that O
may O
affect O
brain O
development O
in O
the O
absence O
of O
Pb B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
exposure O
. O

objectives O
: O
The O
present O
study O
was O
designed O
to O
answer O
these O
questions O
, O
using O
a O
rodent O
model O
of O
early O
childhood O
Pb B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
exposure O
and O
treatment O
with O
succimer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O
a O
widely O
used O
chelating O
agent O
for O
the O
treatment O
of O
Pb O
poisoning O
. O

Results O
: O
Pb B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
exposure O
produced O
lasting O
impairments O
in O
learning O
, O
attention O
, O
inhibitory O
control O
, O
and O
arousal O
regulation O
, O
paralleling O
the O
areas O
of O
dysfunction O
seen O
in O
Pb B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
exposed O
children O
. O

Succimer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
treatment O
of O
the O
Pb B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
exposed O
rats O
significantly O
improved O
learning O
, O
attention O
, O
and O
arousal O
regulation O
, O
although O
the O
efficacy O
of O
the O
treatment O
varied O
as O
a O
function O
of O
the O
Pb B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
exposure O
level O
and O
the O
specific O
functional O
deficit O
. O

In O
contrast O
, O
succimer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
treatment O
of O
rats O
not O
previously O
exposed O
to O
Pb B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
produced O
lasting O
and O
pervasive O
cognitive O
and O
affective O
dysfunction O
comparable O
in O
magnitude O
to O
that O
produced O
by O
the O
higher O
Pb B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
exposure O
regimen O
. O

conclusions O
: O
These O
are O
the O
first O
data O
, O
to O
our O
knowledge O
, O
to O
show O
that O
treatment O
with O
any O
chelating O
agent O
can O
alleviate O
cognitive O
deficits O
due O
to O
Pb B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O
. O

These O
findings O
suggest O
that O
it O
may O
be O
possible O
to O
identify O
a O
succimer B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
treatment O
protocol O
that O
improves O
cognitive O
outcomes O
in O
Pb B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
exposed O
children O
. O

However O
, O
they O
also O
suggest O
that O
succimer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
treatment O
should O
be O
strongly O
discouraged O
for O
children O
who O
do O
not O
have O
elevated O
tissue O
levels O
of O
Pb B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
other O
heavy O
metals O
. O

Caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenge O
test O
in O
panic O
disorder O
and O
depression O
with O
panic O
attacks O
. O

Our O
aim O
was O
to O
observe O
if O
patients O
with O
panic O
disorder O
( O
PD O
) O
and O
patients O
with O
major O
depression O
with O
panic O
attacks O
( O
MDP O
) O
( O
diagnostic O
and O
Statistical O
Manual O
of O
Mental O
disorders O
, O
Fourth O
Edition O
criteria O
) O
respond O
in O
a O
similar O
way O
to O
the O
induction O
of O
panic O
attacks O
by O
an O
oral O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenge O
test O
. O

We O
randomly O
selected O
29 B_TIME[MEASURE]
patients I_TIME[MEASURE]
with O
PD B_DISEASE
, O
27 B_MEASURE
with O
MDP B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
25 B_MEASURE
with O
major B_DISEASE
depression I_DISEASE
without O
panic B_DISEASE
attacks I_DISEASE
( O
MD B_DISEASE
) O
, O
and O
28 B_NUMBER[MEASURE]/B_PERSON
healthy I_NUMBER[MEASURE]/I_PERSON
volunteers I_NUMBER[MEASURE]/I_PERSON
. O

The O
patients B_PERSON/B_LOCATION
had O
no O
psychotropic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
drug I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
for O
at O
least O
a O
4 B_NUMBER[MEASURE]
- O
week B_TIME[MEASURE]
period I_TIME[MEASURE]
. O

In O
a O
randomized O
double O
- O
blind O
experiment O
performed O
in O
2 O
occasions O
7 O
days O
apart O
, O
480 O
mg O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
a O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
free O
( O
placebo O
) O
solution O
were O
administered O
in O
a O
coffee O
form O
and O
anxiety O
scales O
were O
applied O
before O
and O
after O
each O
test O
. O

A O
total O
of O
58 O
. O
6 O
% O
( O
n O
= O
17 O
) O
of O
patients O
with O
PD O
, O
44 O
. O
4 O
% O
( O
n O
= O
12 O
) O
of O
patients O
with O
MDP O
, O
12 O
. O
0 O
% O
( O
n O
= O
3 O
) O
of O
patients O
with O
MD O
, O
and O
7 O
. O
1 O
% O
( O
n O
= O
2 O
) O
of O
control O
subjects O
had O
a O
panic O
attack O
after O
the O
480 O
- O
mg O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenge O
test O
( O
Chi O
( O
2 O
) O
( O
3 O
) O
= O
16 O
. O
22 O
, O
P O
= O
. O
001 O
) O
. O

The O
patients O
with O
PD O
and O
MDP O
were O
more O
sensitive O
to O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
were O
patients O
with O
MD O
and O
healthy O
volunteers O
. O

No O
panic O
attack O
was O
observed O
after O
the O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
free O
solution O
intake O
. O

The O
patients B_PERSON/B_ORGANIZATION
with O
MD B_DISEASE/B_LOCATION
had O
a O
lower B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heart I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
test B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
than O
all O
the O
other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
2 B_NUMBER[MEASURE]
- O
way B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
variance B_TIME[MEASURE]/B_PERSON
, O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
time B_MEASURE/B_ORGANIZATION
interaction I_MEASURE/I_ORGANIZATION
with O
greenhouse B_LOCATION/B_PERSON
- O
Geisser B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
correction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
F B_OTHER/B_LOCATION
( O
3 B_MEASURE
, O
762 B_MEASURE
) O
= O
2 B_MEASURE
. O
85 B_MEASURE
, O
P B_OTHER/B_LOCATION
= O
. O
026 B_MEASURE
) O
. O

Our O
data O
suggest O
that O
there O
is O
an O
association O
between O
panic O
attacks O
, O
no O
matter O
if O
associated O
with O
PD O
or O
MDP O
, O
and O
hyperreactivity O
to O
an O
oral O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
challenge O
test O
. O

mitral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
annuloplasty I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O
a O
ventricular B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
restoration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
method I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
the O
failing O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ventricle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
: O
a O
pilot B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
AND O
Aim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
OF O
THE O
Study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Undersized B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
mitral I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
annuloplasty I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
Map B_LOCATION/B_ORGANIZATION
) O
is O
effective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
patients B_PERSON
with O
dilated B_DISEASE_ADJECTIVE[DISEASE]
cardiomyopathy I_DISEASE_ADJECTIVE[DISEASE]
and O
functional B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
mitral I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
regurgitation I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
MR B_LOCATION
) O
since O
, O
as O
well O
as O
addressing O
the O
MR B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
the O
MAP B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
may O
also O
reshape O
the O
dilated O
left O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT
( O
LV B_LOCATION
) O
base B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O

However O
, O
the O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
benefits I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
possible B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reshaping I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O
LV B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
absence B_DISEASE/B_LOCATION
of O
underlying O
MR B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remain O
incompletely O
understood O
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aim I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
identify O
these O
benefits B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
a O
canine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
of O
acute B_DISEASE
heart I_DISEASE
failure I_DISEASE
. O

methods B_MEASURE
: O
Six B_ENT/B_PERSON
dogs B_ENT/I_PERSON
underwent O
MAP B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
a O
prosthetic B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
band I_MEDICAL_DEVICE[OBJECT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
on O
the O
posterior B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
mitral I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
annulus I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
using O
four B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mattress I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sutures I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
sutures B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEDICAL_DEVICE[OBJECT]
were O
passed O
individually O
through O
four B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_SPORT[ENT]
tourniquets I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_SPORT[ENT]
and O
exteriorized O
untied O
via O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_PRODUCT[OBJECT]
atriotomy I_BODY_PART_OR_ORGAN_COMPONENT/I_PRODUCT[OBJECT]
. O

Sonomicrometry B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
crystals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
implanted O
around O
the O
mitral B_BODY_PART_OR_ORGAN_COMPONENT
annulus I_BODY_PART_OR_ORGAN_COMPONENT
and O
left O
ventricle B_BODY_PART_OR_ORGAN_COMPONENT
to O
measure B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
geometry I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
regional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

acute O
heart O
failure O
was O
induced O
by O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
volume O
loading O
after O
weaning O
from O
cardiopulmonary O
bypass O
; O
an O
absence O
of O
MR O
was O
confirmed O
by O
echocardiography O
. O

MAP B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
accomplished O
by O
cinching O
the O
tourniquets B_LOCATION
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
acquired O
at O
baseline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
after O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
acute B_DISEASE
heart I_DISEASE
failure I_DISEASE
, O
and O
after O
MAP B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
MAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
decreased O
mitral B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
annular I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
dimensions I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
both O
commissure B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
commissure B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O
septal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
lateral B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
directions I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Concomitantly O
, O
the O
diastolic B_MEASURE/B_LOCATION
diameter I_MEASURE/I_LOCATION
of O
the O
LV B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
base I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
and O
LV B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sphericity I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decreased O
( O
i O
. O
e B_DISEASE/B_PROTEIN[GENE]
. O
, O
improved O
) O
from O
37 B_MEASURE
. O
4 B_MEASURE
+ I_MEASURE
/ O
- O
9 B_MEASURE
. O
3 B_MEASURE
to O
35 B_MEASURE
. O
9 B_MEASURE
+ I_MEASURE
/ O
- O
10 B_MEASURE
mm I_MEASURE
( O
p B_MEASURE/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
063 B_MEASURE
) O
, O
and O
from O
67 B_MEASURE
. O
9 B_MEASURE
+ I_MEASURE
/ O
- O
18 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
to O
65 B_MEASURE
. O
3 B_MEASURE
+ I_MEASURE
/ O
- O
18 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
p B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
016 B_MEASURE
) O
, O
respectively O
. O

decreases B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
LV B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
end I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
diastolic B_MEASURE/B_LOCATION
pressure B_MEASURE/I_LOCATION
( O
from O
17 B_MEASURE
+ I_MEASURE
/ O
- O
7 B_MEASURE
to O
15 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
mmHg I_MEASURE
, O
p O
= O
0 B_NUMBER[MEASURE]
. O
0480 B_MEASURE
and O
Tau B_PROTEIN[GENE]/B_DISEASE
( O
from O
48 B_MEASURE
+ I_MEASURE
/ O
- O
8 B_MEASURE
to O
45 B_MEASURE
+ I_MEASURE
/ O
- O
8 B_MEASURE
MS I_MEASURE
, O
p B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
, O
while O
fractional B_MEASURE/B_GENE
shortening B_MEASURE/I_GENE
at O
the O
LV B_MEASURE/B_PROTEIN[GENE]
base B_MEASURE/I_PROTEIN[GENE]
increased O
from O
7 B_MEASURE
. O
7 B_MEASURE
+ I_MEASURE
/ O
- O
4 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
to O
9 B_MEASURE
. O
4 B_MEASURE
+ I_MEASURE
/ O
- O
4 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
( O
p B_PROTEIN[GENE]/B_LOCATION
= O
0 B_NUMBER[MEASURE]
. O
045 B_MEASURE
) O
. O

After O
MAP B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
increases B_DISEASE_ADJECTIVE[DISEASE]
were O
identified O
in O
both O
cardiac B_MEASURE/B_ORGANIZATION
output B_MEASURE/I_ORGANIZATION
( O
from O
1 B_MEASURE
. O
54 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_NUMBER[MEASURE]
. O
57 B_MEASURE
to O
1 B_MEASURE
. O
65 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
57 B_MEASURE/B_PERSON
1 I_MEASURE/I_PERSON
/ O
min B_MEASURE/B_PERSON
) O
and O
Emax B_DISEASE/B_GENE
( O
from O
1 B_MEASURE
. O
86 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
9 B_MEASURE
to O
2 B_MEASURE
. O
41 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
. O
31 B_MEASURE
mmHg I_MEASURE
/ O
ml B_MEASURE/B_PERSON
) O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acquired O
suggest O
that O
isolated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Map B_LOCATION/B_BIO
may O
have O
certain B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
benefits I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
LV B_MEASURE
dimension I_MEASURE
/ O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
acute B_DISEASE
heart I_DISEASE
failure I_DISEASE
, O
even O
in O
the O
absence B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
MR B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
investigations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
warranted O
in O
a O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
chronic B_DISEASE
heart I_DISEASE
failure I_DISEASE
. O

Piperacillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
tazobactam I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
induced O
seizure O
rapidly O
reversed O
by O
high O
flux O
hemodialysis O
in O
a O
patient O
on O
peritoneal O
dialysis O
. O

Despite O
popular O
use O
of O
piperacillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
dire O
neurotoxicity O
associated O
with O
piperacillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
still O
goes O
unrecognized O
, O
leading O
to O
a O
delay O
in O
appropriate O
management O
. O

We O
report O
a O
57 O
- O
year O
- O
old O
woman O
with O
end O
- O
stage O
renal O
disease O
receiving O
continuous O
ambulatory O
peritoneal O
dialysis O
( O
CAPD O
) O
, O
who O
developed O
slurred O
speech O
, O
tremor O
, O
bizarre O
behavior O
, O
progressive O
mental O
confusion O
, O
and O
2 O
episodes O
of O
generalized O
tonic O
- O
clonic O
seizure O
( O
GTCS O
) O
after O
5 O
doses O
of O
piperacillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tazobactam I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 O
g O
/ O
250 O
mg O
) O
were O
given O
for O
bronchiectasis O
with O
secondary O
infection O
. O

The O
laboratory O
data O
revealed O
normal O
plasma O
electrolyte O
and O
ammonia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
but O
leukocytosis O
. O

neurologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
examinations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
dysarthria B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
bilateral B_DISEASE
Babinski I_DISEASE
sign I_DISEASE
. O

Computed B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tomography I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
electroencephalogram B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
were O
unremarkable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Despite O
the O
use O
of O
antiepileptic O
agents O
, O
another O
GTCS O
episode O
recurred O
after O
the O
sixth O
dose O
of O
piperacillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tazobactam I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Brain B_PERSON
magnetic I_PERSON
resonance I_PERSON
imaging I_PERSON
did O
not O
demonstrate O
acute B_DISEASE_ADJECTIVE[DISEASE]
infarction I_DISEASE_ADJECTIVE[DISEASE]
and O
organic B_DISEASE
brain I_DISEASE
lesions I_DISEASE
. O

initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
high B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
flux B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hemodialysis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
rapidly O
reversed O
the O
neurologic B_DISEASE
symptoms I_DISEASE
within O
4 B_TIME[MEASURE]
hours I_TIME[MEASURE]
. O

Piperacillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
encephalopathy O
should O
be O
considered O
in O
any O
uremic O
patients O
with O
unexplained O
neurological O
manifestations O
. O

CAPD O
is O
inefficient O
in O
removing O
piperacillin B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
whereas O
hemodialysis O
can O
rapidly O
terminate O
the O
piperacillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
encephalopathy O
. O

frequency B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
transient B_DISEASE
ipsilateral I_DISEASE
vocal I_DISEASE
cord I_DISEASE
paralysis I_DISEASE
in O
patients B_PERSON/B_BIO
undergoing O
carotid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
endarterectomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
under O
local B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Especially O
because O
of O
improvements B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
clinical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
neurologic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
monitoring I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
, O
carotid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
endarterectomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
done O
under O
local B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
has O
become O
the O
technique B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
choice B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
in O
several B_LOCATION/B_NUMBER[MEASURE]
centers I_LOCATION/I_NUMBER[MEASURE]
. O

temporary B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ipsilateral I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vocal I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nerve I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
palsies I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O
to O
local B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
anesthetics I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
have O
been O
described O
, O
however O
. O

Such B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
complications I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
are O
most O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
situations B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
where O
there O
is O
a O
pre B_LOCATION/B_DISEASE
- O
existing O
contralateral B_DISEASE
paralysis I_DISEASE
. O

We O
therefore O
examined O
the O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
local B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anesthesia I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
vocal B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cord I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
better O
understand O
its O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consequences B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
This O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O
28 B_PERSON
patients I_PERSON
undergoing O
carotid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
endarterectomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
under O
local B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

vocal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cord B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
evaluated O
before O
, O
during O
, O
and O
after O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
postoperative B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
day I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
1 I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
using O
flexible B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
laryngoscopy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Anesthesia O
was O
performed O
by O
injecting O
20 O
to O
40 O
mL O
of O
a O
mixture O
of O
long O
- O
acting O
( O
ropivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
short O
- O
acting O
( O
prilocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
anesthetic O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
All O
patients B_PERSON/B_BIO
had O
normal B_DISEASE
vocal I_DISEASE
cord I_DISEASE
function I_DISEASE
preoperatively O
. O

Twelve B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
( O
43 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
were O
found O
to O
have O
intraoperative B_DISEASE
ipsilateral I_DISEASE
vocal I_DISEASE
cord I_DISEASE
paralysis I_DISEASE
. O

It O
resolved O
in O
all O
cases B_TIME[MEASURE]/B_LOCATION
< I_TIME[MEASURE]/I_LOCATION
or O
= O
24 B_MEASURE/B_SPORT[ENT]
hours I_MEASURE/I_SPORT[ENT]
. O

There O
were O
no O
significant B_DISEASE_ADJECTIVE[DISEASE]
differences I_DISEASE_ADJECTIVE[DISEASE]
in O
operating B_MEASURE
time I_MEASURE
or O
volume B_MEASURE
or O
frequency B_MEASURE
of O
anesthetic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
patients B_PERSON/B_BIO
with O
temporary B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vocal I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cord I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
paralysis I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
compared O
with O
those O
without O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Local B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
led O
to O
temporary B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ipsilateral I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
vocal I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cord I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
paralysis I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
almost O
half B_NUMBER[MEASURE]/B_PERSON
of O
these O
patients B_PERSON/B_ENT
. O

Because O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
existing O
paralysis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
of O
a O
relevant B_MEASURE
frequency I_MEASURE
( O
up O
to O
3 B_MEASURE
% I_MEASURE
) O
, O
a O
preoperative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
vocal B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cord I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
carotid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
endarterectomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
under O
local B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
recommended O
to O
avoid O
intraoperative B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bilateral I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
paralysis I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
patients B_PERSON
with O
preoperative B_DISEASE
contralateral I_DISEASE
vocal I_DISEASE
cord I_DISEASE
paralysis I_DISEASE
, O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
under O
general B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
should O
be O
considered O
. O

impaired O
fear O
recognition O
in O
regular O
recreational O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
. O

Introduction B_TIME[MEASURE]/B_PERSON
: O
The O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
read O
facial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
expressions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
essential B_TIME[MEASURE]/B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
normal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
human I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
social I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
interaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

The O
aim O
of O
the O
present O
study O
was O
to O
conduct O
the O
first O
investigation O
of O
facial O
expression O
recognition O
performance O
in O
recreational O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
. O

Materials O
AND O
methods O
: O
Three O
groups O
, O
comprised O
of O
21 O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
naive O
participants O
( O
CN O
) O
, O
30 O
occasional O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O
OC O
) O
, O
and O
48 O
regular O
recreational O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
RC O
) O
users O
, O
were O
compared O
. O

An O
emotional B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
facial B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
EFE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
task B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
consisting O
of O
a O
male B_PERSON/B_COLOR
and O
female B_PERSON
face I_PERSON
expressing O
six B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
basic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
emotions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
happiness B_DISEASE/B_PERSON
, O
surprise B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
sadness B_DISEASE/B_PERSON
, O
anger B_DISEASE/B_PERSON
, O
fear B_DISEASE/B_PERSON
, O
and O
disgust B_DISEASE/B_PERSON
) O
was O
administered O
. O

Mean B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
percent B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
accuracy B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
latencies B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
correct B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
across O
eight B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
presentations I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
each O
basic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
emotion I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
derived O
. O

participants B_PERSON/B_BIO
were O
also O
assessed O
with O
the O
' O
eyes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
task B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
' O
to O
investigate O
their O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
recognize O
more O
complex B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
emotional I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
states I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
Symptom B_MEASURE/B_PROTEIN[GENE]
Checklist B_MEASURE/I_PROTEIN[GENE]
- O
90 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
revised O
to O
measure O
psychopathology B_DISEASE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
There O
were O
no O
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
differences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
psychopathology B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
' O
eyes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
task B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
' B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
performance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
the O
RC B_PERSON/B_ORGANIZATION
group I_PERSON/I_ORGANIZATION
, O
who O
otherwise O
had O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
illicit I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
substance I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
use I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
histories I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
the O
OC B_LOCATION/B_ORGANIZATION
group I_LOCATION/I_ORGANIZATION
, O
exhibited O
impaired B_DISEASE_ADJECTIVE[DISEASE]
fear I_DISEASE_ADJECTIVE[DISEASE]
recognition I_DISEASE_ADJECTIVE[DISEASE]
accuracy I_DISEASE_ADJECTIVE[DISEASE]
compared O
to O
the O
OC B_LOCATION/B_PERSON
and O
CN B_LOCATION
groups I_LOCATION
. O

The O
RC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
also O
correctly O
identified O
anger B_DISEASE/B_PERSON
, O
fear B_DISEASE/B_PERSON
, O
happiness B_DISEASE/B_PERSON
, O
and O
surprise B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
more O
slowly O
than O
CN B_DISEASE/B_LOCATION
, O
but O
not O
OC B_PERSON/B_LOCATION
participants B_PERSON/I_LOCATION
. O

The O
OC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
was O
slower B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
than O
CN B_DISEASE/B_MEASURE
when O
correctly O
identifying O
disgust B_DISEASE/B_PERSON
. O

The O
selective O
deficit O
in O
fear O
recognition O
accuracy O
manifested O
by O
the O
RC O
group O
cannot O
be O
explained O
by O
the O
subacute O
effects O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
because O
recent O
and O
less O
recent O
users O
of O
these O
drugs O
within O
this O
group O
were O
similarly O
impaired O
. O

Possible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
parallels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
RC B_DISEASE/B_LOCATION
users I_DISEASE/I_LOCATION
and O
psychopaths B_PERSON/B_DISEASE
with O
respect B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
impaired B_DISEASE
fear I_DISEASE
recognition I_DISEASE
, O
amygdala B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dysfunction B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
etiology B_DISEASE
are O
discussed O
. O

damage O
of O
substantia O
nigra O
pars O
reticulata O
during O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
status O
epilepticus O
in O
the O
rat O
: O
immunohistochemical O
study O
of O
neurons O
, O
astrocytes O
and O
serum O
- O
protein O
extravasation O
. O

The O
substantia B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nigra I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
has O
a O
gating O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
controlling O
the O
spread B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
epileptic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
seizure I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
activity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Additionally O
, O
in O
models B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
prolonged B_DISEASE_ADJECTIVE[DISEASE]
status I_DISEASE_ADJECTIVE[DISEASE]
epilepticus O
the O
pars B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
reticulata I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
of O
substantia B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nigra I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
SNR B_PROTEIN[GENE]/B_DISEASE
) O
suffers O
from O
a O
massive B_DISEASE
lesion I_DISEASE
which O
may O
arise O
from O
a O
massive B_DISEASE
metabolic I_DISEASE
derangement I_DISEASE
and O
hyperexcitation B_DISEASE_ADJECTIVE[DISEASE]
developing O
in O
the O
activated O
SNR B_LOCATION/B_BIO
. O

In O
this O
study O
, O
status O
epilepticus O
was O
induced O
by O
systemic O
injection O
of O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
rats O
. O

The O
neuropathology B_DISEASE_ADJECTIVE[DISEASE]
of O
SNR B_DISEASE
was O
investigated O
using O
immunohistochemical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
techniques I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
the O
major B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
emphasis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
time B_TIME[MEASURE]/B_LOCATION
- O
course B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
astrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surviving O
20 B_MEASURE
, O
30 B_MEASURE
, O
40 B_MEASURE
, O
60 B_TIME[MEASURE]
min I_TIME[MEASURE]
, O
2 B_MEASURE
, O
3 B_NUMBER[MEASURE]
, O
6 B_NUMBER[MEASURE]/B_SPORT[ENT]
hours I_NUMBER[MEASURE]/I_SPORT[ENT]
, O
1 B_SEQUENCE[MEASURE]
, O
2 B_NUMBER[MEASURE]
, O
and O
3 B_NUMBER[MEASURE]/B_ENT
days I_NUMBER[MEASURE]/I_ENT
after O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
status B_DISEASE
epilepticus I_DISEASE
were O
perfusion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
fixed O
, O
and O
brains B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
processed O
for O
immunohistochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
SNR B_GENE/B_DISEASE
. O

Nissl O
- O
staining O
and O
antibodies O
against O
the O
neuron O
- O
specific O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
binding O
protein O
, O
parvalbumin O
, O
served O
to O
detect O
neuronal O
damage O
in O
SNR O
. O

antibodies O
against O
the O
astroglia O
- O
specific O
cytoskeletal O
protein O
, O
glial O
fibrillary O
acidic O
protein O
( O
GFAP O
) O
, O
and O
against O
the O
glial O
calcium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
- O
binding O
protein O
, O
S O
- O
100 O
protein O
, O
were O
used O
to O
assess O
the O
status O
of O
astrocytes O
. O

Immunohistochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
serum B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
albumin B_GENE
and O
immunoglobulins B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
taken O
as O
indicator B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
blood B_BODY_PART_OR_ORGAN_COMPONENT
- O
brain B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
barrier B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
disturbances B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
vasogenic B_DISEASE_ADJECTIVE[DISEASE]
edema I_DISEASE_ADJECTIVE[DISEASE]
formation I_DISEASE_ADJECTIVE[DISEASE]
. O

Immunohistochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
staining I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicated O
loss B_DISEASE_ADJECTIVE[DISEASE]
of O
GFAP B_GENE
- O
staining O
already O
at O
30 B_MEASURE/B_LOCATION
min I_MEASURE/I_LOCATION
after O
induction B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
seizures B_DISEASE/B_GENE
in O
an O
oval B_LOCATION/B_DISEASE
focus I_LOCATION/I_DISEASE
situated O
in O
the O
center B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O
SNR B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
while O
sparing O
medial B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
and O
lateral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
aspects I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

At O
1 B_MEASURE
h O
there O
was O
additional B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vacuolation I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
S B_PROTEIN[GENE]/B_DISEASE
- O
100 B_MEASURE/B_LOCATION
protein I_MEASURE/I_LOCATION
staining I_MEASURE/I_LOCATION
. O

By O
2 B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
hours I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
parvalbumin B_GENE
- O
staining B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
changed O
in O
the O
central B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
SNR I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
indicating O
neuronal B_DISEASE
damage I_DISEASE
, O
and O
Nissl B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
staining B_PERSON
visualized O
some O
neuronal B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
distortion B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Staining O
for O
serum B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
proteins B_GENE/B_DISEASE
occurred O
in O
a O
patchy B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
manner I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
throughout O
the O
forebrain B_BODY_PART_OR_ORGAN_COMPONENT
during O
the O
first B_TIME[MEASURE]/B_ENT
hours I_TIME[MEASURE]/I_ENT
. O

By O
6 B_TIME[MEASURE]/B_LOCATION
h O
, O
vasogenic B_PERSON
edema I_PERSON
covered O
the O
lesioned O
SNR B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
. O

By O
24 B_TIME[MEASURE]/B_LOCATION
h O
, O
glial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
neuronal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicated O
a O
massive B_DISEASE/B_MEASURE
lesion I_DISEASE/I_MEASURE
in O
the O
center B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
of O
SNR B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

By O
48 B_MEASURE
- O
72 B_TIME[MEASURE]
h I_TIME[MEASURE]
, O
astrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
surrounding O
the O
lesion B_DISEASE
increased O
in O
size B_MEASURE
, O
and O
polymorphic B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
phagocytotic B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
invaded O
the O
damaged O
area B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O

In O
a O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
surviving O
1 B_NUMBER[MEASURE]/B_LOCATION
to O
5 B_MEASURE/B_ENT
days I_MEASURE/I_ENT
, O
conventional B_DISEASE_ADJECTIVE[DISEASE]
paraffin I_DISEASE_ADJECTIVE[DISEASE]
- O
sections B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
confirmed O
the O
neuronal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
glial B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
damage B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
SNR B_DISEASE
. O

Additional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pathology I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
similar B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
quality I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
in O
the O
globus B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
pallidus I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

Since O
astrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
were O
always O
damaged O
in O
parallel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
in O
SNR B_DISEASE/B_PROTEIN[GENE]
it O
is O
proposed O
that O
the O
anatomical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
functional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interrelationship B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
between O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
astrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
particularly O
tight B_DISEASE_ADJECTIVE[DISEASE]
in O
SNR B_DISEASE/B_PROTEIN[GENE]
. O

Both O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANIZATION
elements I_DISEASE_ADJECTIVE[DISEASE]/I_ORGANIZATION
may O
suffer O
in O
common B_DISEASE/B_LOCATION
from O
metabolic B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
disturbance B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
neurotransmitter B_DISEASE
dysfunction I_DISEASE
as O
occur O
during O
massive B_DISEASE/B_ORGANISM_FUNCTION
status I_DISEASE/I_ORGANISM_FUNCTION
epilepticus I_DISEASE/I_ORGANISM_FUNCTION
. O

Neuroprotective O
effects O
of O
melatonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
upon O
the O
offspring O
cerebellar O
cortex O
in O
the O
rat O
model O
of O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
cortical O
dysplasia O
. O

cortical B_DISEASE/B_GENE
dysplasia I_DISEASE/I_GENE
is O
a O
malformation B_DISEASE
characterized O
by O
defects B_DISEASE_ADJECTIVE[DISEASE]
in O
proliferation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
migration B_ORGANISM_FUNCTION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
maturation B_ORGANISM_FUNCTION/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

This O
study O
was O
designed O
to O
evaluate O
the O
alterations O
in O
offspring O
rat O
cerebellum O
induced O
by O
maternal O
exposure O
to O
carmustine B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
- O
[ O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chloroethyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrosoure I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] O
( O
BCNU B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
to O
investigate O
the O
effects O
of O
exogenous O
melatonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
upon O
cerebellar O
BCNU B_DISEASE
- O
induced O
cortical O
dysplasia O
, O
using O
histological O
and O
biochemical O
analyses O
. O

pregnant O
Wistar O
rats O
were O
assigned O
to O
five O
groups O
: O
intact O
- O
control O
, O
saline O
- O
control O
, O
melatonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
, O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
exposed O
and O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
exposed O
plus O
melatonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

rats O
were O
exposed O
to O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
embryonic O
day O
15 O
and O
melatonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
given O
until O
delivery O
. O

Immuno O
/ O
histochemistry O
and O
electron O
microscopy O
were O
carried O
out O
on O
the O
offspring O
cerebellum O
, O
and O
levels O
of O
malondialdehyde B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dismutase O
were O
determined O
. O

Histopathologically O
, O
typical O
findings O
were O
observed O
in O
the O
cerebella O
from O
the O
control O
groups O
, O
but O
the O
findings O
consistent O
with O
early O
embryonic O
development O
were O
noted O
in O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
exposed O
cortical O
dysplasia O
group O
. O

There O
was O
a O
marked O
increase O
in O
the O
number O
of O
TUNEL O
positive O
cells O
and O
nestin O
positive O
cells O
in O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
exposed O
group O
, O
but O
a O
decreased O
immunoreactivity O
to O
glial O
fibrillary O
acidic O
protein O
, O
synaptophysin O
and O
transforming O
growth O
factor O
beta1 O
was O
observed O
, O
indicating O
a O
delayed O
maturation O
, O
and O
melatonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
significantly O
reversed O
these O
changes O
. O

Malondialdehyde B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O
in O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
exposed O
group O
was O
higher O
than O
those O
in O
control O
groups O
and O
melatonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
decreased O
malondialdehyde B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
in O
BCNU B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
group O
( O
P O
< O
0 O
. O
01 O
) O
, O
while O
there O
were O
no O
significant O
differences O
in O
the O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dismutase O
levels O
between O
these O
groups O
. O

These O
data O
suggest O
that O
exposure O
of O
animals O
to O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
during O
pregnancy O
leads O
to O
delayed O
maturation O
of O
offspring O
cerebellum O
and O
melatonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
protects O
the O
cerebellum O
against O
the O
effects O
of O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

reduced O
cardiotoxicity O
of O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O
in O
the O
form O
of O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
hydroxypropyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
methacrylamide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
conjugates O
: O
and O
experimental O
study O
in O
the O
rat O
. O

A O
rat O
model O
was O
used O
to O
evaluate O
the O
general O
acute O
toxicity O
and O
the O
late O
cardiotoxicity O
of O
4 O
mg O
/ O
kg O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
given O
either O
as O
free O
drug O
or O
in O
the O
form O
of O
three O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydroxypropyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methacrylamide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
HPMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
copolymer O
conjugates O
. O

In O
these O
HPMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
copolymers O
, O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
covalently O
bound O
via O
peptide O
linkages O
that O
were O
either O
non O
- O
biodegradable O
( O
Gly O
- O
Gly O
) O
or O
degradable O
by O
lysosomal O
proteinases O
( O
Gly B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Phe I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Leu I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Gly I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

In O
addition O
, O
one O
biodegradable O
conjugate O
containing O
galactosamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
was O
used O
; O
this O
residue O
was O
targeted O
to O
the O
liver O
. O

Over O
the O
first O
3 O
weeks O
after O
the O
i O
. O
v O
. O
administration O
of O
free O
and O
polymer O
- O
bound O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
all O
animals O
showed O
a O
transient O
reduction O
in O
body O
weight O
. O

However O
, O
the O
maximal O
reduction O
in O
body O
weight O
seen O
in O
animals O
that O
received O
polymer O
- O
bound O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
4 O
mg O
/ O
kg O
) O
was O
significantly O
lower O
than O
that O
observed O
in O
those O
that O
received O
free O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
4 O
mg O
/ O
kg O
) O
or O
a O
mixture O
of O
the O
unmodified O
parent O
HPMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
copolymer O
and O
free O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
4 O
mg O
/ O
kg O
; O
P O
less O
than O
0 O
. O
01 O
) O
. O

Throughout O
the O
study O
( O
20 O
weeks O
) O
, O
deaths O
related O
to O
cardiotoxicity O
were O
observed O
only O
in O
animals O
that O
received O
either O
free O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
the O
mixture O
of O
HPMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
copolymer O
and O
free O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
; O
in O
these O
cases O
, O
histological O
investigations O
revealed O
marked O
changes O
in O
the O
heart O
that O
were O
consistent O
with O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cardiotoxicity O
. O

Sequential O
measurements O
of O
cardiac O
output O
in O
surviving O
animals O
that O
received O
either O
free O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
the O
mixture O
of O
HPMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
copolymer O
and O
free O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
showed O
a O
reduction O
of O
approximately O
30 O
% O
in O
function O
beginning O
at O
the O
4th O
week O
after O
drug O
administration O
. O

The O
heart B_MEASURE/B_DISEASE
rate I_MEASURE/I_DISEASE
in O
these O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
approximately O
12 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
lower B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
that O
measured O
in O
age B_MEASURE/B_LOCATION
- O
matched O
control B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

Animals O
that O
were O
given O
the O
HPMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
copolymer O
conjugates O
containing O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
exhibited O
no O
significant O
change O
in O
cardiac O
output O
throughout O
the O
study O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

In O
addition O
, O
no O
significant O
histological O
change O
was O
observed O
in O
the O
heart O
of O
animals O
that O
received O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
the O
form O
of O
HPMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
copolymer O
conjugates O
and O
were O
killed O
at O
the O
end O
of O
the O
study O
. O

However O
, O
these O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
shown O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
heart B_DISEASE
rate I_DISEASE
beginning O
at O
8 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
after O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
P B_MEASURE
less I_MEASURE
than O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O
( O
abstract B_TIME[MEASURE]/B_LOCATION
TRUNCATED I_TIME[MEASURE]/I_LOCATION
AT O
400 B_LOCATION/B_PERSON
Words I_LOCATION/I_PERSON
) O
. O

Corneal O
ulcers O
associated O
with O
aerosolized O
crack B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocaine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
. O

Purpose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
report O
4 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
corneal B_DISEASE
ulcers I_DISEASE
associated O
with O
drug B_DISEASE
abuse I_DISEASE
. O

The O
pathogenesis B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
ulcers B_DISEASE/B_BIO
and O
management B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O
these O
patients B_PERSON/B_DISEASE
are O
also O
reviewed O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
all O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
corneal B_DISEASE/B_LOCATION
ulcers I_DISEASE/I_LOCATION
associated O
with O
drug B_DISEASE
abuse I_DISEASE
seen O
at O
our O
institution B_LOCATION/B_ORGANIZATION
from O
July B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2006 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
December B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2006 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
Four O
patients O
with O
corneal O
ulcers O
associated O
with O
crack B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocaine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
were O
reviewed O
. O

All O
corneal B_DISEASE/B_BIO
ulcers I_DISEASE/I_BIO
were O
cultured O
, O
and O
the O
patients B_PERSON/B_BIO
were O
admitted O
to O
the O
hospital B_LOCATION
for O
intensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
topical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
antibiotic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Each O
patient B_PERSON/B_LOCATION
received O
comprehensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
care I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
including O
medical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
substance B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANIZATION
abuse I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
consultations I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANIZATION
. O

streptococcal B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
organisms I_BACTERIUM[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
were O
found O
in O
3 B_MEASURE
cases I_MEASURE
and O
Capnocytophaga B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Brevibacterium B_BACTERIUM[BIO]
casei I_BACTERIUM[BIO]
in O
1 B_NUMBER[MEASURE]/B_PERSON
patient I_NUMBER[MEASURE]/I_PERSON
. O

The O
infections B_DISEASE/B_PERSON
responded O
to O
antibiotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Two B_PERSON
patients I_PERSON
needed O
a O
lateral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
tarsorrhaphy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O
persistent B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
epithelial B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
defects B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

conclusions O
: O
Aerosolized O
crack B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocaine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
can O
be O
associated O
with O
the O
development O
of O
corneal O
ulcers O
. O

Drug B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abuse B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O
additional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
challenges I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
management B_PERSON
. O

Not O
only O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
their O
infections B_DISEASE
but O
also O
the O
overall B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
poor I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
health I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
patients B_PERSON/B_LOCATION
and O
increased O
risk B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
noncompliance B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
need I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
be O
addressed O
. O

Comprehensive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
care I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
may O
provide O
the O
patient B_PERSON
the O
opportunity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
discontinue O
their O
substance B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
abuse I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
improve O
their O
overall B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
health I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
prevent O
future B_DISEASE_ADJECTIVE[DISEASE]
corneal I_DISEASE_ADJECTIVE[DISEASE]
complications I_DISEASE_ADJECTIVE[DISEASE]
. O

Topical O
0 O
. O
025 O
% O
capsaicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
chronic O
post O
- O
herpetic O
neuralgia O
: O
efficacy O
, O
predictors O
of O
response O
and O
long O
- O
term O
course O
. O

In O
order O
to O
evaluate O
the O
efficacy O
, O
time O
- O
course O
of O
action O
and O
predictors O
of O
response O
to O
topical O
capsaicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
39 O
patients O
with O
chronic O
post O
- O
herpetic O
neuralgia O
( O
PHN O
) O
, O
median O
duration O
24 O
months O
, O
were O
treated O
with O
0 O
. O
025 O
% O
capsaicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cream O
for O
8 O
weeks O
. O

During O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O
patients B_PERSON/B_ORGANIZATION
rated O
their O
pain B_DISEASE
on O
a O
visual B_MEASURE
analogue I_MEASURE
scale I_MEASURE
( O
VAS B_DISEASE/B_LOCATION
) O
and O
a O
verbal B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scale I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
follow O
- O
up O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
10 B_NUMBER[MEASURE]
- O
12 B_TIME[MEASURE]
months I_TIME[MEASURE]
after O
study B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
onset I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
on O
the O
patients B_PERSON
who O
had O
improved O
. O

nineteen O
patients O
( O
48 O
. O
7 O
% O
) O
substantially O
improved O
after O
the O
8 O
- O
week O
trial O
; O
5 O
( O
12 O
. O
8 O
% O
) O
discontinued O
therapy O
due O
to O
side O
- O
effects O
such O
as O
intolerable O
capsaicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
burning O
sensations O
( O
4 O
) O
or O
mastitis O
( O
1 O
) O
; O
15 O
( O
38 O
. O
5 O
% O
) O
reported O
no O
benefit O
. O

The O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
VAS B_MEASURE
ratings I_MEASURE
was O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
after O
2 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
of O
continuous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
application I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Of O
the O
responders B_MEASURE
72 I_MEASURE
. O
2 B_MEASURE
% I_MEASURE
were O
still O
improved O
at O
the O
follow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
- O
up B_LOCATION/B_TIME[MEASURE]
; O
only O
one B_NUMBER[MEASURE]
- O
third B_SEQUENCE[MEASURE]
of O
them O
had O
continued O
application B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
irregularly O
. O

Treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
dependent B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
on O
patient B_PERSON
' O
s B_MEASURE/B_DISEASE
age I_MEASURE/I_DISEASE
, O
duration B_MEASURE/B_LOCATION
or O
localization B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
PHN B_DISEASE
( O
trigeminal B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involvement B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
excluded O
) O
, O
sensory B_DISEASE
disturbance I_DISEASE
or O
pain B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
character I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Treatment O
response O
was O
not O
correlated O
with O
the O
incidence O
, O
time O
- O
course O
or O
severity O
of O
capsaicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
burning O
. O

If O
confirmed O
in O
controlled O
trials O
, O
the O
long O
- O
term O
results O
of O
this O
open O
, O
non O
- O
randomized O
study O
might O
indicate O
that O
the O
analgesic O
effect O
of O
capsaicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
PHN O
is O
mediated O
by O
both O
interference O
with O
neuropeptide O
metabolism O
and O
morphological O
changes O
( O
perhaps O
degeneration O
) O
of O
nociceptive O
afferents O
. O

Myo B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inositol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
phosphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
MIP B_GENE
) O
synthase O
inhibition O
: O
in O
- O
vivo O
study O
in O
rats O
. O

Lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
the O
prototypic O
mood O
stabilizers O
and O
have O
diverse O
structures O
and O
targets O
. O

Both O
drugs O
influence O
inositol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolism O
. O

Lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibits O
IMPase O
and O
valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibits O
MIP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthase O
. O

This O
study O
shows O
that O
MIP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthase O
inhibition O
does O
not O
replicate O
or O
augment O
the O
effects O
of O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
inositol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitive O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
seizures O
model O
. O

This O
lack O
of O
effects O
may O
stem O
from O
the O
low O
contribution O
of O
de O
- O
novo O
synthesis O
to O
cellular O
inositol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supply O
or O
to O
the O
inhibition O
of O
the O
de O
- O
novo O
synthesis O
by O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
itself O
. O

Non B_DISEASE/B_MEASURE
- O
steroidal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
inflammatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
associated O
acute B_DISEASE
interstitial I_DISEASE
nephritis I_DISEASE
with O
granular B_DISEASE
tubular I_DISEASE
basement I_DISEASE
membrane I_DISEASE
deposits I_DISEASE
. O

Acute B_DISEASE_ADJECTIVE[DISEASE]
tubulo I_DISEASE_ADJECTIVE[DISEASE]
- O
interstitial B_DISEASE
nephritis I_DISEASE
( O
ATIN B_LOCATION/B_ORGANIZATION
) O
is O
an O
important B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cause I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
resulting O
from O
a O
variety B_ENT/B_MEASURE
of O
insults B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
including O
immune B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
complex B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mediated O
tubulo B_DISEASE
- O
interstitial B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
injury I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
but O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
non B_DISEASE/B_PROTEIN[GENE]
- O
steroidal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
anti I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
inflammatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
NSAIDs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
) O
are O
a O
far O
more O
frequent B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cause B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Overall O
, O
as O
an O
entity B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ATIN B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
remains O
under O
- O
diagnosed O
, O
as O
symptoms B_DISEASE
resolve O
spontaneously O
if O
the O
medication B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
stopped O
. O

We O
report O
on O
a O
14 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
- O
old B_PERSON
boy I_PERSON
who O
developed O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
2 I_DISEASE
weeks I_DISEASE
after O
aortic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
valve I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

He O
was O
put O
on O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
following O
surgery O
and O
took O
ibuprofen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
fever O
for O
nearly O
a O
week O
prior O
to O
presentation O
. O

He O
then O
presented O
to O
the O
emergency O
department O
feeling O
quite O
ill O
and O
was O
found O
to O
have O
a O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
urea I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nitrogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
BUN B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O
concentration O
of O
of O
147 O
mg O
/ O
DL O
, O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
15 O
. O
3 O
mg O
/ O
DL O
and O
serum O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
8 O
. O
7 O
mEq O
/ O
l O
. O

dialysis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
was O
immediately O
initiated O
. O

A O
kidney B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
biopsy I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
inflammatory B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infiltrate I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
consistent I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
with O
ATIN B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
in O
the O
tubular B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
basement I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
membrane I_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
TBM B_DISEASE/B_PROTEIN[GENE]
) O
, O
very O
intense B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
granular B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
deposits B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
polyclonal B_PROTEIN[GENE]
IgG I_PROTEIN[GENE]
and O
C3 B_GENE
were O
noted O
. O

He O
needed O
dialysis O
for O
2 O
weeks O
and O
was O
treated O
successfully O
with O
steroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
6 O
months O
. O

His O
renal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recovery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
disappearance B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
proteinuria B_DISEASE
took O
a O
year B_TIME[MEASURE]/B_LOCATION
. O

In O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
this O
is O
a O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
NSAIDs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
ATIN B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
showing O
deposits B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
granular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
immune I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
complex I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
present I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
only O
in O
the O
TBM B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
not O
in O
the O
glomeruli B_DISEASE/B_LOCATION
. O

Rifampicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
associated O
segmental O
necrotizing O
glomerulonephritis O
in O
staphylococcal O
endocarditis O
. O

Segmental O
necrotising O
glomerulonephritis O
has O
been O
reported O
as O
complication O
of O
rifampicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O
in O
patients O
receiving O
treatment O
for O
tuberculosis O
. O

Changing O
epidemiology O
of O
infections O
such O
as O
infective O
endocarditis O
( O
IE O
) O
has O
led O
to O
an O
increase O
in O
the O
use O
of O
rifampicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
Staphylococcal O
infections O
. O

We O
describe O
a O
case O
of O
a O
patient O
with O
Staphylococcal O
IE O
who O
developed O
acute O
renal O
failure O
secondary O
to O
a O
segmental O
necrotising O
glomerulonephritis O
while O
being O
treated O
with O
rifampicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
review O
the O
literature O
regarding O
this O
complication O
of O
rifampicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

Rate O
of O
YMDD O
motif O
mutants O
in O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
untreated O
Iranian O
patients O
with O
chronic O
hepatitis O
B O
virus O
infection O
. O

Background O
: O
Lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
used O
for O
the O
treatment O
of O
chronic O
hepatitis O
B O
patients O
. O

Recent O
studies O
show O
that O
the O
YMDD O
motif O
mutants O
( O
resistant O
hepatitis O
B O
virus O
) O
occur O
as O
natural O
genome O
variability O
in O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
untreated O
chronic O
hepatitis O
B O
patients O
. O

In O
this O
study O
we O
aimed O
to O
determine O
the O
rate O
of O
YMDD O
motif O
mutants O
in O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
untreated O
chronic O
hepatitis O
B O
patients O
in O
Iran O
. O

patients O
AND O
methods O
: O
A O
total O
of O
77 O
chronic O
hepatitis O
B O
patients O
who O
had O
not O
been O
treated O
with O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
included O
in O
the O
study O
. O

Serum B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
patients B_PERSON/B_LOCATION
were O
tested O
by O
polymerase B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
chain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
restriction B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragment B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
length B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymorphism B_GENE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PCR B_LOCATION
- O
RFLP B_PROTEIN[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
for O
detection B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
YMDD B_DISEASE/B_GENE
motif B_DISEASE/I_GENE
mutants B_DISEASE/I_GENE
. O

All O
patients O
were O
also O
tested O
for O
liver O
enzymes O
, O
anti O
- O
HCV O
, O
HBeAg B_DISEASE/B_GENE
, O
and O
anti O
- O
HBe O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Of O
the O
77 B_PERSON
patients I_PERSON
enrolled O
in O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
73 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
were O
male B_PERSON/B_COLOR
and O
27 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
were O
female B_PERSON/B_LOCATION
. O

Mean B_MEASURE/B_LOCATION
ALT I_MEASURE/I_LOCATION
and O
AST B_GENE
levels I_GENE
were O
124 B_MEASURE
. O
4 B_MEASURE
+ I_MEASURE
/ O
- O
73 B_MEASURE
. O
4 B_MEASURE
and O
103 B_MEASURE
. O
1 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
81 B_MEASURE/B_LOCATION
IU I_MEASURE/I_LOCATION
/ O
l B_OTHER/B_MEASURE
, O
respectively O
. O

HBeAg B_DISEASE/B_GENE
was O
positive O
in O
40 O
% O
and O
anti O
- O
HBe O
in O
60 O
% O
of O
the O
patients O
. O

Anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
HCV B_DISEASE
was O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
all O
of O
them O
. O

YMDD O
motif O
mutants O
were O
not O
detected O
in O
any O
of O
the O
patients O
despite O
the O
liver O
enzyme O
levels O
and O
the O
presence O
of O
HBeAg B_DISEASE/B_GENE
or O
anti O
- O
HBe O
. O

conclusion O
: O
Although O
the O
natural O
occurrence O
of O
YMDD O
motif O
mutants O
in O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
untreated O
patients O
with O
chronic O
hepatitis O
B O
has O
been O
reported O
, O
these O
mutants O
were O
not O
detected O
in O
Iranian O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
untreated O
chronic O
hepatitis O
B O
patients O
. O

Branch O
retinal O
vein O
occlusion O
and O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

A O
case O
of O
branch O
retinal O
vein O
occlusion O
associated O
with O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
secondary O
hypertension O
is O
described O
. O

Although O
an O
infrequent O
complication O
of O
selective O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reuptake O
inhibitor O
therapy O
, O
it O
is O
important O
that O
ophthalmologists O
are O
aware O
that O
these O
agents O
can O
cause O
hypertension O
because O
this O
class O
of O
drugs O
is O
widely O
prescribed O
. O

The O
differential O
effects O
of O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
release O
, O
cyclooxygenase O
gene O
expression O
and O
pain O
in O
a O
clinical O
pain O
model O
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
blocking O
nociceptive B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
input B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
surgical B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
sites B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
long O
- O
acting O
local B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthetics I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
might O
directly O
modulate O
inflammation B_DISEASE/B_BACTERIUM[BIO]
. O

In O
the O
present O
study O
, O
we O
describe O
the O
proinflammatory O
effects O
of O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
local O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
PGE2 B_GENE
) O
production O
and O
cyclooxygenase O
( O
Cox O
) O
gene O
expression O
that O
increases O
postoperative O
pain O
in O
human O
subjects O
. O

methods O
: O
subjects O
( O
n O
= O
114 O
) O
undergoing O
extraction O
of O
impacted O
third O
molars O
received O
either O
2 O
% O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
0 O
. O
5 O
% O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
surgery O
and O
either O
rofecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O
mg O
or O
placebo O
orally O
90 O
min O
before O
surgery O
and O
for O
the O
following O
48 O
h O
. O

Oral B_NUMBER[MEASURE]/B_PERSON
mucosal I_NUMBER[MEASURE]/I_PERSON
biopsies I_NUMBER[MEASURE]/I_PERSON
were O
taken O
before O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
48 B_TIME[MEASURE]/B_LOCATION
h B_TIME[MEASURE]/I_LOCATION
after O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

After O
extraction O
, O
a O
microdialysis O
probe O
was O
placed O
at O
the O
surgical O
site O
for O
PGE2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
thromboxane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
B2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
TXB2 B_GENE
) O
measurements O
. O

Results O
: O
The O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
rofecoxib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O
reported O
significantly O
less O
pain O
, O
as O
assessed O
by O
a O
visual O
analog O
scale O
, O
compared O
with O
the O
other O
three O
treatment O
groups O
over O
the O
first O
4 O
h O
. O

However O
, O
the O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
placebo O
group O
reported O
significantly O
more O
pain O
at O
24 O
h O
and O
PGE2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels O
during O
the O
first O
4 O
h O
were O
significantly O
higher O
than O
the O
other O
three O
treatment O
groups O
. O

Moreover O
, O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O
increased O
Cox O
- O
2 O
gene O
expression O
at O
48 O
h O
as O
compared O
with O
the O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
placebo O
group O
. O

Thromboxane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
were O
not O
significantly O
affected O
by O
any O
of O
the O
treatments O
, O
indicating O
that O
the O
effects O
seen O
were O
attributable O
to O
inhibition O
of O
Cox O
- O
2 O
, O
but O
not O
Cox O
- O
1 O
. O

conclusions O
: O
These O
results O
suggest O
that O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
stimulates O
Cox O
- O
2 O
gene O
expression O
after O
tissue O
injury O
, O
which O
is O
associated O
with O
higher O
PGE2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O
and O
pain O
after O
the O
local O
anesthetic O
effect O
dissipates O
. O

p75NTR O
expression O
in O
rat O
urinary O
bladder O
sensory O
neurons O
and O
spinal O
cord O
with O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cystitis O
. O

A O
role B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
nerve B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
growth I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
factor I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
NGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
in O
contributing O
to O
increased O
voiding B_MEASURE/B_DISEASE
frequency B_MEASURE/I_DISEASE
and O
altered B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sensation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
the O
urinary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bladder I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
has O
been O
suggested O
. O

Previous O
studies O
have O
examined O
the O
expression O
and O
regulation O
of O
tyrosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kinase O
receptors O
( O
Trks O
) O
in O
micturition O
reflexes O
with O
urinary O
bladder O
inflammation O
. O

The O
present O
studies O
examine O
the O
expression O
and O
regulation O
of O
another O
receptor O
known O
to O
bind O
NGF O
, O
p75 O
( O
NTR O
) O
, O
after O
various O
durations O
of O
bladder O
inflammation O
induced O
by O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CYP B_LOCATION/B_ORGANIZATION
) O
. O

CYP B_DISEASE/B_BIO
- O
induced O
cystitis O
increased O
( O
P O
< O
or O
= O
0 O
. O
001 O
) O
p75 O
( O
NTR O
) O
expression O
in O
the O
superficial O
lateral O
and O
medial O
dorsal O
horn O
in O
L1 O
- O
L2 O
and O
L6 O
- O
S1 O
spinal O
segments O
. O

The O
number O
of O
p75 O
( O
NTR O
) O
- O
immunoreactive O
( O
- O
IR O
) O
cells O
in O
the O
lumbosacral O
dorsal O
root O
ganglia O
( O
DRG O
) O
also O
increased O
( O
P O
< O
or O
= O
0 O
. O
05 O
) O
with O
CYP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
induced O
cystitis O
( O
acute O
, O
intermediate O
, O
and O
chronic O
) O
. O

quantitative O
, O
real O
- O
time O
polymerase O
chain O
reaction O
also O
demonstrated O
significant O
increases O
( O
P O
< O
or O
= O
0 O
. O
01 O
) O
in O
p75 O
( O
NTR O
) O
mRNA O
in O
DRG O
with O
intermediate O
and O
chronic O
CYP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
induced O
cystitis O
. O

retrograde B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
dye I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- O
tracing O
techniques B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
Fastblue B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
used O
to O
identify O
presumptive B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
bladder I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
afferent I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
lumbosacral B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
DRG B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

In O
bladder B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
afferent B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cells B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
DRG B_DISEASE/B_MEASURE
, O
p75 B_GENE
( O
NTR B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
IR B_PROTEIN[GENE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
also O
increased O
( O
P B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
or O
= O
0 B_MEASURE
. O
01 B_MEASURE
) O
with O
cystitis B_DISEASE
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
increases B_DISEASE_ADJECTIVE[DISEASE]
in O
p75 B_GENE
( O
NTR B_LOCATION
) O
- O
IR B_LOCATION/B_PROTEIN[GENE]
in O
DRG B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
bodies I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
increases B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
P B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
or O
= O
0 B_MEASURE/B_LOCATION
. O
001 B_MEASURE
) O
in O
pericellular B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
encircling O
DRG B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
cells B_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
) O
p75 B_GENE
( O
NTR B_LOCATION/B_ORGANIZATION
) O
- O
IR B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
DRG B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
also O
increased O
. O

confocal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
demonstrated O
that O
pericellular B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
p75 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
NTR B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
IR B_MEASURE/B_PROTEIN[GENE]
was O
not O
colocalized O
with O
the O
glial B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
marker B_GENE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
glial B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fibrillary I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acidic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
GFAP B_GENE
) O
. O

These O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrate O
that O
p75 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NTR B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
expression B_GENE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
micturition B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
reflexes B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
present B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
constitutively O
and O
modified O
by O
bladder B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inflammation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
functional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
significance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
p75 B_GENE
( O
NTR B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
expression B_GENE
in O
micturition B_DISEASE
reflexes I_DISEASE
remains O
to O
be O
determined O
. O

Azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
suicidal O
erythrocyte O
death O
. O

Background O
: O
Azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
widely O
used O
as O
an O
immunosuppressive O
drug O
. O

The O
side O
effects O
of O
azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
include O
anemia O
, O
which O
has O
been O
attributed O
to O
bone O
marrow O
suppression O
. O

Alternatively O
, O
anemia O
could O
result O
from O
accelerated O
suicidal O
erythrocyte O
death O
or O
eryptosis O
, O
which O
is O
characterized O
by O
exposure O
of O
phosphatidylserine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PS B_PROTEIN[GENE]/B_LOCATION
) O
at O
the O
erythrocyte O
surface O
and O
by O
cell O
shrinkage O
. O

methods O
: O
The O
present O
experiments O
explored O
whether O
azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
influences O
eryptosis O
. O

According O
to O
annexin O
V O
binding O
, O
erythrocytes O
from O
patients O
indeed O
showed O
a O
significant O
increase O
of O
PS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O
within O
1 O
week O
of O
treatment O
with O
azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

In O
a O
second O
series O
, O
cytosolic O
Ca2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O
activity O
( O
Fluo3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
fluorescence O
) O
, O
cell O
volume O
( O
forward O
scatter O
) O
, O
and O
PS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
exposure O
( O
annexin O
V O
binding O
) O
were O
determined O
by O
FACS O
analysis O
in O
erythrocytes O
from O
healthy O
volunteers O
. O

Results O
: O
exposure O
to O
azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
> O
or O
= O
2 O
microg O
/ O
mL O
) O
for O
48 O
hours O
increased O
cytosolic O
Ca2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
+ O
activity O
and O
annexin O
V O
binding O
and O
decreased O
forward O
scatter O
. O

The O
effect O
of O
azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
both O
annexin O
V O
binding O
and O
forward O
scatter O
was O
significantly O
blunted O
in O
the O
nominal O
absence O
of O
extracellular O
Ca2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O
. O

conclusions O
: O
Azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
triggers O
suicidal O
erythrocyte O
death O
, O
an O
effect O
presumably O
contributing O
to O
azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
anemia O
. O

Levetiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
an O
adjunct O
to O
phenobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
in O
cats O
with O
suspected O
idiopathic O
epilepsy O
. O

objective O
: O
To O
assess O
pharmacokinetics O
, O
efficacy O
, O
and O
tolerability O
of O
oral O
levetiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administered O
as O
an O
adjunct O
to O
phenobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
in O
cats O
with O
poorly O
controlled O
suspected O
idiopathic O
epilepsy O
. O

Design B_PERSON/B_MEASURE
- O
Open B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
label B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
noncomparative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Animals O
: O
12 O
cats O
suspected O
to O
have O
idiopathic O
epilepsy O
that O
was O
poorly O
controlled O
with O
phenobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
that O
had O
unacceptable O
adverse O
effects O
when O
treated O
with O
phenobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

procedures O
: O
Cats O
were O
treated O
with O
levetiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
20 O
mg O
/ O
kg O
[ O
9 O
. O
1 O
mg O
/ O
lb O
] O
, O
Po O
, O
q O
8 O
h O
) O
. O

After O
a O
minimum O
of O
1 O
week O
of O
treatment O
, O
serum O
levetiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O
were O
measured O
before O
and O
2 O
, O
4 O
, O
and O
6 O
hours O
after O
drug O
administration O
, O
and O
maximum O
and O
minimum O
serum O
concentrations O
and O
elimination O
half O
- O
life O
were O
calculated O
. O

seizure O
frequencies O
before O
and O
after O
initiation O
of O
levetiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
were O
compared O
, O
and O
adverse O
effects O
were O
recorded O
. O

Results O
: O
median O
maximum O
serum O
levetiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentration O
was O
25 O
. O
5 O
microg O
/ O
mL O
, O
median O
minimum O
serum O
levetiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
concentration O
was O
8 O
. O
3 O
microg O
/ O
mL O
, O
and O
median O
elimination O
half O
- O
life O
was O
2 O
. O
9 O
hours O
. O

median O
seizure O
frequency O
prior O
to O
treatment O
with O
levetiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 O
. O
1 O
seizures O
/ O
Mo O
) O
was O
significantly O
higher O
than O
median O
seizure O
frequency O
after O
initiation O
of O
levetiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
( O
0 O
. O
42 O
seizures O
/ O
Mo O
) O
, O
and O
7 O
of O
10 O
cats O
were O
classified O
as O
having O
responded O
to O
levetiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
( O
ie O
, O
reduction O
in O
seizure O
frequency O
of O
> O
or O
= O
50 O
% O
) O
. O

Two B_PERSON/B_ENT
cats I_PERSON/I_ENT
had O
transient B_DISEASE
lethargy I_DISEASE
and O
inappetence B_DISEASE
. O

conclusions O
AND O
Clinical O
relevance O
: O
Results O
suggested O
that O
levetiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
well O
tolerated O
in O
cats O
and O
may O
be O
useful O
as O
an O
adjunct O
to O
phenobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
in O
cats O
with O
idiopathic O
epilepsy O
. O

Serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reuptake O
inhibitors O
, O
paranoia O
, O
and O
the O
ventral O
basal O
ganglia O
. O

antidepressants B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O
previously O
been O
associated O
with O
paranoid B_DISEASE
reactions I_DISEASE
in O
psychiatric B_PERSON/B_BIO
patients I_PERSON/I_BIO
. O

Five O
cases O
of O
paranoid O
exacerbation O
with O
the O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reuptake O
inhibitors O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
amitriptyline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
reported O
here O
. O

elements B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
common I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
to O
these O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O
a O
history B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
paranoid B_DISEASE
symptomatology I_DISEASE
and O
the O
concomitant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
occurrence I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
depressive B_DISEASE
and O
psychotic B_DISEASE
symptoms I_DISEASE
. O

complicated O
depressive O
disorders O
( O
including O
atypicality O
of O
course O
and O
symptomatology O
, O
chronicity O
, O
psychosis O
, O
bipolarity O
, O
and O
secondary O
onset O
in O
the O
course O
of O
a O
primary O
psychosis O
) O
may O
present O
particular O
vulnerability O
to O
paranoid O
exacerbations O
associated O
with O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reuptake O
inhibitors O
. O

Although O
the O
pharmacology O
and O
neurobiology O
of O
paranoia O
remain O
cryptic O
, O
several O
mechanisms O
, O
including O
5HT3 O
receptor O
- O
mediated O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
release O
, O
beta O
- O
noradrenergic O
receptor O
downregulation O
, O
or O
GABAB O
receptor O
upregulation O
acting O
in O
the O
vicinity O
of O
the O
ventral O
basal O
ganglia O
( O
possibly O
in O
lateral O
orbitofrontal O
or O
anterior O
cingulate O
circuits O
) O
, O
might O
apply O
to O
this O
phenomenon O
. O

These O
cases O
call O
attention O
to O
possible O
paranoid O
exacerbations O
with O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reuptake O
blockers O
in O
select O
patients O
and O
raise O
neurobiological O
considerations O
regarding O
paranoia O
. O

Clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
comparison I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
cardiorespiratory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
during O
unilateral B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
conventional B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
spinal B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
anaesthesia B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Spinal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anaesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
widely O
employed O
in O
clinical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
practice I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
but O
has O
the O
main B_DISEASE_ADJECTIVE[DISEASE]
drawback I_DISEASE_ADJECTIVE[DISEASE]
of O
post B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
spinal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
block I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
hypotension I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Efforts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
must O
therefore O
continue O
to O
be O
made O
to O
obviate O
this O
setback B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Objective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
To O
evaluate O
the O
cardiovascular B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
respiratory B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
changes B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
during O
unilateral B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
conventional B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
spinal I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
anaesthesia I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
With O
ethical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
approval I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
we O
studied O
74 B_ORGANIZATION/B_PERSON
American I_ORGANIZATION/I_PERSON
Society I_ORGANIZATION/I_PERSON
of O
Anesthesiologists B_PERSON/B_DISEASE
( O
ASA B_ORGANIZATION/B_LOCATION
) O
, O
physical B_MEASURE/B_PERSON
status I_MEASURE/I_PERSON
class I_MEASURE/I_PERSON
1 I_MEASURE/I_PERSON
and O
2 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
scheduled O
for O
elective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
unilateral I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lower I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
limb I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

patients B_PERSON
were O
randomly O
allocated O
into O
one B_NUMBER[MEASURE]/B_LOCATION
of O
two B_NUMBER[MEASURE]/B_PERSON
groups I_NUMBER[MEASURE]/I_PERSON
: O
lateral B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
conventional B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
spinal I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
anaesthesia I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
groups I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
. O

In O
the O
lateral O
position O
with O
operative O
side O
down O
, O
patients O
recived O
10 O
mg O
( O
2mls O
) O
of O
0 O
. O
5 O
% O
hyperbaric O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
a O
25 O
- O
gauge O
spinal O
needle O
. O

patients B_PERSON
in O
the O
unilateral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
were O
maintained O
in O
the O
lateral B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
position B_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
for O
15 B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
following O
spinal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
while O
those O
in O
the O
conventional B_LOCATION/B_ORGANIZATION
group I_LOCATION/I_ORGANIZATION
were O
turned O
supine B_LOCATION/B_PERSON
immediately O
after O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Blood O
pressure O
, O
heart O
rate O
, O
respiratory O
rate O
and O
oxygen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
saturation O
were O
monitored O
over O
1 O
hour O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Three B_TIME[MEASURE]
patients I_TIME[MEASURE]
( O
8 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
) O
in O
the O
unilateral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
5 B_NUMBER[MEASURE]/B_PERSON
( O
13 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
) O
in O
the O
conventional B_PERSON/B_ORGANIZATION
group I_PERSON/I_ORGANIZATION
developed O
hypotension B_DISEASE
, O
P B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
71 B_MEASURE
. O

Four O
( O
10 O
. O
8 O
% O
) O
patients O
in O
the O
conventional O
group O
and O
1 O
( O
2 O
. O
7 O
% O
) O
in O
the O
unilateral O
group O
, O
P O
= O
0 O
. O
17 O
required O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
to O
treat O
hypotension O
. O

patients B_PERSON
in O
the O
conventional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
had O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
greater I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
fall I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
systolic B_DISEASE/B_GENE
blood I_DISEASE/I_GENE
pressures I_DISEASE/I_GENE
at O
15 B_MEASURE
, O
30 B_MEASURE
and O
45 B_MEASURE/B_ENT
minutes I_MEASURE/I_ENT
when O
compared O
to O
the O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
003 B_MEASURE
, O
0 B_MEASURE/B_LOCATION
. O
001 B_MEASURE
and O
0 B_MEASURE
. O
004 B_MEASURE
) O
. O

The O
mean O
respiratory O
rate O
and O
oxygen B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
saturations O
in O
the O
two O
groups O
were O
similar O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Compared O
to O
conventional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
spinal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
anaesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
unilateral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
spinal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
anaesthesia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
associated O
with O
fewer B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiovascular I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
perturbations I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Also O
, O
the O
type O
of O
spinal O
block O
instituted O
affected O
neither O
the O
respiratory O
rate O
nor O
the O
arterial O
oxygen B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
saturation O
. O

spectrum B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
adverse B_DISEASE_ADJECTIVE[DISEASE]
events I_DISEASE_ADJECTIVE[DISEASE]
after O
generic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
HAART I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
in O
southern B_DISEASE
Indian I_DISEASE
HIV I_DISEASE
- O
infected O
patients B_PERSON/B_LOCATION
. O

To O
determine O
the O
incidence B_MEASURE
of O
clinically O
significant B_DISEASE_ADJECTIVE[DISEASE]
adverse I_DISEASE_ADJECTIVE[DISEASE]
events I_DISEASE_ADJECTIVE[DISEASE]
after O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
fixed O
- O
dose B_MEASURE/B_LOCATION
, O
generic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
highly O
active B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiretroviral I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
HAART B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
among O
HIV B_DISEASE
- O
infected O
individuals B_PERSON/B_LOCATION
in O
South B_LOCATION/B_MEASURE
India I_LOCATION/I_MEASURE
, O
we O
examined O
the O
experiences B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
3154 B_DISEASE
HIV I_DISEASE
- O
infected O
individuals B_PERSON
who O
received O
a O
minimum B_MEASURE
of O
3 B_TIME[MEASURE]
months I_TIME[MEASURE]
of O
generic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
HAART I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O
February B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1996 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
December B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2006 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
tertiary B_LOCATION
HIV I_LOCATION
care I_LOCATION
referral I_LOCATION
center I_LOCATION
in O
South B_LOCATION
India I_LOCATION
. O

The O
most O
common O
regimens O
were O
3TC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O
d4T B_PROTEIN[GENE]
+ O
nevirapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NVP B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
( O
54 O
. O
8 O
% O
) O
, O
zidovudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
AZT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
+ O
3TC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O
NVP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
14 O
. O
5 O
% O
) O
, O
3TC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O
d4T B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O
efavirenz B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
EFV B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
( O
20 O
. O
1 O
% O
) O
, O
and O
AZT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O
3TC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
+ O
EFV B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 O
. O
4 O
% O
) O
. O

The O
most O
common B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
adverse I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
events I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
median B_DISEASE
CD4 I_DISEASE
at O
time B_TIME[MEASURE]/B_LOCATION
of O
event B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
rash B_DISEASE
( O
15 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
; O
CD4 B_MEASURE
, O
285 B_MEASURE/B_BIO
cells I_MEASURE/I_BIO
/ O
microL B_MEASURE/B_LOCATION
) O
and O
peripheral B_DISEASE
neuropathy I_DISEASE
( O
9 B_MEASURE
. O
0 B_MEASURE
% I_MEASURE
and O
348 B_MEASURE
cells I_MEASURE
/ O
microL B_MEASURE/B_PERSON
) O
. O

Clinically O
significant O
anemia O
( O
hemoglobin O
< O
7 O
g O
/ O
DL O
) O
was O
observed O
in O
5 O
. O
4 O
% O
of O
patients O
( O
CD4 O
, O
165 O
cells O
/ O
microL O
) O
and O
hepatitis O
( O
clinical O
jaundice O
with O
alanine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminotransferase O
> O
5 O
times O
upper O
limits O
of O
normal O
) O
in O
3 O
. O
5 O
% O
of O
patients O
( O
CD4 O
, O
260 O
cells O
/ O
microL O
) O
. O

Women B_PERSON/B_BIO
were O
significantly O
more O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
experience O
lactic B_DISEASE
acidosis I_DISEASE
, O
while O
men B_PERSON
were O
significantly O
more O
likely B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
experience O
immune B_DISEASE
reconstitution I_DISEASE
syndrome I_DISEASE
( O
p B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

Among O
the O
patients O
with O
1 O
year O
of O
follow O
- O
up O
, O
NVP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therapy O
was O
significantly O
associated O
with O
developing O
rash O
and O
d4T B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O
with O
developing O
peripheral O
neuropathy O
( O
p O
< O
0 O
. O
05 O
) O
. O

anemia B_DISEASE
and O
hepatitis B_DISEASE
often O
occur O
within O
12 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
of O
initiating O
generic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
HAART I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

frequent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
early B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monitoring I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
these O
toxicities B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
warranted O
in O
developing O
countries B_LOCATION/B_ORGANIZATION
where O
generic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HAART I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
increasingly O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
sensory O
neurotoxicity O
: O
a O
neurophysiological O
study O
. O

Background O
: O
Recent O
studies O
confirmed O
a O
high O
incidence O
of O
sensory O
axonal O
neuropathy O
in O
patients O
treated O
with O
different O
doses O
of O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
study O
' O
s O
aims O
were O
to O
measure O
variations O
in O
sural O
nerve O
sensory O
action O
potential O
( O
SAP O
) O
amplitude O
in O
patients O
with O
refractory O
cutaneous O
lupus O
erythematosus O
( O
CLE O
) O
treated O
with O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
use O
these O
findings O
to O
identify O
the O
neurotoxic O
potential O
of O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
recovery O
capacity O
of O
sensory O
fibres O
after O
discontinuation O
of O
treatment O
. O

patients O
AND O
methods O
: O
Clinical O
and O
electrophysiological O
data O
in O
12 O
female O
patients O
with O
CLE O
during O
treatment O
with O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
up O
to O
47 O
months O
after O
discontinuation O
of O
treatment O
were O
analysed O
. O

Sural B_MEASURE/B_PERSON
nerve I_MEASURE/I_PERSON
SAP I_MEASURE/I_PERSON
amplitude I_MEASURE/I_PERSON
reduction I_MEASURE/I_PERSON
> I_MEASURE/I_PERSON
or O
= O
40 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
was O
the O
criteria B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
discontinuing O
therapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
During O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
11 B_MEASURE/B_PERSON
patients I_MEASURE/I_PERSON
showed O
a O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
sural B_DISEASE/B_GENE
nerve I_DISEASE/I_GENE
SAP I_DISEASE/I_GENE
amplitude I_DISEASE/I_GENE
compared O
to O
baseline B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
9 B_NUMBER[MEASURE]/B_PERSON
with O
a O
reduction B_MEASURE
> I_MEASURE
or O
= O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
and O
2 B_MEASURE
< I_MEASURE
50 I_MEASURE
% I_MEASURE
) O
. O

One B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patient B_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
no O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
SAP B_MEASURE/B_DISEASE
amplitude B_MEASURE/I_DISEASE
. O

Five B_PERSON
patients I_PERSON
complained O
of O
paresthesias B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
leg B_DISEASE
cramps I_DISEASE
. O

After O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
, O
sural O
SAP O
amplitude O
recovered O
in O
3 O
patients O
. O

At O
detection O
of O
reduction O
in O
sural O
nerve O
SAP O
amplitude O
, O
the O
median O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cumulative O
dose O
was O
21 O
. O
4 O
g O
. O

The O
threshold B_MEASURE/B_LOCATION
neurotoxic I_MEASURE/I_LOCATION
dosage I_MEASURE/I_LOCATION
is O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
previously O
reported O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Sural B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nerve B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
SAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
amplitude B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reduction B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
a O
reliable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
sensitive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
marker B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
degeneration B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
recovery B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
sensory B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
fibres I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

This O
electrophysiological O
parameter O
provides O
information O
about O
subclinical O
neurotoxic O
potential O
of O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
but O
is O
not O
helpful O
in O
predicting O
the O
appearance O
of O
sensory O
symptoms O
. O

Five O
cases O
of O
encephalitis O
during O
treatment O
of O
loiasis O
with O
diethylcarbamazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Five O
cases O
of O
encephalitis O
following O
treatment O
with O
diethylcarbamazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DEC B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
were O
observed O
in O
Congolese O
patients O
with O
Loa O
loa O
filariasis O
. O

Two B_NUMBER[MEASURE]/B_PERSON
cases I_NUMBER[MEASURE]/I_PERSON
had O
a O
fatal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
outcome B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
one B_NUMBER[MEASURE]/B_PERSON
resulted O
in O
severe B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sequelae I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
notable O
fact O
was O
that O
this O
complication O
occurred O
in O
three O
patients O
hospitalized O
before O
treatment O
began O
, O
with O
whom O
particularly O
strict O
therapeutic O
precautions O
were O
taken O
, O
i O
. O
e O
. O
, O
initial O
dose O
less O
than O
10 O
mg O
of O
DEC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
very O
gradual O
dose O
increases O
, O
and O
associated O
anti O
- O
allergic O
treatment O
. O

This O
type B_MEASURE/B_DISEASE
of O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
complication B_DISEASE
may O
not O
be O
that O
uncommon B_DISEASE_ADJECTIVE[DISEASE]
in O
highly O
endemic B_PERSON/B_NUMBER[MEASURE]
regions I_PERSON/I_NUMBER[MEASURE]
. O

It O
occurs O
primarily O
, O
but O
not O
exclusively O
, O
in O
subjects B_PERSON/B_BIO
presenting O
with O
a O
high B_DISEASE/B_PERSON
microfilarial I_DISEASE/I_PERSON
load I_DISEASE/I_PERSON
. O

The O
relationship B_PERSON/B_MEASURE
between O
the O
occurrence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
encephalitis B_DISEASE
and O
the O
decrease B_DISEASE_ADJECTIVE[DISEASE]
in O
microfilaremia B_DISEASE/B_GENE
is O
evident B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
pathophysiological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mechanisms I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
discussed O
in O
the O
light B_COLOR/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
observations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
the O
few B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
other I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
comments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
this O
subject B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
published O
in O
the O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
related O
pulmonary O
mass O
and O
unique O
membranous O
glomerulonephritis O
in O
a O
patient O
with O
valvular O
heart O
disease O
: O
diagnostic O
pitfall O
and O
new O
findings O
. O

Amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
an O
anti O
- O
arrhythmic O
drug O
for O
life O
- O
threatening O
tachycardia O
, O
but O
various O
adverse O
effects O
have O
been O
reported O
. O

reported O
herein O
is O
an O
autopsy O
case O
of O
valvular O
heart O
disease O
, O
in O
a O
patient O
who O
developed O
a O
lung O
mass O
( O
1 O
. O
5 O
cm O
in O
diameter O
) O
and O
proteinuria O
( O
2 O
. O
76 O
g O
/ O
day O
) O
after O
treatment O
with O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
a O
long O
time O
. O

The O
lung O
mass O
was O
highly O
suspected O
to O
be O
lung O
cancer O
on O
CT O
and O
positron O
emission O
tomography O
, O
but O
histologically O
the O
lesion O
was O
composed O
of O
lymphoplasmacytic O
infiltrates O
in O
alveolar O
walls O
and O
intra O
- O
alveolar O
accumulation O
of O
foamy O
macrophages O
containing O
characteristic O
myelinoid O
bodies O
, O
indicating O
that O
it O
was O
an O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
related O
lesion O
. O

In O
addition B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
the O
lung B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
tissue I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
had O
unevenly O
distributed O
hemosiderin B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
deposition B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
and O
abnormally O
tortuous B_DISEASE_ADJECTIVE[DISEASE]
capillaries I_DISEASE_ADJECTIVE[DISEASE]
were O
seen O
in O
the O
mass B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
in O
heavily O
hemosiderotic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
lung B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
portions B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
outside O
the O
mass B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

In O
the O
kidneys B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
glomeruli B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
had O
membrane B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
spikes I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
prominent B_DISEASE/B_LOCATION
swelling B_DISEASE/I_LOCATION
of O
podocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O
subepithelial B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
deposits B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
, O
which O
were O
sometimes O
large B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
and O
hump B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
like B_LOCATION/B_BIO
. O

autoimmune B_DISEASE/B_MEASURE
diseases I_DISEASE/I_MEASURE
, O
viral B_DISEASE/B_BIO
hepatitis I_DISEASE/I_BIO
, O
malignant B_DISEASE
neoplasms I_DISEASE
or O
other B_DISEASE
diseases I_DISEASE
with O
a O
known O
relationship B_PERSON/B_MEASURE
to O
membranous B_DISEASE
glomerulonephritis I_DISEASE
were O
not O
found O
. O

The O
present O
case O
highlights O
the O
possibility O
that O
differential O
diagnosis O
between O
an O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
related O
pulmonary O
lesion O
and O
a O
neoplasm O
can O
be O
very O
difficult O
radiologically O
, O
and O
suggests O
that O
membranous O
glomerulonephritis O
might O
be O
another O
possible O
complication O
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
. O

Risk O
of O
coronary O
artery O
disease O
associated O
with O
initial O
sulphonylurea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
of O
patients O
with O
type O
2 O
diabetes O
: O
a O
matched O
case O
- O
control O
study O
. O

aims O
: O
This O
study O
sought O
to O
assess O
the O
risk O
of O
developing O
coronary O
artery O
disease O
( O
CAD O
) O
associated O
with O
initial O
treatment O
of O
type O
2 O
diabetes O
with O
different O
sulphonylureas B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
In O
type B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diabetic I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cases B_PERSON
who O
developed O
CAD B_DISEASE
were O
compared O
retrospectively O
with O
controls B_PERSON/B_LOCATION
that O
did O
not O
. O

The O
20 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]/B_LOCATION
risk I_TIME[MEASURE]/I_LOCATION
of O
CAD B_DISEASE
at O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
diabetes B_DISEASE/B_LOCATION
, O
using O
the O
UKPDS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
risk B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
engine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
was O
used O
to O
match O
cases B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
controls B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
The O
76 B_PERSON/B_MEASURE
cases I_PERSON/I_MEASURE
of O
CAD B_DISEASE/B_LOCATION
were O
compared O
with O
152 B_MEASURE/B_PERSON
controls I_MEASURE/I_PERSON
. O

The O
hazard O
of O
developing O
CAD O
( O
95 O
% O
CI O
) O
associated O
with O
initial O
treatment O
increased O
by O
2 O
. O
4 O
- O
fold O
( O
1 O
. O
3 O
- O
4 O
. O
3 O
, O
P O
= O
0 O
. O
004 O
) O
with O
glibenclamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
2 O
- O
fold O
( O
0 O
. O
9 O
- O
4 O
. O
6 O
, O
P O
= O
0 O
. O
099 O
) O
with O
glipizide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
2 O
. O
9 O
- O
fold O
( O
1 O
. O
6 O
- O
5 O
. O
1 O
, O
P O
= O
0 O
. O
000 O
) O
with O
either O
, O
and O
was O
unchanged O
with O
metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
hazard O
decreased O
0 O
. O
3 O
- O
fold O
( O
0 O
. O
7 O
- O
1 O
. O
7 O
, O
P O
= O
0 O
. O
385 O
) O
with O
glimepiride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
0 O
. O
4 O
- O
fold O
( O
0 O
. O
7 O
- O
1 O
. O
3 O
, O
P O
= O
0 O
. O
192 O
) O
with O
gliclazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
0 O
. O
4 O
- O
fold O
( O
0 O
. O
7 O
- O
1 O
. O
1 O
, O
P O
= O
0 O
. O
09 O
) O
with O
either O
. O

conclusions O
: O
Initiating O
treatment O
of O
type O
2 O
diabetes O
with O
glibenclamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
glipizide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
associated O
with O
increased O
risk O
of O
CAD O
in O
comparison O
to O
gliclazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O
glimepiride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

If O
confirmed O
, O
this O
may O
be O
important O
because O
most O
Indian O
patients O
receive O
the O
cheaper O
older O
sulphonylureas B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
present O
guidelines O
do O
not O
distinguish O
between O
individual O
agents O
. O

reduced O
progression O
of O
adriamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nephropathy O
in O
spontaneously O
hypertensive O
rats O
treated O
by O
losartan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background O
: O
The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
antihypertensive O
effects O
of O
angiotensin B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
II B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
type O
- O
1 O
receptor O
blocker O
, O
losartan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
its O
potential O
in O
slowing O
down O
renal O
disease O
progression O
in O
spontaneously O
hypertensive O
rats O
( O
SHR O
) O
with O
adriamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
ADR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
nephropathy O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Six B_NUMBER[MEASURE]
- O
month B_TIME[MEASURE]
- O
old B_PERSON
female I_PERSON
SHR I_PERSON
were O
randomly O
selected O
in O
six B_TIME[MEASURE]/B_ENT
groups I_TIME[MEASURE]/I_ENT
. O

Two B_LOCATION/B_PERSON
control I_LOCATION/I_PERSON
groups I_LOCATION/I_PERSON
( O
SH B_LOCATION
( O
6 B_MEASURE
) O
, O
SH B_LOCATION
( O
12 B_MEASURE
) O
) O
received O
vehicle B_PRODUCT[OBJECT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Groups O
ADR B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
6 O
) O
, O
ADR B_LOCATION
+ O
LOS B_DISEASE/B_PERSON
( O
6 O
) O
and O
ADR B_LOCATION
( O
12 O
) O
, O
and O
ADR B_LOCATION
+ O
LOS B_PERSON/B_LOCATION
( O
12 O
) O
received O
ADR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 O
mg O
/ O
kg O
/ O
b O
. O
w O
. O
i O
. O
v O
. O
) O
twice O
in O
a O
3 O
- O
week O
interval O
. O

Group O
ADR B_LOCATION
+ O
LOS B_PERSON/B_LOCATION
( O
6 O
) O
received O
losartan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
10 O
mg O
/ O
kg O
/ O
b O
. O
w O
. O
/ O
day O
by O
gavages O
) O
for O
6 O
weeks O
and O
group O
ADR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
+ O
LOS B_PERSON/B_DISEASE
( O
12 O
) O
for O
12 O
weeks O
after O
second O
injection O
of O
ADR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Animals B_BIO/B_NUMBER[MEASURE]
were O
killed O
after O
6 B_NUMBER[MEASURE]
or O
12 B_NUMBER[MEASURE]/B_ENT
weeks I_NUMBER[MEASURE]/I_ENT
, O
respectively O
. O

haemodynamic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
measurements I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
performed O
on O
anaesthetized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
blood B_BODY_PART_OR_ORGAN_COMPONENT
and O
urine B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
taken O
for O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
kidney I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
processed O
for O
morphological B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
Short O
- O
term O
losartan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O
, O
besides O
antihypertensive O
effect O
, O
improved O
glomerular O
filtration O
rate O
and O
ameliorated O
glomerulosclerosis O
resulting O
in O
decreased O
proteinuria O
. O

prolonged O
treatment O
with O
losartan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
further O
reduction O
of O
glomerulosclerosis O
associated O
with O
reduced O
progression O
of O
tubular O
atrophy O
and O
interstitial O
fibrosis O
, O
thus O
preventing O
heavy O
proteinuria O
and O
chronic O
renal O
failure O
. O

Losartan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
reduced O
uraemia O
and O
increased O
urea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
clearance O
in O
advanced O
ADR B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nephropathy O
in O
SHR O
. O

Histological O
examination O
showed O
that O
losartan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
prevent O
tubular O
atrophy O
, O
interstitial O
infiltration O
and O
fibrosis O
in O
ADR B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nephropathy O
. O

conclusion O
: O
Losartan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduces O
the O
rate O
of O
progression O
of O
ADR B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
induced O
focal O
segmental O
glomerulosclerosis O
to O
end O
- O
stage O
renal O
disease O
in O
SHR O
. O

The O
risks O
of O
aprotinin O
and O
tranexamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
cardiac O
surgery O
: O
a O
one O
- O
year O
follow O
- O
up O
of O
1188 O
consecutive O
patients O
. O

Background O
: O
Our O
aim O
was O
to O
investigate O
postoperative O
complications O
and O
mortality O
after O
administration O
of O
aprotinin O
compared O
to O
tranexamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
an O
unselected O
, O
consecutive O
cohort O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Perioperative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
consecutive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
cardiac I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
patients I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
were O
prospectively O
collected O
between O
September B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2005 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
June B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2006 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
university B_LOCATION/B_ORGANIZATION
- O
affiliated O
clinic B_LOCATION/B_ORGANIZATION
( O
n B_MEASURE/B_LOCATION
= O
1188 B_MEASURE
) O
. O

During O
the O
first O
5 O
Mo O
, O
596 O
patients O
received O
aprotinin O
( O
Group O
A O
) O
; O
in O
the O
next O
5 O
Mo O
, O
592 O
patients O
were O
treated O
with O
tranexamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Group O
T O
) O
. O

Except O
for O
antifibrinolytic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
the O
anesthetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
surgical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
protocols I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
remained O
unchanged B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
The O
pre B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
intraoperative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
variables I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
were O
comparable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Postoperatively O
, O
a O
significantly O
higher B_MEASURE
incidence I_MEASURE
of O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
found O
in O
Group B_PERSON/B_BIO
T I_PERSON/I_BIO
( O
4 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
vs O
1 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
, O
P B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

This O
difference B_MEASURE
was O
also O
significant B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
primary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
valve B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
high B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
risk I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
subgroups I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
7 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
vs O
1 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
, O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
003 B_MEASURE
; O
7 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
vs O
2 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
035 B_MEASURE
, O
respectively O
) O
. O

Persistent B_DISEASE
atrial I_DISEASE
fibrillation I_DISEASE
( O
7 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
vs O
2 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
, O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
020 B_MEASURE
) O
and O
renal B_DISEASE
failure I_DISEASE
( O
9 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
vs O
1 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
002 B_MEASURE
) O
were O
also O
more O
common B_DISEASE_ADJECTIVE[DISEASE]
in O
Group B_MEASURE/B_PERSON
T I_MEASURE/I_PERSON
, O
in O
the O
primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
valve I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
surgery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
subgroup I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

On O
the O
contrary B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
among O
primary B_PERSON
coronary I_PERSON
artery I_PERSON
bypass I_PERSON
surgery I_PERSON
patients I_PERSON
, O
there O
were O
more O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
myocardial B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
infarctions B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
renal B_DISEASE
dysfunction I_DISEASE
in O
Group B_PERSON/B_LOCATION
A I_PERSON/I_LOCATION
( O
5 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
vs O
2 B_MEASURE
. O
0 B_MEASURE
% I_MEASURE
, O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
027 B_MEASURE
; O
22 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
vs O
15 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
, O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
036 B_MEASURE
, O
respectively O
) O
. O

The O
1 B_MEASURE
- O
yr B_MEASURE/B_LOCATION
mortality I_MEASURE/I_LOCATION
was O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
after O
aprotinin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
in O
the O
high B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
risk I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
surgery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
17 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
vs O
9 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
P B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
034 B_MEASURE
) O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Both O
antifibrinolytic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
drugs I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
bear O
the O
risk B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
adverse B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depending O
on O
the O
type B_DISEASE/B_MEASURE
of O
cardiac B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Administration O
of O
aprotinin O
should O
be O
avoided O
in O
coronary O
artery O
bypass O
graft O
and O
high O
risk O
patients O
, O
whereas O
administration O
of O
tranexamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
not O
recommended O
in O
valve O
surgery O
. O

Delirium O
in O
an O
elderly O
woman O
possibly O
associated O
with O
administration O
of O
misoprostol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Misoprostol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
associated O
with O
adverse O
reactions O
, O
including O
gastrointestinal O
symptoms O
, O
gynecologic O
problems O
, O
and O
headache O
. O

Changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
mental B_DISEASE_ADJECTIVE[DISEASE]
status I_DISEASE_ADJECTIVE[DISEASE]
, O
however O
, O
have O
not O
been O
reported O
. O

We O
present O
a O
case O
in O
which O
an O
89 O
- O
year O
- O
old O
woman O
in O
a O
long O
- O
term O
care O
facility O
became O
confused O
after O
the O
initiation O
of O
misoprostol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

The O
patient B_PERSON
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
change B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
mental B_DISEASE
status I_DISEASE
was O
first O
reported O
nine B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
after O
the O
initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Her O
delirium O
significantly O
improved O
after O
misoprostol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
discontinued O
and O
her O
mental O
status O
returned O
to O
normal O
within O
a O
week O
. O

Because O
no O
other O
factors O
related O
to O
this O
patient O
changed O
significantly O
, O
the O
delirium O
experienced O
by O
this O
patient O
possibly O
resulted O
from O
misoprostol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

The O
biological O
properties O
of O
the O
optical O
isomers O
of O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
their O
effects O
on O
cardiac O
arrhythmias O
. O

1 B_NUMBER[MEASURE]
. O

The O
optical O
isomers O
of O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
compared O
for O
their O
beta O
- O
blocking O
and O
antiarrhythmic O
activities O
. O
2 O
. O

In O
blocking O
the O
positive O
inotropic O
and O
chronotropic O
responses O
to O
isoprenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
( O
+ O
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
less O
than O
one O
hundredth O
the O
potency O
of O
( O
- O
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

At O
dose O
levels O
of O
( O
+ O
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
attenuated O
the O
responses O
to O
isoprenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
there O
was O
a O
significant O
prolongation O
of O
the O
PR O
interval O
of O
the O
electrocardiogram O
. O
3 O
. O

The O
metabolic O
responses O
to O
isoprenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
dogs O
( O
an O
increase O
in O
circulating O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
lactate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
free O
fatty B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
were O
all O
blocked O
by O
( O
- O
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

( O
+ O
) O
- O
Propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
no O
effect O
on O
fatty B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mobilization O
but O
significantly O
reduced O
the O
increments O
in O
both O
lactate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O
4 O
. O

Both O
isomers O
of O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
possessed O
similar O
depressant O
potency O
on O
isolated O
atrial O
muscle O
taken O
from O
Guinea O
- O
pigs O
. O
5 O
. O

The O
isomers O
of O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exhibited O
similar O
local O
anaesthetic O
potencies O
on O
an O
isolated O
frog O
nerve O
preparation O
at O
a O
level O
approximately O
three O
times O
that O
of O
procaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
racemic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compound I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
significantly O
less O
potent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O
either O
isomer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
. O
6 B_MEASURE/B_LOCATION
. O

Both O
isomers O
of O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
capable O
of O
preventing O
adrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cardiac O
arrhythmias O
in O
cats O
anaesthetized O
with O
halothane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
the O
mean O
dose O
of O
( O
- O
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
0 O
. O
09 O
+ O
/ O
- O
0 O
. O
02 O
mg O
/ O
kg O
whereas O
that O
of O
( O
+ O
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
4 O
. O
2 O
+ O
/ O
- O
1 O
. O
2 O
mg O
/ O
kg O
. O

At O
the O
effective O
dose O
level O
of O
( O
+ O
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
there O
was O
a O
significant O
prolongation O
of O
the O
PR O
interval O
of O
the O
electrocardiogram O
. O

blockade O
of O
arrhythmias O
with O
both O
isomers O
was O
surmountable O
by O
increasing O
the O
dose O
of O
adrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
7 O
. O

Both O
isomers O
of O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
also O
capable O
of O
reversing O
ventricular O
tachycardia O
caused O
by O
ouabain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
anaesthetized O
cats O
and O
dogs O
. O

The O
dose O
of O
( O
- O
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
significantly O
smaller O
than O
that O
of O
( O
+ O
) O
- O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
species O
but O
much O
higher O
than O
that O
required O
to O
produce O
evidence O
of O
beta O
- O
blockade O
. O
8 O
. O

The O
implications B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
these O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
discussed O
. O

Topotecan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
combination O
with O
radiotherapy O
in O
unresectable O
glioblastoma O
: O
a O
phase O
2 O
study O
. O

improving O
glioblastoma B_DISEASE
multiforme I_DISEASE
( O
GBM B_LOCATION/B_ORGANIZATION
) O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
radio B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
remains O
a O
challenge B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Topotecan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
an O
attractive O
option O
as O
it O
exhibits O
growth O
inhibition O
of O
human O
glioma O
as O
well O
as O
brain O
penetration O
. O

The O
present O
study O
assessed O
the O
combination O
of O
radiotherapy O
( O
60 O
Gy O
/ O
30 O
fractions O
/ O
40 O
days O
) O
and O
topotecan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
0 O
. O
9 O
mg O
/ O
m O
( O
2 O
) O
/ O
day O
on O
days O
1 O
- O
5 O
on O
weeks O
1 O
, O
3 O
and O
5 O
) O
in O
50 O
adults O
with O
histologically O
proven O
and O
untreated O
GBM O
. O

The O
incidence B_MEASURE
of O
non B_DISEASE
- O
hematological B_DISEASE
toxicities I_DISEASE
was O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
grade B_MEASURE/B_DISEASE
3 I_MEASURE/I_DISEASE
- O
4 B_MEASURE/B_DISEASE
hematological I_MEASURE/I_DISEASE
toxicities I_MEASURE/I_DISEASE
were O
reported O
in O
20 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
( O
mainly O
lymphopenia B_DISEASE
and O
neutropenia B_DISEASE
) O
. O

Partial B_DISEASE_ADJECTIVE[DISEASE]
response I_DISEASE_ADJECTIVE[DISEASE]
and O
stabilization B_DISEASE
rates I_DISEASE
were O
2 B_MEASURE
% I_MEASURE
and O
32 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
respectively O
, O
with O
an O
overall B_TIME[MEASURE]
time I_TIME[MEASURE]
to O
progression B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
12 B_TIME[MEASURE]
weeks I_TIME[MEASURE]
. O

One B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]/B_PERSON
overall I_TIME[MEASURE]/I_PERSON
survival I_TIME[MEASURE]/I_PERSON
( O
OS B_DISEASE
) O
rate B_MEASURE
was O
42 B_DISEASE_ADJECTIVE[DISEASE]
% I_DISEASE_ADJECTIVE[DISEASE]
, O
with O
a O
median B_MEASURE/B_LOCATION
OS I_MEASURE/I_LOCATION
of O
40 B_NUMBER[MEASURE]/B_ENT
weeks I_NUMBER[MEASURE]/I_ENT
. O

Topotecan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
combination O
with O
radiotherapy O
was O
well O
tolerated O
. O

However O
, O
while O
response B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
stabilization B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
concerned O
one B_NUMBER[MEASURE]
- O
third B_SEQUENCE[MEASURE]
of O
the O
patients B_PERSON
, O
the O
study B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
did O
not O
show O
increased O
benefits B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
terms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
survival B_DISEASE
in O
patients B_PERSON/B_BIO
with O
unresectable B_DISEASE/B_LOCATION
GBM I_DISEASE/I_LOCATION
. O

Long O
- O
term O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
leading O
to O
hyperparathyroidism O
: O
a O
case O
report O
. O

purpose O
: O
This O
paper O
reviews O
the O
effect O
of O
chronic O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O
on O
serum O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O
and O
parathyroid O
glands O
, O
its O
pathogenesis O
, O
and O
treatment O
options O
. O

We O
examined O
the O
case O
of O
a O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
patient O
who O
had O
recurrent O
hypercalcemia O
to O
better O
understand O
the O
disease O
process O
. O

conclusion O
: O
Primary O
hyperparathyroidism O
is O
a O
rare O
but O
potentially O
life O
- O
threatening O
side O
effect O
of O
long O
- O
term O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O
. O

Careful B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
patient B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
selection B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_TIME[MEASURE]
follow I_TIME[MEASURE]
- O
up B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
can O
reduce O
morbidity B_DISEASE/B_MEASURE
. O

practical O
implications O
: O
As O
much O
as O
15 O
% O
of O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
patients O
become O
hypercalcemic O
. O

By O
routinely O
monitoring O
serum O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
, O
healthcare O
providers O
can O
improve O
the O
quality O
of O
life O
of O
this O
patient O
group O
. O

Comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
laryngeal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mask I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
endotracheal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
tube I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
anesthesia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
in O
endoscopic B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sinus I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
surgery I_PERSON/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Background O
: O
The O
purpose O
of O
this O
study O
was O
to O
compare O
surgical O
conditions O
, O
including O
the O
amount O
of O
intraoperative O
bleeding O
as O
well O
as O
intraoperative O
blood O
pressure O
, O
during O
functional O
endoscopic O
sinus O
surgery O
( O
FESS O
) O
using O
flexible O
reinforced O
laryngeal O
mask O
airway O
( O
FRLMA O
) O
versus O
endotracheal O
tube O
( O
ETT O
) O
in O
maintaining O
controlled O
hypotension O
anesthesia O
induced O
by O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
remifentanil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
total O
i O
. O
v O
. O
anesthesia O
( O
TIVA O
) O
. O

methods O
: O
sixty O
normotensive O
American O
Society O
of O
Anesthesiologists O
I O
- O
II O
adult O
patients O
undergoing O
FESS O
under O
controlled O
hypotension O
anesthesia O
caused O
by O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
remifentanil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
TIVA O
were O
randomly O
assigned O
into O
two O
groups O
: O
group O
I O
, O
FRLMA O
; O
group O
II O
, O
ETT O
. O

hemorrhage B_DISEASE
was O
measured O
and O
the O
visibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
operative B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
field I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
evaluated O
according O
to O
a O
six B_NUMBER[MEASURE]
- O
point B_MEASURE/B_LOCATION
scale I_MEASURE/I_LOCATION
. O

Results O
: O
controlled O
hypotension O
was O
achieved O
within O
a O
shorter O
period O
using O
laryngeal O
mask O
using O
lower O
rates O
of O
remifentanil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
and O
lower O
total O
dose O
of O
remifentanil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusion O
: O
In O
summary O
, O
our O
results O
indicate O
that O
airway O
management O
using O
FRLMA O
during O
controlled O
hypotension O
anesthesia O
provided O
better O
surgical O
conditions O
in O
terms O
of O
quality O
of O
operative O
field O
and O
blood O
loss O
and O
allowed O
for O
convenient O
induced O
hypotension O
with O
low O
doses O
of O
remifentanil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
TIVA O
in O
patients O
undergoing O
FESS O
. O

Nonalcoholic O
fatty O
liver O
disease O
during O
valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O
. O

Valproic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
VPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
is O
effective O
for O
the O
treatment O
of O
many O
types O
of O
epilepsy O
, O
but O
its O
use O
can O
be O
associated O
with O
an O
increase O
in O
body O
weight O
. O

We O
report O
a O
case O
of O
nonalcoholic O
fatty O
liver O
disease O
( O
NAFLD O
) O
arising O
in O
a O
child O
who O
developed O
obesity O
during O
VPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
. O

Laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O
hyperinsulinemia B_DISEASE/B_PERSON
with O
insulin B_DISEASE
resistance I_DISEASE
. O

After O
the O
withdrawal O
of O
VPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
, O
our O
patient O
showed O
a O
significant O
weight O
loss O
, O
a O
decrease O
of O
body O
mass O
index O
, O
and O
normalization O
of O
metabolic O
and O
endocrine O
parameters O
; O
Moreover O
, O
ultrasound O
measurements O
showed O
a O
complete O
normalization O
. O

The O
present O
case O
suggests O
that O
obesity O
, O
hyperinsulinemia O
, O
insulin O
resistance O
, O
and O
long O
- O
term O
treatment O
with O
VPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
all O
associated O
with O
the O
development O
of O
NAFLD O
; O
this O
side O
effect O
is O
reversible O
after O
VPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
withdrawal O
. O

Carbimazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O
ANCA O
positive O
vasculitis O
. O

Anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thyroid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
like O
carbimazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
propylthiouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
are O
commonly O
prescribed O
for O
the O
treatment O
of O
hyperthyroidism O
. O

One O
should O
be O
aware O
of O
the O
side O
effects O
of O
antithyroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
medications I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Antineutrophil O
cytoplasmic O
antibody O
( O
ANCA O
) O
- O
- O
associated O
vasculitis O
is O
a O
potentially O
life O
- O
threatening O
adverse O
effect O
of O
antithyroidmedications B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

We O
report O
a O
patient O
with O
Graves O
' O
disease O
who O
developed O
ANCA O
positive O
carbimazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O
vasculitis O
. O

The O
episode B_DISEASE/B_ENT
was O
characterized O
by O
a O
vasculitic B_DISEASE
skin I_DISEASE
rash I_DISEASE
associated O
with O
large B_DISEASE
joint I_DISEASE
arthritis I_DISEASE
, O
pyrexia B_DISEASE
and O
parotiditis B_DISEASE
but O
no O
renal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
or O
pulmonary B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
involvement I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

He O
was O
referred O
to O
us O
for O
neurological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O
he O
had O
difficulty B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
getting O
up O
from O
squatting O
position B_LOCATION/B_MEASURE
and O
was O
suspected O
to O
have O
myositis B_DISEASE
. O

Carbimazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
methimazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
have O
a O
lower O
incidence O
of O
reported O
ANCA O
positive O
side O
effects O
than O
Put O
. O

To O
the O
best O
of O
our O
knowledge O
this O
is O
the O
first O
ANCA O
positive O
carbimazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O
vasculitis O
case O
reported O
from O
India O
. O

Aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
primary O
prevention O
of O
cardiovascular O
events O
: O
an O
update O
of O
the O
evidence O
for O
the O
U O
. O
S O
. O

preventive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
Services I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Task I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
Force I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
. O

Background B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Coronary B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
heart I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
cerebrovascular B_DISEASE
disease I_DISEASE
are O
leading O
causes B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
death B_DISEASE
in O
the O
United B_LOCATION/B_PERSON
States I_LOCATION/I_PERSON
. O

In O
2002 B_MEASURE
, O
the O
U B_OTHER/B_LOCATION
. O
S B_OTHER/B_LOCATION
. O

Preventive O
Services O
Task O
Force O
( O
USPSTF O
) O
strongly O
recommended O
that O
clinicians O
discuss O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
adults O
who O
are O
at O
increased O
risk O
for O
coronary O
heart O
disease O
. O

purpose O
: O
To O
determine O
the O
benefits O
and O
harms O
of O
taking O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
primary O
prevention O
of O
myocardial O
infarctions O
, O
strokes O
, O
and O
death O
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
sources I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
: O
MEDLINE B_ORGANIZATION/B_PERSON
and O
Cochrane B_ORGANIZATION/B_LOCATION
Library I_ORGANIZATION/I_LOCATION
( O
search B_MEASURE/B_LOCATION
dates B_MEASURE/I_LOCATION
, O
1 B_TIME[MEASURE]/B_PERSON
January I_TIME[MEASURE]/I_PERSON
2001 I_TIME[MEASURE]/I_PERSON
to O
28 B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
August I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2008 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
recent B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systematic I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reviews I_ORGANIZATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
reference B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
lists I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
of O
retrieved O
articles B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
suggestions B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O
experts B_PERSON/B_ORGANIZATION
. O

Study O
Selection O
: O
English O
- O
language O
randomized O
, O
controlled O
trials O
( O
RCTs O
) O
; O
case O
- O
control O
studies O
; O
meta O
- O
analyses O
; O
and O
systematic O
reviews O
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
versus O
control O
for O
the O
primary O
prevention O
of O
cardiovascular O
disease O
( O
CVD O
) O
were O
selected O
to O
answer O
the O
following O
questions O
: O
Does O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decrease O
coronary O
heart O
events O
, O
strokes O
, O
death O
from O
coronary O
heart O
events O
or O
stroke O
, O
or O
all O
- O
cause O
mortality O
in O
adults O
without O
known O
CVD O
. O

Does O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increase O
gastrointestinal O
bleeding O
or O
hemorrhagic O
strokes O
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extraction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
All O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
were O
reviewed O
, O
abstracted O
, O
and O
rated O
for O
quality B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
by O
using O
predefined O
USPSTF B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
criteria I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Data O
synthesis O
: O
New O
evidence O
from O
1 O
good O
- O
quality O
RCT O
, O
1 O
good O
- O
quality O
meta O
- O
analysis O
, O
and O
2 O
fair O
- O
quality O
subanalyses O
of O
RCTs O
demonstrates O
that O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
use O
reduces O
the O
number O
of O
CVD O
events O
in O
patients O
without O
known O
CVD O
. O

Men B_PERSON
in O
these O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
experienced O
fewer B_DISEASE/B_MEASURE
myocardial I_DISEASE/I_MEASURE
infarctions I_DISEASE/I_MEASURE
and O
women B_PERSON
experienced O
fewer B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ischemic I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
strokes I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
does O
not O
seem O
to O
affect O
CVD O
mortality O
or O
all O
- O
cause O
mortality O
in O
either O
men O
or O
women O
. O

The O
use O
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
primary O
prevention O
increases O
the O
risk O
for O
major O
bleeding O
events O
, O
primarily O
gastrointestinal O
bleeding O
events O
, O
in O
both O
men O
and O
women O
. O

Men O
have O
an O
increased O
risk O
for O
hemorrhagic O
strokes O
with O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
use O
. O

A O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
RCT I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
meta B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
the O
risk B_DISEASE
for O
hemorrhagic B_DISEASE
strokes I_DISEASE
in O
women B_PERSON/B_BIO
is O
not O
statistically O
significantly O
increased O
. O

limitations O
: O
New O
evidence O
on O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
the O
primary O
prevention O
of O
CVD O
is O
limited O
. O

The O
dose O
of O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
in O
the O
RCTs O
varied O
, O
which O
prevented O
the O
estimation O
of O
the O
most O
appropriate O
dose O
for O
primary O
prevention O
. O

Several B_NUMBER[MEASURE]
of O
the O
RCTs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
conducted O
within O
populations B_LOCATION/B_ORGANIZATION
of O
health B_PERSON/B_LOCATION
professionals I_PERSON/I_LOCATION
, O
which O
potentially O
limits O
generalizability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

conclusion O
: O
Aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reduces O
the O
risk O
for O
myocardial O
infarction O
in O
men O
and O
strokes O
in O
women O
. O

Aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
use O
increases O
the O
risk O
for O
serious O
bleeding O
events O
. O

reducing O
harm O
associated O
with O
anticoagulation O
: O
practical O
considerations O
of O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
in O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
thrombocytopenia O
. O

Argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
a O
hepatically O
metabolized O
, O
direct O
thrombin O
inhibitor O
used O
for O
prophylaxis O
or O
treatment O
of O
thrombosis O
in O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
thrombocytopenia O
( O
Hit O
) O
and O
for O
patients O
with O
or O
at O
risk O
of O
Hit O
undergoing O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O

The O
objective O
of O
this O
review O
is O
to O
summarize O
practical O
considerations O
of O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O
in O
Hit O
. O

The O
US O
FDA O
- O
recommended O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dose O
in O
Hit O
is O
2 O
microg O
/ O
kg O
/ O
min O
( O
reduced O
in O
patients O
with O
hepatic O
impairment O
and O
in O
paediatric O
patients O
) O
, O
adjusted O
to O
achieve O
activated O
partial O
thromboplastin O
times O
( O
aPTTs O
) O
1 O
. O
5 O
- O
3 O
times O
baseline O
( O
not O
> O
100 O
seconds O
) O
. O

contemporary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experiences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicate O
that O
reduced O
doses B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
also O
needed O
in O
patients B_PERSON/B_ORGANIZATION
with O
conditions B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
associated O
with O
hepatic B_DISEASE
hypoperfusion I_DISEASE
, O
e B_GENE/B_DISEASE
. O
g B_GENE/B_MEASURE
. O
heart B_DISEASE
failure I_DISEASE
, O
yet O
are O
unnecessary B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
renal B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
dysfunction B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
adult B_DISEASE
age I_DISEASE
, O
sex B_PERSON/B_DISEASE
, O
race B_SPORT[ENT]/B_PERSON
/ O
ethnicity B_PERSON/B_LOCATION
or O
obesity B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
0 O
. O
5 O
- O
1 O
. O
2 O
microg O
/ O
kg O
/ O
min O
typically O
supports O
therapeutic O
aPTTs O
. O

The O
FDA B_ORGANIZATION/B_TIME[MEASURE]
- O
recommended O
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
during O
PCI B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
25 B_MEASURE
microg I_MEASURE
/ O
kg B_MEASURE
/ O
min B_PERSON/B_TIME[MEASURE]
( O
350 B_MEASURE
microg I_MEASURE
/ O
kg B_MEASURE
initial I_MEASURE
bolus I_MEASURE
) O
, O
adjusted O
to O
achieve O
activated O
clotting B_TIME[MEASURE]/B_LOCATION
times B_TIME[MEASURE]/I_LOCATION
( O
acts B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
of O
300 B_MEASURE
- O
450 B_MEASURE
SEC I_MEASURE
. O

For O
PCI O
, O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
has O
not O
been O
investigated O
in O
hepatically O
impaired O
patients O
; O
dose O
adjustment O
is O
unnecessary O
for O
adult O
age O
, O
sex O
, O
race O
/ O
ethnicity O
or O
obesity O
, O
and O
lesser O
doses O
may O
be O
adequate O
with O
concurrent O
glycoprotein O
IIb O
/ O
IIIa O
inhibition O
. O

Argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
prolongs O
the O
International O
Normalized O
ratio O
, O
and O
published O
approaches O
for O
monitoring O
the O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- O
to O
- O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transition O
should O
be O
followed O
. O

Major O
bleeding O
with O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
0 O
- O
10 O
% O
in O
the O
non O
- O
interventional O
setting O
and O
0 O
- O
5 O
. O
8 O
% O
periprocedurally O
. O

Argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
has O
no O
specific O
antidote O
, O
and O
if O
excessive O
anticoagulation O
occurs O
, O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
infusion O
should O
be O
stopped O
or O
reduced O
. O

improved O
familiarity O
of O
healthcare O
professionals O
with O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
in O
Hit O
, O
including O
in O
special O
populations O
and O
during O
PCI O
, O
may O
facilitate O
reduction O
of O
harm O
associated O
with O
Hit O
( O
e O
. O
g O
. O
fewer O
thromboses O
) O
or O
its O
treatment O
( O
e O
. O
g O
. O
fewer O
argatroban B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
medication O
errors O
) O
. O

Rhabdomyolysis O
and O
brain O
ischemic O
stroke O
in O
a O
heroin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
dependent O
male O
under O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maintenance O
therapy O
. O

Objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
There O
are O
several B_DISEASE_ADJECTIVE[DISEASE]
complications I_DISEASE_ADJECTIVE[DISEASE]
associated O
with O
heroin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
abuse I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
some O
of O
which O
are O
life B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
threatening O
. O

Methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
may O
aggravate O
this O
problem O
. O

Method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
A O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
case I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
description I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
A O
33 O
- O
year O
- O
old O
man O
presented O
with O
rhabdomyolysis O
and O
cerebral O
ischemic O
stroke O
after O
intravenous O
heroin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

He O
had O
used O
heroin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
since O
age O
20 O
, O
and O
had O
used O
150 O
mg O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O
for O
6 O
months O
. O

He O
was O
found O
unconsciousness B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
at O
home B_LOCATION/B_TIME[MEASURE]
and O
was O
sent O
to O
our O
hospital B_LOCATION
. O

In O
the O
ER B_LOCATION
, O
his O
opiate B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
was O
4497 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
ml B_MEASURE/B_PERSON
. O

In O
the O
ICU B_PERSON/B_LOCATION
, O
we O
found O
rhabdomyolysis B_DISEASE
, O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
and O
acute B_DISEASE
respiratory I_DISEASE
failure I_DISEASE
. O

After O
transfer B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
an O
internal B_LOCATION
ward I_LOCATION
, O
we O
noted O
aphasia B_DISEASE
and O
weakness B_DISEASE
of O
his O
left B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
limbs I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

After O
MRI B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
we O
found O
cerebral B_DISEASE_ADJECTIVE[DISEASE]
ischemic I_DISEASE_ADJECTIVE[DISEASE]
infarction I_DISEASE_ADJECTIVE[DISEASE]
. O

conclusion O
: O
Those O
using O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
heroin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
simultaneously O
may O
increase O
risk O
of O
rhabdomyolysis O
and O
ischemic O
stroke O
. O

patients O
under O
methadone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
maintenance O
therapy O
should O
be O
warned O
regarding O
these O
serious O
adverse O
events O
. O

Hypotheses O
of O
heroin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
related O
rhabdomyolysis O
and O
stroke O
in O
heroin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abusers O
are O
discussed O
. O

increased O
vulnerability O
to O
6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
hydroxydopamine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
lesion O
and O
reduced O
development O
of O
dyskinesias O
in O
mice O
lacking O
CB1 O
cannabinoid O
receptors O
. O

Motor O
impairment O
, O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
DA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
neuronal O
activity O
and O
proenkephalin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
PENK B_LOCATION/B_PERSON
) O
gene O
expression O
in O
the O
caudate O
- O
putamen O
( O
CPU O
) O
were O
measured O
in O
6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
OHDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
lesioned O
and O
treated O
( O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
DOPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
+ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
benserazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
CB1 O
Ko O
and O
WT O
mice O
. O

A O
lesion O
induced O
by O
6 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
OHDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
produced O
more O
severe O
motor O
deterioration O
in O
CB1 O
Ko O
mice O
accompanied O
by O
more O
loss O
of O
DA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
neurons O
and O
increased O
PENK B_GENE
gene O
expression O
in O
the O
CPU O
. O

Oxidative B_DISEASE_ADJECTIVE[DISEASE]
/ O
nitrosative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O
neuroinflammatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
parameters I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
estimated O
in O
the O
CPu B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cingulate B_PERSON/B_LOCATION
cortex I_PERSON/I_LOCATION
( O
cG B_DISEASE/B_LOCATION
) O
. O

CB1 O
Ko O
mice O
exhibited O
higher O
MDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
levels O
and O
iNOS O
protein O
expression O
in O
the O
CPU O
and O
Cg O
compared O
to O
WT O
mice O
. O

Treatment O
with O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
DOPA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
+ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
benserazide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
12 O
weeks O
) O
resulted O
in O
less O
severe O
dyskinesias O
in O
CB1 O
Ko O
than O
in O
WT O
mice O
. O

The O
results O
revealed O
that O
the O
lack O
of O
cannabinoid O
CB1 O
receptors O
increased O
the O
severity O
of O
motor O
impairment O
and O
DA B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lesion O
, O
and O
reduced O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DOPA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
dyskinesias O
. O

These O
results O
suggest O
that O
activation O
of O
CB1 O
receptors O
offers O
neuroprotection O
against O
dopaminergic O
lesion O
and O
the O
development O
of O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DOPA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
dyskinesias O
. O

hepatocellular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
oxidant I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
stress I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
following O
intestinal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ischemia I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
reperfusion B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

reperfusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
ischemic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intestine B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
results B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
acute B_DISEASE
liver I_DISEASE
dysfunction I_DISEASE
characterized O
by O
hepatocellular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
enzyme I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
release I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
into O
plasma B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
, O
reduction B_DISEASE_ADJECTIVE[DISEASE]
in O
bile B_MEASURE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
flow B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rate B_MEASURE/I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
neutrophil B_DISEASE
sequestration I_DISEASE
within O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

The O
pathophysiology B_DISEASE
underlying O
this O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hepatic B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injury B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
unknown B_DISEASE_ADJECTIVE[DISEASE]
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
undertaken O
to O
determine O
whether O
oxidants B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
are O
associated O
with O
the O
hepatic B_DISEASE_ADJECTIVE[DISEASE]
injury I_DISEASE_ADJECTIVE[DISEASE]
and O
to O
determine O
the O
relative B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
value B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
several B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
indirect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
methods I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
assessing O
oxidant B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vivo B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

rats B_BIO/B_PERSON
were O
subjected O
to O
a O
standardized B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
intestinal I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
ischemia I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O
reperfusion B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
injury B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Hepatic O
tissue O
was O
assayed O
for O
lipid O
peroxidation O
products O
and O
oxidized B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
reduced I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
glutathione I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

There O
was O
no O
change O
in O
hepatic O
tissue O
total O
glutathione B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
following O
intestinal O
ischemia O
- O
reperfusion O
injury O
. O

Oxidized B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glutathione I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
GSSG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
increased O
significantly O
following O
30 O
and O
60 O
min O
of O
reperfusion O
. O

There O
was O
no O
increase B_DISEASE_ADJECTIVE[DISEASE]
in O
any O
of O
the O
products B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
lipid B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
peroxidation B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O
with O
this O
injury B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

An O
increase O
in O
GSSG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
within O
hepatic O
tissue O
during O
intestinal O
reperfusion O
suggests O
exposure O
of O
hepatocytes O
to O
an O
oxidant O
stress O
. O

The O
lack B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]
increase I_DISEASE_ADJECTIVE[DISEASE]
in O
products B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
lipid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peroxidation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
suggests O
that O
the O
oxidant B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stress B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
of O
insufficient B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
magnitude I_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
result O
in O
irreversible B_DISEASE
injury I_DISEASE
to O
hepatocyte B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
membranes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
data O
also O
suggest O
that O
the O
measurement O
of O
tissue O
GSSG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
may O
be O
a O
more O
sensitive O
indicator O
of O
oxidant O
stress O
than O
measurement O
of O
products O
of O
lipid O
peroxidation O
. O

Animal O
model O
of O
mania O
induced O
by O
ouabain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Evidence O
of O
oxidative O
stress O
in O
submitochondrial O
particles O
of O
the O
rat O
brain O
. O

The O
intracerebroventricular O
( O
ICV O
) O
administration O
of O
ouabain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
a O
Na B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
+ O
) O
/ O
K B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
+ O
) O
- O
ATPase O
inhibitor O
) O
in O
rats O
has O
been O
suggested O
to O
mimic O
some O
symptoms O
of O
human O
bipolar O
mania O
. O

Clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
shown O
that O
bipolar B_DISEASE/B_GENE
disorder I_DISEASE/I_GENE
may O
be O
related O
to O
mitochondrial B_DISEASE
dysfunction I_DISEASE
. O

Herein O
, O
we O
investigated O
the O
behavioral O
and O
biochemical O
effects O
induced O
by O
the O
ICV O
administration O
of O
ouabain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
rats O
. O

To O
achieve O
this O
aim O
, O
the O
effects O
of O
ouabain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O
immediately O
after O
and O
7 O
days O
following O
a O
single O
ICV O
administration O
( O
at O
concentrations O
of O
10 O
( O
- O
2 O
) O
and O
10 O
( O
- O
3 O
) O
M O
) O
on O
locomotion O
was O
measured O
using O
the O
open O
- O
field O
test O
. O

Additionally O
, O
thiobarbituric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reactive O
substances O
( O
TBARSs O
) O
and O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O
were O
measured O
in O
submitochondrial O
particles O
of O
the O
prefrontal O
cortex O
, O
hippocampus O
, O
striatum O
and O
amygdala O
. O

Our O
findings O
demonstrated O
that O
ouabain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
10 O
( O
- O
2 O
) O
and O
10 O
( O
- O
3 O
) O
M O
induced O
hyperlocomotion O
in O
rats O
, O
and O
this O
response O
remained O
up O
to O
7 O
days O
following O
a O
single O
ICV O
injection O
. O

In O
addition O
, O
we O
observed O
that O
the O
persistent O
increase O
in O
the O
rat O
spontaneous O
locomotion O
is O
associated O
with O
increased O
TBARS O
levels O
and O
superoxide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
generation O
in O
submitochondrial O
particles O
in O
the O
prefrontal O
cortex O
, O
striatum O
and O
amygdala O
. O

In O
conclusion O
, O
ouabain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
mania O
- O
like O
behavior O
may O
provide O
a O
useful O
animal O
model O
to O
test O
the O
hypothesis O
of O
the O
involvement O
of O
oxidative O
stress O
in O
bipolar O
disorder O
. O

Intraoperative O
dialysis O
during O
liver O
transplantation O
with O
citrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dialysate O
. O

Liver B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
acutely O
ill B_PERSON/B_DISEASE
patients I_PERSON/I_DISEASE
with O
fulminant B_DISEASE
liver I_DISEASE
failure I_DISEASE
carries O
high B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
intraoperative B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
immediate B_DISEASE_ADJECTIVE[DISEASE]
postoperative I_DISEASE_ADJECTIVE[DISEASE]
risks I_DISEASE_ADJECTIVE[DISEASE]
. O

These O
are O
increased O
with O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
concomitant B_DISEASE
acute I_DISEASE
kidney I_DISEASE
injury I_DISEASE
( O
AKI B_DISEASE
) O
and O
intraoperative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dialysis I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
is O
sometimes O
required O
to O
allow O
the O
transplant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
proceed O
. O

The O
derangements B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
procoagulant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
anticoagulant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pathways I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
during O
fulminant B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
liver B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
can O
lead O
to O
difficulties B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O
anticoagulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
during O
dialysis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
especially O
when O
continued O
in O
the O
operating B_PERSON/B_TIME[MEASURE]
room B_PERSON/I_TIME[MEASURE]
. O

systemic O
anticoagulation O
is O
unsafe O
and O
regional O
citrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
anticoagulation O
in O
the O
absence O
of O
a O
functional O
liver O
carries O
the O
risk O
of O
citrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
toxicity O
. O

Citrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dialysate O
, O
a O
new O
dialysate O
with O
citric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
can O
be O
used O
for O
anticoagulation O
in O
patients O
who O
cannot O
tolerate O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
or O
regional O
citrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
report O
a O
case O
of O
a O
40 O
- O
year O
- O
old O
female O
with O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
fulminant O
liver O
failure O
with O
associated O
AKI O
who O
underwent O
intraoperative O
dialytic O
support O
during O
liver O
transplantation O
anticoagulated O
with O
citrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dialysate O
during O
the O
entire O
procedure O
. O

The O
patient O
tolerated O
the O
procedure O
well O
without O
any O
signs O
of O
citrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
toxicity O
and O
maintained O
adequate O
anticoagulation O
for O
patency O
of O
the O
dialysis O
circuit O
. O

Citrate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dialysate O
is O
a O
safe O
alternative O
for O
intradialytic O
support O
of O
liver O
transplantation O
in O
fulminant O
liver O
failure O
. O

Delirium O
in O
a O
patient O
with O
toxic O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plasma O
concentrations O
: O
the O
role O
of O
a O
pharmacokinetic O
drug O
interaction O
with O
paroxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

objective O
: O
To O
describe O
a O
case O
of O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
delirium O
associated O
with O
a O
pharmacokinetic O
drug O
interaction O
with O
paroxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Case B_TIME[MEASURE]/B_PERSON
summary I_TIME[MEASURE]/I_PERSON
: O
A O
69 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
- O
old B_PERSON
white I_PERSON
female I_PERSON
presented O
to O
the O
emergency B_PERSON/B_LOCATION
department I_PERSON/I_LOCATION
with O
a O
history B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
confusion B_DISEASE
and O
paranoia B_DISEASE
over O
the O
past B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
several I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
days I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

On O
admission O
the O
patient O
was O
taking O
carvedilol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
12 O
mg O
twice O
daily O
, O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O
mg O
/ O
day O
, O
folic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
mg O
/ O
day O
, O
levothyroxine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100 O
microg O
/ O
day O
, O
pantoprazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
40 O
mg O
/ O
day O
, O
paroxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
40 O
mg O
/ O
day O
, O
and O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100 O
mg O
twice O
daily O
. O

Flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
had O
been O
started O
2 O
weeks O
prior O
for O
atrial O
fibrillation O
. O

Laboratory O
test O
findings O
on O
admission O
were O
notable O
only O
for O
a O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
plasma O
concentration O
of O
1360 O
microg O
/ O
L O
( O
reference O
range O
200 O
- O
1000 O
) O
. O

A O
metabolic O
drug O
interaction O
between O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
paroxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
the O
patient O
had O
been O
taking O
for O
more O
than O
5 O
years O
, O
was O
considered O
. O

Paroxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
discontinued O
and O
the O
dose O
of O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
reduced O
to O
50 O
mg O
twice O
daily O
. O

Her O
delirium B_DISEASE
resolved O
3 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
later O
. O

discussion O
: O
Flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pharmacologically O
similar O
agents O
that O
interact O
with O
sodium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
channels O
may O
cause O
delirium O
in O
susceptible O
patients O
. O

A O
MEDLINE O
search O
( O
1966 O
- O
January O
2009 O
) O
revealed O
one O
in O
vivo O
pharmacokinetic O
study O
on O
the O
interaction O
between O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
CYP2D6 O
substrate O
, O
and O
paroxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
CYP2D6 O
inhibitor O
, O
as O
well O
as O
3 O
case O
reports O
of O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
delirium O
. O

According O
to O
the O
Naranjo O
probability O
scale O
, O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
the O
probable O
cause O
of O
the O
patient O
' O
s O
delirium O
; O
the O
Horn O
Drug O
interaction O
probability O
Scale O
indicates O
a O
possible O
pharmacokinetic O
drug O
interaction O
between O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
paroxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusions O
: O
Supratherapeutic O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plasma O
concentrations O
may O
cause O
delirium O
. O

Because O
toxicity O
may O
occur O
when O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
prescribed O
with O
paroxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
other O
potent O
CYP2D6 O
inhibitors O
, O
flecainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
plasma O
concentrations O
should O
be O
monitored O
closely O
with O
commencement O
of O
CYP2D6 O
inhibitors O
. O

efficacy O
of O
everolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
RAD001 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
in O
patients O
with O
advanced O
NSCLC O
previously O
treated O
with O
chemotherapy O
alone O
or O
with O
chemotherapy O
and O
EGFR O
inhibitors O
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
options I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
are O
scarce B_DISEASE_ADJECTIVE[DISEASE]
in O
pretreated B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
advanced O
non B_DISEASE/B_GENE
- O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
cell B_DISEASE
lung I_DISEASE
cancer I_DISEASE
( O
NSCLC B_DISEASE
) O
patients B_PERSON
. O

RAD001 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
an O
oral O
inhibitor O
of O
the O
mammalian O
target O
of O
rapamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
mTOR O
) O
, O
has O
shown O
phase O
I O
efficacy O
in O
NSCLC O
. O

methods O
: O
Stage O
IIIb O
or O
IV O
NSCLC O
patients O
, O
with O
two O
or O
fewer O
prior O
chemotherapy O
regimens O
, O
one O
platinum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O
( O
stratum O
1 O
) O
or O
both O
chemotherapy O
and O
epidermal O
growth O
factor O
receptor O
tyrosine B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase O
inhibitors O
( O
stratum O
2 O
) O
, O
received O
RAD001 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O
mg O
/ O
day O
until O
progression O
or O
unacceptable O
toxicity O
. O

Primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
objective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
overall B_DISEASE
response I_DISEASE
rate I_DISEASE
( O
ORR B_DISEASE/B_LOCATION
) O
. O

Analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
markers B_GENE/B_DISEASE
associated O
with O
the O
mTOR B_DISEASE/B_GENE
pathway I_DISEASE/I_GENE
were O
carried O
out O
on O
archival B_DISEASE/B_PERSON
tumor I_DISEASE/I_PERSON
from O
a O
subgroup B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
immunohistochemistry B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
IHC B_LOCATION/B_ORGANIZATION
) O
and O
direct B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
mutation I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
sequencing O
. O

Results B_MEASURE
: O
eighty B_NUMBER[MEASURE]
- O
five B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
were O
enrolled O
, O
42 B_MEASURE
in O
stratum B_PERSON/B_LOCATION
1 B_PERSON/I_LOCATION
and O
43 B_MEASURE
in O
stratum B_LOCATION/B_PERSON
. O

ORR B_DISEASE/B_PERSON
was O
4 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
7 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
stratum I_MEASURE
1 I_MEASURE
; O
2 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
stratum I_MEASURE
2 I_MEASURE
) O
. O

Overall B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
disease I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
control I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
rate I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
was O
47 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
. O

median B_TIME[MEASURE]/B_PERSON
progression I_TIME[MEASURE]/I_PERSON
- O
free B_TIME[MEASURE]/B_ORGANIZATION
survivals I_TIME[MEASURE]/I_ORGANIZATION
( O
PFSs B_DISEASE
) O
were O
2 B_MEASURE
. O
6 B_MEASURE
( O
stratum B_TIME[MEASURE]/B_PERSON
1 I_TIME[MEASURE]/I_PERSON
) O
and O
2 B_MEASURE
. O
7 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
stratum B_PERSON
2 I_PERSON
) O
. O

Common B_MEASURE/B_PERSON
> B_MEASURE/I_PERSON
or O
= O
grade B_MEASURE/B_DISEASE
3 B_MEASURE/I_DISEASE
events B_MEASURE/I_DISEASE
were O
fatigue B_DISEASE
, O
dyspnea B_DISEASE
, O
stomatitis B_DISEASE
, O
anemia B_DISEASE
, O
and O
thrombocytopenia B_DISEASE
. O

pneumonitis B_DISEASE
, O
probably O
or O
possibly O
related B_DISEASE_ADJECTIVE[DISEASE]
, O
mainly O
grade B_PROTEIN[GENE]/B_DISEASE
1 I_PROTEIN[GENE]/I_DISEASE
/ O
2 B_NUMBER[MEASURE]
, O
occurred O
in O
25 B_LOCATION
% I_LOCATION
. O

Cox B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
IHC B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
scores I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
found O
that O
only O
phospho B_GENE
AKT I_GENE
( O
pAKT B_PROTEIN[GENE]/B_LOCATION
) O
was O
a O
significant B_MEASURE
independent I_MEASURE
predictor I_MEASURE
of O
worse B_DISEASE
PFS I_DISEASE
. O

conclusions O
: O
RAD001 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
10 O
mg O
/ O
day O
was O
well O
tolerated O
, O
showing O
modest O
clinical O
activity O
in O
pretreated O
NSCLC O
. O

Evaluation O
of O
RAD001 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O
standard O
therapy O
for O
metastatic O
NSCLC O
continues O
. O

Posttransplant O
anemia O
: O
the O
role O
of O
sirolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

posttransplant B_DISEASE
anemia I_DISEASE
is O
a O
common B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problem B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
may O
hinder O
patients B_TIME[MEASURE]/B_LOCATION
' I_TIME[MEASURE]/I_LOCATION
quality I_TIME[MEASURE]/I_LOCATION
of O
life B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
occurs O
in O
12 B_MEASURE
to O
76 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
of O
patients B_PERSON/B_DISEASE
, O
and O
is O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
immediate B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
posttransplant I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
period I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

A O
variety B_ENT/B_MEASURE
of O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
identified O
that O
increase O
the O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
posttransplant B_DISEASE
anemia I_DISEASE
, O
of O
which O
the O
level B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
renal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
function I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
is O
most O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Sirolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
mammalian O
target O
of O
rapamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibitor O
, O
has O
been O
implicated O
as O
playing O
a O
special O
role O
in O
posttransplant O
anemia O
. O

This O
review O
considers O
anemia O
associated O
with O
sirolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
including O
its O
presentation O
, O
mechanisms O
, O
and O
management O
. O

Coronary O
computerized O
tomography O
angiography O
for O
rapid O
discharge O
of O
low O
- O
risk O
patients O
with O
cocaine B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
associated O
chest O
pain O
. O

Background O
: O
Most O
patients O
presenting O
to O
emergency O
departments O
( O
eds O
) O
with O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
chest O
pain O
are O
admitted O
for O
at O
least O
12 O
hours O
and O
receive O
a O
' O
rule O
out O
acute O
coronary O
syndrome O
' O
protocol O
, O
often O
with O
noninvasive O
testing O
prior O
to O
discharge O
. O

In O
patients O
without O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
, O
coronary O
computerized O
tomography O
angiography O
( O
CTA O
) O
has O
been O
shown O
to O
be O
useful O
for O
identifying O
a O
group O
of O
patients O
at O
low O
risk O
for O
cardiac O
events O
who O
can O
be O
safely O
discharged O
. O

It O
is O
unclear O
whether O
a O
coronary O
CTA O
strategy O
would O
be O
efficacious O
in O
cocaine B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
associated O
chest O
pain O
, O
as O
coronary O
vasospasm O
may O
account O
for O
some O
of O
the O
ischemia O
. O

We O
studied O
whether O
a O
negative O
coronary O
CTA O
in O
patients O
with O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
chest O
pain O
could O
identify O
a O
subset O
safe O
for O
discharge O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
prospectively O
evaluated O
the O
safety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
coronary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
risk B_MEASURE/B_PERSON
patients I_MEASURE/I_PERSON
who O
presented O
to O
the O
Ed B_PERSON/B_LOCATION
with O
cocaineassociated B_DISEASE
chest I_DISEASE
pain I_DISEASE
( O
self B_PERSON/B_LOCATION
- O
reported O
or O
positive B_DISEASE_ADJECTIVE[DISEASE]
urine I_DISEASE_ADJECTIVE[DISEASE]
test I_DISEASE_ADJECTIVE[DISEASE]
) O
. O

consecutive B_PERSON
patients I_PERSON
received O
either O
immediate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
coronary I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
CTA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
the O
ED B_DISEASE/B_TIME[MEASURE]
( O
without O
serial B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
markers B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
or O
underwent O
coronary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O
a O
brief B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
with O
serial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cardiac I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
marker I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
measurements I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

patients B_PERSON/B_BIO
with O
negative B_DISEASE
coronary I_DISEASE
CTA I_DISEASE
( O
maximal B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
stenosis I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
less I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
50 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
) O
were O
discharged O
. O

The O
main B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
outcome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
30 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]/B_LOCATION
cardiovascular I_TIME[MEASURE]/I_LOCATION
death I_TIME[MEASURE]/I_LOCATION
or O
myocardial B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Results O
: O
A O
total O
of O
59 O
patients O
with O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
chest O
pain O
were O
evaluated O
. O

patients B_PERSON
had O
a O
mean B_MEASURE/B_DISEASE
age I_MEASURE/I_DISEASE
of O
45 B_MEASURE
. O
6 B_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
. O
6 B_TIME[MEASURE]
yrs I_TIME[MEASURE]
and O
were O
86 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
black I_MEASURE/I_PERSON
, O
66 B_PERSON/B_LOCATION
% B_PERSON/I_LOCATION
male B_PERSON/I_LOCATION
. O

seventy B_NUMBER[MEASURE]
- O
nine B_NUMBER[MEASURE]
percent I_NUMBER[MEASURE]
had O
a O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
nonspecific B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ECG I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
85 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
had O
a O
TIMI B_MEASURE/B_LOCATION
score I_MEASURE/I_LOCATION
< O
2 B_MEASURE
. O

Twenty B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
received O
coronary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
immediately O
in O
the O
Ed B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
18 B_NUMBER[MEASURE]
of O
whom O
were O
discharged O
following O
CTA B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
( O
90 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
) O
. O

Thirty B_NUMBER[MEASURE]
- O
nine B_NUMBER[MEASURE]
received O
coronary B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
CTA I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O
a O
brief B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
with O
37 B_NUMBER[MEASURE]
discharged O
home B_LOCATION/B_PERSON
following O
CTA B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
95 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

Six B_PERSON
patients I_PERSON
had O
coronary B_MEASURE/B_DISEASE
stenosis I_MEASURE/I_DISEASE
> I_MEASURE/I_DISEASE
or O
= B_MEASURE
50 I_MEASURE
% I_MEASURE
. O

During O
the O
30 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
follow O
- O
up O
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
no O
patients B_PERSON
died O
of O
a O
cardiovascular B_DISEASE
event I_DISEASE
( O
0 B_MEASURE
% I_MEASURE
; O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
, O
0 B_NUMBER[MEASURE]
- O
6 B_NUMBER[MEASURE]
. O
1 B_MEASURE
% I_MEASURE
) O
and O
no O
patient B_PERSON
sustained O
a O
nonfatal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
myocardial I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
0 B_MEASURE
% I_MEASURE
; O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
, O
0 B_NUMBER[MEASURE]
- O
6 B_MEASURE
. O
1 B_MEASURE
% I_MEASURE
) O
. O

conclusions O
: O
Although O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
myocardial O
ischemia O
can O
result O
from O
coronary O
vasoconstriction O
, O
patients O
with O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
associated O
chest O
pain O
, O
a O
non O
- O
ischemic O
ECG O
, O
and O
a O
TIMI O
risk O
score O
< O
2 O
may O
be O
safely O
discharged O
from O
the O
Ed O
after O
a O
negative O
coronary O
CTA O
with O
a O
low O
risk O
of O
30 O
- O
day O
adverse O
events O
. O

bilateral O
haemorrhagic O
infarction O
of O
the O
globus O
pallidus O
after O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
alcohol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
intoxication O
. O

Cocaine B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
risk O
factor O
for O
both O
ischemic O
and O
haemorrhagic O
stroke O
. O

We O
present O
the O
case O
of O
a O
31 O
- O
year O
- O
old O
man O
with O
bilateral O
ischemia O
of O
the O
globus O
pallidus O
after O
excessive O
alcohol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
intranasal O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
. O

Drug O
- O
related O
globus O
pallidus O
infarctions O
are O
most O
often O
associated O
with O
heroin B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

bilateral O
basal O
ganglia O
infarcts O
after O
the O
use O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
without O
concurrent O
heroin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
, O
have O
never O
been O
reported O
. O

In O
our O
patient O
, O
transient O
cardiac O
arrhythmia O
or O
respiratory O
dysfunction O
related O
to O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
/ O
or O
ethanol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
were O
the O
most O
likely O
causes O
of O
cerebral O
hypoperfusion O
. O

Late B_DISEASE_ADJECTIVE[DISEASE]
fulminant I_DISEASE_ADJECTIVE[DISEASE]
posterior I_DISEASE_ADJECTIVE[DISEASE]
reversible I_DISEASE_ADJECTIVE[DISEASE]
encephalopathy I_DISEASE_ADJECTIVE[DISEASE]
syndrome I_DISEASE_ADJECTIVE[DISEASE]
after O
liver B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
transplant I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

objectives B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
posterior B_DISEASE
leukoencephalopathy I_DISEASE
due O
to O
calcineurin B_GENE
- O
inhibitor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
related O
neurotoxicity B_DISEASE
is O
a O
rare B_DISEASE_ADJECTIVE[DISEASE]
but O
severe B_DISEASE_ADJECTIVE[DISEASE]
complication I_DISEASE_ADJECTIVE[DISEASE]
that O
results O
from O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
immunosuppressive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
primarily O
those O
administered O
after O
a O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
or O
kidney B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
transplant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
) O
. O

The O
pathophysiologic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
that O
disorder B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remain O
unknown B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O

Case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
We O
report O
the O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
46 B_MEASURE
- O
year B_TIME[MEASURE]
- O
old B_PERSON
woman I_PERSON
who O
received O
a O
liver B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
transplant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
our O
center B_LOCATION
as O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
alcoholic B_DISEASE/B_GENE
cirrhosis I_DISEASE/I_GENE
and O
in O
whom O
either O
a O
fulminant B_DISEASE
course I_DISEASE
of O
posterior B_DISEASE
leukoencephalopathy I_DISEASE
or O
posterior B_DISEASE
reversible I_DISEASE
encephalopathy I_DISEASE
syndrome I_DISEASE
developed O
110 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
after O
transplant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

After O
an O
initially O
uneventful B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
course B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
after O
the O
transplant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
the O
patient B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
rapidly O
fell O
into O
deep B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
coma I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Cerebral B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
MRI I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
scan I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
typical B_DISEASE/B_LOCATION
signs B_DISEASE/I_LOCATION
of O
enhancement B_DISEASE
in O
the O
pontine B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
posterior B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
regions I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

switching O
the O
immunosuppressive O
regimen O
from O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
improve O
the O
clinical O
situation O
. O

The O
termination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
any O
calcineurin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulted O
in O
a O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resolution B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
that O
complication B_DISEASE
. O

CONCLUSIONS B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
posterior B_DISEASE
reversible I_DISEASE
encephalopathy I_DISEASE
syndrome I_DISEASE
after O
liver B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
transplant I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O
rare B_DISEASE_ADJECTIVE[DISEASE]
. O

We O
recommend O
a O
complete B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cessation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
any O
calcineurin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
rather O
than O
a O
dose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
reduction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Prolonged B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hypothermia I_DISEASE_ADJECTIVE[DISEASE]
as O
a O
bridge B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
recovery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
for O
cerebral B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
edema I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
intracranial B_DISEASE
hypertension I_DISEASE
associated O
with O
fulminant B_DISEASE
hepatic I_DISEASE
failure I_DISEASE
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
To O
review O
evidence B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
based O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
options I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
in O
patients B_PERSON/B_LOCATION
with O
cerebral B_DISEASE/B_GENE
edema I_DISEASE/I_GENE
complicating O
fulminant B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hepatic I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
FHF B_LOCATION/B_PROTEIN[GENE]
) O
and O
discuss O
the O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
applications I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hypothermia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Method O
: O
Case O
- O
based O
observations O
from O
a O
medical O
intensive O
care O
unit O
( O
MICU O
) O
in O
a O
tertiary O
care O
facility O
in O
a O
27 O
- O
year O
- O
old O
female O
with O
FHF O
from O
acetaminophen B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
resultant O
cerebral O
edema O
. O

Results O
: O
Our O
patient O
was O
admitted O
to O
the O
MICU O
after O
being O
found O
unresponsive O
with O
presumed O
toxicity O
from O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
was O
ingested O
over O
a O
2 O
- O
day O
period O
. O

The O
patient B_PERSON
had O
depressed O
of O
mental B_DISEASE
status I_DISEASE
lasting O
at O
least O
24 B_TIME[MEASURE]/B_PERSON
h I_TIME[MEASURE]/I_PERSON
prior I_TIME[MEASURE]/I_PERSON
to O
admission B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Initial O
evaluation O
confirmed O
FHF O
from O
acetaminophen B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cerebral O
edema O
. O

The O
patient B_PERSON/B_DISEASE
was O
treated O
with O
hyperosmolar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
hyperventilation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
sedation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
and O
chemical B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
paralysis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Her O
intracranial B_GENE
pressure I_GENE
remained O
elevated O
despite O
maximal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
medical I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

We O
then O
initiated O
therapeutic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
hypothermia I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
which O
was O
continued O
for O
5 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
. O

At O
re B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
warming B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
patient B_PERSON
had O
resolution B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
her O
cerebral B_DISEASE
edema I_DISEASE
and O
intracranial B_DISEASE
hypertension I_DISEASE
. O

At O
discharge B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
she O
had O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
neurological B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
hepatic B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functions B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusion O
: O
In O
patients O
with O
FHF O
and O
cerebral O
edema O
from O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overdose O
, O
prolonged O
therapeutic O
hypothermia O
could O
potentially O
be O
used O
as O
a O
life O
saving O
therapy O
and O
a O
bridge O
to O
hepatic O
and O
neurological O
recovery O
. O

A O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hypothermia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients B_PERSON/B_BIO
with O
this O
condition B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
warranted O
. O

Binasal O
visual O
field O
defects O
are O
not O
specific O
to O
vigabatrin B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
study O
investigated O
the O
visual O
defects O
associated O
with O
the O
antiepileptic O
drug O
vigabatrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
VGB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
. O

Two O
hundred O
four O
people O
with O
epilepsy O
were O
grouped O
on O
the O
basis O
of O
antiepileptic O
drug O
therapy O
( O
current O
, O
previous O
, O
or O
no O
exposure O
to O
VGB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
. O

Groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
matched O
with O
respect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
age B_MEASURE/B_PERSON
, O
gender B_PERSON/B_MEASURE
, O
and O
seizure B_MEASURE/B_PERSON
frequency B_MEASURE/I_PERSON
. O

All O
patients B_PERSON
underwent O
objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
electrophysiological B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
wide B_NUMBER[MEASURE]/B_LOCATION
- O
field B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
multifocal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
electroretinography B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
and O
conventional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
visual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
field B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
testing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
static B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
perimetry I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) O
. O

bilateral O
visual O
field O
constriction O
was O
observed O
in O
59 O
% O
of O
patients O
currently O
taking O
VGB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
43 O
% O
of O
patients O
who O
previously O
took O
VGB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
24 O
% O
of O
patients O
with O
no O
exposure O
to O
VGB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Assessment O
of O
retinal O
function O
revealed O
abnormal O
responses O
in O
48 O
% O
of O
current O
VGB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
and O
22 O
% O
of O
prior O
VGB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
users O
, O
but O
in O
none O
of O
the O
patients O
without O
previous O
exposure O
to O
VGB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Bilateral B_DISEASE_ADJECTIVE[DISEASE]
visual I_DISEASE_ADJECTIVE[DISEASE]
field I_DISEASE_ADJECTIVE[DISEASE]
abnormalities I_DISEASE_ADJECTIVE[DISEASE]
are O
common B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
treated O
epilepsy B_PERSON
population I_PERSON
, O
irrespective B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O
drug B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
history B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Assessment O
by O
conventional O
static O
perimetry O
may O
neither O
be O
sufficiently O
sensitive O
nor O
specific O
to O
reliably O
identify O
retinal O
toxicity O
associated O
with O
VGB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

smoking O
of O
crack B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cocaine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
as O
a O
risk O
factor O
for O
HIV O
infection O
among O
people O
who O
use O
injection O
drugs O
. O

Background O
: O
Little O
is O
known O
about O
the O
possible O
role O
that O
smoking O
crack B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cocaine I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
has O
on O
the O
incidence O
of O
HIV O
infection O
. O

Given O
the O
increasing O
use O
of O
crack B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cocaine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
sought O
to O
examine O
whether O
use O
of O
this O
illicit O
drug O
has O
become O
a O
risk O
factor O
for O
HIV O
infection O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
included O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
from O
people B_PERSON
participating O
in O
the O
Vancouver B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
Injection I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Drug I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
users I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
Study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
who O
reported O
injecting O
illicit B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
least O
once O
in O
the O
month B_TIME[MEASURE]/B_LOCATION
before O
enrolment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
lived O
in O
the O
greater B_LOCATION
Vancouver I_LOCATION
area I_LOCATION
, O
were O
HIV B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
enrolment B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
completed O
at O
least O
1 B_NUMBER[MEASURE]/B_PERSON
follow O
- O
up O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
visit I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
determine O
whether O
the O
risk O
of O
HIV O
seroconversion O
among O
daily O
smokers O
of O
crack B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
changed O
over O
time O
, O
we O
used O
Cox O
proportional O
hazards O
regression O
and O
divided O
the O
study O
into O
3 O
periods O
: O
May O
1 O
, O
1996 O
- O
Nov O
. O

30 B_MEASURE
, O
1999 B_MEASURE
( O
period B_TIME[MEASURE]/B_LOCATION
1 I_TIME[MEASURE]/I_LOCATION
) O
, O
Dec B_LOCATION/B_GENE
. O

1 B_TIME[MEASURE]
, O
1999 B_TIME[MEASURE]
- O
Nov B_LOCATION/B_TIME[MEASURE]
. O

30 B_MEASURE
, O
2002 B_TIME[MEASURE]
( O
period B_TIME[MEASURE]/B_LOCATION
2 I_TIME[MEASURE]/I_LOCATION
) O
, O
and O
Dec B_TIME[MEASURE]/B_LOCATION
. O

1 B_TIME[MEASURE]
, O
2002 B_TIME[MEASURE]
- O
Dec B_TIME[MEASURE]
. O

30 B_TIME[MEASURE]/B_LOCATION
, O
2005 B_MEASURE
( O
period B_TIME[MEASURE]
3 I_TIME[MEASURE]
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Overall O
, O
1048 B_NUMBER[MEASURE]/B_PERSON
eligible I_NUMBER[MEASURE]/I_PERSON
injection I_NUMBER[MEASURE]/I_PERSON
drug I_NUMBER[MEASURE]/I_PERSON
users I_NUMBER[MEASURE]/I_PERSON
were O
included O
in O
our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Of O
these O
, O
137 B_NUMBER[MEASURE]
acquired O
HIV B_DISEASE/B_GENE
infection I_DISEASE/I_GENE
during O
follow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
up B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
mean O
proportion O
of O
participants O
who O
reported O
daily O
smoking O
of O
crack B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cocaine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
increased O
from O
11 O
. O
6 O
% O
in O
period O
1 O
to O
39 O
. O
7 O
% O
in O
period O
3 O
. O

After O
adjusting O
for O
potential O
confounders O
, O
we O
found O
that O
the O
risk O
of O
HIV O
seroconversion O
among O
participants O
who O
were O
daily O
smokers O
of O
crack B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cocaine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
increased O
over O
time O
( O
period O
1 O
: O
hazard O
ratio O
[ O
HR O
] O
1 O
. O
03 O
, O
95 O
% O
confidence O
interval O
[ O
CI O
] O
0 O
. O
57 O
- O
1 O
. O
85 O
; O
period O
2 O
: O
HR O
1 O
. O
68 O
, O
95 O
% O
CI O
1 O
. O
01 O
- O
2 O
. O
80 O
; O
and O
period O
3 O
: O
HR O
2 O
. O
74 O
, O
95 O
% O
CI O
1 O
. O
06 O
- O
7 O
. O
11 O
) O
. O

interpretation O
: O
smoking O
of O
crack B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
found O
to O
be O
an O
independent O
risk O
factor O
for O
HIV O
seroconversion O
among O
people O
who O
were O
injection O
drug O
users O
. O

This O
finding O
points O
to O
the O
urgent O
need O
for O
evidence O
- O
based O
public O
health O
initiatives O
targeted O
at O
people O
who O
smoke O
crack B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
cocaine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
improves O
the O
memory O
deficits O
caused O
by O
the O
chemotherapy O
agent O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Cancer B_PERSON
patients I_PERSON
who O
have O
been O
treated O
with O
systemic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adjuvant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
described O
experiencing O
deteriorations B_DISEASE_ADJECTIVE[DISEASE]
in O
cognition B_DISEASE
. O

A O
widely O
used O
chemotherapeutic O
agent O
, O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
fluorouracil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
, O
readily O
crosses O
the O
blood O
- O
brain O
barrier O
and O
so O
could O
have O
a O
direct O
effect O
on O
brain O
function O
. O

In O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
this O
anti B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mitotic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drug I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
could O
reduce O
cell B_DISEASE
proliferation I_DISEASE
in O
the O
neurogenic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
regions I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
adult B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
brain I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
contrast O
reports O
indicate O
that O
hippocampal O
dependent O
neurogenesis O
and O
cognition O
are O
enhanced O
by O
the O
SSRI B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antidepressant O
Fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
this O
investigation O
the O
behavioural O
effects O
of O
chronic O
( O
two O
week O
) O
treatment O
with O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
( O
three O
weeks O
) O
with O
Fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
either O
separately O
or O
in O
combination O
with O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
tested O
on O
adult O
Lister O
hooded O
rats O
. O

Behavioural O
effects O
were O
tested O
using O
a O
context O
dependent O
conditioned O
emotional O
response O
test O
( O
CER O
) O
which O
showed O
that O
animals O
treated O
with O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
a O
significant O
reduction O
in O
freezing O
time O
compared O
to O
controls O
. O

A O
separate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
animals B_BIO/B_PERSON
was O
tested O
using O
a O
hippocampal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
dependent I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
spatial I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
working O
memory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
object B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
location I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
recognition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
OLR B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Animals O
treated O
only O
with O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
significant O
deficits O
in O
their O
ability O
to O
carry O
out O
the O
OLR O
task O
but O
co O
administration O
of O
Fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
improved O
their O
performance O
. O

5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy O
caused O
a O
significant O
reduction O
in O
the O
number O
of O
proliferating O
cells O
in O
the O
sub O
granular O
zone O
of O
the O
dentate O
gyrus O
compared O
to O
controls O
. O

This O
reduction O
was O
eliminated O
when O
Fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
co O
administered O
with O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
its O
own O
had O
no O
effect O
on O
proliferating O
cell O
number O
or O
behaviour O
. O

These O
findings O
suggest O
that O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
can O
negatively O
affect O
both O
cell O
proliferation O
and O
hippocampal O
dependent O
working O
memory O
and O
that O
these O
deficits O
can O
be O
reversed O
by O
the O
simultaneous O
administration O
of O
the O
antidepressant O
Fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

liver O
- O
specific O
ablation O
of O
integrin O
- O
linked O
kinase O
in O
mice O
results O
in O
enhanced O
and O
prolonged O
cell O
proliferation O
and O
hepatomegaly O
after O
phenobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
. O

We O
have O
recently O
demonstrated O
that O
disruption B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
extracellular B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
matrix I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
ECM B_PROTEIN[GENE]/B_LOCATION
) O
/ O
integrin B_GENE
signaling O
via O
elimination B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
integrin B_GENE
- O
linked O
kinase B_ENZYME[GENE]/B_LOCATION
( O
ILK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
) O
in O
hepatocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
interferes O
with O
signals B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
leading O
to O
termination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
liver B_DISEASE/B_ORGANISM_FUNCTION
regeneration B_DISEASE/I_ORGANISM_FUNCTION
. O

This O
study O
investigates O
the O
role O
of O
ILK O
in O
liver O
enlargement O
induced O
by O
phenobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
PB B_PROTEIN[GENE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
. O

Wild O
- O
type O
( O
WT O
) O
and O
ILK O
: O
liver O
- O
/ O
- O
mice O
were O
given O
PB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
0 O
. O
1 O
% O
in O
drinking O
water O
) O
for O
10 O
days O
. O

Livers O
were O
harvested O
on O
2 O
, O
5 O
, O
and O
10 O
days O
during O
PB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration O
. O

In O
the O
hepatocyte B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
specific B_DISEASE_ADJECTIVE[DISEASE]
ILK I_DISEASE_ADJECTIVE[DISEASE]
/ O
liver B_GENE/B_DISEASE
- O
/ B_GENE
- O
mice B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O
the O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
: O
body B_MEASURE
weight I_MEASURE
ratio I_MEASURE
was O
more B_MEASURE
than O
double O
as O
compared O
to O
0 B_MEASURE
h O
at O
day B_TIME[MEASURE]/B_PERSON
2 I_TIME[MEASURE]/I_PERSON
( O
2 B_MEASURE
. O
5 B_TIME[MEASURE]
times I_TIME[MEASURE]
) O
, O
while O
at O
days B_TIME[MEASURE]
5 I_TIME[MEASURE]
and O
10 B_NUMBER[MEASURE]
, O
it O
was O
enlarged O
three B_TIME[MEASURE]
times I_TIME[MEASURE]
. O

In O
the O
WT B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
mice I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
, O
the O
increase B_DISEASE/B_MEASURE
was O
as O
expected O
from O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
literature I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
1 B_MEASURE
. O
8 B_TIME[MEASURE]
times I_TIME[MEASURE]
) O
and O
seems O
to O
have O
leveled O
off O
after O
day B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
2 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
. O

There O
were O
slightly O
increased O
proliferating O
cell O
nuclear O
antigen O
- O
positive O
cells O
in O
the O
ILK O
/ O
liver O
- O
/ O
- O
animals O
at O
day O
2 O
as O
compared O
to O
WT O
after O
PB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administration O
. O

In O
the O
WT B_LOCATION/B_ORGANIZATION
animals I_LOCATION/I_ORGANIZATION
, O
the O
proliferative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
response I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
had O
come O
back O
to O
normal B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
days B_TIME[MEASURE]
5 I_TIME[MEASURE]
and O
10 B_NUMBER[MEASURE]
. O

hepatocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
of O
the O
ILK B_DISEASE/B_PROTEIN[GENE]
/ O
liver B_GENE/B_DISEASE
- O
/ B_PERSON/B_PROTEIN[GENE]
- O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
continued O
to O
proliferate O
up O
until O
day B_DISEASE/B_ORGANISM_FUNCTION
10 I_DISEASE/I_ORGANISM_FUNCTION
. O

ILK O
/ O
liver O
- O
/ O
- O
mice O
also O
showed O
increased O
expression O
of O
key O
genes O
involved O
in O
hepatocyte O
proliferation O
at O
different O
time O
points O
during O
PB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
. O

In O
summary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ECM B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
proteins I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
communicate O
with O
the O
signaling O
machinery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
dividing O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
via O
ILK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
to O
regulate O
hepatocyte B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
proliferation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
termination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
proliferative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

lack O
of O
ILK O
in O
the O
hepatocytes O
imparts O
prolonged O
proliferative O
response O
not O
only O
to O
stimuli O
related O
to O
liver O
regeneration O
but O
also O
to O
xenobiotic O
chemical O
mitogens O
, O
such O
as O
PB B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

decreased O
expression O
of O
Na B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O
K B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
ATPase O
, O
NHE3 O
, O
NBC1 O
, O
AQP1 O
and O
OAT O
in O
Gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
Nephropathy O
. O

The O
present O
study O
was O
aimed O
to O
determine O
whether O
there O
is O
an O
altered O
regulation O
of O
tubular O
transporters O
in O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
nephropathy O
. O

Sprague O
- O
Dawley O
male O
rats O
( O
200 O
~ O
250 O
g O
) O
were O
subcutaneously O
injected O
with O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
100 O
mg O
/ O
kg O
per O
day O
) O
for O
7 O
days O
, O
and O
the O
expression O
of O
tubular O
transporters O
was O
determined O
by O
immunoblotting O
and O
immunohistochemistry O
. O

The O
mRNA B_GENE
and O
protein B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
OAT B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
also O
determined O
. O

Gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
rats O
exhibited O
significantly O
decreased O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
clearance O
along O
with O
increased O
plasma O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
. O

Accordingly O
, O
the O
fractional O
excretion O
of O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
increased O
. O

urine B_MEASURE/B_PERSON
volume I_MEASURE/I_PERSON
was O
increased O
, O
while O
urine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
osmolality I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
and O
free B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
water I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reabsorption I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
decreased O
. O

Immunoblotting O
and O
immunohistochemistry O
revealed O
decreased O
expression O
of O
Na B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
+ O
) O
/ O
K B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
+ O
) O
- O
ATPase O
, O
NHE3 O
, O
NBC1 O
, O
and O
AQP1 O
in O
the O
kidney O
of O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
rats O
. O

The O
expression B_GENE/B_MEASURE
of O
OAT1 B_GENE
and O
OAT3 B_GENE
was O
also O
decreased O
. O

Gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
nephropathy O
may O
at O
least O
in O
part O
be O
causally O
related O
with O
a O
decreased O
expression O
of O
Na B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
+ O
) O
/ O
K B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
+ O
) O
- O
ATPase O
, O
NHE3 O
, O
NBC1 O
, O
AQP1 O
and O
OAT O
. O

acute O
renal O
failure O
after O
high O
- O
dose O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
in O
a O
patient O
with O
ileostomy O
. O

High O
- O
dose O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
HD O
- O
MTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
is O
an O
important O
treatment O
for O
Burkitt O
lymphoma O
, O
but O
can O
cause O
hepatic O
and O
renal O
toxicity O
when O
its O
clearance O
is O
delayed O
. O

We O
report O
a O
case O
of O
acute O
renal O
failure O
after O
HD O
- O
MTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therapy O
in O
a O
patient O
with O
ileostomy O
, O
The O
patient O
was O
a O
3 O
- O
year O
- O
old O
boy O
who O
had O
received O
a O
living O
- O
related O
liver O
transplantation O
for O
congenital O
biliary O
atresia O
. O

At O
day B_TIME[MEASURE]/B_LOCATION
833 I_TIME[MEASURE]/I_LOCATION
after O
the O
transplantation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
he O
was O
diagnosed O
with O
PTLD B_DISEASE
( O
post B_DISEASE/B_MEASURE
- O
transplantation B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
lymphoproliferative B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disorder B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
Burkitt B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- O
type B_DISEASE/B_PERSON
malignant I_DISEASE/I_PERSON
lymphoma I_DISEASE/I_PERSON
) O
. O

During O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
he O
suffered O
ileal B_DISEASE
perforation I_DISEASE
and O
ileostomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
was O
performed O
. O

Subsequent O
HD O
- O
MTX B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
caused O
acute O
renal O
failure O
that O
required O
continuous O
hemodialysis O
. O

We O
supposed O
that O
intravascular B_DISEASE
hypovolemia I_DISEASE
due O
to O
substantial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drainage I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
the O
ileostoma B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
caused O
acute B_DISEASE
prerenal I_DISEASE
failure I_DISEASE
. O

After O
recovery O
of O
his O
renal O
function O
, O
we O
could O
safely O
treat O
the O
patient O
with O
HD O
- O
MTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O
by O
controlling O
drainage O
from O
ileostoma O
with O
total O
parenteral O
nutrition O
. O

longitudinal O
association O
of O
alcohol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O
with O
HIV O
disease O
progression O
and O
psychological O
health O
of O
women O
with O
HIV O
. O

We O
evaluated O
the O
association O
of O
alcohol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
consumption O
and O
depression O
, O
and O
their O
effects O
on O
HIV O
disease O
progression O
among O
women O
with O
HIV O
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
included O
871 B_PERSON
women I_PERSON
with O
HIV B_DISEASE/B_LOCATION
who O
were O
recruited O
from O
1993 B_MEASURE
- O
1995 B_MEASURE
in O
four B_LOCATION
US I_LOCATION
cities I_LOCATION
. O

The O
participants O
had O
physical O
examination O
, O
medical O
record O
extraction O
, O
and O
venipuncture O
, O
CD4 O
+ O
T O
- O
cell O
counts O
determination O
, O
measurement O
of O
depression O
symptoms O
( O
using O
the O
self O
- O
report O
Center O
for O
Epidemiological O
Studies O
- O
Depression O
Scale O
) O
, O
and O
alcohol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O
assessment O
at O
enrollment O
, O
and O
semiannually O
until O
March O
2000 O
. O

Multilevel B_TIME[MEASURE]/B_ORGANIZATION
random I_TIME[MEASURE]/I_ORGANIZATION
coefficient I_TIME[MEASURE]/I_ORGANIZATION
ordinal I_TIME[MEASURE]/I_ORGANIZATION
models I_TIME[MEASURE]/I_ORGANIZATION
as O
well O
as O
multilevel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
with O
joint B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
used O
in O
the O
analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
was O
no O
significant O
association O
between O
level O
of O
alcohol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O
and O
CD4 O
+ O
T O
- O
cell O
counts O
. O

When O
participants O
were O
stratified O
by O
antiretroviral O
therapy O
( O
Art O
) O
use O
, O
the O
association O
between O
alcohol B_DISEASE
and O
CD4 O
+ O
T O
- O
cell O
did O
not O
reach O
statistical O
significance O
. O

The O
association O
between O
alcohol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
consumption O
and O
depression O
was O
significant O
( O
p O
< O
0 O
. O
001 O
) O
. O

Depression B_TIME[MEASURE]/B_DISEASE
had O
a O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
negative B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
CD4 B_GENE/B_MEASURE
+ I_GENE/I_MEASURE
T I_GENE/I_MEASURE
- O
cell B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
counts B_MEASURE/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
over O
time B_TIME[MEASURE]/B_PERSON
regardless O
of O
ART B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
findings O
suggest O
that O
alcohol B_BIO/B_DISEASE
consumption O
has O
a O
direct O
association O
with O
depression O
. O

Moreover O
, O
depression B_DISEASE/B_GENE
is O
associated O
with O
HIV B_DISEASE
disease I_DISEASE
progression I_DISEASE
. O

Our O
findings O
have O
implications O
for O
the O
provision O
of O
alcohol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O
interventions O
and O
psychological O
resources O
to O
improve O
the O
health O
of O
women O
with O
HIV O
. O

Chemokine O
CCL2 O
and O
its O
receptor O
CCR2 O
are O
increased O
in O
the O
hippocampus O
following O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
status O
epilepticus O
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
: O
neuroinflammation B_DISEASE/B_GENE
occurs O
after O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
is O
implicated O
in O
epileptogenesis B_DISEASE_ADJECTIVE[DISEASE]
. O

CCR2 B_GENE
is O
a O
chemokine B_GENE/B_PERSON
receptor I_GENE/I_PERSON
for O
CCL2 B_GENE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
their O
interaction B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
mediates I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
monocyte I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
infiltration I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
neuroinflammatory B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cascade B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
triggered O
in O
different B_DISEASE/B_LOCATION
brain I_DISEASE/I_LOCATION
pathologies I_DISEASE/I_LOCATION
. O

In O
this O
work O
CCR2 O
and O
CCL2 O
expression O
were O
examined O
following O
status O
epilepticus O
( O
SE O
) O
induced O
by O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O
. O

methods O
: O
SE O
was O
induced O
by O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O
. O

Control O
rats O
were O
injected O
with O
saline O
instead O
of O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Five B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
after O
SE B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
CCR2 B_GENE
staining O
in O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
glial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
was O
examined O
using O
imunohistochemical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
number B_MEASURE/B_LOCATION
of O
CCR2 B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
positive I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
was O
determined O
using O
stereology B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
probes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
. O

CCL2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
was O
examined O
by O
molecular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
increased O
CCR2 B_GENE/B_DISEASE
was O
observed O
in O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
after O
SE B_DISEASE
. O

seizures B_DISEASE/B_LOCATION
also O
resulted O
in O
alterations B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
the O
cell B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
types B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expressing O
CCR2 B_GENE
. O

increased O
numbers B_MEASURE
of O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
that O
expressed O
CCR2 B_GENE
was O
observed O
following O
SE B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

microglial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
were O
more O
closely O
apposed O
to O
the O
CCR2 B_GENE
- O
labeled O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LOCATION
in O
SE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
rats B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
experienced O
SE B_DISEASE
exhibited O
CCR2 B_GENE
- O
labeling B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
in O
populations B_LOCATION
of O
hypertrophied B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
astrocytes I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
especially O
in O
CA1 B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
and O
dentate B_BODY_PART_OR_ORGAN_COMPONENT
gyrus I_BODY_PART_OR_ORGAN_COMPONENT
. O

These O
CCR2 B_GENE
+ O
astroctytes B_BIO/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
not O
observed O
in O
control B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rats I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Examination B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CCL2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
showed O
that O
it O
was O
elevated O
in O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
following O
SE B_DISEASE
. O

conclusion O
: O
The O
data O
show O
that O
CCR2 O
and O
CCL2 O
are O
up O
- O
regulated O
in O
the O
hippocampus O
after O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
SE O
. O

seizures B_DISEASE/B_LOCATION
also O
result O
in O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
CCR2 B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
receptor B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
expression B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
neurons B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
astrocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

These O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
might O
be O
involved O
in O
detrimental B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neuroplasticity I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
neuroinflammatory B_DISEASE/B_ORGANISM_FUNCTION
changes I_DISEASE/I_ORGANISM_FUNCTION
that O
occur O
following O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Metallothionein B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
induction O
reduces O
caspase O
- O
3 O
activity O
and O
TNFalpha O
levels O
with O
preservation O
of O
cognitive O
function O
and O
intact O
hippocampal O
neurons O
in O
carmustine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
treated O
rats O
. O

hippocampal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
integrity I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
essential B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
cognitive B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
functions I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

On O
the O
other O
hand O
, O
induction O
of O
metallothionein B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
MT B_LOCATION/B_PROTEIN[GENE]
) O
by O
ZnSO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
its O
role O
in O
neuroprotection O
has O
been O
documented O
. O

The O
present O
study O
aimed O
to O
explore O
the O
effect O
of O
MT B_GENE/B_DISEASE
induction O
on O
carmustine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
BCNU B_LOCATION/B_ORGANIZATION
) O
- O
induced O
hippocampal O
cognitive O
dysfunction O
in O
rats O
. O

A O
total O
of O
60 O
male O
Wistar O
albino O
rats O
were O
randomly O
divided O
into O
four O
groups O
( O
15 O
/ O
group O
) O
: O
The O
control O
group O
injected O
with O
single O
doses O
of O
normal O
saline O
( O
i O
. O
c O
. O
v O
) O
followed O
24 O
h O
later O
by O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
solvent O
( O
i O
. O
v O
) O
. O

The O
second O
group O
administered O
ZnSO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 O
. O
1 O
micromol O
/ O
10 O
microl O
normal O
saline O
, O
i O
. O
c O
. O
v O
, O
once O
) O
then O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
solvent O
( O
i O
. O
v O
) O
after O
24 O
h O
. O

Third O
group O
received O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
20 O
mg O
/ O
kg O
, O
i O
. O
v O
, O
once O
) O
24 O
h O
after O
injection O
with O
normal O
saline O
( O
i O
. O
c O
. O
v O
) O
. O

Fourth O
group O
received O
a O
single O
dose O
of O
ZnSO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
0 O
. O
1 O
micromol O
/ O
10 O
microl O
normal O
saline O
, O
i O
. O
c O
. O
v O
) O
then O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
20 O
mg O
/ O
kg O
, O
i O
. O
v O
, O
once O
) O
after O
24 O
h O
. O

The O
obtained O
data O
revealed O
that O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration O
resulted O
in O
deterioration O
of O
learning O
and O
short O
- O
term O
memory O
( O
STM O
) O
, O
as O
measured O
by O
using O
radial O
arm O
water O
maze O
, O
accompanied O
with O
decreased O
hippocampal O
glutathione B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reductase O
( O
GR O
) O
activity O
and O
reduced O
glutathione B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
GSH B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
content O
. O

Also O
, O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration O
increased O
serum O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNFalpha O
) O
, O
hippocampal O
MT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
malondialdehyde B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
MDA B_LOCATION
) O
contents O
as O
well O
as O
caspase O
- O
3 O
activity O
in O
addition O
to O
histological O
alterations O
. O

ZnSO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
pretreatment O
counteracted O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
inhibition O
of O
GR O
and O
depletion O
of O
GSH B_GENE/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
resulted O
in O
significant O
reduction O
in O
the O
levels O
of O
MDA B_GENE/B_BIO
and O
TNFalpha O
as O
well O
as O
the O
activity O
of O
caspase O
- O
3 O
. O

The O
histological O
features O
were O
improved O
in O
hippocampus O
of O
rats O
treated O
with O
ZnSO B_LOCATION
( I_LOCATION
4 I_LOCATION
) I_LOCATION
+ O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
compared O
to O
only O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
treated O
animals O
. O

In O
conclusion O
, O
MT B_GENE/B_DISEASE
induction O
halts O
BCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
hippocampal O
toxicity O
as O
it O
prevented O
GR O
inhibition O
and O
GSH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
depletion O
and O
counteracted O
the O
increased O
levels O
of O
TNFalpha O
, O
MDA B_GENE/B_BIO
and O
caspase O
- O
3 O
activity O
with O
subsequent O
preservation O
of O
cognition O
. O

fatal O
carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
fulminant O
eosinophilic O
( O
hypersensitivity O
) O
myocarditis O
: O
emphasis O
on O
anatomical O
and O
histological O
characteristics O
, O
mechanisms O
and O
genetics O
of O
drug O
hypersensitivity O
and O
differential O
diagnosis O
. O

The O
most O
severe O
adverse O
reactions O
to O
carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
observed O
in O
the O
haemopoietic O
system O
, O
the O
liver O
and O
the O
cardiovascular O
system O
. O

A O
frequently O
fatal O
, O
although O
exceptionally O
rare O
side O
effect O
of O
carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
necrotizing O
eosinophilic O
( O
hypersensitivity O
) O
myocarditis O
. O

We O
report O
a O
case O
of O
hypersensitivity O
myocarditis O
secondary O
to O
administration O
of O
carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Acute B_DISEASE/B_PERSON
hypersensitivity I_DISEASE/I_PERSON
myocarditis I_DISEASE/I_PERSON
was O
not O
suspected O
clinically O
, O
and O
the O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
made O
post B_DISEASE/B_MEASURE
- O
mortem B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

histology B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
revealed O
diffuse B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infiltration I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
myocardium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
by O
eosinophils B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
lymphocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
with O
myocyte B_DISEASE
damage I_DISEASE
. O

Clinically O
, O
death B_PERSON/B_DISEASE
was O
due O
to O
cardiogenic B_DISEASE
shock I_DISEASE
. O

To O
best O
of O
our O
knowledge O
this O
is O
the O
second O
case O
of O
fatal O
carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
myocarditis O
reported O
in O
English O
literature O
. O

Neuropsychiatric O
behaviors O
in O
the O
MPTP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
marmoset O
model O
of O
Parkinson O
' O
s O
disease O
. O

objectives B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
neuropsychiatric B_DISEASE
symptoms I_DISEASE
are O
increasingly O
recognised O
as O
a O
significant B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problem I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients B_PERSON
with O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
( O
PD B_DISEASE/B_PROTEIN[GENE]
) O
. O

These O
symptoms O
may O
be O
due O
to O
' O
sensitisation O
' O
following O
repeated O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
or O
a O
direct O
effect O
of O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
the O
disease O
state O
. O

The O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
MPTP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
lesioned O
marmoset O
was O
used O
as O
a O
model O
of O
neuropsychiatric O
symptoms O
in O
PD O
patients O
. O

Here O
we O
compare O
the O
time O
course O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
motor O
fluctuations O
and O
neuropsychiatric O
- O
like O
behaviors O
to O
determine O
the O
relationship O
between O
duration O
of O
treatment O
and O
onset O
of O
symptoms O
. O

methods O
: O
Marmosets O
were O
administered O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phenyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tetrahydropyridine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 O
. O
0 O
mg O
/ O
kg O
s O
. O
c O
. O
) O
for O
five O
days O
, O
resulting O
in O
stable O
parkinsonism O
. O

Levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
15 O
mg O
/ O
kg O
and O
benserazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
3 O
. O
75 O
mg O
/ O
kg O
) O
p O
. O
o O
. O

b O
. O
i O
. O
d O
, O
was O
administered O
for O
30 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
days I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Animals O
were O
evaluated O
for O
parkinsonian O
disability O
, O
dyskinesia O
and O
on O
- O
time O
( O
motor O
fluctuations O
) O
and O
neuropsychiatric O
- O
like O
behaviors O
on O
Day O
0 O
( O
prior O
to O
levodopa B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
and O
on O
Days O
1 O
, O
7 O
, O
13 O
, O
27 O
and O
30 O
of O
treatment O
using O
post O
hoc O
DVD O
analysis O
by O
a O
trained O
rater O
, O
blind O
to O
the O
treatment O
day O
. O

Results B_MEASURE
: O
The O
neuropsychiatric B_DISEASE
- O
like B_DISEASE/B_PROTEIN[GENE]
behavior B_DISEASE/I_PROTEIN[GENE]
rating B_DISEASE/I_PROTEIN[GENE]
scale B_DISEASE/I_PROTEIN[GENE]
demonstrated O
high B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interrater B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reliability B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
three B_NUMBER[MEASURE]/B_LOCATION
trained O
raters B_PERSON/B_ORGANIZATION
of O
differing O
professional B_MEASURE/B_PERSON
backgrounds I_MEASURE/I_PERSON
. O

As O
anticipated O
, O
animals O
exhibited O
a O
progressive O
increase O
in O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
motor O
fluctuations O
, O
dyskinesia O
and O
wearing O
- O
off O
, O
that O
correlated O
with O
the O
duration O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O
. O

In O
contrast O
, O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
neuropsychiatric O
- O
like O
behaviors O
were O
present O
on O
Day O
1 O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
and O
their O
severity O
did O
not O
correlate O
with O
duration O
of O
treatment O
. O

conclusions O
: O
The O
data O
suggest O
that O
neuropsychiatric O
disorders O
in O
PD O
are O
more O
likely O
an O
interaction O
between O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
the O
disease O
state O
than O
a O
consequence O
of O
sensitisation O
to O
repeated O
dopaminergic O
therapy O
. O

Contrast B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medium I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephrotoxicity O
after O
renal O
artery O
and O
coronary O
angioplasty O
. O

Background O
: O
Renal O
dysfunction O
induced O
by O
iodinated O
contrast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
medium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
CM B_TIME[MEASURE]/B_DISEASE
) O
administration O
can O
minimize O
the O
benefit O
of O
the O
interventional O
procedure O
in O
patients O
undergoing O
renal O
angioplasty O
( O
PTRA O
) O
. O

purpose O
: O
To O
compare O
the O
susceptibility O
to O
nephrotoxic O
effect O
of O
CM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
patients O
undergoing O
PTRA O
with O
that O
of O
patients O
submitted O
to O
percutaneous O
coronary O
intervention O
( O
PCI O
) O
. O

Material O
AND O
methods O
: O
A O
total O
of O
33 O
patients O
successfully O
treated O
with O
PTRA O
( O
PTRA O
group O
, O
mean O
age O
70 O
+ O
/ O
- O
12 O
years O
, O
23 O
female O
, O
basal O
creatinine B_MEASURE/B_LOCATION
1 O
. O
46 O
+ O
/ O
- O
0 O
. O
79 O
, O
range O
0 O
. O
7 O
- O
4 O
. O
9 O
mg O
/ O
DL O
) O
were O
compared O
with O
33 O
patients O
undergoing O
successful O
PCI O
( O
PCI O
group O
) O
, O
matched O
for O
basal O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
1 O
. O
44 O
+ O
/ O
- O
0 O
. O
6 O
, O
range O
0 O
. O
7 O
- O
3 O
. O
4 O
mg O
/ O
DL O
) O
, O
gender O
, O
and O
age O
. O

In O
both O
groups O
postprocedural O
( O
48 O
h O
) O
serum O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
measured O
. O

Results O
: O
Postprocedural O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O
decreased O
nonsignificantly O
in O
the O
PTRA O
group O
( O
1 O
. O
46 O
+ O
/ O
- O
0 O
. O
8 O
vs O
. O
1 O
. O
34 O
+ O
/ O
- O
0 O
. O
5 O
mg O
/ O
DL O
, O
P O
= O
NS O
) O
and O
increased O
significantly O
in O
the O
PCI O
group O
( O
1 O
. O
44 O
+ O
/ O
- O
0 O
. O
6 O
vs O
. O
1 O
. O
57 O
+ O
/ O
- O
0 O
. O
7 O
mg O
/ O
DL O
, O
P O
< O
0 O
. O
02 O
) O
. O

Changes O
in O
serum O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
after O
intervention O
( O
after O
- O
before O
) O
were O
significantly O
different O
between O
the O
PTRA O
and O
PCI O
groups O
( O
- O
0 O
. O
12 O
+ O
/ O
- O
0 O
. O
5 O
vs O
. O
0 O
. O
13 O
+ O
/ O
- O
0 O
. O
3 O
, O
P O
= O
0 O
. O
014 O
) O
. O

This O
difference O
was O
not O
related O
to O
either O
a O
different O
clinical O
risk O
profile O
or O
to O
the O
volume O
of O
CM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administered O
. O

conclusion O
: O
In O
this O
preliminary O
study O
patients O
submitted O
to O
PTRA O
showed O
a O
lower O
susceptibility O
to O
renal O
damage O
induced O
by O
CM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration O
than O
PCI O
patients O
. O

The O
effectiveness O
of O
PTRA O
on O
renal O
function O
seems O
to O
be O
barely O
influenced O
by O
CM B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxicity O
. O

Diphenhydramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
prevents O
the O
haemodynamic O
changes O
of O
cimetidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
ICU O
patients O
. O

Cimetidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 O
( O
H2 O
) O
antagonist O
, O
produces O
a O
decrease O
in O
arterial O
pressure O
due O
to O
vasodilatation O
, O
especially O
in O
critically O
ill O
patients O
. O

This O
may O
be O
because O
cimetidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acts O
as O
a O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
agonist O
. O

We O
, O
therefore O
, O
investigated O
the O
effects O
of O
the O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
( O
H1 O
) O
receptor O
antagonist O
, O
diphenhydramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
on O
the O
haemodynamic O
changes O
observed O
after O
cimetidine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O
ICU O
patients O
. O

Each O
patient B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
studied O
on O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
separate I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
days I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

In O
a O
random O
fashion O
, O
they O
received O
cimetidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
200 O
mg O
IV O
on O
one O
day O
, O
and O
on O
the O
other O
, O
a O
pretreatment O
of O
diphenhydramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
40 O
mg O
IV O
with O
cimetidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
200 O
mg O
IV O
. O

In O
the O
non O
- O
pretreatment O
group O
, O
mean O
arterial O
pressure O
( O
Map O
) O
decreased O
from O
107 O
. O
4 O
+ O
/ O
- O
8 O
. O
4 O
mmHg O
to O
86 O
. O
7 O
+ O
/ O
- O
11 O
. O
4 O
mmHg O
( O
P O
less O
than O
0 O
. O
01 O
) O
two O
minutes O
after O
cimetidine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Also O
, O
systemic B_DISEASE
vascular I_DISEASE
resistance I_DISEASE
( O
SVR B_DISEASE/B_PROTEIN[GENE]
) O
decreased O
during O
the O
eight B_NUMBER[MEASURE]
- O
minute B_TIME[MEASURE]/B_LOCATION
observation I_TIME[MEASURE]/I_LOCATION
period I_TIME[MEASURE]/I_LOCATION
( O
P B_MEASURE/B_PERSON
less I_MEASURE/I_PERSON
than O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

In O
contrast B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
the O
pretreatment B_TIME[MEASURE]/B_LOCATION
group B_TIME[MEASURE]/I_LOCATION
, O
little B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
haemodynamic I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
change I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
seen O
. O

We O
conclude O
that O
an O
H1 O
antagonist O
may O
be O
useful O
in O
preventing O
hypotension O
caused O
by O
IV O
cimetidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
since O
the O
vasodilating O
activity O
of O
cimetidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
mediated O
, O
in O
part O
, O
through O
the O
H1 O
receptor O
. O

Medical O
and O
psychiatric O
outcomes O
for O
patients O
transplanted O
for O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
acute O
liver O
failure O
: O
a O
case O
- O
control O
study O
. O

Background O
: O
Acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hepatotoxicity O
is O
the O
most O
common O
cause O
of O
acute O
liver O
failure O
( O
ALF O
) O
in O
the O
UK O
. O

patients B_PERSON
often O
consume O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
suicidal B_DISEASE
intent I_DISEASE
or O
with O
a O
background B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
substance B_DISEASE
dependence I_DISEASE
. O

aims O
AND O
methods O
: O
We O
compared O
the O
severity O
of O
pretransplant O
illness O
, O
psychiatric O
co O
- O
morbidity O
, O
medical O
and O
psychosocial O
outcomes O
of O
all O
patients O
who O
had O
undergone O
liver O
transplantation O
( O
Lt O
) O
emergently O
between O
1999 O
- O
2004 O
for O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
ALF O
( O
n O
= O
36 O
) O
with O
age O
- O
and O
sex O
- O
matched O
patients O
undergoing O
emergent O
Lt O
for O
non O
- O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
ALF O
( O
n O
= O
35 O
) O
and O
elective O
Lt O
for O
chronic O
liver O
disease O
( O
CLD O
, O
n O
= O
34 O
) O
. O

Results O
: O
Acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
ALF O
patients O
undergoing O
Lt O
had O
a O
greater O
severity O
of O
pre O
- O
Lt O
illness O
reflected O
by O
higher O
acute O
physiology O
and O
chronic O
Health O
Evaluation O
II O
scores O
and O
requirement O
for O
organ O
support O
compared O
with O
the O
other O
two O
groups O
. O

Twenty O
( O
56 O
% O
) O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
ALF O
patients O
had O
a O
formal O
psychiatric O
diagnosis O
before O
Lt O
( O
non O
- O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
ALF O
= O
0 O
/ O
35 O
, O
CLD O
= O
2 O
/ O
34 O
; O
P O
< O
0 O
. O
01 O
for O
all O
) O
and O
nine O
( O
25 O
% O
) O
had O
a O
previous O
suicide O
attempt O
. O

During O
follow O
- O
up O
( O
median O
5 O
years O
) O
, O
there O
were O
no O
significant O
differences O
in O
rejection O
( O
acute O
and O
chronic O
) O
, O
graft O
failure O
or O
survival O
between O
the O
groups O
( O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
ALF O
1 O
year O
87 O
% O
, O
5 O
years O
75 O
% O
; O
non O
- O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
ALF O
88 O
% O
, O
78 O
% O
; O
CLD O
93 O
% O
, O
82 O
% O
: O
P O
> O
0 O
. O
6 O
log O
rank O
) O
. O

Two O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
ALF O
patients O
reattempted O
suicide O
post O
- O
Lt O
( O
one O
died O
8 O
years O
post O
- O
Lt O
) O
. O

conclusions O
: O
Despite O
a O
high O
prevalence O
of O
psychiatric O
disturbance O
, O
outcomes O
for O
patients O
transplanted O
emergently O
for O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
ALF O
were O
comparable O
to O
those O
transplanted O
for O
non O
- O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
ALF O
and O
electively O
for O
CLD O
. O

multidisciplinary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
approaches I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
with O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
psychiatric I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
follow I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
up B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
contribute O
to O
low B_DISEASE/B_MEASURE
post I_DISEASE/I_MEASURE
- O
transplant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
suicide I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
rates I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
seen O
and O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
rates I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
graft B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O
of O
non B_DISEASE
- O
compliance B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

antithrombotic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cerebral B_DISEASE
microbleeds I_DISEASE
, O
and O
intracerebral B_DISEASE
hemorrhage I_DISEASE
: O
a O
systematic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
review I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
published B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
unpublished B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Background B_TIME[MEASURE]/B_LOCATION
AND O
Purpose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Cerebral B_DISEASE
microbleeds I_DISEASE
( O
MB B_LOCATION/B_PERSON
) O
are O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
risk B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
intracerebral B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hemorrhage I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
ICH B_DISEASE/B_LOCATION
) O
, O
but O
it O
is O
unclear B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
if O
they O
are O
a O
contraindication B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
to O
using O
antithrombotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

insights B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
gained O
by O
pooling O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
MB B_MEASURE/B_DISEASE
frequency B_MEASURE/I_DISEASE
stratified O
by O
antithrombotic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
cohorts B_PERSON
with O
ICH B_DISEASE/B_LOCATION
and O
ischemic B_DISEASE_ADJECTIVE[DISEASE]
stroke I_DISEASE_ADJECTIVE[DISEASE]
( O
IS B_LOCATION
) O
/ O
transient B_DISEASE_ADJECTIVE[DISEASE]
ischemic I_DISEASE_ADJECTIVE[DISEASE]
attack I_DISEASE_ADJECTIVE[DISEASE]
( O
TIA B_LOCATION/B_ORGANIZATION
) O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
performed O
a O
systematic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
review I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
published B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
unpublished B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
cohorts B_PERSON/B_LOCATION
with O
stroke B_DISEASE/B_LOCATION
or O
TIA B_DISEASE/B_LOCATION
to O
compare O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
MB B_DISEASE/B_GENE
in O
: O
( O
1 O
) O
antithrombotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vs O
nonantithrombotic B_PERSON/B_ORGANIZATION
users I_PERSON/I_ORGANIZATION
with O
ICH B_DISEASE/B_LOCATION
; O
( O
2 O
) O
antithrombotic B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vs O
nonusers B_PERSON/B_DISEASE
with O
IS B_DISEASE/B_LOCATION
/ O
TIA B_LOCATION/B_ORGANIZATION
; O
and O
( O
3 B_NUMBER[MEASURE]
) O
ICH B_PERSON/B_LOCATION
vs I_PERSON/I_LOCATION
ischemic I_PERSON/I_LOCATION
events I_PERSON/I_LOCATION
stratified O
by O
antithrombotic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

We O
also O
analyzed O
published O
and O
unpublished B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
follow O
- O
up O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O
determine O
the O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
ICH B_DISEASE
in O
antithrombotic B_PERSON/B_ORGANIZATION
users I_PERSON/I_ORGANIZATION
with O
MB B_DISEASE/B_GENE
. O

Results O
: O
In O
a O
pooled O
analysis O
of O
1460 O
ICH O
and O
3817 O
IS O
/ O
TIA O
, O
MB O
were O
more O
frequent O
in O
ICH O
vs O
IS O
/ O
TIA O
in O
all O
treatment O
groups O
, O
but O
the O
excess O
increased O
from O
2 O
. O
8 O
( O
odds O
ratio O
; O
range O
, O
2 O
. O
3 O
- O
3 O
. O
5 O
) O
in O
nonantithrombotic O
users O
to O
5 O
. O
7 O
( O
range O
, O
3 O
. O
4 O
- O
9 O
. O
7 O
) O
in O
antiplatelet O
users O
and O
8 O
. O
0 O
( O
range O
, O
3 O
. O
5 O
- O
17 O
. O
8 O
) O
in O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
users O
( O
P O
difference O
= O
0 O
. O
01 O
) O
. O

There O
was O
also O
an O
excess O
of O
MB O
in O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
vs O
nonusers O
with O
ICH O
( O
OR O
, O
2 O
. O
7 O
; O
95 O
% O
CI O
, O
1 O
. O
6 O
- O
4 O
. O
4 O
; O
P O
< O
0 O
. O
001 O
) O
but O
none O
in O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
users O
with O
IS O
/ O
TIA O
( O
OR O
, O
1 O
. O
3 O
; O
95 O
% O
CI O
, O
0 O
. O
9 O
- O
1 O
. O
7 O
; O
P O
= O
0 O
. O
33 O
; O
P O
difference O
= O
0 O
. O
01 O
) O
. O

There O
was O
a O
smaller B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
excess B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
MB B_DISEASE/B_GENE
in O
antiplatelet B_PERSON/B_ORGANIZATION
users I_PERSON/I_ORGANIZATION
vs I_PERSON/I_ORGANIZATION
nonusers I_PERSON/I_ORGANIZATION
with O
ICH B_LOCATION/B_PERSON
( O
OR O
, O
1 B_NUMBER[MEASURE]
. O
7 B_MEASURE
; O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
, O
1 B_NUMBER[MEASURE]/B_LOCATION
. O
3 B_MEASURE
- O
2 B_NUMBER[MEASURE]
. O
3 B_MEASURE
; O
P B_OTHER/B_LOCATION
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
, O
but O
findings B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
antiplatelet B_PERSON/B_ORGANIZATION
users I_PERSON/I_ORGANIZATION
with O
IS B_LOCATION
/ O
TIA B_LOCATION/B_ORGANIZATION
( O
OR O
, O
1 B_NUMBER[MEASURE]
. O
4 B_MEASURE
; O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
, O
1 B_NUMBER[MEASURE]
. O
2 B_MEASURE
- O
1 B_NUMBER[MEASURE]
. O
7 B_MEASURE
; O
P B_MEASURE
< I_MEASURE
0 I_MEASURE
. O
001 B_MEASURE
; O
P B_LOCATION
difference I_LOCATION
= O
0 B_MEASURE
. O
25 B_MEASURE
) O
. O

In O
pooled O
follow O
- O
up O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
768 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
antithrombotic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
users I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
MB B_DISEASE/B_GENE
at O
baseline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
associated O
with O
a O
substantially O
increased O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
subsequent B_DISEASE
ICH I_DISEASE
( O
OR O
, O
12 B_MEASURE
. O
1 B_MEASURE
; O
95 B_LOCATION
% I_LOCATION
CI I_LOCATION
, O
3 B_MEASURE
. O
4 B_MEASURE
- O
42 B_MEASURE
. O
5 B_MEASURE
; O
P B_MEASURE
< I_MEASURE
0 I_MEASURE
. O
001 B_MEASURE
) O
. O

conclusions O
: O
The O
excess O
of O
MB O
in O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
with O
ICH O
compared O
to O
other O
groups O
suggests O
that O
MB O
increase O
the O
risk O
of O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
ICH O
. O

Limited B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
prospective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
corroborate O
these O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
, O
but O
larger B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prospective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
urgently O
required O
. O

Studies O
of O
synergy O
between O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
a O
novel O
sodium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
channel O
blocker O
, O
CNSB002 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
rat O
models O
of O
inflammatory O
and O
neuropathic O
pain O
. O

objective O
: O
This O
study O
determined O
the O
antihyperalgesic O
effect O
of O
CNSB002 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
sodium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
channel O
blocker O
with O
antioxidant O
properties O
given O
alone O
and O
in O
combinations O
with O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
rat O
models O
of O
inflammatory O
and O
neuropathic O
pain O
. O

Design O
: O
dose O
response O
curves O
for O
nonsedating O
doses O
of O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
CNSB002 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O
intraperitoneally O
alone O
and O
together O
in O
combinations O
were O
constructed O
for O
antihyperalgesic O
effect O
using O
paw O
withdrawal O
from O
noxious O
heat O
in O
two O
rat O
pain O
models O
: O
carrageenan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
paw O
inflammation O
and O
streptozotocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
STZ B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
induced O
diabetic O
neuropathy O
. O

Results O
: O
The O
maximum O
nonsedating O
doses O
were O
: O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
3 O
. O
2 O
mg O
/ O
kg O
; O
CNSB002 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O
. O
0 O
mg O
/ O
kg O
; O
5 O
. O
0 O
mg O
/ O
kg O
CNSB002 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
with O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 O
. O
2 O
mg O
/ O
kg O
in O
combination O
. O

The O
doses O
calculated O
to O
cause O
50 O
% O
reversal O
of O
hyperalgesia O
( O
ED50 O
) O
were O
7 O
. O
54 O
( O
1 O
. O
81 O
) O
and O
4 O
. O
83 O
( O
1 O
. O
54 O
) O
in O
the O
carrageenan B_DISEASE
model O
and O
44 O
. O
18 O
( O
1 O
. O
37 O
) O
and O
9 O
. O
14 O
( O
1 O
. O
24 O
) O
in O
the O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
neuropathy O
model O
for O
CNSB002 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
respectively O
( O
mg O
/ O
kg O
; O
mean O
, O
SEM O
) O
. O

These O
values B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
greater B_MEASURE
than O
the O
maximum B_MEASURE/B_PERSON
nonsedating I_MEASURE/I_PERSON
doses I_MEASURE/I_PERSON
. O

The O
ED50 O
values O
for O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
given O
in O
combination O
with O
CNSB002 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 O
mg O
/ O
kg O
) O
were O
less O
than O
the O
maximum O
nonsedating O
dose O
: O
0 O
. O
56 O
( O
1 O
. O
55 O
) O
in O
the O
carrageenan B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
model O
and O
1 O
. O
37 O
( O
1 O
. O
23 O
) O
in O
the O
neuropathy O
model O
( O
mg O
/ O
kg O
; O
mean O
, O
SEM O
) O
. O

The O
antinociception O
after O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
3 O
. O
2 O
mg O
/ O
kg O
) O
was O
increased O
by O
co O
- O
administration O
with O
CNSB002 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
28 O
. O
0 O
and O
31 O
. O
7 O
% O
to O
114 O
. O
6 O
and O
56 O
. O
9 O
% O
reversal O
of O
hyperalgesia O
in O
the O
inflammatory O
and O
neuropathic O
models O
, O
respectively O
( O
P O
< O
0 O
. O
01 O
; O
one O
- O
way O
analysis O
of O
variance O
- O
significantly O
greater O
than O
either O
drug O
given O
alone O
) O
. O

conclusions O
: O
The O
maximum O
antihyperalgesic O
effect O
achievable O
with O
nonsedating O
doses O
of O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
increased O
significantly O
when O
the O
drug O
is O
used O
in O
combination O
with O
CNSB002 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
thrombocytopenia O
: O
a O
practical O
review O
. O

Heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
thrombocytopenia O
( O
Hit O
) O
remains O
under O
- O
recognized O
despite O
its O
potentially O
devastating O
outcomes O
. O

It O
begins O
when O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O
stimulates O
the O
formation O
of O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
platelet O
factor O
4 O
antibodies O
, O
which O
in O
turn O
triggers O
the O
release O
of O
procoagulant O
platelet O
particles O
. O

thrombosis B_DISEASE
and O
thrombocytopenia B_DISEASE
that O
follow O
comprise O
the O
2 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
hallmark I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
traits I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
HIT B_DISEASE/B_LOCATION
, O
with O
the O
former B_PERSON/B_DISEASE
largely O
responsible B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
for O
significant B_DISEASE_ADJECTIVE[DISEASE]
vascular I_DISEASE_ADJECTIVE[DISEASE]
complications I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
prevalence B_DISEASE_ADJECTIVE[DISEASE]
of O
HIT B_DISEASE
varies O
among O
several B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
subgroups I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
, O
with O
greater B_MEASURE
incidence I_MEASURE
in O
surgical B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
as O
compared O
with O
medical B_PERSON
populations I_PERSON
. O

Hit O
must O
be O
acknowledged O
for O
its O
intense O
predilection O
for O
thrombosis O
and O
suspected O
whenever O
thrombosis O
occurs O
after O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O
. O

Early B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recognition I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
incorporates O
the O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
serologic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
clues I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
is O
paramount B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O
timely B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
institution I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
of O
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
its O
delay B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
may O
result O
in O
catastrophic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
treatment O
of O
Hit O
mandates O
an O
immediate O
cessation O
of O
all O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
exposure O
and O
the O
institution O
of O
an O
antithrombotic O
therapy O
, O
most O
commonly O
using O
a O
direct B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thrombin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Current B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
diagnostic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
tests I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
which O
primarily O
include O
functional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
antigenic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
assays I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
have O
more B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
confirmatory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
than O
diagnostic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
management B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
HIT B_DISEASE/B_LOCATION
. O

Special O
attention O
must O
be O
paid O
to O
cardiac O
patients O
who O
are O
often O
exposed O
to O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
multiple O
times O
during O
their O
course O
of O
treatment O
. O

Direct B_NUMBER[MEASURE]/B_PERSON
thrombin B_NUMBER[MEASURE]/I_PERSON
inhibitors B_NUMBER[MEASURE]/I_PERSON
are O
appropriate O
, O
evidence O
- O
based O
alternatives O
to O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
patients O
with O
a O
history O
of O
Hit O
, O
who O
need O
to O
undergo O
percutaneous O
coronary O
intervention O
. O

As O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
remains O
one O
of O
the O
most O
frequently O
used O
medications O
today O
with O
potential O
for O
Hit O
with O
every O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O
, O
a O
close O
vigilance O
of O
platelet O
counts O
must O
be O
practiced O
whenever O
heparin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O
initiated O
. O

Abductor O
paralysis O
after O
botox B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O
for O
adductor O
spasmodic O
dysphonia O
. O

objectives O
/ O
hypothesis O
: O
Botulinum O
toxin O
( O
Botox B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
injections O
into O
the O
thyroarytenoid O
muscles O
are O
the O
current O
standard O
of O
care O
for O
adductor O
spasmodic O
dysphonia O
( O
ADSD O
) O
. O

reported O
adverse B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
include O
a O
period B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
breathiness B_DISEASE
, O
throat B_DISEASE
pain I_DISEASE
, O
and O
difficulty B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
swallowing O
liquids B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Here O
we O
report O
multiple O
cases O
of O
bilateral O
abductor O
paralysis O
following O
Botox B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
injections O
for O
ADSD O
, O
a O
complication O
previously O
unreported O
. O

Study B_LOCATION/B_MEASURE
Design I_LOCATION/I_MEASURE
: O
Retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
case I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
series I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

methods O
: O
patients O
that O
received O
Botox B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
injections O
for O
spasmodic O
dysphonia O
between O
January O
2000 O
and O
October O
2009 O
were O
evaluated O
. O

patients B_PERSON
with O
ADSD B_DISEASE/B_LOCATION
were O
identified O
. O

The O
number B_MEASURE
of O
treatments B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
received O
and O
adverse B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
noted O
. O

For O
patients O
with O
bilateral O
abductor O
paralysis O
, O
age O
, O
sex O
, O
paralytic O
Botox B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
dose O
, O
prior O
Botox B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O
, O
and O
course O
following O
paralysis O
were O
noted O
. O

Results O
: O
From O
a O
database O
of O
452 O
patients O
receiving O
Botox B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
352 O
patients O
had O
been O
diagnosed O
with O
ADSD O
. O

Of O
these O
352 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
, O
eight B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
suffered O
bilateral B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
abductor I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
paralysis I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
two B_NUMBER[MEASURE]/B_PERSON
suffered O
this O
complication B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
twice O
. O

All O
affected O
patients B_PERSON
were O
females B_PERSON/B_LOCATION
over O
the O
age B_TIME[MEASURE]/B_LOCATION
of O
50 B_NUMBER[MEASURE]/B_ENT
years I_NUMBER[MEASURE]/I_ENT
. O

Most B_PERSON
patients I_PERSON
had O
received O
treatments B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prior I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
abductor B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
paralysis I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
continued O
receiving B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
after O
paralysis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Seven B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
recovered O
after O
a O
brief B_TIME[MEASURE]
period I_TIME[MEASURE]
of O
activity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
restrictions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
one B_NUMBER[MEASURE]/B_PERSON
underwent O
a O
tracheotomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
incidence O
of O
abductor O
paralysis O
after O
Botox B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
injection O
for O
ADSD O
was O
0 O
. O
34 O
% O
. O

conclusions O
: O
bilateral O
abductor O
paralysis O
is O
a O
rare O
complication O
of O
Botox B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
injections O
for O
ADSD O
, O
causing O
difficulty O
with O
breathing O
upon O
exertion O
. O

The O
likely O
mechanism O
of O
paralysis O
is O
diffusion O
of O
Botox B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
around O
the O
muscular O
process O
of O
the O
arytenoid O
to O
the O
posterior O
cricoarytenoid O
muscles O
. O

The O
paralysis B_DISEASE
is O
temporary B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
watchful B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
waiting O
with O
restriction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
activity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
is O
the O
recommended B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
management I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
. O

mitochondrial O
impairment O
contributes O
to O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cardiac O
dysfunction O
: O
Prevention O
by O
the O
targeted O
antioxidant O
MitoQ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
goal O
of O
this O
study O
was O
to O
assess O
mitochondrial O
function O
and O
ROS O
production O
in O
an O
experimental O
model O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cardiac O
dysfunction O
. O

We O
hypothesized O
that O
cocaine B_DISEASE
abuse I_DISEASE
may O
lead O
to O
altered B_DISEASE
mitochondrial I_DISEASE
function I_DISEASE
that O
in O
turn B_GENE/B_PERSON
may O
cause O
left O
ventricular B_DISEASE
dysfunction I_DISEASE
. O

Seven O
days O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
administration O
to O
rats O
led O
to O
an O
increased O
oxygen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption O
detected O
in O
cardiac O
fibers O
, O
specifically O
through O
complex O
I O
and O
complex O
III O
. O

ROS B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
increased O
, O
specifically O
in O
interfibrillar B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
mitochondria I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
parallel O
there O
was O
a O
decrease O
in O
ATP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O
, O
whereas O
no O
difference O
was O
observed O
in O
subsarcolemmal O
mitochondria O
. O

This O
uncoupling O
effect O
on O
oxidative O
phosphorylation O
was O
not O
detectable O
after O
short O
- O
term O
exposure O
to O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
suggesting O
that O
these O
mitochondrial O
abnormalities O
were O
a O
late O
rather O
than O
a O
primary O
event O
in O
the O
pathological O
response O
to O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

MitoQ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
mitochondrial O
- O
targeted O
antioxidant O
, O
was O
shown O
to O
completely O
prevent O
these O
mitochondrial O
abnormalities O
as O
well O
as O
cardiac O
dysfunction O
characterized O
here O
by O
a O
diastolic O
dysfunction O
studied O
with O
a O
conductance O
catheter O
to O
obtain O
pressure O
- O
volume O
data O
. O

taken O
together O
, O
these O
results O
extend O
previous O
studies O
and O
demonstrate O
that O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cardiac O
dysfunction O
may O
be O
due O
to O
a O
mitochondrial O
defect O
. O

Trimethoprim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
immune O
hemolytic O
anemia O
in O
a O
pediatric O
oncology O
patient O
presenting O
as O
an O
acute O
hemolytic O
transfusion O
reaction O
. O

A O
10 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
- O
old B_PERSON
male I_PERSON
with O
acute B_DISEASE
leukemia I_DISEASE
presented O
with O
post B_DISEASE/B_MEASURE
- O
chemotherapy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
anemia I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

During O
red B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
cell I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
transfusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
he O
developed O
hemoglobinuria B_DISEASE
. O

transfusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
workup I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
immune B_DISEASE
hemolytic I_DISEASE
anemia I_DISEASE
was O
suspected O
because O
of O
positive B_DISEASE
direct I_DISEASE
antiglobulin I_DISEASE
test I_DISEASE
, O
negative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
eluate I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
microspherocytes B_BACTERIUM[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
on O
smear B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pre I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
post B_DISEASE/B_MEASURE
- O
transfusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Drug O
studies O
using O
the O
indirect O
antiglobulin O
test O
were O
strongly O
positive O
with O
trimethoprim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
trimethoprim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfamethoxazole I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
negative O
with O
sulfamethoxazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O

The O
patient B_PERSON/B_DISEASE
recovered O
after O
discontinuing O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
with O
no O
recurrence B_DISEASE
in O
2 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
. O

Other B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
causes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
anemia B_DISEASE
should O
be O
considered O
in O
patients B_PERSON/B_BIO
with O
worse B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
than O
- O
expected O
anemia B_DISEASE
after O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Furthermore O
, O
hemolysis B_DISEASE
during O
transfusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
not O
always O
a O
transfusion B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O
test O
in O
hyperprolactinemia O
: O
loss O
of O
prolactin O
response O
in O
anatomic O
or O
functional O
stalk O
effect O
. O

aim O
: O
Verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
stimulation O
test O
was O
previously O
investigated O
as O
a O
tool O
for O
differential O
diagnosis O
of O
hyperprolactinemia O
, O
but O
with O
conflicting O
results O
. O

Macroprolactinemia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
was O
never O
considered O
in O
those O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Here O
, O
we O
aimed O
to O
re O
- O
investigate O
the O
diagnostic O
value O
of O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
a O
population O
who O
were O
all O
screened O
for O
macroprolactinemia O
. O

Prolactin O
responses O
to O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
65 O
female O
patients O
( O
age O
: O
29 O
. O
9 O
+ O
/ O
- O
8 O
. O
1 O
years O
) O
with O
hyperprolactinemia O
were O
tested O
in O
a O
descriptive O
, O
matched O
case O
- O
control O
study O
. O

methods O
: O
Verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
80 O
mg O
, O
p O
. O
o O
. O
was O
administered O
, O
and O
then O
PRL O
levels O
were O
measured O
at O
8th O
and O
16th O
hours O
, O
by O
immunometric O
chemiluminescence O
. O

Verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
responsiveness O
was O
determined O
by O
peak O
percent O
change O
in O
basal O
prolactin O
levels O
( O
PRL O
) O
. O

Results O
: O
Verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
significantly O
increased O
PRL O
levels O
in O
healthy O
controls O
( O
N O
. O
8 O
, O
PRL O
: O
183 O
% O
) O
, O
macroprolactinoma O
( O
N O
. O
8 O
, O
PRL O
: O
7 O
% O
) O
, O
microprolactinoma O
( O
N O
. O
19 O
, O
PRL O
: O
21 O
% O
) O
, O
macroprolactinemia O
( O
N O
. O
23 O
, O
PRL O
: O
126 O
% O
) O
, O
but O
not O
in O
pseudoprolactinoma O
( O
N O
. O
8 O
, O
PRL O
: O
0 O
. O
8 O
% O
) O
, O
and O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
hyperprolactinemia O
( O
N O
. O
7 O
, O
PRL O
: O
3 O
% O
) O
. O

ROC O
curve O
analysis O
revealed O
that O
unresponsiveness O
to O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
defined O
as O
PRL O
< O
7 O
% O
, O
discriminated O
anatomical O
or O
functional O
stalk O
effect O
( O
sensitivity O
: O
74 O
% O
, O
specificity O
: O
73 O
% O
, O
AUC O
: O
0 O
. O
855 O
+ O
/ O
- O
0 O
. O
04 O
, O
P O
< O
0 O
. O
001 O
, O
CI O
: O
0 O
. O
768 O
- O
0 O
. O
942 O
) O
associated O
with O
pseudoprolactinoma O
or O
risperidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
hyperprolactinemia O
, O
respectively O
. O

conclusion O
: O
Verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
responsiveness O
is O
not O
a O
reliable O
finding O
for O
the O
differential O
diagnosis O
of O
hyperprolactinemia O
. O

However O
, O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
unresponsiveness O
discriminates O
stalk O
effect O
( O
i O
. O
e O
. O
, O
anatomically O
or O
functionally O
inhibited O
dopaminergic O
tonus O
) O
from O
other O
causes O
of O
hyperprolactinemia O
with O
varying O
degrees O
of O
responsiveness O
. O

blockade O
of O
endothelial O
- O
mesenchymal O
transition O
by O
a O
Smad3 O
inhibitor O
delays O
the O
early O
development O
of O
streptozotocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
diabetic O
nephropathy O
. O

objective O
: O
A O
multicenter O
, O
controlled O
trial O
showed O
that O
early O
blockade O
of O
the O
renin O
- O
angiotensin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
system O
in O
patients O
with O
type O
1 O
diabetes O
and O
normoalbuminuria O
did O
not O
retard O
the O
progression O
of O
nephropathy O
, O
suggesting O
that O
other O
mechanism O
( O
s O
) O
are O
involved O
in O
the O
pathogenesis O
of O
early O
diabetic O
nephropathy O
( O
diabetic O
nephropathy O
) O
. O

We O
have O
previously O
demonstrated O
that O
endothelial O
- O
mesenchymal O
- O
transition O
( O
EndoMT O
) O
contributes O
to O
the O
early O
development O
of O
renal O
interstitial O
fibrosis O
independently O
of O
microalbuminuria O
in O
mice O
with O
streptozotocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
STZ B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
induced O
diabetes O
. O

In O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
hypothesized O
that O
blocking O
EndoMT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduces O
the O
early B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
development I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
diabetic B_DISEASE/B_GENE
nephropathy I_DISEASE/I_GENE
. O

Research B_NUMBER[MEASURE]/B_ORGANIZATION
Design I_NUMBER[MEASURE]/I_ORGANIZATION
AND O
METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
EndoMT B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
induced O
in O
a O
mouse B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
pancreatic I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
microvascular I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
endothelial I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cell I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
line I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
( O
MMEC B_DISEASE/B_TIME[MEASURE]
) O
in O
the O
presence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
advanced B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
glycation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
end I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
products I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
AGEs B_DISEASE/B_BACTERIUM[BIO]
) O
and O
in O
the O
endothelial B_DISEASE/B_GENE
lineage I_DISEASE/I_GENE
- O
traceble B_GENE/B_DISEASE
mouse I_GENE/I_DISEASE
line I_GENE/I_DISEASE
Tie2 I_GENE/I_DISEASE
- O
Cre B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
Loxp B_GENE/B_MEASURE
- O
EGFP B_GENE/B_MEASURE
by O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
AGEs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O
with O
nonglycated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mouse I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
albumin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
serving O
as O
a O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Phosphorylated B_PERSON/B_DISEASE
Smad3 I_PERSON/I_DISEASE
was O
detected O
by O
immunoprecipitation B_LOCATION/B_PERSON
/ O
Western B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blotting I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
confocal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

blocking O
studies O
using O
receptor O
for O
Age O
siRNA O
and O
a O
specific O
inhibitor O
of O
Smad3 O
( O
SIS3 O
) O
were O
performed O
in O
MMECs O
and O
in O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
diabetic O
nephropathy O
in O
Tie2 O
- O
Cre O
; O
Loxp O
- O
EGFP O
mice O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
confocal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
real B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
time B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PCR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O
that O
AGEs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
induced O
EndoMT O
in O
MMECs B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
and O
in O
Tie2 B_GENE
- O
Cre B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
Loxp B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
EGFP B_GENE
mice I_GENE
. O

Immunoprecipitation O
/ O
Western O
blotting O
showed O
that O
Smad3 O
was O
activated O
by O
Ages O
but O
was O
inhibited O
by O
SIS3 O
in O
MMECs O
and O
in O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
diabetic O
nephropathy O
. O

confocal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microscopy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
real B_PERSON/B_MEASURE
- O
time B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
PCR I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
further O
demonstrated O
that O
SIS3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
abrogated O
EndoMT B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
reduced O
renal B_DISEASE/B_GENE
fibrosis I_DISEASE/I_GENE
, O
and O
retarded B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
progression I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
nephropathy B_DISEASE
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
EndoMT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
novel B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pathway I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
leading O
to O
early B_DISEASE_ADJECTIVE[DISEASE]
development I_DISEASE_ADJECTIVE[DISEASE]
of O
diabetic B_DISEASE
nephropathy I_DISEASE
. O

blockade B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
EndoMT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
SIS3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O
provide O
a O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
strategy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
retard O
the O
progression B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
diabetic B_DISEASE
nephropathy I_DISEASE
and O
other B_DISEASE/B_GENE
diabetes I_DISEASE/I_GENE
complications I_DISEASE/I_GENE
. O

Cytostatic O
and O
anti O
- O
angiogenic O
effects O
of O
temsirolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
refractory O
mantle O
cell O
lymphoma O
. O

mantle B_DISEASE
cell I_DISEASE
lymphoma I_DISEASE
( O
MCL B_DISEASE
) O
is O
a O
rare B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
aggressive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
type I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
B B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
cell B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
non I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O
Hodgkin B_DISEASE/B_GENE
' O
s B_DISEASE
lymphoma I_DISEASE
. O

patients B_PERSON/B_DISEASE
become O
progressively O
refractory B_DISEASE_ADJECTIVE[DISEASE]
to O
conventional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
their O
prognosis B_DISEASE
is O
poor B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
a O
38 O
% O
remission O
rate O
has O
been O
recently O
reported O
in O
refractory O
MCL O
treated O
with O
temsirolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
mTOR O
inhibitor O
. O
Here O
we O
had O
the O
opportunity O
to O
study O
a O
case O
of O
refractory O
MCL O
who O
had O
tumor O
regression O
two O
months O
after O
temsirolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
, O
and O
a O
progression O
- O
free O
survival O
of O
10 O
months O
. O

In O
this O
case O
, O
lymph O
node O
biopsies O
were O
performed O
before O
and O
six O
months O
after O
temsirolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

comparison O
of O
the O
two O
biopsies O
showed O
that O
temsirolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
inhibited O
tumor O
cell O
proliferation O
through O
cell O
cycle O
arrest O
, O
but O
did O
not O
induce O
any O
change O
in O
the O
number O
of O
apoptotic O
tumor O
cells O
. O

Apart O
from O
this O
cytostatic O
effect O
, O
temsirolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
had O
an O
antiangiogenic O
effect O
with O
decrease O
of O
tumor O
microvessel O
density O
and O
of O
VEGF O
expression O
. O

Moreover O
, O
numerous O
patchy O
, O
well O
- O
limited O
fibrotic O
areas O
, O
compatible O
with O
post O
- O
necrotic O
tissue O
repair O
, O
were O
found O
after O
6 O
- O
month O
temsirolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O
. O

Thus O
, O
temsirolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reduced O
tumor O
burden O
through O
associated O
cytostatic O
and O
anti O
- O
angiogenic O
effects O
. O
This O
dual O
effect O
of O
temsirolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
tumor O
tissue O
could O
contribute O
to O
its O
recently O
reported O
efficiency O
in O
refractory O
MCL O
resistant O
to O
conventional O
chemotherapy O
. O

acute O
renal O
failure O
due O
to O
rifampicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

A O
23 B_MEASURE
- O
year B_TIME[MEASURE]
- O
old B_PERSON
male I_PERSON
patient I_PERSON
with O
bacteriologically O
proven O
pulmonary B_DISEASE
tuberculosis I_DISEASE
was O
treated O
with O
the O
various B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
regimens I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
antituberculosis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
nearly O
15 B_TIME[MEASURE]/B_PERSON
months I_TIME[MEASURE]/I_PERSON
. O

Rifampicin B_PERSON
was O
administered O
thrice O
as O
one O
of O
the O
3 O
- O
4 O
drug O
regimen O
and O
each O
time O
he O
developed O
untoward O
side O
effects O
like O
nausea O
, O
vomiting O
and O
fever O
with O
chills O
and O
rigors O
. O

The O
last B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
episode I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
of O
acute B_DISEASE/B_LOCATION
renal I_DISEASE/I_LOCATION
failure I_DISEASE/I_LOCATION
at O
which O
stage B_TIME[MEASURE]/B_ENT
the O
patient B_PERSON/B_DISEASE
was O
seen O
by O
the O
authors B_PERSON
of O
this O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

The O
patient B_PERSON/B_ORGANIZATION
, O
however O
, O
made O
a O
full B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Syncope O
caused O
by O
hyperkalemia O
during O
use O
of O
a O
combined O
therapy O
with O
the O
angiotensin B_GENE
- O
converting O
enzyme O
inhibitor O
and O
spironolactone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
76 B_TIME[MEASURE]/B_PERSON
year I_TIME[MEASURE]/I_PERSON
- O
old B_PERSON
woman I_PERSON
with O
a O
history B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
coronary B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
bypass I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
grafting I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
prior B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
myocardial B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
transferred O
to O
the O
emergency B_LOCATION
room I_LOCATION
with O
loss B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
consciousness B_DISEASE
due O
to O
marked O
bradycardia B_DISEASE
caused O
by O
hyperkalemia B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
concentration O
of O
serum O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
high O
, O
and O
normal O
sinus O
rhythm O
was O
restored O
after O
correction O
of O
the O
serum O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
level O
. O

The O
cause O
of O
hyperkalemia O
was O
considered O
to O
be O
several O
doses O
of O
spiranolactone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
an O
aldosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
antagonist O
, O
in O
addition O
to O
the O
long O
- O
term O
intake O
of O
ramipril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
an O
ace O
inhibitor O
. O

This O
case B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
good B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
example I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
electrolyte B_DISEASE
imbalance I_DISEASE
causing O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
life I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O
threatening O
cardiac B_DISEASE
events I_DISEASE
. O

Clinicians O
should O
be O
alert O
to O
the O
possibility O
of O
hyperkalemia O
, O
especially O
in O
elderly O
patients O
using O
ace O
/ O
ARB O
in O
combination O
with O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
sparing O
agents O
and O
who O
have O
mild O
renal O
disturbance O
. O

Diffuse O
skeletal O
pain O
after O
administration O
of O
alendronate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background O
: O
Osteoporosis O
is O
caused O
by O
bone O
resorption O
in O
excess O
of O
bone O
formation O
, O
and O
bisphosphonates B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
are O
used O
to O
inhibit O
bone O
resorption O
. O

Alendronate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
biphosphonate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
effective O
for O
both O
the O
treatment O
and O
prevention O
of O
osteoporosis O
in O
postmenopausal O
women O
. O

Side B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
relatively O
few B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
prominently O
gastrointestinal B_DISEASE_ADJECTIVE[DISEASE]
. O

musculoskeletal B_DISEASE
pain I_DISEASE
may O
be O
an O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
these O
patients B_PERSON/B_DISEASE
. O

We O
presented O
a O
patient O
admitted O
to O
our O
out O
- O
patient O
clinic O
with O
diffuse O
skeletal O
pain O
after O
three O
consecutive O
administration O
of O
alendronate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusion O
: O
We O
conclude O
that O
patients O
with O
osteoporosis O
can O
report O
pain O
, O
and O
bisphosphonate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
related O
pain O
should O
also O
be O
considered O
before O
ascribing O
this O
complaint O
to O
osteoporosis O
. O

Cerebrospinal O
fluid O
penetration O
of O
high O
- O
dose O
daptomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
in O
suspected O
Staphylococcus O
aureus O
meningitis O
. O

objective O
: O
To O
report O
a O
case O
of O
methicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
sensitive O
Staphylococcus O
aureus O
( O
MSSA O
) O
bacteremia O
with O
suspected O
MSSA O
meningitis O
treated O
with O
high O
- O
dose O
daptomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
assessed O
with O
concurrent O
serum O
and O
cerebrospinal O
fluid O
( O
CSF O
) O
concentrations O
. O

Case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
summary I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
: O
A O
54 B_MEASURE
- O
year B_TIME[MEASURE]
- O
old B_PERSON
male I_PERSON
presented O
to O
the O
emergency B_LOCATION/B_PERSON
department I_LOCATION/I_PERSON
with O
generalized B_DISEASE
weakness I_DISEASE
and O
presumed O
health B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
- O
care B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
associated O
pneumonia B_DISEASE
shown O
on O
chest B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
radiograph I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Treatment O
was O
empirically O
initiated O
with O
vancomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
levofloxacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
piperacillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
/ O
tazobactam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Blood O
cultures O
revealed O
S O
. O
aureus O
susceptible O
to O
oxacillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Empiric O
antibiotic O
treatment O
was O
narrowed O
to O
nafcillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
on O
day O
4 O
. O

On O
day O
8 O
, O
the O
patient O
developed O
acute O
renal O
failure O
( O
serum O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
1 O
. O
9 O
mg O
/ O
DL O
, O
increased O
from O
1 O
. O
2 O
mg O
/ O
DL O
the O
previous O
day O
and O
0 O
. O
8 O
mg O
/ O
DL O
on O
admission O
) O
. O

The O
patient B_PERSON/B_ORGANIZATION
' O
s B_MEASURE/B_DISEASE
Glasgow I_MEASURE/I_DISEASE
coma I_MEASURE/I_DISEASE
Score I_MEASURE/I_DISEASE
was O
3 B_MEASURE
, O
with O
normal B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shown O
on O
computed B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tomography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scan I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
head B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
72 I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
hours I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
following O
an O
episode B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cardiac B_DISEASE
arrest I_DISEASE
on O
day B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
10 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O

The O
patient B_PERSON/B_ORGANIZATION
experienced O
relapsing O
MSSA B_DISEASE
bacteremia I_DISEASE
on O
day B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
9 I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
increasing O
the O
suspicion B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
a O
central B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
nervous B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
system B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
CNS B_LOCATION/B_ORGANIZATION
) O
infection B_DISEASE/B_LOCATION
. O

Nafcillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
was O
discontinued O
and O
daptomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
9 O
mg O
/ O
kg O
daily O
was O
initiated O
for O
suspected O
meningitis O
and O
was O
continued O
until O
the O
patient O
' O
s O
death O
on O
day O
16 O
. O

Daptomycin B_MEASURE/B_BACTERIUM[BIO]
serum O
and O
CSF O
trough O
concentrations O
were O
11 O
. O
21 O
ug O
/ O
mL O
and O
0 O
. O
52 O
ug O
/ O
mL O
, O
respectively O
, O
prior O
to O
the O
third O
dose O
. O

lumbar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
puncture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O
inconclusive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
no O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blood I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
cultures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
MSSA B_DISEASE/B_BACTERIUM[BIO]
. O

Creatine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kinase O
levels O
were O
normal O
prior O
to O
daptomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
therapy O
and O
were O
not O
reassessed O
. O

discussion O
: O
Daptomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
was O
initiated O
in O
our O
patient O
secondary O
to O
possible O
nafcillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
induced O
acute O
interstitial O
nephritis O
and O
relapsing O
bacteremia O
. O

At O
a O
dose B_MEASURE/B_LOCATION
of O
9 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
, O
resultant B_DISEASE_ADJECTIVE[DISEASE]
penetration I_DISEASE_ADJECTIVE[DISEASE]
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
in O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
more O
consistent B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
with O
inflamed B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
meninges B_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusions O
: O
High O
- O
dose O
daptomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
may O
be O
an O
alternative O
option O
for O
MSSA O
bacteremia O
with O
or O
without O
a O
CNS O
source O
in O
patients O
who O
have O
failed O
or O
cannot O
tolerate O
standard O
therapy O
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clinical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients B_PERSON/B_BIO
with O
confirmed B_DISEASE
meningitis I_DISEASE
is O
warranted O
. O

The O
role O
of O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
convulsions O
induced O
by O
lindane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
rats O
. O

Lindane B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
an O
organochloride O
pesticide O
and O
scabicide O
. O

It O
evokes O
convulsions O
mainly O
trough O
the O
blockage O
of O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
A O
) O
receptors O
. O

Nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
NO B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
gaseous O
neurotransmitter O
, O
has O
contradictor O
role O
in O
epileptogenesis O
due O
to O
opposite O
effects O
of O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
arginine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
precursor O
of O
NO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
syntheses O
( O
NOS O
) O
, O
and O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
NAME I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
NOS O
inhibitor O
) O
observed O
in O
different O
epilepsy O
models O
. O

The O
aim O
of O
the O
current O
study O
was O
to O
determine O
the O
effects O
of O
NO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
behavioral O
and O
EEG O
characteristics O
of O
lindane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
epilepsy O
in O
male O
Wistar O
albino O
rats O
. O

The O
administration O
of O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
arginine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
600 O
, O
800 O
and O
1000 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
in O
dose O
- O
dependent O
manner O
significantly O
increased O
convulsion O
incidence O
and O
severity O
and O
shortened O
latency O
time O
to O
first O
convulsion O
elicited O
by O
lower O
lindane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dose O
( O
4 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

On O
the O
contrary O
, O
pretreatment O
with O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
NAME I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
500 O
, O
700 O
and O
900 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
decreased O
convulsion O
incidence O
and O
severity O
and O
prolonged O
latency O
time O
to O
convulsion O
following O
injection O
with O
a O
convulsive O
dose O
of O
lindane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
8 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

EEG O
analyses O
showed O
increase O
of O
number O
and O
duration O
of O
ictal O
periods O
in O
EEG O
of O
rats O
receiving O
l B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
arginine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
prior O
to O
lindane B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
decrease O
of O
this O
number O
in O
rats O
pretreated O
with O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
NAME I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
results O
support O
the O
conclusion O
that O
NO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plays O
a O
role O
of O
endogenous O
convulsant O
in O
rat O
model O
of O
lindane B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
seizures O
. O

severe O
polyneuropathy O
and O
motor O
loss O
after O
intrathecal O
thiotepa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
combination O
chemotherapy O
: O
description O
of O
two O
cases O
. O

Two O
cases O
of O
severe O
delayed O
neurologic O
toxicity O
related O
to O
the O
administration O
of O
intrathecal O
( O
IT O
) O
combination O
chemotherapy O
including O
thiotepa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O
TSPA B_LOCATION/B_ORGANIZATION
) O
are O
presented O
. O

Both O
cases B_PERSON/B_LOCATION
developed O
axonal B_DISEASE/B_LOCATION
neuropathy I_DISEASE/I_LOCATION
with O
motor B_DISEASE
predominance I_DISEASE
in O
the O
lower B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
extremities I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
1 I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
6 B_TIME[MEASURE]
months I_TIME[MEASURE]
after O
IT O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
administered O
. O

Neurologic O
toxicities O
have O
been O
described O
with O
IT O
- O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
IT O
- O
cytosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
arabinoside I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
IT O
- O
TSPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

To O
our O
knowledge B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
however O
, O
axonal B_DISEASE
neuropathy I_DISEASE
following O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
these O
three B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
not O
been O
previously O
described O
. O

In O
spite O
of O
the O
fact O
that O
TSPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
a O
useful O
IT O
agent O
, O
its O
combination O
with O
MTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ara B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
radiotherapy O
could O
cause O
severe O
neurotoxicity O
. O

This O
unexpected O
complication O
indicates O
the O
need O
for O
further O
toxicology O
research O
on O
IT O
- O
TSPA B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Effects O
of O
cromakalim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pinacidil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
large O
epicardial O
and O
small O
coronary O
arteries O
in O
conscious O
dogs O
. O

The O
effects O
of O
i O
. O
v O
. O
bolus O
administration O
of O
cromakalim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 O
- O
10 O
micrograms O
/ O
kg O
) O
and O
pinacidil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3 O
- O
100 O
micrograms O
/ O
kg O
) O
on O
large O
( O
circumflex O
artery O
) O
and O
small O
coronary O
arteries O
and O
on O
systemic O
hemodynamics O
were O
investigated O
in O
chronically O
instrumented O
conscious O
dogs O
and O
compared O
to O
those O
of O
nitroglycerin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 O
. O
03 O
- O
10 O
micrograms O
/ O
kg O
) O
. O

Nitroglycerin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
up O
to O
0 O
. O
3 O
micrograms O
/ O
kg O
, O
selectively O
increased O
circumflex O
artery O
diameter O
( O
CxAD O
) O
without O
simultaneously O
affecting O
any O
other O
cardiac O
or O
systemic O
hemodynamic O
parameter O
. O

In O
contrast O
, O
cromakalim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pinacidil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
all O
doses O
and O
nitroglycerin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
doses O
higher O
than O
0 O
. O
3 O
micrograms O
/ O
kg O
simultaneously O
and O
dose O
- O
dependently O
increased O
CxAD O
, O
coronary O
blood O
flow O
and O
heart O
rate O
and O
decreased O
coronary O
vascular O
resistance O
and O
aortic O
pressure O
. O

Cromakalim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
approximately O
8 O
- O
to O
9 O
. O
5 O
- O
fold O
more O
potent O
than O
pinacidil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
increasing O
CxAD O
. O

Vasodilation O
of O
large O
and O
small O
coronary O
vessels O
and O
hypotension O
induced O
by O
cromakalim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pinacidil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
not O
affected O
by O
prior O
combined O
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
adrenergic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
muscarinic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
receptors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockade I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
but O
drug O
- O
induced O
tachycardia O
was O
abolished O
. O

When O
circumflex O
artery O
blood O
flow O
was O
maintained O
constant O
, O
the O
increases O
in O
CxAD O
induced O
by O
cromakalim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 O
micrograms O
/ O
kg O
) O
, O
pinacidil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
30 O
micrograms O
/ O
kg O
) O
and O
nitroglycerin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 O
micrograms O
/ O
kg O
) O
were O
reduced O
by O
68 O
+ O
/ O
- O
7 O
, O
54 O
+ O
/ O
- O
9 O
and O
1 O
+ O
/ O
- O
1 O
% O
, O
respectively O
. O

Thus O
, O
whereas O
nitroglycerin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preferentially O
and O
flow O
- O
independently O
dilates O
large O
coronary O
arteries O
, O
cromakalim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pinacidil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dilate O
both O
large O
and O
small O
coronary O
arteries O
and O
this O
effect O
is O
not O
dependent O
upon O
the O
simultaneous O
beta O
adrenoceptors O
- O
mediated O
rise O
in O
myocardial O
metabolic O
demand O
. O

Finally O
, O
two O
mechanisms O
at O
least O
, O
direct O
vasodilation O
and O
flow O
dependency O
, O
are O
involved O
in O
the O
cromakalim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
pinacidil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
increase O
in O
CxAD O
. O

Mefenamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
neutropenia O
and O
renal O
failure O
in O
elderly O
females O
with O
hypothyroidism O
. O

We O
report O
mefenamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
non O
- O
oliguric O
renal O
failure O
and O
severe O
neutropenia O
occurring O
simultaneously O
in O
two O
elderly O
females O
. O

The O
neutropenia B_DISEASE
was O
due O
to O
maturation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
arrest I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
myeloid B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
series B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
one B_PERSON/B_BIO
patient B_PERSON/I_BIO
. O

Both O
patients B_PERSON/B_BIO
were O
also O
hypothyroid B_DISEASE_ADJECTIVE[DISEASE]
, O
but O
it O
is O
not O
clear B_DISEASE_ADJECTIVE[DISEASE]
whether O
this O
was O
a O
predisposing B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factor I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
the O
development B_DISEASE_ADJECTIVE[DISEASE]
of O
these O
adverse B_DISEASE
reactions I_DISEASE
. O

However O
, O
it O
would O
seem O
prudent O
not O
to O
use O
mefenamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
hypothyroid O
patients O
until O
the O
hypothyroidism O
has O
been O
corrected O
. O

Etiology O
of O
hypercalcemia O
in O
hemodialysis O
patients O
on O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
carbonate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
therapy O
. O

Fourteen O
of O
39 O
dialysis O
patients O
( O
36 O
% O
) O
became O
hypercalcemic O
after O
switching O
to O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
carbonate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
as O
their O
principal O
phosphate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
binder O
. O

In O
order O
to O
identify O
risk O
factors O
associated O
with O
the O
development O
of O
hypercalcemia O
, O
indirect O
parameters O
of O
intestinal O
calcium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reabsorption O
and O
bone O
turnover O
rate O
in O
these O
14 O
patients O
were O
compared O
with O
results O
in O
14 O
eucalcemic O
patients O
matched O
for O
age O
, O
sex O
, O
length O
of O
time O
on O
dialysis O
, O
and O
etiology O
of O
renal O
disease O
. O

In O
addition O
to O
experiencing O
hypercalcemic O
episodes O
with O
peak O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
values O
of O
2 O
. O
7 O
to O
3 O
. O
8 O
mmol O
/ O
L O
( O
10 O
. O
7 O
to O
15 O
. O
0 O
mg O
/ O
DL O
) O
, O
patients O
in O
the O
hypercalcemic O
group O
exhibited O
a O
significant O
increase O
in O
the O
mean O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O
obtained O
during O
6 O
months O
before O
the O
switch O
, O
compared O
with O
the O
mean O
value O
obtained O
during O
the O
7 O
months O
of O
observation O
after O
the O
switch O
( O
2 O
. O
4 O
+ O
/ O
- O
0 O
. O
03 O
to O
2 O
. O
5 O
+ O
/ O
- O
0 O
. O
03 O
mmol O
/ O
L O
[ O
9 O
. O
7 O
+ O
/ O
- O
0 O
. O
2 O
to O
10 O
. O
2 O
+ O
/ O
- O
0 O
. O
1 O
mg O
/ O
DL O
] O
, O
P O
= O
0 O
. O
006 O
) O
. O

In O
contrast O
, O
eucalcemic O
patients O
exhibited O
no O
change O
in O
mean O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O
over O
the O
same O
time O
period O
( O
2 O
. O
3 O
+ O
/ O
- O
0 O
. O
05 O
to O
2 O
. O
3 O
+ O
/ O
- O
0 O
. O
05 O
mmol O
/ O
L O
[ O
9 O
. O
2 O
+ O
/ O
- O
0 O
. O
2 O
to O
9 O
. O
2 O
+ O
/ O
- O
0 O
. O
2 O
mg O
/ O
DL O
] O
) O
. O

CaCO3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dosage O
, O
calculated O
dietary O
calcium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intake O
, O
and O
circulating O
levels O
of O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolites O
were O
similar O
in O
both O
groups O
. O

Physical O
activity O
index O
and O
predialysis O
serum O
bicarbonate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
also O
were O
similar O
in O
both O
groups O
. O

However O
, O
there O
was O
a O
significant B_MEASURE
difference I_MEASURE
in O
parameters B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
reflecting O
bone B_DISEASE/B_GENE
turnover I_DISEASE/I_GENE
rates I_DISEASE/I_GENE
between O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O
( O
abstract B_TIME[MEASURE]/B_ORGANIZATION
TRUNCATED I_TIME[MEASURE]/I_ORGANIZATION
AT O
250 B_LOCATION/B_ENT
Words I_LOCATION/I_ENT
) O
. O

Late O
- O
onset O
scleroderma O
renal O
crisis O
induced O
by O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
prednisolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
a O
case O
report O
. O

scleroderma B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
renal I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
crisis I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
SRC B_LOCATION
) O
is O
a O
rare B_DISEASE
complication I_DISEASE
of O
systemic B_DISEASE
sclerosis I_DISEASE
( O
SSc B_LOCATION/B_ORGANIZATION
) O
but O
can O
be O
severe B_DISEASE_ADJECTIVE[DISEASE]
enough O
to O
require O
temporary B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
permanent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
renal I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
replacement I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

moderate O
to O
high O
dose O
corticosteroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
is O
recognized O
as O
a O
major O
risk O
factor O
for O
SRC O
. O

Furthermore O
, O
there O
have O
been O
reports O
of O
thrombotic O
microangiopathy O
precipitated O
by O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
patients O
with O
SSc O
. O

In O
this O
article O
, O
we O
report O
a O
patient O
with O
SRC O
induced O
by O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
corticosteroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
aim O
of O
this O
work O
is O
to O
call O
attention O
to O
the O
risk O
of O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
use O
in O
patients O
with O
SSc O
. O

Methyldopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hemolytic O
anemia O
in O
a O
15 O
year O
old O
presenting O
as O
near O
- O
syncope O
. O

Methyldopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
an O
antihypertensive O
medication O
which O
is O
available O
generically O
and O
under O
the O
trade O
name O
Aldomet B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
is O
widely O
prescribed O
in O
the O
adult O
population O
and O
infrequently O
used O
in O
children O
. O

Methyldopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
causes O
an O
autoimmune O
hemolytic O
anemia O
in O
a O
small O
percentage O
of O
patients O
who O
take O
the O
drug O
. O

We O
report O
a O
case O
of O
methyldopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hemolytic O
anemia O
in O
a O
15 O
- O
year O
- O
old O
boy O
who O
presented O
to O
the O
emergency O
department O
with O
near O
- O
syncope O
. O

The O
boy O
had O
been O
treated O
with O
intravenous O
methyldopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
a O
trauma O
admission O
seven O
weeks O
prior O
to O
presentation O
. O

Evaluation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
revealed O
a O
hemoglobin B_MEASURE
of O
three B_MEASURE
grams I_MEASURE
, O
3 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Coombs I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
polyspecific B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anti I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
human B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin I_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
monospecific B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
IgG I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
reagents I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
a O
warm B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reacting B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
autoantibody B_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Transfusion O
and O
corticosteroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
therapy O
resulted O
in O
a O
complete O
recovery O
of O
the O
patient O
. O

Emergency B_PERSON
physicians I_PERSON
treating O
children B_PERSON/B_DISEASE
must O
be O
aware B_PERSON
of O
this O
syndrome B_DISEASE
in O
order B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
diagnose O
and O
treat O
it O
correctly O
. O

A O
brief B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
review I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
autoimmune B_DISEASE_ADJECTIVE[DISEASE]
and O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hemolytic B_DISEASE
anemias I_DISEASE
is O
provided O
. O

The O
risk O
and O
associated O
factors O
of O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
psychosis O
in O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
dependent O
patients O
in O
Malaysia O
. O

objective O
: O
The O
objective O
of O
this O
study O
was O
to O
determine O
the O
risk O
of O
lifetime O
and O
current O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
psychosis O
in O
patients O
with O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
dependence O
. O

The O
association O
between O
psychiatric O
co O
- O
morbidity O
and O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
psychosis O
was O
also O
studied O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
This O
was O
a O
cross B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
sectional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
conducted O
concurrently O
at O
a O
teaching O
hospital B_LOCATION/B_ORGANIZATION
and O
a O
drug B_LOCATION
rehabilitation I_LOCATION
center I_LOCATION
in O
Malaysia B_LOCATION
. O

patients O
with O
the O
diagnosis O
of O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
based O
on O
DSM O
- O
IV O
were O
interviewed O
using O
the O
Mini O
International O
Neuropsychiatric O
Interview O
( O
M O
. O
I O
. O
N O
. O
I O
. O
) O
for O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
psychosis O
and O
other O
Axis O
I O
psychiatric O
disorders O
. O

The O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
sociodemographic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
background I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
drug B_DISEASE_ADJECTIVE[DISEASE]
use I_DISEASE_ADJECTIVE[DISEASE]
history I_DISEASE_ADJECTIVE[DISEASE]
was O
obtained O
from O
interview B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
medical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
records I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Of O
292 B_PERSON
subjects I_PERSON
, O
47 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
subjects B_PERSON
had O
a O
past B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
history I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
psychotic B_DISEASE
symptoms I_DISEASE
and O
13 B_MEASURE
. O
0 B_MEASURE
% I_MEASURE
of O
the O
patients B_PERSON
were O
having O
current B_DISEASE/B_LOCATION
psychotic I_DISEASE/I_LOCATION
symptoms I_DISEASE/I_LOCATION
. O

Co O
- O
morbid O
major O
depressive O
disorder O
( O
OR O
= O
7 O
. O
18 O
, O
95 O
CI O
= O
2 O
. O
612 O
- O
19 O
. O
708 O
) O
, O
bipolar O
disorder O
( O
OR O
= O
13 O
. O
807 O
, O
95 O
CI O
= O
5 O
. O
194 O
- O
36 O
. O
706 O
) O
, O
antisocial O
personality O
disorder O
( O
OR O
= O
12 O
. O
619 O
, O
95 O
CI O
= O
6 O
. O
702 O
- O
23 O
. O
759 O
) O
and O
heavy O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
uses O
were O
significantly O
associated O
with O
lifetime O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
psychosis O
after O
adjusted O
for O
other O
factors O
. O

Major B_DISEASE/B_PERSON
depressive I_DISEASE/I_PERSON
disorder I_DISEASE/I_PERSON
( O
OR O
= O
2 B_MEASURE
. O
870 B_MEASURE
, O
CI B_LOCATION
= O
1 B_MEASURE
. O
154 B_MEASURE
- O
7 B_MEASURE
. O
142 B_MEASURE
) O
and O
antisocial B_DISEASE/B_PERSON
personality I_DISEASE/I_PERSON
disorder I_DISEASE/I_PERSON
( O
OR O
= O
3 B_MEASURE
. O
299 B_MEASURE
, O
95 B_LOCATION
CI I_LOCATION
= O
1 B_MEASURE
. O
375 B_MEASURE
- O
7 B_MEASURE
. O
914 B_MEASURE
) O
were O
the O
only B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O
with O
current B_DISEASE
psychosis I_DISEASE
. O

conclusion O
: O
There O
was O
a O
high O
risk O
of O
psychosis O
in O
patients O
with O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependence O
. O

It O
was O
associated O
with O
co O
- O
morbid O
affective O
disorder O
, O
antisocial O
personality O
, O
and O
heavy O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
. O

It O
is O
recommended O
that O
all O
cases O
of O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dependence O
should O
be O
screened O
for O
psychotic O
symptoms O
. O

cerebellar B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sensory I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
processing I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
alterations I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
impact O
motor B_DISEASE_ADJECTIVE[DISEASE]
cortical I_DISEASE_ADJECTIVE[DISEASE]
plasticity I_DISEASE_ADJECTIVE[DISEASE]
in O
Parkinson B_PERSON/B_DISEASE
' O
s B_DISEASE
disease I_DISEASE
: O
clues B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
from O
dyskinetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
patients I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
plasticity O
of O
primary O
motor O
cortex O
( O
M1 O
) O
in O
patients O
with O
Parkinson O
' O
s O
disease O
( O
PD O
) O
and O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
dyskinesias O
( O
LIDs O
) O
is O
severely O
impaired O
. O

We O
recently O
reported O
in O
young B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
healthy I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
subjects I_SPECIES[BIO]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
inhibitory O
cerebellar B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
enhanced O
the O
sensorimotor B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
plasticity B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
M1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O
was O
induced O
by O
paired B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
associative I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
PAS B_DISEASE/B_LOCATION
) O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrates O
that O
the O
deficient B_DISEASE/B_LOCATION
sensorimotor I_DISEASE/I_LOCATION
M1 I_DISEASE/I_LOCATION
plasticity I_DISEASE/I_LOCATION
in O
16 B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
LIDs B_DISEASE
could O
be O
reinstated O
by O
a O
single B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
session I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
real B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
inhibitory B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
cerebellar B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
but O
not O
sham O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

This O
was O
evident B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
when O
a O
sensory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
component I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
involved O
in O
the O
induction B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
plasticity B_DISEASE
, O
indicating O
that O
cerebellar B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensory B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
processing B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
involved O
in O
the O
resurgence B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
of O
M1 B_DISEASE/B_ORGANISM_FUNCTION
plasticity I_DISEASE/I_ORGANISM_FUNCTION
. O

The O
benefit B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
inhibitory B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
cerebellar I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
stimulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
on O
LIDs B_DISEASE
is O
known O
. O

To O
explore O
whether O
this O
benefit B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
linked O
to O
the O
restoration B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
sensorimotor B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
plasticity B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
M1 B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
conducted O
an O
additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
looking O
at O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
LIDs B_DISEASE_ADJECTIVE[DISEASE]
and O
PAS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
plasticity B_DISEASE
after O
10 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
sessions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
either O
bilateral B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
real B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inhibitory I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cerebellar I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
sham B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Only O
real B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
not O
sham B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
stimulation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
had O
an O
antidyskinetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
it O
was O
paralleled O
by O
a O
resurgence B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
sensorimotor B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
plasticity B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
M1 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
alterations B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
cerebellar B_DISEASE_ADJECTIVE[DISEASE]
sensory I_DISEASE_ADJECTIVE[DISEASE]
processing I_DISEASE_ADJECTIVE[DISEASE]
function I_DISEASE_ADJECTIVE[DISEASE]
, O
occurring O
secondary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
abnormal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
basal I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
ganglia I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
signals I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
reaching O
it O
, O
may O
be O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
element I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
contributing O
to O
the O
maladaptive B_DISEASE_ADJECTIVE[DISEASE]
sensorimotor I_DISEASE_ADJECTIVE[DISEASE]
plasticity I_DISEASE_ADJECTIVE[DISEASE]
of O
M1 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
emergence B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
abnormal B_DISEASE
involuntary I_DISEASE
movements I_DISEASE
. O

The O
long O
- O
term O
safety O
of O
danazol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
women O
with O
hereditary O
angioedema O
. O

Although O
the O
short O
- O
term O
safety O
( O
less O
than O
or O
equal O
to O
6 O
months O
) O
of O
danazol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
has O
been O
established O
in O
a O
variety O
of O
settings O
, O
no O
information O
exists O
as O
to O
its O
long O
- O
term O
safety O
. O

We O
therefore O
investigated O
the O
long O
- O
term O
safety O
of O
danazol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
performing O
a O
retrospective O
chart O
review O
of O
60 O
female O
patients O
with O
hereditary O
angioedema O
treated O
with O
danazol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
a O
continuous O
period O
of O
6 O
months O
or O
longer O
. O

The O
mean B_TIME[MEASURE]/B_LOCATION
age I_TIME[MEASURE]/I_LOCATION
of O
the O
patients B_PERSON
was O
35 B_MEASURE
. O
2 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
and O
the O
mean B_TIME[MEASURE]/B_LOCATION
duration I_TIME[MEASURE]/I_LOCATION
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
59 B_MEASURE
. O
7 B_TIME[MEASURE]
months I_TIME[MEASURE]
. O

virtually O
all O
patients B_PERSON
experienced O
one B_NUMBER[MEASURE]
or O
more B_NUMBER[MEASURE]/B_PERSON
adverse I_NUMBER[MEASURE]/I_PERSON
reactions I_NUMBER[MEASURE]/I_PERSON
. O

menstrual B_DISEASE
abnormalities I_DISEASE
( O
79 B_MEASURE
% I_MEASURE
) O
, O
weight B_DISEASE
gain I_DISEASE
( O
60 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
, O
muscle B_DISEASE
cramps I_DISEASE
/ O
myalgias B_DISEASE
( O
40 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
and O
transaminase B_DISEASE
elevations I_DISEASE
( O
40 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
were O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
adverse I_DISEASE_ADJECTIVE[DISEASE]
reactions I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
discontinued O
due O
to O
adverse B_DISEASE
reactions I_DISEASE
in O
8 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
. O

No O
patient B_PERSON
has O
died O
or O
suffered O
any O
apparent B_TIME[MEASURE]/B_PERSON
long I_TIME[MEASURE]/I_PERSON
- O
term B_DISEASE_ADJECTIVE[DISEASE]
sequelae I_DISEASE_ADJECTIVE[DISEASE]
that O
were O
directly O
attributable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
the O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

We O
conclude O
that O
, O
despite O
a O
relatively O
high O
incidence O
of O
adverse O
reactions O
, O
danazol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
proven O
to O
be O
remarkably O
safe O
over O
the O
long O
- O
term O
in O
this O
group O
of O
patients O
. O

The O
function O
of O
P2X3 O
receptor O
and O
NK1 O
receptor O
antagonists O
on O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cystitis O
in O
rats O
. O

purpose O
: O
The O
purpose O
of O
the O
study O
is O
to O
explore O
the O
function O
of O
P2X3 O
and O
NK1 O
receptors O
antagonists O
on O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CYP B_LOCATION/B_PROTEIN[GENE]
) O
- O
induced O
cystitis O
in O
rats O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
sixty B_PERSON
female I_PERSON
Sprague I_PERSON
- O
Dawley B_PERSON/B_MEASURE
( O
SD B_MEASURE/B_DISEASE
) O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
randomly O
divided O
into O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
. O

The O
rats O
in O
the O
control O
group O
were O
intraperitoneally O
( O
i O
. O
p O
. O
) O
injected O
with O
0 O
. O
9 O
% O
saline O
( O
4 O
ml O
/ O
kg O
) O
; O
the O
rats O
in O
the O
model O
group O
were O
i O
. O
p O
. O
injected O
with O
CYP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
150 O
mg O
/ O
kg O
) O
; O
and O
the O
rats O
in O
the O
intervention O
group O
were O
i O
. O
p O
. O
injected O
with O
CYP B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
subsequently O
perfusion O
of O
bladder O
with O
P2X3 O
and O
NK1 O
receptors O
' O
antagonists O
, O
Suramin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
GR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
82334 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

spontaneous O
pain O
behaviors O
following O
the O
administration O
of O
CYP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
were O
observed O
. O

Urodynamic B_TIME[MEASURE]/B_LOCATION
parameters I_TIME[MEASURE]/I_LOCATION
, O
bladder B_MEASURE/B_LOCATION
pressure I_MEASURE/I_LOCATION
- O
volume B_MEASURE/B_LOCATION
curve I_MEASURE/I_LOCATION
, O
maximum B_MEASURE/B_LOCATION
voiding I_MEASURE/I_LOCATION
pressure I_MEASURE/I_LOCATION
( O
MVP B_PERSON/B_DISEASE
) O
, O
and O
maximum B_MEASURE/B_LOCATION
cystometric I_MEASURE/I_LOCATION
capacity I_MEASURE/I_LOCATION
( O
MCC B_DISEASE/B_GENE
) O
, O
were O
recorded O
. O

Pathological B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
in O
bladder B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
were O
observed O
. O

immunofluorescence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
used O
to O
detect O
the O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
P2X3 B_GENE
and O
NK1 B_GENE
receptors I_GENE
in O
bladder B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
. O

Results O
: O
Cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
increased O
the O
spontaneous O
pain O
behaviors O
scores O
. O

The O
incidence B_MEASURE
of O
bladder B_DISEASE
instability I_DISEASE
during O
urine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
storage I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
period I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
significantly O
higher B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
intervention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
X B_OTHER/B_PROTEIN[GENE]
( O
2 B_NUMBER[MEASURE]
) O
= O
7 B_MEASURE
. O
619 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
007 B_MEASURE
) O
and O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
X B_OTHER/B_PROTEIN[GENE]
( O
2 B_NUMBER[MEASURE]
) O
= O
13 B_MEASURE
. O
755 B_MEASURE
, O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
000 B_MEASURE
) O
. O

MCC B_DISEASE/B_MEASURE
in O
the O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
and O
intervention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
P B_PROTEIN[GENE]/B_LOCATION
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
. O

Histological B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evident B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
intervention B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
groups I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
rats I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
' I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
bladder I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
included O
edema B_DISEASE
, O
vasodilation B_DISEASE
, O
and O
infiltration B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
inflammatory B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
the O
expression B_GENE/B_MEASURE
of O
P2X3 B_GENE
receptor I_GENE
increased O
in O
urothelium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
suburothelium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
NK1 B_GENE
receptor I_GENE
increased O
in O
suburothelium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
while O
the O
expression B_GENE/B_MEASURE
of O
them O
in O
intervention B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
lower B_DISEASE_ADJECTIVE[DISEASE]
. O

conclusions O
: O
In O
CYP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
induced O
cystitis O
, O
the O
expression O
of O
P2X3 O
and O
NK1 O
receptors O
increased O
in O
urothelium O
and O
/ O
or O
suburothelium O
. O

perfusion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
of O
bladder B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
with O
P2X3 B_GENE
and O
NK1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonists B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ameliorated O
the O
bladder B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

patient O
tolerance O
study O
of O
topical O
chlorhexidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diphosphanilate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
a O
new O
topical O
agent O
for O
burns O
. O

effective B_PERSON/B_LOCATION
topical I_PERSON/I_LOCATION
antimicrobial I_PERSON/I_LOCATION
agents I_PERSON/I_LOCATION
decrease O
infection B_DISEASE
and O
mortality B_DISEASE/B_MEASURE
in O
burn B_BIO/B_DISEASE
patients I_BIO/I_DISEASE
. O

Chlorhexidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
phosphanilate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
CHP B_DISEASE/B_MEASURE
) O
, O
a O
new O
broad O
- O
spectrum O
antimicrobial O
agent O
, O
has O
been O
evaluated O
as O
a O
topical O
burn O
wound O
dressing O
in O
cream O
form O
, O
but O
preliminary O
clinical O
trials O
reported O
that O
it O
was O
painful O
upon O
application O
. O

This O
study O
compared O
various O
concentrations O
of O
CHP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
determine O
if O
a O
tolerable O
concentration O
could O
be O
identified O
with O
retention O
of O
antimicrobial O
efficacy O
. O

Twenty B_NUMBER[MEASURE]
- O
nine B_NUMBER[MEASURE]/B_PERSON
burn I_NUMBER[MEASURE]/I_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
, O
each O
with O
two B_NUMBER[MEASURE]/B_DISEASE
similar I_NUMBER[MEASURE]/I_DISEASE
burns I_NUMBER[MEASURE]/I_DISEASE
which O
could O
be O
separately O
treated O
, O
were O
given O
pairs B_PERSON/B_MEASURE
of O
treatments B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
successive B_MEASURE
12 I_MEASURE
- O
h O
intervals B_TIME[MEASURE]/B_LOCATION
over O
a O
3 B_NUMBER[MEASURE]
- O
day B_TIME[MEASURE]
period I_TIME[MEASURE]
. O

One O
burn O
site O
was O
treated O
with O
each O
of O
four O
different O
CHP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentrations O
, O
from O
0 O
. O
25 O
per O
cent O
to O
2 O
per O
cent O
, O
their O
vehicle O
, O
and O
1 O
per O
cent O
silver B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulphadiazine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
AgSD B_LOCATION/B_DISEASE
) O
cream O
, O
an O
antimicrobial O
agent O
frequently O
used O
for O
topical O
treatment O
of O
burn O
wounds O
. O

The O
other O
site O
was O
always O
treated O
with O
AgSD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cream O
. O

There O
was O
a O
direct O
relationship O
between O
CHP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentration O
and O
patients O
' O
ratings O
of O
pain O
on O
an O
analogue O
scale O
. O

The O
0 O
. O
25 O
per O
cent O
CHP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cream O
was O
closest O
to O
AgSD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
pain O
tolerance O
; O
however O
, O
none O
of O
the O
treatments O
differed O
statistically O
from O
AgSD B_DISEASE/B_MEASURE
or O
from O
each O
other O
. O

In O
addition O
, O
ease O
of O
application O
of O
CHP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
creams O
was O
less O
satisfactory O
than O
that O
of O
AgSD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

It O
was O
concluded O
that O
formulations O
at O
or O
below O
0 O
. O
5 O
per O
cent O
CHP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
may O
prove O
acceptable O
for O
wound O
care O
, O
but O
the O
vehicle O
system O
needs O
pharmaceutical O
improvement O
to O
render O
it O
more O
tolerable O
and O
easier O
to O
use O
. O

acute O
hepatitis O
associated O
with O
clopidogrel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
a O
case O
report O
and O
review O
of O
the O
literature O
. O

Drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hepatotoxicity B_DISEASE
is O
a O
common B_DISEASE_ADJECTIVE[DISEASE]
cause I_DISEASE_ADJECTIVE[DISEASE]
of O
acute B_DISEASE
hepatitis I_DISEASE
, O
and O
the O
recognition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
responsible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
drug B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
may O
be O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
describe O
a O
case O
of O
clopidogrel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
related O
acute O
hepatitis O
. O

The O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
strongly O
suggested O
by O
an O
accurate B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
medical I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
history I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
liver B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biopsy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Reports O
about O
cases O
of O
hepatotoxicity O
due O
to O
clopidogrel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
increasing O
in O
the O
last O
few O
years O
, O
after O
the O
increased O
use O
of O
this O
drug O
. O

In O
conclusion O
, O
we O
believe O
that O
physicians O
should O
carefully O
consider O
the O
risk O
of O
drug O
- O
induced O
hepatic O
injury O
when O
clopidogrel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
prescribed O
. O

Bortezomib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
salvage O
therapy O
in O
patients O
with O
relapsed O
/ O
refractory O
multiple O
myeloma O
: O
analysis O
of O
long O
- O
term O
clinical O
outcomes O
. O

Bortezomib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
bort B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
- O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
dex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
is O
an O
effective O
therapy O
for O
relapsed O
/ O
refractory O
( O
R O
/ O
R O
) O
multiple O
myeloma O
( O
mm O
) O
. O

This O
retrospective O
study O
investigated O
the O
combination O
of O
bort B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
1 O
. O
3 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
, O
4 O
, O
8 O
, O
and O
11 O
every O
3 O
weeks O
) O
and O
dex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
20 O
mg O
on O
the O
day O
of O
and O
the O
day O
after O
bort B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
) O
as O
salvage O
treatment O
in O
85 O
patients O
with O
R O
/ O
R O
mm O
after O
prior O
autologous O
stem O
cell O
transplantation O
or O
conventional O
chemotherapy O
. O

The O
median B_MEASURE
number I_MEASURE
of O
prior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
lines I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_TIME[MEASURE]
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
2 B_NUMBER[MEASURE]
. O

eighty O
- O
seven O
percent O
of O
the O
patients O
had O
received O
immunomodulatory O
drugs O
included O
in O
some O
line O
of O
therapy O
before O
bort B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
dex B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

The O
median O
number O
of O
bort B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
dex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
cycles O
was O
6 O
, O
up O
to O
a O
maximum O
of O
12 O
cycles O
. O

On O
an O
intention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
to O
- O
treat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
basis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
55 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
the O
patients B_PERSON
achieved O
at O
least O
partial B_DISEASE/B_LOCATION
response I_DISEASE/I_LOCATION
, O
including O
19 B_DISEASE/B_LOCATION
% I_DISEASE/I_LOCATION
CR I_DISEASE/I_LOCATION
and O
35 B_PERSON
% I_PERSON
achieved O
at O
least O
very O
good B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
partial I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
response I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
. O

median B_TIME[MEASURE]/B_PERSON
durations I_TIME[MEASURE]/I_PERSON
of O
response B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
time B_TIME[MEASURE]/B_PERSON
to O
next B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O
free B_TIME[MEASURE]/B_LOCATION
interval I_TIME[MEASURE]/I_LOCATION
were O
8 B_MEASURE
, O
11 B_MEASURE
. O
2 B_MEASURE
, O
and O
5 B_MEASURE
. O
1 B_TIME[MEASURE]
months I_TIME[MEASURE]
, O
respectively O
. O

The O
most O
relevant B_DISEASE_ADJECTIVE[DISEASE]
adverse I_DISEASE_ADJECTIVE[DISEASE]
event I_DISEASE_ADJECTIVE[DISEASE]
was O
peripheral B_DISEASE
neuropathy I_DISEASE
, O
which O
occurred O
in O
78 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
of O
the O
patients B_PERSON
( O
grade B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
II I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
, O
38 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
; O
grade B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
III I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
21 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
led O
to O
treatment B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
discontinuation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
6 B_NUMBER[MEASURE]
% I_NUMBER[MEASURE]
. O

With O
a O
median B_MEASURE
follow O
up O
of O
22 B_TIME[MEASURE]/B_DISEASE
months B_TIME[MEASURE]/I_DISEASE
, O
median B_MEASURE/B_PERSON
time I_MEASURE/I_PERSON
to O
progression B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
progression B_DISEASE_ADJECTIVE[DISEASE]
- O
free B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
survival I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
PFS B_LOCATION
) O
and O
overall B_DISEASE_ADJECTIVE[DISEASE]
survival I_DISEASE_ADJECTIVE[DISEASE]
( O
OS B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
were O
8 B_MEASURE
. O
9 B_MEASURE
, O
8 B_MEASURE
. O
7 B_MEASURE
, O
and O
22 B_TIME[MEASURE]
months I_TIME[MEASURE]
, O
respectively O
. O

prolonged O
PFS O
and O
OS O
were O
observed O
in O
patients O
achieving O
CR O
and O
receiving O
bort B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
dex B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
a O
single O
line O
of O
prior O
therapy O
. O

Bort B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
dex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
an O
effective O
salvage O
treatment O
for O
mm O
patients O
, O
particularly O
for O
those O
in O
first O
relapse O
. O

Pubertal O
exposure O
to O
Bisphenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
increases O
anxiety O
- O
like O
behavior O
and O
decreases O
acetylcholinesterase O
activity O
of O
hippocampus O
in O
adult O
male O
mice O
. O

The O
negative O
effects O
of O
Bisphenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
BPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
) O
on O
neurodevelopment O
and O
behaviors O
have O
been O
well O
established O
. O

acetylcholinesterase B_ENZYME[GENE]
( O
ache B_DISEASE/B_LOCATION
) O
is O
a O
regulatory B_ENZYME[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
enzyme B_ENZYME[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
which O
is O
involved O
in O
anxiety B_DISEASE
- O
like B_DISEASE/B_LOCATION
behavior I_DISEASE/I_LOCATION
. O

This O
study O
investigated O
behavioral O
phenotypes O
and O
ache O
activity O
in O
male O
mice O
following O
BPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O
during O
puberty O
. O

On O
postnatal O
day O
( O
PND O
) O
35 O
, O
male O
mice O
were O
exposed O
to O
50mg O
BPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O
kg O
diet O
per O
day O
for O
a O
period O
of O
35 O
days O
. O

On O
PND71 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_TIME[MEASURE]
, O
a O
behavioral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
assay I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
using O
the O
elevated O
plus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
maze I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
EPM B_DISEASE/B_PROTEIN[GENE]
) O
and O
the O
light B_COLOR
/ O
dark B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
test I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
. O

In O
addition B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
AChE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
activity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
measured O
in O
the O
prefrontal B_BODY_PART_OR_ORGAN_COMPONENT
cortex I_BODY_PART_OR_ORGAN_COMPONENT
, O
hypothalamus B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
cerebellum B_BODY_PART_OR_ORGAN_COMPONENT
and O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT
. O

Results O
from O
our O
behavioral O
phenotyping O
indicated O
that O
anxiety O
- O
like O
behavior O
was O
increased O
in O
mice O
exposed O
to O
BPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

ache O
activity O
was O
significantly O
decreased O
in O
the O
hippocampus O
of O
mice O
with O
BPA B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
compared O
to O
control O
mice O
, O
whereas O
no O
difference O
was O
found O
in O
the O
prefrontal O
cortex O
, O
hypothalamus O
and O
cerebellum O
. O

Our O
findings O
showed O
that O
pubertal O
BPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O
increased O
anxiety O
- O
like O
behavior O
, O
which O
may O
be O
associated O
with O
decreased O
ache O
activity O
of O
the O
hippocampus O
in O
adult O
male O
mice O
. O

Further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
necessary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
investigate O
the O
cholinergic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
signaling I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
in O
PBE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
anxiety B_DISEASE
- O
like B_DISEASE_ADJECTIVE[DISEASE]
behaviors I_DISEASE_ADJECTIVE[DISEASE]
. O

Biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Solidago B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
virgaurea I_BIO/I_DISEASE_ADJECTIVE[DISEASE]
extract O
on O
experimental B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
cardiotoxicity B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
. O

Cardiovascular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
diseases I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
CVDs B_DISEASE/B_LOCATION
) O
are O
the O
major B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
health I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
problem I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
advanced O
as O
well O
as O
developing O
countries B_LOCATION/B_ORGANIZATION
of O
the O
world B_LOCATION
. O

The O
aim O
of O
the O
present O
study O
was O
to O
investigate O
the O
protective O
effect O
of O
the O
Solidago O
virgaurea O
extract O
on O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cardiotoxicity O
in O
rats O
. O

The O
subcutaneous O
injection O
of O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
30 O
mg O
/ O
kg O
) O
into O
rats O
twice O
at O
an O
interval O
of O
24 O
h O
, O
for O
two O
consecutive O
days O
, O
led O
to O
a O
significant O
increase O
in O
serum O
lactate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dehydrogenase O
, O
creatine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphokinase O
, O
alanine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transaminase O
, O
aspartate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transaminase O
, O
and O
angiotensin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
converting O
enzyme O
activities O
, O
total O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
triglycerides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
free O
serum O
fatty B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
cardiac O
tissue O
malondialdehyde B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
) O
, O
and O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels O
and O
a O
significant O
decrease O
in O
levels O
of O
glutathione B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
superoxide B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dismutase O
in O
cardiac O
tissue O
as O
compared O
to O
the O
normal O
control O
group O
( O
P O
< O
0 O
. O
05 O
) O
. O

Pretreatment O
with O
S O
. O
virgaurea O
extract O
for O
5 O
weeks O
at O
a O
dose O
of O
250 O
mg O
/ O
kg O
followed O
by O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O
significantly O
prevented O
the O
observed O
alterations O
. O

Captopril B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
50 O
mg O
/ O
kg O
/ O
day O
, O
given O
orally O
) O
, O
an O
inhibitor O
of O
angiotensin B_GENE
- O
converting O
enzyme O
used O
as O
a O
standard O
cardioprotective O
drug O
, O
was O
used O
as O
a O
positive O
control O
in O
this O
study O
. O

The O
data O
of O
the O
present O
study O
suggest O
that O
S O
. O
virgaurea O
extract O
exerts O
its O
protective O
effect O
by O
decreasing O
MDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
level O
and O
increasing O
the O
antioxidant O
status O
in O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
rats O
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
emphasizes O
the O
beneficial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
S B_OTHER/B_LOCATION
. O
virgaurea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
extract B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
as O
a O
cardioprotective B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

' O
Real O
- O
world O
' O
data O
on O
the O
efficacy O
and O
safety O
of O
lenalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients O
with O
relapsed O
/ O
refractory O
multiple O
myeloma O
who O
were O
treated O
according O
to O
the O
standard O
clinical O
practice O
: O
a O
study O
of O
the O
Greek O
Myeloma O
Study O
Group O
. O

Lenalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
RD B_DISEASE/B_PROTEIN[GENE]
) O
is O
a O
standard O
of O
care O
for O
relapsed O
/ O
refractory O
multiple O
myeloma O
( O
RRMM O
) O
, O
but O
there O
is O
limited O
published O
data O
on O
its O
efficacy O
and O
safety O
in O
the O
' O
real O
world O
' O
( O
RW O
) O
, O
according O
to O
the O
International O
Society O
of O
Pharmacoeconomics O
and O
outcomes O
Research O
definition O
. O

We O
studied O
212 O
RRMM O
patients O
who O
received O
RD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
RW O
. O

objective B_LOCATION/B_PERSON
response I_LOCATION/I_PERSON
( O
> B_LOCATION
PR I_LOCATION
( O
partial B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
response I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
) O
) O
rate B_MEASURE/B_LOCATION
was O
77 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
( O
complete B_LOCATION
response I_LOCATION
( O
CR B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
20 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
) O
. O

median B_TIME[MEASURE]/B_PERSON
time I_TIME[MEASURE]/I_PERSON
to O
first B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
best B_SEQUENCE[MEASURE]/B_DISEASE
response I_SEQUENCE[MEASURE]/I_DISEASE
was O
2 B_MEASURE
and O
5 B_TIME[MEASURE]
months I_TIME[MEASURE]
, O
respectively O
. O

median O
time O
to O
CR O
when O
RD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
given O
as O
2nd O
or O
> O
2 O
( O
nd O
) O
- O
line O
treatment O
at O
4 O
and O
11 O
months O
, O
respectively O
. O

Quality O
of O
response O
was O
independent O
of O
previous O
lines O
of O
therapies O
or O
previous O
exposure O
to O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
bortezomib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

median O
duration O
of O
response O
was O
34 O
. O
4 O
months O
, O
and O
it O
was O
higher O
in O
patients O
who O
received O
RD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
until O
progression O
( O
not O
reached O
versus O
19 O
months O
, O
p O
< O
0 O
. O
001 O
) O
. O

Improvement B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
humoral B_DISEASE
immunity I_DISEASE
occurred O
in O
60 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
responders B_PERSON/B_BIO
( O
p B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
and O
in O
the O
majority B_PERSON/B_MEASURE
of O
patients B_PERSON/B_BIO
who O
achieved O
stable B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Adverse B_DISEASE_ADJECTIVE[DISEASE]
events I_DISEASE_ADJECTIVE[DISEASE]
were O
reported O
in O
68 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
patients B_PERSON
( O
myelosuppression B_DISEASE_ADJECTIVE[DISEASE]
in O
49 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
12 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
patients B_PERSON
needed O
hospitalization B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Peripheral B_DISEASE
neuropathy I_DISEASE
was O
observed O
only O
in O
2 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
of O
patients B_PERSON/B_BIO
and O
deep B_DISEASE
vein I_DISEASE
thrombosis I_DISEASE
in O
5 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
. O

Dose B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reductions B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
needed O
in O
31 B_MEASURE
% I_MEASURE
of O
patients B_PERSON/B_LOCATION
and O
permanent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
discontinuation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
38 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
. O

median B_TIME[MEASURE]/B_PERSON
time I_TIME[MEASURE]/I_PERSON
to O
treatment B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
discontinuation I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
16 B_MEASURE
. O
8 B_TIME[MEASURE]
months I_TIME[MEASURE]
. O

Performance O
status O
( O
PS O
) O
and O
initial O
lenalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O
predicted O
for O
treatment O
discontinuation O
. O

extra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
medullary B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
relapses I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurred O
in O
3 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
patients B_PERSON/B_LOCATION
. O

Our O
study O
confirms O
that O
RD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
effective O
and O
safe O
in O
RRMM O
in O
the O
RW O
; O
it O
produces O
durable O
responses O
especially O
in O
patients O
who O
continue O
on O
treatment O
till O
progression O
and O
improves O
humoral O
immunity O
even O
in O
patients O
with O
stable O
disease O
. O

The O
cytogenetic O
action O
of O
ifosfamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
mesna B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
their O
combination O
on O
peripheral O
rabbit O
lymphocytes O
: O
an O
in O
vivo O
/ O
in O
vitro O
cytogenetic O
study O
. O

Ifosfamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
IFO B_LOCATION/B_DISEASE
) O
is O
an O
alkylating O
nitrogen B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mustard O
, O
administrated O
as O
an O
antineoplasmic O
agent O
. O

It O
is O
characterized O
by O
its O
intense B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urotoxic I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
action I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
leading O
to O
hemorrhagic B_DISEASE
cystitis I_DISEASE
. O

This O
side O
effect O
of O
IFO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
raises O
the O
requirement O
for O
the O
co O
- O
administration O
with O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
sulfanylethanesulfonate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Mesna B_DISEASE
) O
aiming O
to O
avoid O
or O
minimize O
this O
effect O
. O

IFO B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Mesna B_LOCATION/B_PERSON
were O
administrated O
separately O
on O
rabbit O
' O
s O
lymphocytes O
in O
vivo O
, O
which O
were O
later O
developed O
in O
vitro O
. O

cytogenetic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
markers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
sister B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
chromatid B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
exchanges B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
SCEs B_LOCATION/B_ORGANIZATION
) O
, O
proliferation B_MEASURE/B_LOCATION
rate B_MEASURE/I_LOCATION
index B_MEASURE/I_LOCATION
( O
PRI B_LOCATION/B_ORGANIZATION
) O
and O
Mitotic B_MEASURE/B_DISEASE
Index B_MEASURE/I_DISEASE
were O
recorded O
. O

Mesna B_PERSON/B_COLOR
' O
s O
action O
, O
in O
conjunction O
with O
IFO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
reduces O
the O
frequency O
of O
SCEs O
, O
in O
comparison O
with O
the O
SCEs O
recordings O
obtained O
when O
IFO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
administered O
alone O
. O

In O
addition O
to O
this O
, O
when O
high O
concentrations O
of O
Mesna B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
administered O
alone O
significant O
reductions O
of O
the O
PRI O
were O
noted O
, O
than O
with O
IFO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acting O
at O
the O
same O
concentration O
on O
the O
lymphocytes O
. O

Mesna B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
significantly O
reduces O
IFO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
' O
s O
genotoxicity O
, O
while O
when O
administered O
in O
high O
concentrations O
it O
acts O
in O
an O
inhibitory O
fashion O
on O
the O
cytostatic O
action O
of O
the O
drug O
. O

Risk O
factors O
and O
predictors O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
dyskinesia O
among O
multiethnic O
Malaysians O
with O
Parkinson O
' O
s O
disease O
. O

chronic O
pulsatile O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
for O
Parkinson O
' O
s O
disease O
( O
PD O
) O
leads O
to O
the O
development O
of O
motor O
fluctuations O
and O
dyskinesia O
. O

We O
studied O
the O
prevalence O
and O
predictors O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
dyskinesia O
among O
multiethnic O
Malaysian O
patients O
with O
PD O
. O

methods O
: O
This O
is O
a O
cross O
- O
sectional O
study O
involving O
95 O
patients O
with O
PD O
on O
uninterrupted O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
for O
at O
least O
6 O
months O
. O

The O
instrument B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
was O
the O
UPDRS B_ENT/B_ORGANIZATION
questionnaires I_ENT/I_ORGANIZATION
. O

The O
predictors B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
dyskinesia B_DISEASE
were O
determined O
using O
multivariate B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
logistic I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regression I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
The O
mean B_MEASURE/B_PERSON
age I_MEASURE/I_PERSON
was O
65 B_MEASURE
. O
6 B_MEASURE
+ I_MEASURE
8 I_MEASURE
. O
5 B_TIME[MEASURE]
years I_TIME[MEASURE]
. O

The O
mean B_MEASURE/B_PERSON
onset I_MEASURE/I_PERSON
age I_MEASURE/I_PERSON
was O
58 B_MEASURE
. O
5 B_MEASURE
+ I_MEASURE
9 I_MEASURE
. O
8 B_TIME[MEASURE]
years I_TIME[MEASURE]
. O

The O
median B_TIME[MEASURE]/B_PERSON
disease I_TIME[MEASURE]/I_PERSON
duration I_TIME[MEASURE]/I_PERSON
was O
6 B_NUMBER[MEASURE]
( O
7 B_MEASURE
) O
years B_TIME[MEASURE]/B_ORGANIZATION
. O

Dyskinesia O
was O
present O
in O
44 O
% O
( O
n O
= O
42 O
) O
with O
median O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O
of O
3 O
years O
. O

There O
were O
64 B_MEASURE
. O
3 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
Chinese I_MEASURE/I_PERSON
, O
31 B_PERSON/B_LOCATION
% I_PERSON/I_LOCATION
Malays I_PERSON/I_LOCATION
, O
and O
3 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
Indians I_MEASURE/I_PERSON
and O
other B_PERSON/B_LOCATION
ethnic I_PERSON/I_LOCATION
groups I_PERSON/I_LOCATION
. O

eighty B_NUMBER[MEASURE]/B_LOCATION
- O
one B_NUMBER[MEASURE]
percent I_NUMBER[MEASURE]
of O
patients B_PERSON
with O
dyskinesia B_DISEASE
had O
clinical B_DISEASE
fluctuations I_DISEASE
. O

patients O
with O
dyskinesia O
had O
lower O
onset O
age O
( O
p O
< O
0 O
. O
001 O
) O
, O
longer O
duration O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
( O
p O
< O
0 O
. O
001 O
) O
, O
longer O
disease O
duration O
( O
p O
< O
0 O
. O
001 O
) O
, O
higher O
total O
daily O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O
( O
p O
< O
0 O
. O
001 O
) O
, O
and O
higher O
total O
UPDRS O
scores O
( O
p O
= O
0 O
. O
005 O
) O
than O
patients O
without O
dyskinesia O
. O

The O
three O
significant O
predictors O
of O
dyskinesia O
were O
duration O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O
, O
onset O
age O
, O
and O
total O
daily O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O
. O

conclusions O
: O
The O
prevalence O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
dyskinesia O
in O
our O
patients O
was O
44 O
% O
. O

The O
most O
significant O
predictors O
were O
duration O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
, O
total O
daily O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O
, O
and O
onset O
age O
. O

dose O
- O
dependent O
neurotoxicity O
of O
high O
- O
dose O
busulfan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O
children O
: O
a O
clinical O
and O
pharmacological O
study O
. O

Busulfan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
is O
known O
to O
be O
neurotoxic O
in O
animals O
and O
humans O
, O
but O
its O
acute O
neurotoxicity O
remains O
poorly O
characterized O
in O
children O
. O

We O
report O
here O
a O
retrospective O
study O
of O
123 O
children O
( O
median O
age O
, O
6 O
. O
5 O
years O
) O
receiving O
high O
- O
dose O
busulfan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O
combined O
chemotherapy O
before O
bone O
marrow O
transplantation O
for O
malignant O
solid O
tumors O
, O
brain O
tumors O
excluded O
. O

Busulfan B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
given O
p O
. O
o O
. O
, O
every O
6 O
hours O
for O
16 O
doses O
over O
4 O
days O
. O

Two B_NUMBER[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
total I_NUMBER[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses I_NUMBER[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
consecutively O
used O
: O
16 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg B_MEASURE
, O
then O
600 B_MEASURE
mg I_MEASURE
/ O
m2 B_MEASURE
. O

The O
dose B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
calculation I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
on O
the O
basis B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
body B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
surface I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
area I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
results O
in O
higher B_MEASURE
doses I_MEASURE
in O
young B_PERSON/B_ORGANIZATION
children I_PERSON/I_ORGANIZATION
than O
in O
older B_PERSON
patients I_PERSON
( O
16 B_MEASURE
to O
28 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
) O
. O

ninety O
- O
six O
patients O
were O
not O
given O
anticonvulsive O
prophylaxis O
; O
7 O
( O
7 O
. O
5 O
% O
) O
developed O
seizures O
during O
the O
4 O
days O
of O
the O
busulfan B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BIO
course O
or O
within O
24 O
h O
after O
the O
last O
dosing O
. O

When O
the O
total O
busulfan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
dose O
was O
taken O
into O
account O
, O
there O
was O
a O
significant O
difference O
in O
terms O
of O
neurotoxicity O
incidence O
among O
patients O
under O
16 O
mg O
/ O
kg O
( O
1 O
of O
57 O
, O
1 O
. O
7 O
% O
) O
and O
patients O
under O
600 O
mg O
/ O
m2 O
( O
6 O
of O
39 O
, O
15 O
. O
4 O
% O
) O
( O
P O
less O
than O
0 O
. O
02 O
) O
. O

Twenty O
- O
seven O
patients O
were O
given O
a O
600 O
- O
mg O
/ O
m2 O
busulfan B_TIME[MEASURE]/B_PERSON
total O
dose O
with O
continuous O
i O
. O
v O
. O
infusion O
of O
clonazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
none O
had O
any O
neurological O
symptoms O
. O

Busulfan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
levels O
were O
measured O
by O
a O
gas O
chromatographic O
- O
mass O
spectrometry O
assay O
in O
the O
plasma O
and O
cerebrospinal O
fluid O
of O
9 O
children O
without O
central O
nervous O
system O
disease O
under O
600 O
mg O
/ O
m2 O
busulfan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
with O
clonazepam B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
busulfan B_PERSON/B_MEASURE
cerebrospinal O
fluid O
: O
plasma O
ratio O
was O
1 O
. O
39 O
. O

This O
was O
significantly O
different O
( O
P O
less O
than O
0 O
. O
02 O
) O
from O
the O
cerebrospinal O
fluid O
: O
plasma O
ratio O
previously O
defined O
in O
children O
receiving O
a O
16 O
- O
mg O
/ O
kg O
total O
dose O
of O
busulfan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

This O
study O
shows O
that O
busulfan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
neurotoxicity O
is O
dose O
- O
dependent O
in O
children O
and O
efficiently O
prevented O
by O
clonazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
busulfan B_MEASURE/B_BIO
dose O
calculated O
on O
the O
basis O
of O
body O
surface O
area O
, O
resulting O
in O
higher O
doses O
in O
young O
children O
, O
was O
followed O
by O
increased O
neurotoxicity O
, O
close O
to O
neurotoxicity O
incidence O
observed O
in O
adults O
. O

Since O
plasma O
pharmacokinetic O
studies O
showed O
a O
faster O
busulfan B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
clearance O
in O
children O
than O
in O
adults O
, O
this O
new O
dose O
may O
approximate O
more O
closely O
the O
adult O
systemic O
exposure O
obtained O
after O
the O
usual O
16 O
- O
mg O
/ O
kg O
total O
dose O
, O
with O
potential O
inferences O
in O
terms O
of O
anticancer O
or O
myeloablative O
effects O
. O

The O
busulfan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
dose O
in O
children O
and O
infants O
undergoing O
bone O
marrow O
transplantation O
should O
be O
reconsidered O
on O
the O
basis O
of O
pharmacokinetic O
studies O
. O

An O
unexpected O
diagnosis O
in O
a O
renal O
- O
transplant O
patient O
with O
proteinuria O
treated O
with O
everolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
AL O
amyloidosis O
. O

Proteinuria O
is O
an O
expected O
complication O
in O
transplant O
patients O
treated O
with O
mammalian O
target O
of O
rapamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibitors O
( O
mTOR O
- O
i O
) O
. O

However O
, O
clinical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
suspicion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
should O
always O
be O
supported O
by O
histological B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
order B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
investigate O
potential B_DISEASE_ADJECTIVE[DISEASE]
alternate I_DISEASE_ADJECTIVE[DISEASE]
diagnoses I_DISEASE_ADJECTIVE[DISEASE]
such I_DISEASE_ADJECTIVE[DISEASE]
as O
acute B_DISEASE_ADJECTIVE[DISEASE]
or O
chronic B_DISEASE_ADJECTIVE[DISEASE]
rejection I_DISEASE_ADJECTIVE[DISEASE]
, O
interstitial B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
fibrosis B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
tubular B_DISEASE
atrophy I_DISEASE
, O
or O
recurrent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
or O
de B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
novo I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
glomerulopathy I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

In O
this O
case O
we O
report O
the O
unexpected O
diagnosis O
of O
amyloidosis O
in O
a O
renal O
- O
transplant O
patient O
with O
pre O
- O
transplant O
monoclonal O
gammapathy O
of O
undetermined O
significance O
who O
developed O
proteinuria O
after O
conversion O
from O
tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
everolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Long O
- O
term O
oral O
galactose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
prevents O
cognitive O
deficits O
in O
male O
Wistar O
rats O
treated O
intracerebroventricularly O
with O
streptozotocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Basic O
and O
clinical O
research O
has O
demonstrated O
that O
dementia O
of O
sporadic O
Alzheimer O
' O
s O
disease O
( O
Sad O
) O
type O
is O
associated O
with O
dysfunction O
of O
the O
insulin O
- O
receptor O
( O
IR O
) O
system O
followed O
by O
decreased O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
transport O
via O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
transporter O
GLUT4 O
and O
decreased O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
metabolism O
in O
brain O
cells O
. O

An O
alternative O
source O
of O
energy O
is O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
galactose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
the O
C O
- O
4 O
- O
epimer O
of O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
which O
is O
transported O
into O
the O
brain O
by O
insulin O
- O
independent O
GLUT3 O
transporter O
where O
it O
might O
be O
metabolized O
to O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
via O
the O
Leloir O
pathway O
. O

exclusively O
parenteral O
daily O
injections O
of O
galactose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induce O
memory O
deterioration O
in O
rodents O
and O
are O
used O
to O
generate O
animal O
aging O
model O
, O
but O
the O
effects O
of O
oral O
galactose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O
on O
cognitive O
functions O
have O
never O
been O
tested O
. O

We O
have O
investigated O
the O
effects O
of O
continuous O
daily O
oral O
galactose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
200 O
mg O
/ O
kg O
/ O
day O
) O
treatment O
on O
cognitive O
deficits O
in O
streptozotocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
( O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
icv O
) O
rat O
model O
of O
Sad O
, O
tested O
by O
Morris O
Water O
maze O
and O
passive O
Avoidance O
test O
, O
respectively O
. O

One O
month O
of O
oral O
galactose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
initiated O
immediately O
after O
the O
STZ B_LOCATION/B_DISEASE
- O
icv O
administration O
, O
successfully O
prevented O
development O
of O
the O
STZ B_LOCATION
- O
icv O
- O
induced O
cognitive O
deficits O
. O

beneficial O
effect O
of O
oral O
galactose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
independent O
of O
the O
rat O
age O
and O
of O
the O
galactose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O
ranging O
from O
100 O
to O
300 O
mg O
/ O
kg O
/ O
day O
. O

Additionally O
, O
oral O
galactose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
led O
to O
the O
appearance O
of O
galactose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
the O
blood O
. O

The O
increase O
of O
galactose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O
in O
the O
cerebrospinal O
fluid O
was O
several O
times O
lower O
after O
oral O
than O
after O
parenteral O
administration O
of O
the O
same O
galactose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O
. O

Oral O
galactose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
exposure O
might O
have O
beneficial O
effects O
on O
learning O
and O
memory O
ability O
and O
could O
be O
worth O
investigating O
for O
improvement O
of O
cognitive O
deficits O
associated O
with O
glucose O
hypometabolism O
in O
AD O
. O

An O
investigation O
of O
the O
pattern O
of O
kidney O
injury O
in O
HIV O
- O
positive O
persons O
exposed O
to O
tenofovir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
disoproxil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
fumarate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
: O
an O
examination O
of O
a O
large O
population O
database O
( O
MHRA O
database O
) O
. O

The O
potential O
for O
tenofovir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
cause O
a O
range O
of O
kidney O
syndromes O
has O
been O
established O
from O
mechanistic O
and O
randomised O
clinical O
trials O
. O

However O
, O
the O
exact B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pattern I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
kidney B_DISEASE_ADJECTIVE[DISEASE]
involvement I_DISEASE_ADJECTIVE[DISEASE]
is O
still O
uncertain B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
undertook O
a O
descriptive O
analysis O
of O
Yellow O
Card O
records O
of O
407 O
HIV O
- O
positive O
persons O
taking O
tenofovir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disoproxil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fumarate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TDF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
as O
part O
of O
their O
antiretroviral O
therapy O
regimen O
and O
submitted O
to O
the O
medicines O
and O
Healthcare O
Products O
regulatory O
Agency O
( O
MHRA O
) O
with O
suspected O
kidney O
adverse O
effects O
. O

Reports B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O
satisfy O
defined O
criteria B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
classified O
as O
acute B_DISEASE
kidney I_DISEASE
injury I_DISEASE
, O
kidney B_DISEASE
tubular I_DISEASE
dysfunction I_DISEASE
and O
Fanconi B_DISEASE/B_PERSON
syndrome I_DISEASE/I_PERSON
. O

Of O
the O
407 O
Yellow O
Card O
records O
analysed O
, O
106 O
satisfied O
criteria O
for O
TDF B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
related O
kidney O
disease O
, O
of O
which O
53 O
( O
50 O
% O
) O
had O
features O
of O
kidney O
tubular O
dysfunction O
, O
35 O
( O
33 O
% O
) O
were O
found O
to O
have O
features O
of O
glomerular O
dysfunction O
and O
18 O
( O
17 O
% O
) O
had O
Fanconi O
syndrome O
. O

The O
median O
TDF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
exposure O
was O
316 O
days O
( O
interquartile O
range O
120 O
- O
740 O
) O
. O

The O
incidence O
of O
hospitalisation O
for O
TDF B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kidney O
adverse O
effects O
was O
high O
, O
particularly O
amongst O
patients O
with O
features O
of O
Fanconi O
syndrome O
. O

The O
pattern B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
kidney B_DISEASE_ADJECTIVE[DISEASE]
syndromes I_DISEASE_ADJECTIVE[DISEASE]
in O
this O
population B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
series I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
mirrors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
reported O
in O
randomised B_MEASURE/B_LOCATION
clinical I_MEASURE/I_LOCATION
trials I_MEASURE/I_LOCATION
. O

Cessation O
of O
TDF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
associated O
with O
complete O
restoration O
of O
kidney O
function O
in O
up O
half O
of O
the O
patients O
in O
this O
report O
. O

Incidence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
postoperative B_DISEASE/B_LOCATION
delirium I_DISEASE/I_LOCATION
is O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
even O
in O
a O
population B_PERSON/B_LOCATION
without O
known O
risk B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Purpose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Postoperative B_DISEASE/B_GENE
delirium I_DISEASE/I_GENE
is O
a O
recognized O
complication B_DISEASE
in O
populations B_LOCATION/B_PERSON
at O
risk B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

The O
aim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
to O
assess O
the O
prevalence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
early B_DISEASE
postoperative I_DISEASE
delirium I_DISEASE
in O
a O
population B_PERSON/B_LOCATION
without O
known O
risk B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
admitted O
to O
the O
ICU B_LOCATION/B_ORGANIZATION
for O
postoperative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
monitoring I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
after O
elective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
major I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

The O
secondary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
investigated O
is O
to O
identify O
eventual B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
independent I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
risk I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
demographic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
anesthetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
used O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
An O
observational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
conducted O
on O
a O
consecutive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
cohort I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
patients B_PERSON
admitted O
to O
our O
ICU B_LOCATION/B_ORGANIZATION
within O
and O
for O
at O
least O
24 B_MEASURE
h O
after O
major B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
surgical I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
procedures I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

exclusion B_PERSON/B_LOCATION
criteria I_PERSON/I_LOCATION
were O
any O
preexisting O
predisposing B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factor B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
delirium B_DISEASE
or O
other B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
potentially O
confounding O
neurological B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dysfunctions B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

patients B_PERSON
were O
assessed O
daily O
using O
the O
confusion B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
assessment I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
method I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
the O
ICU B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
scale B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
3 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
after O
the O
surgical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
procedure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Early B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
postoperative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
delirium I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
incidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
risk I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
then O
assessed O
through O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
different I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
multiple I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
According O
to O
the O
confusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
the O
ICU B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scale I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
28 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
patients B_PERSON
were O
diagnosed O
with O
early B_DISEASE/B_GENE
postoperative I_DISEASE/I_GENE
delirium I_DISEASE/I_GENE
. O

The O
use O
of O
thiopentone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
significantly O
associated O
with O
an O
eight O
- O
fold O
- O
higher O
risk O
for O
delirium O
compared O
to O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
( O
57 O
. O
1 O
% O
vs O
. O
7 O
. O
1 O
% O
, O
RR O
= O
8 O
. O
0 O
, O
X2 O
= O
4 O
. O
256 O
; O
df O
= O
1 O
; O
0 O
. O
05 O
< O
p O
< O
0 O
. O
02 O
) O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
early O
postoperative B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
delirium I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
found O
to O
be O
a O
very O
common B_DISEASE_ADJECTIVE[DISEASE]
complication I_DISEASE_ADJECTIVE[DISEASE]
after O
major B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
, O
even O
in O
a O
population B_PERSON/B_LOCATION
without O
known O
risk B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thiopentone B_DISEASE/B_PERSON
was O
independently O
associated O
with O
an O
increase O
in O
its O
relative O
risk O
. O

A O
single O
neurotoxic O
dose O
of O
methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
a O
long O
- O
lasting O
depressive O
- O
like O
behaviour O
in O
mice O
. O

Methamphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
METH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
triggers O
a O
disruption O
of O
the O
monoaminergic O
system O
and O
METH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abuse O
leads O
to O
negative O
emotional O
states O
including O
depressive O
symptoms O
during O
drug O
withdrawal O
. O

However O
, O
it O
is O
currently O
unknown O
if O
the O
acute O
toxic O
dosage O
of O
METH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
causes O
a O
long O
- O
lasting O
depressive O
phenotype O
and O
persistent O
monoaminergic O
deficits O
. O

Thus O
, O
we O
now O
assessed O
the O
depressive O
- O
like O
behaviour O
in O
mice O
at O
early O
and O
long O
- O
term O
periods O
following O
a O
single O
high O
METH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O
( O
30 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
. O

METH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
did O
not O
alter O
the O
motor O
function O
and O
procedural O
memory O
of O
mice O
as O
assessed O
by O
swimming O
speed O
and O
escape O
latency O
to O
find O
the O
platform O
in O
a O
cued O
version O
of O
the O
water O
maze O
task O
. O

However O
, O
METH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
significantly O
increased O
the O
immobility O
time O
in O
the O
tail O
suspension O
test O
at O
3 O
and O
49 O
days O
post O
- O
administration O
. O

This O
depressive O
- O
like O
profile O
induced O
by O
METH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
accompanied O
by O
a O
marked O
depletion O
of O
frontostriatal O
dopaminergic O
and O
serotonergic O
neurotransmission O
, O
indicated O
by O
a O
reduction O
in O
the O
levels O
of O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
DOPAC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
HVA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
tyrosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hydroxylase O
and O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
observed O
at O
both O
3 O
and O
49 O
days O
post O
- O
administration O
. O

In O
parallel B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
another O
neurochemical B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
feature B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
depression B_DISEASE
- O
- O
astroglial B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dysfunction B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
- O
was O
unaffected B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
cortex B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
and O
the O
striatal B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
the O
astrocytic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
marker I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
glial B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
fibrillary I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
acidic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
protein I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
were O
only O
transiently O
increased O
at O
3 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
. O

These O
findings O
demonstrate O
for O
the O
first O
time O
that O
a O
single O
high O
dose O
of O
METH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induces O
long O
- O
lasting O
depressive O
- O
like O
behaviour O
in O
mice O
associated O
with O
a O
persistent O
disruption O
of O
frontostriatal O
dopaminergic O
and O
serotonergic O
homoeostasis O
. O

Linezolid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
optic O
neuropathy O
. O

Many B_PERSON
systemic I_PERSON
antimicrobials I_PERSON
have O
been O
implicated O
to O
cause O
ocular B_DISEASE
adverse I_DISEASE
effects I_DISEASE
. O

This O
is O
especially O
relevant B_DISEASE_ADJECTIVE[DISEASE]
in O
multidrug B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therapy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
where O
more B_MEASURE/B_PERSON
than O
one B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
cause O
a O
similar B_DISEASE
ocular I_DISEASE
adverse I_DISEASE
effect I_DISEASE
. O

We O
describe O
a O
case O
of O
progressive O
loss O
of O
vision O
associated O
with O
linezolid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
therapy O
. O

A O
45 O
- O
year O
- O
old O
male O
patient O
who O
was O
on O
treatment O
with O
multiple O
second O
- O
line O
anti O
- O
tuberculous O
drugs O
including O
linezolid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
ethambutol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
extensively O
drug O
- O
resistant O
tuberculosis O
( O
XDR O
- O
TB O
) O
presented O
to O
us O
with O
painless O
progressive O
loss O
of O
vision O
in O
both O
eyes O
. O

Color B_DISEASE/B_PERSON
vision I_DISEASE/I_PERSON
was O
defective B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
fundus B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
optic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disc I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
edema I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
both O
eyes B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

Ethambutol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
toxic O
optic O
neuropathy O
was O
suspected O
and O
tablet O
ethambutol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
withdrawn O
. O

Deterioration O
of O
vision O
occurred O
despite O
withdrawal O
of O
ethambutol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Discontinuation O
of O
linezolid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resulted O
in O
marked O
improvement O
of O
vision O
. O

Our O
report O
emphasizes O
the O
need O
for O
monitoring O
of O
visual O
function O
in O
patients O
on O
long O
- O
term O
linezolid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
treatment O
. O

Resuscitation O
with O
lipid O
, O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
both O
in O
levobupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cardiac O
toxicity O
in O
newborn O
piglets O
. O

Background O
: O
The O
optimal O
dosing O
regimens O
of O
lipid O
emulsion O
, O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
both O
are O
not O
yet O
determined O
in O
neonates O
in O
cases O
of O
local O
anaesthetic O
systemic O
toxicity O
( O
Last O
) O
. O

methods O
: O
newborn O
piglets O
received O
levobupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
until O
cardiovascular O
collapse O
occurred O
. O

Standard B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
cardiopulmonary I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
resuscitation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
was O
started O
and O
electrocardiogram B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ECG B_LOCATION/B_ORGANIZATION
) O
was O
monitored O
for O
ventricular B_DISEASE
tachycardia I_DISEASE
, O
fibrillation B_DISEASE
, O
or O
QRS B_DISEASE
prolongation I_DISEASE
. O

Piglets O
were O
then O
randomly O
allocated O
to O
four O
groups O
: O
control O
( O
saline O
) O
, O
Intralipid O
( O
) O
alone O
, O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
, O
or O
a O
combination O
of O
Intralipd O
plus O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

resuscitation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
continued O
for O
30 B_TIME[MEASURE]/B_LOCATION
min I_TIME[MEASURE]/I_LOCATION
or O
until O
there O
was O
a O
return B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
spontaneous B_DISEASE/B_MEASURE
circulation I_DISEASE/I_MEASURE
( O
ROSC B_DISEASE/B_PROTEIN[GENE]
) O
accompanied O
by O
a O
mean B_MEASURE/B_LOCATION
arterial I_MEASURE/I_LOCATION
pressure I_MEASURE/I_LOCATION
at O
or O
superior B_PERSON/B_MEASURE
to O
the O
baseline B_MEASURE/B_LOCATION
pressure B_MEASURE/I_LOCATION
and O
normal B_DISEASE_ADJECTIVE[DISEASE]
sinus I_DISEASE_ADJECTIVE[DISEASE]
rhythm I_DISEASE_ADJECTIVE[DISEASE]
for O
a O
period B_MEASURE/B_LOCATION
of O
30 B_TIME[MEASURE]
min I_TIME[MEASURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
ROSC B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
achieved O
in O
only O
one B_NUMBER[MEASURE]
of O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
piglets I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
compared O
with O
most B_NUMBER[MEASURE]/B_PERSON
of O
the O
treated O
piglets B_BIO/B_PERSON
. O

Mortality B_DISEASE
was O
not O
significantly O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
the O
three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
but O
was O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
all O
the O
treatment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
compared O
with O
control B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

The O
number O
of O
ECG O
abnormalities O
was O
zero O
in O
the O
Intralipid O
only O
group O
, O
but O
14 O
and O
17 O
, O
respectively O
, O
in O
the O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O
lipid O
groups O
( O
P O
< O
0 O
. O
05 O
) O
. O

conclusions O
: O
Lipid O
emulsion O
with O
or O
without O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
were O
equally O
effective O
in O
achieving O
a O
return O
to O
spontaneous O
circulation O
in O
this O
model O
of O
Last O
. O

Epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
or O
in O
combination O
with O
lipid O
was O
associated O
with O
an O
increased O
number O
of O
ECG O
abnormalities O
compared O
with O
lipid O
emulsion O
alone O
. O

incidence O
of O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
thrombocytopenia O
type O
II O
and O
postoperative O
recovery O
of O
platelet O
count O
in O
liver O
graft O
recipients O
: O
a O
retrospective O
cohort O
analysis O
. O

Background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
thrombocytopenia B_DISEASE
in O
patients B_PERSON/B_BIO
with O
end B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stage B_DISEASE
liver I_DISEASE
disease I_DISEASE
is O
a O
common B_DISEASE_ADJECTIVE[DISEASE]
disorder I_DISEASE_ADJECTIVE[DISEASE]
caused O
mainly O
by O
portal B_DISEASE
hypertension I_DISEASE
, O
low B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
levels I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
thrombopoetin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
and O
endotoxemia B_DISEASE
. O

The O
impact O
of O
immune O
- O
mediated O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
thrombocytopenia O
type O
II O
( O
Hit O
type O
II O
) O
as O
a O
cause O
of O
thrombocytopenia O
after O
liver O
transplantation O
is O
not O
yet O
understood O
, O
with O
few O
literature O
citations O
reporting O
contradictory O
results O
. O

The O
aim B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
our O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
demonstrate O
the O
perioperative B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
course I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
thrombocytopenia B_DISEASE
after O
liver B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
and O
determine O
the O
occurrence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
clinical B_DISEASE_ADJECTIVE[DISEASE]
HIT I_DISEASE_ADJECTIVE[DISEASE]
type I_DISEASE_ADJECTIVE[DISEASE]
II I_DISEASE_ADJECTIVE[DISEASE]
. O

Method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
retrospectively O
evaluated O
the O
medical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
records I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
205 B_PERSON
consecutive I_PERSON
adult I_PERSON
patients I_PERSON
who O
underwent O
full B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
size B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
liver I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
between O
January B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2006 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
December B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
2010 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
due B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
to O
end B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stage B_ENT/B_MEASURE
or O
malignant B_DISEASE
liver I_DISEASE
disease I_DISEASE
. O

Preoperative B_TIME[MEASURE]/B_LOCATION
platelet I_TIME[MEASURE]/I_LOCATION
count I_TIME[MEASURE]/I_LOCATION
, O
postoperative B_MEASURE/B_LOCATION
course I_MEASURE/I_LOCATION
of O
platelets B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
clinical B_DISEASE_ADJECTIVE[DISEASE]
signs I_DISEASE_ADJECTIVE[DISEASE]
of O
HIT B_DISEASE
type I_DISEASE
II I_DISEASE
were O
analyzed O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
A O
total B_MEASURE
of O
155 B_MEASURE
( O
75 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
of O
205 B_PERSON/B_BIO
patients I_PERSON/I_BIO
had O
thrombocytopenia B_DISEASE
before O
transplantation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
significantly O
influenced O
by O
Model B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
End B_NUMBER[MEASURE]/B_LOCATION
- O
Stage B_TIME[MEASURE]/B_LOCATION
liver I_TIME[MEASURE]/I_LOCATION
Disease I_TIME[MEASURE]/I_LOCATION
score I_TIME[MEASURE]/I_LOCATION
and O
liver B_DISEASE_ADJECTIVE[DISEASE]
cirrhosis I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
platelet B_MEASURE/B_DISEASE
count I_MEASURE/I_DISEASE
exceeded O
100 B_MEASURE
, O
000 B_MEASURE
/ O
ul B_MEASURE
in O
most B_NUMBER[MEASURE]
of O
the O
patients B_PERSON/B_LOCATION
( O
n B_OTHER/B_MEASURE
= O
193 B_MEASURE
) O
at O
a O
medium B_MEASURE
of O
7 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
d I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Regarding O
HIT B_DISEASE/B_PERSON
II I_DISEASE/I_PERSON
, O
there O
were O
four B_NUMBER[MEASURE]
( O
1 B_MEASURE
. O
95 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
patients B_PERSON
with O
a O
background B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
HIT B_DISEASE
type I_DISEASE
II I_DISEASE
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
incidence B_DISEASE_ADJECTIVE[DISEASE]
of O
HIT B_DISEASE/B_GENE
in O
patients B_PERSON/B_BIO
with O
end B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stage B_DISEASE/B_LOCATION
hepatic I_DISEASE/I_LOCATION
failure I_DISEASE/I_LOCATION
is O
, O
with O
about O
1 B_MEASURE
. O
95 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
rare B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

For O
further O
reduction O
of O
Hit O
type O
II O
, O
the O
use O
of O
intravenous O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
avoided O
and O
the O
prophylactic O
anticoagulation O
should O
be O
performed O
with O
low O
- O
molecular O
- O
weight O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
normalization O
of O
platelet O
count O
. O

Takotsubo O
syndrome O
( O
or O
apical O
ballooning O
syndrome O
) O
secondary O
to O
Zolmitriptan B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Takotsubo B_DISEASE/B_GENE
syndrome I_DISEASE/I_GENE
( O
TS B_LOCATION
) O
, O
also O
known O
as O
broken B_LOCATION
heart I_LOCATION
syndrome I_LOCATION
, O
is O
characterized O
by O
left B_PERSON/B_DISEASE
ventricle I_PERSON/I_DISEASE
apical I_PERSON/I_DISEASE
ballooning I_PERSON/I_DISEASE
with O
elevated B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiac B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biomarkers B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
electrocardiographic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
suggestive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
an O
acute B_DISEASE/B_LOCATION
coronary I_DISEASE/I_LOCATION
syndrome I_DISEASE/I_LOCATION
( O
ie B_DISEASE/B_LOCATION
, O
ST B_NUMBER[MEASURE]/B_DISEASE
- O
segment B_DISEASE_ADJECTIVE[DISEASE]
elevation I_DISEASE_ADJECTIVE[DISEASE]
, O
T B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
wave I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
inversions I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
pathologic B_DISEASE
Q I_DISEASE
waves I_DISEASE
) O
. O

We O
report O
a O
case B_PERSON
of O
54 B_MEASURE
- O
year B_TIME[MEASURE]
- O
old B_PERSON
woman I_PERSON
with O
medical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
history I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
mitral B_DISEASE
valve I_DISEASE
prolapse I_DISEASE
and O
migraines B_DISEASE/B_LOCATION
, O
who O
was O
admitted O
to O
the O
hospital B_LOCATION/B_PERSON
for O
substernal B_DISEASE
chest I_DISEASE
pain I_DISEASE
and O
electrocardiogram B_TIME[MEASURE]/B_LOCATION
demonstrated O
1 B_NUMBER[MEASURE]
/ O
2 B_NUMBER[MEASURE]
mm I_NUMBER[MEASURE]
ST I_NUMBER[MEASURE]
- O
segment B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
elevation I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
leads O
II B_NUMBER[MEASURE]/B_PROTEIN[GENE]
, O
III B_PROTEIN[GENE]/B_LOCATION
, O
aVF B_MEASURE/B_PROTEIN[GENE]
, O
V5 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
V6 B_MEASURE/B_PROTEIN[GENE]
and O
positive B_MEASURE/B_LOCATION
troponin I_MEASURE/I_LOCATION
I O
. O

emergent B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
coronary I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
angiogram I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
revealed O
normal B_DISEASE/B_LOCATION
coronary I_DISEASE/I_LOCATION
arteries I_DISEASE/I_LOCATION
with O
moderately O
reduced O
left O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
ejection I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
fraction I_BODY_PART_OR_ORGAN_COMPONENT/I_MEASURE
with O
wall B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
motion I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abnormalities I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consistent I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
TS B_DISEASE
. O

detailed O
history O
obtained O
retrospectively O
revealed O
that O
the O
patient O
took O
zolmitriptan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sparingly O
only O
when O
she O
had O
migraines O
. O

But O
before O
this O
event O
, O
she O
was O
taking O
zolmitriptan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O
- O
3 O
times O
daily O
for O
several O
days O
because O
of O
a O
persistent O
migraine O
headache O
. O

She O
otherwise O
reported O
that O
she O
is O
quite O
active B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
rides O
horses B_BIO/B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
does O
show O
jumping O
without O
any O
limitations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
her O
physical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

There O
was O
no O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
any O
recent B_DISEASE
stress I_DISEASE
or O
status B_DISEASE
migrainosus I_DISEASE
. O

extensive O
literature O
search O
revealed O
multiple O
cases O
of O
coronary O
artery O
vasospasm O
secondary O
to O
zolmitriptan B_DISEASE/B_LOCATION
, O
but O
none O
of O
the O
cases O
were O
associated O
with O
TS O
. O

Depression O
, O
impulsiveness O
, O
sleep O
, O
and O
memory O
in O
past O
and O
present O
polydrug O
users O
of O
3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
methylenedioxymethamphetamine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
MDMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
ecstasy B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

RATIONALE O
: O
Ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
methylenedioxymethamphetamine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
MDMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
is O
a O
worldwide O
recreational O
drug O
of O
abuse O
. O

Unfortunately O
, O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
human B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
investigating O
its O
psychological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
been O
inconsistent B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

objectives O
: O
The O
present O
study O
aimed O
to O
be O
the O
largest O
to O
date O
in O
sample O
size O
and O
5HT O
- O
related O
behaviors O
; O
the O
first O
to O
compare O
present O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
with O
past O
users O
after O
an O
abstinence O
of O
4 O
or O
more O
years O
, O
and O
the O
first O
to O
include O
robust O
controls O
for O
other O
recreational O
substances O
. O

methods O
: O
A O
sample O
of O
997 O
participants O
( O
52 O
% O
male O
) O
was O
recruited O
to O
four O
control O
groups O
( O
non O
- O
drug O
( O
ND O
) O
, O
alcohol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O
nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
AN B_LOCATION
) O
, O
cannabis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
alcohol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
/ O
nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CAN B_LOCATION/B_EDU[ORGANIZATION]
) O
, O
non O
- O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polydrug O
( O
PD O
) O
) O
, O
and O
two O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
polydrug O
groups O
( O
present O
( O
MDMA B_LOCATION
) O
and O
past O
users O
( O
Ex O
- O
MDMA B_LOCATION/B_PERSON
) O
. O

participants B_PERSON
completed O
a O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
history I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
questionnaire I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
Beck B_DISEASE
Depression I_DISEASE
Inventory I_DISEASE
, O
Barratt B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
Impulsiveness B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
Scale B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
Pittsburgh B_TIME[MEASURE]/B_DISEASE
Sleep I_TIME[MEASURE]/I_DISEASE
Quality I_TIME[MEASURE]/I_DISEASE
Index I_TIME[MEASURE]/I_DISEASE
, O
and O
Wechsler B_DISEASE/B_MEASURE
Memory I_DISEASE/I_MEASURE
Scale I_DISEASE/I_MEASURE
- O
revised O
which O
, O
in O
total B_MEASURE
, O
provided O
13 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
psychometric I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
measures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Results O
: O
While O
the O
CAN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
PD O
groups O
tended O
to O
record O
greater O
deficits O
than O
the O
non O
- O
drug O
controls O
, O
the O
MDMA B_LOCATION
and O
Ex O
- O
MDMA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O
recorded O
greater O
deficits O
than O
all O
the O
control O
groups O
on O
ten O
of O
the O
13 O
psychometric O
measures O
. O

Strikingly O
, O
despite O
prolonged O
abstinence O
( O
mean O
, O
4 O
. O
98 O
; O
range O
, O
4 O
- O
9 O
years O
) O
, O
past O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
showed O
few O
signs O
of O
recovery O
. O

Compared O
with O
present O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
, O
the O
past O
users O
showed O
no O
change O
for O
ten O
measures O
, O
increased O
impairment O
for O
two O
measures O
, O
and O
improvement O
on O
just O
one O
measure O
. O

conclusions O
: O
Given O
this O
record O
of O
impaired O
memory O
and O
clinically O
significant O
levels O
of O
depression O
, O
impulsiveness O
, O
and O
sleep O
disturbance O
, O
the O
prognosis O
for O
the O
current O
generation O
of O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
is O
a O
major O
cause O
for O
concern O
. O

Association O
of O
common O
genetic O
variants O
of O
HOMER1 O
gene O
with O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
adverse O
effects O
in O
Parkinson O
' O
s O
disease O
patients O
. O

Levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
the O
most O
effective O
symptomatic O
therapy O
for O
Parkinson O
' O
s O
disease O
, O
but O
its O
chronic O
use O
could O
lead O
to O
chronic O
adverse O
outcomes O
, O
such O
as O
motor O
fluctuations O
, O
dyskinesia O
and O
visual O
hallucinations O
. O

HOMER1 O
is O
a O
protein O
with O
pivotal O
function O
in O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
transmission O
, O
which O
has O
been O
related O
to O
the O
pathogenesis O
of O
these O
complications O
. O

This O
study O
investigates O
whether O
polymorphisms O
in O
the O
HOMER1 O
gene O
promoter O
region O
are O
associated O
with O
the O
occurrence O
of O
the O
chronic O
complications O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O
. O

A O
total B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
205 B_NUMBER[MEASURE]/B_PERSON
patients B_NUMBER[MEASURE]/I_PERSON
with O
idiopathic B_DISEASE/B_LOCATION
Parkinson I_DISEASE/I_LOCATION
' I_DISEASE/I_LOCATION
s I_DISEASE/I_LOCATION
disease I_DISEASE/I_LOCATION
were O
investigated O
. O

patients B_PERSON
were O
genotyped O
for O
rs4704559 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
rs10942891 B_MEASURE/B_GENE
and O
rs4704560 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
allelic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
discrimination I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
Taqman B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assays I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
rs4704559 B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
allele B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
associated O
with O
a O
lower B_MEASURE/B_LOCATION
prevalence I_MEASURE/I_LOCATION
of O
dyskinesia B_DISEASE
( O
prevalence B_LOCATION
ratio I_LOCATION
( O
PR B_LOCATION
) O
= O
0 B_NUMBER[MEASURE]
. O
615 B_MEASURE
, O
95 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
confidence I_MEASURE/I_LOCATION
interval I_MEASURE/I_LOCATION
( O
CI B_LOCATION
) O
0 B_MEASURE
. O
426 B_MEASURE
- O
0 B_MEASURE
. O
887 B_MEASURE
, O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
009 B_MEASURE
) O
and O
visual B_DISEASE
hallucinations I_DISEASE
( O
PR B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
= O
0 B_MEASURE
. O
515 B_MEASURE
, O
95 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
CI I_MEASURE/I_LOCATION
0 I_MEASURE/I_LOCATION
. O
295 B_MEASURE
- O
0 B_MEASURE
. O
899 B_MEASURE
, O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
020 B_MEASURE
) O
. O

Our O
data O
suggest O
that O
HOMER1 O
rs4704559 O
G O
allele O
has O
a O
protective O
role O
for O
the O
development O
of O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
adverse O
effects O
. O

Crocin B_BIO/B_GENE
improves O
lipid O
dysregulation O
in O
subacute O
diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
exposure O
through O
ERK1 O
/ O
2 O
pathway O
in O
rat O
liver O
. O

Introduction O
: O
Diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Yis O
one O
of O
the O
most O
broadly O
used O
organophosphorus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
insecticides O
in O
agriculture O
. O

It O
has O
been O
shown O
that O
exposure O
to O
diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
may O
interfere O
with O
lipid O
metabolism O
. O

Moreover O
, O
the O
hypolipidemic O
effect O
of O
crocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
has O
been O
established O
. O

Earlier B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
revealed O
the O
major B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
role I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
of O
Extracellular B_GENE
signal I_GENE
- O
regulated O
kinase B_ENZYME[GENE]
( O
ERK B_GENE/B_LOCATION
) O
pathways B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
density B_GENE/B_MEASURE
lipoprotein I_GENE/I_MEASURE
receptor I_GENE/I_MEASURE
( O
LDLr B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
expression B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
aim O
of O
this O
study O
was O
to O
evaluate O
changes O
in O
the O
regulation O
of O
lipid O
metabolism O
, O
ERK O
and O
LDLr O
expression O
in O
the O
liver O
of O
rats O
exposed O
to O
subacute O
diazinon B_DISEASE/B_BIO
. O

Furthermore O
ameliorating O
effect O
of O
crocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
on O
diazinon B_DISEASE/B_BIO
induced O
disturbed O
cholesterol B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
homeostasis O
was O
studied O
. O

methods O
: O
24 O
rats O
were O
divided O
into O
4 O
groups O
and O
received O
following O
treatments O
for O
4 O
weeks O
; O
corn O
oil O
( O
control O
) O
, O
diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
15mg O
/ O
kg O
per O
day O
, O
orally O
) O
and O
crocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
12 O
. O
5 O
and O
25mg O
/ O
kg O
per O
day O
, O
intraperitoneally O
) O
in O
combination O
with O
diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
15 O
mg O
/ O
kg O
) O
. O

The O
levels O
of O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
and O
LDL O
in O
blood O
of O
rats O
were O
analyzed O
. O

Moreover O
mRNA B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
LDLr B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ERK1 B_GENE
/ O
2 B_NUMBER[MEASURE]
as O
well O
as O
protein B_MEASURE/B_LOCATION
levels I_MEASURE/I_LOCATION
of O
total B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
and O
activated O
forms B_DISEASE/B_GENE
of O
ERK1 B_GENE
/ O
2 B_NUMBER[MEASURE]
in O
rat B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
liver I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
were O
evaluated O
by O
Western B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blotting I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
quantitative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
real I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
time I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polymerase I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chain I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaction I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
Our O
data O
showed O
that O
subacute O
exposure O
to O
diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
significantly O
increased O
concentrations O
of O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
triglyceride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
LDL O
. O

Moreover O
diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
decreased O
ERK1 O
/ O
2 O
protein O
phosphorylation O
and O
LDLr O
transcript O
. O

Crocin B_PERSON/B_LOCATION
reduced O
inhibition O
of O
ERK O
activation O
and O
diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
induced O
hyperlipemia O
and O
increased O
levels O
of O
LDLr O
transcript O
. O

conclusions O
: O
Crocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
may O
be O
considered O
as O
a O
novel O
protective O
agent O
in O
diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
induced O
hyperlipemia O
through O
modulating O
of O
ERK O
pathway O
and O
increase O
of O
LDLr O
expression O
. O

GEM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
P O
chemotherapy O
is O
active O
in O
the O
treatment O
of O
relapsed O
Hodgkin O
lymphoma O
. O

Hodgkin B_DISEASE
lymphoma I_DISEASE
( O
HL B_PROTEIN[GENE]/B_DISEASE
) O
is O
a O
relatively O
chemosensitive B_DISEASE_ADJECTIVE[DISEASE]
malignancy I_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
for O
those O
who O
relapse O
, O
high B_MEASURE
- O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
chemotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O
autologous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stem I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cell I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transplant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
of O
choice B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
which O
relies O
on O
adequate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
disease I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
control I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
with O
salvage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chemotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

regimens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
commonly O
used O
often O
require O
inpatient B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
can O
be O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
deliver O
due O
to O
toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Gemcitabine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
activity O
in O
HL O
, O
non O
- O
overlapping O
toxicity O
with O
first O
- O
line O
chemotherapeutics O
, O
and O
may O
be O
delivered O
in O
an O
outpatient O
setting O
. O

In O
this O
retrospective O
single O
- O
centre O
analysis O
, O
patients O
with O
relapsed O
or O
refractory O
HL O
treated O
with O
gemcitabine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
, O
000 O
mg O
/ O
m O
( O
2 O
) O
day O
( O
D O
) O
1 O
, O
D8 O
and O
D15 O
; O
methylprednisolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
, O
000 O
mg O
D1 O
- O
5 O
; O
and O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100 O
mg O
/ O
m O
( O
2 O
) O
D15 O
, O
every O
28 O
days O
( O
GEM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
P O
) O
were O
included O
. O

demographic B_LOCATION/B_TIME[MEASURE]
, O
survival B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
toxicity B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
recorded O
. O

Forty B_NUMBER[MEASURE]
- O
one B_NUMBER[MEASURE]/B_PERSON
eligible I_NUMBER[MEASURE]/I_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
were O
identified O
: O
median B_MEASURE/B_PERSON
age I_MEASURE/I_PERSON
27 I_MEASURE/I_PERSON
. O

One O
hundred O
and O
twenty O
- O
two O
cycles O
of O
GEM B_LOCATION/B_ORGANIZATION
- O
P O
were O
administered O
in O
total O
( O
median O
3 O
cycles O
; O
range O
1 O
- O
6 O
) O
. O

Twenty O
of O
41 O
( O
48 O
% O
) O
patients O
received O
GEM B_LOCATION/B_ORGANIZATION
- O
P O
as O
second O
- O
line O
treatment O
and O
11 O
/ O
41 O
( O
27 O
% O
) O
as O
third O
- O
line O
therapy O
. O

Overall O
response O
rate O
( O
ORR O
) O
to O
GEM B_LOCATION/B_ORGANIZATION
- O
P O
in O
the O
entire O
cohort O
was O
80 O
% O
( O
complete O
response O
( O
CR O
) O
37 O
% O
, O
partial O
response O
44 O
% O
) O
with O
14 O
/ O
15 O
CR O
confirmed O
as O
a O
metabolic O
CR O
on O
Pet O
and O
ORR O
of O
85 O
% O
in O
the O
20 O
second O
- O
line O
patients O
. O

The O
most O
common B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
grade I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
3 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
/ O
4 B_SEQUENCE[MEASURE]/B_LOCATION
toxicities I_SEQUENCE[MEASURE]/I_LOCATION
were O
haematological B_DISEASE_ADJECTIVE[DISEASE]
: O
neutropenia B_DISEASE/B_MEASURE
54 I_DISEASE/I_MEASURE
% I_DISEASE/I_MEASURE
and O
thrombocytopenia B_DISEASE
51 I_DISEASE
% I_DISEASE
. O

median O
follow O
- O
up O
from O
the O
start O
of O
GEM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
P O
was O
4 O
. O
5 O
years O
. O

Following O
GEM B_LOCATION/B_ORGANIZATION
- O
P O
, O
5 O
- O
year O
progression O
- O
free O
survival O
was O
46 O
% O
( O
95 O
% O
confidence O
interval O
( O
CI O
) O
, O
30 O
- O
62 O
% O
) O
and O
5 O
- O
year O
overall O
survival O
was O
59 O
% O
( O
95 O
% O
CI O
, O
43 O
- O
74 O
% O
) O
. O

Fourteen B_NUMBER[MEASURE]/B_PERSON
of O
41 B_NUMBER[MEASURE]/B_PERSON
patients B_NUMBER[MEASURE]/I_PERSON
proceeded O
directly O
to O
autologous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplant I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

GEM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
P O
is O
a O
salvage O
chemotherapy O
with O
relatively O
high O
response O
rates O
, O
leading O
to O
successful O
transplantation O
in O
appropriate O
patients O
, O
in O
the O
treatment O
of O
relapsed O
or O
refractory O
HL O
. O

basal O
functioning O
of O
the O
hypothalamic O
- O
pituitary O
- O
adrenal O
( O
HPA O
) O
axis O
and O
psychological O
distress O
in O
recreational O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
polydrug O
users O
. O

RATIONALE O
: O
Ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
MDMA B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
a O
psychostimulant O
drug O
which O
is O
increasingly O
associated O
with O
psychobiological O
dysfunction O
. O

While O
some O
recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggest O
acute B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
in O
neuroendocrine B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
is O
known O
about O
long B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
term B_MEASURE/B_LOCATION
changes B_MEASURE/I_LOCATION
in O
HPA B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functionality B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
recreational B_PERSON/B_BIO
users B_PERSON/I_BIO
. O

objectives O
: O
The O
current O
study O
is O
the O
first O
to O
explore O
the O
effects O
of O
ecstasy B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
polydrug O
use O
on O
psychological O
distress O
and O
basal O
functioning O
of O
the O
HPA O
axis O
through O
assessing O
the O
secretion O
of O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
across O
the O
diurnal O
period O
. O

Method O
: O
seventy O
- O
six O
participants O
( O
21 O
nonusers O
, O
29 O
light O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
polydrug O
users O
, O
26 O
heavy O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
polydrug O
users O
) O
completed O
a O
substance O
use O
inventory O
and O
measures O
of O
psychological O
distress O
at O
baseline O
, O
then O
two O
consecutive O
days O
of O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_SUBSTANCE[BODY_PART_OR_ORGAN_COMPONENT]
sampling O
( O
on O
awakening O
, O
30 O
min O
post O
awakening O
, O
between O
1400 O
and O
1600 O
hours O
and O
pre O
bedtime O
) O
. O

On O
day B_TIME[MEASURE]/B_LOCATION
2 I_TIME[MEASURE]/I_LOCATION
, O
participants B_PERSON
also O
attended O
the O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
to O
complete O
a O
20 B_MEASURE
- O
min B_PERSON/B_TIME[MEASURE]
multitasking O
stressor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
Both O
user B_PERSON/B_ORGANIZATION
groups I_PERSON/I_ORGANIZATION
exhibited O
significantly O
greater B_MEASURE
levels I_MEASURE
of O
anxiety B_DISEASE
and O
depression B_DISEASE
than O
nonusers B_PERSON/B_MEASURE
. O

On O
day O
1 O
, O
all O
participants O
exhibited O
a O
typical O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
profile O
, O
though O
light O
users O
had O
significantly O
elevated O
levels O
pre O
- O
bed O
. O

On O
day O
2 O
, O
heavy O
users O
demonstrated O
elevated O
levels O
upon O
awakening O
and O
all O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
polydrug O
users O
demonstrated O
elevated O
pre O
- O
bed O
levels O
compared O
to O
non O
- O
users O
. O

significant O
between O
group O
differences O
were O
also O
observed O
in O
afternoon O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
and O
in O
overall O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
secretion O
across O
the O
day O
. O

conclusions O
: O
The O
increases O
in O
anxiety O
and O
depression O
are O
in O
line O
with O
previous O
observations O
in O
recreational O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
polydrug O
users O
. O

Dysregulated O
diurnal O
cortisol B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
may O
be O
indicative O
of O
inappropriate O
anticipation O
of O
forthcoming O
demands O
and O
hypersecretion O
may O
lead O
to O
the O
increased O
psychological O
and O
physical O
morbidity O
associated O
with O
heavy O
recreational O
use O
of O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Ifosfamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
related O
encephalopathy O
: O
the O
need O
for O
a O
timely O
EEG O
evaluation O
. O

Background O
: O
Ifosfamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
an O
alkylating O
agent O
useful O
in O
the O
treatment O
of O
a O
wide O
range O
of O
cancers O
including O
sarcomas O
, O
lymphoma O
, O
gynecologic O
and O
testicular O
cancers O
. O

Encephalopathy O
has O
been O
reported O
in O
10 O
- O
40 O
% O
of O
patients O
receiving O
high O
- O
dose O
IV O
ifosfamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

objective O
: O
To O
highlight O
the O
role O
of O
electroencephalogram O
( O
EEG O
) O
in O
the O
early O
detection O
and O
management O
of O
ifosfamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
related O
encephalopathy O
. O

methods O
: O
retrospective O
chart O
review O
including O
clinical O
data O
and O
EEG O
recordings O
was O
done O
on O
five O
patients O
, O
admitted O
to O
MD O
Anderson O
Cancer O
Center O
between O
years O
2009 O
and O
2012 O
, O
who O
developed O
ifosfamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
related O
acute O
encephalopathy O
. O

Results O
: O
All O
five O
patients O
experienced O
symptoms O
of O
encephalopathy O
soon O
after O
( O
within O
12 O
h O
- O
2 O
days O
) O
receiving O
ifosfamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Two B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
developed O
generalized B_DISEASE
convulsions I_DISEASE
while O
one B_PERSON/B_NUMBER[MEASURE]
patient B_PERSON/I_NUMBER[MEASURE]
developed O
continuous B_DISEASE_ADJECTIVE[DISEASE]
non I_DISEASE_ADJECTIVE[DISEASE]
- O
convulsive B_DISEASE
status I_DISEASE
epilepticus I_DISEASE
( O
NCSE B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
that O
required O
ICU B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
admission I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
intubation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Initial B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
EEG I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
showed O
epileptiform B_DISEASE_ADJECTIVE[DISEASE]
discharges I_DISEASE_ADJECTIVE[DISEASE]
in O
three B_NUMBER[MEASURE]/B_PERSON
patients B_NUMBER[MEASURE]/I_PERSON
; O
run O
of O
triphasic B_DISEASE/B_MEASURE
waves I_DISEASE/I_MEASURE
in O
one B_PERSON/B_NUMBER[MEASURE]
patient I_PERSON/I_NUMBER[MEASURE]
and O
moderate B_DISEASE_ADJECTIVE[DISEASE]
degree I_DISEASE_ADJECTIVE[DISEASE]
diffuse I_DISEASE_ADJECTIVE[DISEASE]
generalized O
slowing B_DISEASE
. O

Mixed B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pattern I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
presence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
both O
sharps B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
and O
triphasic B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
waves B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
were O
also O
noted O
. O

repeat O
EEGs B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
within O
24 B_MEASURE
_ I_MEASURE
h O
of O
symptom B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
onset I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
showed O
marked B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
improvement B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
was O
correlated O
with O
clinical B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
improvement I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

conclusions O
: O
severity O
of O
ifosfamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
related O
encephalopathy O
correlates O
with O
EEG O
changes O
. O

We O
suggest O
a O
timely O
EEG O
evaluation O
for O
patients O
receiving O
ifosfamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
who O
develop O
features O
of O
encephalopathy O
. O

incidence O
of O
contrast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
nephropathy O
in O
hospitalised O
patients O
with O
cancer O
. O

objectives O
: O
To O
determine O
the O
frequency O
of O
and O
possible O
factors O
related O
to O
contrast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
nephropathy O
( O
CIN O
) O
in O
hospitalised O
patients O
with O
cancer O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
ninety B_MEASURE/B_PERSON
adult B_MEASURE/I_PERSON
patients B_MEASURE/I_PERSON
were O
enrolled O
. O

patients B_PERSON/B_LOCATION
with O
risk B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
factors I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
for O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
were O
excluded O
. O

Blood O
samples O
were O
examined O
the O
day O
before O
contrast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
enhanced O
computed O
tomography O
( O
CT O
) O
and O
serially O
for O
3 O
days O
thereafter O
. O

CIN O
was O
defined O
as O
an O
increase O
in O
serum O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
Cr B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
of O
0 O
. O
5 O
mg O
/ O
DL O
or O
more O
, O
or O
elevation O
of O
Cr B_LOCATION/B_MEASURE
to O
25 O
% O
over O
baseline O
. O

relationships B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
CIN B_DISEASE
and O
possible B_DISEASE/B_ORGANIZATION
risk I_DISEASE/I_ORGANIZATION
factors I_DISEASE/I_ORGANIZATION
were O
investigated O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
CIN B_DISEASE/B_GENE
was O
detected O
in O
18 B_MEASURE
/ O
90 B_MEASURE
( O
20 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
patients B_PERSON
. O

CIN B_DISEASE
developed O
in O
25 B_MEASURE
. O
5 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
patients I_MEASURE/I_PERSON
who O
underwent O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
in O
11 B_PERSON
% I_PERSON
patients I_PERSON
who O
did O
not O
( O
P B_OTHER/B_MEASURE
= O
0 B_MEASURE
. O
1 B_MEASURE
) O
. O

CIN B_DISEASE
more O
frequently O
developed O
in O
patients B_PERSON
who O
had O
undergone O
CT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
within O
45 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
after O
the O
last B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
chemotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
005 B_MEASURE
) O
; O
it O
was O
also O
an O
independent B_DISEASE_ADJECTIVE[DISEASE]
risk I_DISEASE_ADJECTIVE[DISEASE]
factor I_DISEASE_ADJECTIVE[DISEASE]
( O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
017 B_MEASURE
) O
. O

CIN O
was O
significantly O
more O
after O
treatment O
with O
bevacizumab B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
irinotecan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
P O
= O
0 O
. O
021 O
) O
and O
in O
patients O
with O
hypertension O
( O
P O
= O
0 O
. O
044 O
) O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
incidence B_MEASURE/B_DISEASE
of O
CIN B_DISEASE/B_LOCATION
after O
CT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
hospitalised B_PERSON/B_LOCATION
oncological B_PERSON/I_LOCATION
patients B_PERSON/I_LOCATION
was O
20 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

CIN B_DISEASE/B_GENE
developed O
4 B_NUMBER[MEASURE]
. O
5 B_MEASURE
- O
times B_TIME[MEASURE]/B_LOCATION
more O
frequently O
in O
patients B_PERSON
with O
cancer B_DISEASE/B_LOCATION
who O
had O
undergone O
recent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
chemotherapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Hypertension O
and O
the O
combination O
of O
bevacizumab B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
irinotecan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
additional O
risk O
factors O
for O
CIN O
development O
. O

Key B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Points I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
. O

Contrast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
nephropathy O
( O
CIN O
) O
is O
a O
concern O
for O
oncological O
patients O
undergoing O
CT O
. O

. O
CIN B_DISEASE
occurs O
more O
often O
when O
CT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
is O
performed O
< O
45 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
after O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

. O
Hypertension O
and O
treatment O
with O
bevacizumab B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
appear O
to O
be O
additional O
risk O
factors O
. O

syndrome O
of O
inappropriate O
antidiuretic O
hormone O
secretion O
associated O
with O
desvenlafaxine B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

objective O
: O
To O
report O
a O
case O
of O
syndrome O
of O
inappropriate O
anti O
- O
diuretic O
hormone O
( O
SIADH O
) O
secretion O
associated O
with O
desvenlafaxine B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Case B_TIME[MEASURE]/B_PERSON
summary I_TIME[MEASURE]/I_PERSON
: O
A O
57 B_NUMBER[MEASURE]
- O
year B_PERSON/B_TIME[MEASURE]
old B_PERSON/I_TIME[MEASURE]
female B_PERSON/I_TIME[MEASURE]
with O
hyponatraemia B_DISEASE
. O

Her O
medications O
included O
desvenlafaxine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
symptoms O
included O
nausea O
, O
anxiety O
and O
confusion O
. O

The O
serum O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
at O
this O
time O
was O
120 O
mmol O
/ O
L O
, O
serum O
osmolality O
was O
263 O
mosmol O
/ O
kg O
, O
urine O
osmolality O
410 O
mosmol O
/ O
kg O
and O
urine O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
63 O
mmol O
/ O
L O
, O
consistent O
with O
a O
diagnosis O
of O
SIADH O
. O

Desvenlafaxine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
ceased O
and O
fluid O
restriction O
implemented O
. O

After O
4 O
days O
the O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
increased O
to O
128 O
mmol O
/ O
L O
and O
fluid O
restriction O
was O
relaxed O
. O

During O
her O
further O
3 O
weeks O
inpatient O
admission O
the O
serum O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
ranged O
from O
134 O
to O
137 O
mmol O
/ O
L O
during O
treatment O
with O
mirtazapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

discussion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
SIADH B_DISEASE
has O
been O
widely O
reported O
with O
a O
range B_MEASURE
of O
antidepressants B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
case O
report O
suggests O
that O
desvenlafaxine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
might O
cause O
clinically O
significant O
hyponatremia O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Clinicians B_PERSON
should O
be O
aware B_PERSON
of O
the O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
antidepressants B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
cause O
hyponatremia B_DISEASE
, O
and O
take O
appropriate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
corrective I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
action I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
where O
necessary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Oxidative O
stress O
on O
cardiotoxicity O
after O
treatment O
with O
single O
and O
multiple O
doses O
of O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
mechanism O
of O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
- O
induced O
cardiotoxicity O
remains O
controversial O
. O

Wistar O
rats O
( O
n O
= O
66 O
) O
received O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
injections O
intraperitoneally O
and O
were O
randomly O
assigned O
to O
2 O
experimental O
protocols O
: O
( O
1 O
) O
rats O
were O
killed O
before O
( O
- O
24 O
h O
, O
n O
= O
8 O
) O
and O
24 O
h O
after O
( O
+ O
24 O
h O
, O
n O
= O
8 O
) O
a O
single O
dose O
of O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
4 O
mg O
/ O
kg O
body O
weight O
) O
to O
determine O
the O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acute O
effect O
and O
( O
2 O
) O
rats O
( O
n O
= O
58 O
) O
received O
4 O
injections O
of O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
4 O
mg O
/ O
kg O
body O
weight O
/ O
week O
) O
and O
were O
killed O
before O
the O
first O
injection O
( O
M0 O
) O
and O
1 O
week O
after O
each O
injection O
( O
M1 O
, O
M2 O
, O
M3 O
, O
and O
M4 O
) O
to O
determine O
the O
chronological O
effects O
. O

Animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
used O
at O
M0 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
n B_OTHER/B_MEASURE
= O
8 B_MEASURE
) O
were O
also O
used O
at O
moment B_MEASURE
- O
24 B_TIME[MEASURE]/B_LOCATION
h I_TIME[MEASURE]/I_LOCATION
of O
acute B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Cardiac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
total I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antioxidant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
performance I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
TAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
, O
DNA B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
damage B_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
morphology B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
analyses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
were O
carried O
out O
at O
each O
time B_MEASURE/B_LOCATION
point B_MEASURE/I_LOCATION
. O

Single O
dose O
of O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
associated O
with O
increased O
cardiac O
disarrangement O
, O
necrosis O
, O
and O
DNA O
damage O
( O
strand O
breaks O
( O
SBS O
) O
and O
oxidized O
pyrimidines O
) O
and O
decreased O
tap O
. O

The O
chronological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
an O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
cumulative B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
body B_DISEASE/B_GENE
weight I_DISEASE/I_GENE
( O
R B_MEASURE/B_PROTEIN[GENE]
= B_MEASURE/I_PROTEIN[GENE]
- O
0 B_NUMBER[MEASURE]
. O
99 B_MEASURE
, O
p O
= O
0 B_NUMBER[MEASURE]
. O
011 B_MEASURE
) O
, O
necrosis B_DISEASE/B_GENE
( O
R B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
1 B_MEASURE
. O
00 B_MEASURE
, O
p O
= O
0 B_NUMBER[MEASURE]
. O
004 B_MEASURE
) O
, O
TAP B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
R B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
0 B_NUMBER[MEASURE]
. O
95 B_MEASURE
, O
p O
= O
0 B_NUMBER[MEASURE]
. O
049 B_MEASURE
) O
, O
and O
DNA B_PROTEIN[GENE]/B_DISEASE
SBs I_PROTEIN[GENE]/I_DISEASE
( O
R B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
- O
0 B_MEASURE
. O
95 B_MEASURE
, O
p O
= O
0 B_NUMBER[MEASURE]
. O
049 B_MEASURE
) O
. O

DNA B_DISEASE/B_GENE
SBs I_DISEASE/I_GENE
damage I_DISEASE/I_GENE
was O
negatively O
associated O
with O
TAP B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
R B_MEASURE/B_PROTEIN[GENE]
= B_MEASURE/I_PROTEIN[GENE]
- O
0 B_MEASURE
. O
98 B_MEASURE
, O
p O
= O
0 B_MEASURE
. O
018 B_MEASURE
) O
, O
and O
necrosis B_DISEASE/B_GENE
( O
R B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
= O
- O
0 B_NUMBER[MEASURE]
. O
97 B_MEASURE
, O
p O
= O
0 B_MEASURE
. O
027 B_MEASURE
) O
. O

Our O
results O
suggest O
that O
oxidative O
damage O
is O
associated O
with O
acute O
cardiotoxicity O
induced O
by O
a O
single O
dose O
of O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
only O
. O

increased O
resistance O
to O
the O
oxidative O
stress O
is O
plausible O
for O
the O
multiple O
dose O
of O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thus O
, O
different B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
involved O
in O
acute B_DISEASE_ADJECTIVE[DISEASE]
toxicity I_DISEASE_ADJECTIVE[DISEASE]
versus O
chronic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
toxicity I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Tacrolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
related O
seizure O
after O
pediatric O
liver O
transplantation O
- O
- O
a O
single O
- O
center O
experience O
. O

To O
identify O
the O
risk B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
new B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
- O
onset B_DISEASE
seizures I_DISEASE
after O
pediatric B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
LT I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
to O
assess O
their O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
implications B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
long B_TIME[MEASURE]/B_LOCATION
- O
term B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prognosis B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
laboratory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
27 B_PERSON
consecutive I_PERSON
children I_PERSON
who O
underwent O
LT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
January B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2007 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
December B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2010 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
our O
center B_LOCATION
were O
analyzed O
retrospectively O
. O

patients B_PERSON
were O
divided O
into O
seizures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
a O
non B_DISEASE/B_MEASURE
- O
seizures B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Pre B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
operative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
operative B_PERSON/B_ORGANIZATION
, O
and O
post B_DISEASE
- O
operative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
data I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
collected O
. O

seizures B_DISEASE
occurred O
in O
four B_MEASURE/B_ENT
children I_MEASURE/I_ENT
, O
an O
incidence B_DISEASE/B_MEASURE
of O
14 B_MEASURE
. O
8 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
. O

All O
exhibited O
generalized O
tonic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
clonic B_DISEASE_ADJECTIVE[DISEASE]
seizures I_DISEASE_ADJECTIVE[DISEASE]
within O
the O
first B_TIME[MEASURE]/B_ORGANIZATION
two I_TIME[MEASURE]/I_ORGANIZATION
wk I_TIME[MEASURE]/I_ORGANIZATION
after O
LT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Univariate O
analysis O
showed O
that O
the O
risk O
factors O
associated O
with O
seizures O
after O
pediatric O
Lt O
included O
gender O
, O
pediatric O
end O
- O
stage O
liver O
disease O
score O
before O
surgery O
, O
Child O
- O
Pugh O
score O
before O
surgery O
, O
serum O
total O
bilirubin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
after O
surgery O
, O
and O
trough O
TAC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O
. O

Multivariate O
analysis O
showed O
that O
trough O
TAC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O
was O
the O
only O
independent O
risk O
factor O
associated O
with O
the O
seizures O
. O

All O
children B_PERSON/B_BIO
who O
experienced O
seizures B_DISEASE
survived O
with O
good B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
graft I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
function I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
remained O
seizure B_DISEASE
- O
free B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
without O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
epileptic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
over O
a O
mean B_MEASURE
follow O
- O
up O
period B_TIME[MEASURE]/B_LOCATION
of O
33 B_MEASURE
. O
7 B_MEASURE
+ I_MEASURE
14 I_MEASURE
. O
6 B_TIME[MEASURE]
months I_TIME[MEASURE]
. O

High O
trough O
TAC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
level O
was O
the O
predominant O
factor O
that O
contributed O
to O
seizures O
in O
the O
early O
post O
- O
operative O
period O
after O
pediatric O
Lt O
. O

High O
PELD O
and O
Child O
- O
Pugh O
scores O
before O
Lt O
and O
high O
post O
- O
operative O
serum O
Tbil O
may O
be O
contributory O
risk O
factors O
for O
TAC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
related O
seizures O
. O

The O
flavonoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
apigenin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
delays O
forgetting O
of O
passive O
avoidance O
conditioning O
in O
rats O
. O

The O
present O
experiments O
were O
performed O
to O
study O
the O
effect O
of O
the O
flavonoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
apigenin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
20 O
mg O
/ O
kg O
intraperitoneally O
( O
i O
. O
p O
. O
) O
, O
1 O
h O
before O
acquisition O
) O
, O
on O
24 O
h O
retention O
performance O
and O
forgetting O
of O
a O
step O
- O
through O
passive O
avoidance O
task O
, O
in O
young O
male O
Wistar O
rats O
. O

There O
were O
no O
differences O
between O
saline O
- O
and O
apigenin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
groups O
in O
the O
24 O
h O
retention O
trial O
. O

Furthermore O
, O
apigenin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
prevent O
the O
amnesia O
induced O
by O
scopolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1mg O
/ O
kg O
, O
i O
. O
p O
. O
, O
30 O
min O
before O
the O
acquisition O
) O
. O

The O
saline O
- O
and O
apigenin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
rats O
that O
did O
not O
step O
through O
into O
the O
dark O
compartment O
during O
the O
cut O
- O
off O
time O
( O
540 O
s O
) O
were O
retested O
weekly O
for O
up O
to O
eight O
weeks O
. O

In O
the O
saline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
first B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
significant I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
decline I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
passive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
avoidance I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
response I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
observed O
at O
four B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
, O
and O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
memory I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
loss I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
found O
five B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
after O
the O
acquisition B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
of O
the O
passive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
avoidance I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
task I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

At O
the O
end O
of O
the O
experimental O
period O
, O
60 O
% O
of O
the O
animals O
treated O
with O
apigenin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
still O
did O
not O
step O
through O
. O

These O
data O
suggest O
that O
1 O
) O
apigenin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
delays O
the O
long O
- O
term O
forgetting O
but O
did O
not O
modulate O
the O
24 O
h O
retention O
of O
fear O
memory O
and O
2 O
) O
the O
obtained O
beneficial O
effect O
of O
apigenin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
passive O
avoidance O
conditioning O
is O
mediated O
by O
mechanisms O
that O
do O
not O
implicate O
its O
action O
on O
the O
muscarinic O
cholinergic O
system O
. O

Histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonists O
and O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tubocurarine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hypotension O
in O
cardiac O
surgical O
patients O
. O

Hemodynamic O
effects O
and O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
release O
by O
bolus O
injection O
of O
0 O
. O
35 O
mg O
/ O
kg O
of O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tubocurarine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
studied O
in O
24 O
patients O
. O

H1 O
- O
and O
H2 O
- O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonists O
or O
placebo O
were O
given O
before O
dosing O
with O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
tubocurarine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
in O
a O
randomized O
double O
- O
blind O
fashion O
to O
four O
groups O
: O
group O
1 O
- O
- O
placebo O
; O
group O
2 O
- O
- O
cimetidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
4 O
mg O
/ O
kg O
, O
plus O
placebo O
; O
group O
3 O
- O
- O
chlorpheniramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
0 O
. O
1 O
mg O
/ O
kg O
, O
plus O
placebo O
; O
and O
group O
4 O
- O
- O
cimetidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O
chlorpheniramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
release O
occurred O
in O
most O
patients O
, O
the O
highest O
level O
2 O
minutes O
after O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tubocurarine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dosing O
. O

Group O
1 O
had O
a O
moderate O
negative O
correlation O
between O
plasma O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
change O
and O
systemic O
vascular O
resistance O
( O
r O
= O
0 O
. O
58 O
; O
P O
less O
than O
0 O
. O
05 O
) O
not O
present O
in O
group O
4 O
. O

Prior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dosing I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
antagonists B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partially O
prevented O
the O
fall B_DISEASE_ADJECTIVE[DISEASE]
in O
systemic B_DISEASE/B_GENE
vascular B_DISEASE/I_GENE
resistance B_DISEASE/I_GENE
. O

These O
data O
demonstrate O
that O
the O
hemodynamic O
changes O
associated O
with O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tubocurarine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dosing O
are O
only O
partially O
explained O
by O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
release O
. O

Thus O
prior B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dosing O
with O
H1 B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
H2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
antagonists B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
provides O
only O
partial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
protection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Cholecystokinin B_PERSON/B_LOCATION
- I_PERSON/I_LOCATION
octapeptide I_PERSON/I_LOCATION
restored O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
hippocampal O
long O
- O
term O
potentiation O
impairment O
in O
rats O
. O

Cholecystokinin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
octapeptide I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
( O
CCK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
which O
is O
a O
typical O
brain O
- O
gut O
peptide O
, O
exerts O
a O
wide O
range O
of O
biological O
activities O
on O
the O
central O
nervous O
system O
. O

We O
have O
previously O
reported O
that O
CCK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
8 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
significantly O
alleviated O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
amnesia O
and O
reversed O
spine O
density O
decreases O
in O
the O
CA1 O
region O
of O
the O
hippocampus O
in O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
animals O
. O

Here O
, O
we O
investigated O
the O
effects O
of O
CCK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
8 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
long O
- O
term O
potentiation O
( O
LTP O
) O
in O
the O
lateral O
perforant O
path O
( O
LPP O
) O
- O
granule O
cell O
synapse O
of O
rat O
dentate O
gyrus O
( O
DG O
) O
in O
acute O
saline O
or O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
rats O
. O

Population B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
spikes I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
PS B_LOCATION/B_PROTEIN[GENE]
) O
, O
which O
were O
evoked O
by O
stimulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
LPP B_DISEASE/B_PROTEIN[GENE]
, O
were O
recorded O
in O
the O
DG B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
region I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

acute O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
30mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
treatment O
significantly O
attenuated O
hippocampal O
LTP O
and O
CCK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
8 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
1ug O
, O
i O
. O
c O
. O
v O
. O
) O
restored O
the O
amplitude O
of O
PS O
that O
was O
attenuated O
by O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O
. O

Furthermore O
, O
microinjection O
of O
CCK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
8 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
0 O
. O
1 O
and O
1ug O
, O
i O
. O
c O
. O
v O
. O
) O
also O
significantly O
augmented O
hippocampal O
LTP O
in O
saline O
- O
treated O
( O
1ml O
/ O
kg O
, O
s O
. O
c O
. O
) O
rats O
. O

Pre O
- O
treatment O
of O
the O
CCK2 O
receptor O
antagonist O
L O
- O
365 O
, O
260 O
( O
10ug O
, O
i O
. O
c O
. O
v O
) O
reversed O
the O
effects O
of O
CCK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
8 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
the O
CCK1 O
receptor O
antagonist O
L O
- O
364 O
, O
718 O
( O
10ug O
, O
i O
. O
c O
. O
v O
) O
did O
not O
. O

The O
present O
results O
demonstrate O
that O
CCK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
attenuates O
the O
effect O
of O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
hippocampal O
LTP O
through O
CCK2 O
receptors O
and O
suggest O
an O
ameliorative O
function O
of O
CCK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
8 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
memory O
impairment O
. O

Glial O
activation O
and O
post O
- O
synaptic O
neurotoxicity O
: O
the O
key O
events O
in O
Streptozotocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ICV O
) O
induced O
memory O
impairment O
in O
rats O
. O

In O
the O
present O
study O
the O
role O
of O
glial O
activation O
and O
post O
synaptic O
toxicity O
in O
ICV O
Streptozotocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
STZ B_DISEASE/B_LOCATION
) O
induced O
memory O
impaired O
rats O
was O
explored O
. O

In O
experiment O
set O
up O
1 O
: O
Memory O
deficit O
was O
found O
in O
Morris O
water O
maze O
test O
on O
14 O
- O
16 O
days O
after O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ICV O
; O
3mg O
/ O
kg O
) O
administration O
. O

STZ B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
causes O
increased O
expression O
of O
GFAP O
, O
CD11b O
and O
TNF O
- O
a O
indicating O
glial O
activation O
and O
neuroinflammation O
. O

STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
significantly O
increased O
the O
level O
of O
ROS O
, O
nitrite B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
Ca B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
2 O
+ O
) O
and O
reduced O
the O
mitochondrial O
activity O
in O
synaptosomal O
preparation O
illustrating O
free O
radical O
generation O
and O
excitotoxicity O
. O

increased O
expression O
and O
activity O
of O
Caspase O
- O
3 O
was O
also O
observed O
in O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
treated O
rat O
which O
specify O
apoptotic O
cell O
death O
in O
hippocampus O
and O
cortex O
. O

STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O
showed O
decrease O
expression O
of O
post O
synaptic O
markers O
CaMKIIa O
and O
PSD O
- O
95 O
, O
while O
, O
expression O
of O
pre O
synaptic O
markers O
( O
synaptophysin O
and O
snap O
- O
25 O
) O
remains O
unaltered O
indicating O
selective O
post O
synaptic O
neurotoxicity O
. O

Oral O
treatment O
with O
Memantine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
10mg O
/ O
kg O
) O
and O
Ibuprofen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
50 O
mg O
/ O
kg O
) O
daily O
for O
13 O
days O
attenuated O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O
glial O
activation O
, O
apoptotic O
cell O
death O
and O
post O
synaptic O
neurotoxicity O
in O
rat O
brain O
. O

Further O
, O
in O
experiment O
set O
up O
2 O
: O
where O
memory O
function O
was O
not O
affected O
i O
. O
e O
. O
7 O
- O
9 O
days O
after O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
. O

The O
level O
of O
GFAP O
, O
CD11b O
, O
TNF O
- O
a O
, O
ROS O
and O
nitrite B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
were O
increased O
. O

On O
the O
other O
hand O
, O
apoptotic O
marker O
, O
synaptic O
markers O
, O
mitochondrial O
activity O
and O
Ca B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
2 O
+ O
) O
levels O
remained O
unaffected O
. O

collective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
indicates O
that O
neuroinflammatory B_DISEASE_ADJECTIVE[DISEASE]
process I_DISEASE_ADJECTIVE[DISEASE]
and O
oxidative B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stress I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
occurs O
earlier O
to O
apoptosis B_DISEASE/B_LOCATION
and O
does O
not O
affect O
memory B_DISEASE_ADJECTIVE[DISEASE]
function I_DISEASE_ADJECTIVE[DISEASE]
. O

Present O
study O
clearly O
suggests O
that O
glial O
activation O
and O
post O
synaptic O
neurotoxicity O
are O
the O
key O
factors O
in O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O
memory O
impairment O
and O
neuronal O
cell O
death O
. O

comparison O
of O
effects O
of O
isotonic O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
diltiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
prevention O
of O
contrast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
nephropathy O
. O

Introduction O
AND O
objective O
: O
Contrast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
nephropathy O
( O
CIN O
) O
significantly O
increases O
the O
morbidity O
and O
mortality O
of O
patients O
. O

The O
aim O
of O
this O
study O
is O
to O
investigate O
and O
compare O
the O
protective O
effects O
of O
isotonic O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bicarbonate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
and O
isotonic O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
infusion O
with O
diltiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
calcium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
channel O
blocker O
, O
in O
preventing O
CIN O
. O

Materials O
AND O
methods O
: O
Our O
study O
included O
patients O
who O
were O
administered O
30 O
- O
60 O
mL O
of O
iodinated O
contrast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent O
for O
percutaneous O
coronary O
angiography O
( O
PCAG O
) O
, O
all O
with O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values O
between O
1 O
. O
1 O
and O
3 O
. O
1 O
mg O
/ O
DL O
. O

patients B_PERSON
were O
divided O
into O
three B_ORGANIZATION/B_LOCATION
groups B_ORGANIZATION/I_LOCATION
and O
each O
group B_ORGANIZATION/B_LOCATION
had O
20 B_TIME[MEASURE]/B_PERSON
patients B_TIME[MEASURE]/I_PERSON
. O

The O
first O
group O
of O
patients O
was O
administered O
isotonic O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
; O
the O
second O
group O
was O
administered O
a O
solution O
that O
of O
5 O
% O
dextrose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bicarbonate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
while O
the O
third O
group O
was O
administered O
isotonic O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
before O
and O
after O
the O
contrast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O
. O

The O
third O
group O
received O
an O
additional O
injection O
of O
diltiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
day O
before O
and O
first O
2 O
days O
after O
the O
contrast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SEQUENCE[MEASURE]
injection O
. O

All O
of O
the O
patients O
' O
plasma O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
urea I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nitrogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
BUN B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O
and O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
were O
measured O
on O
the O
second O
and O
seventh O
day O
after O
the O
administration O
of O
intravenous O
contrast B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
material O
. O

Results O
: O
The O
basal O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
were O
similar O
for O
all O
three O
groups O
( O
p O
> O
0 O
. O
05 O
) O
. O

Among O
a O
total O
of O
60 O
patients O
included O
in O
the O
study O
, O
16 O
patients O
developed O
acute O
renal O
failure O
( O
ARF O
) O
on O
the O
second O
day O
after O
contrast B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
material O
was O
injected O
( O
26 O
. O
6 O
% O
) O
. O

The O
number B_MEASURE/B_PERSON
of O
patients B_PERSON
who O
developed O
ARF B_DISEASE
on O
the O
second B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
day I_TIME[MEASURE]/I_BODY_PART_OR_ORGAN_COMPONENT
after O
the O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
five B_NUMBER[MEASURE]
( O
25 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
, O
in O
the O
second B_SEQUENCE[MEASURE]/B_ORGANIZATION
group I_SEQUENCE[MEASURE]/I_ORGANIZATION
was O
six B_NUMBER[MEASURE]
( O
30 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
) O
and O
the O
third B_SEQUENCE[MEASURE]/B_ORGANIZATION
group I_SEQUENCE[MEASURE]/I_ORGANIZATION
was O
five B_NUMBER[MEASURE]
( O
25 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
( O
p B_MEASURE/B_LOCATION
> I_MEASURE/I_LOCATION
0 I_MEASURE/I_LOCATION
. O
05 B_MEASURE
) O
. O

conclusion O
: O
There O
was O
no O
significant O
difference O
between O
isotonic O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bicarbonate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
isotonic O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
diltiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
application O
in O
prevention O
of O
CIN O
. O

Neurocognitive O
and O
neuroradiologic O
central O
nervous O
system O
late O
effects O
in O
children O
treated O
on O
Pediatric O
Oncology O
Group O
( O
POG O
) O
P9605 O
( O
standard O
risk O
) O
and O
P9201 O
( O
lesser O
risk O
) O
acute O
lymphoblastic O
leukemia O
protocols O
( O
ACCL0131 O
) O
: O
a O
methotrexate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
consequence O
. O

A O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
from O
the O
Children B_ORGANIZATION/B_LOCATION
' I_ORGANIZATION/I_LOCATION
s I_ORGANIZATION/I_LOCATION
Oncology I_ORGANIZATION/I_LOCATION
Group I_ORGANIZATION/I_LOCATION
. O

concerns O
about O
long O
- O
term O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
neurotoxicity O
in O
the O
1990s O
led O
to O
modifications O
in O
intrathecal O
( O
IT O
) O
therapy O
, O
leucovorin O
rescue O
, O
and O
frequency O
of O
systemic O
MTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
in O
children O
with O
acute O
lymphoblastic O
leukemia O
. O

In O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
neurocognitive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
neuroradiologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
leukoencephalopathy B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
compared O
in O
children B_PERSON/B_BIO
treated O
with O
intense B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
central B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
nervous B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
system B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
CNS B_LOCATION/B_ORGANIZATION
) O
- O
directed O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
( O
P9605 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
versus B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
those O
receiving O
fewer B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
CNS B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O
directed O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O
intensive B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
consolidation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
P9201 B_MEASURE/B_PROTEIN[GENE]
) O
. O

A O
total B_MEASURE
of O
66 B_MEASURE/B_PERSON
children I_MEASURE/I_PERSON
from O
16 B_PERSON/B_ORGANIZATION
Pediatric I_PERSON/I_ORGANIZATION
Oncology I_PERSON/I_ORGANIZATION
Group I_PERSON/I_ORGANIZATION
institutions I_PERSON/I_ORGANIZATION
with O
' B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
standard B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
' O
acute B_DISEASE
lymphoblastic I_DISEASE
leukemia I_DISEASE
, O
1 B_MEASURE
. O
00 B_MEASURE
to O
9 B_MEASURE
. O
99 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
at O
diagnosis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
without O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
CNS B_DISEASE
leukemia I_DISEASE
at O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
enrolled O
on O
ACCL0131 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
28 B_MEASURE
from O
P9201 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
38 B_MEASURE
from O
P9605 B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Magnetic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resonance I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
scans I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
standard B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neuropsychological I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tests I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
performed O
> B_MEASURE/B_LOCATION
2 I_MEASURE/I_LOCATION
. O
6 B_TIME[MEASURE]
years I_TIME[MEASURE]
after O
the O
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

significantly O
more B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
P9605 B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
patients B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
developed O
leukoencephalopathy B_DISEASE
compared O
with O
P9201 B_PERSON
patients I_PERSON
( O
68 B_PERSON/B_MEASURE
% I_PERSON/I_MEASURE
, O
95 B_MEASURE
% I_MEASURE
confidence I_MEASURE
interval I_MEASURE
49 I_MEASURE
% I_MEASURE
- O
83 B_MEASURE
% I_MEASURE
vs I_MEASURE
. O
22 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
95 B_MEASURE
% I_MEASURE
confidence I_MEASURE
interval I_MEASURE
5 I_MEASURE
% I_MEASURE
- O
44 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
; O
P B_MEASURE/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
001 B_MEASURE
) O
identified O
as O
late O
as O
7 B_MEASURE
. O
7 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
after O
the O
end B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Overall O
, O
40 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
patients B_PERSON
scored O
< O
85 B_MEASURE
on O
either O
verbal B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
Performance B_MEASURE/B_EDU[ORGANIZATION]
IQ B_MEASURE/I_EDU[ORGANIZATION]
. O

Children B_PERSON
on O
both O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
significant B_DISEASE
attention I_DISEASE
problems I_DISEASE
, O
but O
P9605 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
children I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
scored O
below O
average B_MEASURE/B_SOCIAL_CIRCUMSTANCES
on O
more O
neurocognitive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
measures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
than O
those O
treated O
on O
P9201 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
82 B_MEASURE
% I_MEASURE
, O
14 B_NUMBER[MEASURE]
/ O
17 B_MEASURE
measures I_MEASURE
vs I_MEASURE
. O
24 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
4 B_MEASURE
/ O
17 B_MEASURE
measures I_MEASURE
) O
. O

This O
supports O
ongoing O
concerns O
about O
intensive O
MTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O
as O
a O
major O
contributor O
to O
CNS O
late O
effects O
. O

Tranexamic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overdosage O
- O
induced O
generalized O
seizure O
in O
renal O
failure O
. O

We O
report O
a O
45 B_MEASURE
- O
year B_TIME[MEASURE]
- O
old B_PERSON
lady I_PERSON
with O
chronic B_DISEASE/B_GENE
kidney I_DISEASE/I_GENE
disease I_DISEASE/I_GENE
stage I_DISEASE/I_GENE
4 I_DISEASE/I_GENE
due O
to O
chronic B_DISEASE
tubulointerstial I_DISEASE
disease I_DISEASE
. O

She O
was O
admitted O
to O
our O
center B_LOCATION
for O
severe B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
anemia I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
due O
to O
menorrhagia B_DISEASE
and O
deterioration B_DISEASE_ADJECTIVE[DISEASE]
of O
renal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

She O
was O
infused O
three B_MEASURE/B_LOCATION
units B_MEASURE/I_LOCATION
of O
packed O
cells B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
during O
a O
session B_TIME[MEASURE]
of O
hemodialysis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Tranexamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TNA B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
1 O
g O
8 O
- O
hourly O
was O
administered O
to O
her O
to O
control O
bleeding O
per O
vaginum O
. O

Two O
hours O
after O
the O
sixth O
dose O
of O
TNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
she O
had O
an O
episode O
of O
generalized O
tonic O
clonic O
convulsions O
. O

TNA B_ORGANIZATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
discontinued O
. O

investigations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
patient B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
revealed O
no O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
structural B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
central B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nervous B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abnormalities B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
could O
have O
provoked O
the O
convulsions B_DISEASE
. O

She O
did O
not O
require O
any O
further B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
dialytic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
support I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

She O
had O
no O
further B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
episodes I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
of O
convulsion B_DISEASE
till O
dis B_MEASURE
- O
charge B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
and O
during O
the O
two B_TIME[MEASURE]/B_LOCATION
months I_TIME[MEASURE]/I_LOCATION
of O
follow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
up B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thus O
, O
the O
precipitating O
cause O
of O
convulsions O
was O
believed O
to O
be O
an O
overdose O
of O
TNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Pre O
- O
treatment O
of O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cardiovascular O
depression O
using O
different O
lipid O
formulations O
of O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background O
: O
Pre O
- O
treatment O
with O
lipid O
emulsions O
has O
been O
shown O
to O
increase O
lethal O
doses O
of O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
the O
lipid O
content O
of O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
alleviate O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cardiotoxicity O
. O

The O
aim O
of O
this O
study O
is O
to O
investigate O
the O
effects O
of O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
intralipid O
or O
medialipid O
emulsions O
on O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cardiotoxicity O
. O

methods O
: O
rats O
were O
anaesthetised O
with O
ketamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
were O
given O
0 O
. O
5 O
mg O
/ O
kg O
/ O
min O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
intralipid O
( O
Group O
P O
) O
, O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
medialipid O
( O
Group O
L O
) O
, O
or O
saline O
( O
Group O
C O
) O
over O
20 O
min O
. O

Thereafter O
, O
2 O
mg O
/ O
kg O
/ O
min O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O
. O
5 O
% O
was O
infused O
. O

We O
recorded O
time O
to O
first O
dysrhythmia O
occurrence O
, O
respective O
times O
to O
25 O
% O
and O
50 O
% O
reduction O
of O
the O
heart O
rate O
( O
HR O
) O
and O
mean O
arterial O
pressure O
, O
and O
time O
to O
asystole O
and O
total O
amount O
of O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption O
. O

Blood B_BODY_PART_OR_ORGAN_COMPONENT
and O
tissue B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
samples I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
collected O
following O
asystole B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
The O
time B_TIME[MEASURE]/B_DISEASE
to O
first O
dysrhythmia B_DISEASE_ADJECTIVE[DISEASE]
occurrence I_DISEASE_ADJECTIVE[DISEASE]
, O
time B_MEASURE/B_LOCATION
to O
25 B_SEQUENCE[MEASURE]/B_LOCATION
% I_SEQUENCE[MEASURE]/I_LOCATION
and O
50 B_MEASURE
% I_MEASURE
reductions I_MEASURE
in O
HR B_MEASURE/B_DISEASE
, O
and O
time B_TIME[MEASURE]/B_DISEASE
to O
asystole B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
longer B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
Group B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
P I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
than O
the O
other B_TIME[MEASURE]/B_PERSON
groups I_TIME[MEASURE]/I_PERSON
. O

The O
cumulative O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O
given O
at O
those O
time O
points O
was O
higher O
in O
Group O
P O
. O
plasma O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O
were O
significantly O
lower O
in O
Group O
P O
than O
in O
Group O
C O
. O
Bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
in O
the O
brain O
and O
heart O
were O
significantly O
lower O
in O
Group O
P O
and O
Group O
L O
than O
in O
Group O
C O
. O

conclusion O
: O
We O
conclude O
that O
pre O
- O
treatment O
with O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
intralipid O
, O
compared O
with O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
medialipid O
or O
saline O
, O
delayed O
the O
onset O
of O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cardiotoxic O
effects O
as O
well O
as O
reduced O
plasma O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
. O

Further O
studies O
are O
needed O
to O
explore O
tissue O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O
of O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
medialipid O
and O
adapt O
these O
results O
to O
clinical O
practice O
. O

Drug O
- O
induced O
acute O
liver O
injury O
Within O
12 O
Hours O
After O
Fluvastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Therapy O
. O

Although O
statins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O
generally O
well O
- O
tolerated O
drugs O
, O
recent O
cases O
of O
drug O
- O
induced O
liver O
injury O
associated O
with O
their O
use O
have O
been O
reported O
. O

A O
52 O
- O
year O
- O
old O
Chinese O
man O
reported O
with O
liver O
damage O
, O
which O
appeared O
12 O
hours O
after O
beginning O
treatment O
with O
fluvastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

patient B_PERSON
presented O
with O
complaints B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
increasing O
nausea B_DISEASE/B_MEASURE
, O
anorexia B_DISEASE
, O
and O
upper B_DISEASE
abdominal I_DISEASE
pain I_DISEASE
. O

His O
laboratory O
values O
showed O
elevated O
creatine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
kinase O
and O
transaminases O
. O

Testing B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
autoantibodies B_DISEASE
was O
also O
negative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
liver O
biochemistries O
eventually O
normalized O
within O
3 O
weeks O
of O
stopping O
the O
fluvastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Therefore O
, O
when O
prescribing O
statins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
possibility B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
hepatic B_DISEASE
damage I_DISEASE
should O
be O
taken O
into O
account B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Fluconazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
associated O
agranulocytosis O
and O
thrombocytopenia O
. O

Case O
: O
We O
describe O
a O
second O
case O
of O
fluconazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
associated O
agranulocytosis O
with O
thrombocytopenia O
and O
recovery O
upon O
discontinuation O
of O
therapy O
. O

The O
patient O
began O
to O
have O
changes O
in O
white O
blood O
cells O
and O
platelets O
within O
48 O
h O
of O
administration O
of O
fluconazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
began O
to O
recover O
with O
48 O
h O
of O
discontinuation O
. O

This O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
highlights O
that O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
blood B_DISEASE
dyscrasias I_DISEASE
can O
occur O
unexpectedly O
as O
a O
result B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
a O
commonly O
used O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
thought O
to O
be O
' O
safe B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
. O

conclusion O
: O
According O
to O
Naranjo O
' O
s O
algorithm O
the O
likelihood O
that O
our O
patient O
' O
s O
agranulocytosis O
and O
thrombocytopenia O
occurred O
as O
a O
result O
of O
therapy O
with O
fluconazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
probable O
, O
with O
a O
total O
of O
six O
points O
. O

We O
feel O
that O
the O
weight B_MEASURE
of O
the O
overall B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
this O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
strong B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

In O
particular O
the O
temporal O
relationship O
of O
bone O
marrow O
suppression O
to O
the O
initiation O
of O
fluconazole B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
the O
abatement O
of O
symptoms O
that O
rapidly O
reversed O
immediately O
following O
discontinuation O
. O

Two O
- O
dimensional O
speckle O
tracking O
echocardiography O
combined O
with O
high O
- O
sensitive O
cardiac O
troponin O
T O
in O
early O
detection O
and O
prediction O
of O
cardiotoxicity O
during O
epirubicine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
based O
chemotherapy O
. O

aims O
: O
To O
investigate O
whether O
alterations O
of O
myocardial O
strain O
and O
high O
- O
sensitive O
cardiac O
troponin O
T O
( O
cTnT O
) O
could O
predict O
future O
cardiac O
dysfunction O
in O
patients O
after O
epirubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O
. O

methods O
: O
seventy O
- O
five O
patients O
with O
non O
- O
Hodgkin O
lymphoma O
treated O
with O
epirubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
studied O
. O

Blood B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
collection I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
echocardiography B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
performed O
at O
baseline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
, O
1 B_TIME[MEASURE]/B_LOCATION
day I_TIME[MEASURE]/I_LOCATION
after O
the O
third B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cycle I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
1 B_TIME[MEASURE]/B_LOCATION
day I_TIME[MEASURE]/I_LOCATION
after O
completion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

patients B_PERSON
were O
studied O
using O
echocardiography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
follow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
up B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Global B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
longitudinal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
GLS B_LOCATION/B_ORGANIZATION
) O
, O
circumferential B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
( O
GCS B_LOCATION/B_ORGANIZATION
) O
, O
and O
radial B_MEASURE/B_LOCATION
strain B_MEASURE/I_LOCATION
( O
GRS B_LOCATION
) O
were O
calculated O
using O
speckle B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
tracking I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
echocardiography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Left O
ventricular B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
ejection B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
fraction B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
was O
analysed O
by O
real B_NUMBER[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
time B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
3D I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
echocardiography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

cardiotoxicity B_DISEASE/B_LOCATION
was O
defined O
as O
a O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
the O
LVEF B_MEASURE/B_DISEASE
of O
> B_MEASURE/B_LOCATION
5 I_MEASURE/I_LOCATION
% I_MEASURE/I_LOCATION
to O
< O
55 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
with O
symptoms B_DISEASE_ADJECTIVE[DISEASE]
of O
heart B_DISEASE
failure I_DISEASE
or O
an O
asymptomatic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduction I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
LVEF B_MEASURE/B_LOCATION
of O
> O
10 B_MEASURE
% I_MEASURE
to O
< O
55 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
: O
Fourteen B_MEASURE/B_PERSON
patients I_MEASURE/I_PERSON
( O
18 B_MEASURE
. O
67 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
developed O
cardiotoxicity B_DISEASE/B_GENE
after O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

GLS B_LOCATION/B_ORGANIZATION
( O
- O
18 B_MEASURE
. O
48 B_MEASURE
+ O
1 B_MEASURE
. O
72 B_MEASURE
% I_MEASURE
vs I_MEASURE
. O
- O
15 B_MEASURE
. O
96 B_MEASURE
+ O
1 B_MEASURE
. O
6 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
GCS B_LOCATION
( O
- O
20 B_MEASURE
. O
93 B_MEASURE
+ I_MEASURE
2 I_MEASURE
. O
86 B_MEASURE
% I_MEASURE
vs I_MEASURE
. O
- O
19 B_MEASURE
. O
20 B_MEASURE
+ O
3 B_MEASURE
. O
21 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
and O
GRS B_LOCATION/B_DISEASE
( O
39 B_MEASURE
. O
23 B_MEASURE
+ I_MEASURE
6 I_MEASURE
. O
44 B_MEASURE
% I_MEASURE
vs I_MEASURE
. O
34 B_MEASURE
. O
98 B_MEASURE
+ O
6 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
) O
were O
markedly O
reduced O
and O
cTnT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O
elevated O
from O
0 B_NUMBER[MEASURE]
. O
0010 B_MEASURE
+ I_MEASURE
0 I_MEASURE
. O
0020 B_MEASURE
to O
0 B_NUMBER[MEASURE]
. O
0073 B_MEASURE
+ I_MEASURE
0 I_MEASURE
. O
0038 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
mL B_MEASURE/B_LOCATION
( O
P B_OTHER/B_MEASURE
all O
< O
0 B_MEASURE
. O
01 B_MEASURE
) O
at O
the O
completion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
chemotherapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
compared O
with O
baseline B_TIME[MEASURE]/B_LOCATION
values I_TIME[MEASURE]/I_LOCATION
. O

A O
> B_MEASURE
15 I_MEASURE
. O
9 B_MEASURE
% I_MEASURE
decrease I_MEASURE
in O
GLS B_MEASURE
[ I_MEASURE
sensitivity I_MEASURE
, O
86 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
; O
specificity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
75 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
; O
area B_LOCATION/B_MEASURE
under O
the O
curve B_MEASURE
( O
AUC B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
= O
0 B_MEASURE
. O
815 B_MEASURE
; O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
001 B_MEASURE
] I_MEASURE
and O
a O
> O
0 B_MEASURE
. O
004 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
mL B_MEASURE/B_LOCATION
elevation I_MEASURE/I_LOCATION
in O
cTnT B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
sensitivity B_MEASURE
, O
79 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
; O
specificity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
64 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
; O
AUC B_LOCATION/B_MEASURE
= O
0 B_MEASURE
. O
757 B_MEASURE
; O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
005 B_MEASURE
) O
from O
baseline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
to O
the O
third B_MEASURE/B_LOCATION
cycle I_MEASURE/I_LOCATION
of O
chemotherapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
predicted O
later B_DISEASE_ADJECTIVE[DISEASE]
cardiotoxicity I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
GLS B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remained O
the O
only B_MEASURE/B_LOCATION
independent I_MEASURE/I_LOCATION
predictor I_MEASURE/I_LOCATION
of O
cardiotoxicity B_DISEASE
( O
P B_OTHER/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
000 B_MEASURE
) O
. O

conclusions O
: O
GLS O
combined O
with O
cTnT O
may O
provide O
a O
reliable O
and O
non O
- O
invasive O
method O
to O
predict O
cardiac O
dysfunction O
in O
patients O
receiving O
anthracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
based O
chemotherapy O
. O

Prevention O
of O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
myoclonus O
: O
which O
is O
superior O
: O
Fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
midazolam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
a O
combination O
. O

A O
Retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
comparative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Background O
: O
In O
this O
retrospective O
comparative O
study O
, O
we O
aimed O
to O
compare O
the O
effectiveness O
of O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
midazolam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
a O
combination O
of O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
midazolam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
prevent O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
myoclonus O
. O

Material B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
AND O
METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
performed O
based O
on O
anesthesia B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
records I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Depending O
on O
the O
drugs O
that O
would O
be O
given O
before O
the O
induction O
of O
anesthesia O
with O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
patients O
were O
separated O
into O
4 O
groups O
: O
no O
pretreatment O
( O
Group O
NP O
) O
, O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
ug O
. O
kg O
- O
1 O
( O
Group O
F O
) O
, O
midazolam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O
. O
03 O
mg O
. O
kg O
- O
1 O
( O
Group O
M O
) O
, O
and O
midazolam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O
. O
015 O
mg O
. O
kg O
- O
1 O
+ O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O
. O
5 O
ug O
. O
kg O
- O
1 O
( O
Group O
FM O
) O
. O

patients O
who O
received O
the O
same O
anesthetic O
procedure O
were O
selected O
: O
2 O
minutes O
after O
intravenous O
injections O
of O
the O
pretreatment O
drugs O
, O
anesthesia O
is O
induced O
with O
0 O
. O
3 O
mg O
. O
kg O
- O
1 O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injected O
intravenously O
over O
a O
period O
of O
20 O
- O
30 O
seconds O
. O

Myoclonic O
movements O
are O
evaluated O
, O
which O
were O
observed O
and O
graded O
according O
to O
clinical O
severity O
during O
the O
2 O
minutes O
after O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O
. O

The O
severity O
of O
pain O
due O
to O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O
, O
mean O
arterial O
pressure O
, O
heart O
rate O
, O
and O
adverse O
effects O
were O
also O
evaluated O
. O

Results B_MEASURE
: O
Study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
showed O
that O
myoclonus B_DISEASE_ADJECTIVE[DISEASE]
incidence I_DISEASE_ADJECTIVE[DISEASE]
was O
85 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
40 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
70 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
, O
and O
25 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
in O
Group B_LOCATION
NP I_LOCATION
, O
Group B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Group B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
M I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
Group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
FM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
respectively O
, O
and O
were O
significantly O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
Group B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
F I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
FM B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
. O

conclusions O
: O
We O
conclude O
that O
pretreatment O
with O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
combination O
of O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
midazolam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
effective O
in O
preventing O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
myoclonus O
. O

Convulsant O
effect O
of O
lindane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
regional O
brain O
concentration O
of O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Lindane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
gamma B_PROTEIN[GENE]/B_LOCATION
- I_PROTEIN[GENE]/I_LOCATION
hexachlorocyclohexane I_PROTEIN[GENE]/I_LOCATION
) O
is O
an O
organochlorine O
insecticide O
with O
known O
neurotoxic O
effects O
. O

Its O
mechanism O
of O
action O
is O
not O
well O
understood O
although O
it O
has O
been O
proposed O
that O
lindane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acts O
as O
a O
non O
- O
competitive O
antagonist O
at O
the O
gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminobutyric I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
- O
A O
receptor O
. O

We O
studied O
the O
effect O
of O
lindane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
150 O
mg O
/ O
kg O
) O
on O
the O
GABAergic O
and O
dopaminergic O
systems O
by O
measuring O
the O
concentration O
of O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
its O
metabolites O
in O
7 O
brain O
areas O
at O
the O
onset O
of O
seizures O
. O

All O
animals O
suffered O
tonic O
convulsions O
at O
18 O
. O
3 O
+ O
/ O
- O
1 O
. O
4 O
min O
after O
lindane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration O
. O

The O
concentration O
of O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
only O
slightly O
but O
significantly O
decreased O
in O
the O
colliculi O
without O
modifications O
in O
the O
other O
areas O
. O

The O
concentration O
of O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
increased O
in O
the O
mesencephalon O
and O
that O
of O
its O
metabolite O
DOPAC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
also O
increased O
in O
the O
mesencephalon O
and O
the O
striatum O
. O

Cholestatic O
presentation O
of O
yellow O
phosphorus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
poisoning O
. O

Yellow O
phosphorus B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
component O
of O
certain O
pesticide O
pastes O
and O
fireworks O
, O
is O
well O
known O
to O
cause O
hepatotoxicity O
. O

poisoning O
with O
yellow O
phosphorus B_BIO/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
classically O
manifests O
with O
acute O
hepatitis O
leading O
to O
acute O
liver O
failure O
which O
may O
need O
liver O
transplantation O
. O

We O
present O
a O
case O
of O
yellow O
phosphorus B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
poisoning O
in O
which O
a O
patient O
presented O
with O
florid O
clinical O
features O
of O
cholestasis O
highlighting O
the O
fact O
that O
cholestasis O
can O
rarely O
be O
a O
presenting O
feature O
of O
yellow O
phosphorus B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
hepatotoxicity O
. O

Vasovagal O
syncope O
and O
severe O
bradycardia O
following O
intranasal O
dexmedetomidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
pediatric O
procedural O
sedation O
. O

We O
report O
syncope O
and O
bradycardia O
in O
an O
11 O
- O
year O
- O
old O
girl O
following O
administration O
of O
intranasal O
dexmedetomidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
sedation O
for O
a O
voiding O
cystourethrogram O
. O

Following O
successful B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
completion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
VCUG B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
a O
60 B_MEASURE
- O
min B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
recovery B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
the O
patient B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
' O
s B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
level I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
consciousness B_DISEASE
and O
vital B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
signs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
returned O
to O
presedation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Upon O
leaving O
the O
sedation B_LOCATION
area I_LOCATION
, O
the O
patient B_PERSON/B_LOCATION
collapsed O
, O
with O
no O
apparent B_DISEASE
inciting I_DISEASE
event I_DISEASE
. O

The O
patient B_PERSON
quickly O
regained O
consciousness B_DISEASE/B_MEASURE
and O
no O
injury B_DISEASE
occurred O
. O

The O
primary B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abnormality B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
found O
was O
persistent B_DISEASE
bradycardia I_DISEASE
, O
and O
she O
was O
admitted O
to O
the O
hospital B_LOCATION/B_ORGANIZATION
for O
telemetric B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
observation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

The O
bradycardia B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lasted O
~ O
2 B_MEASURE
h O
, O
and O
further B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiac I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
workup I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
no O
underlying B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
abnormality I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Unanticipated B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
and O
previously O
unreported B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcomes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
witnessed O
as O
we O
expand O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
certain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sedatives I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
alternative B_NUMBER[MEASURE]/B_LOCATION
routes B_NUMBER[MEASURE]/I_LOCATION
of O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Paradoxical O
severe O
agitation O
induced O
by O
add O
- O
on O
high O
- O
doses O
quetiapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
schizo O
- O
affective O
disorder O
. O

We O
report O
the O
case O
of O
a O
35 O
- O
year O
- O
old O
patient O
suffering O
from O
schizo O
- O
affective O
disorder O
since O
the O
age O
of O
19 O
years O
, O
treated O
by O
a O
combination O
of O
first O
- O
generation O
antipsychotics O
, O
zuclopenthixol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
100 O
mg O
/ O
day O
) O
and O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1200 O
mg O
/ O
day O
) O
( O
serum O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
= O
0 O
. O
85 O
mEq O
/ O
l O
) O
. O

This O
patient B_PERSON
had O
no O
associated B_DISEASE
personality I_DISEASE
disorder I_DISEASE
( O
particularly O
no O
antisocial B_DISEASE
disorder I_DISEASE
) O
and O
no O
substance B_DISEASE
abuse I_DISEASE
disorder I_DISEASE
. O

Within O
the O
48 O
h O
following O
the O
gradual O
introduction O
of O
quetiapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
up O
to O
600 O
mg O
/ O
day O
) O
, O
the O
patient O
presented O
severe O
agitation O
without O
an O
environmental O
explanation O
, O
contrasting O
with O
the O
absence O
of O
a O
history O
of O
aggressiveness O
or O
personality O
disorder O
. O

The O
diagnoses B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
manic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
shift I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
akathisia B_DISEASE
were O
dismissed O
. O

The O
withdrawal O
and O
the O
gradual O
reintroduction O
of O
quetiapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 O
weeks O
later O
, O
which O
led O
to O
another O
severe O
agitation O
, O
enabled O
us O
to O
attribute O
the O
agitation O
specifically O
to O
quetiapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Antioxidant O
effects O
of O
bovine O
lactoferrin O
on O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hypertension O
in O
rat O
. O

Dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
( O
Dex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
) O
induced O
hypertension O
is O
associated O
with O
enhanced O
oxidative O
stress O
. O

Lactoferrin O
( O
LF O
) O
is O
an O
iron B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
binding O
glycoprotein O
with O
antihypertensive O
properties O
. O

In O
this O
study O
, O
we O
investigated O
the O
effect O
of O
chronic O
administration O
of O
LF O
on O
oxidative O
stress O
and O
hypertension O
upon O
Dex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration O
. O

Male O
Wistar O
rats O
were O
treated O
by O
Dex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
30 O
u O
g O
/ O
kg O
/ O
day O
subcutaneously O
) O
or O
saline O
for O
14 O
days O
. O

Oral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
bovine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
LF I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
30 B_MEASURE
, O
100 B_MEASURE
, O
300 B_MEASURE
mg I_MEASURE
/ O
kg B_TIME[MEASURE]
) O
was O
given O
from O
day B_TIME[MEASURE]
8 I_TIME[MEASURE]
to O
14 B_MEASURE
in O
a O
reversal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

In O
a O
prevention O
study O
, O
rats O
received O
4 O
days O
of O
LF O
treatment O
followed O
by O
Dex B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
continued O
during O
the O
test O
period O
. O

Systolic B_MEASURE/B_DISEASE
blood I_MEASURE/I_DISEASE
pressure I_MEASURE/I_DISEASE
( O
SBP B_DISEASE/B_PROTEIN[GENE]
) O
was O
measured O
using O
tail B_BODY_PART_OR_ORGAN_COMPONENT/B_MEASURE
- O
cuff B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

thymus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
weight I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
used O
as O
a O
marker B_MEASURE/B_DISEASE
of O
glucocorticoid B_MEASURE/B_ORGANISM_FUNCTION
activity B_MEASURE/I_ORGANISM_FUNCTION
. O

plasma O
hydrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
peroxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
H2O2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
concentration O
and O
ferric O
reducing O
antioxidant O
power O
( O
FRAP O
) O
value O
were O
determined O
. O

Dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
significantly O
increased O
SBP O
and O
plasma O
H2O2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O
and O
decreased O
thymus O
and O
body O
weights O
. O

LF O
lowered O
( O
P O
< O
0 O
. O
01 O
) O
and O
dose O
dependently O
prevented O
( O
P O
< O
0 O
. O
001 O
) O
Dex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
hypertension O
. O

LF O
prevented O
body O
weight O
loss O
and O
significantly O
reduced O
the O
elevated O
plasma O
H2O2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
increased O
FRAP O
values O
. O

chronic O
administration O
of O
LF O
strongly O
reduced O
the O
blood O
pressure O
and O
production O
of O
ROS O
and O
improved O
antioxidant O
capacity O
in O
Dex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hypertension O
, O
suggesting O
the O
role O
of O
inhibition O
of O
oxidative O
stress O
as O
another O
mechanism O
of O
antihypertensive O
action O
of O
LF O
. O

The O
association O
between O
tranexamic B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
convulsive O
seizures O
after O
cardiac O
surgery O
: O
a O
multivariate O
analysis O
in O
11 O
529 O
patients O
. O

Because O
of O
a O
lack B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
contemporary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
regarding O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
after O
cardiac B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
we O
undertook O
a O
retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
prospectively O
collected O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
11 B_PERSON/B_LOCATION
529 I_PERSON/I_LOCATION
patients I_PERSON/I_LOCATION
in O
whom O
cardiopulmonary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
bypass I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
used O
from O
January B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2004 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
December B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2010 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
convulsive B_DISEASE
seizure I_DISEASE
was O
defined O
as O
a O
transient B_DISEASE_ADJECTIVE[DISEASE]/B_ENT
episode I_DISEASE_ADJECTIVE[DISEASE]/I_ENT
of O
disturbed B_DISEASE
brain I_DISEASE
function I_DISEASE
characterised O
by O
abnormal B_DISEASE
involuntary I_DISEASE
motor I_DISEASE
movements I_DISEASE
. O

Multivariate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
regression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
performed O
to O
identify O
independent B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
predictors I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
postoperative B_DISEASE_ADJECTIVE[DISEASE]
seizures I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
total B_MEASURE
of O
100 B_MEASURE
( O
0 B_MEASURE
. O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
patients B_PERSON/B_LOCATION
developed O
postoperative B_DISEASE
convulsive I_DISEASE
seizures I_DISEASE
. O

Generalised B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
focal B_DISEASE/B_PERSON
seizures I_DISEASE/I_PERSON
were O
identified O
in O
68 B_MEASURE
and O
32 B_TIME[MEASURE]
patients I_TIME[MEASURE]
, O
respectively O
. O

The O
median B_MEASURE
( O
IQR B_MEASURE/B_LOCATION
[ O
range B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
) O
time B_MEASURE
after O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
when O
the O
seizure B_DISEASE
occurred O
was O
7 B_MEASURE
( O
6 B_MEASURE
- O
12 B_MEASURE
[ I_MEASURE
1 I_MEASURE
- O
216 B_MEASURE
] I_MEASURE
) O
h B_TIME[MEASURE]/B_OTHER
and O
8 B_MEASURE
( O
6 B_MEASURE
- O
11 B_MEASURE
[ I_MEASURE
4 I_MEASURE
- O
18 B_MEASURE
] I_MEASURE
) O
h B_TIME[MEASURE]/B_OTHER
, O
respectively O
. O

Epileptiform B_DISEASE_ADJECTIVE[DISEASE]
findings I_DISEASE_ADJECTIVE[DISEASE]
on O
electroencephalography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
seen O
in O
19 B_TIME[MEASURE]/B_LOCATION
patients B_TIME[MEASURE]/I_LOCATION
. O

Independent O
predictors O
of O
postoperative O
seizures O
included O
age O
, O
female O
sex O
, O
redo O
cardiac O
surgery O
, O
calcification O
of O
ascending O
aorta O
, O
congestive O
heart O
failure O
, O
deep O
hypothermic O
circulatory O
arrest O
, O
duration O
of O
aortic O
cross O
- O
clamp O
and O
tranexamic B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

When O
tested O
in O
a O
multivariate O
regression O
analysis O
, O
tranexamic B_DISEASE/B_BIO
acid I_DISEASE/I_BIO
was O
a O
strong O
independent O
predictor O
of O
seizures O
( O
OR O
14 O
. O
3 O
, O
95 O
% O
CI O
5 O
. O
5 O
- O
36 O
. O
7 O
; O
p O
< O
0 O
. O
001 O
) O
. O

patients B_PERSON
with O
convulsive B_DISEASE
seizures I_DISEASE
had O
2 B_MEASURE
. O
5 B_TIME[MEASURE]
times I_TIME[MEASURE]
higher I_TIME[MEASURE]
in O
- O
hospital B_MEASURE/B_LOCATION
mortality I_MEASURE/I_LOCATION
rates I_MEASURE/I_LOCATION
and O
twice O
the O
length B_MEASURE
of O
hospital B_LOCATION/B_PERSON
stay O
compared O
with O
patients B_PERSON
without O
convulsive B_DISEASE/B_PERSON
seizures I_DISEASE/I_PERSON
. O

Mean O
( O
IQR B_MEASURE/B_LOCATION
[ O
range B_TIME[MEASURE]/B_LOCATION
] I_TIME[MEASURE]/I_LOCATION
) O
length B_MEASURE/B_LOCATION
of O
stay B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
in O
the O
intensive B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
care I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
unit I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
was O
115 B_MEASURE
( O
49 B_MEASURE
- O
228 B_MEASURE
[ O
32 B_MEASURE
- O
481 B_MEASURE
] I_MEASURE
) O
h O
in O
patients B_PERSON
with O
convulsive B_DISEASE
seizures I_DISEASE
compared O
with O
26 B_MEASURE
( O
22 B_MEASURE
- O
69 B_TIME[MEASURE]
[ I_TIME[MEASURE]
14 I_TIME[MEASURE]
- O
1080 B_MEASURE
] O
) O
h O
in O
patients B_PERSON/B_LOCATION
without O
seizures B_DISEASE/B_PERSON
( O
p B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O

Convulsive B_DISEASE_ADJECTIVE[DISEASE]
seizures I_DISEASE_ADJECTIVE[DISEASE]
are O
a O
serious B_DISEASE_ADJECTIVE[DISEASE]
postoperative I_DISEASE_ADJECTIVE[DISEASE]
complication I_DISEASE_ADJECTIVE[DISEASE]
after O
cardiac B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

As O
tranexamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
the O
only O
modifiable O
factor O
, O
its O
administration O
, O
particularly O
in O
doses O
exceeding O
80 O
mg O
. O
kg O
( O
- O
1 O
) O
, O
should O
be O
weighed O
against O
the O
risk O
of O
postoperative O
seizures O
. O

Dysfunctional O
overnight O
memory O
consolidation O
in O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
. O

Sleep B_DISEASE
plays O
an O
important B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
role B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
consolidation B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
integration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
memory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
a O
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
called O
overnight B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
memory I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
consolidation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Previous O
studies O
indicate O
that O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
have O
marked O
and O
persistent O
neurocognitive O
and O
sleep O
- O
related O
impairments O
. O

We O
extend O
past O
research O
by O
examining O
overnight O
memory O
consolidation O
among O
regular O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
( O
n O
= O
12 O
) O
and O
drug O
naive O
healthy O
controls O
( O
n O
= O
26 O
) O
. O

Memory B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recall I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
word B_PERSON/B_BIO
pairs I_PERSON/I_BIO
was O
evaluated O
before O
and O
after O
a O
period B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sleep B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
with O
and O
without O
interference B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
prior I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
to O
testing B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

In O
addition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
we O
assessed O
neurocognitive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
performances I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
across O
tasks B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
learning B_PERSON/B_DISEASE
, O
memory B_PERSON/B_DISEASE
and O
executive B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
functioning I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
users O
demonstrated O
impaired O
overnight O
memory O
consolidation O
, O
a O
finding O
that O
was O
more O
pronounced O
following O
associative O
interference O
. O

Additionally O
, O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
demonstrated O
impairments O
on O
tasks O
recruiting O
frontostriatal O
and O
hippocampal O
neural O
circuitry O
, O
in O
the O
domains O
of O
proactive O
interference O
memory O
, O
long O
- O
term O
memory O
, O
encoding O
, O
working O
memory O
and O
complex O
planning O
. O

We O
suggest O
that O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
dysfunction O
in O
fronto O
- O
temporal O
circuitry O
may O
underlie O
overnight O
consolidation O
memory O
impairments O
in O
regular O
ecstasy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
users O
. O

Normoammonemic O
encephalopathy O
: O
solely O
valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
or O
multiple O
mechanisms O
. O

A O
77 B_MEASURE
- O
year B_TIME[MEASURE]
- O
old B_PERSON
woman I_PERSON
presented O
with O
subacute B_DISEASE
onset I_DISEASE
progressive I_DISEASE
confusion I_DISEASE
, O
aggression B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
auditory B_DISEASE
hallucinations I_DISEASE
and O
delusions B_DISEASE
. O

In O
the O
preceding O
months O
, O
the O
patient O
had O
a O
number O
of O
admissions O
with O
transient O
unilateral O
hemiparesis O
with O
facial O
droop O
, O
and O
had O
been O
started O
on O
valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
presumed O
hemiplegic O
migraine O
. O

Valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
withdrawn O
soon O
after O
admission O
and O
her O
cognitive O
abilities O
have O
gradually O
improved O
over O
3 O
months O
of O
follow O
- O
up O
. O

Valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O
taken O
prior O
to O
withdrawal O
were O
subtherapeutic O
and O
the O
patient O
was O
normoammonaemic O
. O

EEG O
undertaken O
during O
inpatient O
stay O
showed O
changes O
consistent O
with O
encephalopathy O
, O
and O
low O
titre O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspartate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NMDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
receptor O
antibodies O
were O
present O
in O
this O
patient O
. O

The O
possible O
aetiologies O
of O
valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
encephalopathy O
and O
NMDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor O
- O
associated O
encephalitis O
present O
a O
diagnostic O
dilemma O
. O

We O
present O
a O
putative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
combinatorial I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
hypothesis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
to O
explain O
this O
patient B_PERSON/B_BIO
' O
s B_DISEASE_ADJECTIVE[DISEASE]
symptoms I_DISEASE_ADJECTIVE[DISEASE]
. O

Cerebellar O
and O
oculomotor O
dysfunction O
induced O
by O
rapid O
infusion O
of O
pethidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pethidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
an O
opioid O
that O
gains O
its O
popularity O
for O
the O
effective O
pain O
control O
through O
acting O
on O
the O
opioid O
- O
receptors O
. O

However O
, O
rapid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pain I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
relief I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sometimes O
brings O
about O
unfavourable B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
largely O
limit O
its O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
utility I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Common B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
include O
nausea B_DISEASE
, O
vomiting B_DISEASE
and O
hypotension B_DISEASE
. O

In O
patients O
with O
impaired O
renal O
and O
liver O
function O
, O
and O
those O
who O
need O
long O
- O
term O
pain O
control O
, O
pethidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
cause O
excitatory O
central O
nervous O
system O
( O
CNS O
) O
effects O
through O
its O
neurotoxic O
metabolite O
, O
norpethidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
resulting O
in O
irritability O
and O
seizure O
attack O
. O

On O
the O
contrary O
, O
though O
not O
clinically O
apparent O
, O
pethidine B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potentially O
causes O
inhibitory O
impacts O
on O
the O
CNS O
and O
impairs O
normal O
cerebellar O
and O
oculomotor O
function O
in O
the O
short O
term O
. O

In O
this O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
, O
we O
highlight O
opioid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
s B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
inhibitory I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
side I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O
the O
cerebellar B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
structure I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
causes O
dysmetria B_DISEASE
, O
dysarthria B_DISEASE/B_LOCATION
, O
reduced O
smooth B_DISEASE/B_MEASURE
pursuit I_DISEASE/I_MEASURE
gain I_DISEASE/I_MEASURE
and O
decreased O
saccadic B_DISEASE
velocity I_DISEASE
. O

Baboon O
syndrome O
induced O
by O
ketoconazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

A O
27 O
- O
year O
- O
old O
male O
patient O
presented O
with O
a O
maculopapular O
eruption O
on O
the O
flexural O
areas O
and O
buttocks O
after O
using O
oral O
ketoconazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
patient O
was O
diagnosed O
with O
drug O
- O
induced O
baboon O
syndrome O
based O
on O
his O
history O
, O
which O
included O
prior O
sensitivity O
to O
topical O
ketoconazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
a O
physical O
examination O
, O
and O
histopathological O
findings O
. O

Baboon B_DISEASE/B_PROTEIN[GENE]
syndrome B_DISEASE/I_PROTEIN[GENE]
is O
a O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
or O
contact B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
allergen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
related O
maculopapular B_DISEASE
eruption I_DISEASE
that O
typically O
involves O
the O
flexural B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
gluteal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
areas I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

To O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
reported O
case O
of O
ketoconazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
baboon O
syndrome O
in O
the O
English O
literature O
. O

A O
Case O
of O
sudden O
cardiac O
Death O
due O
to O
Pilsicainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
Torsades O
de O
Pointes O
. O

An O
84 O
- O
year O
- O
old O
male O
received O
oral O
pilsicainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
pure O
sodium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
channel O
blocker O
with O
slow O
recovery O
kinetics O
, O
to O
convert O
his O
paroxysmal O
atrial O
fibrillation O
to O
a O
sinus O
rhythm O
; O
the O
patient O
developed O
sudden O
cardiac O
death O
two O
days O
later O
. O

The O
Holter B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrocardiogram I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
was O
worn O
by O
chance B_PERSON
, O
revealed O
torsade B_DISEASE/B_LOCATION
de I_DISEASE/I_LOCATION
pointes I_DISEASE/I_LOCATION
with O
gradually O
prolonged O
QT B_TIME[MEASURE]/B_DISEASE
intervals I_TIME[MEASURE]/I_DISEASE
. O

This O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
rapidly O
absorbed O
from O
the O
gastrointestinal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
most B_DISEASE/B_MEASURE
of O
it O
is O
excreted O
from O
the O
kidney B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

Although O
the O
patient O
' O
s O
renal O
function O
was O
not O
highly O
impaired O
and O
the O
dose O
of O
pilsicainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
low O
, O
the O
plasma O
concentration O
of O
pilsicainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
have O
been O
high O
, O
which O
can O
produce O
torsades O
de O
pointes O
in O
the O
octogenarian O
. O

Although O
the O
oral O
administration O
of O
class O
IC O
drugs O
, O
including O
pilsicainide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
effective O
to O
terminate O
atrial O
fibrillation O
, O
careful O
consideration O
must O
be O
taken O
before O
giving O
these O
drugs O
to O
octogenarians O
. O

All B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trans I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
retinoic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
inflammatory O
myositis O
in O
a O
patient O
with O
acute O
promyelocytic O
leukemia O
. O

All B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
trans I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
retinoic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
ATRA B_LOCATION/B_ORGANIZATION
) O
, O
a O
component O
of O
standard O
therapy O
for O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
, O
is O
associated O
with O
potentially O
serious O
but O
treatable O
adverse O
effects O
involving O
numerous O
organ O
systems O
, O
including O
rare O
skeletal O
muscle O
involvement O
. O

Only O
a O
handful O
of O
cases O
of O
ATRA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
myositis O
in O
children O
have O
been O
reported O
, O
and O
none O
in O
the O
radiology O
literature O
. O

We O
present O
such O
a O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
15 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
- O
old B_PERSON
boy I_PERSON
with O
APL B_DISEASE/B_GENE
, O
where O
recognition B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
imaging B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
findings I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
played O
a O
crucial B_PERSON/B_MEASURE
role I_PERSON/I_MEASURE
in O
making O
the O
diagnosis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
facilitated B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prompt I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
effective B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Tolerability O
of O
lomustine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
combination O
with O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
dogs O
with O
lymphoma O
. O

This O
retrospective O
study O
describes O
toxicity O
associated O
with O
a O
protocol O
of O
lomustine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CCNU B_LOCATION
) O
and O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CTX B_LOCATION/B_ORGANIZATION
) O
in O
dogs O
with O
lymphoma O
. O

CCNU B_LOCATION
was O
administered O
per O
OS O
( O
Po O
) O
at O
a O
targeted O
dosage O
of O
60 O
mg O
/ O
m O
( O
2 O
) O
body O
surface O
area O
on O
day O
0 O
, O
CTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
Po O
at O
a O
targeted O
dosage O
of O
250 O
mg O
/ O
m O
( O
2 O
) O
divided O
over O
days O
0 O
through O
4 O
, O
and O
all O
dogs O
received O
prophylactic O
antibiotics O
. O

Ninety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
treatments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
given O
to O
the O
57 B_PERSON/B_BIO
dogs I_PERSON/I_BIO
included O
in O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Neutropenia O
was O
the O
principal O
toxic O
effect O
, O
and O
the O
overall O
frequency O
of O
grade O
4 O
neutropenia O
after O
the O
first O
treatment O
of O
CCNU B_LOCATION
/ O
CTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
was O
30 O
% O
( O
95 O
% O
confidence O
interval O
, O
19 O
- O
43 O
% O
) O
. O

The O
mean B_MEASURE/B_DISEASE
body I_MEASURE/I_DISEASE
weight I_MEASURE/I_DISEASE
of O
dogs B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
grade B_DISEASE
4 I_DISEASE
neutropenia I_DISEASE
( O
19 B_MEASURE
. O
7 B_MEASURE
kg I_MEASURE
+ O
13 B_MEASURE
. O
4 B_MEASURE
kg I_MEASURE
) O
was O
significantly O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
the O
mean B_MEASURE/B_PERSON
body I_MEASURE/I_PERSON
weight I_MEASURE/I_PERSON
of O
dogs B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
did O
not O
develop O
grade B_DISEASE
4 I_DISEASE
neutropenia I_DISEASE
( O
31 B_MEASURE
. O
7 B_MEASURE
kg I_MEASURE
+ O
12 B_MEASURE
. O
4 B_MEASURE
kg I_MEASURE
; O
P B_OTHER/B_PROTEIN[GENE]
= O
. O
005 B_MEASURE
) O
. O

One B_NUMBER[MEASURE]/B_PERSON
dog I_NUMBER[MEASURE]/I_PERSON
( O
3 B_PERSON
% I_PERSON
) O
developed O
hematologic B_DISEASE
changes I_DISEASE
suggestive I_DISEASE
of O
hepatotoxicity B_DISEASE
. O

No O
dogs B_BIO/B_PERSON
had O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
either O
renal B_DISEASE_ADJECTIVE[DISEASE]
toxicity I_DISEASE_ADJECTIVE[DISEASE]
or O
hemorrhagic B_DISEASE
cystitis I_DISEASE
. O

Adverse B_DISEASE_ADJECTIVE[DISEASE]
gastrointestinal I_DISEASE_ADJECTIVE[DISEASE]
effects I_DISEASE_ADJECTIVE[DISEASE]
were O
uncommon B_DISEASE_ADJECTIVE[DISEASE]
. O

On O
the O
basis O
of O
the O
findings O
reported O
herein O
, O
a O
dose O
of O
60 O
mg O
/ O
m O
( O
2 O
) O
of O
CCNU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
combined O
with O
250 O
mg O
/ O
m O
( O
2 O
) O
of O
CTX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
divided O
over O
5 O
days O
) O
q O
4 O
wk O
is O
tolerable O
in O
tumor O
- O
bearing O
dogs O
. O

Nelarabine B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
neurotoxicity O
with O
concurrent O
intrathecal O
chemotherapy O
: O
Case O
report O
and O
review O
of O
literature O
. O

severe O
nelarabine B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
neurotoxicity O
in O
a O
patient O
who O
received O
concurrent O
intrathecal O
( O
IT O
) O
chemotherapy O
is O
reported O
. O

A O
37 B_MEASURE
- O
year B_TIME[MEASURE]
- O
old B_PERSON
Caucasian I_PERSON
woman I_PERSON
with O
a O
history B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
T B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
cell B_DISEASE/B_GENE
lymphoblastic I_DISEASE/I_GENE
lymphoma I_DISEASE/I_GENE
was O
admitted O
for O
relapsed B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
disease I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

She O
was O
originally O
treated O
with O
induction B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O
by O
an O
autologous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplant I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

She O
developed O
relapsed B_DISEASE
disease I_DISEASE
10 I_DISEASE
months I_DISEASE
later O
with O
leukemic B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involvement B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

She O
was O
re O
- O
induced O
with O
nelarabine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
1500 O
mg O
/ O
m O
( O
2 O
) O
on O
days O
1 O
, O
3 O
, O
and O
5 O
with O
1 O
dose O
of O
IT O
cytarabine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
100 O
mg O
on O
day O
2 O
as O
central O
nervous O
system O
( O
CNS O
) O
prophylaxis O
. O

At O
the O
time B_TIME[MEASURE]/B_LOCATION
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
she O
was O
on O
continuous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
renal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replacement I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O
to O
sequelae B_DISEASE_ADJECTIVE[DISEASE]
of O
tumor B_DISEASE
lysis I_DISEASE
syndrome I_DISEASE
( O
TLS B_DISEASE/B_GENE
) O
. O

She O
tolerated O
therapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
well O
, O
entered O
a O
complete B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
remission I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
recovered O
her O
renal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

She O
received O
a O
second O
cycle O
of O
nelarabine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
without O
additional O
IT O
prophylaxis O
one O
month O
later O
. O

A O
week B_TIME[MEASURE]
after O
this O
second B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
cycle I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
she O
noted O
numbness B_DISEASE
in O
her O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
extremities I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

predominantly O
sensory B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
though O
also O
motor B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
autonomic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
peripheral B_DISEASE_ADJECTIVE[DISEASE]
neuropathy I_DISEASE_ADJECTIVE[DISEASE]
started O
in O
her O
feet B_BODY_PART_OR_ORGAN_COMPONENT
, O
ascended O
proximally O
to O
the O
mid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
thoracic B_BODY_PART_OR_ORGAN_COMPONENT
region I_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
eventually O
included O
her O
distal B_BODY_PART_OR_ORGAN_COMPONENT
upper I_BODY_PART_OR_ORGAN_COMPONENT
extremities I_BODY_PART_OR_ORGAN_COMPONENT
. O

A O
magnetic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MRI B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
of O
her O
spine B_BODY_PART_OR_ORGAN_COMPONENT
demonstrated O
changes B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
C2 B_PROTEIN[GENE]
to O
C6 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consistent I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
subacute B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
combined O
degeneration B_DISEASE
. O

Nelarabine B_DISEASE/B_PERSON
was O
felt O
to O
be O
the O
cause O
of O
her O
symptoms O
. O

Her O
neuropathy B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
stabilized O
and O
showed O
slight B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
improvement I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
ultimately O
received O
an O
unrelated B_DISEASE_ADJECTIVE[DISEASE]
, O
reduced O
- O
intensity B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
allogeneic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
transplant I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
while O
in O
complete B_DISEASE_ADJECTIVE[DISEASE]
remission I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
relapsed O
disease B_TIME[MEASURE]/B_ENT
10 I_TIME[MEASURE]/I_ENT
weeks I_TIME[MEASURE]/I_ENT
later O
. O

She O
is O
currently O
being O
treated O
with O
best B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
supportive I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
care I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
our O
knowledge O
, O
this O
is O
the O
first O
published O
case O
report O
of O
severe O
neurotoxicity O
caused O
by O
nelarabine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
a O
patient O
who O
received O
concurrent O
IT O
chemotherapy O
. O

Valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hyperammonemic O
encephalopathy O
in O
a O
renal O
transplanted O
patient O
. O

Neurological B_DISEASE
complications I_DISEASE
after O
renal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
constitute O
an O
important B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
cause I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
morbidity B_DISEASE
and O
mortality B_DISEASE
. O

Their O
differential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diagnosis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
difficult B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
essential B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
subsequent B_PERSON/B_DISEASE
patient I_PERSON/I_DISEASE
' O
s B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
management I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hyperammonemic O
encephalopathy O
is O
an O
uncommon O
but O
serious O
effect O
of O
valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
. O

Here O
, O
we O
describe O
the O
case O
of O
a O
15 O
- O
year O
- O
old O
girl O
who O
was O
on O
a O
long O
- O
term O
therapy O
with O
valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due O
to O
epilepsy O
and O
revealed O
impaired O
consciousness O
with O
hyperammonemia O
12 O
days O
after O
renal O
transplantation O
. O

After O
withdraw O
of O
valproate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
patients O
' O
symptoms O
resolved O
within O
24 O
h O
. O

Clinicians O
should O
increase O
their O
awareness O
for O
potential O
complication O
of O
valproate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
especially O
in O
transplanted O
patients O
. O

Necrotising O
fasciitis O
after O
bortezomib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
containing O
regimen O
in O
an O
elderly O
patient O
of O
Waldenstrom O
macroglobulinaemia O
. O

Bortezomib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
and O
high O
- O
dose O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
containing O
regimens O
are O
considered O
to O
be O
generally O
tolerable O
with O
few O
severe O
bacterial O
infections O
in O
patients O
with O
B O
- O
cell O
malignancies O
. O

However O
, O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
is O
limited O
concerning O
the O
safety B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
the O
regimen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
elderly B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients I_PERSON/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
report O
a O
case O
of O
a O
76 O
- O
year O
- O
old O
man O
with O
Waldenstrom O
macroglobulinaemia O
who O
suffered O
necrotising O
fasciitis O
without O
neutropenia O
after O
the O
combination O
treatment O
with O
bortezomib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
high O
- O
dose O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
rituximab O
. O

Despite O
immediate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
intravenous I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
antimicrobial I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
he O
succumbed O
23 B_MEASURE/B_LOCATION
h O
after O
the O
onset B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Physicians O
should O
recognise O
the O
possibility O
of O
fatal O
bacterial O
infections O
related O
to O
bortezomib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O
high O
- O
dose O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
elderly O
patients O
, O
and O
we O
believe O
this O
case O
warrants O
further O
investigation O
. O

An O
integrated O
characterization O
of O
serological O
, O
pathological O
, O
and O
functional O
events O
in O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cardiotoxicity O
. O

Many B_PERSON
efficacious I_PERSON
cancer I_PERSON
treatments I_PERSON
cause O
significant B_DISEASE
cardiac I_DISEASE
morbidity I_DISEASE
, O
yet O
biomarkers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O
functional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
indices I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
early B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
damage I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
which O
would O
allow O
monitoring B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
intervention B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
are O
lacking O
. O

In O
this O
study O
, O
we O
have O
utilized O
a O
rat O
model O
of O
progressive O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
- O
induced O
cardiomyopathy O
, O
applying O
multiple O
approaches O
, O
including O
cardiac O
magnetic O
resonance O
imaging O
( O
MRI O
) O
, O
to O
provide O
the O
most O
comprehensive O
characterization O
to O
date O
of O
the O
timecourse O
of O
serological O
, O
pathological O
, O
and O
functional O
events O
underlying O
this O
toxicity O
. O

Hannover O
Wistar O
rats O
were O
dosed O
with O
1 O
. O
25 O
mg O
/ O
kg O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
weekly O
for O
8 O
weeks O
followed O
by O
a O
4 O
week O
off O
- O
dosing O
' O
recovery O
' O
period O
. O

Electron B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscopy I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
myocardium B_BODY_PART_OR_ORGAN_COMPONENT
revealed O
subcellular B_DISEASE_ADJECTIVE[DISEASE]
degeneration I_DISEASE_ADJECTIVE[DISEASE]
and O
marked O
mitochondrial B_DISEASE/B_GENE
changes I_DISEASE/I_GENE
after O
a O
single B_MEASURE/B_DISEASE
dose B_MEASURE/I_DISEASE
. O

Histopathological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
progressive B_DISEASE
cardiomyocyte I_DISEASE
degeneration I_DISEASE
, O
hypertrophy B_DISEASE
/ O
cytomegaly O
, O
and O
extensive B_DISEASE/B_GENE
vacuolation I_DISEASE/I_GENE
after O
two B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Extensive B_DISEASE
replacement I_DISEASE
fibrosis I_DISEASE
( O
quantified O
by O
Sirius B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
red I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
staining I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
developed O
during O
the O
off O
- O
dosing O
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
. O

Functional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
indices I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
assessed O
by O
cardiac B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
MRI I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
including O
left O
ventricular B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
ejection I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
fraction I_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
LVEF B_LOCATION/B_MEASURE
) O
, O
cardiac B_MEASURE/B_LOCATION
output B_MEASURE/I_LOCATION
, O
and O
E B_OTHER/B_PROTEIN[GENE]
/ O
A B_LOCATION/B_MEASURE
ratio I_LOCATION/I_MEASURE
) O
declined O
progressively O
, O
reaching O
statistical B_MEASURE/B_DISEASE
significance I_MEASURE/I_DISEASE
after O
two B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
and O
culminating O
in O
' O
clinical B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
LV B_DISEASE_ADJECTIVE[DISEASE]
dysfunction I_DISEASE_ADJECTIVE[DISEASE]
by O
12 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weeks I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
peak B_BODY_PART_OR_ORGAN_COMPONENT
myocardial I_BODY_PART_OR_ORGAN_COMPONENT
contrast I_BODY_PART_OR_ORGAN_COMPONENT
enhancement I_BODY_PART_OR_ORGAN_COMPONENT
and O
serological B_DISEASE
cardiac I_DISEASE
troponin I_DISEASE
I I_DISEASE
( O
cTnI B_LOCATION/B_PROTEIN[GENE]
) O
emerged O
after O
eight B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
importantly O
preceding O
the O
LVEF B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
decline B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
< O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
. O

Troponin O
I O
levels O
positively O
correlated O
with O
delayed O
and O
peak O
gadolinium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
contrast O
enhancement O
, O
histopathological O
grading O
, O
and O
diastolic O
dysfunction O
. O

In O
summary B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
subcellular B_DISEASE/B_GENE
cardiomyocyte I_DISEASE/I_GENE
degeneration I_DISEASE/I_GENE
was O
the O
earliest B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
marker I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
, O
followed O
by O
progressive B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
functional B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decline B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
histopathological B_DISEASE
manifestations I_DISEASE
. O

Myocardial B_DISEASE
contrast I_DISEASE
enhancement I_DISEASE
and O
elevations B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
cTnI B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
occurred O
later O
. O

However O
, O
all O
indices B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
predated O
' B_PERSON/B_BIO
clinical I_PERSON/I_BIO
' O
LV B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dysfunction B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
thus O
warrant O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
predictive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
biomarkers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Intradermal O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
capsaicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
injections O
: O
intra O
- O
and O
interindividual O
variability O
of O
provoked O
hyperalgesia O
and O
allodynia O
. O

Intradermal O
injections O
of O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
capsaicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
attractive O
to O
use O
in O
human O
experimental O
pain O
models O
because O
hyperalgesia O
and O
allodynia O
mimic O
isolated O
aspects O
of O
clinical O
pain O
disorders O
. O

The O
aim B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
was O
to O
investigate O
the O
reproducibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
these O
models B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Twenty O
healthy O
male O
volunteers O
( O
mean O
age O
24 O
years O
; O
range O
18 O
- O
38 O
years O
) O
received O
intradermal O
injections O
of O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
capsaicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
volar O
forearm O
. O

magnitudes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
secondary B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
pinprick I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
hyperalgesia I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
brush B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
evoked O
allodynia B_DISEASE
were O
investigated O
using O
von B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
frey B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
filaments B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
gauges B_MEASURE
10 I_MEASURE
, O
15 B_MEASURE
, O
60 B_MEASURE
and O
100 B_MEASURE
g I_MEASURE
) O
and O
brush B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
strokes I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Areas B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
secondary B_DISEASE
hyperalgesia I_DISEASE
and O
allodynia B_DISEASE
were O
quantified O
immediately O
after O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
after O
15 B_MEASURE
, O
30 B_MEASURE
and O
60 B_TIME[MEASURE]
min I_TIME[MEASURE]
. O

Two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
identical I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
separated O
by O
at O
least O
7 B_NUMBER[MEASURE]/B_ENT
days I_NUMBER[MEASURE]/I_ENT
were O
performed O
. O

reproducibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
across O
and O
within O
volunteers B_PERSON/B_LOCATION
( O
inter B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
and O
intra B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
individual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
variation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
respectively O
) O
was O
assessed O
using O
intraclass B_MEASURE/B_ORGANIZATION
correlation I_MEASURE/I_ORGANIZATION
coefficient I_MEASURE/I_ORGANIZATION
( O
ICC B_ORGANIZATION/B_DISEASE
) O
and O
coefficient B_MEASURE
of O
variation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
CV B_LOCATION/B_ORGANIZATION
) O
. O

Secondary O
pinprick O
hyperalgesia O
was O
observed O
as O
a O
marked O
increase O
in O
the O
visual O
analogue O
scale O
( O
VAS O
) O
response O
to O
von O
Frey O
gauges O
60 O
and O
100 O
g O
( O
P O
< O
0 O
. O
001 O
) O
after O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O
. O

For O
capsaicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
secondary O
pinprick O
hyperalgesia O
was O
detected O
with O
all O
von O
Frey O
gauges O
( O
P O
< O
0 O
. O
001 O
) O
. O

Glutamate B_PERSON/B_LOCATION
evoked O
reproducible O
VAS O
response O
to O
all O
von O
Frey O
gauges O
( O
ICC O
> O
0 O
. O
60 O
) O
and O
brush O
strokes O
( O
ICC O
> O
0 O
. O
83 O
) O
. O

Capsaicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection O
was O
reproducible O
for O
secondary O
hyperalgesia O
( O
ICC O
> O
0 O
. O
70 O
) O
and O
allodynia O
( O
ICC O
> O
0 O
. O
71 O
) O
. O

Intra B_DISEASE/B_MEASURE
- O
individual B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
variability I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
generally O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
for O
the O
VAS B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
response B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
von B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
frey I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
brush B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
compared O
with O
areas B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
secondary B_DISEASE
hyperalgesia I_DISEASE
and O
allodynia B_DISEASE
. O

In O
conclusion O
, O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
capsaicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
yield O
reproducible O
hyperalgesic O
and O
allodynic O
responses O
, O
and O
the O
present O
model O
is O
well O
suited O
for O
basic O
research O
, O
as O
well O
as O
for O
assessing O
the O
modulation O
of O
central O
phenomena O
. O

Ocular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
specific B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
ER I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
stress I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
reduction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
rescues O
glaucoma O
in O
murine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
glucocorticoid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
induced O
glaucoma B_DISEASE
. O

Administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
glucocorticoids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O
ocular B_DISEASE
hypertension I_DISEASE
in O
some O
patients B_PERSON/B_BIO
. O

If O
untreated B_DISEASE_ADJECTIVE[DISEASE]
, O
these O
patients B_PERSON/B_BIO
can O
develop O
a O
secondary B_DISEASE_ADJECTIVE[DISEASE]
glaucoma I_DISEASE_ADJECTIVE[DISEASE]
that O
resembles O
primary B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
open I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
angle B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
glaucoma I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
POAG B_LOCATION
) O
. O

The O
underlying B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathology I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
glaucoma B_DISEASE
is O
not O
fully O
understood O
, O
due B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
in O
part B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
lack B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
an O
appropriate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Here O
, O
we O
developed O
a O
murine B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
model I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
of O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
glaucoma B_DISEASE
that O
exhibits O
glaucoma B_DISEASE_ADJECTIVE[DISEASE]
features I_DISEASE_ADJECTIVE[DISEASE]
that O
are O
observed O
in O
patients B_PERSON/B_BIO
. O

Treatment O
of O
WT O
mice O
with O
topical O
ocular O
0 O
. O
1 O
% O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
led O
to O
elevation O
of O
intraocular O
pressure O
( O
IOP O
) O
, O
functional O
and O
structural O
loss O
of O
retinal O
ganglion O
cells O
, O
and O
axonal O
degeneration O
, O
resembling O
glucocorticoid O
- O
induced O
glaucoma O
in O
human O
patients O
. O

Furthermore O
, O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
ocular O
hypertension O
was O
associated O
with O
chronic O
ER O
stress O
of O
the O
trabecular O
meshwork O
( O
TM O
) O
. O

Similar O
to O
patients O
, O
withdrawal O
of O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
reduced O
elevated O
IOP O
and O
ER O
stress O
in O
this O
animal O
model O
. O

Dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O
the O
transcriptional O
factor O
CHOP O
, O
a O
marker O
for O
chronic O
ER O
stress O
, O
in O
the O
anterior O
segment O
tissues O
, O
and O
Chop O
deletion O
reduced O
ER O
stress O
in O
these O
tissues O
and O
prevented O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
ocular O
hypertension O
. O

Furthermore O
, O
reduction O
of O
ER O
stress O
in O
the O
TM O
with O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phenylbutyrate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
prevented O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
ocular O
hypertension O
in O
WT O
mice O
. O

Our O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
ER B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
stress B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
contributes O
to O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
ocular B_DISEASE/B_GENE
hypertension I_DISEASE/I_GENE
and O
suggest O
that O
reducing O
ER B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
stress B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
has O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
as O
a O
therapeutic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
strategy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
for O
treating O
glucocorticoid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
glaucoma B_DISEASE
. O

Effects O
of O
ginsenosides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
opioid O
- O
induced O
hyperalgesia O
in O
mice O
. O

opioid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hyperalgesia B_DISEASE
( O
OIH B_DISEASE/B_LOCATION
) O
is O
characterized O
by O
nociceptive B_DISEASE
sensitization I_DISEASE
caused O
by O
the O
cessation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
chronic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
opioid B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

OIH B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
can O
limit O
the O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
opioid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analgesics I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
complicate O
withdrawal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
opioid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
addiction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
this O
study O
, O
we O
investigated O
the O
effects O
of O
Re B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Rg1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
Rb1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
ginsenosides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
the O
bioactive O
components O
of O
ginseng O
, O
on O
OIH O
. O

OIH O
was O
achieved O
in O
mice O
after O
subcutaneous O
administration O
of O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
7 O
consecutive O
days O
three O
times O
per O
day O
. O

During O
withdrawal O
( O
days O
8 O
and O
9 O
) O
, O
these O
mice O
were O
administered O
Re B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
Rg1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
or O
Rb1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intragastrically O
two O
times O
per O
day O
. O

On O
the O
test O
day O
( O
day O
10 O
) O
, O
mice O
were O
subjected O
to O
the O
thermal O
sensitivity O
test O
and O
the O
acetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
writhing O
test O
. O

Re B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
300 O
mg O
/ O
kg O
) O
inhibited O
OIH O
in O
both O
the O
thermal O
sensitivity O
test O
and O
the O
acetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
writhing O
test O
. O

However O
, O
the O
Rg1 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
and I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
Rb1 I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
ginsenosides I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
failed O
to O
prevent O
OIH O
in O
either O
test O
. O

Furthermore O
, O
Rg1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
showed O
a O
tendency O
to O
aggravate O
OIH O
in O
the O
acetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
induced O
writhing O
test O
. O

Our O
data O
suggested O
that O
the O
ginsenoside B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
Re I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
not O
Rg1 B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
Rb1 B_PROTEIN[GENE]/B_LOCATION
, O
may O
contribute O
toward O
reversal O
of O
OIH O
. O

A O
comparison O
of O
severe O
hemodynamic O
disturbances O
between O
dexmedetomidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
sedation O
in O
neurocritical O
care O
patients O
. O

objective O
: O
Dexmedetomidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
commonly O
used O
sedatives O
in O
neurocritical O
care O
as O
they O
allow O
for O
frequent O
neurologic O
examinations O
. O

However O
, O
both O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
associated O
with O
significant B_DISEASE
hemodynamic I_DISEASE
side I_DISEASE
effects I_DISEASE
. O

The O
primary O
objective O
of O
this O
study O
is O
to O
compare O
the O
prevalence O
of O
severe O
hemodynamic O
effects O
in O
neurocritical O
care O
patients O
receiving O
dexmedetomidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Design B_PERSON/B_MEASURE
: O
Multicenter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
propensity B_MEASURE/B_PERSON
- O
matched O
cohort B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

setting B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Neurocritical B_PERSON/B_ORGANIZATION
care I_PERSON/I_ORGANIZATION
units I_PERSON/I_ORGANIZATION
at O
two B_LOCATION/B_MEASURE
academic I_LOCATION/I_MEASURE
medical I_LOCATION/I_MEASURE
centers I_LOCATION/I_MEASURE
with O
dedicated O
neurocritical B_PERSON/B_ORGANIZATION
care I_PERSON/I_ORGANIZATION
teams I_PERSON/I_ORGANIZATION
and O
board B_ORGANIZATION/B_LOCATION
- O
certified O
neurointensivists B_PERSON/B_ORGANIZATION
. O

patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Neurocritical B_PERSON/B_LOCATION
care I_PERSON/I_LOCATION
patients I_PERSON/I_LOCATION
admitted O
between O
July B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2009 I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
September B_TIME[MEASURE]
2012 I_TIME[MEASURE]
were O
evaluated O
and O
then O
matched O
1 B_MEASURE
: O
1 B_MEASURE
based O
on O
propensity B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
scoring O
of O
baseline B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
characteristics I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

interventions O
: O
continuous O
sedation O
with O
dexmedetomidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

measurements O
AND O
Main O
Results O
: O
A O
total O
of O
342 O
patients O
( O
105 O
dexmedetomidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
237 O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
were O
included O
in O
the O
analysis O
, O
with O
190 O
matched O
( O
95 O
in O
each O
group O
) O
by O
propensity O
score O
. O

The O
primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
outcome I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
a O
composite B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
severe B_DISEASE
hypotension I_DISEASE
( O
mean B_DISEASE/B_GENE
arterial I_DISEASE/I_GENE
pressure I_DISEASE/I_GENE
< O
60 B_MEASURE
mm I_MEASURE
Hg I_MEASURE
) O
and O
bradycardia B_DISEASE
( O
heart B_MEASURE/B_DISEASE
rate I_MEASURE/I_DISEASE
< O
50 B_MEASURE
beats I_MEASURE
/ O
min B_TIME[MEASURE]/B_PERSON
) O
during O
sedative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
infusion I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
. O

No O
difference B_MEASURE
in O
the O
primary B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
composite I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
outcome I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
the O
unmatched B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
30 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
vs I_MEASURE/I_LOCATION
30 I_MEASURE/I_LOCATION
% I_MEASURE/I_LOCATION
, O
p O
= O
0 B_MEASURE
. O
94 B_MEASURE
) O
or O
matched O
cohorts B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
28 B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
% I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
vs I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
34 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
% I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
p O
= O
0 B_MEASURE
. O
35 B_MEASURE
) O
could O
be O
found O
. O

When O
analyzed O
separately O
, O
no O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
found O
in O
the O
prevalence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
severe B_DISEASE
hypotension I_DISEASE
or O
bradycardia B_DISEASE
in O
either O
the O
unmatched B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
or O
matched O
cohorts B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusions O
: O
severe O
hypotension O
and O
bradycardia O
occur O
at O
similar O
prevalence O
in O
neurocritical O
care O
patients O
who O
receive O
dexmedetomidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

providers B_PERSON
should O
similarly O
consider O
the O
likelihood B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hypotension B_DISEASE
or O
bradycardia B_DISEASE
before O
starting O
either O
sedative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Hydroxytyrosol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
ameliorates O
oxidative O
stress O
and O
mitochondrial O
dysfunction O
in O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cardiotoxicity O
in O
rats O
with O
breast O
cancer O
. O

Oxidative O
stress O
is O
involved O
in O
several O
processes O
including O
cancer O
, O
aging O
and O
cardiovascular O
disease O
, O
and O
has O
been O
shown O
to O
potentiate O
the O
therapeutic O
effect O
of O
drugs O
such O
as O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
causes O
significant O
cardiotoxicity O
characterized O
by O
marked O
increases O
in O
oxidative O
stress O
and O
mitochondrial O
dysfunction O
. O

Herein O
, O
we O
investigate O
whether O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
chronic O
cardiac O
toxicity O
can O
be O
ameliorated O
with O
the O
antioxidant O
hydroxytyrosol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
in O
rats O
with O
breast O
cancer O
. O

Thirty O
- O
six O
rats O
bearing O
breast O
tumors O
induced O
chemically O
were O
divided O
into O
4 O
groups O
: O
control O
, O
hydroxytyrosol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O
0 O
. O
5mg O
/ O
kg O
, O
5days O
/ O
week O
) O
, O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1mg O
/ O
kg O
/ O
week O
) O
, O
and O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
plus O
hydroxytyrosol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O

Cardiac B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
disturbances B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
the O
cellular B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O
mitochondrial B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
level I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]
, O
mitochondrial B_GENE/B_LOCATION
electron I_GENE/I_LOCATION
transport I_GENE/I_LOCATION
chain I_GENE/I_LOCATION
complexes I_GENE/I_LOCATION
I I_GENE/I_LOCATION
- O
IV B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
apoptosis B_DISEASE/B_GENE
- O
inducing O
factor B_MEASURE/B_BIO
, O
and O
oxidative B_DISEASE/B_GENE
stress I_DISEASE/I_GENE
markers I_DISEASE/I_GENE
have O
been O
analyzed O
. O

Hydroxytyrosol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
improved O
the O
cardiac O
disturbances O
enhanced O
by O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
by O
significantly O
reducing O
the O
percentage O
of O
altered O
mitochondria O
and O
oxidative O
damage O
. O

These O
results O
suggest O
that O
hydroxytyrosol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
improve O
the O
mitochondrial O
electron O
transport O
chain O
. O

This O
study O
demonstrates O
that O
hydroxytyrosol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
protect O
rat O
heart O
damage O
provoked O
by O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
decreasing O
oxidative O
damage O
and O
mitochondrial O
alterations O
. O

Amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
myxoedema O
coma O
. O

A O
62 O
- O
year O
- O
old O
man O
was O
found O
to O
have O
bradycardia O
, O
hypothermia O
and O
respiratory O
failure O
3 O
weeks O
after O
initiation O
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
for O
atrial O
fibrillation O
. O

Thyroid O
- O
stimulating O
hormone O
was O
found O
to O
be O
168 O
uIU O
/ O
mL O
( O
NL O
. O
0 O
. O
3 O
- O
5 O
uIU O
/ O
mL O
) O
and O
free O
thyroxine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
FT4 O
) O
was O
< O
0 O
. O
2 O
ng O
/ O
DL O
( O
NL O
. O
0 O
. O
8 O
- O
1 O
. O
8 O
ng O
/ O
DL O
) O
. O

He O
received O
intravenous O
fluids O
, O
vasopressor O
therapy O
and O
stress O
dose O
steroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
he O
was O
intubated O
and O
admitted O
to O
the O
intensive O
care O
unit O
. O

He O
received O
500 O
ug O
of O
intravenous O
levothyroxine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
first O
18 O
h O
of O
therapy O
, O
and O
150 O
ug O
intravenous O
daily O
thereafter O
. O

haemodynamic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
improvement I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
, O
along O
with O
complete B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recovery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
mental B_DISEASE
status I_DISEASE
, O
occurred O
after O
48 B_MEASURE
h O
. O

Twelve B_TIME[MEASURE]/B_LOCATION
hours I_TIME[MEASURE]/I_LOCATION
after O
the O
initiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
therapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
FT4 B_GENE
was O
0 B_MEASURE
. O
96 B_MEASURE/B_PERSON
ng I_MEASURE/I_PERSON
/ O
DL B_PROTEIN[GENE]/B_MEASURE
. O

The O
patient O
was O
maintained O
on O
levothyroxine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
175 O
( O
g O
POorally O
daily O
. O

A O
thyroid B_SEQUENCE[MEASURE]/B_PERSON
ultrasound I_SEQUENCE[MEASURE]/I_PERSON
showed O
diffuse B_DISEASE
heterogeneity I_DISEASE
. O

The O
24 O
hour O
excretion O
of O
iodine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
3657 O
( O
mcg O
( O
25 O
- O
756 O
( O
mcg O
) O
. O

The O
only O
two O
cases O
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
myxoedema O
coma O
in O
the O
literature O
report O
patient O
death O
despite O
supportive O
therapy O
and O
thyroid O
hormone O
replacement O
. O

This O
case O
represents O
the O
most O
thoroughly O
investigated O
case O
of O
amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
myxoedema O
coma O
with O
a O
history O
significant O
for O
subclinical O
thyroid O
disease O
. O

Use O
of O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
catheter O
- O
directed O
thrombolysis O
with O
alteplase O
in O
an O
oncology O
patient O
with O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
thrombocytopenia O
with O
thrombosis O
. O

purpose O
: O
The O
case O
of O
an O
oncology O
patient O
who O
developed O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
thrombocytopenia O
with O
thrombosis O
( O
HITT O
) O
and O
was O
treated O
with O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O
catheter O
- O
directed O
thrombolysis O
( O
CDT O
) O
with O
alteplase O
is O
presented O
. O

summary O
: O
A O
63 O
- O
year O
- O
old O
Caucasian O
man O
with O
renal O
amyloidosis O
undergoing O
peripheral O
blood O
stem O
cell O
collection O
for O
an O
autologous O
stem O
cell O
transplant O
developed O
extensive O
bilateral O
upper O
- O
extremity O
deep O
venous O
thrombosis O
( O
DVT O
) O
and O
pulmonary O
embolism O
secondary O
to O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
thrombocytopenia O
. O

A O
continuous O
i O
. O
v O
. O
infusion O
of O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
initiated O
, O
and O
the O
patient O
was O
managed O
on O
the O
general O
medical O
floor O
. O

After O
one B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
week I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
he O
was O
transferred O
to O
the O
intensive B_LOCATION/B_PERSON
care I_LOCATION/I_PERSON
unit I_LOCATION/I_PERSON
with O
cardiopulmonary B_DISEASE
compromise I_DISEASE
related O
to O
superior B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
vena I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cava I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
SVC B_DISEASE/B_PROTEIN[GENE]
) O
syndrome B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

A O
percutaneous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mechanical I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
thrombectomy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
CDT B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
with O
alteplase B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
attempted O
, O
but O
the O
procedure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
aborted O
due O
to O
epistaxis O
. O

The O
epistaxis O
resolved O
the O
next O
day O
, O
and O
the O
patient O
was O
restarted O
on O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
second B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
percutaneous I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
mechanical I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thrombectomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
performed O
six B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
later O
and O
resulted O
in O
partial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
revascularization I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
SVC B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
central B_DISEASE/B_LOCATION
veins I_DISEASE/I_LOCATION
. O

Postthrombectomy O
continuous O
CDT O
with O
alteplase O
was O
commenced O
while O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
withheld O
, O
and O
complete O
patency O
of O
the O
SVC O
and O
central O
veins O
was O
achieved O
after O
three O
days O
of O
therapy O
. O

Alteplase O
was O
discontinued O
, O
and O
the O
patient O
was O
reinitiated O
on O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
ultimately O
, O
he O
was O
transitioned O
to O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
for O
long O
- O
term O
anticoagulation O
. O

Although O
the O
patient B_PERSON/B_BIO
recovered O
, O
he O
experienced O
permanent B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vision I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hearing B_DISEASE
loss I_DISEASE
, O
as O
well O
as O
end B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stage B_DISEASE_ADJECTIVE[DISEASE]
renal I_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
. O

conclusion O
: O
A O
63 O
- O
year O
- O
old O
man O
with O
renal O
amyloidosis O
and O
SVC O
syndrome O
secondary O
to O
HITT O
was O
successfully O
treated O
with O
argatroban B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
CDT O
with O
alteplase O
. O

Effects O
of O
dehydroepiandrosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
schizophrenia O
models O
in O
mice O
. O

objective O
: O
To O
examine O
the O
effects O
of O
dehydroepiandrosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
DHEA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
on O
animal O
models O
of O
schizophrenia O
. O

methods O
: O
seventy O
Swiss O
albino O
female O
mice O
( O
25 O
- O
35 O
g O
) O
were O
divided O
into O
4 O
groups O
: O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
free O
( O
control O
) O
, O
amphetamine B_MEASURE
, O
50 O
, O
and O
100 O
mg O
/ O
kg O
DHEA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
DHEA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
intraperitoneally O
( O
IP O
) O
for O
5 O
days O
. O

Amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
3 O
mg O
/ O
kg O
IP O
) O
induced O
hyper O
locomotion O
, O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 O
. O
5 O
mg O
/ O
kg O
subcutaneously O
[ O
Sc O
] O
) O
induced O
climbing O
, O
and O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 O
. O
5 O
mg O
/ O
kg O
Sc O
) O
induced O
catalepsy O
tests O
were O
used O
as O
animal O
models O
of O
schizophrenia O
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
conducted O
at O
the O
Animal B_LOCATION/B_PERSON
Experiment I_LOCATION/I_PERSON
Laboratories I_LOCATION/I_PERSON
, O
Department B_ORGANIZATION/B_LOCATION
of O
Pharmacology B_EDU[ORGANIZATION]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Medical B_LOCATION/B_EDU[ORGANIZATION]
School B_LOCATION/I_EDU[ORGANIZATION]
, O
Eskisehir B_LOCATION
Osmangazi I_LOCATION
University I_LOCATION
, O
Eskisehir B_LOCATION/B_PERSON
, O
Turkey B_LOCATION
between O
March B_TIME[MEASURE]/B_LOCATION
and O
May B_TIME[MEASURE]
2012 I_TIME[MEASURE]
. O

Statistical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
carried O
out O
using O
Kruskal B_PERSON/B_LOCATION
- O
Wallis B_PERSON
test I_PERSON
for O
hyper B_SPORT[ENT]/B_LOCATION
locomotion B_SPORT[ENT]/I_LOCATION
, O
and O
one B_NUMBER[MEASURE]
- O
way B_SEQUENCE[MEASURE]/B_LOCATION
ANOVA I_SEQUENCE[MEASURE]/I_LOCATION
for O
climbing B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
catalepsy B_SPORT[ENT]/B_LOCATION
tests I_SPORT[ENT]/I_LOCATION
. O

Results O
: O
In O
the O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
locomotion O
test O
, O
there O
were O
significant O
increases O
in O
all O
movements O
compared O
with O
the O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
free O
group O
. O

Both O
DHEA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O
mg O
/ O
kg O
( O
p O
< O
0 O
. O
05 O
) O
, O
and O
100 O
mg O
/ O
kg O
( O
p O
< O
0 O
. O
01 O
) O
significantly O
decreased O
all O
movements O
compared O
with O
the O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
locomotion O
group O
. O

There O
was O
a O
significant O
difference O
between O
groups O
in O
the O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
catalepsy O
test O
( O
p O
< O
0 O
. O
05 O
) O
. O

There O
was O
no O
significant O
difference O
between O
groups O
in O
terms O
of O
total O
climbing O
time O
in O
the O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
climbing O
test O
( O
p O
> O
0 O
. O
05 O
) O
. O

conclusion O
: O
We O
observed O
that O
DHEA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduced O
locomotor O
activity O
and O
increased O
catalepsy O
at O
both O
doses O
, O
while O
it O
had O
no O
effect O
on O
climbing O
behavior O
. O

We O
suggest O
that O
DHEA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
displays O
typical O
neuroleptic O
- O
like O
effects O
, O
and O
may O
be O
used O
in O
the O
treatment O
of O
schizophrenia O
. O

availability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
human B_PERSON/B_SPECIES[BIO]
induced O
pluripotent B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
stem O
cell B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_BIO
- O
derived O
cardiomyocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
assessment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
drug B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
potential I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
QT B_DISEASE
prolongation I_DISEASE
. O

Field O
potential O
duration O
( O
FPD O
) O
in O
human O
- O
induced O
pluripotent O
stem O
cell O
- O
derived O
cardiomyocytes O
( O
hips O
- O
CMs O
) O
, O
which O
can O
express O
QT O
interval O
in O
an O
electrocardiogram O
, O
is O
reported O
to O
be O
a O
useful O
tool O
to O
predict O
K B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
+ O
) O
channel O
and O
Ca B_LOCATION/B_PERSON
( O
2 O
+ O
) O
channel O
blocker O
effects O
on O
QT O
interval O
. O

However O
, O
there O
is O
no O
report B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
showing O
that O
this O
technique B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
can O
be O
used O
to O
predict O
multichannel B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
blocker I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
potential I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O
QT B_DISEASE
prolongation I_DISEASE
. O

The O
aim B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
is O
to O
show O
that O
FPD B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
MEA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
Multielectrode B_MEASURE/B_LOCATION
array B_MEASURE/I_LOCATION
) O
of O
hips B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- O
CMS B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
detect O
QT B_DISEASE
prolongation I_DISEASE
induced O
by O
multichannel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blockers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

hips B_LOCATION/B_DISEASE
- O
CMS B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
were O
seeded O
onto O
MEA B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
FPD B_DISEASE_ADJECTIVE[DISEASE]
was O
measured O
for O
2min B_MEASURE/B_LOCATION
every O
10min B_TIME[MEASURE]
for O
30min B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
exposure I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O
the O
vehicle B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
each O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
concentration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

IKr O
and O
IKs O
blockers O
concentration O
- O
dependently O
prolonged O
corrected O
FPD O
( O
FPDc O
) O
, O
whereas O
Ca B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
2 O
+ O
) O
channel O
blockers O
concentration O
- O
dependently O
shortened O
FPDc O
. O

Also O
, O
the O
multichannel O
blockers O
Amiodarone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Paroxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Terfenadine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Citalopram B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prolonged O
FPDc O
in O
a O
concentration O
dependent O
manner O
. O

Finally O
, O
the O
IKr O
blockers O
, O
Terfenadine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
Citalopram B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
are O
reported O
to O
cause O
Torsade O
de O
Pointes O
( O
TdP O
) O
in O
clinical O
practice O
, O
produced O
early O
afterdepolarization O
( O
EAD O
) O
. O

hips B_DISEASE/B_PROTEIN[GENE]
- O
CMS B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
using O
MEA B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
system I_LOCATION/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
FPDc B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
predict O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
candidates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
QT B_DISEASE/B_GENE
interval I_DISEASE/I_GENE
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
shows O
that O
this O
assay B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
can O
help O
detect O
EAD B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O
TDP B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

dermal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
developmental I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
toxicity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
phenylimide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
herbicides I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Background O
: O
S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
53482 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
23121 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
are O
N O
- O
phenylimide O
herbicides O
and O
produced O
embryolethality O
, O
teratogenicity O
( O
mainly O
ventricular O
septal O
defects O
and O
wavy O
ribs O
) O
, O
and O
growth O
retardation O
in O
rats O
in O
conventional O
oral O
developmental O
toxicity O
studies O
. O

Our O
objective B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
in O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
investigate O
whether O
the O
compounds B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induce O
developmental B_DISEASE/B_LOCATION
toxicity I_DISEASE/I_LOCATION
via O
the O
dermal B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
route I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
is O
more O
relevant B_DISEASE_ADJECTIVE[DISEASE]
to O
occupational B_DISEASE_ADJECTIVE[DISEASE]/B_SPECIES[BIO]
exposure B_DISEASE_ADJECTIVE[DISEASE]/I_SPECIES[BIO]
, O
hence O
better O
addressing O
human B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
risks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

methods O
: O
S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
53482 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
was O
administered O
dermally O
to O
rats O
at O
30 O
, O
100 O
, O
and O
300 O
mg O
/ O
kg O
during O
organogenesis O
, O
and O
S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
23121 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
at O
200 O
, O
400 O
, O
and O
800 O
mg O
/ O
kg O
( O
the O
maximum O
applicable O
dose O
level O
) O
. O

Fetuses B_PERSON/B_LOCATION
were O
obtained O
by O
a O
cesarean B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
section I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
and O
examined O
for O
external B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
visceral B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
, O
and O
skeletal B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alterations I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
Dermal O
exposure O
of O
rats O
to O
S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
53482 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
300 O
mg O
/ O
kg O
produced O
patterns O
of O
developmental O
toxicity O
similar O
to O
those O
resulting O
from O
oral O
exposure O
. O

toxicity B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O
embryolethality B_DISEASE
, O
teratogenicity B_DISEASE
, O
and O
growth B_DISEASE/B_ORGANISM_FUNCTION
retardation I_DISEASE/I_ORGANISM_FUNCTION
. O

Dermal O
administration O
of O
S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
23121 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
800 O
mg O
/ O
kg O
resulted O
in O
an O
increased O
incidence O
of O
embryonic O
death O
and O
ventricular O
septal O
defect O
, O
but O
retarded O
fetal O
growth O
was O
not O
observed O
as O
it O
was O
following O
oral O
exposure O
to O
S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
23121 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusions O
: O
Based O
on O
the O
results O
, O
S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
53482 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
23121 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
teratogenic O
when O
administered O
dermally O
to O
pregnant O
rats O
as O
were O
the O
compounds O
administered O
orally O
. O

Thus O
, O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
mechanism B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
its O
human B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
relevancy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
become O
more O
important B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

rates O
of O
Renal O
toxicity O
in O
Cancer O
patients O
receiving O
Cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
With O
and O
Without O
Mannitol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Background O
: O
Cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
widely O
used O
antineoplastic O
. O

One O
of O
the O
major O
complications O
of O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
is O
dose O
- O
limiting O
nephrotoxicity O
. O

There O
are O
many O
strategies O
to O
prevent O
this O
toxicity O
, O
including O
the O
use O
of O
mannitol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
as O
a O
nephroprotectant O
in O
combination O
with O
hydration O
. O

objective O
: O
We O
aimed O
to O
evaluate O
the O
rates O
of O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
nephrotoxicity O
in O
cancer O
patients O
receiving O
single O
- O
agent O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
and O
without O
mannitol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

methods O
: O
This O
single O
- O
center O
retrospective O
analysis O
was O
a O
quasi O
experiment O
created O
by O
the O
national O
mannitol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
shortage O
. O

Data O
were O
collected O
on O
adult O
cancer O
patients O
receiving O
single O
- O
agent O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
an O
outpatient O
from O
January O
2011 O
to O
September O
2012 O
. O

The O
primary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
outcome B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
acute B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
kidney I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
injury I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
AKI B_DISEASE/B_GENE
) O
. O

Results O
: O
We O
evaluated O
143 O
patients O
who O
received O
single O
- O
agent O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
97 O
. O
2 O
% O
of O
patients O
had O
head O
and O
neck O
cancer O
as O
their O
primary O
malignancy O
. O

patients O
who O
did O
not O
receive O
mannitol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
more O
likely O
to O
develop O
nephrotoxicity O
: O
odds O
ratio O
[ O
OR O
] O
= O
2 O
. O
646 O
( O
95 O
% O
CI O
= O
1 O
. O
008 O
, O
6 O
. O
944 O
; O
P O
= O
0 O
. O
048 O
) O
. O

patients B_PERSON
who O
received O
the O
100 B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mg I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
m B_OTHER/B_MEASURE
( O
2 B_TIME[MEASURE]/B_LOCATION
) O
dosing B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
patients B_PERSON/B_LOCATION
who O
had O
a O
history B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
hypertension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
also O
had O
a O
higher B_MEASURE
likelihood I_MEASURE
of O
developing O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
OR O
= O
11 B_MEASURE
. O
494 B_MEASURE
( O
95 B_LOCATION/B_MEASURE
% I_LOCATION/I_MEASURE
CI I_LOCATION/I_MEASURE
= O
4 B_MEASURE
. O
149 B_MEASURE
, O
32 B_MEASURE
. O
258 B_MEASURE
; O
P B_MEASURE
< I_MEASURE
0 I_MEASURE
. O
0001 B_MEASURE
) O
and O
OR O
= O
3 B_MEASURE
. O
219 B_MEASURE
( O
95 B_LOCATION/B_MEASURE
% I_LOCATION/I_MEASURE
CI I_LOCATION/I_MEASURE
= O
1 B_MEASURE
. O
228 B_MEASURE
, O
8 B_MEASURE
. O
439 B_MEASURE
; O
P B_OTHER/B_LOCATION
= O
0 B_MEASURE
. O
017 B_MEASURE
) O
, O
respectively O
. O

conclusions O
: O
When O
limited O
quantities O
of O
mannitol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
available O
, O
it O
should O
preferentially O
be O
given O
to O
patients O
at O
particularly O
high O
risk O
of O
nephrotoxicity O
. O

Our O
analysis O
suggests O
that O
those O
patients O
receiving O
the O
dosing O
schedule O
of O
100 O
mg O
/ O
m O
( O
2 O
) O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
every O
3 O
weeks O
and O
those O
with O
hypertension O
are O
at O
the O
greatest O
risk O
of O
nephrotoxicity O
and O
would O
benefit O
from O
the O
addition O
of O
mannitol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protects O
against O
seizures O
, O
learning O
and O
memory O
impairments O
and O
oxidative O
damage O
induced O
by O
pentylenetetrazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
kindling O
in O
mice O
. O

Cognitive B_DISEASE
impairment I_DISEASE
, O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
and O
severe B_DISEASE_ADJECTIVE[DISEASE]
comorbidity I_DISEASE_ADJECTIVE[DISEASE]
of O
epilepsy B_DISEASE/B_LOCATION
, O
greatly O
diminishes O
the O
quality B_MEASURE
of O
life B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

However O
, O
current B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapeutic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
interventions I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
epilepsy B_DISEASE/B_LOCATION
can O
also O
cause O
untoward B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cognitive I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Thus O
, O
there O
is O
an O
urgent B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
need I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
for O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
kinds I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
targeting O
both O
seizures B_DISEASE
and O
cognition B_DISEASE
deficits I_DISEASE
. O

Oxidative B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
considered O
to O
play O
an O
important B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
role I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
epileptogenesis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
cognitive B_DISEASE/B_ORGANISM_FUNCTION
deficits I_DISEASE/I_ORGANISM_FUNCTION
, O
and O
antioxidants B_LOCATION/B_PERSON
have O
a O
putative B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiepileptic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
potential I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
the O
most O
commonly O
prescribed O
antidiabetic O
oral O
drug O
, O
has O
antioxidant O
properties O
. O

This O
study O
was O
designed O
to O
evaluate O
the O
ameliorative O
effects O
of O
metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O
seizures O
, O
cognitive O
impairment O
and O
brain O
oxidative O
stress O
markers O
observed O
in O
pentylenetetrazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
kindling O
animals O
. O

Male O
C57BL O
/ O
6 O
mice O
were O
administered O
with O
subconvulsive O
dose O
of O
pentylenetetrazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
37 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
every O
other O
day O
for O
14 O
injections O
. O

Metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
injected O
intraperitoneally O
in O
dose O
of O
200mg O
/ O
kg O
along O
with O
alternate O
- O
day O
PTZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
found O
that O
metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suppressed O
the O
progression O
of O
kindling O
, O
ameliorated O
the O
cognitive O
impairment O
and O
decreased O
brain O
oxidative O
stress O
. O

Thus O
the O
present O
study O
concluded O
that O
metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
may O
be O
a O
potential O
agent O
for O
the O
treatment O
of O
epilepsy O
as O
well O
as O
a O
protective O
medicine O
against O
cognitive O
impairment O
induced O
by O
seizures O
. O

P53 O
inhibition O
exacerbates O
late O
- O
stage O
anthracycline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cardiotoxicity O
. O

aims O
: O
Doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
is O
an O
effective O
anti O
- O
cancer O
therapeutic O
, O
but O
is O
associated O
with O
both O
acute O
and O
late O
- O
stage O
cardiotoxicity O
. O

Children O
are O
particularly O
sensitive O
to O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
heart O
failure O
. O

Here O
, O
the O
impact O
of O
p53 O
inhibition O
on O
acute O
vs O
. O
late O
- O
stage O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
cardiotoxicity O
was O
examined O
in O
a O
juvenile O
model O
. O

methods O
AND O
Results O
: O
Two O
- O
week O
- O
old O
MHC O
- O
CB7 O
mice O
( O
which O
express O
dominant O
- O
interfering O
p53 O
in O
cardiomyocytes O
) O
and O
their O
non O
- O
transgenic O
( O
Non O
- O
TXG O
) O
littermates O
received O
weekly O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injections O
for O
5 O
weeks O
( O
25 O
mg O
/ O
kg O
cumulative O
dose O
) O
. O

One O
week O
after O
the O
last O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
( O
acute O
stage O
) O
, O
MHC O
- O
CB7 O
mice O
exhibited O
improved O
cardiac O
function O
and O
lower O
levels O
of O
cardiomyocyte O
apoptosis O
when O
compared O
with O
the O
Non O
- O
TXG O
mice O
. O

surprisingly O
, O
by O
13 O
weeks O
following O
the O
last O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
( O
late O
stage O
) O
, O
MHC O
- O
CB7 O
exhibited O
a O
progressive O
decrease O
in O
cardiac O
function O
and O
higher O
rates O
of O
cardiomyocyte O
apoptosis O
when O
compared O
with O
Non O
- O
TXG O
mice O
. O

p53 O
inhibition O
blocked O
transient O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
STAT3 O
activation O
in O
MHC O
- O
CB7 O
mice O
, O
which O
was O
associated O
with O
enhanced O
induction O
of O
the O
DNA O
repair O
proteins O
Ku70 O
and O
Ku80 O
. O

mice O
with O
cardiomyocyte O
- O
restricted O
deletion O
of O
STAT3 O
exhibited O
worse O
cardiac O
function O
, O
higher O
levels O
of O
cardiomyocyte O
apoptosis O
, O
and O
a O
greater O
induction O
of O
Ku70 O
and O
Ku80 O
in O
response O
to O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
during O
the O
acute O
stage O
when O
compared O
with O
control O
animals O
. O

conclusion O
: O
These O
data O
support O
a O
model O
wherein O
a O
p53 O
- O
dependent O
cardioprotective O
pathway O
, O
mediated O
via O
STAT3 O
activation O
, O
mitigates O
DOX B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
myocardial O
stress O
during O
drug O
delivery O
. O

Furthermore O
, O
these O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
an O
explanation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
to O
how O
p53 B_DISEASE
inhibition I_DISEASE
can O
result O
in O
cardioprotection B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O
, O
paradoxically O
, O
enhanced O
cardiotoxicity B_DISEASE
long O
after O
the O
cessation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Metronidazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
encephalopathy O
: O
an O
uncommon O
scenario O
. O

Metronidazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
produce O
neurological O
complications O
although O
it O
is O
not O
a O
common O
scenario O
. O

We O
present O
a O
case O
where O
a O
patient O
developed O
features O
of O
encephalopathy O
following O
prolonged O
metronidazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intake O
. O

Magnetic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resonance I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
MRI B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
brain B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
showed O
abnormal B_DISEASE
signal I_DISEASE
intensity I_DISEASE
involving O
both O
dentate B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
nuclei I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
cerebellum B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
splenium B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
of O
corpus B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
callosum I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
diagnosis O
of O
metronidazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
toxicity O
was O
made O
by O
the O
MRI O
findings O
and O
supported O
clinically O
. O

Aconitine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
Ca2 B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O
overload O
causes O
arrhythmia O
and O
triggers O
apoptosis O
through O
p38 O
MAPK O
signaling O
pathway O
in O
rats O
. O

Aconitine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
a O
major O
bioactive O
diterpenoid O
alkaloid O
with O
high O
content O
derived O
from O
herbal O
aconitum O
plants O
. O

emerging O
evidence O
indicates O
that O
voltage O
- O
dependent O
Na B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
+ O
) O
channels O
have O
pivotal O
roles O
in O
the O
cardiotoxicity O
of O
aconitine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

However O
, O
no O
reports O
are O
available O
on O
the O
role O
of O
Ca B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 O
+ O
) O
in O
aconitine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
poisoning O
. O

In O
this O
study O
, O
we O
explored O
the O
importance O
of O
pathological O
Ca B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
2 O
+ O
) O
signaling O
in O
aconitine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
poisoning O
in O
vitro O
and O
in O
vivo O
. O

We O
found O
that O
Ca B_LOCATION/B_MEASURE
( O
2 O
+ O
) O
overload O
lead O
to O
accelerated O
beating O
rhythm O
in O
adult O
rat O
ventricular O
myocytes O
and O
caused O
arrhythmia O
in O
conscious O
freely O
moving O
rats O
. O

To O
investigate O
effects O
of O
aconitine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
myocardial O
injury O
, O
we O
performed O
cytotoxicity O
assay O
in O
neonatal O
rat O
ventricular O
myocytes O
( O
NRVMs O
) O
, O
as O
well O
as O
measured O
lactate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dehydrogenase O
level O
in O
the O
culture O
medium O
of O
NRVMs O
and O
activities O
of O
serum O
cardiac O
enzymes O
in O
rats O
. O

The O
results O
showed O
that O
aconitine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
resulted O
in O
myocardial O
injury O
and O
reduced O
NRVMs O
viability O
dose O
- O
dependently O
. O

To O
confirm O
the O
pro O
- O
apoptotic O
effects O
, O
we O
performed O
flow O
cytometric O
detection O
, O
cardiac O
histology O
, O
transmission O
electron O
microscopy O
and O
terminal O
deoxynucleotidyl O
transferase O
- O
mediated O
dUTP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
biotin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Nick O
end O
labeling O
assay O
. O

The O
results O
showed O
that O
aconitine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
stimulated O
apoptosis O
time O
- O
dependently O
. O

The O
expression O
analysis O
of O
Ca B_LOCATION/B_PERSON
( O
2 O
+ O
) O
handling O
proteins O
demonstrated O
that O
aconitine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
promoted O
Ca B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
2 O
+ O
) O
overload O
through O
the O
expression O
regulation O
of O
Ca B_LOCATION/B_PERSON
( O
2 O
+ O
) O
handling O
proteins O
. O

The O
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
apoptosis B_DISEASE/B_GENE
- O
related O
proteins B_GENE/B_DISEASE
revealed O
that O
pro B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
apoptotic B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protein I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
upregulated O
, O
and O
anti B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
apoptotic B_GENE/B_DISEASE
protein I_GENE/I_DISEASE
BCL I_GENE/I_DISEASE
- O
2 B_MEASURE/B_PROTEIN[GENE]
expression I_MEASURE/I_PROTEIN[GENE]
was O
downregulated O
. O

Furthermore O
, O
increased O
phosphorylation B_GENE_EXPRESSION_ADJECTIVE[GENE]/B_MEASURE
of O
MAPK B_GENE
family I_GENE
members I_GENE
, O
especially O
the O
P B_GENE
- O
p38 B_GENE
/ O
p38 B_GENE
ratio I_GENE
was O
found O
in O
cardiac B_DISEASE
tissues I_DISEASE
. O

Hence O
, O
our O
results O
suggest O
that O
aconitine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
significantly O
aggravates O
Ca B_LOCATION/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 O
+ O
) O
overload O
and O
causes O
arrhythmia O
and O
finally O
promotes O
apoptotic O
development O
via O
phosphorylation O
of O
P38 O
mitogen O
- O
activated O
protein O
kinase O
. O

chronic O
treatment O
with O
metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
suppresses O
toll O
- O
like O
receptor O
4 O
signaling O
and O
attenuates O
left O
ventricular O
dysfunction O
following O
myocardial O
infarction O
. O

acute O
treatment O
with O
metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
has O
a O
protective O
effect O
in O
myocardial O
infarction O
by O
suppression O
of O
inflammatory O
responses O
due O
to O
activation O
of O
AMP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
activated O
protein O
kinase O
( O
AMPK O
) O
. O

In O
the O
present O
study O
, O
the O
effect O
of O
chronic O
pre O
- O
treatment O
with O
metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
cardiac O
dysfunction O
and O
toll O
- O
like O
receptor O
4 O
( O
TLR4 O
) O
activities O
following O
myocardial O
infarction O
and O
their O
relation O
with O
AMPK O
were O
assessed O
. O

Male O
Wistar O
rats O
were O
randomly O
assigned O
to O
one O
of O
5 O
groups O
( O
n O
= O
6 O
) O
: O
normal O
control O
and O
groups O
were O
injected O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
after O
chronic O
pre O
- O
treatment O
with O
0 O
, O
25 O
, O
50 O
, O
or O
100mg O
/ O
kg O
of O
metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
twice O
daily O
for O
14 O
days O
. O

Isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
100mg O
/ O
kg O
) O
was O
injected O
subcutaneously O
on O
the O
13th O
and O
14th O
days O
to O
induce O
acute O
myocardial O
infarction O
. O

Isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
alone O
decreased O
left O
ventricular O
systolic O
pressure O
and O
myocardial O
contractility O
indexed O
as O
LVdp O
/ O
dtmax O
and O
LVdp O
/ O
dtmin O
. O

The O
left O
ventricular O
dysfunction O
was O
significantly O
lower O
in O
the O
groups O
treated O
with O
25 O
and O
50mg O
/ O
kg O
of O
metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Metfromin O
markedly O
lowered O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
elevation O
in O
the O
levels O
of O
TLR4 O
mRNA O
, O
myeloid O
differentiation O
protein O
88 O
( O
MyD88 O
) O
, O
tumor O
necrosis O
factor O
- O
alpha O
( O
TNF O
- O
a O
) O
, O
and O
interleukin O
6 O
( O
IL O
- O
6 O
) O
in O
the O
heart O
tissues O
. O

Similar B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
also O
seen O
in O
the O
serum B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
TNF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
a B_PROTEIN[GENE]
and O
IL B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
6 B_NUMBER[MEASURE]
. O

However O
, O
the O
lower B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
doses I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
25 B_MEASURE
and O
50mg B_MEASURE
/ O
kg B_MEASURE
were O
more O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
than O
100mg B_MEASURE
/ O
kg B_MEASURE
. O

Phosphorylated O
AMPKa O
( O
p O
- O
AMPK O
) O
in O
the O
myocardium O
was O
significantly O
elevated O
by O
25mg O
/ O
kg O
of O
metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
slightly O
by O
50mg O
/ O
kg O
, O
but O
not O
by O
100mg O
/ O
kg O
. O

chronic O
pre O
- O
treatment O
with O
metformin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
reduces O
post O
- O
myocardial O
infarction O
cardiac O
dysfunction O
and O
suppresses O
inflammatory O
responses O
, O
possibly O
through O
inhibition O
of O
TLR4 O
activities O
. O

This O
mechanism B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
be O
considered O
as O
a O
target B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
to O
protect O
infarcted B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
myocardium B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

unusual B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
complications I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
antithyroid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
drug I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
: O
four B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
case I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
reports I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
and O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Two O
cases O
of O
propylthiouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
associated O
acute O
hepatitis O
, O
one O
case O
of O
fatal O
methimazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
associated O
hepatocellular O
necrosis O
and O
one O
case O
of O
propylthiouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
associated O
lupus O
- O
like O
syndrome O
are O
described O
. O

The O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
related O
to O
antithyroid B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drug I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
mechanisms B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
their O
occurrence B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
are O
reviewed O
and O
the O
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
complications B_DISEASE
of O
thyroidectomy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
radioiodine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
compared O
to O
those O
of O
antithyroid B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drugs I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

It O
is O
concluded O
that O
in O
most B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
circumstances I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
131I I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
is O
the O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
choice B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
for O
hyperthyroidism B_DISEASE/B_PERSON
. O

Neuroleptic O
malignant O
syndrome O
induced O
by O
combination O
therapy O
with O
tetrabenazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
tiapride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
Japanese O
patient O
with O
Huntington O
' O
s O
disease O
at O
the O
terminal O
stage O
of O
recurrent O
breast O
cancer O
. O

We O
herein O
describe O
the O
case O
of O
an O
81 O
- O
year O
- O
old O
Japanese O
woman O
with O
neuroleptic O
malignant O
syndrome O
that O
occurred O
36 O
days O
after O
the O
initiation O
of O
combination O
therapy O
with O
tiapride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
75 O
mg O
/ O
day O
) O
and O
tetrabenazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
12 O
. O
5 O
mg O
/ O
day O
) O
for O
Huntington O
' O
s O
disease O
. O

The O
patient O
had O
been O
treated O
with O
tiapride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
tetrabenazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
without O
any O
adverse O
effects O
before O
the O
administration O
of O
the O
combination O
therapy O
. O

She O
also O
had O
advanced O
breast B_DISEASE
cancer I_DISEASE
when O
the O
combination B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
initiated O
. O

To O
the O
best O
of O
our O
knowledge O
, O
the O
occurrence O
of O
neuroleptic O
malignant O
syndrome O
due O
to O
combination O
therapy O
with O
tetrabenazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
tiapride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
not O
been O
previously O
reported O
. O

Tetrabenazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
administered O
very O
carefully O
in O
combination O
with O
other O
neuroleptic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
particularly O
in O
patients O
with O
a O
worsening O
general O
condition O
. O

A O
metoprolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terbinafine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combination O
induced O
bradycardia O
. O

To O
report O
a O
sinus O
bradycardia O
induced O
by O
metoprolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
terbinafine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
drug O
- O
drug O
interaction O
and O
its O
management O
. O

A O
63 O
year O
- O
old O
Caucasian O
man O
on O
metoprolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
200 O
mg O
/ O
day O
for O
stable O
coronary O
artery O
disease O
was O
prescribed O
a O
90 O
- O
day O
course O
of O
oral O
terbinafine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
250 O
mg O
/ O
day O
for O
onychomycosis O
. O

On O
the O
49th O
day O
of O
terbinafine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
, O
he O
was O
brought O
to O
the O
emergency O
room O
for O
a O
decrease O
of O
his O
global O
health O
status O
, O
confusion O
and O
falls O
. O

The O
electrocardiogram B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
a O
37 B_MEASURE
beats I_MEASURE
/ O
min B_TIME[MEASURE]/B_LOCATION
sinus I_TIME[MEASURE]/I_LOCATION
bradycardia I_TIME[MEASURE]/I_LOCATION
. O

A O
score O
of O
7 O
on O
the O
Naranjo O
adverse O
drug O
reaction O
probability O
scale O
indicates O
a O
probable O
relationship O
between O
the O
patient O
' O
s O
sinus O
bradycardia O
and O
the O
drug O
interaction O
between O
metoprolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
terbinafine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
heart O
rate O
ameliorated O
first O
with O
a O
decrease O
in O
the O
dose O
of O
metoprolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
was O
subsequently O
changed O
to O
bisoprolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
heart O
rate O
remained O
normal O
. O

By O
inhibiting O
the O
cytochrome O
P450 O
2D6 O
, O
terbinafine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
had O
decreased O
metoprolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' O
s O
clearance O
, O
leading O
in O
metoprolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
accumulation O
which O
has O
resulted O
in O
clinically O
significant O
sinus O
bradycardia O
. O

Optochiasmatic O
and O
peripheral O
neuropathy O
due O
to O
ethambutol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
overtreatment O
. O

Ethambutol B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
known O
to O
cause O
optic O
neuropathy O
and O
, O
more O
rarely O
, O
axonal O
polyneuropathy O
. O

We O
characterize O
the O
clinical O
, O
neurophysiological O
, O
and O
neuroimaging O
findings O
in O
a O
72 O
- O
year O
- O
old O
man O
who O
developed O
visual O
loss O
and O
paresthesias O
after O
11 O
weeks O
of O
exposure O
to O
a O
supratherapeutic O
dose O
of O
ethambutol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
case O
demonstrates O
the O
selective O
vulnerability O
of O
the O
anterior O
visual O
pathways O
and O
peripheral O
nerves O
to O
ethambutol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxicity O
. O

Testosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ameliorates O
streptozotocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
memory O
impairment O
in O
male O
rats O
. O

aim O
: O
To O
study O
the O
effects O
of O
testosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
streptozotocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
STZ B_DISEASE/B_LOCATION
) O
- O
induced O
memory O
impairment O
in O
male O
rats O
. O

methods O
: O
Adult O
male O
Wistar O
rats O
were O
intracerebroventricularly O
( O
icv O
) O
infused O
with O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
750 O
ug O
) O
on O
d O
1 O
and O
d O
3 O
, O
and O
a O
passive O
avoidance O
task O
was O
assessed O
2 O
weeks O
after O
the O
first O
injection O
of O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

castration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
surgery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O
performed O
in O
another O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
rats B_BIO/B_PERSON
, O
and O
the O
passive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
avoidance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
task B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
assessed O
4 B_TIME[MEASURE]
weeks I_TIME[MEASURE]
after O
the O
operation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Testosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
1 O
mg O
. O
kg O
( O
- O
1 O
) O
. O
d O
( O
- O
1 O
) O
, O
Sc O
) O
, O
the O
androgen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor O
antagonist O
flutamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 O
mg O
. O
kg O
( O
- O
1 O
) O
. O
d O
( O
- O
1 O
) O
, O
IP O
) O
, O
the O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor O
antagonist O
tamoxifen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
1 O
mg O
. O
kg O
( O
- O
1 O
) O
. O
d O
( O
- O
1 O
) O
, O
IP O
) O
or O
the O
aromatase O
inhibitor O
letrozole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
4 O
mg O
. O
kg O
( O
- O
1 O
) O
. O
d O
( O
- O
1 O
) O
, O
IP O
) O
were O
administered O
for O
6 O
d O
after O
the O
first O
injection O
of O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Results O
: O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
and O
castration O
markedly O
decreased O
both O
STL1 O
( O
the O
short O
memory O
) O
and O
STL2 O
( O
the O
long O
memory O
) O
in O
passive O
avoidance O
tests O
. O

Testosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
replacement O
almost O
restored O
the O
STL1 O
and O
STL2 O
in O
castrated O
rats O
, O
and O
significantly O
prolonged O
the O
STL1 O
and O
STL2 O
in O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
rats O
. O

Administration O
of O
flutamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
letrozole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
tamoxifen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
significantly O
impaired O
the O
memory O
in O
intact O
rats O
, O
and O
significantly O
attenuated O
the O
testosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
replacement O
in O
improving O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
and O
castration O
- O
induced O
memory O
impairment O
. O

conclusion O
: O
Testosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
ameliorates O
STZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
and O
castration O
- O
induced O
memory O
impairment O
in O
male O
Wistar O
rats O
. O

behavioral O
and O
neurochemical O
studies O
in O
mice O
pretreated O
with O
garcinielliptone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
seizures O
. O

Garcinielliptone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
FC I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
( O
GFC B_MEASURE
) O
isolated O
from O
hexanic O
fraction O
seed O
extract O
of O
species O
Platonia O
insignis O
Mart O
. O

It O
is O
widely O
used O
in O
folk B_LOCATION/B_PERSON
medicine I_LOCATION/I_PERSON
to O
treat O
skin B_DISEASE
diseases I_DISEASE
in O
both O
humans B_PERSON/B_BIO
and O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
well O
as O
the O
seed B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
decoction I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
has O
been O
used O
to O
treat O
diarrheas B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
inflammatory B_DISEASE
diseases I_DISEASE
. O

However O
, O
there O
is O
no O
research O
on O
GFC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
effects O
in O
the O
central O
nervous O
system O
of O
rodents O
. O

The O
present O
study O
aimed O
to O
evaluate O
the O
GFC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects O
at O
doses O
of O
25 O
, O
50 O
or O
75 O
mg O
/ O
kg O
on O
seizure O
parameters O
to O
determine O
their O
anticonvulsant O
activity O
and O
its O
effects O
on O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
r B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
aminobutyric I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
, O
glutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
aspartate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
glutathione B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
levels O
as O
well O
as O
on O
acetylcholinesterase O
( O
ache O
) O
activity O
in O
mice O
hippocampus O
after O
seizures O
. O

GFC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O
an O
increased O
latency O
to O
first O
seizure O
, O
at O
doses O
25mg O
/ O
kg O
( O
20 O
. O
12 O
+ O
2 O
. O
20 O
min O
) O
, O
50mg O
/ O
kg O
( O
20 O
. O
95 O
+ O
2 O
. O
21 O
min O
) O
or O
75 O
mg O
/ O
kg O
( O
23 O
. O
43 O
+ O
1 O
. O
99 O
min O
) O
when O
compared O
with O
seized O
mice O
. O

In O
addition O
, O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
content O
of O
mice O
hippocampus O
treated O
with O
GFC75 O
plus O
P400 O
showed O
an O
increase O
of O
46 O
. O
90 O
% O
when O
compared O
with O
seized O
mice O
. O

In O
aspartate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
glutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
levels O
detected O
a O
decrease O
of O
5 O
. O
21 O
% O
, O
13 O
. O
55 O
% O
and O
21 O
. O
80 O
% O
, O
respectively O
in O
mice O
hippocampus O
treated O
with O
GFC75 O
plus O
P400 O
when O
compared O
with O
seized O
mice O
. O

Hippocampus B_BIO/B_PERSON
mice I_BIO/I_PERSON
treated O
with O
GFC75 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plus O
P400 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
showed O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
AChE B_DISEASE/B_MEASURE
activity I_DISEASE/I_MEASURE
( O
63 B_MEASURE
. O
30 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
when O
compared O
with O
seized O
mice B_BIO/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
results O
indicate O
that O
GFC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
can O
exert O
anticonvulsant O
activity O
and O
reduce O
the O
frequency O
of O
installation O
of O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
status O
epilepticus O
, O
as O
demonstrated O
by O
increase O
in O
latency O
to O
first O
seizure O
and O
decrease O
in O
mortality O
rate O
of O
animals O
. O

In O
conclusion O
, O
our O
data O
suggest O
that O
GFC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
may O
influence O
in O
epileptogenesis O
and O
promote O
anticonvulsant O
actions O
in O
pilocarpine B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O
by O
modulating O
the O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
contents O
and O
of O
ache O
activity O
in O
seized O
mice O
hippocampus O
. O

This O
compound B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
produce O
neuronal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protection I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
it O
can O
be O
considered O
as O
an O
anticonvulsant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Standard B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
operating I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
procedures I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
antibiotic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O
the O
occurrence B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
acute B_DISEASE
kidney I_DISEASE
injury I_DISEASE
: O
a O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
non B_DISEASE
- O
interventional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
observational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Introduction B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Acute B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
kidney I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
injury I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
AKI B_DISEASE/B_LOCATION
) O
occurs O
in O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
hospitalized O
and O
66 B_PERSON/B_MEASURE
% B_PERSON/I_MEASURE
of O
Intensive B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
Care I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
Unit I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
( O
ICU B_LOCATION/B_ORGANIZATION
) O
patients B_PERSON/B_LOCATION
. O

It O
increases O
mortality B_DISEASE
, O
hospital B_MEASURE/B_PERSON
length I_MEASURE/I_PERSON
of O
stay B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
, O
and O
costs B_DISEASE
. O

The O
aim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
was O
to O
investigate O
, O
whether O
there O
is O
an O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
adherence B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
guidelines B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
( O
standard B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
operating I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
procedures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
SOP B_DISEASE/B_GENE
) O
) O
for O
potentially O
nephrotoxic B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antibiotics B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
the O
occurrence B_DISEASE_ADJECTIVE[DISEASE]
of O
AKI B_DISEASE
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
carried O
out O
as O
a O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
non B_DISEASE
- O
interventional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
observational B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Data B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_GENE
collection I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_GENE
was O
performed O
over O
a O
total B_MEASURE/B_LOCATION
of O
170 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
in O
three B_MEASURE/B_LOCATION
ICUs I_MEASURE/I_LOCATION
at O
Charite B_PERSON/B_LOCATION
- O
Universitaetsmedizin B_LOCATION/B_PERSON
Berlin I_LOCATION/I_PERSON
. O

A O
total O
of O
675 O
patients O
were O
included O
; O
163 O
of O
these O
had O
therapy O
with O
vancomycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
tobramycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
; O
were O
> O
18 O
years O
; O
and O
treated O
in O
the O
ICU O
for O
> O
24 O
hours O
. O

patients B_PERSON
with O
an O
adherence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
SOP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
> O
70 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
were O
classified O
into O
the O
high B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
adherence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
HAG B_LOCATION/B_ORGANIZATION
) O
and O
patients B_PERSON
with O
an O
adherence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
< O
70 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
into O
the O
low B_MEASURE/B_LOCATION
adherence I_MEASURE/I_LOCATION
group I_MEASURE/I_LOCATION
( O
LAG B_LOCATION/B_ORGANIZATION
) O
. O

AKI B_DISEASE
was O
defined O
according O
to O
rifle B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
criteria I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Adherence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
SOPs B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
was O
evaluated O
by O
retrospective B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expert I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
audit I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Development B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
AKI B_DISEASE
was O
compared O
between O
groups B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
exact B_NUMBER[MEASURE]/B_PERSON
Chi2 I_NUMBER[MEASURE]/I_PERSON
- O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
multivariate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
logistic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
two B_NUMBER[MEASURE]/B_LOCATION
- O
sided B_LOCATION/B_MEASURE
P I_LOCATION/I_MEASURE
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
lag B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consisted O
of O
75 B_MEASURE/B_PERSON
patients I_MEASURE/I_PERSON
( O
46 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
versus O
88 B_MEASURE
HAG I_MEASURE
patients I_MEASURE
( O
54 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

AKI B_DISEASE/B_GENE
occurred O
significantly O
more O
often O
in O
LAG B_PERSON/B_DISEASE
with O
36 B_MEASURE/B_DISEASE
% I_MEASURE/I_DISEASE
versus I_MEASURE/I_DISEASE
21 I_MEASURE/I_DISEASE
% I_MEASURE/I_DISEASE
in O
HAG B_PERSON/B_LOCATION
( O
P B_OTHER/B_MEASURE
= O
0 B_MEASURE
. O
035 B_MEASURE
) O
. O

Basic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
characteristics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
were O
comparable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
except O
an O
increased O
rate B_MEASURE
of O
soft B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
tissue I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
infections I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
LAG B_PERSON/B_ORGANIZATION
. O

Multivariate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
revealed O
an O
odds B_MEASURE
ratio I_MEASURE
of O
2 B_MEASURE
. O
5 B_MEASURE
- O
fold B_MEASURE
for O
lag B_PROTEIN[GENE]/B_DISEASE
to O
develop O
AKI B_DISEASE
compared O
with O
HAG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
95 B_MEASURE
% I_MEASURE
confidence I_MEASURE
interval I_MEASURE
1 I_MEASURE
. O
195 B_MEASURE
to O
5 B_MEASURE
. O
124 B_MEASURE
, O
P B_OTHER/B_MEASURE
= O
0 B_MEASURE
. O
039 B_MEASURE
) O
. O

Conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
: O
Low B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
adherence B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
SOPs B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
for O
potentially O
nephrotoxic B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
antibiotics B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
was O
associated O
with O
a O
higher B_DISEASE_ADJECTIVE[DISEASE]
occurrence I_DISEASE_ADJECTIVE[DISEASE]
of O
AKI B_DISEASE
. O

Trial B_LOCATION
registration I_LOCATION
: O
Current B_NUMBER[MEASURE]/B_LOCATION
Controlled I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Trials I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ISRCTN54598675 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

registered O
17 B_PERSON
August I_PERSON
2007 I_PERSON
. O

Rhabdomyolysis O
in O
a O
hepatitis O
C O
virus O
infected O
patient O
treated O
with O
telaprevir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
simvastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
46 O
- O
year O
old O
man O
with O
a O
chronic O
hepatitis O
C O
virus O
infection O
received O
triple O
therapy O
with O
ribavirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
pegylated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interferon I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
telaprevir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
patient O
also O
received O
simvastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

One B_TIME[MEASURE]/B_LOCATION
month I_TIME[MEASURE]/I_LOCATION
after O
starting O
the O
antiviral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
patient B_PERSON
was O
admitted O
to O
the O
hospital B_LOCATION/B_ORGANIZATION
because O
he O
developed O
rhabdomyolysis B_DISEASE
. O

At O
admission O
simvastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
and O
all O
antiviral O
drugs O
were O
discontinued O
because O
toxicity O
due O
to O
a O
drug O
- O
drug O
interaction O
was O
suspected O
. O

The O
creatine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kinase O
peaked O
at O
62 O
, O
246 O
IU O
/ O
L O
and O
the O
patient O
was O
treated O
with O
intravenous O
normal O
saline O
. O

The O
patient B_PERSON/B_BIO
' O
s O
renal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
remained O
unaffected B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Fourteen O
days O
after O
hospitalization O
, O
creatine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
kinase O
level O
had O
returned O
to O
230 O
IU O
/ O
L O
and O
the O
patient O
was O
discharged O
. O

Telaprevir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
considered O
the O
probable O
causative O
agent O
of O
an O
interaction O
with O
simvastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
according O
to O
the O
Drug O
interaction O
probability O
Scale O
. O

The O
interaction O
is O
due O
to O
inhibition O
of O
CYP3A4 O
- O
mediated O
simvastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clearance O
. O

Simvastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
plasma O
concentration O
increased O
30 O
times O
in O
this O
patient O
and O
statin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
induced O
muscle O
toxicity O
is O
related O
to O
the O
concentration O
of O
the O
statin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
in O
blood O
. O

In O
conclusion O
, O
with O
this O
case O
we O
illustrate O
that O
telaprevir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
well O
as O
statins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
susceptible O
to O
clinical O
relevant O
drug O
- O
drug O
interactions O
. O

combination O
of O
bortezomib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
VTD O
) O
as O
a O
consolidation O
therapy O
after O
autologous O
stem O
cell O
transplantation O
for O
symptomatic O
multiple O
myeloma O
in O
Japanese O
patients O
. O

consolidation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
patients B_PERSON/B_BIO
with O
multiple B_DISEASE
myeloma I_DISEASE
( O
mm B_TIME[MEASURE]/B_LOCATION
) O
has O
been O
widely O
adopted O
to O
improve O
treatment B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
response I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
following O
autologous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stem I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
cell I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

In O
this O
study O
, O
we O
retrospectively O
analyzed O
the O
safety O
and O
efficacy O
of O
combination O
regimen O
of O
bortezomib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
VTD O
) O
as O
consolidation O
therapy O
in O
24 O
Japanese O
patients O
with O
newly O
diagnosed O
mm O
. O

VTD O
consisted O
of O
bortezomib B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
dose O
of O
1 O
. O
3 O
mg O
/ O
m O
( O
2 O
) O
and O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
dose O
of O
40 O
mg O
/ O
day O
on O
days O
1 O
, O
8 O
, O
15 O
, O
and O
22 O
of O
a O
35 O
- O
day O
cycle O
, O
with O
daily O
oral O
thalidomide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
dose O
of O
100 O
mg O
/ O
day O
. O

Grade B_DISEASE/B_TIME[MEASURE]
3 B_DISEASE/I_TIME[MEASURE]
- O
4 B_DISEASE
neutropenia I_DISEASE
and O
thrombocytopenia B_DISEASE
were O
documented O
in O
four B_NUMBER[MEASURE]
and O
three B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
( O
17 B_MEASURE
and O
13 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
, O
respectively O
, O
but O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dose I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
reduction I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O
to O
cytopenia B_DISEASE
was O
not O
required O
in O
any O
case B_PERSON
. O

Peripheral B_DISEASE
neuropathy I_DISEASE
was O
common B_DISEASE_ADJECTIVE[DISEASE]
( O
63 B_MEASURE
% I_MEASURE
) O
, O
but O
severe B_MEASURE/B_LOCATION
grade I_MEASURE/I_LOCATION
3 I_MEASURE/I_LOCATION
- O
4 B_DISEASE
peripheral I_DISEASE
neuropathy I_DISEASE
was O
not O
observed O
. O

Very O
good B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
partial I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
response I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
or O
better B_DISEASE_ADJECTIVE[DISEASE]
response I_DISEASE_ADJECTIVE[DISEASE]
( O
> O
VGPR B_MEASURE
) O
rates B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
before O
and O
after O
consolidation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
54 B_MEASURE
and O
79 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
respectively O
. O

patients B_PERSON
had O
a O
significant B_MEASURE
probability I_MEASURE
of O
improving O
from O
< B_PROTEIN[GENE]/B_DISEASE
VGPR I_PROTEIN[GENE]/I_DISEASE
before O
consolidation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
to O
> B_MEASURE
VGPR I_MEASURE
after O
consolidation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
( O
p B_PROTEIN[GENE]/B_MEASURE
= O
0 B_MEASURE
. O
041 B_MEASURE
) O
. O

The O
VTD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regimen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
safe B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
a O
consolidation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_MEASURE
in O
the O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
MM B_DISEASE/B_LOCATION
in O
Japanese B_PERSON/B_LOCATION
population I_PERSON/I_LOCATION
. O

conversion O
to O
sirolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
ameliorates O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
nephropathy O
in O
the O
rat O
: O
focus O
on O
serum O
, O
urine O
, O
gene O
, O
and O
protein O
renal O
expression O
biomarkers O
. O

protocols O
of O
conversion O
from O
cyclosporin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CsA B_LOCATION/B_ORGANIZATION
) O
to O
sirolimus B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SRL B_LOCATION/B_ORGANIZATION
) O
have O
been O
widely O
used O
in O
immunotherapy O
after O
transplantation O
to O
prevent O
CsA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
nephropathy O
, O
but O
the O
molecular O
mechanisms O
underlying O
these O
protocols O
remain O
nuclear O
. O

This O
study O
aimed O
to O
identify O
the O
molecular O
pathways O
and O
putative O
biomarkers O
of O
CsA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
to O
- O
SRL B_DISEASE
conversion O
in O
a O
rat O
model O
. O

Four O
animal O
groups O
( O
n O
= O
6 O
) O
were O
tested O
during O
9 O
weeks O
: O
control O
, O
CsA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
SRL B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
conversion O
( O
CsA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
3 O
weeks O
followed O
by O
SRL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
6 O
weeks O
) O
. O

Classical B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
emergent B_BODY_PART_OR_ORGAN_COMPONENT/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum I_BODY_PART_OR_ORGAN_COMPONENT/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
urinary B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
kidney B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissue I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
gene B_GENE
and O
protein B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_GENE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
markers B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
assessed O
. O

Renal O
lesions O
were O
analyzed O
in O
hematoxylin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
eosin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
periodic O
acid O
- O
Schiff O
, O
and O
Masson O
' O
s O
trichrome O
stains O
. O

SRL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
treated O
rats O
presented O
proteinuria O
and O
NGAL O
( O
serum O
and O
urinary O
) O
as O
the O
best O
markers O
of O
renal O
impairment O
. O

Short O
CsA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
presented O
slight O
or O
even O
absent O
kidney O
lesions O
and O
TGF O
- O
b O
, O
NF O
- O
kb O
, O
mTOR O
, O
PCNA O
, O
TP53 O
, O
Kim O
- O
1 O
, O
and O
CTGF O
as O
relevant O
gene O
and O
protein O
changes O
. O

prolonged O
CsA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O
aggravated O
renal O
damage O
, O
without O
clear O
changes O
on O
the O
traditional O
markers O
, O
but O
with O
changes O
in O
serums O
TGF O
- O
b O
and O
IL O
- O
7 O
, O
TBARs O
clearance O
, O
and O
kidney O
TGF O
- O
b O
and O
mTOR O
. O

conversion O
to O
SRL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prevented O
CsA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
renal O
damage O
evolution O
( O
absent O
/ O
mild O
grade O
lesions O
) O
, O
while O
NGAL O
( O
serum O
versus O
urine O
) O
seems O
to O
be O
a O
feasible O
biomarker O
of O
CsA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
replacement O
to O
SRL B_DISEASE
. O

Kinin O
B2 O
receptor O
deletion O
and O
blockage O
ameliorates O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
acute O
renal O
injury O
. O

Cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
has O
been O
adopted O
in O
some O
chemotherapies O
; O
however O
, O
this O
drug O
can O
induce O
acute O
kidney O
injury O
due O
its O
ability O
to O
negatively O
affect O
renal O
function O
, O
augment O
serum O
levels O
of O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
urea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
increase O
the O
acute O
tubular O
necrosis O
score O
and O
up O
- O
regulate O
cytokines O
( O
e O
. O
g O
. O
, O
IL O
- O
1b O
and O
TNF O
- O
a O
) O
. O

The O
kinin B_GENE/B_DISEASE
B2 I_GENE/I_DISEASE
receptor I_GENE/I_DISEASE
has O
been O
associated O
with O
the O
inflammation B_DISEASE
process I_DISEASE
, O
as O
well O
as O
the O
regulation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
cytokine B_DISEASE
expression I_DISEASE
, O
and O
its O
deletion B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
resulted O
in O
an O
improvement B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
diabetic B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephropathy I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
status I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
examine O
the O
role O
of O
the O
kinin O
B2 O
receptor O
in O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
acute O
kidney O
injury O
, O
kinin O
B2 O
receptor O
knockout O
mice O
were O
challenged O
with O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Additionally O
, O
WT O
mice O
were O
treated O
with O
a O
B2 O
receptor O
antagonist O
after O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration O
. O

B2 B_GENE
receptor I_GENE
- O
deficient B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mice I_BIO/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
less O
sensitive B_DISEASE_ADJECTIVE[DISEASE]
to O
this O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
than O
the O
WT B_PERSON/B_BIO
mice I_PERSON/I_BIO
, O
as O
shown O
by O
reduced B_DISEASE
weight I_DISEASE
loss I_DISEASE
, O
better B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
preservation I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
kidney B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
function I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
, O
down O
regulation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
inflammatory B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cytokines I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
less O
acute B_DISEASE
tubular I_DISEASE
necrosis I_DISEASE
. O

Moreover O
, O
treatment O
with O
the O
kinin O
B2 O
receptor O
antagonist O
effectively O
reduced O
the O
levels O
of O
serum O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
blood O
urea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
after O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
. O

Thus O
, O
our O
data O
suggest O
that O
the O
kinin O
B2 O
receptor O
is O
involved O
in O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
acute O
kidney O
injury O
by O
mediating O
the O
necrotic O
process O
and O
the O
expression O
of O
inflammatory O
cytokines O
, O
thus O
resulting O
in O
declined O
renal O
function O
. O

These O
results O
highlight O
the O
kinin O
B2 O
receptor O
antagonist O
treatment O
in O
amelioration O
of O
nephrotoxicity O
induced O
by O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O
. O

Safety O
and O
efficacy O
of O
fluocinolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intravitreal O
implant O
( O
0 O
. O
59 O
mg O
) O
in O
birdshot O
retinochoroidopathy O
. O

purpose O
: O
To O
report O
the O
treatment O
outcomes O
of O
the O
fluocinolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intravitreal O
implant O
( O
0 O
. O
59 O
mg O
) O
in O
patients O
with O
birdshot O
retinochoroidopathy O
whose O
disease O
is O
refractory O
or O
intolerant O
to O
conventional O
immunomodulatory O
therapy O
. O

methods B_MEASURE
: O
A O
retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
case I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
series I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involving O
11 B_PERSON/B_BIO
birdshot I_PERSON/I_BIO
retinochoroidopathy I_PERSON/I_BIO
patients I_PERSON/I_BIO
( O
11 B_MEASURE/B_ENT
eyes I_MEASURE/I_ENT
) O
. O

Eleven O
patients O
( O
11 O
eyes O
) O
underwent O
surgery O
for O
fluocinolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acetonide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
implant O
( O
0 O
. O
59 O
mg O
) O
. O

Treatment O
outcomes O
of O
interest O
were O
noted O
at O
baseline O
, O
before O
fluocinolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
implant O
, O
and O
then O
at O
6 O
months O
, O
1 O
year O
, O
2 O
years O
, O
3 O
years O
, O
and O
beyond O
3 O
years O
. O

Disease B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
activity I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
markers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
including O
signs B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
ocular B_DISEASE
inflammation I_DISEASE
, O
evidence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
retinal B_DISEASE
vasculitis I_DISEASE
, O
Swedish B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
interactive I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
threshold I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
algorithm I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
- O
short B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
wavelength I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
automated O
perimetry B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
Humphrey I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
visual I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
field I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
analysis I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
electroretinographic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
parameters I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
and O
optical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
coherence I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
tomography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
recorded O
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
on O
occurrence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
cataract B_DISEASE
and O
raised O
intraocular B_DISEASE/B_MEASURE
pressure I_DISEASE/I_MEASURE
were O
collected O
in O
all O
eyes B_BODY_LOCATION_OR_REGION[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
intraocular B_DISEASE
inflammation I_DISEASE
was O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
54 B_MEASURE
. O
5 B_MEASURE
, O
9 B_MEASURE
. O
9 B_MEASURE
, O
11 B_MEASURE
. O
1 B_MEASURE
, O
and O
0 B_MEASURE
% I_MEASURE
of O
patients B_PERSON
at O
baseline B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
6 B_MEASURE/B_LOCATION
months I_MEASURE/I_LOCATION
, O
1 B_TIME[MEASURE]
year I_TIME[MEASURE]
, O
2 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
, O
3 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
, O
and O
beyond O
3 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
after O
receiving O
the O
implant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
respectively O
. O

Active B_DISEASE_ADJECTIVE[DISEASE]
vasculitis I_DISEASE_ADJECTIVE[DISEASE]
was O
noted O
in O
36 B_MEASURE
. O
3 B_MEASURE
% I_MEASURE
patients I_MEASURE
at O
baseline B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O
0 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
at O
3 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
of O
follow B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
up B_MEASURE/B_LOCATION
. O

More B_MEASURE/B_LOCATION
than O
20 B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
% I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
47 B_MEASURE
. O
61 B_MEASURE
- O
67 B_MEASURE
. O
2 B_MEASURE
% I_MEASURE
) O
reduction B_DISEASE_ADJECTIVE[DISEASE]
in O
central B_DISEASE
retinal I_DISEASE
thickness I_DISEASE
was O
noted O
in O
all O
patients B_PERSON/B_BIO
with O
cystoid B_DISEASE/B_LOCATION
macular I_DISEASE/I_LOCATION
edema I_DISEASE/I_LOCATION
at O
6 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
months I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
1 B_TIME[MEASURE]
year I_TIME[MEASURE]
, O
2 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
, O
and O
3 B_TIME[MEASURE]/B_LOCATION
years I_TIME[MEASURE]/I_LOCATION
postimplant I_TIME[MEASURE]/I_LOCATION
. O

At O
baseline B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
54 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
patients I_MEASURE
were O
on O
immunomodulatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
percentage B_MEASURE/B_PERSON
decreased O
to O
45 B_MEASURE
. O
45 B_MEASURE
, O
44 B_MEASURE
. O
4 B_MEASURE
, O
and O
14 B_MEASURE
. O
28 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
at O
1 B_TIME[MEASURE]/B_PERSON
year I_TIME[MEASURE]/I_PERSON
, O
2 B_SEQUENCE[MEASURE]/B_ENT
years I_SEQUENCE[MEASURE]/I_ENT
, O
and O
3 B_MEASURE/B_LOCATION
years I_MEASURE/I_LOCATION
postimplant I_MEASURE/I_LOCATION
, O
respectively O
. O

Adverse B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
events I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O
increased O
intraocular B_DISEASE
pressure I_DISEASE
( O
54 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
) O
and O
cataract B_DISEASE
formation I_DISEASE
( O
100 B_MEASURE
% I_MEASURE
) O
. O

conclusion O
: O
The O
data O
suggest O
that O
fluocinolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetonide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
implant O
( O
0 O
. O
59 O
mg O
) O
helps O
to O
control O
inflammation O
in O
otherwise O
treatment O
- O
refractory O
cases O
of O
birdshot O
retinochoroidopathy O
. O

It O
is O
associated O
with O
significant B_DISEASE_ADJECTIVE[DISEASE]
side I_DISEASE_ADJECTIVE[DISEASE]
effects I_DISEASE_ADJECTIVE[DISEASE]
of O
cataract B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ocular B_DISEASE
hypertension I_DISEASE
requiring O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

optimal O
precurarizing O
dose O
of O
rocuronium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
decrease O
fasciculation O
and O
myalgia O
following O
succinylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration O
. O

Background O
: O
Succinylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
commonly O
produces O
frequent O
adverse O
effects O
, O
including O
muscle O
fasciculation O
and O
myalgia O
. O

The O
current O
study O
identified O
the O
optimal O
dose O
of O
rocuronium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
prevent O
succinylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
fasciculation O
and O
myalgia O
and O
evaluated O
the O
influence O
of O
rocuronium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
on O
the O
speed O
of O
onset O
produced O
by O
succinylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
This O
randomized B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
double B_MEASURE/B_PERSON
- O
blinded B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
conducted O
in O
100 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
randomly O
allocated O
into O
five B_LOCATION/B_ORGANIZATION
groups I_LOCATION/I_ORGANIZATION
of O
20 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
each O
. O

patients O
were O
randomized O
to O
receive O
0 O
. O
02 O
, O
0 O
. O
03 O
, O
0 O
. O
04 O
, O
0 O
. O
05 O
and O
0 O
. O
06 O
mg O
/ O
kg O
rocuronium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
a O
precurarizing O
dose O
. O

neuromuscular B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
monitoring I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
after O
each O
precurarizing O
dose B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
recorded O
from O
the O
adductor B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
pollicis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
muscle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
using O
acceleromyography B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
train B_LOCATION/B_NUMBER[MEASURE]
- O
of O
- O
four B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
ulnar B_BODY_PART_OR_ORGAN_COMPONENT
nerve I_BODY_PART_OR_ORGAN_COMPONENT
. O

All O
patients O
received O
succinylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
1 O
. O
5 O
mg O
/ O
kg O
at O
2 O
minutes O
after O
the O
precurarization O
, O
and O
were O
assessed O
the O
incidence O
and O
severity O
of O
fasciculations O
, O
while O
myalgia O
was O
assessed O
at O
24 O
hours O
after O
surgery O
. O

Results O
: O
The O
incidence O
and O
severity O
of O
visible O
muscle O
fasciculation O
was O
significantly O
less O
with O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
P O
< O
0 O
. O
001 O
) O
. O

Those O
of O
myalgia O
tend O
to O
decrease O
according O
to O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
but O
there O
was O
no O
significance O
( O
P O
= O
0 O
. O
072 O
) O
. O

The O
onset O
time O
of O
succinylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
significantly O
longer O
with O
increasing O
the O
amount O
of O
precurarizing O
dose O
of O
rocuronium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
P O
< O
0 O
. O
001 O
) O
. O

conclusions O
: O
Precurarization O
with O
0 O
. O
04 O
mg O
/ O
kg O
rocuronium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
the O
optimal O
dose O
considering O
the O
reduction O
in O
the O
incidence O
and O
severity O
of O
fasciculation O
and O
myalgia O
with O
acceptable O
onset O
time O
, O
and O
the O
safe O
and O
effective O
precurarization O
. O

absence O
of O
PKC O
- O
alpha O
attenuates O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
nephrogenic O
diabetes O
insipidus O
. O

Lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
an O
effective O
antipsychotic O
, O
induces O
nephrogenic O
diabetes O
insipidus O
( O
NDI O
) O
in O
40 O
% O
of O
patients O
. O

The O
decreased O
capacity O
to O
concentrate O
urine O
is O
likely O
due O
to O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
acutely O
disrupting O
the O
cAMP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pathway O
and O
chronically O
reducing O
urea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transporter O
( O
UT O
- O
A1 O
) O
and O
water O
channel O
( O
AQP2 O
) O
expression O
in O
the O
inner O
medulla O
. O

targeting O
an O
alternative O
signaling O
pathway O
, O
such O
as O
PKC O
- O
mediated O
signaling O
, O
may O
be O
an O
effective O
method O
of O
treating O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
polyuria O
. O

PKC O
- O
alpha O
null O
mice O
( O
PKCa O
Ko O
) O
and O
strain O
- O
matched O
wild O
type O
( O
WT O
) O
controls O
were O
treated O
with O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
for O
0 O
, O
3 O
or O
5 O
days O
. O

WT B_BIO/B_PERSON
mice I_BIO/I_PERSON
had O
increased O
urine B_MEASURE/B_DISEASE
output I_MEASURE/I_DISEASE
and O
lowered O
urine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
osmolality I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
after O
3 B_NUMBER[MEASURE]
and O
5 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
whereas O
PKCa B_BIO/B_GENE
Ko I_BIO/I_GENE
mice I_BIO/I_GENE
had O
no O
change B_MEASURE
in O
urine B_MEASURE
output I_MEASURE
or O
concentration B_MEASURE
. O

Western B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blot I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O
that O
AQP2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
expression I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
in O
medullary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tissues I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
lowered O
after O
3 B_NUMBER[MEASURE]
and O
5 B_SEQUENCE[MEASURE]/B_ENT
days I_SEQUENCE[MEASURE]/I_ENT
in O
WT B_PROTEIN[GENE]/B_BIO
mice I_PROTEIN[GENE]/I_BIO
; O
however O
, O
AQP2 B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
was O
unchanged B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
PKCa B_PERSON/B_GENE
Ko I_PERSON/I_GENE
. O

Similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
results I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
observed O
with O
UT B_GENE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
A1 B_MEASURE
expression I_MEASURE
. O

Animals O
were O
also O
treated O
with O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
6 O
weeks O
. O

Lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
WT O
mice O
had O
19 O
- O
fold O
increased O
urine O
output O
whereas O
treated O
PKCa O
Ko O
animals O
had O
a O
4 O
- O
fold O
increase O
in O
output O
. O

AQP2 O
and O
UT O
- O
A1 O
expression O
was O
lowered O
in O
6 O
week O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
treated O
WT O
animals O
whereas O
in O
treated O
PKCa O
Ko O
mice O
, O
AQP2 O
was O
only O
reduced O
by O
2 O
- O
fold O
and O
UT O
- O
A1 O
expression O
was O
unaffected O
. O

Urinary O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
elevated O
in O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
fed O
WT O
but O
not O
in O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
fed O
PKCa O
Ko O
mice O
. O

Our O
data O
show O
that O
ablation O
of O
PKCa O
preserves O
AQP2 O
and O
UT O
- O
A1 O
protein O
expression O
and O
localization O
in O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
NDI O
, O
and O
prevents O
the O
development O
of O
the O
severe O
polyuria O
associated O
with O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

Is O
Dysguesia O
Going O
to O
be O
a O
Rare O
or O
a O
Common O
Side O
- O
effect O
of O
Amlodipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE

A O
very O
rare O
side O
- O
effect O
of O
amlodipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
dysguesia O
. O

A O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O
only O
one B_NUMBER[MEASURE]
case I_NUMBER[MEASURE]
. O

We O
report O
a O
case O
about O
a O
female O
with O
essential O
hypertension O
on O
drug O
treatment O
with O
amlodipine B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
developed O
loss O
of O
taste O
sensation O
. O

condition B_PERSON
moderately O
improved O
on O
stoppage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
for O
25 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

We O
conclude O
that O
amlodipine B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
cause O
dysguesia O
. O

Here O
, O
we O
describe O
the O
clinical O
presentation O
and O
review O
the O
relevant O
literature O
on O
amlodipine B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dysguesia O
. O

Rhabdomyolysis O
in O
association O
with O
simvastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
dosage O
increment O
in O
clarithromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

Clarithromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
the O
most O
documented O
cytochrome O
P450 O
3A4 O
( O
CYP3A4 O
) O
inhibitor O
to O
cause O
an O
adverse O
interaction O
with O
simvastatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
particular O
case O
is O
of O
interest O
as O
rhabdomyolysis O
only O
occurred O
after O
an O
increase O
in O
the O
dose O
of O
clarithromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
patient B_PERSON/B_ORGANIZATION
developed O
raised O
cardiac B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
biomarkers B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
without O
any O
obvious B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiac I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
issues I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
a O
phenomenon B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
that O
has O
been O
linked O
to O
rhabdomyolysis B_DISEASE
previously O
. O

To O
date B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
there O
has O
been O
no O
reported O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
of O
rhabdomyolysis B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
structure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
cardiac B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
muscle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Clinicians B_PERSON
need O
to O
be O
aware B_PERSON
of O
prescribing O
concomitant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
medications I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
increase O
the O
risk B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
myopathy B_DISEASE/B_GENE
or O
inhibit O
the O
CYP3A4 B_GENE/B_DISEASE
enzyme B_GENE/I_DISEASE
. O

Our O
case O
suggests O
that O
troponin O
elevation O
could O
be O
associated O
with O
statin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
rhabdomyolysis O
, O
which O
may O
warrant O
further O
studies O
. O

characterization O
of O
a O
novel O
BCHE O
' O
silent O
' O
allele O
: O
point O
mutation O
( O
p O
. O
Val204Asp O
) O
causes O
loss O
of O
activity O
and O
prolonged O
apnea O
with O
suxamethonium B_DISEASE
. O

Butyrylcholinesterase O
deficiency O
is O
characterized O
by O
prolonged O
apnea O
after O
the O
use O
of O
muscle O
relaxants O
( O
suxamethonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O
mivacurium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
in O
patients O
who O
have O
mutations O
in O
the O
BCHE O
gene O
. O

Here O
, O
we O
report O
a O
case O
of O
prolonged O
neuromuscular O
block O
after O
administration O
of O
suxamethonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
leading O
to O
the O
discovery O
of O
a O
novel O
BCHE O
variant O
( O
c O
. O
695T O
> O
A O
, O
p O
. O
Val204Asp O
) O
. O

Inhibition B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
studies I_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
kinetic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
molecular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dynamics I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
undertaken O
to O
understand O
how O
this O
mutation B_CELL_OR_MOLECULAR_DYSFUNCTION[DISEASE]
disrupts O
the O
catalytic B_LOCATION/B_ENZYME[GENE]
triad B_LOCATION/I_ENZYME[GENE]
and O
determines O
a O
' O
silent B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
' O
phenotype B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Low O
activity O
of O
patient O
plasma O
butyrylcholinesterase O
with O
butyrylthiocholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
BTC B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
benzoylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
values O
of O
dibucaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
fluoride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
numbers O
fit O
with O
heterozygous O
atypical O
silent O
genotype O
. O

electrophoretic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
plasma B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
BChE I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
proband B_PERSON
and O
his O
mother B_PERSON
showed O
that O
patient B_PERSON/B_BIO
has O
a O
reduced O
amount B_MEASURE/B_LOCATION
of O
tetrameric B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
enzyme I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
plasma B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
and O
that O
minor B_PERSON/B_NUMBER[MEASURE]
fast O
- O
moving O
BChE B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
components I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
monomer B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
dimer B_GENE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
monomer B_GENE
- O
albumin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conjugate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
missing O
. O

kinetic O
analysis O
showed O
that O
the O
p O
. O
Val204Asp O
/ O
p O
. O
Asp70Gly O
- O
p O
. O
Ala539Thr O
BChE O
displays O
a O
pure O
Michaelian O
behavior O
with O
BTC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
as O
the O
substrate O
. O

Both O
catalytic O
parameters O
km O
= O
265 O
um O
for O
BTC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
two O
times O
higher O
than O
that O
of O
the O
atypical O
enzyme O
, O
and O
a O
low O
Vmax O
are O
consistent O
with O
the O
absence O
of O
activity O
against O
suxamethonium B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
. O

Molecular O
dynamic O
( O
MD O
) O
simulations O
showed O
that O
the O
overall O
effect O
of O
the O
mutation O
p O
. O
Val204Asp O
is O
disruption O
of O
hydrogen B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bonding O
between O
Gln223 O
and O
Glu441 O
, O
leading O
Ser198 O
and O
His438 O
to O
move O
away O
from O
each O
other O
with O
subsequent O
disruption O
of O
the O
catalytic O
triad O
functionality O
regardless O
of O
the O
type O
of O
substrate O
. O

MD B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
also O
showed O
that O
the O
enzyme B_MEASURE
volume I_MEASURE
is O
increased O
, O
suggesting O
a O
pre B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
denaturation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
state B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

This O
fits O
with O
the O
reduced O
concentration B_MEASURE
of O
p B_MEASURE/B_PROTEIN[GENE]
. O
Ala204Asp B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
/ O
p B_PROTEIN[GENE]/B_LOCATION
. O
Asp70Gly B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
- O
p B_PROTEIN[GENE]/B_LOCATION
. O
Ala539Thr B_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
tetrameric I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I_METABOLITE[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
plasma B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
non O
- O
detectable B_DISEASE_ADJECTIVE[DISEASE]
fast I_DISEASE_ADJECTIVE[DISEASE]
moving I_DISEASE_ADJECTIVE[DISEASE]
- O
bands B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
on O
electrophoresis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
gels I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

delayed O
anemia O
after O
treatment O
with O
injectable O
artesunate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
Democratic O
Republic O
of O
the O
Congo O
: O
a O
manageable O
issue O
. O

cases O
of O
delayed O
hemolytic O
anemia O
have O
been O
described O
after O
treatment O
with O
injectable O
artesunate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
current O
World O
Health O
Organization O
( O
WHO O
) O
- O
recommended O
first O
- O
line O
drug O
for O
the O
treatment O
of O
severe O
malaria O
. O

A O
total O
of O
350 O
patients O
( O
215 O
[ O
61 O
. O
4 O
% O
] O
< O
5 O
years O
of O
age O
and O
135 O
[ O
38 O
. O
6 O
% O
] O
> O
5 O
years O
of O
age O
) O
were O
followed O
- O
up O
after O
treatment O
with O
injectable O
artesunate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
severe O
malaria O
in O
hospitals O
and O
health O
centers O
of O
the O
Democratic O
Republic O
of O
the O
Congo O
. O

Complete B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
series I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
hemoglobin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
Hb B_PROTEIN[GENE]
) O
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
201 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patients I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

A O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
Hb B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
between O
2 B_NUMBER[MEASURE]
and O
5 B_MEASURE
g I_MEASURE
/ O
dL B_TIME[MEASURE]/B_PROTEIN[GENE]
was O
detected O
in O
23 B_NUMBER[MEASURE]
( O
11 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
patients B_PERSON/B_BIO
during O
the O
follow O
- O
up O
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

For O
five B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
, O
Hb B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
decreased O
below O
5 B_MEASURE/B_PROTEIN[GENE]
g I_MEASURE/I_PROTEIN[GENE]
/ O
dL B_TIME[MEASURE]/B_PROTEIN[GENE]
during O
at O
least O
one B_NUMBER[MEASURE]/B_PERSON
follow O
- O
up O
visit B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

All O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
delayed B_DISEASE
anemia I_DISEASE
were O
clinically O
manageable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
resolved O
within O
one B_TIME[MEASURE]
month I_TIME[MEASURE]
. O

Regulation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
and O
apoptotic O
pathways O
by O
betaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
attenuates O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
acute O
myocardial O
injury O
in O
rats O
. O

The O
present O
study O
was O
designed O
to O
investigate O
the O
cardioprotective O
effects O
of O
betaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
acute O
myocardial O
ischemia O
induced O
experimentally O
in O
rats O
focusing O
on O
regulation O
of O
signal O
transducer O
and O
activator O
of O
transcription O
3 O
( O
STAT3 O
) O
and O
apoptotic O
pathways O
as O
the O
potential O
mechanism O
underlying O
the O
drug O
effect O
. O

Male O
Sprague O
Dawley O
rats O
were O
treated O
with O
betaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
100 O
, O
200 O
, O
and O
400 O
mg O
/ O
kg O
) O
orally O
for O
40 O
days O
. O

acute O
myocardial O
ischemic O
injury O
was O
induced O
in O
rats O
by O
subcutaneous O
injection O
of O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
85 O
mg O
/ O
kg O
) O
, O
for O
two O
consecutive O
days O
. O

serum B_TIME[MEASURE]/B_LOCATION
cardiac I_TIME[MEASURE]/I_LOCATION
marker I_TIME[MEASURE]/I_LOCATION
enzyme I_TIME[MEASURE]/I_LOCATION
, O
histopathological B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
variables I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
and O
expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
protein B_GENE
levels I_GENE
were O
analyzed O
. O

Oral O
administration O
of O
betaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
200 O
and O
400 O
mg O
/ O
kg O
) O
significantly O
reduced O
the O
level O
of O
cardiac O
marker O
enzyme O
in O
the O
serum O
and O
prevented O
left O
ventricular O
remodeling O
. O

Western O
blot O
analysis O
showed O
that O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
phosphorylation O
of O
STAT3 O
was O
maintained O
or O
further O
enhanced O
by O
betaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O
in O
myocardium O
. O

Furthermore O
, O
betaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
200 O
and O
400 O
mg O
/ O
kg O
) O
treatment O
increased O
the O
ventricular O
expression O
of O
Bcl O
- O
2 O
and O
reduced O
the O
level O
of O
Bax O
, O
therefore O
causing O
a O
significant O
increase O
in O
the O
ratio O
of O
Bcl O
- O
2 O
/ O
Bax O
. O

The O
protective O
role O
of O
betaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
myocardial O
damage O
was O
further O
confirmed O
by O
histopathological O
examination O
. O

In O
summary O
, O
our O
results O
showed O
that O
betaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreatment O
attenuated O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
acute O
myocardial O
ischemia O
via O
the O
regulation O
of O
STAT3 O
and O
apoptotic O
pathways O
. O

Quetiapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
neutropenia O
in O
a O
bipolar O
patient O
with O
hepatocellular O
carcinoma O
. O

objective O
: O
Quetiapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
a O
dibenzothiazepine O
derivative O
, O
similar O
to O
clozapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
has O
the O
highest O
risk O
of O
causing O
blood O
dyscrasias O
, O
especially O
neutropenia O
. O

There O
are O
some O
case O
reports O
about O
this O
side O
effect O
of O
quetiapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
possible O
risk O
factors O
are O
seldom O
discussed O
and O
identified O
. O

A O
case O
of O
a O
patient O
with O
hepatocellular O
carcinoma O
that O
developed O
neutropenia O
after O
treatment O
with O
quetiapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
described O
here O
. O

Case B_MEASURE
Report I_MEASURE
: O
A O
62 B_MEASURE
- O
year B_TIME[MEASURE]
- O
old B_PERSON
Taiwanese I_PERSON
widow I_PERSON
with O
bipolar B_DISEASE
disorder I_DISEASE
was O
diagnosed O
with O
hepatocellular B_DISEASE
carcinoma I_DISEASE
at O
age B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
60 I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

She O
developed O
leucopenia O
after O
being O
treated O
with O
quetiapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

After O
quetiapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
discontinued O
, O
her O
white O
blood O
cell O
count O
returned O
to O
normal O
. O

conclusions O
: O
Although O
neutropenia O
is O
not O
a O
common O
side O
effect O
of O
quetiapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
physicians O
should O
be O
cautious O
about O
its O
presentation O
and O
associated O
risk O
factors O
. O

Hepatic O
dysfunction O
may O
be O
one O
of O
the O
possible O
risk O
factors O
, O
and O
concomitant O
fever O
may O
be O
a O
diagnostic O
marker O
for O
adverse O
reaction O
to O
quetiapine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

lateral O
antebrachial O
cutaneous O
neuropathy O
after O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
injection O
at O
lateral O
epicondyle O
. O

Background O
AND O
objectives O
: O
This O
report O
aimed O
to O
present O
a O
case O
of O
lateral O
antebrachial O
cutaneous O
neuropathy O
( O
LACNP O
) O
that O
occurred O
after O
a O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
injection O
in O
the O
lateral O
epicondyle O
to O
treat O
lateral O
epicondylitis O
in O
a O
40 O
- O
year O
- O
old O
woman O
. O

Material O
AND O
Method O
: O
A O
40 O
- O
year O
- O
old O
woman O
presented O
with O
decreased O
sensation O
and O
paresthesia O
over O
her O
right O
lateral O
forearm O
; O
the O
paresthesia O
had O
occurred O
after O
a O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O
in O
the O
right O
lateral O
epicondyle O
3 O
months O
before O
. O

Her O
sensation B_DISEASE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
light B_DISEASE/B_MEASURE
touch I_DISEASE/I_MEASURE
and O
pain B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
diminished O
over O
the O
lateral B_MEASURE/B_LOCATION
side I_MEASURE/I_LOCATION
of O
the O
right B_BODY_PART_OR_ORGAN_COMPONENT
forearm I_BODY_PART_OR_ORGAN_COMPONENT
and O
wrist B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
area I_BODY_PART_OR_ORGAN_COMPONENT/I_BIO
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
The O
sensory B_MEASURE
action I_MEASURE
potential I_MEASURE
amplitude I_MEASURE
of O
the O
right B_BODY_PART_OR_ORGAN_COMPONENT/B_LOCATION
lateral I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
antebrachial I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
cutaneous I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
nerve I_BODY_PART_OR_ORGAN_COMPONENT/I_LOCATION
( O
LACN B_DISEASE/B_PROTEIN[GENE]
) O
( O
6 B_MEASURE
. O
2 B_MEASURE
UV I_MEASURE
) O
was O
lower B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
that O
of O
the O
left B_BODY_PART_OR_ORGAN_COMPONENT
( O
13 B_MEASURE
. O
1 B_MEASURE/B_PERSON
UV I_MEASURE/I_PERSON
) O
. O

The O
difference B_MEASURE
of O
amplitude B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
both O
sides B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
was O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
because O
there O
was O
more B_MEASURE
than O
a O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
reduction I_MEASURE/I_PERSON
. O

She O
was O
diagnosed O
with O
right B_DISEASE/B_LOCATION
LACNP I_DISEASE/I_LOCATION
( O
mainly O
axonal B_DISEASE_ADJECTIVE[DISEASE]
involvement I_DISEASE_ADJECTIVE[DISEASE]
) O
on O
the O
basis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
the O
clinical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
manifestation I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
electrodiagnostic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
findings I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Her O
symptoms B_DISEASE
improved O
through O
physical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
but O
persisted O
to O
some O
degree B_TIME[MEASURE]/B_LOCATION
. O

conclusion O
: O
This O
report O
describes O
the O
case O
of O
a O
woman O
with O
LACNP O
that O
developed O
after O
a O
steroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
injection O
for O
the O
treatment O
of O
lateral O
epicondylitis O
. O

An O
electrodiagnostic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
including O
a O
nerve B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
conduction I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
the O
LACN B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
, O
was O
helpful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
to O
diagnose O
right B_DISEASE
LACNP I_DISEASE
and O
to O
find O
the O
passage B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
of O
the O
LACN B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
on O
the O
lateral B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
epicondyle I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Curcumin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevents O
maleate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
nephrotoxicity O
: O
relation O
to O
hemodynamic O
alterations O
, O
oxidative O
stress O
, O
mitochondrial O
oxygen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption O
and O
activity O
of O
respiratory O
complex O
I O
. O

The O
potential O
protective O
effect O
of O
the O
dietary O
antioxidant O
curcumin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
120 O
mg O
/ O
kg O
/ O
day O
for O
6 O
days O
) O
against O
the O
renal O
injury O
induced O
by O
maleate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
evaluated O
. O

Tubular O
proteinuria O
and O
oxidative O
stress O
were O
induced O
by O
a O
single O
injection O
of O
maleate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
400 O
mg O
/ O
kg O
) O
in O
rats O
. O

Maleate B_DISEASE
- O
induced O
renal O
injury O
included O
increase O
in O
renal O
vascular O
resistance O
and O
in O
the O
urinary O
excretion O
of O
total O
protein O
, O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
neutrophil O
gelatinase O
- O
associated O
lipocalin O
( O
NGAL O
) O
and O
N O
- O
acetyl O
b O
- O
D O
- O
glucosaminidase O
( O
NAG O
) O
, O
upregulation O
of O
kidney O
injury O
molecule O
( O
Kim O
) O
- O
1 O
, O
decrease O
in O
renal O
blood O
flow O
and O
claudin O
- O
2 O
expression O
besides O
of O
necrosis O
and O
apoptosis O
of O
tubular O
cells O
on O
24 O
h O
. O

Oxidative B_DISEASE
stress I_DISEASE
was O
determined O
by O
measuring O
the O
oxidation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
lipids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
proteins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
diminution B_DISEASE_ADJECTIVE[DISEASE]
in O
renal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
Nrf2 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
levels I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
also O
conducted O
in O
renal B_DISEASE_ADJECTIVE[DISEASE]/B_PROTEIN[GENE]
epithelial B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
LLC B_DISEASE_ADJECTIVE[DISEASE]/I_PROTEIN[GENE]
- O
PK1 B_NUMBER[MEASURE]/B_BIO
cells I_NUMBER[MEASURE]/I_BIO
and O
in O
mitochondria B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
isolated O
from O
kidneys B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
of O
all O
the O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

Maleate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
cell O
damage O
and O
reactive O
oxygen B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
species O
( O
ROS O
) O
production O
in O
LLC O
- O
PK1 O
cells O
in O
culture O
. O

In O
addition O
, O
maleate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O
reduced O
oxygen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption O
in O
ADP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stimulated O
mitochondria O
and O
diminished O
respiratory O
control O
index O
when O
using O
malate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
glutamate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
substrate O
. O

The O
activities B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
both O
complex B_LOCATION/B_PERSON
I O
and O
aconitase B_PROTEIN[GENE]/B_TIME[MEASURE]
were O
also O
diminished O
. O

All O
the O
above O
- O
described O
alterations O
were O
prevented O
by O
curcumin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
concluded O
that O
curcumin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
able O
to O
attenuate O
in O
vivo O
maleate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
nephropathy O
and O
in O
vitro O
cell O
damage O
. O

The O
in O
vivo O
protection O
was O
associated O
to O
the O
prevention O
of O
oxidative O
stress O
and O
preservation O
of O
mitochondrial O
oxygen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption O
and O
activity O
of O
respiratory O
complex O
I O
, O
and O
the O
in O
vitro O
protection O
was O
associated O
to O
the O
prevention O
of O
ROS O
production O
. O

Anticonvulsant O
actions O
of O
MK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
801 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
model O
of O
status O
epilepticus O
in O
rats O
. O

MK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
801 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
noncompetitive O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspartate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NMDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
receptor O
antagonist O
, O
was O
tested O
for O
anticonvulsant O
effects O
in O
rats O
using O
two O
seizure O
models O
, O
coadministration O
of O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
administration O
of O
a O
high O
dose O
of O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
. O

Three B_NUMBER[MEASURE]/B_PERSON
major I_NUMBER[MEASURE]/I_PERSON
results I_NUMBER[MEASURE]/I_PERSON
are O
reported O
. O

First O
, O
pretreatment O
with O
MK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
801 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produced O
an O
effective O
and O
dose O
- O
dependent O
anticonvulsant O
action O
with O
the O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model O
but O
not O
with O
rats O
treated O
with O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
alone O
, O
suggesting O
that O
different O
biochemical O
mechanisms O
control O
seizures O
in O
these O
two O
models O
. O

Second O
, O
the O
anticonvulsant O
effect O
of O
MK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
801 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
model O
only O
occurred O
after O
initial O
periods O
of O
seizure O
activity O
. O

This O
observation O
is O
suggested O
to O
be O
an O
in O
vivo O
demonstration O
of O
the O
conclusion O
derived O
from O
in O
vitro O
experiments O
that O
MK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
801 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
binding O
requires O
agonist O
- O
induced O
opening O
of O
the O
channel O
sites O
of O
the O
NMDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor O
. O

Third O
, O
although O
it O
is O
relatively O
easy O
to O
block O
seizures O
induced O
by O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pilocarpine B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
administration O
of O
anticonvulsants O
prior O
to O
pilocarpine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
it O
is O
more O
difficult O
to O
terminate O
ongoing O
status O
epilepticus O
and O
block O
the O
lethality O
of O
the O
seizures O
. O

Administration O
of O
MK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
801 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
30 O
or O
60 O
min O
after O
pilocarpine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
i O
. O
e O
. O
, O
during O
status O
epilepticus O
, O
gradually O
reduced O
electrical O
and O
behavioral O
seizure O
activity O
and O
greatly O
enhanced O
the O
survival O
rate O
. O

These O
results O
suggest O
that O
activation O
of O
NMDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O
plays O
an O
important O
role O
in O
status O
epilepticus O
and O
brain O
damage O
in O
the O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
model O
. O

This O
was O
further O
supported O
by O
results O
showing O
that O
nonconvulsive O
doses O
of O
NMDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
synergistic O
, O
resulting O
in O
status O
epilepticus O
and O
subsequent O
mortality O
. O

continuous O
infusion O
tobramycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
combined O
with O
carbenicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
infections O
in O
cancer O
patients O
. O

The O
cure B_MEASURE
rate I_MEASURE
of O
infections B_DISEASE
in O
cancer B_PERSON/B_LOCATION
patients I_PERSON/I_LOCATION
is O
adversely O
affected O
by O
neutropenia B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
1 B_MEASURE
, O
000 B_MEASURE
/ O
mm3 B_MEASURE
) O
. O

In O
particular B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
patients B_PERSON/B_BIO
with O
severe B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
neutropenia B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
less B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
than O
100 B_MEASURE
/ O
mm3 B_MEASURE
) O
have O
shown O
a O
poor B_DISEASE_ADJECTIVE[DISEASE]
response I_DISEASE_ADJECTIVE[DISEASE]
to O
antibiotics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

To O
overcome O
the O
adverse O
effects O
of O
neutropenia O
, O
tobramycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
given O
by O
continuous O
infusion O
and O
combined O
with O
intermittent O
carbenicillin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
. O

Tobramycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
given O
to O
a O
total O
daily O
dose O
of O
300 O
mg O
/ O
m2 O
and O
carbenicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
given O
at O
a O
dose O
of O
5 O
GM O
every O
four O
hours O
. O

There O
were O
125 B_DISEASE
infectious I_DISEASE
episodes I_DISEASE
in O
116 B_PERSON/B_BIO
cancer I_PERSON/I_BIO
patients I_PERSON/I_BIO
receiving O
myelosuppressive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
chemotherapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
overall B_MEASURE/B_PERSON
cure I_MEASURE/I_PERSON
rate I_MEASURE/I_PERSON
was O
70 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
. O

pneumonia B_DISEASE
was O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
infection I_DISEASE_ADJECTIVE[DISEASE]
and O
61 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
59 B_PERSON/B_TIME[MEASURE]
episodes I_PERSON/I_TIME[MEASURE]
were O
cured O
. O

Gram B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
bacilli I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
were O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
causative I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
organisms I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
and O
69 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
these O
infections B_DISEASE/B_BIO
were O
cured O
. O

The O
most O
common B_DISEASE_ADJECTIVE[DISEASE]/B_BACTERIUM[BIO]
pathogen I_DISEASE_ADJECTIVE[DISEASE]/I_BACTERIUM[BIO]
was O
Klebsiella B_BACTERIUM[BIO]/B_DISEASE
pneumoniae I_BACTERIUM[BIO]/I_DISEASE
and O
this O
, O
together O
with O
Escherichia B_BACTERIUM[BIO]
coli I_BACTERIUM[BIO]
and O
Pseudomonas B_BACTERIUM[BIO]
aeruginosa I_BACTERIUM[BIO]
, O
accounted O
for O
74 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
all O
gram B_BACTERIUM[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
negative B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
bacillary B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
infections B_DISEASE_ADJECTIVE[DISEASE]/I_BIO
. O

Response B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
not O
influenced O
by O
the O
initial B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
neutrophil B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
count B_MEASURE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
with O
a O
62 B_MEASURE
% I_MEASURE
cure I_MEASURE
rate I_MEASURE
for O
39 B_DISEASE/B_PERSON
episodes I_DISEASE/I_PERSON
associated O
with O
severe B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neutropenia B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
failure B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
neutrophil B_MEASURE
count I_MEASURE
to O
increase O
during O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
adversely O
affected O
response B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Azotemia B_DISEASE
was O
the O
major B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
side B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
effect B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
recognized O
, O
and O
it O
occurred O
in O
11 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
episodes B_ENT/B_PERSON
. O

Major O
azotemia O
( O
serum O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
greater O
than O
2 O
. O
5 O
mg O
/ O
DL O
or O
BUN O
greater O
than O
50 O
mg O
/ O
DL O
) O
occurred O
in O
only O
2 O
% O
. O

Azotemia O
was O
not O
related O
to O
duration O
of O
therapy O
or O
serum O
tobramycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
concentration O
. O

This O
antibiotic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
regimen I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
showed O
both O
therapeutic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
efficacy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
acceptable B_DISEASE_ADJECTIVE[DISEASE]
renal I_DISEASE_ADJECTIVE[DISEASE]
toxicity I_DISEASE_ADJECTIVE[DISEASE]
for O
these O
patients B_PERSON/B_BIO
. O

incidence O
of O
solid O
tumours O
among O
pesticide O
applicators O
exposed O
to O
the O
organophosphate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insecticide O
diazinon B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O
the O
Agricultural O
Health O
Study O
: O
an O
updated O
analysis O
. O

objective O
: O
Diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
a O
common O
organophosphate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
insecticide O
with O
genotoxic O
properties O
, O
was O
previously O
associated O
with O
lung O
cancer O
in O
the O
Agricultural O
Health O
Study O
( O
AHS O
) O
cohort O
, O
but O
few O
other O
epidemiological O
studies O
have O
examined O
diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
associated O
cancer O
risk O
. O

We O
used O
updated O
diazinon B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
exposure O
and O
cancer O
incidence O
information O
to O
evaluate O
solid O
tumour O
risk O
in O
the O
AHS O
. O

methods O
: O
Male O
pesticide O
applicators O
in O
Iowa O
and O
North O
Carolina O
reported O
lifetime O
diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
use O
at O
enrolment O
( O
1993 O
- O
1997 O
) O
and O
follow O
- O
up O
( O
1998 O
- O
2005 O
) O
; O
cancer O
incidence O
was O
assessed O
through O
2010 O
( O
North O
Carolina O
) O
/ O
2011 O
( O
Iowa O
) O
. O

Among O
applicators B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O
usage B_DISEASE
information I_DISEASE
sufficient I_DISEASE
to O
evaluate O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
- O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patterns I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
we O
used O
Poisson B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
regression I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
estimate O
adjusted B_MEASURE/B_DISEASE
rate I_MEASURE/I_DISEASE
ratios I_MEASURE/I_DISEASE
( O
RRs B_LOCATION/B_ORGANIZATION
) O
and O
95 B_MEASURE
% I_MEASURE
CI I_MEASURE
for O
cancer B_LOCATION/B_ORGANIZATION
sites I_LOCATION/I_ORGANIZATION
with O
> B_MEASURE
10 I_MEASURE
exposed O
cases B_PERSON/B_LOCATION
for O
both O
lifetime B_TIME[MEASURE]
( O
Lt B_PERSON/B_LOCATION
) O
exposure B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
and O
intensity B_MEASURE/B_DISEASE
- O
weighted O
( O
IW B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
lifetime B_TIME[MEASURE]/B_ENT
exposure I_TIME[MEASURE]/I_ENT
days I_TIME[MEASURE]/I_ENT
( O
accounting O
for O
factors B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
impacting O
exposure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
) O
. O

Results O
: O
We O
observed O
elevated O
lung O
cancer O
risks O
( O
N O
= O
283 O
) O
among O
applicators O
with O
the O
greatest O
number O
of O
Lt O
( O
RR O
= O
1 O
. O
60 O
; O
95 O
% O
CI O
1 O
. O
11 O
to O
2 O
. O
31 O
; O
Ptrend O
= O
0 O
. O
02 O
) O
and O
IW O
days O
of O
diazinon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
use O
( O
RR O
= O
1 O
. O
41 O
; O
95 O
% O
CI O
0 O
. O
98 O
to O
2 O
. O
04 O
; O
Ptrend O
= O
0 O
. O
08 O
) O
. O

Kidney B_DISEASE/B_MEASURE
cancer I_DISEASE/I_MEASURE
( O
N B_OTHER/B_LOCATION
= O
94 B_MEASURE
) O
risks B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
non B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
significantly O
elevated O
( O
RRLT B_LOCATION
days I_LOCATION
= O
1 B_MEASURE
. O
77 B_MEASURE
; O
95 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
CI I_MEASURE/I_LOCATION
0 I_MEASURE/I_LOCATION
. O
90 B_MEASURE
to O
3 B_MEASURE
. O
51 B_MEASURE
; O
Ptrend B_LOCATION/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
09 B_MEASURE
; O
RRIW B_TIME[MEASURE]
days I_TIME[MEASURE]
1 I_TIME[MEASURE]
. O
37 B_MEASURE
; O
95 B_MEASURE
% I_MEASURE
CI I_MEASURE
0 I_MEASURE
. O
64 B_MEASURE
to O
2 B_MEASURE
. O
92 B_MEASURE
; O
Ptrend B_LOCATION
= O
0 B_MEASURE
. O
50 B_MEASURE
) O
, O
as O
were O
risks B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
aggressive B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
prostate I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
cancer I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
N B_OTHER/B_LOCATION
= O
656 B_MEASURE
) O
. O

conclusions O
: O
Our O
updated O
evaluation O
of O
diazinon B_DISEASE/B_BIO
provides O
additional O
evidence O
of O
an O
association O
with O
lung O
cancer O
risk O
. O

newly O
identified O
links B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
kidney B_DISEASE/B_LOCATION
cancer I_DISEASE/I_LOCATION
and O
associations B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
aggressive B_DISEASE/B_ORGANISM_FUNCTION
prostate I_DISEASE/I_ORGANISM_FUNCTION
cancer I_DISEASE/I_ORGANISM_FUNCTION
require O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

associations O
of O
Ozone B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
PM2 O
. O
5 O
concentrations O
With O
Parkinson O
' O
s O
Disease O
Among O
participants O
in O
the O
Agricultural O
Health O
Study O
. O

objective O
: O
This O
study O
describes O
associations O
of O
ozone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
fine O
particulate B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
matter I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
with O
Parkinson O
' O
s O
disease O
observed O
among O
farmers O
in O
North O
Carolina O
and O
Iowa O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
used O
logistic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
regression I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
to O
determine O
the O
associations B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
pollutants B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O
self B_PERSON/B_LOCATION
- O
reported O
, O
doctor B_PERSON/B_LOCATION
- O
diagnosed O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
. O

Daily O
predicted O
pollutant B_MEASURE/B_LOCATION
concentrations B_MEASURE/I_LOCATION
were O
used O
to O
derive O
surrogates B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
long B_TIME[MEASURE]/B_LOCATION
- O
term B_TIME[MEASURE]/B_LOCATION
exposure I_TIME[MEASURE]/I_LOCATION
and O
link O
them O
to O
study O
participants B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
' I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
geocoded I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
addresses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

Results O
: O
We O
observed O
positive O
associations O
of O
Parkinson O
' O
s O
disease O
with O
ozone B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
odds O
ratio O
= O
1 O
. O
39 O
; O
95 O
% O
CI O
: O
0 O
. O
98 O
to O
1 O
. O
98 O
) O
and O
fine O
particulate B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
matter I_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
odds O
ratio O
= O
1 O
. O
34 O
; O
95 O
% O
CI O
: O
0 O
. O
93 O
to O
1 O
. O
93 O
) O
in O
North O
Carolina O
but O
not O
in O
Iowa O
. O

CONCLUSIONS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
: O
The O
plausibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
of O
an O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
of O
ambient B_NUMBER[MEASURE]/B_LOCATION
concentrations I_NUMBER[MEASURE]/I_LOCATION
of O
these O
pollutants B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
Parkinson B_DISEASE_ADJECTIVE[DISEASE]
' I_DISEASE_ADJECTIVE[DISEASE]
s I_DISEASE_ADJECTIVE[DISEASE]
disease I_DISEASE_ADJECTIVE[DISEASE]
risk I_DISEASE_ADJECTIVE[DISEASE]
is O
supported O
by O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrating O
damage B_DISEASE
to O
dopaminergic B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
neurons I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
at O
relevant B_MEASURE/B_LOCATION
concentrations I_MEASURE/I_LOCATION
. O

Additional B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
needed O
to O
address O
uncertainties B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
related O
to O
confounding O
and O
to O
examine O
temporal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
associations B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
we O
observed O
. O

Low O
functional O
programming O
of O
renal O
AT2R O
mediates O
the O
developmental O
origin O
of O
glomerulosclerosis O
in O
adult O
offspring O
induced O
by O
prenatal O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O
. O

UNASSIGNED O
: O
Our O
previous O
study O
has O
indicated O
that O
prenatal O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O
( O
PCE O
) O
could O
induce O
intrauterine O
growth O
retardation O
( O
IUGR O
) O
of O
offspring O
. O

Recent B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
suggested O
that O
IUGR B_DISEASE
is O
a O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
factor B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
for O
glomerulosclerosis B_DISEASE
. O

However O
, O
whether O
PCE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
could O
induce O
glomerulosclerosis B_DISEASE/B_GENE
and O
its O
underlying B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mechanisms I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
remain O
unknown B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aimed O
to O
demonstrate O
the O
induction B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
glomerulosclerosis O
in O
adult B_PERSON
offspring O
by O
PCE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
its O
intrauterine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
programming I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
mechanisms I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

A O
rat B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
IUGR B_DISEASE
was O
established O
by O
PCE B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
, O
male B_PERSON/B_BIO
fetuses I_PERSON/I_BIO
and O
adult B_PERSON/B_BIO
offspring I_PERSON/I_BIO
at O
the O
age B_TIME[MEASURE]/B_LOCATION
of O
postnatal B_TIME[MEASURE]
week I_TIME[MEASURE]
24 I_TIME[MEASURE]
were O
euthanized O
. O

The O
results O
revealed O
that O
the O
adult O
offspring O
kidneys O
in O
the O
PCE O
group O
exhibited O
glomerulosclerosis O
as O
well O
as O
interstitial O
fibrosis O
, O
accompanied O
by O
elevated O
levels O
of O
serum O
creatinine B_MEASURE/B_GENE
and O
urine O
protein O
. O

Renal O
angiotensin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor O
type O
2 O
( O
AT2R O
) O
gene O
expression O
in O
adult O
offspring O
was O
reduced O
by O
PCE O
, O
whereas O
the O
renal O
angiotensin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
II I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
receptor O
type O
1A O
( O
AT1aR O
) O
/ O
AT2R O
expression O
ratio O
was O
increased O
. O

The O
fetal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
kidneys B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
the O
PCE B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
group I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
displayed O
an O
enlarged O
Bowman B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
' I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
s I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
space I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
a O
shrunken B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glomerular I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tuft I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
accompanied O
by O
a O
reduced O
cortex B_MEASURE/B_DISEASE
width I_MEASURE/I_DISEASE
and O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
nephrogenic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
zone I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
/ O
cortical B_MEASURE/B_LOCATION
zone B_MEASURE/I_LOCATION
ratio B_MEASURE/I_LOCATION
. O

observation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
electronic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
microscope I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
revealed O
structural B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
damage I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
podocytes B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
; O
the O
reduced B_DISEASE_ADJECTIVE[DISEASE]/B_GENE_EXPRESSION_ADJECTIVE[GENE]
expression B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
level B_DISEASE_ADJECTIVE[DISEASE]/I_GENE_EXPRESSION_ADJECTIVE[GENE]
of O
podocyte B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
marker I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
genes I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
, O
nephrin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
and O
podocin B_GENE/B_BACTERIUM[BIO]
, O
was O
also O
detected O
by O
q O
- O
PCR B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Moreover O
, O
AT2R O
gene O
and O
protein O
expressions O
in O
fetal O
kidneys O
were O
inhibited O
by O
PCE O
, O
associated O
with O
the O
repression O
of O
the O
gene O
expression O
of O
glial O
- O
cell O
- O
line O
- O
derived O
neurotrophic O
factor O
( O
GDNF O
) O
/ O
tyrosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
kinase O
receptor O
( O
c O
- O
Ret O
) O
signaling O
pathway O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O
that O
PCE B_DISEASE
could O
induce O
dysplasia B_DISEASE/B_ORGANISM_FUNCTION
of O
fetal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
kidneys I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
as O
well O
as O
glomerulosclerosis B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
of O
adult B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
offspring I_PERSON/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
the O
low B_DISEASE_ADJECTIVE[DISEASE]
functional I_DISEASE_ADJECTIVE[DISEASE]
programming I_DISEASE_ADJECTIVE[DISEASE]
of O
renal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_GENE
AT2R I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_GENE
might O
mediate O
the O
developmental B_DISEASE_ADJECTIVE[DISEASE]
origin I_DISEASE_ADJECTIVE[DISEASE]
of O
adult B_DISEASE
glomerulosclerosis I_DISEASE
. O

1 B_DISEASE
, I_DISEASE
3 I_DISEASE
- I_DISEASE
Butadiene I_DISEASE
, O
CML O
and O
the O
t O
( O
9 O
: O
22 O
) O
translocation O
: O
A O
reality O
check O
. O

UNASSIGNED O
: O
Epidemiological O
studies O
of O
1 B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
, I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
3 I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
- I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
butadiene I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
have O
suggest O
that O
exposures O
to O
humans O
are O
associated O
with O
chronic O
myeloid O
leukemia O
( O
CML O
) O
. O

CML B_DISEASE/B_LOCATION
has O
a O
well O
- O
documented O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
ionizing O
radiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
but O
reports B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
associations B_ORGANIZATION/B_DISEASE
with O
chemical B_DISEASE
exposures I_DISEASE
have O
been O
questioned O
. O

Ionizing O
radiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
capable B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
inducing O
the O
requisite B_DISEASE
CML I_DISEASE
- O
associated O
t B_GENE/B_DISEASE
( O
9 B_MEASURE
: O
22 B_MEASURE
) O
translocation B_GENE/B_DISEASE
( O
Philadelphia B_LOCATION/B_ORGANIZATION
chromosome I_LOCATION/I_ORGANIZATION
) O
in O
appropriate B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vitro B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
, O
thus O
far O
, O
chemicals B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
have O
not O
shown O
this O
capacity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

We O
have O
proposed O
that O
1 B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
, I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
3 I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
- I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
butadiene I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
metabolites O
be O
so O
tested O
as O
a O
reality O
check O
on O
the O
epidemiological O
reports O
. O

In O
order B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
conduct O
reliable B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
this O
regard B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
it O
is O
essential B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
a O
positive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
for O
induction B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
be O
available B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
used O
ionizing O
radiation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
to O
develop O
such O
a O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
described O
here O
demonstrate O
that O
this O
agent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
does O
in O
fact B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induce O
pathogenic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
t O
( O
9 B_MEASURE
: O
22 B_MEASURE
) O
translocations B_DISEASE/B_GENE
in O
a O
human B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
myeloid I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
cell I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
line I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
in O
vitro B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
but O
does O
so O
at O
low B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
frequencies B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

conditions O
that O
will O
be O
required O
for O
studies O
of O
1 B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
3 I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
butadiene I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
are O
discussed O
. O

Cancer O
incidence O
and O
metolachlor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
use O
in O
the O
Agricultural O
Health O
Study O
: O
An O
update O
. O

UNASSIGNED O
: O
Metolachlor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
, O
a O
widely O
used O
herbicide O
, O
is O
classified O
as O
a O
Group O
C O
carcinogen O
by O
the O
U O
. O
S O
. O

Environmental B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Protection B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Agency B_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
based O
on O
increased O
liver B_DISEASE/B_ORGANISM_FUNCTION
neoplasms I_DISEASE/I_ORGANISM_FUNCTION
in O
female B_PERSON/B_BIO
rats I_PERSON/I_BIO
. O

Epidemiologic O
studies O
of O
the O
health O
effects O
of O
metolachlor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
have O
been O
limited O
. O

The O
agricultural B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
Health I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
Study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
AHS B_LOCATION/B_ORGANIZATION
) O
is O
a O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
cohort I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
including O
licensed O
private B_PERSON/B_LOCATION
and O
commercial B_ORGANIZATION/B_PERSON
pesticide B_ORGANIZATION/I_PERSON
applicators B_ORGANIZATION/I_PERSON
in O
Iowa B_LOCATION
and O
North B_LOCATION
Carolina I_LOCATION
enrolled O
1993 B_MEASURE
- O
1997 B_MEASURE
. O

We O
evaluated O
cancer O
incidence O
through O
2010 O
/ O
2011 O
( O
NC O
/ O
IA O
) O
for O
49 O
, O
616 O
applicators O
, O
53 O
% O
of O
whom O
reported O
ever O
using O
metolachlor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O

We O
used O
Poisson O
regression O
to O
evaluate O
relations O
between O
two O
metrics O
of O
metolachlor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
use O
( O
lifetime O
days O
, O
intensity O
- O
weighted O
lifetime O
days O
) O
and O
cancer O
incidence O
. O

We O
saw O
no O
association O
between O
metolachlor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
use O
and O
incidence O
of O
all O
cancers O
combined O
( O
n O
= O
5 O
, O
701 O
with O
a O
5 O
- O
year O
lag O
) O
or O
most O
site O
- O
specific O
cancers O
. O

For O
liver B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
cancer B_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
in O
analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
restricted O
to O
exposed B_PERSON/B_ORGANIZATION
workers I_PERSON/I_ORGANIZATION
, O
elevations B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
observed O
at O
higher B_MEASURE/B_LOCATION
categories B_MEASURE/I_LOCATION
of O
use B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
not O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
trends O
for O
both O
lifetime O
and O
intensity O
- O
weighted O
lifetime O
days O
of O
metolachor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
were O
positive O
and O
statistically O
significant O
with O
an O
unexposed O
reference O
group O
. O

A O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
pattern B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
was O
observed O
for O
follicular B_DISEASE
cell I_DISEASE
lymphoma I_DISEASE
, O
but O
no O
other B_DISEASE/B_MEASURE
lymphoma I_DISEASE/I_MEASURE
subtypes I_DISEASE/I_MEASURE
. O

An O
earlier O
suggestion O
of O
increased O
lung O
cancer O
risk O
at O
high O
levels O
of O
metolachlor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
use O
in O
this O
cohort O
was O
not O
confirmed O
in O
this O
update O
. O

This O
suggestion O
of O
an O
association O
between O
metolachlor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O
liver O
cancer O
among O
pesticide O
applicators O
is O
a O
novel O
finding O
and O
echoes O
observation O
of O
increased O
liver O
neoplasms O
in O
some O
animal O
studies O
. O

However O
, O
our O
findings O
for O
both O
liver O
cancer O
and O
follicular O
cell O
lymphoma O
warrant O
follow O
- O
up O
to O
better O
differentiate O
effects O
of O
metolachlor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
use O
from O
other O
factors O
. O

mechanisms O
underlying O
Latent O
Disease O
Risk O
Associated O
with O
Early O
- O
Life O
Arsenic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O
: O
Current O
Research O
trends O
and O
Scientific O
gaps O
. O

Background O
: O
millions O
of O
individuals O
worldwide O
, O
particularly O
those O
living O
in O
rural O
and O
developing O
areas O
, O
are O
exposed O
to O
harmful O
levels O
of O
inorganic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
arsenic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
iAs B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
in O
their O
drinking O
water O
. O

Inorganic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
As I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
exposure O
during O
key O
developmental O
periods O
is O
associated O
with O
a O
variety O
of O
adverse O
health O
effects O
including O
those O
that O
are O
evident O
in O
adulthood O
. O

There O
is O
considerable O
interest O
in O
identifying O
the O
molecular O
mechanisms O
that O
relate O
early O
- O
life O
iAs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O
to O
the O
development O
of O
these O
latent O
diseases O
, O
particularly O
in O
relationship O
to O
cancer O
. O

objectives O
: O
This O
work O
summarizes O
research O
on O
the O
molecular O
mechanisms O
that O
underlie O
the O
increased O
risk O
of O
cancer O
development O
in O
adulthood O
that O
is O
associated O
with O
early O
- O
life O
iAs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O
. O

discussion O
: O
Epigenetic O
reprogramming O
that O
imparts O
functional O
changes O
in O
gene O
expression O
, O
the O
development O
of O
cancer O
stem O
cells O
, O
and O
immunomodulation O
are O
plausible O
underlying O
mechanisms O
by O
which O
early O
- O
life O
iAs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O
elicits O
latent O
carcinogenic O
effects O
. O

conclusions O
: O
Evidence O
is O
mounting O
that O
relates O
early O
- O
life O
iAs B_HAZARDOUS_OR_POISONOUS_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
exposure O
and O
cancer O
development O
later O
in O
life O
. O

Future B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
research I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
should O
include O
animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O
address O
mechanistic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
hypotheses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
human B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
populations I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
integrate O
early B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
- O
life B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
molecular B_DISEASE_ADJECTIVE[DISEASE]
alterations I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
latent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
disease I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
outcomes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Nifedipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O
bradycardia O
in O
a O
patient O
with O
autonomic O
neuropathy O
. O

An O
80 B_PERSON
year I_PERSON
old I_PERSON
diabetic I_PERSON
male I_PERSON
with O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
peripheral B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
autonomic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
neuropathy I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
admitted O
with O
chest B_DISEASE
pain I_DISEASE
. O

He O
was O
found O
to O
have O
atrial O
flutter O
at O
a O
ventricular O
rate O
of O
70 O
/ O
min O
which O
slowed O
down O
to O
30 O
- O
40 O
/ O
min O
when O
nifedipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
60 O
mg O
) O
in O
3 O
divided O
doses O
, O
during O
which O
he O
was O
paced O
at O
a O
rate O
of O
70 O
/ O
min O
. O

This O
is O
inconsistent O
with O
the O
well O
- O
established O
finding O
that O
nifedipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O
tachycardia O
in O
normally O
innervated O
hearts O
. O

However O
, O
in O
hearts B_PERSON/B_BIO
deprived O
of O
compensatory B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sympathetic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
drive I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
it O
may O
lead O
to O
bradycardia B_DISEASE
. O

The O
effect O
of O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intoxication O
. O

The O
effectiveness O
of O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pretreatment O
in O
preventing O
the O
toxic O
effects O
of O
high O
doses O
of O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
studied O
in O
rats O
. O

In O
this O
model O
, O
toxic O
effects O
were O
induced O
by O
intraperitoneal O
( O
i O
. O
p O
. O
) O
injection O
of O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
75 O
mg O
/ O
kg O
( O
100 O
% O
death O
rate O
) O
or O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
70 O
mg O
/ O
kg O
( O
82 O
% O
death O
rate O
) O
. O

Haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
failed O
to O
prevent O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
seizures O
, O
but O
did O
lower O
the O
mortality O
rate O
at O
most O
doses O
tested O
. O

Haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
decreased O
the O
incidence O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
seizures O
at O
the O
two O
highest O
doses O
, O
but O
the O
lowering O
of O
the O
mortality O
rate O
did O
not O
reach O
statistical O
significance O
at O
any O
dose O
. O

These O
data O
suggest O
a O
protective O
role O
for O
the O
central O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
blocker O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
death O
from O
high O
- O
dose O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O
without O
reducing O
the O
incidence O
of O
seizures O
. O

In O
contrast O
, O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
demonstrated O
an O
ability O
to O
reduce O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
seizures O
without O
significantly O
reducing O
mortality O
. O

Autoradiographic O
evidence O
of O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O
sites O
in O
nuclei O
of O
diethylstilbesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O
hamster O
renal O
carcinomas O
. O

Estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
binding O
sites O
were O
demonstrated O
by O
autoradiography O
in O
one O
transplantable O
and O
five O
primary O
diethylstilbesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induced O
renal O
carcinomas O
in O
three O
hamsters O
. O

Radiolabelling O
, O
following O
the O
in O
vivo O
injection O
of O
3H O
- O
17 O
beta O
estradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
was O
increased O
only O
over O
the O
nuclei O
of O
tumor O
cells O
; O
stereologic O
analysis O
revealed O
a O
4 O
. O
5 O
- O
to O
6 O
. O
7 O
- O
times O
higher O
concentration O
of O
reduced O
silver B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
grains O
over O
nuclei O
than O
cytoplasm O
of O
these O
cells O
. O

Despite O
rapid O
tubular O
excretion O
of O
estradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O
peaked O
in O
less O
than O
1 O
h O
, O
the O
normal O
cells O
did O
not O
appear O
to O
bind O
the O
ligand O
. O

This O
is O
the O
first O
published O
report O
documenting O
the O
preferential O
in O
vivo O
binding O
of O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
nuclei O
of O
cells O
in O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O
hamster O
renal O
carcinomas O
. O

Bradycardia O
due O
to O
biperiden B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

In O
a O
38 O
- O
year O
- O
old O
male O
patient O
suffering O
from O
a O
severe O
postzosteric O
trigeminal O
neuralgia O
, O
intravenous O
application O
of O
10 O
mg O
biperiden B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
lactate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
led O
to O
a O
long O
- O
lasting O
paradoxical O
reaction O
characterized O
by O
considerable O
bradycardia O
, O
dysarthria O
, O
and O
dysphagia O
. O

The O
heart O
rate O
was O
back O
to O
normal O
within O
12 O
hours O
upon O
administration O
of O
orciprenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
under O
cardiac O
monitoring O
in O
an O
intensive O
care O
unit O
. O

Bradycardia O
induced O
by O
biperiden B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
attributed O
to O
the O
speed O
of O
injection O
and O
to O
a O
dose O
- O
related O
dual O
effect O
of O
atropine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
like O
drugs O
on O
muscarine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptors O
. O

deliberate O
hypotension O
induced O
by O
labetalol B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
with O
halothane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
enflurane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O
isoflurane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
middle O
- O
ear O
surgery O
. O

The O
feasibility O
of O
using O
labetalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
an O
alpha O
- O
and O
beta O
- O
adrenergic O
blocking O
agent O
, O
as O
a O
hypotensive O
agent O
in O
combination O
with O
inhalation O
anaesthetics O
( O
halothane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
enflurane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
isoflurane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
was O
studied O
in O
23 O
adult O
patients O
undergoing O
middle O
- O
ear O
surgery O
. O

The O
mean O
arterial O
pressure O
was O
decreased O
from O
86 O
+ O
/ O
- O
5 O
( O
s O
. O
e O
. O
mean O
) O
mmHg O
to O
52 O
+ O
/ O
- O
1 O
mmHg O
( O
11 O
. O
5 O
+ O
/ O
- O
0 O
. O
7 O
to O
6 O
. O
9 O
+ O
/ O
- O
0 O
. O
1 O
kPa O
) O
for O
98 O
+ O
/ O
- O
10 O
min O
in O
the O
halothane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
H B_OTHER/B_PROTEIN[GENE]
) O
group O
, O
from O
79 O
+ O
/ O
- O
5 O
to O
53 O
+ O
/ O
- O
1 O
mmHg O
( O
10 O
. O
5 O
+ O
/ O
- O
0 O
. O
7 O
to O
7 O
. O
1 O
+ O
/ O
- O
0 O
. O
1 O
kPa O
) O
for O
129 O
+ O
/ O
- O
11 O
min O
in O
the O
enflurane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
E B_OTHER/B_PROTEIN[GENE]
) O
group O
, O
and O
from O
80 O
+ O
/ O
- O
4 O
to O
49 O
+ O
/ O
- O
1 O
mmHg O
( O
10 O
. O
7 O
+ O
/ O
- O
0 O
. O
5 O
to O
6 O
. O
5 O
+ O
/ O
- O
0 O
. O
1 O
kPa O
) O
for O
135 O
+ O
/ O
- O
15 O
min O
in O
the O
isoflurane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
I B_OTHER/B_MEASURE
) O
group O
. O

The O
mean O
H B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
concentration O
during O
hypotension O
in O
the O
inspiratory O
gas O
was O
0 O
. O
7 O
+ O
/ O
- O
0 O
. O
1 O
vol O
% O
, O
the O
mean O
E B_OTHER/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O
1 O
. O
6 O
+ O
/ O
- O
0 O
. O
2 O
vol O
% O
, O
and O
the O
mean O
I B_OTHER/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O
1 O
. O
0 O
+ O
/ O
- O
0 O
. O
1 O
vol O
% O
. O

In O
addition O
, O
the O
patients O
received O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tubocurarine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
initial O
dose O
of O
labetalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
lowering O
blood O
pressure O
was O
similar O
, O
0 O
. O
52 O
- O
0 O
. O
59 O
mg O
/ O
kg O
, O
in O
all O
the O
groups O
. O

During O
hypotension B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
the O
heart B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
rate B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
was O
stable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
without O
tachy B_DISEASE
- O
or O
bradycardia B_DISEASE
. O

The O
operating B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
conditions I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
regarding O
bleeding B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
estimated O
in O
a O
double B_MEASURE/B_COLOR
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
manner I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
and O
did O
not O
differ O
significantly O
between O
the O
groups B_ORGANIZATION/B_PERSON
. O

During O
hypotension O
, O
the O
serum O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentration O
rose O
significantly O
in O
all O
groups O
from O
the O
values O
before O
hypotension O
and O
returned O
postoperatively O
to O
the O
initial O
level O
in O
the O
other O
groups O
, O
except O
the O
isoflurane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O
. O

After O
hypotension B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
there O
was O
no O
rebound B_DISEASE_ADJECTIVE[DISEASE]
phenomenon I_DISEASE_ADJECTIVE[DISEASE]
in O
either O
blood B_DISEASE/B_PROTEIN[GENE]
pressure B_DISEASE/I_PROTEIN[GENE]
or O
heart B_MEASURE/B_DISEASE
rate B_MEASURE/I_DISEASE
. O

These O
results O
indicate O
that O
labetalol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
induces O
easily O
adjustable O
hypotension O
without O
compensatory O
tachycardia O
and O
rebound O
hypertension O
. O

Convulsion O
following O
intravenous O
fluorescein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
angiography O
. O

Tonic O
- O
clonic O
seizures O
followed O
intravenous O
fluorescein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection O
for O
fundus O
angiography O
in O
a O
47 O
- O
year O
- O
old O
male O
. O

Despite O
precautions O
this O
adverse O
reaction O
recurred O
on O
re O
- O
exposure O
to O
intravenous O
fluorescein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pharmacology O
of O
ACC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prodrug O
) O
. O

ACC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
9653 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
the O
disodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ester I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydroxymethyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diphenylhydantoin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
is O
a O
prodrug O
of O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
advantageous O
physicochemical O
properties O
. O

ACC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
rapidly O
converted O
enzymatically O
to O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vivo O
. O

ACC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
equivalent O
anticonvulsant O
activity O
against O
seizures O
induced O
by O
maximal O
electroshock O
( O
MES O
) O
in O
mice O
following O
i O
. O
p O
. O
, O
oral O
, O
or O
i O
. O
v O
. O
administration O
. O

The O
ED50 O
doses O
were O
16 O
mg O
/ O
kg O
for O
i O
. O
v O
. O
ACC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
8 O
mg O
/ O
kg O
for O
i O
. O
v O
. O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

ACC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
similar O
antiarrhythmic O
activity O
against O
ouabain B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
ventricular O
tachycardia O
in O
anesthetized O
dogs O
. O

The O
total O
doses O
of O
ACC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
necessary O
to O
convert O
the O
arrhythmia O
to O
a O
normal O
sinus O
rhythm O
were O
24 O
+ O
/ O
- O
6 O
and O
14 O
+ O
/ O
- O
3 O
mg O
/ O
kg O
, O
respectively O
. O

Only O
phenytoin B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
displayed O
in O
vitro O
antiarrhythmic O
activity O
against O
strophanthidin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
arrhythmias O
in O
Guinea O
pig O
right O
atria O
. O

In O
anesthetized O
dogs O
, O
a O
high O
dose O
of O
ACC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
31 O
mg O
/ O
kg O
) O
was O
infused O
over O
15 O
, O
20 O
, O
and O
30 O
min O
and O
the O
responses O
were O
compared O
to O
an O
equimolar O
dose O
of O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
21 O
mg O
/ O
kg O
) O
. O

The O
ACC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatments O
produced O
similar O
marked O
reductions O
in O
diastolic O
blood O
pressure O
and O
contractile O
force O
( O
LVdP O
/ O
dt O
) O
. O

The O
maximum O
effects O
of O
each O
treatment O
occurred O
at O
the O
time O
of O
maximum O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
levels O
. O

acute O
toxicity O
studies O
of O
ACC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
carried O
out O
in O
mice O
, O
rats O
, O
rabbits O
, O
and O
dogs O
by O
i O
. O
v O
. O
, O
i O
. O
m O
. O
, O
and O
i O
. O
p O
. O
routes O
of O
administration O
. O

The O
systemic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxic B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signs B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
both O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
were O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
occurred O
at O
approximately O
equivalent B_MEASURE/B_LOCATION
doses I_MEASURE/I_LOCATION
. O

importantly O
, O
the O
local O
irritation O
of O
ACC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
9653 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
markedly O
less O
than O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sodium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
following O
i O
. O
m O
. O
administration O
. O
( O
abstract O
TRUNCATED O
AT O
250 O
Words O
) O
. O

Tachyphylaxis O
to O
systemic O
but O
not O
to O
airway O
responses O
during O
prolonged O
therapy O
with O
high O
dose O
inhaled O
salbutamol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
asthmatics O
. O

High O
doses O
of O
inhaled O
salbutamol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
produce O
substantial O
improvements O
in O
airway O
response O
in O
patients O
with O
asthma O
, O
and O
are O
associated O
with O
dose O
- O
dependent O
systemic O
beta O
- O
adrenoceptor O
responses O
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
investigate O
whether O
tachyphylaxis O
occurs O
during O
prolonged O
treatment O
with O
high O
dose O
inhaled O
salbutamol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Twelve O
asthmatic O
patients O
( O
FEV1 O
, O
81 O
+ O
/ O
- O
4 O
% O
predicted O
) O
, O
requiring O
only O
occasional O
inhaled O
beta O
- O
agonists O
as O
their O
sole O
therapy O
, O
were O
given O
a O
14 O
- O
day O
treatment O
with O
high O
dose O
inhaled O
salbutamol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
HDS O
) O
, O
4 O
, O
000 O
micrograms O
daily O
, O
low O
dose O
inhaled O
salbutamol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
LDS O
) O
, O
800 O
micrograms O
daily O
, O
or O
placebo O
( O
Pi O
) O
by O
metered O
- O
dose O
inhaler O
in O
a O
double O
- O
blind O
, O
randomized O
crossover O
design O
. O

During O
the O
14 O
- O
day O
run O
- O
in O
and O
during O
washout O
periods O
, O
inhaled O
beta O
- O
agonists O
were O
withheld O
and O
ipratropium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bromide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
substituted O
for O
rescue O
purposes O
. O

At O
the O
end O
of O
each O
14 O
- O
day O
treatment O
, O
a O
dose O
- O
response O
curve O
( O
DRC O
) O
was O
performed O
, O
and O
airway O
( O
FEV1 O
, O
FEF25 O
- O
75 O
) O
chronotropic O
( O
HR O
) O
, O
tremor O
, O
and O
metabolic O
( O
K B_OTHER/B_LOCATION
, O
Glu B_LOCATION/B_PERSON
) O
responses O
were O
measured O
at O
each O
step O
( O
from O
100 O
to O
4 O
, O
000 O
micrograms O
) O
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
had O
no O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
baseline B_DISEASE
values I_DISEASE
. O

There O
were O
dose B_MEASURE
- O
dependent B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increases I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
FEV1 B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
FEF25 B_LOCATION
- O
75 B_MEASURE
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE/B_LOCATION
. O
001 B_MEASURE
) O
, O
and O
pretreatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
with O
HDS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
did O
not O
displace O
the O
DRC B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
to O
the O
right B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

DRC O
for O
HR O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
K B_OTHER/B_LOCATION
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
and O
Glu B_LOCATION/B_PERSON
( O
p O
less O
than O
0 O
. O
005 O
) O
were O
attenuated O
after O
treatment O
with O
HDS O
compared O
with O
Pi O
. O

There O
were O
also O
differences O
between O
HDS O
and O
LDS O
for O
HR O
( O
p O
less O
than O
0 O
. O
001 O
) O
and O
Glu B_LOCATION/B_PROTEIN[GENE]
( O
p O
less O
than O
0 O
. O
05 O
) O
responses O
. O

frequency B_MEASURE
and O
severity B_MEASURE
of O
subjective B_DISEASE
adverse I_DISEASE
effects I_DISEASE
were O
also O
reduced O
after O
HDS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
: O
tremor B_DISEASE
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE
. O
001 B_MEASURE
) O
, O
palpitations B_DISEASE
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE
. O
001 B_MEASURE
) O
. O
( O
abstract B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TRUNCATED O
AT O
250 B_LOCATION/B_ENT
Words I_LOCATION/I_ENT
) O
. O

Phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
induced O
fatal O
hepatic O
injury O
. O

A O
61 O
year O
old O
female O
developed O
fatal O
hepatic O
failure O
after O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
. O

A O
typical B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
multisystem I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
clinical I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pattern I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
precedes O
the O
manifestations B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
hepatic B_DISEASE/B_LOCATION
injury I_DISEASE/I_LOCATION
. O

The O
hematologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pathologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
features I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
indicate O
a O
mixed B_DISEASE
hepatocellular I_DISEASE
damage I_DISEASE
due O
to O
drug B_DISEASE
hypersensitivity I_DISEASE
. O

In O
a O
patient O
receiving O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
who O
presents O
a O
viral O
- O
like O
illness O
, O
early O
recognition O
and O
discontinuation O
of O
the O
drug O
are O
mandatory O
. O

Treatment O
of O
lethal O
pertussis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
vaccine B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
reaction O
with O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
H1 O
antagonists O
. O

We O
studied O
mortality B_DISEASE
after O
pertussis B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immunization I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
mouse B_BIO/B_LOCATION
. O

Without O
treatment B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
73 B_MEASURE
of O
92 B_PERSON
animals I_PERSON
( O
80 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
died O
after O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
bovine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
serum I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
albumin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
BSA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
on O
day B_TIME[MEASURE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 B_TIME[MEASURE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
pertussis B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
immunization I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

After O
pretreatment O
with O
3 O
mg O
of O
cyproheptadine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
2 O
mg O
mianserin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
2 O
mg O
chlorpheniramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
only O
5 O
of O
105 O
animals O
( O
5 O
% O
) O
died O
after O
receiving O
BSA O
on O
day O
+ O
7 O
( O
p O
less O
than O
0 O
. O
001 O
) O
. O

blockade O
of O
histamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
H1 O
receptors O
may O
reduce O
mortality O
in O
pertussis O
immunization O
- O
induced O
encephalopathy O
in O
mice O
. O

Support O
for O
adrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
hypertension O
hypothesis O
: O
18 O
hour O
pressor O
effect O
after O
6 O
hours O
adrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
. O

In O
a O
double O
blind O
, O
crossover O
study O
6 O
h O
infusions O
of O
adrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
15 O
ng O
/ O
kg O
/ O
min O
; O
1 O
ng O
= O
5 O
. O
458 O
pmol O
) O
, O
noradrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
30 O
ng O
/ O
kg O
/ O
min O
; O
1 O
ng O
= O
5 O
. O
911 O
pmol O
) O
, O
and O
a O
5 O
% O
dextrose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution O
( O
5 O
. O
4 O
ml O
/ O
h O
) O
, O
were O
given O
to O
ten O
healthy O
volunteers O
in O
random O
order O
2 O
weeks O
apart O
. O

By O
means B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intra B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
arterial B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
ambulatory I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
monitoring I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
the O
haemodynamic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
followed O
for O
18 B_MEASURE
h O
after O
the O
infusions B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
stopped O
. O

Adrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
but O
not O
noradrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
caused O
a O
delayed O
and O
protracted O
pressor O
effect O
. O

Over O
the O
total O
postinfusion O
period O
systolic O
and O
diastolic O
arterial O
pressure O
were O
6 O
( O
SEM O
2 O
) O
% O
and O
7 O
( O
2 O
) O
% O
, O
respectively O
, O
higher O
than O
after O
dextrose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
infusion O
( O
ANOVA O
, O
p O
less O
than O
0 O
. O
001 O
) O
. O

Thus O
, O
' O
stress O
' O
levels O
of O
adrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
230 O
pg O
/ O
ml O
) O
for O
6 O
h O
cause O
a O
delayed O
and O
protracted O
pressor O
effect O
. O

These O
findings O
are O
strong O
support O
for O
the O
adrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
hypertension O
hypothesis O
in O
man O
. O

Effect O
of O
alkylxanthines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
acute O
renal O
failure O
in O
the O
rat O
. O

Adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonists O
have O
been O
previously O
shown O
to O
be O
of O
benefit O
in O
some O
ischaemic O
and O
nephrotoxic O
models O
of O
acute O
renal O
failure O
( O
ARF O
) O
. O

In O
the O
present O
study O
, O
the O
effects O
of O
three O
alkylxanthines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
with O
different O
potencies O
as O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonists O
8 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
phenyltheophylline I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, O
theophylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
enprofylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
were O
examined O
in O
rats O
developing O
acute O
renal O
failure O
after O
4 O
daily O
injections O
of O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
200 O
mg O
kg O
- O
1 O
) O
. O

Renal O
function O
was O
assessed O
by O
biochemical O
( O
plasma O
urea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
, O
functional O
( O
urine O
analysis O
and O
[ O
3H O
] O
inulin O
and O
[ O
14C O
] O
p B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminohippuric I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
clearances O
) O
and O
morphological O
( O
degree O
of O
necrosis O
) O
indices O
. O

The O
various B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
drug I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatments I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
produced O
improvements B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
some O
, O
but O
not O
all O
, O
measurements B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
renal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

However O
, O
any O
improvement O
produced O
by O
drug O
treatment O
was O
largely O
a O
result O
of O
a O
beneficial O
effect O
exerted O
by O
its O
vehicle O
( O
polyethylene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
glycol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
NaOH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
lack O
of O
any O
consistent O
protective O
effect O
noted O
with O
the O
alkylxanthines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tested O
in O
the O
present O
study O
indicates O
that O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plays O
little O
, O
if O
any O
, O
pathophysiological O
role O
in O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
ARF O
. O

adverse O
ocular O
reactions O
possibly O
associated O
with O
isotretinoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
total O
of O
261 O
adverse O
ocular O
reactions O
occurred O
in O
237 O
patients O
who O
received O
isotretinoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
commonly O
used O
drug O
in O
the O
treatment O
of O
severe O
cystic O
acne O
. O

Blepharoconjunctivitis B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
subjective B_DISEASE_ADJECTIVE[DISEASE]
complaints I_DISEASE_ADJECTIVE[DISEASE]
of O
dry B_DISEASE
eyes I_DISEASE
, O
blurred B_DISEASE
vision I_DISEASE
, O
contact B_DISEASE
lens I_DISEASE
intolerance I_DISEASE
, O
and O
photodermatitis B_DISEASE
are O
reversible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
side I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

More O
serious B_DISEASE_ADJECTIVE[DISEASE]
ocular I_DISEASE_ADJECTIVE[DISEASE]
adverse I_DISEASE_ADJECTIVE[DISEASE]
reactions I_DISEASE_ADJECTIVE[DISEASE]
include O
papilledema B_DISEASE
, O
pseudotumor B_DISEASE
cerebri I_DISEASE
, O
and O
white B_COLOR
or O
gray B_DISEASE
subepithelial I_DISEASE
corneal I_DISEASE
opacities I_DISEASE
; O
all O
of O
these O
are O
reversible B_DISEASE_ADJECTIVE[DISEASE]
if O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
discontinued O
. O

reported O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
decreased B_DISEASE
dark I_DISEASE
adaptation I_DISEASE
are O
under O
investigation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Isotretinoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
contraindicated O
in O
pregnancy O
because O
of O
the O
many O
reported O
congenital O
abnormalities O
after O
maternal O
use O
( O
including O
microphthalmos O
, O
orbital O
hypertelorism O
, O
and O
optic O
nerve O
hypoplasia O
) O
. O

Procaterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
terbutaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
bronchial O
asthma O
. O

A O
double B_MEASURE/B_PERSON
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
placebo B_LOCATION/B_PERSON
- O
controlled O
, O
cross O
- O
over O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Procaterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
a O
new O
beta O
- O
2 O
adrenoceptor O
stimulant O
, O
was O
studied O
in O
a O
double O
- O
blind O
, O
placebo O
- O
controlled O
, O
cross O
- O
over O
trial O
in O
patients O
with O
bronchial O
asthma O
. O

Oral O
procaterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O
micrograms O
b O
. O
d O
. O
, O
procaterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100 O
micrograms O
b O
. O
d O
. O
, O
and O
terbutaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O
mg O
t O
. O
i O
. O
d O
. O
, O
were O
compared O
when O
given O
randomly O
in O
1 O
- O
week O
treatment O
periods O
. O

The O
best O
clinical O
effect O
was O
found O
with O
terbutaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Both O
anti O
- O
asthmatic O
and O
tremorgenic O
effects O
of O
procaterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
dose O
- O
related O
. O

Procaterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O
effective O
in O
the O
doses O
tested O
, O
and O
a O
twice O
daily O
regimen O
would O
appear O
to O
be O
suitable O
with O
this O
drug O
. O

Subacute O
effects O
of O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
B O
24 O
/ O
76 O
on O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
rat O
heart O
hypertrophy O
in O
correlation O
with O
blood O
pressure O
. O

We O
compared O
the O
potential O
beta O
- O
receptor O
blocker O
, O
B O
24 O
/ O
76 O
i O
. O
e O
. O
1 O
- O
( O
2 O
, O
4 O
- O
dichlorophenoxy O
) O
- O
3 O
[ O
2 O
- O
3 O
, O
4 O
- O
dimethoxyphenyl O
) O
ethanolamino O
] O
- O
prop O
an O
- O
2 O
- O
ol O
, O
which O
is O
characterized O
by O
beta O
1 O
- O
adrenoceptor O
blocking O
and O
beta O
2 O
- O
adrenoceptor O
stimulating O
properties O
with O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
studies O
were O
performed O
using O
an O
experimental O
model O
of O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
heart O
hypertrophy O
in O
rats O
. O

A O
correlation B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
blood B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pressure I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
neither O
found O
in O
the O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
nor O
in O
the O
attempt B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
suppress O
the O
development B_DISEASE_ADJECTIVE[DISEASE]
of O
heart B_DISEASE/B_GENE
hypertrophy I_DISEASE/I_GENE
with O
the O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
beta B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- O
receptor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
blockers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Both O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
blockers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
influenced O
the O
development B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
hypertrophy B_DISEASE
to O
a O
different B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
reproducible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extent I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
was O
possible O
to O
suppress O
the O
increased O
ornithine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decarboxylase O
activity O
with O
both O
beta O
- O
blockers O
in O
hypertrophied O
hearts O
, O
but O
there O
was O
no O
effect O
on O
the O
heart O
mass O
. O

Neither O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nor O
B O
24 O
/ O
76 O
could O
stop O
the O
changes O
in O
the O
characteristic O
myosin O
isoenzyme O
pattern O
of O
the O
hypertrophied O
rat O
heart O
. O

Thus O
, O
the O
investigations O
did O
not O
provide O
any O
evidence O
that O
the O
beta O
- O
receptor O
blockers O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
B O
24 O
/ O
76 O
have O
the O
potency O
to O
prevent O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
producing O
heart O
hypertrophy O
. O

increased O
anxiogenic O
effects O
of O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
panic O
disorders O
. O

The O
effects O
of O
oral O
administration O
of O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 O
mg O
/ O
kg O
) O
on O
behavioral O
ratings O
, O
somatic O
symptoms O
, O
blood O
pressure O
and O
plasma O
levels O
of O
3 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methoxy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydroxyphenethyleneglycol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MHPG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
and O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
determined O
in O
17 O
healthy O
subjects O
and O
21 O
patients O
meeting O
DSM O
- O
III O
criteria O
for O
agoraphobia O
with O
panic O
attacks O
or O
panic O
disorder O
. O

Caffeine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
produced O
significantly O
greater O
increases O
in O
subject O
- O
rated O
anxiety O
, O
nervousness O
, O
fear O
, O
nausea O
, O
palpitations O
, O
restlessness O
, O
and O
tremors O
in O
the O
patients O
compared O
with O
healthy O
subjects O
. O

In O
the O
patients O
, O
but O
not O
the O
healthy O
subjects O
, O
these O
symptoms O
were O
significantly O
correlated O
with O
plasma O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
. O

seventy O
- O
one O
percent O
of O
the O
patients O
reported O
that O
the O
behavioral O
effects O
of O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
similar O
to O
those O
experienced O
during O
panic O
attacks O
. O

Caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
did O
not O
alter O
plasma O
MHPG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels O
in O
either O
the O
healthy O
subjects O
or O
patients O
. O

Caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
increased O
plasma O
cortisol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
equally O
in O
the O
patient O
and O
healthy O
groups O
. O

Because O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
an O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O
antagonist O
, O
these O
results O
suggest O
that O
some O
panic O
disorder O
patients O
may O
have O
abnormalities O
in O
neuronal O
systems O
involving O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

patients O
with O
anxiety O
disorders O
may O
benefit O
by O
avoiding O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
containing O
foods O
and O
beverages O
. O

comparison O
of O
the O
effect O
of O
oxitropium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bromide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
of O
slow O
- O
release O
theophylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
nocturnal O
asthma O
. O

The O
effects O
of O
a O
new O
inhaled O
antimuscarinic O
drug O
, O
oxitropium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bromide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
of O
a O
slow O
- O
release O
theophylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparation O
upon O
nocturnal O
asthma O
were O
compared O
in O
a O
placebo O
- O
controlled O
double O
- O
blind O
study O
. O

Two O
samples O
were O
studied O
: O
12 O
patients O
received O
oxitropium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
600 O
micrograms O
( O
6 O
subjects O
) O
or O
at O
400 O
micrograms O
t O
. O
i O
. O
d O
. O

( O
6 O
subjects O
) O
whereas O
11 O
received O
theophylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
300 O
mg O
b O
. O
i O
. O
d O
. O

morning B_DISEASE
dipping I_DISEASE
, O
assessed O
by O
the O
fall B_DISEASE/B_MEASURE
in O
peak B_MEASURE/B_PROTEIN[GENE]
flow B_MEASURE/I_PROTEIN[GENE]
overnight O
, O
was O
significantly O
reduced O
in O
the O
periods B_TIME[MEASURE]/B_LOCATION
when O
either O
active B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drug I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
was O
taken O
, O
whereas O
no O
difference B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
was O
noticed O
during O
the O
placebo B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
administration I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

No O
significant O
difference O
was O
noticed O
between O
results O
obtained O
with O
either O
active O
drug O
, O
as O
well O
as O
with O
either O
dosage O
of O
oxitropium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

No O
subject O
reported O
side O
effects O
of O
oxitropium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
compared O
to O
three O
subjects O
reporting O
nausea O
, O
vomiting O
and O
tremors O
after O
theophylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Oxitropium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
proves O
to O
be O
a O
valuable O
alternative O
to O
theophylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
nocturnal O
asthma O
, O
since O
it O
is O
equally O
potent O
, O
safer O
and O
does O
not O
require O
the O
titration O
of O
dosage O
. O

Penicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anaphylaxis O
. O

A O
case O
of O
oral O
penicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anaphylaxis O
is O
described O
, O
and O
the O
terminology O
, O
occurrence O
, O
clinical O
manifestations O
, O
pathogenesis O
, O
prevention O
, O
and O
treatment O
of O
anaphylaxis O
are O
reviewed O
. O

Emergency O
physicians O
should O
be O
aware O
of O
oral O
penicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anaphylaxis O
in O
order O
to O
prevent O
its O
occurrence O
by O
prescribing O
the O
antibiotic O
judiciously O
and O
knowledgeably O
and O
to O
offer O
optimal O
medical O
therapy O
once O
this O
life O
- O
threatening O
reaction O
has O
begun O
. O

Reversible O
valproic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
dementia O
: O
a O
case O
report O
. O

Reversible O
valproic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
dementia O
was O
documented O
in O
a O
21 O
- O
year O
- O
old O
man O
with O
epilepsy O
who O
had O
a O
3 O
- O
year O
history O
of O
insidious O
progressive O
decline O
in O
global O
cognitive O
abilities O
documented O
by O
serial O
neuropsychological O
studies O
. O

repeat O
neuropsychological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
testing I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
weeks I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
discontinuation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
dramatic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
improvement I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
IQ B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
memory B_PERSON/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
naming B_TIME[MEASURE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
other B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
tasks I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
commensurate I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
with O
clinical B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
his O
intellectual B_MEASURE/B_PERSON
capacity I_MEASURE/I_PERSON
. O

possible O
pathophysiological O
mechanisms O
which O
may O
have O
been O
operative O
in O
this O
case O
include O
: O
a O
direct O
central O
nervous O
system O
( O
CNS O
) O
toxic O
effect O
of O
valproic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
a O
paradoxical O
epileptogenic O
effect O
secondary O
to O
the O
drug O
; O
and O
an O
indirect O
CNS O
toxic O
effect O
mediated O
through O
valproic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hyperammonemia O
. O

reversal O
of O
scopolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
amnesia O
of O
passive O
avoidance O
by O
pre O
- O
and O
post O
- O
training O
naloxone B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
a O
series O
of O
five O
experiments O
, O
the O
modulating O
role O
of O
naloxone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
a O
scopolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
retention O
deficit O
in O
a O
passive O
avoidance O
paradigm O
was O
investigated O
in O
mice O
. O

Scopolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
but O
not O
methyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
scopolamine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
1 O
and O
3 O
mg O
/ O
kg O
) O
, O
induced O
an O
amnesia O
as O
measured O
by O
latency O
and O
duration O
parameters O
. O

Naloxone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
0 O
. O
3 O
, O
1 O
, O
3 O
, O
and O
10 O
mg O
/ O
kg O
) O
injected O
prior O
to O
training O
attenuated O
the O
retention O
deficit O
with O
a O
peak O
of O
activity O
at O
3 O
mg O
/ O
kg O
. O

The O
effect O
of O
naloxone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
could O
be O
antagonized O
with O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 O
, O
3 O
, O
and O
10 O
mg O
/ O
kg O
) O
, O
demonstrating O
the O
opioid O
specificity O
of O
the O
naloxone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect O
. O

Post O
- O
training O
administration O
of O
naloxone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3 O
mg O
/ O
kg O
) O
as O
a O
single O
or O
as O
a O
split O
dose O
also O
attenuated O
the O
scopolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
amnesia O
. O

Control O
experiments O
indicated O
that O
neither O
an O
increase O
in O
pain O
sensitivity O
( O
pre O
- O
training O
naloxone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
nor O
an O
induced O
aversive O
state O
( O
post O
- O
training O
naloxone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
appear O
to O
be O
responsible O
for O
the O
influence O
of O
naloxone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
the O
scopolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
retention O
deficit O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
extend O
previous B_LOCATION/B_MEASURE
findings I_LOCATION/I_MEASURE
implicating O
a O
cholinergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
opioid B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
interaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
memory B_DISEASE
processes I_DISEASE
. O

A O
possible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
mechanism I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
this O
interaction B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involving O
the O
septo B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
hippocampal B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
cholinergic I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
pathway I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
is O
discussed O
. O

electron O
microscopic O
investigations O
of O
the O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
lesions O
of O
the O
urinary O
bladder O
of O
the O
rat O
and O
their O
prevention O
by O
mesna B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

fully O
developed O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cystitis O
is O
characterized O
by O
nearly O
complete O
detachment O
of O
the O
urothelium O
, O
severe O
submucosal O
edema O
owing O
to O
damage O
to O
the O
microvascular O
bed O
and O
focal O
muscle O
necroses O
. O

The O
initial O
response O
to O
the O
primary O
attack O
by O
the O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolites O
seems O
to O
be O
fragmentation O
of O
the O
luminal B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
membrane O
. O

This O
damages O
the O
cellular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
barrier I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
against O
the O
hypertonic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
urine I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Subsequent B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
breaks I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
the O
lateral B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cell I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
membranes I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
superficial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE
and O
in O
all O
the O
plasma B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
membranes I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
intermediate B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
basal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
intercellular B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE
and O
intracellular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
edema I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
disintegration B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
desmosomes B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
and O
hemidesmosomes B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
lead O
to O
progressive B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
degeneration I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
detachment B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
epithelial B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O
exposure B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
splitting B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
basal B_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
membrane I_CELL_COMPONENT[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
morphological B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
endothelial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
which O
become O
more O
pronounced O
in O
the O
later B_TIME[MEASURE]/B_LOCATION
stages I_TIME[MEASURE]/I_LOCATION
of O
the O
experiment B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
involvement B_DISEASE/B_MEASURE
of O
blood B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
vessels I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
regardless O
of O
their O
diameter B_MEASURE/B_LOCATION
and O
the O
location B_MEASURE
- O
dependent B_MEASURE/B_LOCATION
extent I_MEASURE/I_LOCATION
of O
the O
damage B_DISEASE
indicate O
a O
direct B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
type B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
damage B_DISEASE
which O
is O
preceded O
by O
a O
mediator B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
permeability B_DISEASE/B_MEASURE
, O
the O
morphological B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
correlate I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
which O
is O
the O
formation B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
of O
gaps B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
interendothelial B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
cell B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
connections B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
on O
the O
venules B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
changes O
can O
be O
effectively O
prevented O
by O
mesna B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

The O
only B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sign I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
possible B_DISEASE
involvement I_DISEASE
is O
the O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
number B_MEASURE/B_LOCATION
of O
specific B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
granules I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
with O
a O
presumed B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
lysosomal B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
function B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
in O
the O
superficial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
cells I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

increase O
in O
intragastric O
pressure O
during O
suxamethonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
muscle O
fasciculations O
in O
children O
: O
inhibition O
by O
alfentanil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Changes O
in O
intragastric O
pressure O
after O
the O
administration O
of O
suxamethonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
1 O
. O
5 O
mg O
kg O
- O
1 O
i O
. O
v O
. O
were O
studied O
in O
32 O
children O
( O
mean O
age O
6 O
. O
9 O
yr O
) O
pretreated O
with O
either O
physiological O
saline O
or O
alfentanil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O
micrograms O
kg O
- O
1 O
. O

Anaesthesia O
was O
induced O
with O
thiopentone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O
mg O
kg O
- O
1 O
. O

The O
incidence O
and O
intensity O
of O
muscle O
fasciculations O
caused O
by O
suxamethonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
significantly O
greater O
in O
the O
control O
than O
in O
the O
alfentanil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O
. O

The O
intragastric O
pressure O
during O
muscle O
fasciculations O
was O
significantly O
higher O
in O
the O
control O
group O
( O
16 O
+ O
/ O
- O
0 O
. O
7 O
( O
SEM O
) O
cm O
H2O B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
than O
in O
the O
alfentanil B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
group O
( O
7 O
. O
7 O
+ O
/ O
- O
1 O
. O
5 O
( O
SEM O
) O
cm O
H2O B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

The O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
intragastric B_DISEASE/B_MEASURE
pressure B_DISEASE/I_MEASURE
was O
directly O
related O
to O
the O
intensity B_MEASURE
of O
muscle B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
fasciculations I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
regression B_MEASURE
line I_MEASURE
: O
y B_MEASURE/B_PROTEIN[GENE]
= O
0 B_MEASURE
. O
5 B_MEASURE
+ I_MEASURE
4 I_MEASURE
. O
78x B_MEASURE
with O
r B_PROTEIN[GENE]/B_MEASURE
of O
0 B_MEASURE
. O
78 B_MEASURE
) O
. O

It O
is O
concluded O
that O
intragastric O
pressure O
increases O
significantly O
during O
muscle O
fasciculations O
caused O
by O
suxamethonium B_DISEASE
in O
healthy O
children O
. O

Alfentanil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
50 O
micrograms O
kg O
- O
1 O
effectively O
inhibits O
the O
incidence O
and O
intensity O
of O
suxamethonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
muscle O
fasciculations O
; O
Moreover O
, O
intragastric O
pressure O
remains O
at O
its O
control O
value O
. O

acute O
insulin O
treatment O
normalizes O
the O
resistance O
to O
the O
cardiotoxic O
effect O
of O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
streptozotocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
diabetic O
rats O
. O

A O
morphometric O
study O
of O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O
myocardial O
fibrosis O
. O

The O
acute O
effect O
of O
insulin O
treatment O
on O
the O
earlier O
reported O
protective O
effect O
of O
streptozotocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
diabetes O
against O
the O
cardiotoxic O
effect O
of O
high O
doses O
of O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ISO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
was O
investigated O
in O
rats O
. O

Thirty O
to O
135 O
min O
after O
the O
injection O
of O
crystalline O
insulin O
, O
ISO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
given O
subcutaneously O
and O
when O
ISO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induced O
fibrosis O
in O
the O
myocardium O
was O
morphometrically O
analyzed O
7 O
days O
later O
, O
a O
highly O
significant O
correlation O
( O
r O
= O
0 O
. O
83 O
, O
2 O
p O
= O
0 O
. O
006 O
) O
to O
the O
slope O
of O
the O
fall O
in O
blood O
glucose B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
after O
insulin O
treatment O
appeared O
. O

The O
myocardial O
content O
of O
catecholamines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
estimated O
in O
these O
8 O
day O
diabetic O
rats O
. O

The O
norepinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
content O
was O
significantly O
increased O
while O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
remained O
unchanged O
. O

An O
enhanced O
sympathetic O
nervous O
system O
activity O
with O
a O
consequent O
down O
regulation O
of O
the O
myocardial O
beta O
- O
adrenergic O
receptors O
could O
, O
therefore O
, O
explain O
this O
catecholamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resistance O
. O

The O
rapid O
reversion O
after O
insulin O
treatment O
excludes O
the O
possibility O
that O
streptozotocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
itself O
causes O
the O
ISO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
resistance O
and O
points O
towards O
a O
direct O
insulin O
effect O
on O
myocardial O
catecholamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sensitivity O
in O
diabetic O
rats O
. O

The O
phenomenon B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
described O
might O
elucidate O
pathogenetic B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
behind O
toxic B_DISEASE
myocardial I_DISEASE
cell I_DISEASE
degeneration I_DISEASE
and O
may O
possibly O
have O
relevance B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
acute B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiovascular I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
complications I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
diabetic B_PERSON/B_DISEASE
patients I_PERSON/I_DISEASE
. O

differential O
effects O
of O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
on O
seizures O
produced O
by O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
rats O
. O

The O
muscarinic O
cholinergic O
agonist O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
induces O
in O
rats O
seizures O
and O
status O
epilepticus O
followed O
by O
widespread O
damage O
to O
the O
forebrain O
. O

The O
present O
study O
was O
designed O
to O
investigate O
the O
effect O
of O
5 O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
, O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salicylate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
phenylbutazone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ibuprofen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
mefenamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
on O
seizures O
produced O
by O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

Pretreatment O
of O
rats O
with O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salicylate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ED50 O
103 O
mg O
/ O
kg O
( O
60 O
- O
174 O
) O
, O
and O
phenylbutazone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
59 O
mg O
/ O
kg O
( O
50 O
- O
70 O
) O
converted O
the O
non O
- O
convulsant O
dose O
of O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
200 O
mg O
/ O
kg O
, O
to O
a O
convulsant O
one O
. O

Indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
1 O
- O
10 O
mg O
/ O
kg O
, O
and O
ibuprofen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
10 O
- O
100 O
mg O
/ O
kg O
, O
failed O
to O
modulate O
seizures O
produced O
by O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Mefenamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
26 O
( O
22 O
- O
30 O
) O
mg O
/ O
kg O
, O
prevented O
seizures O
and O
protected O
rats O
from O
seizure O
- O
related O
brain O
damage O
induced O
by O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
380 O
mg O
/ O
kg O
. O

These O
results O
indicate O
that O
non O
- O
steroidal O
anti O
- O
inflammatory O
drugs O
differentially O
modulate O
the O
threshold O
for O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
induced O
seizures O
. O

acute O
neurologic O
dysfunction O
after O
high O
- O
dose O
etoposide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
for O
malignant O
glioma O
. O

Etoposide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
VP B_LOCATION/B_PROTEIN[GENE]
- I_LOCATION/I_PROTEIN[GENE]
16 I_LOCATION/I_PROTEIN[GENE]
- I_LOCATION/I_PROTEIN[GENE]
213 I_LOCATION/I_PROTEIN[GENE]
) O
has O
been O
used O
in O
the O
treatment O
of O
many O
solid O
tumors O
and O
hematologic O
malignancies O
. O

When O
used O
in O
high B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
doses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
and O
in O
conjunction B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
autologous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
bone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
marrow I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transplantation I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
this O
agent B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
several B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
resistant B_DISEASE_ADJECTIVE[DISEASE]
cancers I_DISEASE_ADJECTIVE[DISEASE]
including O
malignant B_DISEASE
glioma I_DISEASE
. O

In O
six B_NUMBER[MEASURE]
of O
eight B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
( O
75 B_TIME[MEASURE]/B_LOCATION
% I_TIME[MEASURE]/I_LOCATION
) O
who O
we O
treated O
for O
recurrent B_DISEASE_ADJECTIVE[DISEASE]
or O
resistant B_DISEASE_ADJECTIVE[DISEASE]
glioma I_DISEASE_ADJECTIVE[DISEASE]
, O
sudden B_DISEASE
severe I_DISEASE
neurologic I_DISEASE
deterioration I_DISEASE
occurred O
. O

This O
developed O
a O
median O
of O
9 O
days O
after O
initiation O
of O
high O
- O
dose O
etoposide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

Significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
clinical I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
manifestations I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
have O
included O
confusion B_DISEASE
, O
papilledema B_DISEASE
, O
somnolence B_DISEASE
, O
exacerbation B_DISEASE
of O
motor B_DISEASE
deficits I_DISEASE
, O
and O
sharp B_DISEASE_ADJECTIVE[DISEASE]
increase I_DISEASE_ADJECTIVE[DISEASE]
in O
seizure B_DISEASE/B_MEASURE
activity I_DISEASE/I_MEASURE
. O

These O
abnormalities O
resolved O
rapidly O
after O
initiation O
of O
high O
- O
dose O
intravenous O
dexamethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

In O
all O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
computerized B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
tomographic I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
CT B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
brain B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
scans I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
demonstrated O
stability B_DISEASE_ADJECTIVE[DISEASE]
in O
tumor B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
size I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
peritumor B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
edema I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
when O
compared O
with O
pretransplant B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
scans I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
complication O
appears O
to O
represent O
a O
significant O
new O
toxicity O
of O
high O
- O
dose O
etoposide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
for O
malignant O
glioma O
. O

Progressive O
bile O
duct O
injury O
after O
thiabendazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
administration O
. O

A O
27 O
- O
yr O
- O
old O
man O
developed O
jaundice O
2 O
wk O
after O
exposure O
to O
thiabendazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

cholestasis B_DISEASE/B_PERSON
persisted O
for O
3 B_TIME[MEASURE]
yr I_TIME[MEASURE]
, O
at O
which O
time B_TIME[MEASURE]/B_LOCATION
a O
liver B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplant I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
performed O
. O

Two B_PERSON
liver I_PERSON
biopsy I_PERSON
specimens I_PERSON
and O
the O
hepatectomy B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
specimen I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
were O
remarkable B_DISEASE_ADJECTIVE[DISEASE]
for O
almost O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disappearance B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
interlobular B_DISEASE
bile I_DISEASE
ducts I_DISEASE
. O

prominent B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
fibrosis I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
hepatocellular B_DISEASE
regeneration I_DISEASE
were O
also O
present B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
; O
however O
, O
the O
lobular B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
architecture I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
was O
preserved O
. O

This O
case B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
represents O
an O
example B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
' B_PERSON/B_LOCATION
idiosyncratic I_PERSON/I_LOCATION
' O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
liver B_DISEASE
damage I_DISEASE
in O
which O
the O
primary B_LOCATION/B_PERSON
target I_LOCATION/I_PERSON
of O
injury B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
the O
bile B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
duct I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

An O
autoimmune B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathogenesis B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
bile B_DISEASE/B_BIO
duct I_DISEASE/I_BIO
destruction I_DISEASE/I_BIO
is O
suggested O
. O

differential O
effects O
of O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
dihydropyridine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
calcium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
channel I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
therapeutic O
implications O
. O

increasing O
recognition O
of O
the O
importance O
of O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
the O
pathogenesis O
of O
cardiovascular O
disease O
has O
stimulated O
research O
into O
the O
use O
of O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
channel I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blocking I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
for O
treatment O
of O
a O
variety O
of O
cardiovascular O
diseases O
. O

The O
favorable B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
efficacy I_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
and O
tolerability B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
profiles B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
these O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
make O
them O
attractive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
therapeutic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
modalities B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Clinical O
applications O
of O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
channel I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
parallel O
their O
tissue O
selectivity O
. O

In O
contrast O
to O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
diltiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
are O
roughly O
equipotent O
in O
their O
actions O
on O
the O
heart O
and O
vascular O
smooth O
muscle O
, O
the O
dihydropyridine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
calcium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
channel I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
a O
group O
of O
potent O
peripheral O
vasodilator O
agents O
that O
exert O
minimal O
electrophysiologic O
effects O
on O
cardiac O
nodal O
or O
conduction O
tissue O
. O

As O
the O
first O
dihydropyridine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
available O
for O
use O
in O
the O
United O
States O
, O
nifedipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
controls O
angina O
and O
hypertension O
with O
minimal O
depression O
of O
cardiac O
function O
. O

Additional O
members O
of O
this O
group O
of O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
channel I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
have O
been O
studied O
for O
a O
variety O
of O
indications O
for O
which O
they O
may O
offer O
advantages O
over O
current O
therapy O
. O

Once O
or O
twice O
daily O
dosage O
possible O
with O
nitrendipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
nisoldipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
offers O
a O
convenient O
administration O
schedule O
, O
which O
encourages O
patient O
compliance O
in O
long O
- O
term O
therapy O
of O
hypertension O
. O

The O
coronary O
vasodilating O
properties O
of O
nisoldipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
led O
to O
the O
investigation O
of O
this O
agent O
for O
use O
in O
angina O
. O

Selectivity O
for O
the O
cerebrovascular O
bed O
makes O
nimodipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
potentially O
useful O
in O
the O
treatment O
of O
subarachnoid O
hemorrhage O
, O
migraine O
headache O
, O
dementia O
, O
and O
stroke O
. O

In O
general O
, O
the O
dihydropyridine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
calcium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
channel I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
blockers I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
usually O
well O
tolerated O
, O
with O
headache O
, O
facial O
flushing O
, O
palpitations O
, O
edema O
, O
nausea O
, O
anorexia O
, O
and O
dizziness O
being O
the O
more O
common O
adverse O
effects O
. O

The O
enhancement O
of O
aminonucleoside B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephrosis O
by O
the O
co O
- O
administration O
of O
protamine O
. O

An O
experimental O
model O
of O
focal O
segmental O
glomerular O
sclerosis O
( O
FSGS O
) O
was O
developed O
in O
rats O
by O
the O
combined O
administration O
of O
puromycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminonucleoside I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
AMNS B_LOCATION/B_ORGANIZATION
) O
and O
protamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PS B_LOCATION/B_DISEASE
) O
. O

Male O
Sprague O
- O
Dawley O
rats O
, O
uninephrectomized O
three O
weeks O
before O
, O
received O
daily O
injections O
of O
subcutaneous O
AMNS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
( O
1 O
mg O
/ O
100 O
g O
body O
wt O
) O
and O
intravenous O
PS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
2 O
separated O
doses O
of O
2 O
. O
5 O
mg O
/ O
100 O
g O
body O
wt O
) O
for O
four O
days O
. O

The O
series B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
injections B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
repeated O
another O
three B_TIME[MEASURE]
times I_TIME[MEASURE]
at O
10 B_TIME[MEASURE]/B_LOCATION
day I_TIME[MEASURE]/I_LOCATION
intervals I_TIME[MEASURE]/I_LOCATION
. O

The O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
sacrificed O
on O
days B_TIME[MEASURE]
24 I_TIME[MEASURE]
, O
52 B_MEASURE
, O
and O
80 B_MEASURE
. O

They O
developed O
nephrotic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
syndrome I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
finally O
renal B_DISEASE
failure I_DISEASE
. O

The O
time O
- O
course O
curve O
of O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
clearance O
dropped O
and O
showed O
significant O
difference O
( O
P O
less O
than O
0 O
. O
01 O
) O
from O
that O
of O
each O
control O
group O
, O
such O
as O
, O
AMNS B_LOCATION/B_ORGANIZATION
alone O
, O
PS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
or O
saline O
injected O
. O

Their O
glomeruli B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
showed O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
progressive B_DISEASE_ADJECTIVE[DISEASE]
FSGS I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
ultrastructural O
studies O
in O
the O
initial O
stage O
revealed O
significant O
lack O
of O
particles O
of O
perfused O
ruthenium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
red O
on O
the O
lamina O
rara O
externa O
and O
marked O
changes O
in O
epithelial O
cell O
cytoplasm O
. O

Therefore O
, O
it O
is O
suggested O
that O
the O
administration O
of O
PS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
enhances O
the O
toxicity O
of O
AMNS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
glomerulus O
and O
readily O
produces O
progressive O
FSGS O
in O
rats O
resulting O
in O
the O
end O
- O
stage O
renal O
disease O
. O

Theophylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
neurotoxicity O
in O
pregnant O
rats O
. O

The O
purpose O
of O
this O
investigation O
was O
to O
determine O
whether O
the O
neurotoxicity O
of O
theophylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
altered O
in O
advanced O
pregnancy O
. O

Sprague O
- O
Dawley O
rats O
that O
were O
20 O
days O
pregnant O
and O
nonpregnant O
rats O
of O
the O
same O
age O
and O
strain O
received O
infusions O
of O
aminophylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
until O
onset O
of O
maximal O
seizures O
which O
occurred O
after O
28 O
and O
30 O
minutes O
respectively O
. O

Theophylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
concentrations O
at O
this O
endpoint O
in O
serum O
( O
total O
) O
and O
CSF O
were O
similar O
but O
serum O
( O
free O
) O
and O
brain O
concentrations O
were O
slightly O
different O
in O
pregnant O
rats O
. O

Theophylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
serum O
protein O
binding O
determined O
by O
equilibrium O
dialysis O
was O
lower O
in O
pregnant O
rats O
. O

Fetal B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
serum I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
seizures B_DISEASE/B_ORGANISM_FUNCTION
in O
the O
mother B_PERSON
were O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
maternal B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
brain I_BODY_PART_OR_ORGAN_COMPONENT/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
CSF B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
concentrations I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
and O
correlated O
significantly O
with O
the O
former B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

It O
is O
concluded O
that O
advanced O
pregnancy O
has O
a O
negligible O
effect O
on O
the O
neurotoxic O
response O
to O
theophylline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
rats O
. O

Hyperkalemia O
induced O
by O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
naproxen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
reversed O
by O
fludrocortisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
have O
described O
a O
patient O
with O
severe O
rheumatoid O
arthritis O
and O
a O
history O
of O
mefenamic B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephropathy O
in O
whom O
hyperkalemia O
and O
inappropriate O
hypoaldosteronism O
were O
caused O
by O
both O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
naproxen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
without O
major O
decline O
in O
renal O
function O
. O

It O
is O
likely O
that O
preexisting O
renal O
disease O
predisposed O
this O
patient O
to O
type O
IV O
renal O
tubular O
acidosis O
with O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthetase O
inhibitors O
. O

Because O
he O
was O
unable O
to O
discontinue O
nonsteroidal O
anti O
- O
inflammatory O
drug O
therapy O
, O
fludrocortisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
added O
, O
correcting O
the O
hyperkalemia O
and O
allowing O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
therapy O
to O
be O
continued O
safely O
. O

Hypotension O
as O
a O
manifestation O
of O
cardiotoxicity O
in O
three O
patients O
receiving O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

cardiac O
symptoms O
, O
including O
hypotension O
, O
developed O
in O
three O
patients O
with O
advanced O
colorectal O
carcinoma O
while O
being O
treated O
with O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CDDP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
and O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
FU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
. O

In O
two B_PERSON/B_BIO
patients I_PERSON/I_BIO
, O
hypotension B_DISEASE
was O
associated O
with O
severe B_DISEASE_ADJECTIVE[DISEASE]
left O
ventricular B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
dysfunction I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

All O
three B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
required O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
discontinuation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

Cardiac B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
enzymes I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
remained O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
despite O
transient B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
electrocardiographic I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
EKG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
changes B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
presentation O
and O
cardiac O
evaluation O
( O
hemodynamic O
, O
echocardiographic O
, O
and O
scintigraphic O
) O
of O
these O
patients O
suggest O
new O
manifestations O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
FU I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiotoxicity O
that O
may O
be O
influenced O
by O
CDDP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

The O
possible B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pathophysiologic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
mechanisms I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
discussed O
. O

fatal O
aplastic O
anemia O
in O
a O
patient O
treated O
with O
carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
case O
of O
fatal O
aplastic O
anemia O
due O
to O
carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
in O
an O
epileptic O
woman O
is O
reported O
. O

Despite O
concerns O
of O
fatal O
bone O
marrow O
toxicity O
due O
to O
carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
this O
is O
only O
the O
fourth O
documented O
and O
published O
report O
. O

Carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
a O
safe O
drug O
, O
but O
physicians O
and O
patients O
should O
be O
aware O
of O
the O
exceedingly O
rare O
but O
potentially O
fatal O
side O
effects O
, O
better O
prevented O
by O
clinical O
than O
by O
laboratory O
monitoring O
. O

participation O
of O
a O
bulbospinal O
serotonergic O
pathway O
in O
the O
rat O
brain O
in O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hypotension O
and O
bradycardia O
. O

The O
effects O
of O
microinjection O
of O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
1 O
- O
10 O
micrograms O
in O
1 O
microliter O
) O
into O
a O
region O
adjacent O
to O
the O
ventrolateral O
surface O
of O
the O
medulla O
oblongata O
on O
cardiovascular O
function O
were O
assessed O
in O
urethane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
anesthetized O
rats O
. O

Intramedullary O
administration O
of O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
saline O
vehicle O
, O
caused O
a O
dose O
- O
dependent O
decrease O
in O
both O
the O
mean O
arterial O
pressure O
and O
the O
heart O
rate O
. O

The O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
induced O
hypotension O
was O
antagonized O
by O
prior O
spinal O
transection O
, O
but O
not O
bilateral O
vagotomy O
. O

On O
the O
other O
hand O
, O
the O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
induced O
bradycardia O
was O
antagonized O
by O
prior O
bilateral O
vagotomy O
, O
but O
not O
spinal O
transection O
. O

Furthermore O
, O
selective O
destruction O
of O
the O
spinal O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
HT B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
nerves O
, O
produced O
by O
bilateral O
spinal O
injection O
of O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dihydroxytryptamine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
reduced O
the O
magnitude O
of O
the O
vasodepressor O
or O
the O
bradycardiac O
responses O
to O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
microinjected O
into O
the O
area O
near O
the O
ventrolateral O
surface O
of O
the O
medulla O
oblongata O
in O
rats O
. O

The O
data O
indicate O
that O
a O
bulbospinal O
serotonergic O
pathway O
is O
involved O
in O
development O
of O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hypotension O
and O
bradycardia O
. O

The O
induced B_DISEASE
hypotension I_DISEASE
is O
brought O
about O
by O
a O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
sympathetic B_DISEASE/B_GENE
efferent I_DISEASE/I_GENE
activity I_DISEASE/I_GENE
, O
whereas O
the O
induced O
bradycardia B_DISEASE
was O
due O
to O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
vagal B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
efferent B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activity B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Hypertension O
in O
neuroblastoma O
induced O
by O
imipramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Hypertension B_DISEASE/B_GENE
is O
a O
well O
- O
known O
finding B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
some O
patients B_PERSON/B_BIO
with O
neuroblastoma B_DISEASE/B_LOCATION
. O

However O
, O
it O
has O
not O
previously O
been O
described O
in O
association O
with O
the O
use O
of O
Imipramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
report O
the O
occurrence O
of O
severe O
hypertension O
( O
blood O
pressure O
190 O
/ O
160 O
) O
in O
a O
4 O
- O
year O
- O
old O
girl O
with O
neuroblastoma O
who O
was O
given O
Imipramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
control O
a O
behavior O
disorder O
. O

It O
was O
determined O
later O
that O
this O
patient B_PERSON
' O
s B_DISEASE
tumor I_DISEASE
was O
recurring O
at O
the O
time B_TIME[MEASURE]/B_LOCATION
of O
her O
hypertensive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
episode I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Since O
she O
had O
no O
blood O
pressure O
elevation O
at O
initial O
diagnosis O
and O
none O
following O
discontinuation O
of O
the O
Imipramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
when O
she O
was O
in O
florid O
relapse O
) O
, O
we O
believe O
that O
this O
drug O
rather O
than O
her O
underlying O
disease O
alone O
caused O
her O
hypertension O
. O

The O
mechanism O
for O
this O
reaction O
is O
believed O
to O
be O
increased O
levels O
of O
vasoactive O
catecholamines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
due O
to O
interference O
of O
their O
physiologic O
inactivation O
by O
Imipramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

From O
this O
experience B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
we O
urge O
extreme B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caution I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
tricyclic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antidepressants I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
children B_PERSON/B_BIO
with O
active B_DISEASE
neuroblastoma I_DISEASE
. O

Rechallenge O
of O
patients O
who O
developed O
oral O
candidiasis O
or O
hoarseness O
with O
beclomethasone B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
dipropionate I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Of O
158 O
asthmatic O
patients O
who O
were O
placed O
on O
inhaled O
beclomethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
15 O
( O
9 O
. O
5 O
% O
) O
developed O
either O
hoarseness O
( O
8 O
) O
, O
oral O
thrush O
( O
6 O
) O
, O
or O
both O
( O
1 O
) O
. O

When O
their O
adverse O
reactions O
subsided O
, O
seven O
of O
these O
15 O
patients O
were O
rechallenged O
with O
inhaled O
beclomethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
included O
five B_NUMBER[MEASURE]
cases I_NUMBER[MEASURE]
who O
developed O
hoarseness B_DISEASE
and O
three B_NUMBER[MEASURE]
who O
developed O
candidiasis B_DISEASE
. O

One B_PERSON
patient I_PERSON
had O
both O
. O

Oral B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
thrush I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
did O
not O
recur B_DISEASE_ADJECTIVE[DISEASE]
, O
but O
60 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
( O
3 B_MEASURE
/ O
5 B_SEQUENCE[MEASURE]
) O
of O
patients B_PERSON/B_BIO
with O
hoarseness B_DISEASE
had O
recurrence B_DISEASE
. O

We O
conclude O
that O
patients O
may O
be O
restarted O
on O
inhaled O
beclomethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
clinically O
indicated O
; O
however O
, O
because O
of O
the O
high O
recurrence O
rate O
, O
patients O
who O
develop O
hoarseness O
should O
not O
be O
re O
- O
challenged O
. O

Concomitant O
use O
of O
oral O
prednisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
topical O
beclomethasone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
increase O
the O
risk O
of O
developing O
hoarseness O
or O
candidiasis O
. O

Cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cardiotoxicity O
: O
an O
analysis O
of O
dosing O
as O
a O
risk O
factor O
. O

patients O
who O
undergo O
bone O
marrow O
transplantation O
are O
generally O
immunosuppressed O
with O
a O
dose O
of O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CYA B_LOCATION/B_ORGANIZATION
) O
which O
is O
usually O
calculated O
based O
on O
the O
patient O
' O
s O
weight O
. O

At O
these O
high O
doses O
of O
CYA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
serious O
cardiotoxicity O
may O
occur O
, O
but O
definitive O
risk O
factors O
for O
the O
development O
of O
such O
cardiotoxicity O
have O
not O
been O
described O
. O

Since O
chemotherapeutic O
agent O
toxicity O
generally O
correlates O
with O
dose O
per O
body O
surface O
area O
, O
we O
retrospectively O
calculated O
the O
dose O
of O
CYA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients O
transplanted O
at O
our O
institution O
to O
determine O
whether O
the O
incidence O
of O
CYA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiotoxicity O
correlated O
with O
the O
dose O
per O
body O
surface O
area O
. O

eighty O
patients O
who O
were O
to O
receive O
CYA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
50 O
mg O
/ O
kg O
/ O
d O
for O
four O
days O
as O
preparation O
for O
marrow O
grafting O
underwent O
a O
total O
of O
84 O
transplants O
for O
aplastic O
anemia O
, O
Wiskott O
- O
Aldrich O
syndrome O
, O
or O
severe O
combined O
immunodeficiency O
syndrome O
. O

Fourteen O
of O
84 O
( O
17 O
% O
) O
patients O
had O
symptoms O
and O
signs O
consistent O
with O
CYA B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiotoxicity O
within O
ten O
days O
of O
receiving O
1 O
to O
4 O
doses O
of O
CYA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Six B_NUMBER[MEASURE]
of O
the O
14 B_PERSON
patients I_PERSON
died O
with O
congestive B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
heart I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
dose O
of O
CYA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
per O
body O
surface O
area O
was O
calculated O
for O
all O
patients O
and O
the O
patients O
were O
divided O
into O
two O
groups O
based O
on O
daily O
CYA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O
: O
Group O
1 O
, O
CYA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
less O
than O
or O
equal O
to O
1 O
. O
55 O
g O
/ O
m2 O
/ O
d O
; O
Group O
2 O
, O
CYA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
greater O
than O
1 O
. O
55 O
g O
/ O
m2 O
/ O
d O
. O

Cardiotoxicity O
that O
was O
thought O
to O
be O
related O
to O
CYA B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
occurred O
in O
1 O
/ O
32 O
( O
3 O
% O
) O
of O
patients O
in O
Group O
1 O
and O
in O
13 O
/ O
52 O
( O
25 O
% O
) O
patients O
in O
Group O
2 O
( O
P O
less O
than O
0 O
. O
025 O
) O
. O

congestive B_DISEASE/B_LOCATION
heart I_DISEASE/I_LOCATION
failure I_DISEASE/I_LOCATION
caused O
or O
contributed O
to O
death B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
0 B_MEASURE
/ O
32 B_TIME[MEASURE]
patients I_TIME[MEASURE]
in O
Group B_MEASURE/B_LOCATION
1 I_MEASURE/I_LOCATION
v O
6 B_NUMBER[MEASURE]
/ O
52 B_MEASURE
( O
12 B_MEASURE
% I_MEASURE
) O
of O
patients B_PERSON
in O
Group B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
2 I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
( O
P B_MEASURE/B_PERSON
less I_MEASURE/I_PERSON
than O
0 B_MEASURE
. O
25 B_MEASURE
) O
. O

There O
was O
no O
difference B_MEASURE
in O
the O
rate B_MEASURE
of O
engraftment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
evaluable B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_PERSON
patients I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_PERSON
in O
the O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
groups I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
P B_MEASURE/B_LOCATION
greater I_MEASURE/I_LOCATION
than O
0 B_MEASURE
. O
5 B_MEASURE
) O
. O

We O
conclude O
that O
the O
CYA B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiotoxicity O
correlates O
with O
CYA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dosage O
as O
calculated O
by O
body O
surface O
area O
, O
and O
that O
patients O
with O
aplastic O
anemia O
and O
immunodeficiencies O
can O
be O
effectively O
prepared O
for O
bone O
marrow O
grafting O
at O
a O
CYA B_MEASURE
dose O
of O
1 O
. O
55 O
g O
/ O
m2 O
/ O
d O
for O
four O
days O
with O
a O
lower O
incidence O
of O
cardiotoxicity O
than O
patients O
whose O
CYA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dosage O
is O
calculated O
based O
on O
weight O
. O

This O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reaffirms O
the O
principle B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
that O
drug B_DISEASE
toxicity I_DISEASE
correlates O
with O
dose B_MEASURE/B_DISEASE
per O
body B_TIME[MEASURE]/B_PERSON
surface I_TIME[MEASURE]/I_PERSON
area I_TIME[MEASURE]/I_PERSON
. O

Studies O
of O
risk O
factors O
for O
aminoglycoside B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nephrotoxicity O
. O

The O
epidemiology O
of O
aminoglycoside B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
nephrotoxicity O
is O
not O
fully O
understood O
. O

Experimental O
studies O
in O
healthy O
human O
volunteers O
indicate O
aminoglycosides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cause O
proximal O
tubular O
damage O
in O
most O
patients O
, O
but O
rarely O
, O
if O
ever O
, O
cause O
glomerular O
or O
tubular O
dysfunction O
. O

Clinical O
trials O
of O
aminoglycosides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
seriously O
ill O
patients O
indicate O
that O
the O
relative O
risk O
for O
developing O
acute O
renal O
failure O
during O
therapy O
ranges O
from O
8 O
to O
10 O
and O
that O
the O
attributable O
risk O
is O
70 O
% O
to O
80 O
% O
. O

Further O
analysis O
of O
these O
data O
suggests O
that O
the O
duration O
of O
therapy O
, O
plasma O
aminoglycoside B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels O
, O
liver O
disease O
, O
advanced O
age O
, O
high O
initial O
estimated O
creatinine B_BODY_PART_OR_ORGAN_COMPONENT
clearance O
and O
, O
possibly O
, O
female O
gender O
all O
increase O
the O
risk O
for O
nephrotoxicity O
. O

Other B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
causes B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
shock B_DISEASE
, O
appear O
to O
have O
an O
additive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

predictive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
models I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
have O
been O
developed O
from O
these O
analyses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
that O
should O
be O
useful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
identifying O
patients B_PERSON/B_LOCATION
at O
high B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
risk I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

These O
models O
may O
also O
be O
useful O
in O
developing O
insights O
into O
the O
pathophysiology O
of O
aminoglycoside B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
nephrotoxicity O
. O

Central B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
action I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
narcotic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
analgesics I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Part B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
IV I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

noradrenergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
influences I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
on O
the O
activity B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
analgesics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
effect O
of O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
naphazoline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
xylometazoline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
analgesia O
induced O
by O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
codeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pentazocine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
on O
cataleptic O
effect O
of O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
codine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
studied O
in O
rats O
. O

The O
biochemical O
assays O
on O
the O
influence O
of O
four O
analgesics O
on O
the O
brain O
concentration O
and O
turnover O
of O
noradrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
NA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
were O
also O
performed O
. O

It O
was O
found O
that O
three O
drugs O
stimulating O
central O
NA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptors O
failed O
to O
affect O
the O
analgesic O
ED50 O
of O
all O
antinociceptive O
agents O
and O
they O
enhanced O
catalepsy O
induced O
by O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Codeine B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
catalepsy O
was O
increased O
by O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
decreased O
by O
naphazoline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
xylometazoline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
brain O
concentration O
of O
NA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
changed O
by O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
one O
of O
the O
doses O
of O
codeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
45 O
mg O
/ O
kg O
) O
slightly O
enhanced O
it O
. O

Pentazocine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
dose O
- O
dependently O
decreased O
the O
brain O
level O
of O
NA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
rate O
of O
NA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
turnover O
was O
not O
altered O
by O
analgesics O
except O
for O
the O
higher O
dose O
of O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 O
. O
2 O
mg O
/ O
kg O
) O
following O
which O
the O
disappearance O
of O
NA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
from O
the O
brain O
was O
diminished O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
are O
discussed O
in O
the O
light B_COLOR/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
various B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
non B_DISEASE/B_MEASURE
- O
uniform B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
from O
the O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

It O
is O
suggested O
that O
in O
rats O
the O
brain O
NA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
plays O
a O
less O
important O
function O
than O
the O
other O
monoamines B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
behavioural O
activity O
of O
potent O
analgesics O
. O

Flurothyl B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
seizure O
thresholds O
in O
mice O
treated O
neonatally O
with O
a O
single O
injection O
of O
monosodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glutamate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MSG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
: O
evaluation O
of O
experimental O
parameters O
in O
flurothyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seizure O
testing O
. O

Monosodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glutamate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MSG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
administration O
to O
neonatal O
rodents O
produces O
convulsions O
and O
results O
in O
numerous O
biochemical O
and O
behavioral O
deficits O
. O

These O
studies O
were O
undertaken O
to O
determine O
if O
neonatal O
administration O
of O
MSG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
produced O
permanent O
alterations O
in O
seizure O
susceptibility O
, O
since O
previous O
investigations O
were O
inconclusive O
. O

A O
flurothyl B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
ether I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
seizure O
screening O
technique O
was O
used O
to O
evaluate O
seizure O
susceptibility O
in O
adult O
mice O
that O
received O
neonatal O
injections O
of O
MSG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
4 O
mg O
/ O
g O
and O
1 O
mg O
/ O
g O
) O
. O

MSG B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
resulted O
in O
significant O
reductions O
in O
whole O
brain O
weight O
but O
did O
not O
alter O
seizure O
threshold O
. O

A O
naloxone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
5 O
mg O
/ O
kg O
) O
challenge O
was O
also O
ineffective O
in O
altering O
the O
seizure O
thresholds O
of O
either O
control O
of O
MSG B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
treated O
mice O
. O

Flurothyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
ether I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
produced O
hypothermia O
which O
was O
correlated O
with O
the O
duration O
of O
flurothyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O
; O
however O
, O
the O
relationship O
of O
hypothermia O
to O
seizure O
induction O
was O
unclear O
. O

Flurothyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
seizure O
testing O
proved O
to O
be O
a O
rapid O
and O
reliable O
technique O
with O
which O
to O
evaluate O
seizure O
susceptibility O
. O

Susceptibility O
to O
seizures O
produced O
by O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
rats O
after O
microinjection O
of O
isoniazid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vinyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
GABA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
into O
the O
substantia O
nigra O
. O

Pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
given O
intraperitoneally O
to O
rats O
, O
reproduces O
the O
neuropathological O
sequelae O
of O
temporal O
lobe O
epilepsy O
and O
provides O
a O
relevant O
animal O
model O
for O
studying O
mechanisms O
of O
buildup O
of O
convulsive O
activity O
and O
pathways O
operative O
in O
the O
generalization O
and O
propagation O
of O
seizures O
within O
the O
forebrain O
. O

In O
the O
present O
study O
, O
the O
effects O
of O
manipulating O
the O
activity O
of O
the O
gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminobutyric I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
- O
mediated O
synaptic O
inhibition O
within O
the O
substantia O
nigra O
on O
seizures O
produced O
by O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
rats O
, O
were O
investigated O
. O

In O
animals O
pretreated O
with O
microinjections O
of O
isoniazid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
150 O
micrograms O
, O
an O
inhibitor O
of O
activity O
of O
the O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
synthesizing O
enzyme O
, O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glutamic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
decarboxylase O
, O
into O
the O
substantia O
nigra O
pars O
reticulata O
( O
SNR O
) O
, O
bilaterally O
, O
non O
- O
convulsant O
doses O
of O
pilocarpine B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
100 O
and O
200 O
mg O
/ O
kg O
, O
resulted O
in O
severe O
motor O
limbic O
seizures O
and O
status O
epilepticus O
. O

Electroencephalographic O
and O
behavioral O
monitoring O
revealed O
a O
profound O
reduction O
of O
the O
threshold O
for O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
convulsions O
. O

Morphological O
analysis O
of O
frontal O
forebrain O
sections O
with O
light O
microscopy O
revealed O
seizure O
- O
related O
damage O
to O
the O
hippocampal O
formation O
, O
thalamus O
, O
amygdala O
, O
olfactory O
cortex O
, O
substantia O
nigra O
and O
neocortex O
, O
which O
is O
typically O
observed O
with O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
doses O
exceeding O
350 O
mg O
/ O
kg O
. O

bilateral O
intrastriatal O
injections O
of O
isoniazid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
did O
not O
augment O
seizures O
produced O
by O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
200 O
mg O
/ O
kg O
. O

Application O
of O
an O
irreversible O
inhibitor O
of O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transaminase O
, O
gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
vinyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
GABA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
, B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
hex B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
enoic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
acid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
) O
, O
5 O
micrograms O
, O
into O
the O
SNR O
, O
bilaterally O
, O
suppressed O
the O
appearance O
of O
electrographic O
and O
behavioral O
seizures O
produced O
by O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
380 O
mg O
/ O
kg O
. O

This O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
was O
also O
sufficient B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
protect O
animals B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
occurrence B_DISEASE
of O
brain B_DISEASE
damage I_DISEASE
. O

Microinjections O
of O
gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
vinyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
GABA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
5 O
micrograms O
, O
into O
the O
dorsal O
striatum O
, O
bilaterally O
, O
failed O
to O
prevent O
the O
development O
of O
convulsions O
produced O
by O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
380 O
mg O
/ O
kg O
. O

The O
results O
demonstrate O
that O
the O
threshold O
for O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
seizures O
in O
rats O
is O
subjected O
to O
the O
regulation O
of O
the O
GABA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
mediated O
synaptic O
inhibition O
within O
the O
substantia O
nigra O
. O

Human B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
canine B_SPECIES[BIO]/B_BODY_PART_OR_ORGAN_COMPONENT
ventricular I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
vasoactive I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
intestinal I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
polypeptide I_SPECIES[BIO]/I_BODY_PART_OR_ORGAN_COMPONENT
: O
decrease O
with O
heart B_DISEASE
failure I_DISEASE
. O

vasoactive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
intestinal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
polypeptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
VIP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
is O
a O
systemic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
coronary B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
vasodilator I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
may O
have O
positive B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
inotropic B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Myocardial B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
levels I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
VIP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
assayed O
before O
and O
after O
the O
development B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
heart B_DISEASE
failure I_DISEASE
in O
two B_SPECIES[BIO]/B_PERSON
canine I_SPECIES[BIO]/I_PERSON
models I_SPECIES[BIO]/I_PERSON
. O

In O
the O
first O
, O
cobalt B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cardiomyopathy O
was O
induced O
in O
eight O
dogs O
; O
VIP O
( O
by O
radioimmunoassay O
) O
decreased O
from O
35 O
+ O
/ O
- O
11 O
pg O
/ O
mg O
protein O
( O
mean O
+ O
/ O
- O
SD O
) O
to O
5 O
+ O
/ O
- O
4 O
pg O
/ O
mg O
protein O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

In O
six O
dogs O
with O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
heart O
failure O
, O
VIP O
decreased O
from O
31 O
+ O
/ O
- O
7 O
to O
11 O
+ O
/ O
- O
4 O
pg O
/ O
mg O
protein O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

In O
addition B_MEASURE/B_LOCATION
, O
VIP B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
content I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
left O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT
muscle I_BODY_PART_OR_ORGAN_COMPONENT
of O
resected O
failing O
hearts B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
10 B_PERSON
patients I_PERSON
receiving O
a O
heart B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
transplant I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
compared O
with O
the O
papillary B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
muscles I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
14 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
( O
five B_NUMBER[MEASURE]
with O
rheumatic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
nine B_NUMBER[MEASURE]
with O
myxomatous B_DISEASE
degeneration I_DISEASE
) O
receiving O
mitral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
valve I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
prostheses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
lowest B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
myocardial B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
VIP B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration B_MEASURE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
in O
the O
hearts B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON
with O
coronary B_DISEASE
disease I_DISEASE
( O
one B_NUMBER[MEASURE]/B_PERSON
patient I_NUMBER[MEASURE]/I_PERSON
receiving O
a O
transplant B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
three B_NUMBER[MEASURE]/B_PERSON
receiving O
mitral B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
prostheses I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
) O
( O
6 B_MEASURE
. O
3 B_MEASURE
+ I_MEASURE
/ O
- O
1 B_MEASURE
. O
9 B_MEASURE
pg I_MEASURE
/ O
mg B_MEASURE
protein I_MEASURE
) O
. O

The O
other B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
patients B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
undergoing O
transplantation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
had O
an O
average B_MEASURE
ejection I_MEASURE
fraction I_MEASURE
of O
17 B_MEASURE
% I_MEASURE
+ I_MEASURE
/ O
- O
6 B_MEASURE
% I_MEASURE
and O
a O
VIP B_MEASURE
level I_MEASURE
of O
8 B_MEASURE
. O
8 B_MEASURE
+ I_MEASURE
/ O
- O
3 B_MEASURE
. O
9 B_MEASURE
pg I_MEASURE
/ O
mg B_MEASURE
protein I_MEASURE
. O

The O
hearts B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
without O
coronary B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
artery I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
disease I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
average B_MEASURE/B_PERSON
ejection B_MEASURE/I_PERSON
fraction B_MEASURE/I_PERSON
of O
this O
group B_MEASURE/B_ORGANIZATION
62 I_MEASURE/I_ORGANIZATION
% I_MEASURE/I_ORGANIZATION
+ I_MEASURE/I_ORGANIZATION
/ O
- O
10 B_MEASURE
% I_MEASURE
) O
had O
a O
VIP B_MEASURE
concentration I_MEASURE
of O
14 B_MEASURE
. O
1 B_MEASURE/B_LOCATION
+ I_MEASURE/I_LOCATION
/ O
- O
7 B_MEASURE
. O
9 B_MEASURE
pg I_MEASURE
/ O
mg B_MEASURE
protein I_MEASURE
, O
and O
this O
was O
greater B_MEASURE
than O
in O
hearts B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
of O
the O
patients B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
with O
coronary B_DISEASE
disease I_DISEASE
and O
the O
hearts B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
of O
patients B_PERSON
receiving O
a O
transplant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
P B_MEASURE/B_PERSON
less I_MEASURE/I_PERSON
than O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

Myocardial O
catecholamines B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
also O
determined O
in O
14 O
subjects O
; O
a O
weak O
correlation O
( O
r O
= O
0 O
. O
57 O
, O
P O
less O
than O
0 O
. O
05 O
) O
between O
the O
tissue O
concentrations O
of O
VIP O
and O
norepinephrine B_LOCATION/B_ORGANIZATION
was O
noted O
. O
( O
abstract O
TRUNCATED O
AT O
250 O
Words O
) O
. O

Non O
- O
invasive O
detection O
of O
coronary O
artery O
disease O
by O
body O
surface O
electrocardiographic O
mapping O
after O
dipyridamole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
. O

Electrocardiographic O
changes O
after O
dipyridamole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
( O
0 O
. O
568 O
mg O
/ O
kg O
/ O
4 O
min O
) O
were O
studied O
in O
41 O
patients O
with O
coronary O
artery O
disease O
and O
compared O
with O
those O
after O
submaximal O
treadmill O
exercise O
by O
use O
of O
the O
body O
surface O
mapping O
technique O
. O

patients B_PERSON
were O
divided O
into O
three B_MEASURE/B_ORGANIZATION
groups B_MEASURE/I_ORGANIZATION
; O
19 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
without O
myocardial B_DISEASE/B_LOCATION
infarction I_DISEASE/I_LOCATION
( O
non B_LOCATION
- O
MI B_LOCATION/B_ORGANIZATION
group I_LOCATION/I_ORGANIZATION
) O
, O
14 B_NUMBER[MEASURE]
with O
anterior B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
infarction I_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
( O
Ant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
MI B_LOCATION/B_DISEASE
) O
and O
eight B_NUMBER[MEASURE]
with O
inferior B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
infarction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
Inf B_DISEASE/B_PROTEIN[GENE]
- O
MI B_LOCATION/B_DISEASE
) O
. O

eighty B_NUMBER[MEASURE]
- O
seven B_NUMBER[MEASURE]
unipolar I_NUMBER[MEASURE]
electrocardiograms I_NUMBER[MEASURE]
( O
ECGs B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
distributed O
over O
the O
entire B_LOCATION/B_BODY_PART_OR_ORGAN_COMPONENT
thoracic I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
surface I_LOCATION/I_BODY_PART_OR_ORGAN_COMPONENT
were O
simultaneously O
recorded O
. O

After O
dipyridamole B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
ischemic O
ST O
- O
segment O
depression O
( O
0 O
. O
05 O
MV O
or O
more O
) O
was O
observed O
in O
84 O
% O
of O
the O
non O
- O
MI O
group O
, O
29 O
% O
of O
the O
ant O
- O
MI O
group O
, O
63 O
% O
of O
the O
INF O
- O
MI O
group O
and O
61 O
% O
of O
the O
total O
population O
. O

Exercise B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
ST B_DISEASE
depression I_DISEASE
was O
observed O
in O
84 B_PERSON/B_MEASURE
% I_PERSON/I_MEASURE
of O
the O
non B_LOCATION
- O
MI B_PERSON/B_ORGANIZATION
group I_PERSON/I_ORGANIZATION
, O
43 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
Ant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
MI B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
38 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
Inf B_DISEASE/B_LOCATION
- O
MI B_ORGANIZATION/B_LOCATION
group B_ORGANIZATION/I_LOCATION
and O
61 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
the O
total B_MEASURE/B_PERSON
. O

For O
individual B_PERSON
patients I_PERSON
, O
there O
were O
no O
obvious B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
between O
the O
body B_MEASURE
surface I_MEASURE
distribution I_MEASURE
of O
ST B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depression B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
tests B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
increase O
in O
pressure O
rate O
product O
after O
dipyridamole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
was O
significantly O
less O
than O
that O
during O
the O
treadmill O
exercise O
. O

The O
data O
suggest O
that O
the O
dipyridamole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
myocardial O
ischemia O
is O
caused O
by O
the O
inhomogenous O
distribution O
of O
myocardial O
blood O
flow O
. O

We O
conclude O
that O
the O
dipyridamole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ECG O
test O
is O
as O
useful O
as O
the O
exercise O
ECG O
test O
for O
the O
assessment O
of O
coronary O
artery O
disease O
. O

Bradycardia O
after O
high O
- O
dose O
intravenous O
methylprednisolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

In O
5 O
consecutive O
patients O
with O
rheumatoid O
arthritis O
who O
received O
intravenous O
high O
- O
dose O
methylprednisolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
MP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
therapy O
( O
1 O
g O
daily O
for O
2 O
or O
3 O
consecutive O
days O
) O
, O
a O
decline O
in O
pulse O
rate O
was O
observed O
, O
most O
pronounced O
on O
day O
4 O
. O

In O
one B_NUMBER[MEASURE]
of O
the O
5 B_PERSON
patients I_PERSON
the O
bradycardia B_DISEASE
was O
associated O
with O
complaints B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
substernal B_DISEASE
pressure I_DISEASE
. O

reversal B_MEASURE/B_PERSON
to O
normal B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
heart I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
rate I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
was O
found O
on O
day B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
7 I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Electrocardiographic B_PERSON/B_ORGANIZATION
registrations I_PERSON/I_ORGANIZATION
showed O
sinus B_DISEASE_ADJECTIVE[DISEASE]
bradycardia I_DISEASE_ADJECTIVE[DISEASE]
in O
all O
cases B_PERSON/B_BIO
. O

No O
significant B_DISEASE_ADJECTIVE[DISEASE]
changes I_DISEASE_ADJECTIVE[DISEASE]
in O
plasma B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
electrolytes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
found O
. O

careful O
observation O
of O
patients O
receiving O
high O
- O
dose O
MP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
recommended O
. O

High O
- O
dose O
MP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
contraindicated O
in O
patients O
with O
known O
heart O
disease O
. O

Two O
cases O
of O
downbeat O
nystagmus O
and O
oscillopsia O
associated O
with O
carbamazepine B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Downbeat B_DISEASE/B_LOCATION
nystagmus I_DISEASE/I_LOCATION
is O
often O
associated O
with O
structural B_DISEASE
lesions I_DISEASE
at O
the O
craniocervical B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
junction I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
but O
has O
occasionally O
been O
reported O
as O
a O
manifestation B_DISEASE
of O
metabolic B_DISEASE_ADJECTIVE[DISEASE]
imbalance I_DISEASE_ADJECTIVE[DISEASE]
or O
drug B_DISEASE
intoxication I_DISEASE
. O

We O
recorded O
the O
eye O
movements O
of O
two O
patients O
with O
reversible O
downbeat O
nystagmus O
related O
to O
carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

The O
nystagmus O
of O
both O
patients O
resolved O
after O
reduction O
of O
the O
serum O
carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
. O

Neuroradiologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
investigations I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
including O
magnetic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resonance I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imaging I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
scans I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
both O
patients B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
showed O
no O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intracranial B_DISEASE
abnormality I_DISEASE
. O

In O
patients B_PERSON/B_LOCATION
with O
downbeat B_DISEASE/B_LOCATION
nystagmus I_DISEASE/I_LOCATION
who O
are O
taking O
anticonvulsant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medications I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
consideration B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
should O
be O
given O
to O
reduction B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
dose B_MEASURE/B_DISEASE
before O
further B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
undertaken O
. O

Improvement O
by O
denopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TA B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
064 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
of O
pentobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cardiac O
failure O
in O
the O
dog O
heart O
- O
lung O
preparation O
. O

The O
efficacy O
of O
denopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
an O
orally O
active O
beta O
1 O
- O
adrenoceptor O
agonist O
, O
in O
improving O
cardiac O
failure O
was O
assessed O
in O
dog O
heart O
- O
lung O
preparations O
. O

cardiac O
functions O
depressed O
by O
pentobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
118 O
+ O
/ O
- O
28 O
mg O
; O
mean O
value O
+ O
/ O
- O
SD O
) O
such O
that O
cardiac O
output O
and O
maximum O
rate O
of O
rise O
of O
left O
ventricular O
pressure O
( O
LV O
dP O
/ O
dt O
Max O
) O
had O
been O
reduced O
by O
about O
35 O
% O
and O
26 O
% O
of O
the O
respective O
controls O
were O
improved O
by O
denopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 O
- O
300 O
micrograms O
) O
in O
a O
dose O
- O
dependent O
manner O
. O

With O
100 O
micrograms O
denopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
almost O
complete O
restoration O
of O
cardiac O
performance O
was O
attained O
, O
associated O
with O
a O
slight O
increase O
in O
heart O
rate O
. O

No O
arrhythmias O
were O
induced O
by O
these O
doses O
of O
denopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
results O
warrant O
clinical O
trials O
of O
denopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
treatment O
of O
cardiac O
failure O
. O

Clonazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
monotherapy O
for O
epilepsy O
in O
childhood O
. O

sixty O
patients O
( O
age O
- O
range O
one O
month O
to O
14 O
years O
) O
with O
other O
types O
of O
epilepsy O
than O
infantile O
spasms O
were O
treated O
with O
clonazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

disappearance B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
seizures B_DISEASE
and O
normalization B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
abnormal B_DISEASE
EEG I_DISEASE
with O
disappearance B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
seizures B_DISEASE
were O
recognized O
in O
77 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
and O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
, O
respectively O
. O

seizures B_DISEASE/B_PERSON
disappeared O
in O
71 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
the O
patients B_PERSON/B_LOCATION
with O
generalized B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
seizures I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
and O
89 B_NUMBER[MEASURE]
% I_NUMBER[MEASURE]
of O
partial B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
seizures I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
. O

Improvement B_DISEASE_ADJECTIVE[DISEASE]
of O
abnormal B_DISEASE
EEG I_DISEASE
was O
noticed O
in O
76 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
of O
diffuse B_DISEASE_ADJECTIVE[DISEASE]
paroxysms I_DISEASE_ADJECTIVE[DISEASE]
and O
in O
67 B_PERSON/B_MEASURE
% B_PERSON/I_MEASURE
of O
focal B_DISEASE_ADJECTIVE[DISEASE]
paroxysms I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
excellent B_MEASURE/B_PERSON
cases I_MEASURE/I_PERSON
, O
mean B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effective B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dosages B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
0 B_MEASURE
. O
086 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
021 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
/ O
day B_TIME[MEASURE]/B_PERSON
in O
infants B_PERSON
and O
0 B_MEASURE
. O
057 B_MEASURE
+ I_MEASURE
/ O
- O
0 B_MEASURE
. O
022 B_MEASURE
mg I_MEASURE
/ O
kg B_MEASURE
/ O
day B_TIME[MEASURE]/B_PERSON
in O
schoolchildren B_PERSON/B_BIO
, O
this O
difference B_MEASURE
was O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
( O
p B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
less B_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
than O
0 B_MEASURE/B_LOCATION
. O
005 B_MEASURE
) O
. O

The O
incidence B_MEASURE
of O
side B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
such I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
drowsiness B_DISEASE
and O
ataxia B_DISEASE
was O
only O
5 B_DISEASE_ADJECTIVE[DISEASE]
% I_DISEASE_ADJECTIVE[DISEASE]
. O

Postmarketing O
study O
of O
timolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
hydrochlorothiazide B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antihypertensive O
therapy O
. O

A O
postmarketing O
surveillance O
study O
was O
conducted O
to O
determine O
the O
safety O
and O
efficacy O
of O
a O
fixed O
- O
ratio O
combination O
containing O
10 O
mg O
of O
timolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maleate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
25 O
mg O
of O
hydrochlorothiazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
administered O
twice O
daily O
for O
one O
month O
to O
hypertensive O
patients O
. O

Data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
9 B_MEASURE
, O
037 B_TIME[MEASURE]
patients I_TIME[MEASURE]
were O
collected O
by O
1 B_MEASURE
, O
455 B_MEASURE
participating O
physicians B_PERSON/B_LOCATION
. O

Mean O
systolic O
blood O
pressure O
decreased O
25 O
mmHg O
and O
mean O
diastolic O
blood O
pressure O
declined O
15 O
mmHg O
after O
one O
month O
of O
timolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
hydrochlorothiazide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
therapy O
( O
P O
less O
than O
0 O
. O
01 O
, O
both O
comparisons O
) O
. O

Age B_TIME[MEASURE]/B_PERSON
, O
race B_SPORT[ENT]/B_PERSON
, O
and O
sex B_PERSON/B_MEASURE
appeared O
to O
have O
no O
influence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
blood B_DISEASE/B_MEASURE
pressure I_DISEASE/I_MEASURE
. O

The O
antihypertensive B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
greater B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
patients B_PERSON/B_BIO
with O
more O
severe B_DISEASE
hypertension I_DISEASE
. O

Overall O
, O
1 B_MEASURE
, O
453 B_MEASURE
patients I_MEASURE
experienced O
a O
total B_MEASURE/B_ENT
of O
2 B_MEASURE
, O
658 B_TIME[MEASURE]
adverse I_TIME[MEASURE]
events I_TIME[MEASURE]
, O
the O
most O
common B_DISEASE_ADJECTIVE[DISEASE]
being I_DISEASE_ADJECTIVE[DISEASE]
fatigue I_DISEASE_ADJECTIVE[DISEASE]
, O
dizziness B_DISEASE
, O
and O
weakness B_DISEASE
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
590 B_MEASURE
patients I_MEASURE
was O
discontinued O
because O
of O
adverse B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
events I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Salicylate B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephropathy O
in O
the O
Gunn O
rat O
: O
potential O
role O
of O
prostaglandins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

We O
examined O
the O
potential O
role O
of O
prostaglandins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
development O
of O
analgesic O
nephropathy O
in O
the O
Gunn O
strain O
of O
rat O
. O

The O
homozygous O
Gunn O
rats O
have O
unconjugated O
hyperbilirubinemia O
due O
to O
the O
absence O
of O
glucuronyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
transferase O
, O
leading O
to O
marked O
bilirubin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deposition O
in O
renal O
medulla O
and O
papilla O
. O

These O
rats B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
also O
highly O
susceptible B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
develop O
papillary B_DISEASE
necrosis I_DISEASE
with O
analgesic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
administration I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

We O
used O
homozygous B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
( O
jj B_LOCATION/B_PERSON
) O
and O
phenotypically O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
heterozygous I_DISEASE_ADJECTIVE[DISEASE]/I_GENE
( O
jJ B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
animals B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Four O
groups O
of O
rats O
( O
n O
= O
7 O
) O
were O
studied O
: O
jj O
and O
jJ O
rats O
treated O
either O
with O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
300 O
mg O
/ O
kg O
every O
other O
day O
or O
sham O
- O
treated O
. O

After O
one O
week O
, O
slices O
of O
cortex O
, O
outer O
and O
inner O
medulla O
from O
one O
kidney O
were O
incubated O
in O
buffer O
and O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O
was O
determined O
by O
radioimmunoassay O
. O

The O
other B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
kidney I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
was O
examined O
histologically O
. O

A O
marked O
corticomedullary O
gradient O
of O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O
was O
observed O
in O
all O
groups O
. O

PGE2 B_GENE
synthesis O
was O
significantly O
higher O
in O
outer O
medulla O
, O
but O
not O
cortex O
or O
inner O
medulla O
, O
of O
jj O
( O
38 O
+ O
/ O
- O
6 O
ng O
/ O
mg O
prot O
) O
than O
jJ O
rats O
( O
15 O
+ O
/ O
- O
3 O
) O
( O
p O
less O
than O
0 O
. O
01 O
) O
. O

Aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment O
reduced O
PGE2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O
in O
all O
regions O
, O
but O
outer O
medullary O
PGE2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
remained O
higher O
in O
jj O
( O
18 O
+ O
/ O
- O
3 O
) O
than O
jJ O
rats O
( O
9 O
+ O
/ O
- O
2 O
) O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

PGF2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
was O
also O
significantly O
higher O
in O
the O
outer O
medulla O
of O
jj O
rats O
with O
and O
without O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administration O
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

The O
changes O
in O
renal O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O
were O
accompanied O
by O
evidence O
of O
renal O
damage O
in O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
treated O
jj O
but O
not O
jJ O
rats O
as O
evidenced O
by O
: O
increased O
incidence O
and O
severity O
of O
hematuria O
( O
p O
less O
than O
0 O
. O
01 O
) O
; O
increased O
serum O
creatinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
p O
less O
than O
0 O
. O
05 O
) O
; O
and O
increase O
in O
outer O
medullary O
histopathologic O
lesions O
( O
p O
less O
than O
0 O
. O
005 O
compared O
to O
either O
sham O
- O
treated O
jj O
or O
aspirin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
jJ O
) O
. O

These O
results O
suggest O
that O
enhanced O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O
contributes O
to O
maintenance O
of O
renal O
function O
and O
morphological O
integrity O
, O
and O
that O
inhibition O
of O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O
may O
lead O
to O
pathological O
renal O
medullary O
lesions O
and O
deterioration O
of O
renal O
function O
. O

Prophylactic O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
early O
phase O
of O
suspected O
myocardial O
infarction O
. O

Four O
hundred O
two O
patients O
with O
suspected O
myocardial O
infarction O
seen O
within O
6 O
hours O
of O
the O
onset O
of O
symptoms O
entered O
a O
double O
- O
blind O
randomized O
trial O
of O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vs O
placebo O
. O

During O
the O
1 B_TIME[MEASURE]/B_ENT
hour I_TIME[MEASURE]/I_ENT
after O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
incidence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
ventricular B_DISEASE_ADJECTIVE[DISEASE]
fibrillation I_DISEASE_ADJECTIVE[DISEASE]
or O
sustained O
ventricular B_DISEASE
tachycardia I_DISEASE
among O
the O
204 B_PERSON
patients I_PERSON
with O
acute B_DISEASE
myocardial I_DISEASE
infarction I_DISEASE
was O
low B_MEASURE/B_COLOR
, O
1 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
. O

Lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
given O
in O
a O
300 O
mg O
dose O
intramuscularly O
followed O
by O
100 O
mg O
intravenously O
, O
did O
not O
prevent O
sustained O
ventricular O
tachycardia O
, O
although O
there O
was O
a O
significant O
reduction O
in O
the O
number O
of O
patients O
with O
warning O
arrhythmias O
between O
15 O
and O
45 O
minutes O
after O
the O
administration O
of O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p O
less O
than O
0 O
. O
05 O
) O
. O

The O
average O
plasma O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O
10 O
minutes O
after O
administration O
for O
patients O
without O
a O
myocardial O
infarction O
was O
significantly O
higher O
than O
that O
for O
patients O
with O
an O
acute O
infarction O
. O

The O
mean O
plasma O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
level O
of O
patients O
on O
beta O
- O
blocking O
agents O
was O
no O
different O
from O
that O
in O
patients O
not O
on O
beta O
blocking O
agents O
. O

During O
the O
1 O
- O
hour O
study O
period O
, O
the O
incidence O
of O
central O
nervous O
system O
side O
effects O
was O
significantly O
greater O
in O
the O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O
, O
hypotension O
occurred O
in O
11 O
patients O
, O
nine O
of O
whom O
had O
received O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
four O
patients O
died O
from O
asystole O
, O
three O
of O
whom O
had O
had O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

We O
cannot O
advocate O
the O
administration O
of O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prophylactically O
in O
the O
early O
hours O
of O
suspected O
myocardial O
infarction O
. O

Evidence O
for O
a O
cholinergic O
role O
in O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
catalepsy O
. O

experiments O
in O
mice O
tested O
previous O
evidence O
that O
activation O
of O
cholinergic O
systems O
promotes O
catalepsy O
and O
that O
cholinergic O
mechanisms O
need O
to O
be O
intact O
for O
full O
expression O
of O
neuroleptic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
catalepsy O
. O

Large O
doses O
of O
the O
cholinomimetic O
, O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
could O
induce O
catalepsy O
when O
peripheral O
cholinergic O
receptors O
were O
blocked O
. O

Low O
doses O
of O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caused O
a O
pronounced O
enhancement O
of O
the O
catalepsy O
that O
was O
induced O
by O
the O
dopaminergic O
blocker O
, O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

A O
muscarinic O
receptor O
blocker O
, O
atropine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
disrupted O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
catalepsy O
. O

Intracranial O
injection O
of O
an O
acetylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
synthesis O
inhibitor O
, O
hemicholinium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
prevented O
the O
catalepsy O
that O
is O
usually O
induced O
by O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

These O
findings O
suggest O
the O
hypothesis O
that O
the O
catalepsy O
that O
is O
produced O
by O
neuroleptics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
such O
as O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
actually O
mediated O
by O
intrinsic O
central O
cholinergic O
systems O
. O

Alternatively O
, O
activation B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
of O
central B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
cholinergic I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
systems I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
could O
promote O
catalepsy B_DISEASE/B_ORGANISM_FUNCTION
by O
suppression B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
dopaminergic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
systems B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Cardiovascular O
dysfunction O
and O
hypersensitivity O
to O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pentobarbital I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
induced O
by O
chronic O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
chloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
ingestion O
. O

Barium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
supplemented O
Long O
- O
Evans O
hooded O
rats O
were O
characterized O
by O
a O
persistent O
hypertension O
that O
was O
evident O
after O
1 O
month O
of O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
100 O
micrograms O
/ O
ml O
mineral O
fortified O
water O
) O
treatment O
. O

Analysis O
of O
in O
vivo O
myocardial O
excitability O
, O
contractility O
, O
and O
metabolic O
characteristics O
at O
16 O
months O
revealed O
other O
significant O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
disturbances O
within O
the O
cardiovascular O
system O
. O

The O
most O
distinctive O
aspect O
of O
the O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
effect O
was O
a O
demonstrated O
hypersensitivity O
of O
the O
cardiovascular O
system O
to O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pentobarbital I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Under O
barbiturate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O
, O
virtually O
all O
of O
the O
myocardial O
contractile O
indices O
were O
depressed O
significantly O
in O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
exposed O
rats O
relative O
to O
the O
corresponding O
control O
- O
fed O
rats O
. O

The O
lack O
of O
a O
similar O
response O
to O
ketamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
xylazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
anesthesia O
revealed O
that O
the O
cardiovascular O
actions O
of O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pentobarbital I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
rats O
were O
linked O
specifically O
to O
this O
anesthetic O
, O
and O
were O
not O
representative O
of O
a O
generalized O
anesthetic O
response O
. O

Other O
myocardial O
pathophysiologic O
and O
metabolic O
changes O
induced O
by O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
manifest O
, O
irrespective O
of O
the O
anesthetic O
employed O
. O

The O
contractile O
element O
shortening O
velocity O
of O
the O
cardiac O
muscle O
fibers O
was O
significantly O
slower O
in O
both O
groups O
of O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
rats O
relative O
to O
the O
control O
groups O
, O
irrespective O
of O
the O
anesthetic O
regimen O
. O

Similarly O
, O
significant O
disturbances O
in O
myocardial O
energy O
metabolism O
were O
detected O
in O
the O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
exposed O
rats O
which O
were O
consistent O
with O
the O
reduced O
contractile O
element O
shortening O
velocity O
. O

In O
addition O
, O
the O
excitability O
of O
the O
cardiac O
conduction O
system O
was O
depressed O
preferentially O
in O
the O
atrioventricular O
nodal O
region O
of O
hearts O
from O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
exposed O
rats O
. O

Overall O
, O
the O
altered O
cardiac O
contractility O
and O
excitability O
characteristics O
, O
the O
myocardial O
metabolic O
disturbances O
, O
and O
the O
hypersensitivity O
of O
the O
cardiovascular O
system O
to O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pentobarbital I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
suggest O
the O
existence O
of O
a O
heretofore O
undescribed O
cardiomyopathic O
disorder O
induced O
by O
chronic O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
exposure O
. O

These O
experimental O
findings O
represent O
the O
first O
indication O
that O
life O
- O
long O
barium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
ingestion O
may O
have O
significant O
adverse O
effects O
on O
the O
mammalian O
cardiovascular O
system O
. O

Propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antagonism O
of O
phenylpropanolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hypertension O
. O

Phenylpropanolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
PPA B_DISEASE
) O
overdose O
can O
cause O
severe O
hypertension O
, O
intracerebral O
hemorrhage O
, O
and O
death O
. O

We O
studied O
the O
efficacy O
and O
safety O
of O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
treatment O
of O
PPA B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hypertension O
. O

subjects O
received O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
either O
by O
mouth O
for O
48 O
hours O
before O
PPA B_DISEASE
or O
as O
a O
rapid O
intravenous O
infusion O
after O
PPA B_DISEASE
. O

PPA B_MEASURE/B_DISEASE
, O
75 O
mg O
alone O
, O
increased O
blood O
pressure O
( O
31 O
+ O
/ O
- O
14 O
mm O
Hg O
systolic O
, O
20 O
+ O
/ O
- O
5 O
mm O
Hg O
diastolic O
) O
, O
and O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
pretreatment O
antagonized O
this O
increase O
( O
12 O
+ O
/ O
- O
10 O
mm O
Hg O
systolic O
, O
10 O
+ O
/ O
- O
7 O
mm O
Hg O
diastolic O
) O
. O

Intravenous O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
after O
PPA B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
also O
decreased O
blood O
pressure O
. O

Left O
ventricular O
function O
( O
assessed O
by O
echocardiography O
) O
showed O
that O
PPA B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
increased O
the O
stroke O
volume O
30 O
% O
( O
from O
62 O
. O
5 O
+ O
/ O
- O
20 O
. O
9 O
to O
80 O
. O
8 O
+ O
/ O
- O
22 O
. O
4 O
ml O
) O
, O
the O
ejection O
fraction O
9 O
% O
( O
from O
64 O
% O
+ O
/ O
- O
10 O
% O
to O
70 O
% O
+ O
/ O
- O
7 O
% O
) O
, O
and O
cardiac O
output O
14 O
% O
( O
from O
3 O
. O
6 O
+ O
/ O
- O
0 O
. O
6 O
to O
4 O
. O
1 O
+ O
/ O
- O
1 O
. O
0 O
L O
/ O
min O
) O
. O

Intravenous O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reversed O
these O
effects O
. O

systemic O
vascular O
resistance O
was O
increased O
by O
PPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
28 O
% O
( O
from O
1710 O
+ O
/ O
- O
200 O
to O
2190 O
+ O
/ O
- O
700 O
dyne O
X O
SEC O
/ O
cm5 O
) O
and O
was O
further O
increased O
by O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
22 O
% O
( O
to O
2660 O
+ O
/ O
- O
1200 O
dyne O
X O
SEC O
/ O
cm5 O
) O
. O

We O
conclude O
that O
PPA B_DISEASE/B_GENE
increases O
blood O
pressure O
by O
increasing O
systemic O
vascular O
resistance O
and O
cardiac O
output O
, O
and O
that O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antagonizes O
this O
increase O
by O
reversing O
the O
effect O
of O
PPA B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
cardiac O
output O
. O

That O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
antagonizes O
the O
pressor O
effect O
of O
PPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
is O
in O
contrast O
to O
the O
interaction O
in O
which O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
enhances O
the O
pressor O
effect O
of O
norepinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

This O
is O
probably O
because O
PPA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
has O
less O
beta O
2 O
activity O
than O
does O
norepinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
. O

Mesangial O
function O
and O
glomerular O
sclerosis O
in O
rats O
with O
aminonucleoside B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephrosis O
. O

The O
possible O
relationship O
between O
mesangial O
dysfunction O
and O
development O
of O
glomerular O
sclerosis O
was O
studied O
in O
the O
puromycin B_DISEASE
aminonucleoside I_DISEASE
( O
PAN B_DISEASE
) O
model O
. O

Five O
male O
Wistar O
rats O
received O
repeated O
subcutaneous O
PAN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injections O
; O
five O
controls O
received O
saline O
only O
. O

After O
4 O
weeks O
the O
PAN B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rats O
were O
severely O
proteinuric O
( O
190 O
+ O
/ O
- O
80 O
mg O
/ O
24 O
hr O
) O
, O
and O
all O
rats O
were O
given O
colloidal O
carbon B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CC O
) O
intravenously O
. O

At O
5 O
months O
glomerular O
sclerosis O
was O
found O
in O
7 O
. O
6 O
+ O
/ O
- O
3 O
. O
4 O
% O
of O
the O
glomeruli O
of O
PAN B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rats O
; O
glomeruli O
of O
the O
controls O
were O
normal O
. O

Glomeruli O
of O
PAN B_DISEASE
rats O
contained O
significantly O
more O
CC O
than O
glomeruli O
of O
controls O
. O

Glomeruli B_PERSON/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
with O
sclerosis B_DISEASE
contained O
significantly O
more O
CC B_DISEASE/B_GENE
than O
non B_DISEASE
- O
sclerotic B_DISEASE/B_LOCATION
glomeruli I_DISEASE/I_LOCATION
in O
the O
same B_BODY_PART_OR_ORGAN_COMPONENT/B_ENT
kidneys I_BODY_PART_OR_ORGAN_COMPONENT/I_ENT
. O

CC B_GENE/B_DISEASE
was O
preferentially O
localized O
within O
the O
sclerotic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
areas I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
affected B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
glomeruli I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

Since O
mesangial O
CC O
clearance O
from O
the O
mesangium O
did O
not O
change O
during O
chronic O
PAN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
, O
we O
conclude O
that O
this O
preferential O
CC O
localization O
within O
the O
lesions O
is O
caused O
by O
an O
increased O
CC O
uptake O
shortly O
after O
injection O
in O
apparent O
vulnerable O
areas O
where O
sclerosis O
will O
develop O
subsequently O
. O

cluster O
analysis O
showed O
a O
random O
distribution O
of O
lesions O
in O
the O
PAN B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
glomeruli O
in O
concordance O
with O
the O
random O
localization O
of O
mesangial O
areas O
with O
dysfunction O
in O
this O
model O
. O

Similar O
to O
the O
remnant O
kidney O
model O
in O
PAN B_DISEASE_ADJECTIVE[DISEASE]
nephrosis O
the O
development O
of O
glomerular O
sclerosis O
may O
be O
related O
to O
' O
mesangial O
overloading O
. O
' O
. O

relationship O
between O
nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
seizures O
and O
hippocampal O
nicotinic O
receptors O
. O

A O
controversy B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
existed O
for O
several B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
years I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
concerning O
the O
physiological B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relevance B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
nicotinic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
receptor I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
measured O
by O
alpha B_PROTEIN[GENE]/B_MEASURE
- O
bungarotoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Using O
mice O
derived O
from O
a O
classical O
F2 O
and O
backcross O
genetic O
design O
, O
a O
relationship O
between O
nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
seizures O
and O
alpha O
- O
bungarotoxin O
nicotinic O
receptor O
concentration O
was O
found O
. O

mice O
sensitive O
to O
the O
convulsant O
effects O
of O
nicotine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
had O
greater O
alpha O
- O
bungarotoxin O
binding O
in O
the O
hippocampus O
than O
seizure O
insensitive O
mice O
. O

The O
binding O
sites O
from O
seizure O
sensitive O
and O
resistant O
mice O
were O
equally O
affected O
by O
treatment O
with O
dithiothreitol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
, O
trypsin O
or O
heat O
. O

Thus O
it O
appears O
that O
the O
difference B_MEASURE
between O
seizure B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
sensitive I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
and O
insensitive B_DISEASE_ADJECTIVE[DISEASE]
animals I_DISEASE_ADJECTIVE[DISEASE]
may O
be O
due B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
a O
difference B_MEASURE
in O
hippocampal B_MEASURE/B_DISEASE
nicotinic I_MEASURE/I_DISEASE
receptor I_MEASURE/I_DISEASE
concentration I_MEASURE/I_DISEASE
as O
measured O
with O
alpha B_PROTEIN[GENE]
- O
bungarotoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
binding I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
role O
of O
p B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
aminophenol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
nephrotoxicity O
: O
effect O
of O
bis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
p I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrophenyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
phosphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
p B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aminophenol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephrotoxicity O
and O
metabolism O
in O
Fischer O
344 O
rats O
. O

Acetaminophen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
produces O
proximal O
tubular O
necrosis O
in O
Fischer O
344 O
( O
F344 O
) O
rats O
. O

Recently O
, O
p B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
aminophenol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
PAP B_GENE/B_DISEASE
) O
, O
a O
known O
potent O
nephrotoxicant O
, O
was O
identified O
as O
a O
metabolite O
of O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
F344 O
rats O
. O

The O
purpose O
of O
this O
study O
was O
to O
determine O
if O
PAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
formation O
is O
a O
requisite O
step O
in O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
nephrotoxicity O
. O

Therefore O
, O
the O
effect O
of O
bis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
p I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nitrophenyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
phosphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
BNPP B_DISEASE/B_GENE
) O
, O
an O
acylamidase O
inhibitor O
, O
on O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
PAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
nephrotoxicity O
and O
metabolism O
was O
determined O
. O

BNPP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
1 O
to O
8 O
mm O
) O
reduced O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deacetylation O
and O
covalent O
binding O
in O
F344 O
renal O
cortical O
homogenates O
in O
a O
concentration O
- O
dependent O
manner O
. O

Pretreatment O
of O
animals O
with O
BNPP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
prior O
to O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
PAP B_PROTEIN[GENE]/B_DISEASE
administration O
resulted O
in O
marked O
reduction O
of O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
900 O
mg O
/ O
kg O
) O
nephrotoxicity O
but O
not O
PAP B_PROTEIN[GENE]
nephrotoxicity O
. O

This O
result O
was O
not O
due O
to O
altered O
disposition O
of O
either O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
acetylated O
metabolites O
in O
plasma O
or O
renal O
cortical O
and O
hepatic O
tissue O
. O

Rather O
, O
BNPP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pretreatment O
reduced O
the O
fraction O
of O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
excreted O
as O
PAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
by O
64 O
and O
75 O
% O
after O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
doses O
of O
750 O
and O
900 O
mg O
/ O
kg O
. O

BNPP B_DISEASE/B_GENE
did O
not O
alter O
the O
excretion O
of O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
or O
any O
of O
its O
non O
- O
deacetylated O
metabolites O
nor O
did O
BNPP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
alter O
excretion O
of O
PAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
or O
its O
metabolites O
after O
PAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
doses O
of O
150 O
and O
300 O
mg O
/ O
kg O
. O

Therefore O
, O
the O
BNPP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
reduction O
in O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
nephrotoxicity O
appears O
to O
be O
due O
to O
inhibition O
of O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
deacetylation O
. O

It O
is O
concluded O
that O
PAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
formation O
, O
in O
vivo O
, O
accounts O
, O
at O
least O
in O
part O
, O
for O
APAP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
renal O
tubular O
necrosis O
. O

Morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
seizures O
in O
newborn O
infants O
. O

Two O
neonates O
suffered O
from O
generalized O
seizures O
during O
the O
course O
of O
intravenous O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
post O
- O
operative O
analgesia O
. O

They O
received O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
doses O
of O
32 O
micrograms O
/ O
kg O
/ O
hr O
and O
40 O
micrograms O
/ O
kg O
/ O
hr O
larger O
than O
a O
group O
of O
10 O
neonates O
who O
received O
6 O
- O
24 O
micrograms O
/ O
kg O
/ O
hr O
and O
had O
no O
seizures O
. O

plasma O
concentrations O
of O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
these O
neonates O
was O
excessive O
( O
60 O
and O
90 O
mg O
/ O
ml O
) O
. O

Other O
known O
reasons O
for O
seizures O
were O
ruled O
out O
and O
the O
convulsions O
stopped O
a O
few O
hours O
after O
cessation O
of O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
did O
not O
reoccur O
in O
the O
subsequent O
8 O
months O
. O

It O
is O
suggested O
that O
post O
- O
operative O
intravenous O
morphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
not O
exceed O
20 O
micrograms O
/ O
kg O
/ O
ml O
in O
neonates O
. O

Indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
induced O
hypotension O
in O
sodium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
volume O
depleted O
rats O
. O

After O
a O
single O
oral O
dose O
of O
4 O
mg O
/ O
kg O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
IDM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
to O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
volume O
depleted O
rats O
plasma O
renin O
activity O
( O
PRA O
) O
and O
systolic O
blood O
pressure O
fell O
significantly O
within O
four O
hours O
. O

In O
sodium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
repleted O
animals O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
did O
not O
change O
systolic O
blood O
pressure O
( O
BP O
) O
although O
plasma O
renin O
activity O
was O
decreased O
. O

Thus O
, O
indomethacin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
by O
inhibition O
of O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O
may O
diminish O
the O
blood O
pressure O
maintaining O
effect O
of O
the O
stimulated O
renin O
- O
angiotensin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
system O
in O
sodium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
volume O
depletion O
. O

On O
the O
antiarrhythmic O
activity O
of O
one O
N O
- O
substituted O
piperazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
derivative O
of O
trans B_LOCATION
- I_LOCATION
2 I_LOCATION
- I_LOCATION
amino I_LOCATION
- I_LOCATION
3 I_LOCATION
- I_LOCATION
hydroxy I_LOCATION
- I_LOCATION
1 I_LOCATION
, I_LOCATION
2 I_LOCATION
, I_LOCATION
3 I_LOCATION
, I_LOCATION
4 I_LOCATION
- I_LOCATION
tetrahydroanaphthalene I_LOCATION
. O

The O
antiarrhythmic O
activity O
of O
the O
compound O
N B_TIME[MEASURE]/B_PROTEIN[GENE]
- B_TIME[MEASURE]/I_PROTEIN[GENE]
( B_TIME[MEASURE]/I_PROTEIN[GENE]
trans B_TIME[MEASURE]/I_PROTEIN[GENE]
- B_TIME[MEASURE]/I_PROTEIN[GENE]
3 B_TIME[MEASURE]/I_PROTEIN[GENE]
- B_TIME[MEASURE]/I_PROTEIN[GENE]
hydroxy B_TIME[MEASURE]/I_PROTEIN[GENE]
- B_TIME[MEASURE]/I_PROTEIN[GENE]
1 B_TIME[MEASURE]/I_PROTEIN[GENE]
, B_TIME[MEASURE]/I_PROTEIN[GENE]
2 B_TIME[MEASURE]/I_PROTEIN[GENE]
, B_TIME[MEASURE]/I_PROTEIN[GENE]
3 B_TIME[MEASURE]/I_PROTEIN[GENE]
, B_TIME[MEASURE]/I_PROTEIN[GENE]
4 B_TIME[MEASURE]/I_PROTEIN[GENE]
- B_TIME[MEASURE]/I_PROTEIN[GENE]
tetrahydro B_TIME[MEASURE]/I_PROTEIN[GENE]
- B_TIME[MEASURE]/I_PROTEIN[GENE]
2 B_TIME[MEASURE]/I_PROTEIN[GENE]
- B_TIME[MEASURE]/I_PROTEIN[GENE]
naphthyl B_TIME[MEASURE]/I_PROTEIN[GENE]
) B_TIME[MEASURE]/I_PROTEIN[GENE]
- B_TIME[MEASURE]/I_PROTEIN[GENE]
N B_TIME[MEASURE]/I_PROTEIN[GENE]
- B_TIME[MEASURE]/I_PROTEIN[GENE]
( B_TIME[MEASURE]/I_PROTEIN[GENE]
3 B_TIME[MEASURE]/I_PROTEIN[GENE]
- B_TIME[MEASURE]/I_PROTEIN[GENE]
oxo B_TIME[MEASURE]/I_PROTEIN[GENE]
- B_TIME[MEASURE]/I_PROTEIN[GENE]
3 B_TIME[MEASURE]/I_PROTEIN[GENE]
- B_TIME[MEASURE]/I_PROTEIN[GENE]
phenyl B_TIME[MEASURE]/I_PROTEIN[GENE]
- B_TIME[MEASURE]/I_PROTEIN[GENE]
2 B_TIME[MEASURE]/I_PROTEIN[GENE]
- B_TIME[MEASURE]/I_PROTEIN[GENE]
methylpropyl B_TIME[MEASURE]/I_PROTEIN[GENE]
) B_TIME[MEASURE]/I_PROTEIN[GENE]
- B_TIME[MEASURE]/I_PROTEIN[GENE]
piperazine B_TIME[MEASURE]/I_PROTEIN[GENE]
hydrochloride B_TIME[MEASURE]/I_PROTEIN[GENE]
, O
referred O
to O
as O
P11 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
is O
studied O
on O
anaesthesized O
cats O
and O
Wistar O
albino O
rats O
, O
as O
well O
as O
on O
non O
- O
anaesthesized O
rabbits O
. O

Four O
types O
of O
experimental O
arrhythmia O
are O
used O
- O
- O
with O
BaCl2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
with O
chloroform B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
adrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
with O
strophantine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
G I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
with O
aconitine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
compound O
P11 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
introduced O
in O
doses O
of O
0 O
. O
25 O
and O
0 O
. O
50 O
mg O
/ O
kg O
intravenously O
and O
10 O
mg O
/ O
kg O
orally O
. O

The O
compound O
manifests O
antiarrhythmic O
activity O
in O
all O
models O
of O
experimental O
arrhythmia O
used O
, O
causing O
greatest O
inhibition O
on O
the O
arrhythmia O
induced O
by O
chloroform B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
adrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
in O
90 O
per O
cent O
) O
and O
with O
BaCl2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
in O
84 O
per O
cent O
) O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
obtained O
are O
associated O
with O
the O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
adrenoblocking B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
and O
with O
the O
membrane B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
stabilizing O
action B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
compound B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Recurrent O
subarachnoid O
hemorrhage O
associated O
with O
aminocaproic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
and O
acute O
renal O
artery O
thrombosis O
. O

Case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Epsilon B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
aminocaproic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
acid I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
EACA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
) O
has O
been O
used O
to O
prevent O
rebleeding O
in O
patients O
with O
subarachnoid O
hemorrhage O
( O
SAH O
) O
. O

Although O
this O
agent O
does O
decrease O
the O
frequency O
of O
rebleeding O
, O
several O
reports O
have O
described O
thrombotic O
complications O
of O
EACA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O
. O

These O
complications O
have O
included O
clinical O
deterioration O
and O
intracranial O
vascular O
thrombosis O
in O
patients O
with O
SAH O
, O
arteriolar O
and O
capillary O
fibrin O
thrombi O
in O
patients O
with O
fibrinolytic O
syndromes O
treated O
with O
EACA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
other O
thromboembolic O
phenomena O
. O

Since O
intravascular O
fibrin O
thrombi O
are O
often O
observed O
in O
patients O
with O
fibrinolytic O
disorders O
, O
EACA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
should O
not O
be O
implicated O
in O
the O
pathogenesis O
of O
fibrin O
thrombi O
in O
patients O
with O
disseminated O
intravascular O
coagulation O
or O
other O
' O
consumption O
coagulopathies O
. O
' O
This O
report O
describes O
subtotal O
infarction O
of O
the O
kidney O
due O
to O
thrombosis O
of O
a O
normal O
renal O
artery O
. O

This O
occlusion O
occurred O
after O
EACA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
in O
a O
patient O
with O
SAH O
and O
histopathological O
documentation O
of O
recurrent O
SAH O
. O

The O
corresponding B_DISEASE
clinical I_DISEASE
event I_DISEASE
was O
characterized O
by O
marked B_DISEASE
hypertension I_DISEASE
and O
abrupt B_DISEASE
neurological I_DISEASE
deterioration I_DISEASE
. O

Effect O
of O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
Pseudomonas O
infections O
in O
monkeys O
. O

In O
rhesus B_SPECIES[BIO]
monkeys I_SPECIES[BIO]
, O
intravenous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
challenge I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
with O
0 B_MEASURE/B_LOCATION
. O
6 B_MEASURE
x O
10 B_NUMBER[MEASURE]
( O
10 B_MEASURE
) O
to O
2 B_MEASURE
. O
2 B_MEASURE
x O
10 B_MEASURE
( O
10 B_MEASURE
) O
Pseudomonas B_SPECIES[BIO]/B_DISEASE_ADJECTIVE[DISEASE]
aeruginosa I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
organisms I_SPECIES[BIO]/I_DISEASE_ADJECTIVE[DISEASE]
caused O
acute B_DISEASE
illness I_DISEASE
of O
4 B_NUMBER[MEASURE]/B_LOCATION
to O
5 B_TIME[MEASURE]
days I_TIME[MEASURE]
' I_TIME[MEASURE]
duration I_TIME[MEASURE]
with O
spontaneous B_DISEASE
recovery I_DISEASE
in O
13 B_NUMBER[MEASURE]/B_PERSON
of O
15 B_MEASURE/B_PERSON
monkeys B_MEASURE/I_PERSON
; O
blood B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
cultures I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
became O
negative B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
3 I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
17 B_SEQUENCE[MEASURE]/B_ENT
days I_SEQUENCE[MEASURE]/I_ENT
after O
challenge B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Leukocytosis B_DISEASE_ADJECTIVE[DISEASE]
was O
observed O
in O
all O
monkeys B_BIO/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Intravenous O
or O
intratracheal O
inoculation O
of O
2 O
. O
0 O
to O
2 O
. O
5 O
mg O
of O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
followed O
by O
leukopenia O
in O
4 O
to O
5 O
days O
. O

Intravenous O
inoculation O
of O
4 O
. O
2 O
x O
10 O
( O
10 O
) O
to O
7 O
. O
8 O
x O
10 O
( O
10 O
) O
pyocin O
type O
6 O
Pseudomonas O
organisms O
in O
monkeys O
given O
vincristine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
4 O
days O
previously O
resulted O
in O
fatal O
infection O
in O
11 O
of O
14 O
monkeys O
, O
whereas O
none O
of O
four O
receiving O
Pseudomonas O
alone O
died O
. O

These O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O
that O
an O
antimetabolite B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
leukopenia B_DISEASE
predisposes O
to O
severe B_DISEASE
Pseudomonas I_DISEASE
sepsis I_DISEASE
and O
that O
such B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
monkeys I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
may O
serve O
as O
a O
biological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
comparative B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
efficacy I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
of O
antimicrobial B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

modification O
by O
propranolol B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
cardiovascular O
effects O
of O
induced O
hypoglycaemia O
. O

The O
cardiovascular B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
hypoglycaemia B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
with O
and O
without O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
blockade B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
were O
compared O
in O
fourteen B_TIME[MEASURE]/B_PERSON
healthy I_TIME[MEASURE]/I_PERSON
men I_TIME[MEASURE]/I_PERSON
. O

Eight O
received O
insulin O
alone O
, O
and O
eight O
, O
including O
two O
of O
the O
original O
insulin O
- O
only O
group O
, O
were O
given O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
insulin O
. O

In O
the O
insulin B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
period B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
of O
hypoglycaemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
associated O
with O
an O
increase B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
heart B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
rate B_MEASURE/B_ENT
and O
a O
fall B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
diastolic B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
blood I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
- O
pressure B_MEASURE
. O

In O
the O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
insulin O
group O
there O
was O
a O
significant O
fall O
in O
heart O
- O
rate O
in O
most O
subjects O
and O
an O
increase O
in O
diastolic O
pressure O
. O

Typical O
S O
- O
T O
/ O
T O
changes O
occurred O
in O
the O
insulin O
- O
group O
but O
in O
none O
of O
the O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
insulin O
group O
. O

Hypertension B_DISEASE/B_PERSON
in O
diabetics B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prone I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
hypoglycaemia B_DISEASE/B_GENE
attacks I_DISEASE/I_GENE
should O
not O
be O
treated O
with O
beta B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
blockers B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
because O
these O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
cause O
a O
sharp B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rise I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
blood B_BODY_PART_OR_ORGAN_COMPONENT
- O
pressure B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
such B_PERSON/B_BIO
patients I_PERSON/I_BIO
. O

Long O
- O
term O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
in O
pregnancy O
: O
maternal O
and O
fetal O
outcome O
. O

Propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
beta O
- O
adrenergic O
blocking O
agent O
, O
has O
found O
an O
important O
position O
in O
the O
practice O
of O
medicine O
. O

Its O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
pregnancy B_PERSON
, O
however O
, O
is O
an O
open B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
question I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
number B_MEASURE/B_PERSON
of O
detrimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
side I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
have O
been O
reported O
in O
the O
fetus B_PERSON/B_BIO
and O
neonate B_PERSON/B_BIO
. O

Ten O
patients O
and O
12 O
pregnancies O
are O
reported O
where O
chronic O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
administered O
. O

Five O
patients O
with O
serial O
pregnancies O
with O
and O
without O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
are O
also O
examined O
. O

maternal B_PERSON
, O
fetal B_PERSON
, O
and O
neonatal B_PERSON
complications I_PERSON
are O
examined O
. O

An O
attempt B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
made O
to O
differentiate O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
- O
related O
complications B_DISEASE
from O
maternal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
disease I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
- O
related O
complications B_DISEASE
. O

We O
conclude O
that O
previously O
reported O
hypoglycemia O
, O
hyperbilirubinemia O
, O
polycythemia O
, O
neonatal O
apnea O
, O
and O
bradycardia O
are O
not O
invariable O
and O
cannot O
be O
statistically O
correlated O
with O
chronic O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O
. O

Growth B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
retardation I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
, O
however O
, O
appears O
to O
be O
significant B_DISEASE_ADJECTIVE[DISEASE]
in O
both O
of O
our O
series B_SPORT[ENT]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Central O
excitatory O
actions O
of O
flurazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

toxic O
actions O
of O
flurazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
FZP B_PROTEIN[GENE]/B_DISEASE
) O
were O
studied O
in O
cats O
, O
mice O
and O
rats O
. O

High B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
doses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
caused O
an O
apparent B_DISEASE
central I_DISEASE
excitation I_DISEASE
, O
most O
clearly O
seen O
as O
clonic B_DISEASE_ADJECTIVE[DISEASE]
convulsions I_DISEASE_ADJECTIVE[DISEASE]
, O
superimposed O
on O
general B_DISEASE
depression I_DISEASE
. O

Following O
a O
lethal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dose I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
death B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
always O
associated O
with O
convulsions B_DISEASE
. O

comparing O
the O
relative B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivity B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
central B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
depression B_DISEASE_ADJECTIVE[DISEASE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
excitation B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
revealed O
that O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
least O
likely B_DISEASE_ADJECTIVE[DISEASE]
to O
have O
convulsions B_DISEASE
at O
doses B_TIME[MEASURE]/B_LOCATION
that O
did O
not O
first B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cause O
loss B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
consciousness B_DISEASE
, O
while O
cats B_SPECIES[BIO]
most O
clearly O
showed O
marked O
central B_DISEASE
excitatory I_DISEASE
actions I_DISEASE
. O

signs O
of O
FZP B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
toxocity O
in O
cats O
included O
excessive O
salivation O
, O
extreme O
apprehensive O
behavior O
, O
retching O
, O
muscle O
tremors O
and O
convulsions O
. O

An O
interaction O
between O
FZP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
and O
pentylenetetrazol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
PTZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
was O
shown O
by O
pretreating O
mice O
with O
FZP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
before O
PTZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
challenge O
. O

As O
a O
function O
of O
dose O
, O
FZP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
first O
protected O
against O
convulsions O
and O
death O
. O

At O
higher B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
doses I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
however O
, O
convulsions B_DISEASE
again O
emerged O
. O

These O
doses O
of O
FZP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
lower O
than O
those O
that O
would O
alone O
cause O
convulsions O
. O

These O
results O
may O
be O
relevant O
to O
the O
use O
of O
FZP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
clinical O
situations O
in O
which O
there O
is O
increased O
neural O
excitability O
, O
such O
as O
epilepsy O
or O
sedative O
- O
hypnotic O
drug O
withdrawal O
. O

Use O
of O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
treatment O
of O
idiopathic O
orthostatic O
hypotension O
. O

Five B_PERSON
patients I_PERSON
with O
idiopathic B_DISEASE/B_GENE
orthostatic I_DISEASE/I_GENE
hypotension I_DISEASE/I_GENE
who O
had O
physiologic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
biochemical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
evidence I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
severe B_DISEASE
autonomic I_DISEASE
dysfunction I_DISEASE
were O
included O
in O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

They O
all O
exhibited O
markedly O
reduced O
plasma O
catecholamines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
plasma O
renin O
activity O
in O
both O
recumbent O
and O
upright O
positions O
and O
had O
marked O
hypersensitivity O
to O
the O
pressor O
effects O
of O
infused O
norepinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

Treatment O
with O
propanolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administered O
intravenously O
( O
1 O
- O
5 O
mg O
) O
produced O
increases O
in O
supine O
and O
upright O
blood O
pressure O
in O
4 O
of O
the O
5 O
individuals O
with O
rises O
ranging O
from O
11 O
/ O
6 O
to O
22 O
/ O
11 O
mmHg O
. O

chronic O
oral O
administration O
of O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
40 O
- O
160 O
mg O
/ O
day O
) O
also O
elevated O
the O
blood O
pressures O
of O
these O
individuals O
with O
increases O
in O
the O
order O
of O
20 O
- O
35 O
/ O
15 O
- O
25 O
mmg O
being O
observed O
. O

In O
1 O
patient O
, O
marked O
hypertension O
was O
induced O
by O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
drug O
had O
to O
be O
withdrawn O
. O

It O
otherwise O
was O
well O
tolerated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
no O
important B_DISEASE_ADJECTIVE[DISEASE]
side I_DISEASE_ADJECTIVE[DISEASE]
effects I_DISEASE_ADJECTIVE[DISEASE]
were O
observed O
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
has O
been O
continued O
in O
3 B_PERSON/B_BIO
individuals I_PERSON/I_BIO
for O
6 B_NUMBER[MEASURE]
- O
13 B_TIME[MEASURE]
months I_TIME[MEASURE]
with O
persistence B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
pressor B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
although O
there O
appears O
to O
have O
been O
some O
decrease B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
degree B_MEASURE
of O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
time B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Hemodynamic O
measurements O
in O
1 O
of O
the O
patients O
demonstrated O
an O
increase O
in O
total O
peripheral O
resistance O
and O
essentially O
no O
change O
in O
cardiac O
output O
following O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O
. O

The O
studies O
suggest O
that O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
useful O
drug O
in O
selected O
patients O
with O
severe O
idiopathic O
orthostatic O
hypotension O
. O

Total O
intravenous O
anesthesia O
with O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

III B_NUMBER[MEASURE]
. O

Some O
observations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
adults B_PERSON/B_LOCATION
. O

An O
investigation O
was O
undertaken O
to O
determine O
the O
dosage O
of O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
required O
to O
maintain O
sleep O
in O
adults O
undergoing O
surgery O
under O
regional O
local O
anesthesia O
. O

Premedication O
of O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
10 O
mg O
and O
atropine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O
. O
5 O
mg O
was O
given O
, O
and O
sleep O
was O
induced O
and O
maintained O
by O
intermittent O
intravenous O
injections O
of O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O
. O
1 O
/ O
mg O
/ O
kg O
, O
given O
whenever O
the O
patient O
would O
open O
his O
eyes O
on O
request O
. O

A O
mean O
overall O
dose O
of O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
17 O
. O
4 O
microgram O
/ O
kg O
/ O
min O
. O
was O
required O
to O
maintain O
sleep O
, O
but O
great O
individual O
variation O
occurred O
, O
with O
older O
patients O
requiring O
less O
drug O
. O

The O
investigation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
discontinued O
after O
18 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
patients I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O
of O
the O
frequency B_MEASURE/B_LOCATION
and O
intensity B_MEASURE
of O
side B_DISEASE_ADJECTIVE[DISEASE]
- O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
particularly O
pain B_DISEASE
and O
myoclonia B_DISEASE
, O
which O
caused O
the O
technique B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
be O
abandoned O
in O
two B_MEASURE/B_LOCATION
cases I_MEASURE/I_LOCATION
. O

It O
is O
considered O
unlikely O
that O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
will O
prove O
to O
be O
the O
hypnotic O
of O
choice O
for O
a O
totally O
intravenous O
anesthetic O
technique O
in O
adults O
because O
of O
the O
high O
incidence O
of O
myoclonia O
after O
prolonged O
administration O
. O

In O
several B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
patients I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
uncontrollable I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
muscle I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
movements I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
persisted O
for O
many B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
after O
complete B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
recovery I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
of O
consciousness B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
cardiac B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
beta I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
adrenoceptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
man B_PERSON/B_BIO
. O

We O
compared O
the O
effects O
of O
single O
doses O
of O
50 O
mg O
atenolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
cardioselective O
) O
, O
40 O
mg O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
nonselective O
) O
, O
and O
placebo O
on O
both O
exercise O
- O
and O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
tachycardia O
in O
two O
experiments O
involving O
nine O
normal O
subjects O
. O

Maximal O
exercise O
heart O
rate O
was O
reduced O
from O
187 O
+ O
/ O
- O
4 O
( O
SEM O
) O
after O
placebo O
to O
146 O
+ O
/ O
- O
7 O
bpm O
after O
atenolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
and O
138 O
+ O
/ O
- O
6 O
bpm O
after O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
there O
were O
no O
differences O
between O
the O
drugs O
. O

The O
effects O
on O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
tachycardia O
were O
determined O
before O
and O
after O
atropine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 O
. O
04 O
mg O
/ O
kg O
IV O
) O
. O

Isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
sensitivity O
was O
determined O
as O
the O
intravenous O
dose O
that O
increased O
heart O
rate O
by O
25 O
bpm O
( O
CD25 O
) O
and O
this O
was O
increased O
from O
1 O
. O
8 O
+ O
/ O
- O
0 O
. O
3 O
micrograms O
after O
placebo O
to O
38 O
. O
9 O
+ O
/ O
- O
8 O
. O
3 O
micrograms O
after O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
8 O
. O
3 O
+ O
/ O
- O
1 O
. O
7 O
micrograms O
after O
atenolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

The O
difference B_MEASURE
in O
the O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
two B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
significant B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

After O
atropine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
the O
CD25 O
was O
unchanged O
after O
placebo O
( O
2 O
. O
3 O
+ O
/ O
- O
0 O
. O
3 O
micrograms O
) O
and O
atenolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
7 O
. O
7 O
+ O
/ O
- O
1 O
. O
3 O
micrograms O
) O
; O
it O
was O
reduced O
after O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
24 O
. O
8 O
+ O
/ O
- O
5 O
. O
0 O
micrograms O
) O
, O
but O
remained O
different O
from O
atenolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
. O

This O
change O
with O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sensitivity O
was O
calculated O
as O
the O
apparent O
Ka O
, O
this O
was O
unchanged O
by O
atropine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
11 O
. O
7 O
+ O
/ O
- O
2 O
. O
1 O
and O
10 O
. O
1 O
+ O
/ O
- O
2 O
. O
5 O
ml O
/ O
ng O
) O
. O

These O
data O
are O
consistent O
with O
the O
hypothesis O
that O
exercise O
- O
induced O
tachycardia O
results O
largely O
from O
beta O
1 O
- O
receptor O
activation O
that O
is O
blocked O
by O
both O
cardioselective O
and O
nonselective O
drugs O
, O
whereas O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
activates O
both O
beta O
1 O
- O
and O
beta O
2 O
- O
receptors O
so O
that O
after O
cardioselective O
blockade O
there O
remains O
a O
beta O
2 O
- O
component O
that O
can O
be O
blocked O
with O
a O
nonselective O
drug O
. O

While O
there O
appear O
to O
be O
beta B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
2 I_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
receptors B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
human B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
heart I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
their O
physiologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
pathologic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
roles I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
remain O
to O
be O
defined O
. O

hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
breast B_DISEASE
cancer I_DISEASE
. O

This O
paper B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PRODUCT[OBJECT]
reports O
the O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
a O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
50 B_PERSON
menopausal I_PERSON
women I_PERSON
receiving O
hormonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replacement I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
majority B_PERSON
( O
29 O
) O
had O
surgical B_PERSON/B_LOCATION
menopause I_PERSON/I_LOCATION
; O
their O
mean B_TIME[MEASURE]
age I_TIME[MEASURE]
was O
45 B_MEASURE
. O
7 B_MEASURE/B_ENT
years I_MEASURE/I_ENT
. O

It O
was O
hypothesized O
that O
progestins B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
could O
equilibrate O
the O
effects O
of O
the O
estrogenic O
stimulation O
on O
the O
mammary O
and O
endometrial O
target O
tissues O
of O
women O
on O
hormonal O
replacement O
therapy O
. O

The O
treatment O
schedule O
consisted O
of O
conjugated B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
estrogens I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
Premarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
1 O
. O
25 O
mg O
/ O
day O
for O
21 O
days O
and O
Medroxyprogesterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
10 O
mg O
/ O
day O
for O
10 O
days O
in O
each O
month O
. O

The O
mean B_TIME[MEASURE]/B_PERSON
treatment I_TIME[MEASURE]/I_PERSON
period I_TIME[MEASURE]/I_PERSON
was O
18 B_TIME[MEASURE]
months I_TIME[MEASURE]
. O

During O
the O
follow O
- O
up O
period B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
attention B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
was O
paid O
to O
breast B_DISEASE_ADJECTIVE[DISEASE]
modifications I_DISEASE_ADJECTIVE[DISEASE]
as O
evidenced O
by O
symptomatology B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
physical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
examination I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
, O
and O
plate B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thermography I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Mastodynia B_DISEASE_ADJECTIVE[DISEASE]
was O
reported O
by O
21 B_PERSON
patients I_PERSON
, O
and O
physical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
examination I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
a O
light B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
breast B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
firmness B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
12 B_NUMBER[MEASURE]/B_PERSON
women I_NUMBER[MEASURE]/I_PERSON
and O
a O
moderate B_DISEASE_ADJECTIVE[DISEASE]
increase I_DISEASE_ADJECTIVE[DISEASE]
in O
breast B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
nodularity B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
in O
2 B_PERSON/B_NUMBER[MEASURE]
women I_PERSON/I_NUMBER[MEASURE]
. O

Themography B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
confirmed O
the O
existence B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
an O
excessive B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
breast I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulation I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
1 B_PERSON/B_NUMBER[MEASURE]
women B_PERSON/I_NUMBER[MEASURE]
who O
complained O
of O
moderate B_DISEASE
mastodynia I_DISEASE
and O
in O
5 B_NUMBER[MEASURE]
of O
the O
7 B_PERSON/B_SPORT[ENT]
women I_PERSON/I_SPORT[ENT]
who O
complained O
of O
severe B_DISEASE
mastodynia I_DISEASE
. O

Normalization O
was O
obtained O
by O
halving O
the O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
dose O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
suggest O
that O
hormonal B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
replacement I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
can O
be O
safely O
prescribed O
if O
the O
following B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
criteria I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
are O
satisfied O
: O
1 B_SEQUENCE[MEASURE]
) O
preliminary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
a O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
metabolic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
cytologic B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
mammographic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_EDU[ORGANIZATION]
perspective I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_EDU[ORGANIZATION]
; O
2 B_NUMBER[MEASURE]
) O
cyclic B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
schedule I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
with O
a O
progestative B_MEASURE/B_LOCATION
phase I_MEASURE/I_LOCATION
of O
10 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
days I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
; O
and O
3 B_NUMBER[MEASURE]
) O
periodic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
complete I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
follow I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- O
up B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
with O
accurate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
thermographic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evaluation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
breast B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
target I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
tissues I_DISEASE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Early O
infections O
in O
kidney O
, O
heart O
, O
and O
liver O
transplant O
recipients O
on O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

eighty B_NUMBER[MEASURE]
- O
one B_NUMBER[MEASURE]/B_PERSON
renal I_NUMBER[MEASURE]/I_PERSON
, O
seventeen B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
heart I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
twenty B_NUMBER[MEASURE]
- O
four B_NUMBER[MEASURE]
liver I_NUMBER[MEASURE]
transplant I_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
were O
followed O
for O
infection B_DISEASE
. O

seventeen O
renal O
patients O
received O
azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Aza B_SPECIES[BIO]/B_LOCATION
) O
and O
prednisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
part O
of O
a O
randomized O
trial O
of O
immunosuppression O
with O
21 O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
- O
prednisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
renal O
transplant O
patients O
. O

All O
others O
received O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
prednisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
randomized O
Aza B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
patients O
had O
more O
overall O
infections O
( O
P O
less O
than O
0 O
. O
05 O
) O
and O
more O
nonviral O
infections O
( O
P O
less O
than O
0 O
. O
02 O
) O
than O
the O
randomized O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O
. O

Heart O
and O
liver O
patients O
had O
more O
infections O
than O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
renal O
patients O
but O
fewer O
infections O
than O
the O
Aza B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
renal O
patients O
. O

There O
were O
no O
infectious O
deaths O
in O
renal O
transplant O
patients O
on O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
or O
Aza B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
, O
but O
infection O
played O
a O
major O
role O
in O
3 O
out O
of O
6 O
cardiac O
transplant O
deaths O
and O
in O
8 O
out O
of O
9 O
liver O
transplant O
deaths O
. O

Renal O
patients O
on O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
the O
fewest O
bacteremias O
. O

Analysis B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
site B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
infection B_DISEASE
showed O
a O
preponderance B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
abdominal B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
infections I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
in O
liver B_PERSON/B_BIO
patients I_PERSON/I_BIO
, O
intrathoracic B_DISEASE
infections I_DISEASE
in O
heart B_PERSON/B_BIO
patients I_PERSON/I_BIO
, O
and O
urinary B_DISEASE/B_PERSON
tract I_DISEASE/I_PERSON
infections I_DISEASE/I_PERSON
in O
renal B_PERSON/B_BIO
patients I_PERSON/I_BIO
. O

pulmonary O
infections O
were O
less O
common O
in O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
renal O
patients O
than O
in O
Aza B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
- O
treated O
patients O
( O
P O
less O
than O
0 O
. O
05 O
) O
. O

Aza B_PERSON/B_BIO
patients O
had O
significantly O
more O
staphylococcal O
infections O
than O
all O
other O
transplant O
groups O
( O
P O
less O
than O
0 O
. O
005 O
) O
, O
and O
systemic O
fungal O
infections O
occurred O
only O
in O
the O
liver O
transplant O
group O
. O

Cytomegalovirus O
( O
CMV O
) O
shedding O
or O
serological O
rises O
in O
antibody O
titer O
, O
or O
both O
occurred O
in O
78 O
% O
of O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
patients O
and O
76 O
% O
of O
Aza B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
patients O
. O

Of O
the O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients O
, O
15 O
% O
had O
symptoms O
related O
to O
CMV O
infection O
. O

Serological O
evidence O
for O
Epstein O
Barr O
virus O
infection O
was O
found O
in O
20 O
% O
of O
65 O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
patients O
studied O
. O

Three B_NUMBER[MEASURE]/B_PERSON
had O
associated O
symptoms B_DISEASE
, O
and O
one B_NUMBER[MEASURE]/B_PERSON
developed O
a O
lymphoma B_DISEASE
. O

Structure O
- O
activity O
and O
dose O
- O
effect O
relationships O
of O
the O
antagonism O
of O
picrotoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
induced O
seizures O
by O
cholecystokinin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
fragments O
and O
analogues O
of O
cholecystokinin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
in O
mice O
. O

Intraperitoneal O
administration O
of O
cholecystokinin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
octapeptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
sulphate O
ester O
( O
CCK B_LOCATION/B_GENE
- I_LOCATION/I_GENE
8 I_LOCATION/I_GENE
- O
SE O
) O
and O
nonsulphated O
cholecystokinin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
octapeptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
CCK B_LOCATION
- I_LOCATION
8 I_LOCATION
- O
NS O
) O
enhanced O
the O
latency O
of O
seizures O
induced O
by O
picrotoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
in O
mice O
. O

Experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
and O
C B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
terminal B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fragments B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
that O
the O
C B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
terminal B_PROTEIN[GENE]/B_LOCATION
tetrapeptide B_PROTEIN[GENE]/I_LOCATION
( O
CCK B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
5 B_MEASURE/B_LOCATION
- O
8 B_NUMBER[MEASURE]
) O
was O
the O
active B_LOCATION/B_PERSON
centre I_LOCATION/I_PERSON
of O
the O
CCK B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
octapeptide B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
molecule B_PROTEIN[GENE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
analogues O
CCK B_LOCATION
- I_LOCATION
8 I_LOCATION
- O
SE O
and O
CCK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
NS O
( O
dose O
range O
0 O
. O
2 O
- O
6 O
. O
4 O
mumol O
/ O
kg O
) O
and O
caerulein B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O
range O
0 O
. O
1 O
- O
0 O
. O
8 O
mumol O
/ O
kg O
) O
showed O
bell O
- O
shaped O
dose O
- O
effect O
curves O
, O
with O
the O
greatest O
maximum O
inhibition O
for O
CCK B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
8 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
- O
NS O
. O

The O
peptide O
CCK O
- O
5 O
- O
8 O
had O
weak O
anticonvulsant O
activity O
in O
comparison O
to O
the O
octapeptides O
, O
3 O
. O
2 O
mumol O
/ O
kg O
and O
larger O
doses O
of O
the O
reference O
drug O
, O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
totally O
prevented O
picrotoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- O
induced O
seizures O
and O
mortality O
. O

The O
maximum O
effect O
of O
the O
peptides O
tested O
was O
less O
than O
that O
of O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

experiments O
with O
analogues O
and O
derivatives O
of O
CCK O
- O
5 O
- O
8 O
demonstrated O
that O
the O
effectiveness O
of O
the O
beta O
- O
alanyl O
derivatives O
of O
CCK O
- O
5 O
- O
8 O
were O
enhanced O
and O
that O
they O
were O
equipotent O
with O
CCK B_LOCATION/B_ORGANIZATION
- I_LOCATION/I_ORGANIZATION
8 I_LOCATION/I_ORGANIZATION
- O
SE O
. O

Of O
the O
CCK O
- O
2 O
- O
8 O
analogues O
, O
Ser O
( O
SO3H O
) O
7 O
- O
AC O
- O
CCK O
- O
2 O
- O
8 O
- O
SE O
and O
Thr O
( O
SO3H O
) O
7 O
- O
AC O
- O
CCK O
- O
2 O
- O
8 O
- O
SE O
and O
Hyp O
( O
SO3H O
) O
- O
AC O
- O
CCK O
- O
2 O
- O
8 O
- O
SE O
were O
slightly O
more O
active O
than O
CCK B_LOCATION
- I_LOCATION
8 I_LOCATION
- O
SE O
. O

Vasopressin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
as O
a O
possible O
contributor O
to O
hypertension O
. O

The O
role O
of O
vasopressin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
pressor O
agent O
to O
the O
hypertensive O
process O
was O
examined O
. O

Vasopressin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
plays O
a O
major O
role O
in O
the O
pathogenesis O
of O
DOCA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
salt O
hypertension O
, O
since O
the O
elevation O
of O
blood O
pressure O
was O
not O
substantial O
in O
the O
rats O
with O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
diabetes O
insipidus O
after O
DOCA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
salt O
treatment O
. O

Administration O
of O
DDAVP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
which O
has O
antidiuretic O
action O
but O
minimal O
vasopressor O
effect O
failed O
to O
increase O
blood O
pressure O
to O
the O
levels O
observed O
after O
administration O
of O
AVP O
. O

Furthermore O
, O
the O
pressor O
action O
of O
vasopressin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
appears O
to O
be O
important O
in O
the O
development O
of O
this O
model O
of O
hypertension O
, O
since O
the O
enhanced O
pressor O
responsiveness O
to O
the O
hormone O
was O
observed O
in O
the O
initial O
stage O
of O
hypertension O
. O

increased O
secretion O
of O
vasopressin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
from O
neurohypophysis O
also O
promotes O
the O
function O
of O
the O
hormone O
as O
a O
pathogenetic O
factor O
in O
hypertension O
. O

An O
unproportional O
release O
of O
vasopressin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O
to O
plasma O
osmolality O
may O
be O
induced O
by O
the O
absence O
of O
an O
adjusting O
control O
of O
angiotensin B_GENE/B_MEASURE
II O
forming O
and O
receptor O
binding O
capacity O
for O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
balance O
in O
the O
brain O
. O

However O
, O
the O
role O
of O
vasopressin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
remains O
to O
be O
determined O
in O
human O
essential O
hypertension O
. O

toxic O
hepatitis O
induced O
by O
disulfiram B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
in O
a O
non O
- O
alcoholic O
. O

A O
reversible O
toxic O
liver O
damage O
was O
observed O
in O
a O
non O
- O
alcoholic O
woman O
treated O
with O
disulfiram B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
. O

The O
causative B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
relationship I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
proven O
by O
challenge B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Atrial O
thrombosis O
involving O
the O
heart O
of O
F O
- O
344 O
rats O
ingesting O
quinacrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
hydrochloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

Quinacrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
hydrochloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
toxic O
for O
the O
heart O
of O
F O
- O
344 O
rats O
. O

rats O
treated O
with O
500 O
ppm O
quinacrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
hydrochloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
the O
diet O
all O
developed O
a O
high O
incidence O
of O
left O
atrial O
thrombosis O
. O

The O
lesion B_DISEASE
was O
associated O
with O
cardiac B_DISEASE
hypertrophy I_DISEASE
and O
dilatation B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
focal B_DISEASE
myocardial I_DISEASE
degeneration I_DISEASE
. O

rats B_BIO/B_PERSON
died O
from O
cardiac B_DISEASE
hypertrophy I_DISEASE
with O
severe B_DISEASE_ADJECTIVE[DISEASE]
acute I_DISEASE_ADJECTIVE[DISEASE]
and O
chronic B_DISEASE
congestion I_DISEASE
of O
the O
lungs B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
liver B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
and O
other B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
organs I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

seventy O
percent O
of O
rats O
given O
250 O
ppm O
quinacrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
1 O
, O
000 O
ppm O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nitrite I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
simultaneously O
in O
the O
diet O
had O
thrombosis O
of O
the O
atria O
of O
the O
heart O
, O
while O
untreated O
control O
rats O
in O
this O
laboratory O
did O
not O
have O
atrial O
thrombosis O
. O

Sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
nitrite I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
combination O
with O
quinacrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
appeared O
to O
have O
no O
additional O
effect O
. O

alternating O
sinus O
rhythm O
and O
intermittent O
sinoatrial O
block O
induced O
by O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

alternating O
sinus O
rhythm O
and O
intermittent O
sinoatrial O
( O
S O
- O
A O
) O
block O
was O
observed O
in O
a O
57 O
- O
year O
- O
old O
woman O
, O
under O
treatment O
for O
angina O
with O
80 O
mg O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O
. O

The O
electrocardiogram B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
showed O
alternation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
short B_DISEASE_ADJECTIVE[DISEASE]
P I_DISEASE_ADJECTIVE[DISEASE]
- O
P B_MEASURE
intervals I_MEASURE
and O
occasional B_DISEASE/B_MEASURE
pauses I_DISEASE/I_MEASURE
. O

These O
pauses B_DISEASE/B_TIME[MEASURE]
were O
always O
preceded O
by O
the O
short B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
P I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
P B_MEASURE
intervals I_MEASURE
and O
were O
usually O
followed O
by O
one B_NUMBER[MEASURE]/B_PERSON
or O
two B_NUMBER[MEASURE]
P I_NUMBER[MEASURE]
- O
P B_TIME[MEASURE]/B_LOCATION
intervals I_TIME[MEASURE]/I_LOCATION
of O
0 B_MEASURE
. O
92 B_MEASURE
- O
0 B_NUMBER[MEASURE]
. O
95 B_MEASURE
s I_MEASURE
representing O
the O
basic B_TIME[MEASURE]/B_PERSON
sinus I_TIME[MEASURE]/I_PERSON
cycle I_TIME[MEASURE]/I_PERSON
. O

Following O
these O
basic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sinus B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cycles B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
alternating O
rhythm B_ENT/B_DISEASE
started O
with O
the O
longer B_LOCATION/B_PROTEIN[GENE]
P I_LOCATION/I_PROTEIN[GENE]
- O
P B_MEASURE
interval I_MEASURE
. O

The O
long B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
P I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
- O
P B_LOCATION/B_MEASURE
intervals I_LOCATION/I_MEASURE
ranged O
between O
1 B_MEASURE/B_LOCATION
. O
04 B_MEASURE
- O
1 B_MEASURE
. O
12 B_TIME[MEASURE]
s I_TIME[MEASURE]
and O
the O
short B_MEASURE/B_LOCATION
P I_MEASURE/I_LOCATION
- O
P B_MEASURE/B_LOCATION
intervals I_MEASURE/I_LOCATION
between O
0 B_MEASURE/B_LOCATION
. O
80 B_MEASURE
- O
0 B_MEASURE
. O
84 B_MEASURE
s I_MEASURE
, O
respectively O
. O

The O
duration B_MEASURE/B_LOCATION
of O
the O
pauses B_DISEASE/B_TIME[MEASURE]
were O
equal B_MEASURE
or O
almost O
equal B_MEASURE
to O
one B_NUMBER[MEASURE]
short I_NUMBER[MEASURE]
plus O
one B_NUMBER[MEASURE]/B_LOCATION
long I_NUMBER[MEASURE]/I_LOCATION
P I_NUMBER[MEASURE]/I_LOCATION
- O
P B_MEASURE/B_LOCATION
interval I_MEASURE/I_LOCATION
or O
to O
twice O
the O
basic B_MEASURE
sinus I_MEASURE
cycle I_MEASURE
. O

In O
one B_MEASURE/B_ENT
recording I_MEASURE/I_ENT
a O
short B_TIME[MEASURE]
period I_TIME[MEASURE]
of O
regular B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
sinus I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rhythm I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
intermittent B_MEASURE
2 I_MEASURE
/ O
1 B_SEQUENCE[MEASURE]/B_LOCATION
S I_SEQUENCE[MEASURE]/I_LOCATION
- O
A B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
block I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
. O

This O
short B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
sinus B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
rhythm I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
interrupted O
by O
sudden B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
prolongation B_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
P B_OTHER/B_LOCATION
- O
P B_MEASURE/B_LOCATION
interval I_MEASURE/I_LOCATION
starting O
the O
alternative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
rhythm I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

There O
were O
small B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
changes I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
in O
the O
shape B_MEASURE/B_LOCATION
of O
the O
P B_LOCATION
waves I_LOCATION
and O
P B_PROTEIN[GENE]/B_LOCATION
- O
R B_MEASURE/B_LOCATION
intervals I_MEASURE/I_LOCATION
. O

S B_DISEASE/B_PROTEIN[GENE]
- O
A B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conduction B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
through O
two B_LOCATION
pathways I_LOCATION
, O
the O
first B_SEQUENCE[MEASURE]/B_LOCATION
with O
2 B_NUMBER[MEASURE]
/ O
1 B_MEASURE
block O
the O
second B_SEQUENCE[MEASURE]/B_PERSON
having O
0 B_MEASURE/B_LOCATION
. O
12 B_MEASURE
- O
0 B_MEASURE
. O
14 B_MEASURE
s I_MEASURE
longer I_MEASURE
conduction I_MEASURE
time I_MEASURE
and O
with O
occasional B_TIME[MEASURE]
2 I_TIME[MEASURE]
/ O
1 B_MEASURE/B_LOCATION
block I_MEASURE/I_LOCATION
was O
proposed O
for O
the O
explanation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
alternating O
P B_OTHER/B_LOCATION
- O
P B_MEASURE
interval I_MEASURE
and O
other B_DISEASE/B_PROTEIN[GENE]
electrocardiographic B_DISEASE/I_PROTEIN[GENE]
features B_DISEASE/I_PROTEIN[GENE]
seen O
. O

Atropine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
1 O
mg O
given O
intravenously O
resulted O
in O
shortening O
of O
all O
P O
- O
P O
intervals O
without O
changing O
the O
rhythm O
. O

The O
abnormal O
rhythm O
disappeared O
with O
the O
withdrawal O
of O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
when O
the O
drug O
was O
restarted O
a O
2 O
/ O
1 O
S O
- O
A O
block O
was O
seen O
. O

This O
was O
accepted O
as O
evidence O
for O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
being O
the O
cause O
of O
this O
conduction O
disorder O
. O

Antitumor O
effect O
, O
cardiotoxicity O
, O
and O
nephrotoxicity O
of O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
IgM O
solid O
immunocytoma O
- O
bearing O
Lou O
/ O
M O
/ O
WSL O
rat O
. O

Antitumor O
activity O
, O
cardiotoxicity O
, O
and O
nephrotoxicity O
induced O
by O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
studied O
in O
Lou O
/ O
M O
/ O
WSL O
inbred O
rats O
each O
bearing O
a O
transplantable O
solid O
IgM O
immunocytoma O
. O

Animals O
with O
a O
tumor O
( O
diameter O
, O
15 O
. O
8 O
+ O
/ O
- O
3 O
. O
3 O
mm O
) O
were O
treated O
with O
IV O
injections O
of O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
5 O
consecutive O
days O
, O
followed O
by O
1 O
weekly O
injection O
for O
7 O
weeks O
( O
dose O
range O
, O
0 O
. O
015 O
- O
4 O
. O
0 O
mg O
/ O
kg O
body O
wt O
) O
. O

tumor O
regression O
was O
observed O
with O
0 O
. O
5 O
mg O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg O
. O

Complete O
disappearance O
of O
the O
tumor O
was O
induced O
with O
1 O
. O
0 O
mg O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
kg O
. O

Histologic O
evidence O
of O
cardiotoxicity O
scored O
as O
grade O
III O
was O
only O
observed O
at O
a O
dose O
of O
1 O
. O
0 O
mg O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O
kg O
. O

Light O
microscopic O
evidence O
of O
renal O
damage O
was O
seen O
above O
a O
dose O
of O
0 O
. O
5 O
mg O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
/ O
kg O
, O
which O
resulted O
in O
albuminuria O
and O
very O
low O
serum O
albumin O
levels O
. O

In O
the O
group O
that O
received O
1 O
. O
0 O
mg O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
/ O
kg O
, O
the O
serum O
albumin O
level O
decreased O
from O
33 O
. O
6 O
+ O
/ O
- O
4 O
. O
1 O
to O
1 O
. O
5 O
+ O
/ O
- O
0 O
. O
5 O
g O
/ O
liter O
. O

ascites B_DISEASE
and O
hydrothorax B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
were O
observed O
simultaneously O
. O

The O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
experiments I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
performed O
with O
non B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
- O
tumor B_DISEASE
- O
bearing B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
rats B_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O
in O
which O
no O
major B_DISEASE
differences I_DISEASE
were O
observed O
. O

In O
conclusion B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
antitumor B_DISEASE
activity I_DISEASE
, O
cardiotoxicity B_DISEASE
, O
and O
nephrotoxicity B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
studied O
simultaneously O
in O
the O
same B_PERSON/B_LOCATION
Lou B_PERSON/I_LOCATION
/ O
M B_OTHER/B_PERSON
/ O
WSL B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
rat I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

albuminuria B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O
to O
renal B_DISEASE
damage I_DISEASE
led O
to O
extremely O
low B_DISEASE
serum I_DISEASE
albumin I_DISEASE
levels I_DISEASE
, O
so O
ascites B_DISEASE
and O
hydrothorax B_DISEASE
were O
not O
necessarily O
a O
consequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
the O
observed B_DISEASE
cardiomyopathy I_DISEASE
. O

Intraoperative O
bradycardia O
and O
hypotension O
associated O
with O
timolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
eye O
drops O
. O

A O
69 O
- O
yr O
- O
old O
man O
, O
who O
was O
concurrently O
being O
treated O
with O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitrate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
timolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
maleate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
eye O
drops O
, O
developed O
a O
bradycardia O
and O
became O
hypotensive O
during O
halothane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
anaesthesia O
. O

Both O
timolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
subsequently O
identified O
in O
a O
24 O
- O
h O
collection O
of O
urine O
. O

Timolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
but O
not O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
was O
detected O
in O
a O
sample O
of O
plasma O
removed O
during O
surgery O
; O
the O
plasma O
concentration O
of O
timolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
2 O
. O
6 O
ng O
ml O
- O
1 O
) O
was O
consistent O
with O
partial O
beta O
- O
adrenoceptor O
blockade O
. O

It O
is O
postulated O
that O
this O
action O
may O
have O
been O
enhanced O
during O
halothane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
anaesthesia O
with O
resultant O
bradycardia O
and O
hypotension O
. O

Pilocarpine B_PERSON/B_LOCATION
may O
have O
had O
a O
contributory O
effect O
. O

Succinylcholine B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
apnoea O
: O
attempted O
reversal O
with O
anticholinesterases O
. O

Anticholinesterases O
were O
administered O
in O
an O
attempt O
to O
antagonize O
prolonged O
neuromuscular O
blockade O
following O
the O
administration O
of O
succinylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
a O
patient O
later O
found O
to O
be O
homozygous O
for O
atypical O
plasma O
cholinesterase O
. O

Edrophonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
10 O
mg O
, O
given O
74 O
min O
after O
succinylcholine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
, O
when O
train O
- O
of O
- O
four O
stimulation O
was O
characteristic O
of O
phase O
II O
block O
, O
produced O
partial O
antagonism O
which O
was O
not O
sustained O
. O

repeated O
doses O
of O
edrophonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
70 O
mg O
and O
neostigmine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
2 O
. O
5 O
mg O
did O
not O
antagonize O
or O
augment O
the O
block O
. O

spontaneous O
respiration O
recommenced O
200 O
min O
after O
succinylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
administration O
. O

It O
is O
concluded O
that O
anticholinesterases O
are O
only O
partially O
effective O
in O
restoring O
neuromuscular O
function O
in O
succinylcholine B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
apnoea O
despite O
muscle O
twitch O
activity O
typical O
of O
phase O
II O
block O
. O

Effect O
of O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
omega I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
131 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
heptadecanoic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
myocardial O
scintigraphy O
and O
echocardiography O
in O
dogs O
. O

The O
effects O
of O
serial O
treatment O
with O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
dynamic O
myocardial O
scintigraphy O
with O
[ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
omega I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
I I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
131 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
] I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
heptadecanoic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
131 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
HA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
) O
, O
and O
on O
global O
left O
- O
ventricular O
function O
determined O
echocardiographically O
, O
were O
studied O
in O
a O
group O
of O
nine O
mongrel O
dogs O
. O

Total O
extractable O
myocardial O
lipid O
was O
compared O
postmortem O
between O
a O
group O
of O
control O
dogs O
and O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
dogs O
. O

A O
significant O
and O
then O
progressive O
fall O
in O
global O
LV O
function O
was O
observed O
at O
a O
cumulative O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose O
of O
4 O
mg O
/ O
kg O
. O

A O
significant O
increase O
in O
the O
myocardial O
t1 O
/ O
2 O
of O
the O
I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
131 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
only O
at O
a O
higher O
cumulative O
dose O
, O
10 O
mg O
/ O
kg O
. O

No O
significant O
alteration O
in O
total O
extractable O
myocardial O
lipids O
was O
observed O
between O
control O
dogs O
and O
those O
treated O
with O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Our O
findings O
suggest O
that O
the O
changes O
leading O
to O
an O
alteration O
of O
myocardial O
dynamic O
imaging O
with O
I B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
131 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
not O
the O
initiating O
factor O
in O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiotoxicity O
. O

hemodynamics B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
myocardial B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
metabolism B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
under O
deliberate B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
hypotension I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

An O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
dogs B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Coronary O
blood O
flow O
, O
cardiac O
work O
and O
metabolism O
were O
studied O
in O
dogs O
under O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitroprusside I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SNP B_LOCATION/B_ORGANIZATION
) O
and O
trimetaphan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TMP B_LOCATION/B_ORGANIZATION
) O
deliberate O
hypotension O
( O
20 O
% O
and O
40 O
% O
mean O
pressure O
decrease O
from O
baseline O
) O
. O

Regarding O
the O
effects O
of O
drug O
- O
induced O
hypotension O
on O
coronary O
blood O
flow O
, O
aortic O
and O
coronary O
sinus O
metabolic O
data O
( O
pH O
, O
pO2 O
, O
pCO2 O
) O
we O
could O
confirm O
that O
nitroprusside B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hypotension O
could O
be O
safely O
used O
to O
30 O
% O
mean O
blood O
pressure O
decrease O
from O
control O
, O
trimetaphan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
hypotension O
to O
20 O
% O
mean O
blood O
pressure O
decrease O
. O

cardiac O
work O
was O
significantly O
reduced O
during O
SNP B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
hypotension O
. O

Myocardial O
O2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption O
and O
O2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
availability O
were O
directly O
dependent O
on O
the O
coronary O
perfusion O
. O

Careful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
invasive I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
monitoring I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
blood B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pressure I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
gases I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
of O
the O
ECG B_DISEASE/B_PROTEIN[GENE]
ST B_DISEASE/I_PROTEIN[GENE]
- O
T B_NUMBER[MEASURE]/B_LOCATION
segment I_NUMBER[MEASURE]/I_LOCATION
is O
mandatory B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Evidence O
for O
a O
selective O
brain O
noradrenergic O
involvement O
in O
the O
locomotor O
stimulant O
effects O
of O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
rat O
. O

Male O
rats O
received O
the O
noradrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neurotoxin O
DSP4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
50 O
mg O
/ O
kg O
) O
7 O
days O
prior O
to O
injection O
of O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amphetamine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 O
or O
40 O
mumol O
/ O
kg O
i O
. O
p O
. O
) O
. O

The O
hyperactivity O
induced O
by O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
amphetamine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 O
mumol O
/ O
kg O
) O
was O
significantly O
reduced O
by O
DSP4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pretreatment O
. O

However O
, O
the O
increased O
rearings O
and O
the O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
stereotypies O
were O
not O
blocked O
by O
pretreatment O
with O
DSP4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
reduction O
of O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
hyperactivity O
induced O
by O
DSP4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
blocked O
by O
pretreatment O
with O
the O
noradrenaline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
uptake O
blocking O
agent O
, O
desipramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
prevents O
the O
neurotoxic O
action O
of O
DSP4 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

The O
present O
results O
suggest O
a O
selective O
involvement O
of O
central O
noradrenergic O
neurones O
in O
the O
locomotor O
stimulant O
effect O
of O
amphetamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
the O
rat O
. O

accelerated O
junctional O
rhythms O
during O
oral O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

This O
study O
examined O
the O
frequency O
of O
atrioventricular O
( O
AV O
) O
dissociation O
and O
accelerated O
junctional O
rhythms O
in O
59 O
patients O
receiving O
oral O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

accelerated O
junctional B_DISEASE
rhythms I_DISEASE
and O
AV B_DISEASE
dissociation I_DISEASE
were O
frequent B_DISEASE_ADJECTIVE[DISEASE]
in O
patients B_PERSON/B_BIO
with O
supraventricular B_DISEASE/B_PROTEIN[GENE]
tachyarrhythmias B_DISEASE/I_PROTEIN[GENE]
, O
particularly O
AV B_DISEASE/B_PERSON
nodal I_DISEASE/I_PERSON
reentry I_DISEASE/I_PERSON
. O

Verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administration O
to O
these O
patients O
led O
to O
an O
asymptomatic O
increase O
in O
activity O
of O
these O
junctional O
pacemakers O
. O

In O
patients O
with O
various O
chest O
pain O
syndromes O
, O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neither O
increased O
the O
frequency O
of O
junctional O
rhythms O
nor O
suppressed O
their O
role O
as O
escape O
rhythms O
under O
physiologically O
appropriate O
circumstances O
. O

Interstrain O
variation O
in O
acute O
toxic O
response O
to O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
among O
inbred O
mice O
. O

acute O
toxic O
dosage O
- O
dependent O
behavioral O
effects O
of O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
compared O
in O
adult O
males O
from O
seven O
inbred O
mouse O
strains O
( O
A O
/ O
J O
, O
BALB O
/ O
cJ O
, O
CBA O
/ O
J O
, O
C3H O
/ O
HeJ O
, O
C57BL O
/ O
6J O
, O
DBA O
/ O
2J O
, O
SWR O
/ O
J O
) O
. O

C57BL O
/ O
6J O
, O
chosen O
as O
a O
' O
prototypic O
' O
mouse O
strain O
, O
was O
used O
to O
determine O
behavioral O
responses O
to O
a O
broad O
range O
( O
5 O
- O
500 O
mg O
/ O
kg O
) O
of O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O
. O

Five O
phenotypic O
characteristics O
- O
- O
locomotor O
activity O
, O
righting O
ability O
, O
clonic O
seizure O
induction O
, O
stress O
- O
induced O
lethality O
, O
death O
without O
external O
stress O
- O
- O
were O
scored O
at O
various O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O
in O
drug O
- O
naive O
animals O
under O
empirically O
optimized O
, O
rigidly O
constant O
experimental O
conditions O
. O

mice O
( O
n O
= O
12 O
for O
each O
point O
) O
received O
single O
IP O
injections O
of O
a O
fixed O
volume O
/ O
g O
body O
weight O
of O
physiological O
saline O
carrier O
with O
or O
without O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
doses O
ranging O
from O
125 O
- O
500 O
mg O
/ O
kg O
. O

Loss B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
righting O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
scored O
at O
1 B_NUMBER[MEASURE]
, O
3 B_MEASURE
, O
5 B_SEQUENCE[MEASURE]
min I_SEQUENCE[MEASURE]
post I_SEQUENCE[MEASURE]
dosing I_SEQUENCE[MEASURE]
and O
at O
5 B_TIME[MEASURE]/B_LOCATION
min I_TIME[MEASURE]/I_LOCATION
intervals I_TIME[MEASURE]/I_LOCATION
thereafter O
for O
20 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
min I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

In O
the O
same B_PERSON/B_ENT
animals I_PERSON/I_ENT
the O
occurrence B_DISEASE/B_MEASURE
of O
clonic B_DISEASE
seizures I_DISEASE
was O
scored O
as O
to O
time B_TIME[MEASURE]/B_LOCATION
of O
onset B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
severity B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
for O
20 B_TIME[MEASURE]/B_DISEASE
min B_TIME[MEASURE]/I_DISEASE
after O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

When O
these O
proceeded O
to O
tonic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
seizures I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
death B_PERSON/B_DISEASE
occurred O
in O
less B_MEASURE
than O
20 B_TIME[MEASURE]
min I_TIME[MEASURE]
. O

Animals B_BIO/B_PERSON
surviving O
for O
20 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
min I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
immediately O
stressed O
by O
a O
swim B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
in O
25 B_TIME[MEASURE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
degrees I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
water I_TIME[MEASURE]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
death B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
producing O
tonic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
seizures B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
were O
scored O
for O
2 B_DISEASE
min I_DISEASE
. O

In O
other O
animals O
locomotor O
activity O
was O
measured O
15 O
or O
60 O
min O
after O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administration O
. O

By O
any O
single O
behavioral O
criterion O
or O
a O
combination O
of O
these O
criteria O
, O
marked O
differences O
in O
response O
to O
toxic O
caffeine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
doses O
were O
observed O
between O
strains O
. O

These O
results O
indicate O
that O
behavioral O
toxicity O
testing O
of O
alkylxanthines B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
a O
single O
mouse O
strain O
may O
be O
misleading O
and O
suggest O
that O
toxic O
responses O
of O
the O
central O
nervous O
system O
to O
this O
class O
of O
compounds O
are O
genetically O
influenced O
in O
mammals O
. O

Treatment O
of O
ovarian O
cancer O
with O
a O
combination O
of O
cis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
platinum I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
adriamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
hexamethylmelamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

During O
the O
last O
2 O
1 O
/ O
2 O
years O
, O
38 O
patients O
with O
ovarian O
cancer O
were O
treated O
with O
a O
combination O
of O
cisplatinum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
CPDD B_LOCATION/B_ORGANIZATION
) O
, O
50 O
mg O
/ O
m2 O
, O
adriamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
30 O
mg O
/ O
m2 O
, O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
300 O
mg O
/ O
m2 O
, O
on O
day O
1 O
; O
and O
hexamethylmelamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
HMM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
, O
6 O
mg O
/ O
kg O
daily O
, O
for O
14 O
days O
. O

Each O
course B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
repeated O
monthly O
. O

2 B_PERSON
patients I_PERSON
had O
stage B_DISEASE_ADJECTIVE[DISEASE]
II I_DISEASE_ADJECTIVE[DISEASE]
, O
14 B_TIME[MEASURE]/B_DISEASE
stage I_TIME[MEASURE]/I_DISEASE
III I_TIME[MEASURE]/I_DISEASE
and O
22 B_SEQUENCE[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
stage I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
IV I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
disease I_SEQUENCE[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

14 O
of O
the O
38 O
patients O
were O
previously O
treated O
with O
chemotherapy O
, O
1 O
with O
radiation O
, O
6 O
with O
both O
chemotherapy O
and O
radiation O
, O
and O
17 O
did O
not O
have O
any O
treatment O
before O
CPDD B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
combination O
. O

31 B_MEASURE
of O
the O
38 B_MEASURE/B_PERSON
cases I_MEASURE/I_PERSON
( O
81 B_MEASURE
. O
5 B_MEASURE
% I_MEASURE
) O
demonstrated O
objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
lasting O
for O
2 B_TIME[MEASURE]
months I_TIME[MEASURE]
or O
more B_TIME[MEASURE]/B_LOCATION
. O

These O
responses B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
partial B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
19 B_NUMBER[MEASURE]
and O
complete B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
12 B_MEASURE
cases I_MEASURE
. O

hematologic B_DISEASE
toxicity I_DISEASE
was O
moderate B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
with O
reversible B_DISEASE
anemia I_DISEASE
developing O
in O
71 B_PERSON/B_MEASURE
% B_PERSON/I_MEASURE
of O
patients B_PERSON/B_DISEASE
. O

Gastrointestinal O
side O
effects O
from O
CPDD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
were O
universal O
. O

HMM B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gastrointestinal O
toxicity O
necessitated O
discontinuation O
of O
the O
drug O
in O
5 O
patients O
. O

Severe B_DISEASE_ADJECTIVE[DISEASE]
nephrotoxicity I_DISEASE_ADJECTIVE[DISEASE]
was O
observed O
in O
2 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
but O
was O
reversible B_DISEASE_ADJECTIVE[DISEASE]
. O

There O
were O
no O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O
related O
deaths B_DISEASE
. O

Nontraumatic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dissecting I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
aneurysm I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
basilar B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
artery I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE
. O

A O
case O
of O
nontraumatic O
dissecting O
aneurysm O
of O
the O
basilar O
artery O
in O
association O
with O
hypertension O
, O
smoke O
, O
and O
oral B_DISEASE
contraceptives I_DISEASE
is O
reported O
in O
a O
young O
female O
patient O
with O
a O
locked O
- O
in O
syndrome O
. O

A O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
for O
the O
measurement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tremor B_DISEASE/B_GENE
, O
and O
a O
comparison B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
effects B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
of O
tocolytic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
beta I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
mimetics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
permitting O
measurement B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
finger B_DISEASE/B_MEASURE
tremor B_DISEASE/I_MEASURE
as O
a O
displacement B_TIME[MEASURE]/B_LOCATION
- O
time B_MEASURE
curve I_MEASURE
is O
described O
, O
using O
a O
test B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEDICAL_DEVICE[OBJECT]
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEDICAL_DEVICE[OBJECT]
with O
simple B_DISEASE_ADJECTIVE[DISEASE]/B_PRODUCT[OBJECT]
amplitude B_DISEASE_ADJECTIVE[DISEASE]/I_PRODUCT[OBJECT]
calibration B_DISEASE_ADJECTIVE[DISEASE]/I_PRODUCT[OBJECT]
. O

The O
coordinates B_LOCATION/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
inversion B_LOCATION/B_MEASURE
points I_LOCATION/I_MEASURE
of O
the O
displacement B_TIME[MEASURE]/B_LOCATION
- O
time B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
curves B_MEASURE/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
transferred O
through O
graphical B_PRODUCT[OBJECT]/B_LOCATION
input I_PRODUCT[OBJECT]/I_LOCATION
equipment I_PRODUCT[OBJECT]/I_LOCATION
to O
punched B_PERSON/B_PRODUCT[OBJECT]
tape I_PERSON/I_PRODUCT[OBJECT]
. O

By O
means B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
computer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
program I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
periods B_MEASURE/B_LOCATION
and O
amplitudes B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
tremor B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
oscillations I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
calculated O
and O
classified O
. O

The O
event B_MEASURE
frequency I_MEASURE
for O
each O
class B_PERSON/B_MEASURE
of O
periods B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
and O
amplitudes B_TIME[MEASURE]/B_ENT
was O
determined O
. O

The O
actions O
of O
fenoterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrobromide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ritodrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HCl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
placebo O
given O
to O
10 O
healthy O
subjects O
by O
intravenous O
infusion O
in O
a O
double O
- O
blind O
crossover O
study O
were O
tested O
by O
this O
method O
. O

At O
therapeutic B_TIME[MEASURE]/B_LOCATION
doses I_TIME[MEASURE]/I_LOCATION
both O
substances B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
raised O
the O
mean B_MEASURE/B_DISEASE
tremor I_MEASURE/I_DISEASE
amplitude I_MEASURE/I_DISEASE
to O
about O
three B_MEASURE/B_LOCATION
times I_MEASURE/I_LOCATION
the O
control B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
. O

At O
the O
same B_TIME[MEASURE]/B_LOCATION
time I_TIME[MEASURE]/I_LOCATION
, O
the O
mean B_TIME[MEASURE]
period I_TIME[MEASURE]
within O
each O
class B_PERSON/B_LOCATION
of O
amplitudes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
shortened O
by O
10 B_MEASURE/B_LOCATION
- O
- O
20 B_TIME[MEASURE]
MS I_TIME[MEASURE]
, O
whereas O
the O
mean B_MEASURE
periods I_MEASURE
calculated O
from O
all O
oscillations B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
together O
did O
not O
change O
significantly O
. O

After O
the O
end O
of O
fenoterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrobromide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
, O
tremor O
amplitudes O
decreased O
significantly O
faster O
than O
those O
following O
ritodrin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
HCl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
. O

Propylthiouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hepatic O
damage O
. O

Two O
cases O
of O
propylthiouracil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
liver O
damage O
have O
been O
observed O
. O

The O
first B_SEQUENCE[MEASURE]
case I_SEQUENCE[MEASURE]
is O
of O
an O
acute B_DISEASE_ADJECTIVE[DISEASE]
type I_DISEASE_ADJECTIVE[DISEASE]
of O
damage B_DISEASE
, O
proven O
by O
rechallenge B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
; O
the O
second B_SEQUENCE[MEASURE]/B_PERSON
presents O
a O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
histologic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
picture I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
resembling O
chronic B_DISEASE/B_GENE
active I_DISEASE/I_GENE
hepatitis I_DISEASE/I_GENE
, O
with O
spontaneous B_DISEASE
remission I_DISEASE
. O

Studies O
on O
the O
bradycardia O
induced O
by O
bepridil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Bepridil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
a O
novel O
active O
compound O
for O
prophylactic O
treatment O
of O
anginal O
attacks O
, O
induced O
persistent O
bradycardia O
and O
a O
non O
- O
specific O
anti O
- O
tachycardial O
effect O
, O
the O
mechanisms O
of O
which O
were O
investigated O
in O
vitro O
and O
in O
vivo O
. O

In O
vitro O
perfusion O
of O
bepridil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
life O
- O
support O
medium O
for O
isolated O
Sino O
- O
atrial O
tissue O
from O
rabbit O
heart O
, O
caused O
a O
reduction O
in O
action O
potential O
( O
AP O
) O
spike O
frequency O
( O
recorded O
by O
KCl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
microelectrodes O
) O
starting O
at O
doses O
of O
5 O
X O
10 O
( O
- O
6 O
) O
M O
. O

This O
effect B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
was O
dose B_MEASURE
- O
dependent B_DISEASE_ADJECTIVE[DISEASE]
up O
to O
concentrations B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
5 B_MEASURE
X I_MEASURE
10 I_MEASURE
( O
- O
5 B_MEASURE
) O
M B_OTHER/B_MEASURE
, O
whereupon B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
blockade I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
sinus B_DISEASE/B_GENE
activity B_DISEASE/I_GENE
set O
in O
. O

Bepridil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O
a O
dose O
of O
5 O
X O
10 O
( O
- O
6 O
) O
M O
, O
induced O
a O
concomitant O
reduction O
in O
AP O
amplitude O
( O
falling O
from O
71 O
+ O
/ O
- O
8 O
MV O
to O
47 O
+ O
/ O
- O
6 O
MV O
) O
, O
maximum O
systolic O
depolarization O
velocity O
( O
phase O
0 O
) O
which O
fell O
from O
1 O
. O
85 O
+ O
/ O
- O
0 O
. O
35 O
V O
/ O
s O
to O
0 O
. O
84 O
+ O
/ O
- O
0 O
. O
28 O
V O
/ O
s O
, O
together O
with O
maximum O
diastolic O
depolarization O
velocity O
( O
phase O
4 O
) O
which O
fell O
from O
38 O
+ O
/ O
- O
3 O
MV O
/ O
s O
to O
24 O
+ O
/ O
- O
5 O
MV O
/ O
s O
. O

In O
vivo O
injection O
of O
bepridil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
a O
dose O
of O
5 O
mg O
/ O
kg O
( O
i O
. O
v O
. O
) O
into O
6 O
anaesthetized O
dogs O
which O
had O
undergone O
ablation O
of O
all O
the O
extrinsic O
cardiac O
afferent O
nerve O
supply O
, O
together O
with O
a O
bilateral O
medullo O
- O
adrenalectomy O
, O
caused O
a O
marked O
reduction O
in O
heart O
rate O
which O
fell O
from O
98 O
. O
7 O
+ O
/ O
- O
4 O
. O
2 O
beats O
/ O
min O
to O
76 O
+ O
/ O
- O
5 O
. O
3 O
beats O
/ O
min O
sustained O
for O
more O
than O
45 O
min O
. O

It O
is O
concluded O
that O
bepridil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reduces O
heart O
rate O
by O
acting O
directly O
on O
the O
sinus O
node O
. O

This O
effect O
, O
which O
results O
in O
a O
flattening O
of O
the O
phase O
0 O
and O
phase O
4 O
slope O
, O
together O
with O
a O
longer O
AP O
duration O
, O
may O
be O
due O
to O
an O
increase O
in O
the O
time O
constants O
of O
slow O
inward O
ionic O
currents O
( O
already O
demonstrated O
elsewhere O
) O
, O
but O
also O
to O
an O
increased O
time O
constant O
for O
deactivation O
of O
the O
outward O
potassium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
current O
( O
IP O
) O
. O

Hepatitis O
and O
renal O
tubular O
acidosis O
after O
anesthesia O
with O
methoxyflurane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

A O
69 O
- O
year O
- O
old O
man O
operated O
for O
acute O
cholecystitis O
under O
methoxyflurane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
anesthesia O
developed O
postoperatively O
a O
hepatic O
insufficiency O
syndrome O
and O
renal O
tubular O
acidosis O
. O

massive B_PERSON
bleeding I_PERSON
appeared O
during O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
which O
lasted O
for O
six B_TIME[MEASURE]/B_ENT
hours I_TIME[MEASURE]/I_ENT
. O

Postoperative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
evolution I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
under O
supportive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
therapy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
favourable B_DISEASE_ADJECTIVE[DISEASE]
. O

Complete B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
recovery I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
confirmed O
by O
repeated O
controls B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performed O
over O
a O
period B_MEASURE/B_LOCATION
of O
one B_TIME[MEASURE]
year I_TIME[MEASURE]
after O
surgery B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Pituitary O
response O
to O
luteinizing O
hormone O
- O
releasing O
hormone O
during O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hyperprolactinemia O
. O

The O
effects O
of O
a O
6 O
- O
hour O
infusion O
with O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
on O
serum O
prolactin O
and O
luteinizing O
hormone O
( O
LH O
) O
levels O
was O
studied O
in O
a O
group O
of O
male O
subjects O
. O

Five B_TIME[MEASURE]/B_ENT
hours I_TIME[MEASURE]/I_ENT
after O
starting O
the O
infusions B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
pituitary B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
responses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
to O
LH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
releasing O
hormone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
LH B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
RH B_PROTEIN[GENE]/B_DISEASE
) O
was O
carried O
out O
. O

Control O
patients O
received O
infusions O
of O
0 O
. O
9 O
% O
NaCl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
solution O
. O

During O
the O
course O
of O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
infusions O
, O
significant O
hyperprolactinemia O
was O
found O
, O
together O
with O
an O
abolished O
pituitary O
response O
to O
LH O
- O
RH O
, O
as O
compared O
with O
responses O
of O
control O
subjects O
. O

Antirifampicin O
antibodies O
in O
acute O
rifampicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
renal O
failure O
. O

5 O
patients O
with O
acute O
renal O
failure O
( O
3 O
with O
thrombopenia O
and O
hemolysis O
) O
induced O
by O
the O
reintroduction O
of O
rifampicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
are O
described O
. O

No O
correlation B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
found O
between O
the O
severity B_MEASURE
of O
clinical B_DISEASE
manifestations I_DISEASE
and O
the O
total B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
dose I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
taken O
by O
the O
patients B_PERSON
. O

In O
all O
but O
1 B_NUMBER[MEASURE]/B_PERSON
patient I_NUMBER[MEASURE]/I_PERSON
, O
antirifampicin B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antibodies I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
were O
detected O
. O

Antibodies B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
suggested O
to O
be O
of O
the O
IgM B_GENE/B_DISEASE
class B_GENE/I_DISEASE
were O
detected O
in O
all O
3 B_PERSON
patients I_PERSON
with O
hematological B_DISEASE/B_GENE
disorders I_DISEASE/I_GENE
. O

The O
pattern B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
non B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
specific B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
acute I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tubular I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
necrosis I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
found O
in O
the O
2 B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
biopsied I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
patients I_PERSON/I_BODY_PART_OR_ORGAN_COMPONENT
, O
indistinguishable B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
from O
that O
of O
ischemic B_DISEASE/B_PERSON
origin I_DISEASE/I_PERSON
, O
raised O
the O
possibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
vascular B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
- O
mediated O
damage B_DISEASE
. O

In O
3 B_PERSON/B_TIME[MEASURE]
patients I_PERSON/I_TIME[MEASURE]
, O
the O
possibility B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
a O
triggering O
immunoallergic B_DISEASE_ADJECTIVE[DISEASE]
mechanism I_DISEASE_ADJECTIVE[DISEASE]
is O
discussed O
. O

Cardiovascular O
effects O
of O
hypotension O
induced O
by O
adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
triphosphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitroprusside I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
dogs O
with O
denervated O
hearts O
. O

Adenosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
triphosphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
ATP B_ORGANIZATION/B_GENE
) O
and O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitroprusside I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SNP B_PROTEIN[GENE]/B_LOCATION
) O
are O
administered O
to O
patients O
to O
induce O
and O
control O
hypotension O
during O
anesthesia O
. O

SNP B_LOCATION/B_ORGANIZATION
is O
authorized O
for O
clinical O
use O
in O
USA O
and O
UK O
, O
and O
ATP B_GENE/B_DISEASE
is O
clinically O
used O
in O
other O
countries O
such O
as O
Japan O
. O

We O
investigated O
how O
these O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
act O
on O
the O
cardiovascular B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
systems I_BODY_PART_OR_ORGAN_COMPONENT/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
20 B_PERSON/B_ENT
dogs I_PERSON/I_ENT
whose O
hearts B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
been O
denervated O
by O
a O
procedure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
we O
had O
devised O
. O

ATP B_ORGANIZATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 O
dogs O
) O
or O
SNP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
10 O
dogs O
) O
was O
administered O
to O
reduce O
mean O
arterial O
pressure O
by O
30 O
% O
to O
70 O
% O
of O
control O
. O

Before O
, O
during O
and O
after O
induced B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
hypotension I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
we O
measured O
major B_DISEASE/B_GENE
cardiovascular B_DISEASE/I_GENE
parameters B_DISEASE/I_GENE
. O

Hypotension O
induced O
by O
ATP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
accompanied O
by O
significant O
decreases O
in O
mean O
pulmonary O
arterial O
pressure O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
central O
venous O
pressure O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
left O
ventricular O
end O
- O
diastolic O
pressure O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
total O
peripheral O
resistance O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
rate O
pressure O
product O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
total O
body O
oxygen B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
consumption O
( O
p O
less O
than O
0 O
. O
05 O
) O
, O
and O
heart O
rate O
( O
p O
less O
than O
0 O
. O
001 O
) O
; O
all O
these O
variables O
returned O
normal O
within O
30 O
min O
after O
ATP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
stopped O
. O

cardiac B_PERSON/B_MEASURE
output I_PERSON/I_MEASURE
did O
not O
change B_MEASURE
. O

During O
hypotension O
produced O
by O
SNP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
similar O
decreases O
were O
observed O
in O
mean O
pulmonary O
arterial O
pressure O
( O
p O
less O
than O
0 O
. O
01 O
) O
, O
central O
venous O
pressure O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
left O
ventricular O
end O
- O
diastolic O
pressure O
( O
p O
less O
than O
0 O
. O
01 O
) O
, O
total O
peripheral O
resistance O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
rate O
pressure O
product O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
and O
oxygen B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
content O
difference O
between O
arterial O
and O
mixed O
venous O
blood O
( O
p O
less O
than O
0 O
. O
05 O
) O
, O
while O
heart O
rate O
( O
p O
less O
than O
0 O
. O
001 O
) O
and O
cardiac O
output O
( O
p O
less O
than O
0 O
. O
05 O
) O
were O
increased O
. O

Recoveries O
of O
heart O
rate O
and O
left O
ventricular O
end O
- O
diastolic O
pressure O
were O
not O
shown O
within O
60 O
min O
after O
SNP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
had O
been O
stopped O
. O

Both O
ATP B_ORGANIZATION/B_LOCATION
and O
SNP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
should O
act O
on O
the O
pacemaker O
tissue O
of O
the O
heart O
. O

Comparative O
study O
: O
Endografine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
diatrizoate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
Vasurix B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
polyvidone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
( O
acetrizoate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
Dimer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
iocarmate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
and O
Hexabrix B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
ioxaglate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
in O
hysterosalpingography O
. O

Side O
effects O
of O
hysterosalpingography O
with O
Dimer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Hexabrix B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
Vasurix B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
polyvidone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
Endografine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
142 O
consecutive O
patients O
, O
receiving O
one O
of O
the O
four O
tested O
media O
were O
evaluated O
from O
replies O
to O
postal O
questionnaires O
. O

The O
Dimer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
X I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O
had O
a O
higher O
incidence O
of O
nausea O
and O
dizziness O
. O

The O
Endografine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group O
had O
a O
higher O
incidence O
of O
abdominal O
pain O
. O

These O
differences B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occur O
especially O
in O
the O
age B_PERSON
groups I_PERSON
under O
30 B_NUMBER[MEASURE]/B_ENT
years I_NUMBER[MEASURE]/I_ENT
. O

Hexabrix B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
Vasurix B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
polyvidone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
considered O
the O
best O
contrast B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
media I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
hysterosalpingography O
and O
perhaps O
because O
of O
its O
low O
toxicity O
Hexabrix B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
should O
be O
preferred O
. O

Post O
- O
suxamethonium B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
pains O
in O
Nigerian O
surgical O
patients O
. O

contrary O
to O
an O
earlier O
report O
by O
Coxon O
, O
scoline B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pain O
occurs O
in O
African O
negroes O
. O

Its O
incidence B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
determined O
in O
a O
prospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
involving O
a O
total B_MEASURE/B_LOCATION
of O
100 B_MEASURE
Nigerian I_MEASURE
patients I_MEASURE
( O
50 B_LOCATION/B_ENT
out I_LOCATION/I_ENT
- O
patients B_PERSON/B_DISEASE
and O
50 B_MEASURE
in O
- O
patients B_PERSON/B_ORGANIZATION
) O
. O

About O
62 O
% O
of O
the O
out O
- O
patients O
developed O
scoline B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pain O
as O
compared O
with O
about O
26 O
% O
among O
the O
in O
- O
patients O
. O

The O
abolition O
of O
muscle O
fasciculations O
( O
by O
0 O
. O
075mg O
/ O
kg O
dose O
of O
Fazadinium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
did O
not O
influence O
the O
occurrence O
of O
scoline B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pain O
. O

Neither O
the O
type O
of O
induction O
agent O
( O
Althesin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
Thiopentone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
nor O
the O
salt O
preparation O
of O
suxamethonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
used O
( O
chloride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
bromide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
, O
affected O
the O
incidence O
of O
scoline B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pain O
. O

invasive O
carcinoma O
of O
the O
renal O
pelvis O
following O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
for O
nonmalignant O
disease O
. O

A O
47 O
- O
year O
- O
old O
woman O
with O
right O
hydroureteronephrosis O
due O
to O
ureterovesical O
junction O
obstruction O
had O
gross O
hematuria O
after O
being O
treated O
for O
five O
years O
wtih O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
cerebral O
vasculitis O
. O

A O
right B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
nephroureterectomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
required O
for O
control B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
bleeding B_DISEASE
. O

The O
pathology B_DISEASE/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specimen I_DISEASE/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
contained O
clinically O
occult B_DISEASE
invasive I_DISEASE
carcinoma I_DISEASE
of O
the O
renal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
pelvis I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Although O
the O
ability O
of O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
cause O
hemorrhagic O
cystitis O
and O
urine O
cytologic O
abnormalities O
indistinguishable O
from O
high O
grade O
carcinoma O
is O
well O
known O
, O
it O
is O
less O
widely O
appreciated O
that O
it O
is O
also O
associated O
with O
carcinoma O
of O
the O
urinary O
tract O
. O

Twenty B_DISEASE
carcinomas I_DISEASE
of O
the O
urinary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
bladder I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
one B_NUMBER[MEASURE]/B_LOCATION
carcinoma I_NUMBER[MEASURE]/I_LOCATION
of O
the O
prostate B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
have O
been O
reported O
in O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
its O
use B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

The O
present O
case O
is O
the O
first O
carcinoma O
of O
the O
renal O
pelvis O
reported O
in O
association O
with O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
. O

It O
is O
the O
third O
urinary O
tract O
cancer O
reported O
in O
association O
with O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
for O
nonmalignant O
disease O
. O

The O
association O
of O
the O
tumor O
with O
preexisting O
hydroureteronephrosis O
suggests O
that O
stasis O
prolonged O
and O
intensified O
exposure O
of O
upper O
urinary O
tract O
epithelium O
to O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

patients O
who O
are O
candidates O
for O
long O
- O
term O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
should O
be O
routinely O
evaluated O
for O
obstructive O
uropathy O
. O

medial O
changes O
in O
arterial O
spasm O
induced O
by O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
norepinephrine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
normal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
rats I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
the O
media B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
small B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
arteries I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
0 B_MEASURE/B_LOCATION
. O
4 B_MEASURE
- O
- O
0 B_MEASURE
. O
2 B_MEASURE
mm I_MEASURE
in O
diameter B_MEASURE
) O
previously O
was O
shown O
to O
contain O
intracellular B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
vacuoles I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
, O
identified O
ultrastructurally O
as O
herniations B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
one B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
smooth I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
muscle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
cell I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
into O
another O
. O

The O
hypothesis B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
intense B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vasoconstriction B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
would O
increase O
the O
number B_MEASURE
of O
such B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
vacuoles B_DISEASE_ADJECTIVE[DISEASE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
has O
been O
tested O
. O

In O
the O
media O
of O
the O
saphenous O
artery O
and O
its O
distal O
branch O
, O
vasoconstriction O
induced O
by O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
norepinephrine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
produced O
many O
cell O
- O
to O
- O
cell O
hernias O
within O
15 O
minutes O
. O

At O
1 B_TIME[MEASURE]/B_LOCATION
day I_TIME[MEASURE]/I_LOCATION
their O
number B_MEASURE/B_PERSON
was O
reduced O
to O
about O
1 B_MEASURE
/ O
10 B_SEQUENCE[MEASURE]
of O
the O
original B_MEASURE/B_ORGANIZATION
number B_MEASURE/I_ORGANIZATION
. O

By O
7 B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
days I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
the O
vessel B_DISEASE/B_MEASURE
was O
almost O
restored O
to O
normal B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

triple B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
stimulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
over O
1 B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
day I_NUMBER[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
induced O
more B_DISEASE
severe I_DISEASE
changes I_DISEASE
in O
the O
media B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
. O

These O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suggest O
that O
smooth B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
muscle I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
are O
susceptible B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
to O
damage B_DISEASE
in O
the O
course B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
their O
specific B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
data I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
discussed O
in O
relation B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
to O
medial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
observed O
in O
other B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
instances I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
arterial B_DISEASE
spasm I_DISEASE
. O

Endothelial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
changes I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
that O
developed O
in O
the O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
experimental I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
described O
in O
a O
previous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
paper I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

bilateral O
retinal O
artery O
and O
choriocapillaris O
occlusion O
following O
the O
injection O
of O
long O
- O
acting O
corticosteroid B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
suspensions O
in O
combination O
with O
other O
drugs O
: O
I O
. O

Clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
studies I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Two O
well O
- O
documented O
cases O
of O
bilateral O
retinal O
artery O
and O
choriocapillaris O
occlusions O
with O
blindness O
following O
head O
and O
neck O
soft O
- O
tissue O
injection O
with O
methylprednisolone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acetate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
combination O
with O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
penicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
reported O
. O

One B_PERSON
case I_PERSON
had O
only O
a O
unilateral B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
injection I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
acute B_DISEASE_ADJECTIVE[DISEASE]
observations I_DISEASE_ADJECTIVE[DISEASE]
included O
hazy B_DISEASE
sensorium I_DISEASE
, O
superior B_DISEASE
gaze I_DISEASE
palsy I_DISEASE
, O
pupillary B_DISEASE
abnormalities I_DISEASE
, O
and O
conjunctival B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hemorrhages I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
with O
edema B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Follow O
- O
up O
changes B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
showed O
marked B_DISEASE
visual I_DISEASE
loss I_DISEASE
, O
constricted B_DISEASE
visual I_DISEASE
fields I_DISEASE
, O
optic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nerve I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pallor I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
vascular B_DISEASE
attenuation I_DISEASE
, O
and O
chorioretinal B_DISEASE
atrophy I_DISEASE
. O

The O
literature B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
reviewed O
, O
and O
possible B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
causes I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
are O
discussed O
. O

Abnormalities O
of O
the O
pupil O
and O
visual O
- O
evoked O
potential O
in O
quinine B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
amblyopia O
. O

Total O
blindness O
with O
a O
transient O
tonic O
pupillary O
response O
, O
denervation O
supersensitivity O
, O
and O
abnormal O
visual O
- O
evoked O
potentials O
developed O
in O
a O
54 O
- O
year O
- O
old O
man O
after O
the O
use O
of O
quinine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
sulfate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
for O
leg O
cramps O
. O

He O
later O
recovered O
normal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
visual I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
acuity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

A O
transient O
tonic O
pupillary O
response O
, O
denervation O
supersensitivity O
, O
and O
abnormal O
visual O
- O
evoked O
potentials O
in O
quinine B_DISEASE/B_PROTEIN[GENE]
toxicity O
, O
to O
our O
knowledge O
, O
have O
not O
been O
previously O
reported O
. O

Suxamethonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
jaw O
stiffness O
and O
myalgia O
associated O
with O
atypical O
cholinesterase O
: O
case O
report O
. O

An O
11 O
- O
year O
- O
old O
boy O
was O
given O
halothane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
nitrous B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
oxygen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
pancuronium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
0 O
. O
4 O
mg O
and O
suxamethonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
100 O
mg O
for O
induction O
of O
anaesthesia O
. O

In O
response B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
this O
a O
marked O
jaw B_DISEASE
stiffness I_DISEASE
occurred O
which O
lasted O
for O
two B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
and O
the O
anaesthesia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
were O
terminated O
. O

Four B_TIME[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
hours B_TIME[MEASURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
apnoea B_DISEASE
ensued O
and O
he O
suffered O
generalized B_DISEASE
severe I_DISEASE
myalgia I_DISEASE
lasting O
for O
one B_TIME[MEASURE]
week I_TIME[MEASURE]
. O

He O
was O
found O
to O
have O
atypical O
plasma O
cholinesterase O
with O
a O
dibucaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
number O
of O
12 O
, O
indicating O
homozygocity O
. O

This O
was O
verified O
by O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
family B_PERSON/B_LOCATION
. O

The O
case O
shows O
that O
prolonged O
jaw O
rigidity O
and O
myalgia O
may O
occur O
after O
suxamethonium B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
patients O
with O
atypical O
cholinesterase O
despite O
pretreatment O
with O
pancuronium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
hyperkalemia O
in O
three O
patients O
with O
gouty O
arthritis O
. O

We O
describe O
three O
patients O
in O
whom O
severe O
, O
life O
- O
threatening O
hyperkalemia O
and O
renal O
insufficiency O
developed O
after O
treatment O
of O
acute O
gouty O
arthritis O
with O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
complication O
may O
result O
from O
an O
inhibition O
of O
prostaglandin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
synthesis O
and O
consequent O
hyporeninemic O
hypoaidosteronism O
. O

careful O
attention O
to O
renal O
function O
and O
potassium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
balance O
in O
patients O
receiving O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
other O
nonsteroidal O
anti O
- O
inflammatory O
agents O
, O
particularly O
in O
those O
patients O
with O
diabetes O
mellitus O
or O
preexisting O
renal O
disease O
, O
will O
help O
prevent O
this O
potentially O
serious O
complication O
. O

Etomidate B_MEASURE
: O
a O
foreshortened O
clinical O
trial O
. O

A O
clinical O
evaluation O
of O
etomidate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
for O
outpatient O
cystoscopy O
was O
embarked O
upon O
. O

Unpremedicated O
patients O
were O
given O
fentanyl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
microgram O
/ O
kg O
followed O
by O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O
. O
3 O
mg O
/ O
kg O
. O

Anaesthesia O
was O
maintained O
with O
intermittent O
etomidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
2 O
- O
4 O
mg O
doses O
. O

patients B_PERSON
were O
interviewed O
personally O
later O
the O
same B_TIME[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
day I_TIME[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
by O
questionnaire B_NUMBER[MEASURE]/B_LOCATION
three I_NUMBER[MEASURE]/I_LOCATION
to O
four B_NUMBER[MEASURE]/B_ENT
weeks I_NUMBER[MEASURE]/I_ENT
later O
. O

The O
trial B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
discontinued O
after O
20 B_TIME[MEASURE]
cases I_TIME[MEASURE]
because O
of O
an O
unacceptable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
incidence B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
side B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Venous B_DISEASE_ADJECTIVE[DISEASE]
pain I_DISEASE_ADJECTIVE[DISEASE]
occurred O
in O
68 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
patients B_PERSON
and O
50 B_PERSON/B_MEASURE
% I_PERSON/I_MEASURE
had O
redness B_DISEASE
, O
pain B_DISEASE
or O
swelling O
related O
to O
the O
injection B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
site I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
, O
in O
some O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
lasting O
up O
to O
three B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
after O
anaesthesia B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

skeletal B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
movements I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
occurred O
in O
50 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
of O
patients B_PERSON
; O
30 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
experienced O
respiratory B_DISEASE
upset I_DISEASE
, O
one B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sufficiently O
severe B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
to O
necessitate B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
abandoning O
the O
technique B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

nausea B_DISEASE
and O
vomiting B_DISEASE
occurred O
in O
40 B_PERSON/B_LOCATION
% I_PERSON/I_LOCATION
and O
25 B_PERSON/B_LOCATION
% I_PERSON/I_LOCATION
had O
disturbing B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
emergence I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
psychoses I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
dyskinesias O
are O
improved O
by O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

We O
evaluated O
the O
severity O
of O
motor O
disability O
and O
dyskinesias O
in O
seven O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
responsive O
patients O
with O
Parkinson O
' O
s O
disease O
after O
an O
acute O
challenge O
with O
the O
mixed O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O
, O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
before O
and O
after O
the O
administration O
of O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
20 O
mg O
twice O
per O
day O
) O
for O
11 O
+ O
/ O
- O
1 O
days O
. O

After O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
, O
there O
was O
a O
significant O
47 O
% O
improvement O
( O
p O
< O
0 O
. O
05 O
) O
of O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
dyskinesias O
without O
modification O
of O
parkinsonian O
motor O
disability O
. O

The O
dyskinesias B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
were O
reduced O
predominantly O
in O
the O
lower B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
limbs I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
during O
the O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
disappearance B_MEASURE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
dystonic B_DISEASE
dyskinesias I_DISEASE
( O
onset B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
and O
end B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
of O
- O
dose B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
dyskinesias B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
) O
and O
in O
the O
upper B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
limbs I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
during O
choreic B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
mid B_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
- O
dose B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
dyskinesias B_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
. O

The O
results O
suggest O
that O
increased O
brain O
serotoninergic O
transmission O
with O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
may O
reduce O
levodopa B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
or O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O
- O
induced O
dyskinesias O
without O
aggravating O
parkinsonian O
motor O
disability O
. O

A O
large O
population O
- O
based O
follow O
- O
up O
study O
of O
trimethoprim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfamethoxazole I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
trimethoprim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
cephalexin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
for O
uncommon O
serious O
drug O
toxicity O
. O

We O
conducted O
a O
population O
- O
based O
45 O
- O
day O
follow O
- O
up O
study O
of O
232 O
, O
390 O
people O
who O
were O
prescribed O
trimethoprim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sulfamethoxazole I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
TMP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
SMZ B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
) O
, O
266 O
, O
951 O
prescribed O
trimethoprim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
, O
and O
196 O
, O
397 O
prescribed O
cephalexin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
to O
estimate O
the O
risk O
of O
serious O
liver O
, O
blood O
, O
skin O
, O
and O
renal O
disorders O
resulting O
in O
referral O
or O
hospitalization O
associated O
with O
these O
drugs O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
based O
on O
information B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
recorded O
on O
office B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
computers I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
selected B_PERSON/B_ORGANIZATION
general I_PERSON/I_ORGANIZATION
practitioners I_PERSON/I_ORGANIZATION
in O
the O
United B_LOCATION/B_ORGANIZATION
Kingdom I_LOCATION/I_ORGANIZATION
, O
together O
with O
a O
review B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
records I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
risk O
of O
clinically O
important O
idiopathic O
liver O
disease O
was O
similar O
for O
persons O
prescribed O
TMP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SMZ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 O
. O
2 O
/ O
100 O
, O
000 O
) O
and O
those O
prescribed O
trimethoprim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
( O
3 O
. O
8 O
/ O
100 O
, O
000 O
) O
. O

The O
risk O
for O
those O
prescribed O
cephalexin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
somewhat O
lower O
( O
2 O
. O
0 O
/ O
100 O
, O
000 O
) O
. O

Only O
five O
patients O
experienced O
blood O
disorders O
, O
one O
of O
whom O
was O
exposed O
to O
TMP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SMZ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
of O
seven O
with O
erythema O
multiforme O
and O
Stevens O
- O
Johnson O
syndrome O
, O
four O
were O
exposed O
to O
TMP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
SMZ I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
one O
case O
of O
toxic O
epidermal O
necrolysis O
occurred O
in O
a O
patient O
who O
took O
cephalexin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

Finally O
, O
only O
five B_TIME[MEASURE]/B_PERSON
cases B_TIME[MEASURE]/I_PERSON
of O
acute B_DISEASE
parenchymal I_DISEASE
renal I_DISEASE
disease I_DISEASE
occurred O
, O
none B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
likely I_DISEASE_ADJECTIVE[DISEASE]/I_TIME[MEASURE]
to O
be O
caused O
by O
a O
study B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

We O
conclude O
that O
the O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
the O
serious B_DISEASE_ADJECTIVE[DISEASE]
diseases I_DISEASE_ADJECTIVE[DISEASE]
studied O
is O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O
the O
three B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
compares O
reasonably O
with O
the O
risk B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
many B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
other I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
antibiotics I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Clinical O
safety O
of O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients O
with O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
myocardial O
infarction O
. O

Study O
objective O
: O
To O
evaluate O
the O
safety O
of O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
setting O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
myocardial O
infarction O
( O
MI O
) O
. O

Design B_PERSON/B_MEASURE
: O
A O
retrospective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
multicenter B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

setting B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
Twenty B_NUMBER[MEASURE]
- O
nine B_NUMBER[MEASURE]/B_LOCATION
university I_NUMBER[MEASURE]/I_LOCATION
, O
university B_LOCATION/B_PERSON
- O
affiliated O
, O
or O
community B_PERSON/B_LOCATION
hospitals I_PERSON/I_LOCATION
during O
a O
6 B_NUMBER[MEASURE]
- O
year B_TIME[MEASURE]
period I_TIME[MEASURE]
( O
total B_MEASURE/B_LOCATION
of O
117 B_NUMBER[MEASURE]/B_LOCATION
cumulative I_NUMBER[MEASURE]/I_LOCATION
hospital I_NUMBER[MEASURE]/I_LOCATION
- O
years B_TIME[MEASURE]/B_LOCATION
) O
. O

participants O
: O
patients O
with O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
MI O
who O
received O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
the O
emergency O
department O
. O

Results O
: O
Of O
29 O
patients O
who O
received O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
setting O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
MI O
, O
no O
patient O
died O
; O
exhibited O
bradydysrhythmias O
, O
ventricular O
tachycardia O
, O
or O
ventricular O
fibrillation O
; O
or O
experienced O
seizures O
after O
administration O
of O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
95 O
% O
confidence O
interval O
, O
0 O
% O
to O
11 O
% O
) O
. O

conclusion O
: O
Despite O
theoretical O
concerns O
that O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
may O
enhance O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
toxicity O
, O
the O
use O
of O
lidocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
patients O
with O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
MI O
was O
not O
associated O
with O
significant O
cardiovascular O
or O
central O
nervous O
system O
toxicity O
. O

Experimental B_DISEASE
progressive I_DISEASE
muscular I_DISEASE
dystrophy I_DISEASE
and O
its O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
with O
high B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
doses I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
anabolizing O
agents B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
are O
still O
a O
long B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
way I_LOCATION/I_DISEASE_ADJECTIVE[DISEASE]
from O
discovering O
an O
unequivocal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pathogenetic I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interpretation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
progressive B_DISEASE
muscular I_DISEASE
dystrophy I_DISEASE
in O
man B_PERSON/B_BIO
. O

Noteworthy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
efforts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
have O
been O
made O
in O
the O
experimental B_LOCATION/B_ORGANIZATION
field I_LOCATION/I_ORGANIZATION
; O
a O
recessive B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
autosomic B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
form B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
found O
in O
the O
mouse B_SPECIES[BIO]/B_DISEASE
seems O
to O
bear O
the O
closest B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
resemblance I_MEASURE/I_DISEASE_ADJECTIVE[DISEASE]
to O
the O
human B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
form I_SPECIES[BIO]/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
the O
genetic B_LOCATION/B_MEASURE
point I_LOCATION/I_MEASURE
of O
view B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Myopathy O
due O
to O
lack O
of O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
E I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
myopathy O
induced O
by O
certain O
viruses O
have O
much O
in O
common O
anatomically O
and O
pathologically O
with O
the O
human O
form O
. O

The O
authors O
induced O
myodystrophy O
in O
the O
rat O
by O
giving O
it O
a O
diet O
lacking O
in O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
pharmacological O
characteristics O
of O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
E I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
the O
degenerative O
changes O
brought O
about O
by O
its O
deficiency O
, O
especially O
in O
the O
muscles O
, O
are O
illustrated O
. O

It O
is O
thus O
confirmed O
that O
the O
histological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
myopathic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
rat I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
muscle I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
induced O
experimentally O
are O
extraordinarily O
similar B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
those O
of O
human B_DISEASE_ADJECTIVE[DISEASE]/B_BIO
myopathy I_DISEASE_ADJECTIVE[DISEASE]/I_BIO
as O
confirmed O
during O
biopsies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
performed O
at O
the O
Orthopaedic B_LOCATION/B_ORGANIZATION
Traumatological I_LOCATION/I_ORGANIZATION
Centre I_LOCATION/I_ORGANIZATION
, O
Florence B_LOCATION
. O

The O
encouraging O
results O
obtained O
in O
various O
authoratative O
departments O
in O
myopathic O
patients O
by O
using O
anabolizing O
steroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
encouraged O
the O
authors O
to O
investigate O
the O
beneficial O
effects O
of O
one O
anabolizing O
agent O
( O
Dianabol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
CIBA B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
at O
high O
doses O
in O
rats O
rendered O
myopathic O
by O
a O
diet O
deficient O
in O
vitamin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
E I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

In O
this O
way B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
they O
obtained O
appreciable B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
body B_MEASURE
weight I_MEASURE
( O
increased O
from O
50 B_MEASURE
to O
70 B_MEASURE
g I_MEASURE
after O
forty B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
days I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
at O
a O
dose B_MEASURE/B_DISEASE
of O
5 B_MEASURE
mg I_MEASURE
per O
day B_TIME[MEASURE]
of O
anabolizing B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
) O
, O
but O
most B_SEQUENCE[MEASURE]
of O
all O
they O
found O
histological B_DISEASE_ADJECTIVE[DISEASE]/B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes I_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
due I_DISEASE_ADJECTIVE[DISEASE]/I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
' O
regenerative B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
' O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
the O
muscle B_BODY_PART_OR_ORGAN_COMPONENT
tissue I_BODY_PART_OR_ORGAN_COMPONENT
, O
which O
however O
maintained O
its O
myopathic B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
characteristics B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ORGANIZATION
that O
were O
not O
treated O
with O
the O
anabolizing B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agent I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

The O
authors O
conclude O
by O
affirming O
the O
undoubted O
efficacy O
of O
the O
anabolizing O
steroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
experimental O
myopathic O
disease O
, O
but O
they O
have O
reservations O
as O
to O
the O
transfer O
of O
the O
results O
into O
the O
human O
field O
, O
where O
high O
dosage O
cannot O
be O
carried O
out O
continuously O
because O
of O
the O
effects O
of O
the O
drug O
on O
virility O
; O
because O
the O
tissue O
injury O
too O
often O
occurs O
at O
an O
irreversible O
stage O
vis O
- O
a O
- O
vis O
the O
' O
regeneration O
' O
of O
the O
muscle O
tissue O
; O
and O
finally O
because O
the O
dystrophic O
injurious O
agent O
is O
certainly O
not O
the O
lack O
of O
vitamin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
E I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
but O
something O
as O
yet O
unknown O
. O

Paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
3 O
- O
hour O
infusion O
given O
alone O
and O
combined O
with O
carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
preliminary O
results O
of O
dose O
- O
escalation O
trials O
. O

Paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Taxol B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
Bristol O
- O
Myers O
Squibb O
Company O
, O
Princeton O
, O
NJ O
) O
by O
3 O
- O
hour O
infusion O
was O
combined O
with O
carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
a O
phase O
I O
/ O
II O
study O
directed O
to O
patients O
with O
non O
- O
small O
cell O
lung O
cancer O
. O

Carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
given O
at O
a O
fixed O
target O
area O
under O
the O
concentration O
- O
time O
curve O
of O
6 O
. O
0 O
by O
the O
Calvert O
formula O
, O
whereas O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
escalated O
in O
patient O
cohorts O
from O
150 O
mg O
/ O
m2 O
( O
dose O
level O
I O
) O
to O
175 O
, O
200 O
, O
225 O
, O
and O
250 O
mg O
/ O
m2 O
. O

The O
225 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
mg B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
/ O
m2 B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
was O
expanded O
for O
the O
phase B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
II I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
since O
the O
highest B_MEASURE/B_LOCATION
level I_MEASURE/I_LOCATION
achieved O
( O
250 B_MEASURE
mg I_MEASURE
/ O
m2 B_MEASURE/B_LOCATION
) O
required O
modification B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
because O
of O
nonhematologic B_DISEASE
toxicities I_DISEASE
( O
arthralgia B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
sensory B_DISEASE
neuropathy I_DISEASE
) O
. O

Therapeutic B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
effects I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
noted O
at O
all O
dose B_MEASURE/B_LOCATION
levels B_MEASURE/I_LOCATION
, O
with O
objective B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
responses I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
17 B_NUMBER[MEASURE]
( O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
complete B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
15 B_DISEASE_ADJECTIVE[DISEASE]
partial I_DISEASE_ADJECTIVE[DISEASE]
regressions I_DISEASE_ADJECTIVE[DISEASE]
) O
of O
41 B_NUMBER[MEASURE]
previously O
untreated B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
patients I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Toxicities O
were O
compared O
with O
a O
cohort O
of O
patients O
in O
a O
phase O
I O
trial O
of O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
at O
identical O
dose O
levels O
. O

Carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
did O
not O
appear O
to O
add O
to O
the O
hematologic O
toxicities O
observed O
, O
and O
the O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
carboplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
combination O
could O
be O
dosed O
every O
3 O
weeks O
. O

The O
dose O
- O
dependent O
effect O
of O
misoprostol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
renal O
dysfunction O
in O
well O
compensated O
cirrhosis O
. O

Misoprostol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
200 O
micrograms O
) O
has O
been O
shown O
to O
acutely O
counteract O
the O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
renal O
dysfunction O
in O
well O
compensated O
cirrhotic O
patients O
. O

The O
aim O
of O
this O
study O
was O
to O
determine O
if O
the O
prophylactic O
value O
of O
misoprostol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
dose O
- O
dependent O
. O

parameters O
of O
renal O
hemodynamics O
and O
tubular O
sodium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
and O
water O
handling O
were O
assessed O
by O
clearance O
techniques O
in O
26 O
well O
compensated O
cirrhotic O
patients O
before O
and O
after O
an O
oral O
combination O
of O
50 O
mg O
of O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
various O
doses O
of O
misoprostol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
200 O
- O
micrograms O
dose O
was O
able O
to O
totally O
abolish O
the O
deleterious O
renal O
effects O
of O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
whereas O
the O
800 O
- O
micrograms O
dose O
resulted O
in O
significant O
worsening O
of O
renal O
hemodynamics O
and O
sodium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
retention O
. O

These O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
maximal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
in O
the O
hour B_BODY_PART_OR_ORGAN_COMPONENT/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
immediately O
after O
medications B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
slowly O
returned O
toward O
base B_LOCATION/B_COLOR
- O
line B_MEASURE/B_ORGANIZATION
levels I_MEASURE/I_ORGANIZATION
thereafter O
. O

These O
results O
suggest O
that O
the O
renal O
protective O
effects O
of O
misoprostol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
dose O
- O
dependent O
. O

However O
, O
until O
this O
apparent O
ability O
of O
200 O
micrograms O
of O
misoprostol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
prevent O
the O
adverse O
effects O
of O
indomethacin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
renal O
function O
is O
confirmed O
with O
chronic O
frequent O
dosing O
, O
it O
would O
be O
prudent O
to O
avoid O
nonsteroidal O
anti O
- O
inflammatory O
therapy O
in O
patients O
with O
cirrhosis O
. O

increased O
frequency O
and O
severity O
of O
angio O
- O
oedema O
related O
to O
long O
- O
term O
therapy O
with O
angiotensin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
converting I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
enzyme I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
two O
patients O
. O

Adverse B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reactions B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
well O
recognized O
as O
a O
cause B_DISEASE
of O
acute B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
or O
chronic B_DISEASE_ADJECTIVE[DISEASE]
urticaria I_DISEASE_ADJECTIVE[DISEASE]
, O
and O
angio B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- O
oedema B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Angiotensin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
converting I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
enzyme I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
ACE I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
, O
used O
to O
treat O
hypertension O
and O
congestive O
heart O
failure O
, O
were O
introduced O
in O
Europe O
in O
the O
middle O
of O
the O
eighties O
, O
and O
the O
use O
of O
these O
drugs O
has O
increased O
progressively O
. O

Soon O
after O
the O
introduction O
of O
ACE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
acute O
bouts O
of O
angio O
- O
oedema O
were O
reported O
in O
association O
with O
the O
use O
of O
these O
drugs O
. O

We O
wish O
to O
draw O
attention O
to O
the O
possibility O
of O
adverse O
reactions O
to O
ACE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
inhibitors I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
after O
long O
- O
term O
use O
and O
in O
patients O
with O
pre O
- O
existing O
angio O
- O
oedema O
. O

Myoclonus O
associated O
with O
lorazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
in O
very O
- O
low O
- O
birth O
- O
weight O
infants O
. O

Lorazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
being O
used O
with O
increasing O
frequency O
as O
a O
sedative O
in O
the O
newborn O
and O
the O
young O
infant O
. O

concern O
has O
been O
raised O
with O
regard O
to O
the O
safety O
of O
lorazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
this O
age O
group O
, O
especially O
in O
very O
- O
low O
- O
birth O
- O
weight O
( O
VLBW O
; O
< O
1 O
, O
500 O
g O
) O
infants O
. O

Three O
young O
infants O
, O
all O
of O
birth O
weight O
< O
1 O
, O
500 O
g O
, O
experienced O
myoclonus O
following O
the O
intravenous O
administration O
of O
lorazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
potential B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
neurotoxic I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
effects I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
and O
its O
vehicle B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
) O
in O
this O
population B_PERSON/B_LOCATION
are O
discussed O
. O

Injectable O
lorazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
should O
be O
used O
with O
caution O
in O
VLBW O
infants O
. O

Transvenous B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
right I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pacing I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O
cardiopulmonary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
resuscitation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
pediatric B_PERSON/B_BIO
patients I_PERSON/I_BIO
with O
acute B_DISEASE
cardiomyopathy I_DISEASE
. O

We O
describe O
the O
cardiopulmonary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
resuscitation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
efforts I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
on O
five B_PERSON/B_BIO
patients I_PERSON/I_BIO
who O
presented O
in O
acute B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
circulatory I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
failure I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
from O
myocardial B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysfunction I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Three O
patients O
had O
acute O
viral O
myocarditis O
, O
one O
had O
a O
carbamazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
acute O
eosinophilic O
myocarditis O
, O
and O
one O
had O
cardiac O
hemosiderosis O
resulting O
in O
acute O
cardiogenic O
shock O
. O

All O
patients B_PERSON/B_LOCATION
were O
continuously O
monitored O
with O
central B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
venous I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
arterial B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
catheters B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O
addition B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
routine B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
noninvasive I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
monitoring I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

An O
introducer B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
sheath I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
a O
pacemaker B_MEDICAL_DEVICE[OBJECT]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
and O
sterile B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pacing I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
wires I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
made O
readily O
available B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
the O
patients B_PERSON/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
should O
the O
need B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
arise O
to O
terminate O
resistant B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiac I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
dysrhythmias I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

All O
patients B_PERSON
developed O
cardiocirculatory B_DISEASE
arrest I_DISEASE
associated O
with O
extreme B_DISEASE
hypotension I_DISEASE
and O
dysrhythmias B_DISEASE
within O
the O
first B_TIME[MEASURE]/B_SPORT[ENT]
48 I_TIME[MEASURE]/I_SPORT[ENT]
hours I_TIME[MEASURE]/I_SPORT[ENT]
of O
their O
admission B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
to O
the O
pediatric B_LOCATION/B_ORGANIZATION
intensive I_LOCATION/I_ORGANIZATION
care I_LOCATION/I_ORGANIZATION
unit I_LOCATION/I_ORGANIZATION
( O
PICU B_LOCATION/B_ORGANIZATION
) O
. O

Right B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
ventricular I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
pacemaker I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
wires I_DISEASE_ADJECTIVE[DISEASE]/I_PERSON
were O
inserted O
in O
all O
of O
them O
during O
cardiopulmonary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
resuscitation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
CPR B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
. O

In O
four B_PERSON/B_MEASURE
patients I_PERSON/I_MEASURE
, O
cardiac B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pacing I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
was O
used O
, O
resulting O
in O
a O
temporary B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
captured O
rhythm B_DISEASE/B_MEASURE
and O
restoration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
their O
cardiac B_MEASURE/B_BODY_PART_OR_ORGAN_COMPONENT
output B_MEASURE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

These O
patients B_PERSON
had O
a O
second B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
event B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cardiac B_DISEASE
arrest I_DISEASE
, O
resulting O
in O
death B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
within O
10 B_NUMBER[MEASURE]/B_LOCATION
to O
60 B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
. O

In O
one B_PERSON/B_MEASURE
patient B_PERSON/I_MEASURE
, O
cardiac B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
pacing I_PERSON/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
not O
used O
, O
because O
he O
converted O
to O
normal B_DISEASE
sinus I_DISEASE
rhythm I_DISEASE
by O
electrical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
defibrillation I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
within O
three B_TIME[MEASURE]/B_ENT
minutes I_TIME[MEASURE]/I_ENT
of O
initiating O
CPR B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

We O
conclude O
that O
cardiac B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
pacing I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
during O
resuscitative B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
efforts I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
in O
pediatric B_PERSON/B_LOCATION
patients I_PERSON/I_LOCATION
suffering O
from O
acute B_DISEASE
myocardial I_DISEASE
dysfunction I_DISEASE
may O
not O
have O
long B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
term B_TIME[MEASURE]/B_LOCATION
value I_TIME[MEASURE]/I_LOCATION
in O
and O
of O
itself O
; O
however O
, O
if O
temporary B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hemodynamic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stability I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
is O
achieved O
by O
this O
procedure B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
, O
it O
may O
provide O
additional B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
time I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
needed O
to O
institute O
other B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
therapeutic I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
modalities I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

efficacy O
and O
safety O
of O
granisetron B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
selective O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
hydroxytryptamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- O
3 O
receptor O
antagonist O
, O
in O
the O
prevention O
of O
nausea O
and O
vomiting O
induced O
by O
high O
- O
dose O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

purpose O
: O
To O
assess O
the O
antiemetic O
effects O
and O
safety O
profile O
of O
four O
different O
doses O
of O
granisetron B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Kytril B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
; O
SmithKline O
Beecham O
Pharmaceuticals O
, O
Philadelphia O
, O
PA O
) O
when O
administered O
as O
a O
single O
intravenous O
( O
IV O
) O
dose O
for O
prophylaxis O
of O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
nausea O
and O
vomiting O
. O

patients O
AND O
methods O
: O
One O
hundred O
eighty O
- O
four O
chemotherapy O
- O
naive O
patients O
receiving O
high O
- O
dose O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
81 O
to O
120 O
mg O
/ O
m2 O
) O
were O
randomized O
to O
receive O
one O
of O
four O
granisetron B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
doses O
( O
5 O
, O
10 O
, O
20 O
, O
or O
40 O
micrograms O
/ O
kg O
) O
administered O
before O
chemotherapy O
. O

patients B_PERSON/B_DISEASE
were O
observed O
on O
an O
inpatient B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
basis I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
for O
18 B_NUMBER[MEASURE]
to O
24 B_TIME[MEASURE]/B_SPORT[ENT]
hours I_TIME[MEASURE]/I_SPORT[ENT]
, O
and O
vital B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signs I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
nausea B_DISEASE
, O
vomiting B_DISEASE
, O
retching B_DISEASE
, O
and O
appetite B_DISEASE
were O
assessed O
. O

Safety B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analyses I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O
incidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
adverse B_DISEASE
experiences I_DISEASE
and O
laboratory B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
parameter B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Results O
: O
After O
granisetron B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
doses O
of O
5 O
, O
10 O
, O
20 O
, O
and O
40 O
micrograms O
/ O
kg O
, O
a O
major O
response O
( O
< O
or O
= O
two O
vomiting O
or O
retching O
episodes O
, O
and O
no O
antiemetic O
rescue O
) O
was O
recorded O
in O
23 O
% O
, O
57 O
% O
, O
58 O
% O
, O
and O
60 O
% O
of O
patients O
, O
respectively O
, O
and O
a O
complete O
response O
( O
no O
vomiting O
or O
retching O
, O
and O
no O
antiemetic O
rescue O
) O
in O
18 O
% O
, O
41 O
% O
, O
40 O
% O
, O
and O
47 O
% O
of O
patients O
, O
respectively O
. O

There O
was O
a O
statistically O
longer B_TIME[MEASURE]
time I_TIME[MEASURE]
to O
first B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
episode B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
nausea B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
P B_MEASURE
= I_MEASURE
. O
0015 B_MEASURE
) O
and O
vomiting B_DISEASE
( O
P B_OTHER/B_LOCATION
= O
. O
0001 B_MEASURE
) O
, O
and O
fewer B_PERSON
patients I_PERSON
were O
administered O
additional B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
antiemetic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
medication I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
10 B_MEASURE
- O
micrograms B_MEASURE/B_LOCATION
/ O
kg B_MEASURE
dosing I_MEASURE
groups I_MEASURE
than O
in O
the O
5 B_MEASURE
- O
micrograms B_MEASURE/B_LOCATION
/ O
kg B_MEASURE/B_ORGANIZATION
dosing I_MEASURE/I_ORGANIZATION
group I_MEASURE/I_ORGANIZATION
. O

As O
granisetron B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dose O
increased O
, O
appetite O
return O
increased O
( O
P O
= O
. O
040 O
) O
. O

headache B_DISEASE
was O
the O
most O
frequently O
reported O
adverse B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
event B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
20 B_MEASURE/B_DISEASE
% I_MEASURE/I_DISEASE
) O
. O

conclusion O
: O
A O
single O
10 O
- O
, O
20 O
- O
, O
or O
40 O
- O
micrograms O
/ O
kg O
dose O
of O
granisetron B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
effective O
in O
controlling O
vomiting O
in O
57 O
% O
to O
60 O
% O
of O
patients O
who O
received O
cisplatin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
doses O
greater O
than O
81 O
mg O
/ O
m2 O
and O
totally O
prevented O
vomiting O
in O
40 O
% O
to O
47 O
% O
of O
patients O
. O

There O
were O
no O
statistically O
significant B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
differences I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
efficacy B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
between O
the O
10 B_MEASURE
- O
micrograms B_MEASURE/B_LOCATION
/ O
kg B_MEASURE/B_PERSON
dose I_MEASURE/I_PERSON
and O
the O
20 B_MEASURE
- O
and O
40 B_MEASURE
- O
micrograms B_MEASURE/B_BIO
/ O
kg B_MEASURE/B_PERSON
doses I_MEASURE/I_PERSON
. O

Granisetron B_PERSON
was O
well O
tolerated O
at O
all O
doses O
. O

adverse O
interaction O
between O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

objective O
: O
To O
report O
two O
cases O
of O
a O
possible O
adverse O
interaction O
between O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
resulting O
in O
atrioventricular O
( O
AV O
) O
block O
in O
both O
patients O
and O
severe O
hypotension O
in O
one O
patient O
. O

Case O
SUMMARIES O
: O
A O
54 O
- O
year O
- O
old O
woman O
with O
hyperaldosteronism O
was O
treated O
with O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
480 O
mg O
/ O
d O
and O
spironolactone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
100 O
mg O
/ O
d O
. O

After O
the O
addition O
of O
a O
minimal O
dose O
of O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 O
. O
15 O
mg O
bid O
) O
, O
she O
developed O
complete O
AV O
block O
and O
severe O
hypotension O
, O
which O
resolved O
upon O
cessation O
of O
all O
medications O
. O

A O
65 O
- O
year O
- O
old O
woman O
was O
treated O
with O
extended O
- O
release O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
240 O
mg O
/ O
d O
. O

After O
the O
addition O
of O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
0 O
. O
15 O
mg O
bid O
she O
developed O
complete O
AV O
block O
, O
which O
resolved O
after O
all O
therapy O
was O
stopped O
. O

discussion O
: O
An O
adverse O
interaction O
between O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
not O
been O
reported O
previously O
. O

We O
describe O
two B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
such I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
cases I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
discuss O
the O
various B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
might O
cause O
such O
an O
interaction B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Clinicians B_PERSON
should O
be O
acquainted O
with O
this O
possibly O
fatal B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
interaction I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
between O
two B_NUMBER[MEASURE]/B_PERSON
commonly O
used O
antihypertensive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

conclusions O
: O
caution O
is O
recommended O
in O
combining O
clonidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
verapamil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
therapy O
, O
even O
in O
patients O
who O
do O
not O
have O
sinus O
or O
AV O
node O
dysfunction O
. O

The O
two B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
drugs I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
may O
act O
synergistically O
on O
both O
the O
AV B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
node I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
peripheral B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
circulation B_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

Pharmacological O
studies O
on O
a O
new O
dihydrothienopyridine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
calcium I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonist O
, O
S B_LOCATION
- I_LOCATION
312 I_LOCATION
- I_LOCATION
d I_LOCATION
. O

5th B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
communication I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
: O
anticonvulsant B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

S B_MEASURE/B_LOCATION
- I_MEASURE/I_LOCATION
312 I_MEASURE/I_LOCATION
, O
S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
312 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PROTEIN[GENE]
, O
but O
not O
S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
312 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
, O
L O
- O
type O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
channel O
antagonists O
, O
showed O
anticonvulsant O
effects O
on O
the O
audiogenic O
tonic O
convulsions O
in O
DBA O
/ O
2 O
mice O
; O
and O
their O
ED50 O
values O
were O
18 O
. O
4 O
( O
12 O
. O
8 O
- O
27 O
. O
1 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
and O
15 O
. O
0 O
( O
10 O
. O
2 O
- O
23 O
. O
7 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O
, O
respectively O
, O
while O
that O
of O
flunarizine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
34 O
. O
0 O
( O
26 O
. O
0 O
- O
44 O
. O
8 O
) O
mg O
/ O
kg O
, O
p O
. O
o O
. O

Although O
moderate O
anticonvulsant O
effects O
of O
S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
312 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
d I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
in O
higher O
doses O
were O
observed O
against O
the O
clonic O
convulsions O
induced O
by O
pentylenetetrazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
85 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
or O
bemegride B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
40 O
mg O
/ O
kg O
, O
s O
. O
c O
. O
) O
, O
no O
effects O
were O
observed O
in O
convulsions O
induced O
by O
N B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
methyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
aspartate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
picrotoxin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
or O
electroshock O
in O
Slc O
: O
ddY O
mice O
. O

S B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
312 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
d I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
may O
be O
useful O
in O
the O
therapy O
of O
certain O
types O
of O
human O
epilepsy O
. O

Transmural O
myocardial O
infarction O
with O
sumatriptan B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

For O
sumatriptan B_PERSON/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
tightness O
in O
the O
chest O
caused O
by O
an O
unknown O
mechanism O
has O
been O
reported O
in O
3 O
- O
5 O
% O
of O
users O
. O

We O
describe O
a O
47 O
- O
year O
- O
old O
woman O
with O
an O
acute O
myocardial O
infarction O
after O
administration O
of O
sumatriptan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
6 O
mg O
subcutaneously O
for O
cluster O
headache O
. O

The O
patient B_PERSON/B_BIO
had O
no O
history B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
underlying O
ischaemic B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
heart I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
disease I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
or O
Prinzmetal B_PERSON
' O
s B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
angina I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

She O
recovered O
without O
complications B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Flumazenil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
induces O
seizures O
and O
death O
in O
mixed O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intoxications O
. O

Study O
hypothesis O
: O
Administration O
of O
the O
benzodiazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonist O
flumazenil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
unmask O
seizures O
in O
mixed O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
benzodiazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intoxication O
. O

Design O
: O
Male O
Sprague O
- O
Dawley O
rats O
received O
100 O
mg O
/ O
kg O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
IP O
alone O
, O
5 O
mg O
/ O
kg O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
, O
or O
a O
combination O
of O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Three O
minutes O
later O
, O
groups O
were O
challenged O
with O
vehicle O
or O
flumazenil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 O
or O
10 O
mg O
/ O
kg O
IP O
. O

Animal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
behavior B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
seizures B_DISEASE/B_ORGANISM_FUNCTION
( O
time B_TIME[MEASURE]
to O
and O
incidence B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
) O
, O
death B_DISEASE
( O
time B_TIME[MEASURE]/B_LOCATION
to O
and O
incidence B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
and O
cortical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
EEG B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
tracings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
were O
recorded O
. O

interventions O
: O
Administration O
of O
flumazenil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
animals O
after O
they O
had O
received O
a O
combination O
dose O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Results O
: O
In O
group O
1 O
, O
animals O
received O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O
by O
vehicle O
. O

This O
resulted O
in O
100 B_PERSON
% I_PERSON
developing O
seizures B_DISEASE
and O
death B_DISEASE
. O

Group O
2 O
received O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
followed O
by O
vehicle O
. O

Animals B_BIO/B_NUMBER[MEASURE]
became O
somnolent B_DISEASE_ADJECTIVE[DISEASE]/B_PERSON
and O
none B_PERSON/B_NUMBER[MEASURE]
died O
. O

Group O
3 O
received O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O
by O
5 O
mg O
/ O
kg O
flumazenil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Animals O
became O
somnolent O
after O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
then O
active O
after O
flumazenil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
. O

In O
group O
4 O
, O
a O
combination O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
administered O
simultaneously O
. O

This O
resulted O
in O
no O
overt B_DISEASE
or O
EEG B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
detectable B_DISEASE
seizures I_DISEASE
and O
a O
50 B_MEASURE
% I_MEASURE
incidence I_MEASURE
of O
death B_DISEASE
. O

Group O
5 O
received O
a O
similar O
combination O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
followed O
later O
by O
5 O
mg O
/ O
kg O
flumazenil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
resulted O
in O
an O
increased O
incidence B_MEASURE
of O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
90 B_DISEASE
% I_DISEASE
( O
P B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
. O
01 B_MEASURE
) O
, O
and O
death B_DISEASE
, O
100 B_TIME[MEASURE]/B_LOCATION
% I_TIME[MEASURE]/I_LOCATION
( O
P B_MEASURE
< I_MEASURE
or O
= O
. O
01 B_MEASURE
) O
, O
compared O
with O
group B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Group O
6 O
received O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
followed O
by O
10 O
mg O
/ O
kg O
flumazenil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

This O
also O
resulted O
in O
an O
increased O
incidence B_MEASURE
of O
seizures B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
90 B_DISEASE
% I_DISEASE
( O
P B_MEASURE
< I_MEASURE
or O
= O
. O
01 B_MEASURE
) O
, O
and O
death B_DISEASE
, O
90 B_MEASURE
% I_MEASURE
( O
P B_MEASURE
< I_MEASURE
or O
= O
. O
05 B_MEASURE
) O
, O
compared O
with O
group B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
. O

conclusion O
: O
Flumazenil B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
can O
unmask O
seizures O
and O
increase O
the O
incidence O
of O
death O
in O
a O
model O
of O
combined O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intoxications O
. O

mechanisms O
for O
protective O
effects O
of O
free O
radical O
scavengers O
on O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
mediated O
nephropathy O
in O
rats O
. O

Studies O
were O
performed O
to O
examine O
the O
mechanisms O
for O
the O
protective O
effects O
of O
free O
radical O
scavengers O
on O
gentamicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
( O
GM B_ORGANIZATION/B_PROTEIN[GENE]
) O
- O
mediated O
nephropathy O
. O

Administration O
of O
GM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
at O
40 O
mg O
/ O
kg O
Sc O
for O
13 O
days O
to O
rats O
induced O
a O
significant O
reduction O
in O
renal O
blood O
flow O
( O
RBF O
) O
and O
inulin O
clearance O
( O
CIn O
) O
as O
well O
as O
marked O
tubular O
damage O
. O

A O
significant O
reduction O
in O
urinary O
guanosine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cyclic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
monophosphate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
cGMP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
excretion O
and O
a O
significant O
increase O
in O
renal O
cortical O
renin O
and O
endothelin O
- O
1 O
contents O
were O
also O
observed O
in O
GM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
mediated O
nephropathy O
. O

Superoxide B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
dismutase O
( O
SOD O
) O
or O
dimethylthiourea B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
DMTU B_LOCATION/B_ORGANIZATION
) O
significantly O
lessened O
the O
GM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
decrement O
in O
CIn O
. O

The O
SOD O
- O
induced O
increase O
in O
glomerular O
filtration O
rate O
was O
associated O
with O
a O
marked O
improvement O
in O
RBF O
, O
an O
increase O
in O
urinary O
cGMP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
excretion O
, O
and O
a O
decrease O
in O
renal O
renin O
and O
endothelin O
- O
1 O
content O
. O

SOD B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
attenuate O
the O
tubular B_DISEASE_ADJECTIVE[DISEASE]
damage I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
contrast O
, O
DMTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
significantly O
reduced O
the O
tubular O
damage O
and O
lipid O
peroxidation O
, O
but O
it O
did O
not O
affect O
renal O
hemodynamics O
and O
vasoactive O
substances O
. O

Neither O
SOD O
nor O
DMTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
affected O
the O
renal O
cortical O
GM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
content O
in O
GM B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
treated O
rats O
. O

These O
results O
suggest O
that O
1 O
) O
both O
SOD O
and O
DMTU B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
have O
protective O
effects O
on O
GM B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
mediated O
nephropathy O
, O
2 O
) O
the O
mechanisms O
for O
the O
protective O
effects O
differ O
for O
SOD O
and O
DMTU B_LOCATION/B_ORGANIZATION
, O
and O
3 O
) O
superoxide B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
anions O
play O
a O
critical O
role O
in O
GM B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
renal O
vasoconstriction O
. O

Cephalothin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
induced O
immune O
hemolytic O
anemia O
. O

A O
patient O
with O
renal O
disease O
developed O
Coombs O
- O
positive O
hemolytic O
anemia O
while O
receiving O
cephalothin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
therapy O
. O

An O
anti O
- O
cephalothin B_VIRUS[BIO]/B_DISEASE
IgG O
antibody O
was O
detected O
in O
the O
patient O
' O
s O
serum O
and O
in O
the O
eluates O
from O
her O
erythrocytes O
. O

In O
addition O
, O
nonimmunologic O
binding O
of O
normal O
and O
patient O
' O
s O
serum O
proteins O
to O
her O
own O
and O
cephalothin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
coated O
normal O
red O
cells O
was O
demonstrated O
. O

Skin O
tests O
and O
in O
vitro O
lymphocyte O
stimulation O
revealed O
that O
the O
patient O
was O
sensitized O
to O
cephalothin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
and O
also O
to O
ampicillin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Careful B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
investigation I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hemolytic B_DISEASE_ADJECTIVE[DISEASE]
anemias I_DISEASE_ADJECTIVE[DISEASE]
reveals O
the O
complexity B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
immune B_DISEASE_ADJECTIVE[DISEASE]
mechanisms I_DISEASE_ADJECTIVE[DISEASE]
involved O
. O

Assessment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cardiomyocyte B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
DNA B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
synthesis B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
during O
hypertrophy B_DISEASE/B_ORGANISM_FUNCTION
in O
adult B_SPECIES[BIO]/B_DISEASE
mice I_SPECIES[BIO]/I_DISEASE
. O

The O
ability B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
cardiomyocytes B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
to O
synthesize O
DNA B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
response B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
experimentally O
induced O
cardiac B_DISEASE
hypertrophy I_DISEASE
was O
assessed O
in O
adult B_SPECIES[BIO]
mice I_SPECIES[BIO]
. O

Isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
delivered O
by O
osmotic O
minipump O
implantation O
in O
adult O
C3Heb O
/ O
FeJ O
mice O
resulted O
in O
a O
46 O
% O
increase O
in O
heart O
weight O
and O
a O
19 O
. O
3 O
% O
increase O
in O
cardiomyocyte O
area O
. O

No O
DNA B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
as O
assessed O
by O
autoradiographic B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
analysis I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
isolated B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiomyocytes B_GENE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
observed O
in O
control B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
or O
hypertrophic B_DISEASE/B_ENT
hearts I_DISEASE/I_ENT
. O

A O
survey B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
15 B_MEASURE/B_BIO
independent I_MEASURE/I_BIO
inbred I_MEASURE/I_BIO
strains I_MEASURE/I_BIO
of O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
that O
ventricular B_MEASURE/B_PERSON
cardiomyocyte B_MEASURE/I_PERSON
nuclear B_MEASURE/I_PERSON
number B_MEASURE/I_PERSON
ranged O
from O
3 B_NUMBER[MEASURE]
to O
13 B_MEASURE
% I_MEASURE
mononucleate I_MEASURE
, O
suggesting O
that O
cardiomyocyte B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
terminal B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
differentiation B_DISEASE_ADJECTIVE[DISEASE]/I_GENE
is O
influenced O
directly O
or O
indirectly O
by O
genetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
background I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

To O
determine O
whether O
the O
capacity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
for O
reactive B_DISEASE/B_GENE
DNA I_DISEASE/I_GENE
synthesis I_DISEASE/I_GENE
was O
also O
subject B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
to O
genetic B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
regulation I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
cardiac B_DISEASE
hypertrophy I_DISEASE
was O
induced O
in O
the O
strains B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
of O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
comprising O
the O
extremes B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
the O
nuclear B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
number B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
survey B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
. O

These O
data O
indicate O
that O
adult O
mouse O
atrial O
and O
ventricular O
cardiomyocytes O
do O
not O
synthesize O
DNA O
in O
response O
to O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cardiac O
hypertrophy O
. O

Central O
cardiovascular O
effects O
of O
AVP B_LOCATION/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ANP O
in O
normotensive O
and O
spontaneously O
hypertensive O
rats O
. O

The O
purpose O
of O
the O
present O
study O
was O
to O
compare O
influence O
of O
central O
arginine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
vasopressin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
AVP B_LOCATION/B_PROTEIN[GENE]
) O
and O
of O
atrial O
natriuretic O
peptide O
( O
ANP O
) O
on O
control O
of O
arterial O
blood O
pressure O
( O
Map O
) O
and O
heart O
rate O
( O
HR O
) O
in O
normotensive O
( O
WKY O
) O
and O
spontaneously O
hypertensive O
( O
SHR O
) O
rats O
. O

Three B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
series I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
experiments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
performed O
on O
30 B_MEASURE/B_LOCATION
WKY I_MEASURE/I_LOCATION
and O
30 B_TIME[MEASURE]/B_LOCATION
SHR I_TIME[MEASURE]/I_LOCATION
, O
chronically O
instrumented O
with O
guide B_MEDICAL_DEVICE[OBJECT]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tubes I_MEDICAL_DEVICE[OBJECT]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
the O
lateral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ventricle I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
( O
LV B_PROTEIN[GENE]/B_BODY_PART_OR_ORGAN_COMPONENT
) O
and O
arterial B_BODY_PART_OR_ORGAN_COMPONENT/B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
venous B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
catheters I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Map O
and O
HR O
were O
monitored O
before O
and O
after O
i O
. O
v O
. O
injections O
of O
either O
vehicle O
or O
1 O
, O
10 O
and O
50 O
ng O
of O
AVP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
25 O
, O
125 O
and O
500 O
ng O
of O
ANP O
. O

sensitivity O
of O
cardiac O
component O
of O
baroreflex O
( O
CCB O
) O
, O
expressed O
as O
a O
slope O
of O
the O
regression O
line O
was O
determined O
from O
relationships O
between O
systolic O
arterial O
pressure O
( O
SAP O
) O
and O
HR O
period O
( O
HRp O
) O
during O
phenylephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Phe B_LOCATION/B_PERSON
) O
- O
induced O
hypertension O
and O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nitroprusside I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
SN B_LOCATION/B_ORGANIZATION
) O
- O
induced O
hypotension O
. O

CCB O
was O
measured O
before O
and O
after O
administration O
of O
either O
vehicle O
, O
AVP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
ANP O
, O
or O
both O
peptides O
together O
. O

increases O
of O
Map O
occurred O
after O
LV O
administration O
of O
1 O
, O
10 O
and O
50 O
ng O
of O
AVP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
in O
WKY O
and O
of O
10 O
and O
50 O
ng O
in O
SHR O
. O

ANP O
did O
not O
cause O
significant O
changes O
in O
Map O
in O
both O
strains O
as O
compared O
to O
vehicle O
, O
but O
it O
abolished O
AVP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
Map O
increase O
in O
WKY O
and O
SHR O
. O

CCB O
was O
reduced O
in O
WKY O
and O
SHR O
after O
LV O
administration O
of O
AVP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
SN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
hypotension O
. O

In O
SHR O
but O
not O
in O
WKY O
administration O
of O
ANP O
, O
AVP B_LOCATION/B_GENE
and O
ANP O
+ O
AVP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
decreased O
CCB O
during O
Phe B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
induced O
Map O
elevation O
. O

The O
results O
indicate O
that O
centrally O
applied O
AVP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
ANP O
exert O
differential O
effects O
on O
blood O
pressure O
and O
baroreflex O
control O
of O
heart O
rate O
in O
WKY O
and O
SHR O
and O
suggest O
interaction O
of O
these O
two O
peptides O
in O
blood O
pressure O
regulation O
at O
the O
level O
of O
central O
nervous O
system O
. O

Cutaneous O
exposure O
to O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
like O
anticoagulant O
causing O
an O
intracerebral O
hemorrhage O
: O
a O
case O
report O
. O

A O
case O
of O
intercerebral O
hematoma O
due O
to O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
coagulopathy O
is O
presented O
. O

The O
39 O
- O
year O
- O
old O
woman O
had O
spread O
a O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_SPECIES[BIO]
- O
type O
rat O
poison O
around O
her O
house O
weekly O
using O
her O
bare O
hands O
, O
with O
no O
washing O
post O
application O
. O

Percutaneous O
absorption O
of O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
causing O
coagulopathy O
, O
reported O
three O
times O
in O
the O
past O
, O
is O
a O
significant O
risk O
if O
protective O
measures O
, O
such O
as O
gloves O
, O
are O
not O
used O
. O

An O
adverse O
drug O
interaction O
with O
piroxicam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
she O
took O
occasionally O
, O
may O
have O
exacerbated O
the O
coagulopathy O
. O

Pediatric O
heart O
transplantation O
without O
chronic O
maintenance O
steroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

From O
1986 B_TIME[MEASURE]
to O
February B_TIME[MEASURE]
1993 I_TIME[MEASURE]
, O
40 B_PERSON/B_ENT
children I_PERSON/I_ENT
aged O
2 B_TIME[MEASURE]
months I_TIME[MEASURE]
to O
18 B_TIME[MEASURE]
years I_TIME[MEASURE]
( O
average B_MEASURE
age I_MEASURE
10 I_MEASURE
. O
4 B_MEASURE
+ I_MEASURE
/ O
- O
5 B_MEASURE
. O
8 B_TIME[MEASURE]
years I_TIME[MEASURE]
) O
underwent O
heart B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
transplantation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

Indications O
for O
transplantation O
were O
idiopathic O
cardiomyopathy O
( O
52 O
% O
) O
, O
congenital O
heart O
disease O
( O
35 O
% O
) O
with O
and O
without O
prior O
repair O
( O
71 O
% O
and O
29 O
% O
, O
respectively O
) O
, O
hypertrophic O
cardiomyopathy O
( O
5 O
% O
) O
, O
valvular O
heart O
disease O
( O
3 O
% O
) O
, O
and O
doxorubicin B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
cardiomyopathy O
( O
5 O
% O
) O
. O

patients O
were O
managed O
with O
cyclosporine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
azathioprine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

No O
prophylaxis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
antilymphocyte B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
globulin I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
used O
. O

Steroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
were O
given O
to O
39 O
% O
of O
patients O
for O
refractory O
rejection O
, O
but O
weaning O
was O
always O
attempted O
and O
generally O
successful O
( O
64 O
% O
) O
. O

Five O
patients O
( O
14 O
% O
) O
received O
maintenance O
steroids B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Four B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
died O
in O
the O
perioperative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
and O
one B_NUMBER[MEASURE]/B_PERSON
died O
4 B_TIME[MEASURE]/B_LOCATION
months I_TIME[MEASURE]/I_LOCATION
later O
. O

There O
have O
been O
no O
deaths B_DISEASE
related O
to O
rejection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
infection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Average B_TIME[MEASURE]/B_PERSON
follow I_TIME[MEASURE]/I_PERSON
- O
up B_LOCATION/B_MEASURE
was O
36 B_MEASURE
+ I_MEASURE
/ O
- O
19 B_TIME[MEASURE]/B_PERSON
months I_TIME[MEASURE]/I_PERSON
( O
range B_MEASURE
1 I_MEASURE
to O
65 B_TIME[MEASURE]
months I_TIME[MEASURE]
) O
. O

cumulative B_PERSON/B_LOCATION
survival I_PERSON/I_LOCATION
is O
88 B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
% B_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
at O
5 B_TIME[MEASURE]/B_LOCATION
years I_TIME[MEASURE]/I_LOCATION
. O

In O
patients B_PERSON
less I_PERSON
than O
7 B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
of O
age B_TIME[MEASURE]/B_PERSON
, O
rejection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
monitored O
noninvasively O
. O

In O
the O
first B_TIME[MEASURE]/B_LOCATION
postoperative B_TIME[MEASURE]/I_LOCATION
month B_TIME[MEASURE]/I_LOCATION
, O
89 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
of O
patients B_PERSON
were O
treated O
for O
rejection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

freedom B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
serious B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infections I_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
83 B_MEASURE
% I_MEASURE
at O
1 B_TIME[MEASURE]
month I_TIME[MEASURE]
and O
65 B_MEASURE
% I_MEASURE
at O
1 B_TIME[MEASURE]/B_PERSON
year I_TIME[MEASURE]/I_PERSON
. O

Cytomegalovirus O
infections O
were O
treated O
successfully O
with O
ganciclovir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
11 O
patients O
. O

No O
impairment B_DISEASE_ADJECTIVE[DISEASE]
of O
growth B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
observed O
in O
children B_PERSON/B_BIO
who O
underwent O
transplantation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
compared O
with O
a O
control B_PERSON/B_BIO
population I_PERSON/I_BIO
. O

Twenty B_NUMBER[MEASURE]
- O
one B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
( O
60 B_MEASURE/B_LOCATION
% I_MEASURE/I_LOCATION
) O
have O
undergone O
annual B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
catheterizations I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
and O
no O
sign B_LOCATION/B_DISEASE_ADJECTIVE[DISEASE]
of O
graft B_DISEASE
atherosclerosis I_DISEASE
has O
been O
observed O
. O

seizures B_DISEASE
occurred O
in O
five B_TIME[MEASURE]
patients I_TIME[MEASURE]
( O
14 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
) O
and O
hypertension B_DISEASE
was O
treated O
in O
10 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
( O
28 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
. O

No O
patient B_PERSON/B_DISEASE
was O
disabled O
and O
no O
lymphoproliferative B_DISEASE_ADJECTIVE[DISEASE]
disorder I_DISEASE_ADJECTIVE[DISEASE]
was O
observed O
. O
( O
abstract B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
TRUNCATED I_MEASURE
AT O
250 B_PERSON/B_LOCATION
Words B_PERSON/I_LOCATION
) O
. O

Delirium O
during O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
treatment O
. O

A O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

The O
correlation B_MEASURE/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
between O
high B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
serum I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
tricyclic I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
antidepressant I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
concentrations I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
and O
central B_DISEASE
nervous I_DISEASE
system I_DISEASE
side I_DISEASE
effects I_DISEASE
has O
been O
well O
established O
. O

Only O
a O
few O
reports O
exist O
, O
however O
, O
on O
the O
relationship O
between O
the O
serum O
concentrations O
of O
selective O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
reuptake O
inhibitors O
( O
SSRIs O
) O
and O
their O
toxic O
effects O
. O

In O
some O
cases O
, O
a O
high O
serum O
concentration O
of O
citalopram B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
> O
600 O
nmol O
/ O
L O
) O
in O
elderly O
patients O
has O
been O
associated O
with O
increased O
somnolence O
and O
movement O
difficulties O
. O

widespread B_DISEASE_ADJECTIVE[DISEASE]
cognitive I_DISEASE_ADJECTIVE[DISEASE]
disorders I_DISEASE_ADJECTIVE[DISEASE]
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
delirium B_DISEASE/B_LOCATION
, O
have O
not O
been O
previously O
linked O
with O
high B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
blood I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
levels I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
SSRIs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

In O
this O
report O
, O
we O
describe O
a O
patient O
with O
acute O
hyperkinetic O
delirium O
connected O
with O
a O
high O
serum O
total O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
fluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O
desmethylfluoxetine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
concentration O
. O

pulmonary O
edema O
and O
shock O
after O
high O
- O
dose O
aracytine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
lymphoma O
; O
possible O
role O
of O
TNF O
- O
alpha O
and O
PAF O
. O

Four O
out O
of O
23 O
consecutive O
patients O
treated O
with O
high O
- O
dose O
Ara B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
for O
lymphomas O
in O
our O
institution O
developed O
a O
strikingly O
similar O
syndrome O
during O
the O
perfusion O
. O

It O
was O
characterized O
by O
the O
onset B_DISEASE_ADJECTIVE[DISEASE]
of O
fever B_DISEASE
, O
diarrhea B_DISEASE
, O
shock B_DISEASE
, O
pulmonary B_DISEASE
edema I_DISEASE
, O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
, O
metabolic B_DISEASE
acidosis I_DISEASE
, O
weight B_DISEASE
gain I_DISEASE
and O
leukocytosis B_DISEASE
. O

thorough B_PERSON
bacteriological I_PERSON
screening I_PERSON
failed O
to O
provide O
evidence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
infection B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Sequential O
biological O
assays O
of O
IL O
- O
1 O
, O
IL O
- O
2 O
, O
TNF O
and O
PAF O
were O
performed O
during O
Ara B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
infusion O
to O
ten O
patients O
, O
including O
the O
four O
who O
developed O
the O
syndrome O
. O

TNF B_LOCATION/B_ORGANIZATION
and O
PAF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
activity I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
was O
found O
in O
the O
serum B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
respectively O
two B_NUMBER[MEASURE]
and O
four B_NUMBER[MEASURE]
of O
the O
cases B_PERSON/B_BIO
, O
but O
not O
in O
the O
six B_BODY_PART_OR_ORGAN_COMPONENT/B_PERSON
controls I_BODY_PART_OR_ORGAN_COMPONENT/I_PERSON
. O

As O
TNF O
and O
PAF O
are O
thought O
to O
be O
involved O
in O
the O
development O
of O
septic O
shock O
and O
adult O
respiratory O
distress O
syndrome O
, O
we O
hypothesize O
that O
high O
- O
dose O
Ara B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
C I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
be O
associated O
with O
cytokine O
release O
. O

protective O
effect O
of O
clentiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cardiac O
injury O
in O
rats O
. O

We O
investigated O
the O
effects O
of O
clentiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
benzothiazepine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
antagonist O
, O
on O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cardiomyopathy O
in O
rats O
. O

With O
2 O
- O
week O
chronic O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
infusion O
, O
16 O
of O
30 O
rats O
died O
within O
4 O
days O
, O
and O
severe O
ischemic O
lesions O
and O
fibrosis O
of O
the O
left O
ventricles O
were O
observed O
. O

In O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
rats O
, O
left O
atrial O
and O
left O
ventricular O
papillary O
muscle O
contractile O
responses O
to O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
reduced O
, O
but O
responses O
to O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
normal O
or O
enhanced O
compared O
to O
controls O
. O

Left O
ventricular B_BODY_PART_OR_ORGAN_COMPONENT
alpha I_BODY_PART_OR_ORGAN_COMPONENT
and O
beta B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
adrenoceptor I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
densities I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
were O
also O
reduced O
compared O
to O
controls B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
. O

Treatment O
with O
clentiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevented O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
death O
( O
P O
< O
. O
05 O
) O
, O
and O
attenuated O
the O
ventricular O
ischemic O
lesions O
and O
fibrosis O
, O
in O
a O
dose O
- O
dependent O
manner O
. O

Left O
atrial O
and O
left O
ventricular O
papillary O
muscle O
contractile O
responses O
to O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
reduced O
compared O
to O
controls O
in O
groups O
treated O
with O
clentiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
, O
but O
combined O
with O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
clentiazem B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
restored O
left O
atrial O
responses O
and O
enhanced O
left O
ventricular O
papillary O
responses O
to O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

On O
the O
other O
hand O
clentiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
prevent O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
down O
- O
regulation O
of O
alpha O
and O
beta O
adrenoceptors O
. O

Interestingly O
, O
clentiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
infused O
alone O
, O
resulted O
in O
decreased O
adrenergic O
receptor O
densities O
in O
the O
left O
ventricle O
. O

Clentiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
also O
did O
not O
prevent O
the O
enhanced O
responses O
to O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
seen O
in O
the O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
animals O
, O
although O
the O
high O
dose O
of O
clentiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
partially O
attenuated O
the O
maximal O
response O
to O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O
to O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
animals O
. O

In O
conclusion O
, O
clentiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
attenuated O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cardiac O
injury O
, O
possibly O
through O
its O
effect O
on O
the O
adrenergic O
pathway O
. O

Kaliuretic O
effect O
of O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dopa I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treatment O
in O
parkinsonian O
patients O
. O

Hypokalemia O
, O
sometimes O
severe O
, O
was O
observed O
in O
some O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
dopa I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
parkinsonian O
patients O
. O

The O
influence O
of O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
dopa I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
on O
the O
renal O
excretion O
of O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
studied O
in O
3 O
patients O
with O
hypokalemia O
and O
in O
5 O
normokalemic O
patients O
by O
determination O
of O
renal O
plasma O
flow O
, O
glomerular O
filtration O
rate O
, O
plasma O
concentration O
of O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
well O
as O
urinary O
excretion O
of O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
aldosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Dopa I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intake O
was O
found O
to O
cause O
an O
increased O
excretion O
of O
potassium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
sometimes O
also O
of O
sodium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
in O
the O
hypokalemic O
but O
not O
in O
the O
normokalemic O
patients O
. O

This O
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
the O
renal B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
function I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
could O
be O
prohibited O
by O
the O
administration B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
a O
peripheral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
DOPA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
decarbodylase I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
inhibitor I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

It O
is O
not O
known O
why O
this O
effect O
occurred O
in O
some O
individuals O
but O
not O
in O
others O
, O
but O
our O
results O
indicate O
a O
correlation O
between O
aldosterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
production O
and O
this O
renal O
effect O
of O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dopa I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

Cocaine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
induced O
myocardial O
ischemia O
. O

We O
report O
a O
case O
of O
myocardial O
ischemia O
induced O
by O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
ischemia O
probably O
induced O
by O
coronary O
artery O
spasm O
was O
reversed O
by O
nitroglycerin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
blocking O
agents O
. O

Doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
cardiotoxicity O
monitored O
by O
ECG O
in O
freely O
moving O
mice O
. O

A O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
test O
potential B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
protectors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
laboratory O
animals O
, O
histology O
is O
most O
commonly O
used O
to O
study O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cardiotoxicity O
. O

However O
, O
for O
monitoring O
during O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
, O
large B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
numbers I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
animals B_BIO/B_PERSON
are O
needed O
. O

Recently O
we O
developed O
a O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
method I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
to O
measure O
ECG B_DISEASE
values I_DISEASE
in O
freely O
moving O
mice B_SPECIES[BIO]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
by O
telemetry B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

With O
this O
model O
we O
investigated O
the O
effect O
of O
chronic O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
on O
the O
ECG O
of O
freely O
moving O
BALB O
/ O
c O
mice O
and O
the O
efficacy O
of O
ICRF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
187 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
protective O
agent O
. O

The O
ST O
interval O
significantly O
widened O
from O
15 O
. O
0 O
+ O
/ O
- O
1 O
. O
5 O
to O
56 O
. O
8 O
+ O
/ O
- O
11 O
. O
8 O
MS O
in O
week O
10 O
( O
7 O
weekly O
doses O
of O
4 O
mg O
/ O
kg O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
given O
i O
. O
v O
. O
plus O
3 O
weeks O
of O
observation O
) O
. O

The O
ECG B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
the O
control B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
animals I_PERSON/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
did O
not O
change O
during O
the O
entire B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

After O
sacrifice O
the O
hearts O
of O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- O
treated O
animals O
were O
enlarged O
and O
the O
atria O
were O
hypertrophic O
. O

As O
this O
schedule O
exerted O
more O
toxicity O
than O
needed O
to O
investigate O
protective O
agents O
, O
the O
protection O
of O
ICRF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
187 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
determined O
using O
a O
dose O
schedule O
with O
lower O
general O
toxicity O
( O
6 O
weekly O
doses O
of O
4 O
mg O
/ O
kg O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
given O
i O
. O
v O
. O
plus O
2 O
weeks O
of O
observation O
) O
. O

On O
this O
schedule O
, O
the O
animals O
' O
hearts O
appeared O
normal O
after O
sacrifice O
and O
ICRF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
187 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
50 O
mg O
/ O
kg O
given O
i O
. O
p O
. O
1 O
h O
before O
doxorubicin B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
) O
provided O
almost O
full O
protection O
. O

These O
data B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
were O
confirmed O
by O
histology B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
this O
new B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
is O
very O
sensitive B_DISEASE_ADJECTIVE[DISEASE]
and O
enables O
monitoring B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
development B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
of O
cardiotoxicity B_DISEASE
with O
time B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

These O
findings O
result O
in O
a O
model O
that O
allows O
the O
testing O
of O
protectors O
against O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
cardiotoxicity O
as O
demonstrated O
by O
the O
protection O
provided O
by O
ICRF B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
187 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
. O

Epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
dysrhythmogenicity O
is O
not O
enhanced O
by O
subtoxic O
bupivacaine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
in O
dogs O
. O

Since O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
may O
both O
precipitate O
dysrhythmias O
, O
circulating O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
regional O
anesthesia O
could O
potentiate O
dysrhythmogenic O
effects O
of O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
therefore O
examined O
whether O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
alters O
the O
dysrhythmogenicity O
of O
subsequent O
administration O
of O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
conscious O
, O
healthy O
dogs O
and O
in O
anesthetized O
dogs O
with O
myocardial O
infarction O
. O

Forty O
- O
one O
conscious O
dogs O
received O
10 O
micrograms O
. O
kg O
- O
1 O
. O
min O
- O
1 O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

seventeen B_PERSON
animals I_PERSON
responded O
with O
ventricular B_DISEASE
tachycardia I_DISEASE
( O
VT B_PROTEIN[GENE]/B_DISEASE
) O
within O
3 B_TIME[MEASURE]
min I_TIME[MEASURE]
. O

After O
3 O
h O
, O
these O
responders O
randomly O
received O
1 O
or O
2 O
mg O
/ O
kg O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
saline O
over O
5 O
min O
, O
followed O
by O
10 O
micrograms O
. O
kg O
- O
1 O
. O
min O
- O
1 O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups O
, O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
caused O
fewer O
prodysrhythmic O
effects O
than O
without O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

VT B_DISEASE/B_PERSON
appeared O
in O
fewer B_TIME[MEASURE]
dogs I_TIME[MEASURE]
and O
at O
a O
later B_MEASURE/B_LOCATION
time I_MEASURE/I_LOCATION
, O
and O
there O
were O
more O
sinoatrial B_DISEASE
beats I_DISEASE
and O
less B_DISEASE
ectopies I_DISEASE
. O

Epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
shortened O
QT O
less O
after O
bupivacaine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
than O
in O
control O
animals O
. O

One O
day O
after O
experimental O
myocardial O
infarction O
, O
six O
additional O
halothane B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
anesthetized O
dogs O
received O
4 O
micrograms O
. O
kg O
- O
1 O
. O
min O
- O
1 O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
until O
VT O
appeared O
. O

After O
45 O
min O
, O
1 O
mg O
/ O
kg O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
injected O
over O
5 O
min O
, O
again O
followed O
by O
4 O
micrograms O
. O
kg O
- O
1 O
. O
min O
- O
1 O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
these O
dogs O
, O
the O
prodysrhythmic O
response O
to O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
also O
mitigated O
by O
preceding O
bupivacaine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
antagonizes O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
dysrhythmogenicity O
in O
conscious O
dogs O
susceptible O
to O
VT O
and O
in O
anesthetized O
dogs O
with O
spontaneous O
postinfarct O
dysrhythmias O
. O

There O
is O
no O
evidence O
that O
systemic O
subtoxic O
bupivacaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration O
enhances O
the O
dysrhythmogenicity O
of O
subsequent O
epinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

Milk O
- O
alkali O
syndrome O
induced O
by O
1 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
25 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
OH I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
) I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
2D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
a O
patient O
with O
hypoparathyroidism O
. O

Milk O
- O
alkali O
syndrome O
was O
first O
described O
70 O
years O
ago O
in O
the O
context O
of O
the O
treatment O
of O
peptic O
ulcer O
disease O
with O
large O
amounts O
of O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
alkali B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Although O
with O
current O
ulcer O
therapy O
( O
H O
- O
2 O
blockers O
, O
omeprazole B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
sucralfate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
) O
, O
the O
frequency O
of O
milk O
- O
alkali O
syndrome O
has O
decreased O
significantly O
, O
the O
classic O
triad O
of O
hypercalcemia O
, O
alkalosis O
, O
and O
renal O
impairment O
remains O
the O
hallmark O
of O
the O
syndrome O
. O

milk B_DISEASE
- O
alkali B_DISEASE
syndrome I_DISEASE
can O
present O
serious B_DISEASE_ADJECTIVE[DISEASE]
and O
occasionally O
life B_TIME[MEASURE]/B_BODY_PART_OR_ORGAN_COMPONENT
- O
threatening O
illness B_DISEASE
unless O
diagnosed O
and O
treated O
appropriately O
. O

This O
article O
presents O
a O
patient O
with O
hypoparathyroidism O
who O
was O
treated O
with O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
carbonate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
calcitriol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
resulting O
in O
two O
admissions O
to O
the O
hospital O
for O
milk O
- O
alkali O
syndrome O
. O

The O
patient O
was O
successfully O
treated O
with O
intravenous O
pamidronate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
his O
first O
admission O
and O
with O
hydrocortisone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
second O
. O

This O
illustrates O
intravenous O
pamidronate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
a O
valuable O
therapeutic O
tool O
when O
milk O
- O
alkali O
syndrome O
presents O
as O
hypercalcemic O
emergency O
. O

Famotidine B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O
associated O
delirium O
. O

A O
series B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
six B_ENT/B_PERSON
cases I_ENT/I_PERSON
. O

Famotidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
histamine O
H2 O
- O
receptor O
antagonist O
used O
in O
inpatient O
settings O
for O
prevention O
of O
stress O
ulcers O
and O
is O
showing O
increasing O
popularity O
because O
of O
its O
low O
cost O
. O

Although O
all O
of O
the O
currently O
available O
H2 O
- O
receptor O
antagonists O
have O
shown O
the O
propensity O
to O
cause O
delirium O
, O
only O
two O
previously O
reported O
cases O
have O
been O
associated O
with O
famotidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

The O
authors O
report O
on O
six O
cases O
of O
famotidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
associated O
delirium O
in O
hospitalized O
patients O
who O
cleared O
completely O
upon O
removal O
of O
famotidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
pharmacokinetics O
of O
famotidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
reviewed O
, O
with O
no O
change O
in O
its O
metabolism O
in O
the O
elderly O
population O
seen O
. O

The O
implications O
of O
using O
famotidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
elderly O
persons O
are O
discussed O
. O

Encephalopathy O
during O
amitriptyline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
: O
are O
neuroleptic O
malignant O
syndrome O
and O
serotonin O
syndrome O
spectrum O
disorders O
. O

This O
report O
describes O
a O
case O
of O
encephalopathy O
developed O
in O
the O
course O
of O
amitriptyline B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
, O
during O
a O
remission O
of O
unipolar O
depression O
. O

This O
patient B_PERSON/B_BIO
could O
have O
been O
diagnosed O
as O
having O
either O
neuroleptic B_DISEASE
malignant I_DISEASE
syndrome I_DISEASE
( O
NMS B_LOCATION
) O
or O
serotonin B_DISEASE
syndrome I_DISEASE
( O
SS B_LOCATION
) O
. O

The O
major O
determinant O
of O
the O
symptoms O
may O
have O
been O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
/ O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
imbalance O
in O
the O
central O
nervous O
system O
. O

The O
NMS B_DISEASE/B_GENE
- O
like B_DISEASE
encephalopathy I_DISEASE
that O
develops O
in O
association B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
the O
use B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
of O
antidepressants B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicates O
that O
NMS B_LOCATION
and O
SS B_DISEASE
are O
spectrum B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
disorders I_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
induced O
by O
drugs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
with O
both O
antidopaminergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
serotonergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

genetic O
separation O
of O
tumor O
growth O
and O
hemorrhagic O
phenotypes O
in O
an O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
tumor O
. O

chronic O
administration O
of O
estrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
to O
the O
Fischer O
344 O
( O
F344 O
) O
rat O
induces O
growth O
of O
large O
, O
hemorrhagic O
pituitary O
tumors O
. O

Ten O
weeks O
of O
diethylstilbestrol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DES B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
) O
treatment O
caused O
female O
F344 O
rat O
pituitaries O
to O
grow O
to O
an O
average O
of O
109 O
. O
2 O
+ O
/ O
- O
6 O
. O
3 O
mg O
( O
mean O
+ O
/ O
- O
SE O
) O
versus O
11 O
. O
3 O
+ O
/ O
- O
1 O
. O
4 O
mg O
for O
untreated O
rats O
, O
and O
to O
become O
highly O
hemorrhagic O
. O

The O
same O
DES B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O
produced O
no O
significant O
growth O
( O
8 O
. O
9 O
+ O
/ O
- O
0 O
. O
5 O
mg O
for O
treated O
females O
versus O
8 O
. O
7 O
+ O
/ O
- O
1 O
. O
1 O
for O
untreated O
females O
) O
or O
morphological O
changes O
in O
Brown O
Norway O
( O
BN O
) O
rat O
pituitaries O
. O

An O
F1 O
hybrid O
of O
F344 O
and O
BN O
exhibited O
significant O
pituitary O
growth O
after O
10 O
weeks O
of O
DES B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
treatment O
with O
an O
average O
mass O
of O
26 O
. O
3 O
+ O
/ O
- O
0 O
. O
7 O
mg O
compared O
with O
8 O
. O
6 O
+ O
/ O
- O
0 O
. O
9 O
mg O
for O
untreated O
rats O
. O

surprisingly O
, O
the O
F1 B_DISEASE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
hybrid B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
tumors B_DISEASE/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
were O
not O
hemorrhagic B_DISEASE_ADJECTIVE[DISEASE]
and O
had O
hemoglobin B_MEASURE/B_LOCATION
content B_MEASURE/I_LOCATION
and O
outward B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
appearance I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
identical I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
to O
that O
of O
BN B_PERSON/B_DISEASE
. O

Expression B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
of O
both O
growth B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
and O
morphological B_DISEASE_ADJECTIVE[DISEASE]/B_ORGANISM_FUNCTION
changes B_DISEASE_ADJECTIVE[DISEASE]/I_ORGANISM_FUNCTION
is O
due O
to O
multiple B_DISEASE/B_GENE
genes I_DISEASE/I_GENE
. O

However O
, O
while O
DES B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
pituitary O
growth O
exhibited O
quantitative O
, O
additive O
inheritance O
, O
the O
hemorrhagic O
phenotype O
exhibited O
recessive O
, O
epistatic O
inheritance O
. O

Only O
5 B_MEASURE
of O
the O
160 B_MEASURE/B_PERSON
F2 I_MEASURE/I_PERSON
pituitaries I_MEASURE/I_PERSON
exhibited O
the O
hemorrhagic B_DISEASE/B_MEASURE
phenotype I_DISEASE/I_MEASURE
; O
36 B_MEASURE
of O
the O
160 B_MEASURE/B_PERSON
F2 I_MEASURE/I_PERSON
pituitaries I_MEASURE/I_PERSON
were O
in O
the O
F344 B_MEASURE/B_LOCATION
range B_MEASURE/I_LOCATION
of O
mass B_MEASURE/B_ORGANISM_FUNCTION
, O
but O
31 B_NUMBER[MEASURE]
of O
these O
were O
not O
hemorrhagic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
, O
indicating O
that O
the O
hemorrhagic B_DISEASE_ADJECTIVE[DISEASE]
phenotype I_DISEASE_ADJECTIVE[DISEASE]
is O
not O
merely O
a O
consequence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
extensive B_DISEASE/B_ORGANISM_FUNCTION
growth I_DISEASE/I_ORGANISM_FUNCTION
. O

The O
hemorrhagic B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
F2 I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
pituitaries I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
were O
all O
among O
the O
most O
massive B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
, O
indicating O
that O
some O
of O
the O
genes B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
regulate O
both O
phenotypes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

increased O
expression O
of O
neuronal O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
synthase O
in O
bladder O
afferent O
pathways O
following O
chronic O
bladder O
irritation O
. O

Immunocytochemical O
techniques O
were O
used O
to O
examine O
alterations O
in O
the O
expression O
of O
neuronal O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
synthase O
( O
NOS O
) O
in O
bladder O
pathways O
following O
acute O
and O
chronic O
irritation O
of O
the O
urinary O
tract O
of O
the O
rat O
. O

Chemical O
cystitis O
was O
induced O
by O
cyclophosphamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
CYP B_PROTEIN[GENE]/B_LOCATION
) O
which O
is O
metabolized O
to O
acrolein B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
an O
irritant O
eliminated O
in O
the O
urine O
. O

injection O
of O
CYP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
( O
n O
= O
10 O
, O
75 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
) O
2 O
hours O
prior O
to O
perfusion O
( O
acute O
treatment O
) O
of O
the O
animals O
increased O
Fos O
- O
immunoreactivity O
( O
IR O
) O
in O
neurons O
in O
the O
dorsal O
commissure O
, O
dorsal O
horn O
, O
and O
autonomic O
regions O
of O
spinal O
segments O
( O
L1 O
- O
L2 O
and O
L6 O
- O
S1 O
) O
which O
receive O
afferent O
inputs O
from O
the O
bladder O
, O
urethra O
, O
and O
ureter O
. O

Fos O
- O
IR O
in O
the O
spinal O
cord O
was O
not O
changed O
in O
rats O
receiving O
chronic O
CYP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
treatment O
( O
n O
= O
15 O
, O
75 O
mg O
/ O
kg O
, O
i O
. O
p O
. O
, O
every O
3rd O
day O
for O
2 O
weeks O
) O
. O

In O
control O
animals O
and O
in O
animals O
treated O
acutely O
with O
CYP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
only O
small O
numbers O
of O
NOS O
- O
IR O
cells O
( O
0 O
. O
5 O
- O
0 O
. O
7 O
cell O
profiles O
/ O
sections O
) O
were O
detected O
in O
the O
L6 O
- O
S1 O
dorsal O
root O
ganglia O
( O
DRG O
) O
. O

chronic O
CYP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
administration O
significantly O
( O
P O
< O
or O
= O
. O
002 O
) O
increased O
bladder O
weight O
by O
60 O
% O
and O
increased O
( O
7 O
- O
to O
11 O
- O
fold O
) O
the O
numbers O
of O
NOS O
- O
immunoreactive O
( O
IR O
) O
afferent O
neurons O
in O
the O
L6 O
- O
S1 O
DRG O
. O

A O
small B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
increase I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
( O
1 B_MEASURE
. O
5 B_MEASURE
- O
fold B_MEASURE
) O
also O
occurred O
in O
the O
L1 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DRG I_PROTEIN[GENE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
no O
change B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
was O
detected O
in O
the O
L2 B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
L5 B_PROTEIN[GENE]/B_DISEASE
DRG I_PROTEIN[GENE]/I_DISEASE
. O

bladder O
afferent O
cells O
in O
the O
L6 O
- O
S1 O
DRG O
labeled O
by O
Fluorogold O
( O
40 O
microliters O
) O
injected O
into O
the O
bladder O
wall O
did O
not O
exhibit O
NOS O
- O
IR O
in O
control O
animals O
; O
however O
, O
following O
chronic O
CYP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
administration O
, O
a O
significant O
percentage O
of O
bladder O
afferent O
neurons O
were O
NOS O
- O
IR O
: O
L6 O
( O
19 O
. O
8 O
+ O
/ O
- O
4 O
. O
6 O
% O
) O
and O
S1 O
( O
25 O
. O
3 O
+ O
/ O
- O
2 O
. O
9 O
% O
) O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
that O
neuronal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gene I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
expression I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
visceral B_DISEASE/B_SPECIES[BIO]
sensory B_DISEASE/I_SPECIES[BIO]
pathways B_DISEASE/I_SPECIES[BIO]
can O
be O
upregulated O
by O
chemical B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
irritation B_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
afferent B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
in O
the O
urinary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
/ O
or O
that O
pathological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
changes B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_CELL[BODY_PART_OR_ORGAN_COMPONENT]
in O
the O
urinary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
tract I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
can O
initiate O
chemical B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
signals B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
that O
alter O
the O
chemical B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
properties B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
visceral B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
afferent I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
neurons I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Effects O
of O
a O
new O
calcium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonist O
, O
CD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
832 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
on O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
myocardial O
ischemia O
in O
dogs O
with O
partial O
coronary O
stenosis O
. O

Effects O
of O
CD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
832 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ISO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
) O
- O
induced O
myocardial O
ischemia O
were O
studied O
in O
dogs O
with O
partial O
coronary O
stenosis O
of O
the O
left O
circumflex O
coronary O
artery O
and O
findings O
were O
compared O
with O
those O
for O
nifedipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
diltiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
the O
presence O
of O
coronary O
artery O
stenosis O
, O
3 O
- O
min O
periods O
of O
intracoronary O
ISO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
infusion O
( O
10 O
ng O
/ O
kg O
/ O
min O
) O
increased O
heart O
rate O
and O
maximal O
rate O
of O
left O
ventricular O
pressure O
rise O
, O
which O
resulted O
in O
a O
decrease O
in O
percentage O
segmental O
shortening O
and O
ST O
- O
segment O
elevation O
of O
the O
epicardial O
electrocardiogram O
. O

After O
the O
control O
ISO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
with O
stenosis O
was O
performed O
, O
equihypotensive O
doses O
of O
CD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
832 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
3 O
and O
10 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
7 O
) O
, O
nifedipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 O
and O
3 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
9 O
) O
or O
diltiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
10 O
and O
30 O
micrograms O
/ O
kg O
/ O
min O
, O
n O
= O
7 O
) O
were O
infused O
5 O
min O
before O
and O
during O
the O
second O
and O
third O
ISO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
infusion O
. O

Both O
CD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
832 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
and O
diltiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
not O
nifedipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
significantly O
reduced O
the O
increase O
in O
heart O
rate O
induced O
by O
ISO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
. O

In O
contrast O
to O
nifedipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
CD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
832 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
10 O
micrograms O
/ O
kg O
/ O
min O
) O
prevented O
the O
decrease O
in O
percentage O
segmental O
shortening O
from O
32 O
+ O
/ O
- O
12 O
% O
to O
115 O
+ O
/ O
- O
26 O
% O
of O
the O
control O
value O
( O
P O
< O
. O
01 O
) O
and O
ST O
- O
segment O
elevation O
from O
5 O
. O
6 O
+ O
/ O
- O
1 O
. O
0 O
MV O
to O
1 O
. O
6 O
+ O
/ O
- O
1 O
. O
3 O
MV O
( O
P O
< O
. O
01 O
) O
at O
3 O
min O
after O
ISO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
with O
stenosis O
. O

Diltiazem B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
30 O
micrograms O
/ O
kg O
/ O
min O
) O
also O
prevented O
the O
decrease O
in O
percentage O
segmental O
shortening O
from O
34 O
+ O
/ O
- O
14 O
% O
to O
63 O
+ O
/ O
- O
18 O
% O
of O
the O
control O
value O
( O
P O
< O
. O
05 O
) O
and O
ST O
- O
segment O
elevation O
from O
4 O
. O
7 O
+ O
/ O
- O
0 O
. O
7 O
MV O
to O
2 O
. O
1 O
+ O
/ O
- O
0 O
. O
7 O
MV O
( O
P O
< O
. O
01 O
) O
at O
3 O
min O
after O
ISO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
with O
stenosis O
. O

These O
data O
show O
that O
CD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
832 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
improves O
myocardial O
ischemia O
during O
ISO B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
infusion O
with O
stenosis O
and O
suggest O
that O
the O
negative O
chronotropic O
property O
of O
CD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
832 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
plays O
a O
major O
role O
in O
the O
beneficial O
effects O
of O
CD B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
832 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
. O

The O
effect O
of O
recombinant O
human O
insulin O
- O
like O
growth O
factor O
- O
I O
on O
chronic O
puromycin B_DISEASE_ADJECTIVE[DISEASE]
aminonucleoside I_DISEASE_ADJECTIVE[DISEASE]
nephropathy O
in O
rats O
. O

We O
recently O
demonstrated O
that O
recombinant O
hGH O
exacerbates O
renal O
functional O
and O
structural O
injury O
in O
chronic O
puromycin B_DISEASE
aminonucleoside I_DISEASE
( O
PAN B_DISEASE/B_LOCATION
) O
nephropathy O
, O
an O
experimental O
model O
of O
glomerular O
disease O
. O

Therefore O
, O
we O
examined O
whether O
recombinant O
human O
( O
rh O
) O
IGF O
- O
I O
is O
a O
safer O
alternative O
for O
the O
treatment O
of O
growth O
failure O
in O
rats O
with O
chronic O
PAN B_DISEASE_ADJECTIVE[DISEASE]
nephropathy O
. O

The O
glomerulopathy O
was O
induced O
by O
seven O
serial O
injections O
of O
PAN B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
over O
12 O
wk O
. O

Experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
( O
n B_MEASURE/B_LOCATION
= O
6 B_MEASURE
) O
received O
rhIGF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
I B_OTHER/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
400 B_MEASURE/B_LOCATION
micrograms I_MEASURE/I_LOCATION
/ O
d B_OTHER/B_TIME[MEASURE]
, O
whereas O
control B_PERSON/B_BIO
rats I_PERSON/I_BIO
( O
n B_LOCATION
= O
6 B_MEASURE
) O
received O
the O
vehicle B_PRODUCT[OBJECT]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

rhIGF B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
I O
improved O
weight B_DISEASE/B_GENE
gain I_DISEASE/I_GENE
by O
14 B_DISEASE/B_MEASURE
% B_DISEASE/I_MEASURE
( O
p B_MEASURE/B_LOCATION
< I_MEASURE/I_LOCATION
0 I_MEASURE/I_LOCATION
. O
05 B_MEASURE
) O
, O
without O
altering O
hematocrit B_DISEASE
or O
blood B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
pressure B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
in O
rats B_BIO/B_PERSON
with O
renal B_DISEASE/B_GENE
disease I_DISEASE/I_GENE
. O

Urinary O
protein O
excretion O
was O
unaltered O
by O
rhIGF O
- O
I O
treatment O
in O
rats O
with O
chronic O
PAN B_DISEASE
nephropathy O
. O

After O
12 O
wk O
, O
the O
inulin O
clearance O
was O
higher O
in O
rhIGF O
- O
I O
- O
treated O
rats O
, O
0 O
. O
48 O
+ O
/ O
- O
0 O
. O
08 O
versus O
0 O
. O
24 O
+ O
/ O
- O
0 O
. O
06 O
mL O
/ O
min O
/ O
100 O
g O
of O
body O
weight O
in O
untreated O
PAN B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
nephropathy O
animals O
, O
p O
< O
0 O
. O
05 O
. O

The O
improvement O
in O
GFR O
was O
not O
associated O
with O
enhanced O
glomerular O
hypertrophy O
or O
increased O
segmental O
glomerulosclerosis O
, O
tubulointerstitial O
injury O
, O
or O
renal O
cortical O
malondialdehyde B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
content O
. O

In O
rats O
with O
PAN B_DISEASE
nephropathy O
, O
administration O
of O
rhIGF O
- O
I O
increased O
IGF O
- O
I O
and O
GH O
receptor O
gene O
expression O
, O
without O
altering O
the O
steady O
state O
level O
of O
IGF O
- O
I O
receptor O
mRNA O
. O

In O
normal O
rats O
with O
intact O
kidneys O
, O
rhIGF O
- O
I O
administration O
( O
n O
= O
4 O
) O
did O
not O
alter O
weight O
gain O
, O
blood O
pressure O
, O
proteinuria O
, O
GFR O
, O
glomerular O
planar O
area O
, O
renal O
cortical O
malondialdehyde B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
content O
, O
or O
glomerular O
or O
tubulointerstitial O
damage O
, O
compared O
with O
untreated O
animals O
( O
n O
= O
4 O
) O
. O

rhIGF B_GENE/B_MEASURE
- O
I O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
reduced O
the O
steady B_GENE/B_LOCATION
state I_GENE/I_LOCATION
renal I_GENE/I_LOCATION
IGF I_GENE/I_LOCATION
- O
I O
mRNA B_MEASURE/B_LOCATION
level B_MEASURE/I_LOCATION
but O
did O
not O
modify O
gene B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
expression B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
of O
the O
IGF B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
I O
or O
GH B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
receptors I_GENE/I_DISEASE_ADJECTIVE[DISEASE]
. O

We O
conclude O
that O
: O
1 O
) O
administration O
of O
rhIGF O
- O
I O
improves O
growth O
and O
GFR O
in O
rats O
with O
chronic O
PAN B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
nephropathy O
and O
2 O
) O
unlike O
rhGH O
, O
long O
- O
term O
use O
of O
rhIGF O
- O
I O
does O
not O
worsen O
renal O
functional O
and O
structural O
injury O
in O
this O
disease O
model O
. O

Nefiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
DM B_MEASURE/B_PROTEIN[GENE]
- I_MEASURE/I_PROTEIN[GENE]
9384 I_MEASURE/I_PROTEIN[GENE]
) O
reverses O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
amnesia O
of O
a O
passive O
avoidance O
response O
: O
delayed O
emergence O
of O
the O
memory O
retention O
effects O
. O

Nefiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
a O
novel O
pyrrolidone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
derivative O
which O
attenuates O
scopolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
learning O
and O
post O
- O
training O
consolidation O
deficits O
. O

Given O
that O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
inhibits O
passive O
avoidance O
retention O
when O
given O
during O
training O
or O
in O
a O
defined O
10 O
- O
12h O
post O
- O
training O
period O
, O
we O
evaluated O
the O
ability O
of O
nefiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
attenuate O
amnesia O
induced O
by O
dopaminergic O
agonism O
. O

A O
step O
- O
down O
passive O
avoidance O
paradigm O
was O
employed O
and O
nefiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3 O
mg O
/ O
kg O
) O
and O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 O
. O
5 O
mg O
/ O
kg O
) O
were O
given O
alone O
or O
in O
combination O
during O
training O
and O
at O
the O
10 O
- O
12h O
post O
- O
training O
period O
of O
consolidation O
. O

Co O
- O
administration O
of O
nefiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
training O
or O
10h O
thereafter O
produced O
no O
significant O
anti O
- O
amnesic O
effect O
. O

However O
, O
administration O
of O
nefiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
during O
training O
completely O
reversed O
the O
amnesia O
induced O
by O
apomorphine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
at O
the O
10h O
post O
- O
training O
time O
and O
the O
converse O
was O
also O
true O
. O

These O
effects O
were O
not O
mediated O
by O
a O
dopaminergic O
mechanism O
as O
nefiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
at O
millimolar O
concentrations O
, O
failed O
to O
displace O
either O
[ O
3H O
] O
SCH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
23390 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
or O
[ O
3H O
] O
spiperone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
binding O
from O
D1 O
or O
D2 O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O
subtypes O
, O
respectively O
. O

It O
is O
suggested O
that O
nefiracetam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
augments O
molecular O
processes O
in O
the O
early O
stages O
of O
events O
which O
ultimately O
lead O
to O
consolidation O
of O
memory O
. O

Phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
encephalopathy O
as O
probable O
idiosyncratic O
reaction O
: O
case O
report O
. O

A O
case O
of O
phenytoin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
DPH B_DISEASE/B_PROTEIN[GENE]
) O
encephalopathy O
with O
increasing O
seizures O
and O
EEG O
and O
mental O
changes O
is O
described O
. O

Despite O
adequate O
oral O
dosage O
of O
DPH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
5 O
mg O
/ O
kg O
/ O
daily O
) O
the O
plasma O
level O
was O
very O
low O
( O
2 O
. O
8 O
microgramg O
/ O
ml O
) O
. O

The O
encephalopathy B_DISEASE
was O
probably O
an O
idiosyncratic B_DISEASE_ADJECTIVE[DISEASE]
and O
not O
toxic B_DISEASE_ADJECTIVE[DISEASE]
or O
allergic B_DISEASE_ADJECTIVE[DISEASE]
reaction I_DISEASE_ADJECTIVE[DISEASE]
. O

In O
fact O
the O
concentration O
of O
free O
DPH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
normal O
, O
the O
patient O
presented O
a O
retarded O
morbilliform O
rash O
during O
DPH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
treatment O
, O
the O
protidogram O
was O
normal O
, O
and O
an O
intradermic O
DPH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
injection O
had O
no O
local O
effect O
. O

The O
authors O
conclude O
that O
in O
a O
patient O
starting O
DPH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
treatment O
an O
unexpected O
increase O
in O
seizures O
, O
with O
EEG O
and O
mental O
changes O
occurring O
simultaneously O
, O
should O
alert O
the O
physician O
to O
the O
possible O
need O
for O
eliminating O
DPH B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
from O
the O
therapeutic O
regimen O
, O
even O
if O
plasma O
concentrations O
are O
low O
. O

Prevention O
and O
treatment O
of O
endometrial O
disease O
in O
climacteric O
women O
receiving O
oestrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

The O
treatment O
regimens O
are O
described O
in O
74 O
patients O
with O
endometrial O
disease O
among O
850 O
climacteric O
women O
receiving O
oestrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O
. O

Cystic O
hyperplasia O
was O
associated O
with O
unopposed O
oestrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
therapy O
without O
progestagen B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

Two O
courses O
of O
21 O
days O
of O
5 O
mg O
norethisterone B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
daily O
caused O
reversion O
to O
normal O
in O
all O
57 O
cases O
of O
cystic O
hyperplasia O
and O
6 O
of O
the O
8 O
cases O
of O
atypical O
hyperplasia O
. O

4 O
cases O
of O
endometrial O
carcinoma O
referred O
from O
elsewhere O
demonstrated O
the O
problems O
of O
inappropriate O
and O
unsupervised O
unopposed O
oestrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
and O
the O
difficulty O
in O
distinguishing O
severe O
hyperplasia O
from O
malignancy O
. O

Cyclical O
low O
- O
dose O
oestrogen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
with O
7 O
- O
- O
13 O
days O
of O
progestagen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
does O
not O
seem O
to O
increase O
the O
risk O
of O
endometrial O
hyperplasia O
or O
carcinoma O
. O

Effects O
of O
exercise O
on O
the O
severity O
of O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
myocardial O
infarction O
. O

The O
effect O
of O
exercise O
on O
the O
severity O
of O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
myocardial O
infarction O
was O
studied O
in O
male O
rats O
. O

ninety B_NUMBER[MEASURE]
- O
three B_NUMBER[MEASURE]
rats I_NUMBER[MEASURE]
were O
randomly O
divided O
into O
three B_MEASURE/B_LOCATION
groups B_MEASURE/I_LOCATION
. O

The O
exercise O
- O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
E O
- O
1 O
) O
and O
exercise O
control O
( O
EC O
) O
groups O
exercised O
daily O
for O
thirty O
days O
on O
a O
treadmill O
at O
1 O
mph O
, O
2 O
% O
grade O
while O
animals O
of O
the O
sedentary O
- O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
S O
- O
I O
) O
group O
remained O
sedentary O
. O

Eight B_PERSON/B_ENT
animals I_PERSON/I_ENT
were O
assigned O
to O
the O
sedentary B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
control I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
( O
SC B_PROTEIN[GENE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
group B_ORGANIZATION/B_LOCATION
which O
remained O
sedentary B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
throughout O
the O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Forty O
- O
eight O
hours O
after O
the O
final O
exercise O
period O
, O
S O
- O
I O
and O
E O
- O
I O
animals O
received O
a O
single O
subcutaneous O
injection O
of O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
250 O
mg O
/ O
kg O
body O
weight O
) O
. O

Animals O
of O
the O
S O
- O
I O
group O
exhibited O
significantly O
( O
PP O
less O
than O
0 O
. O
05 O
) O
greater O
mortality O
from O
the O
effects O
of O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
than O
animals O
of O
the O
E O
- O
I O
group O
. O

serum O
CPK O
activity O
for O
E O
- O
I O
animals O
was O
significantly O
( O
p O
less O
than O
0 O
. O
05 O
) O
greater O
than O
for O
animals O
in O
the O
S O
- O
I O
and O
EC O
groups O
twenty O
hours O
following O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
injection O
. O

No O
statistically O
significant O
differences O
were O
observed O
between O
the O
two O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
treated O
groups O
for O
severity O
of O
the O
induced O
lesions O
, O
changes O
in O
heart O
weight O
, O
or O
heart O
weight O
to O
body O
weight O
ratios O
. O

The O
results O
indicated O
that O
exercise O
reduced O
the O
mortality O
associated O
with O
the O
effects O
of O
large O
dosages O
of O
isoproterenol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
but O
had O
little O
on O
the O
severity O
of O
the O
infarction O
. O

Human O
corticotropin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
- O
releasing O
hormone O
and O
thyrotropin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
releasing O
hormone O
modulate O
the O
hypercapnic O
ventilatory O
response O
in O
humans O
. O

Human O
corticotropin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
releasing O
hormone O
( O
hCRH O
) O
and O
thyrotropin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
releasing O
hormone O
( O
TRH O
) O
are O
known O
to O
stimulate O
ventilation O
after O
i O
. O
v O
. O
administration O
in O
humans O
. O

In O
a O
placebo B_LOCATION/B_PERSON
- O
controlled O
, O
single B_NUMBER[MEASURE]/B_LOCATION
- O
blind B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
study I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
we O
aimed O
to O
clarify O
if O
both O
peptides B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
act O
by O
altering O
central B_DISEASE
chemosensitivity I_DISEASE
. O

Two O
subsequent O
CO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
rebreathing O
tests O
were O
performed O
in O
healthy O
young O
volunteers O
. O

During O
the O
first O
test O
0 O
. O
9 O
% O
NaCl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
given O
i O
. O
v O
. O
; O
during O
the O
second O
test O
200 O
micrograms O
of O
hCRH O
( O
n O
= O
12 O
) O
or O
400 O
micrograms O
of O
TRH O
( O
n O
= O
6 O
) O
was O
administered O
i O
. O
v O
. O
Nine O
subjects O
received O
0 O
. O
9 O
% O
NaCl B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
i O
. O
v O
. O
during O
both O
rebreathing O
manoeuvres O
. O

The O
CO2 B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
response O
curves O
for O
the O
two O
tests O
were O
compared O
within O
the O
same O
subject O
. O

In O
the O
hCRH O
group O
a O
marked O
parallel O
shift O
of O
the O
CO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
response O
curve O
to O
the O
left O
was O
observed O
after O
hCRH O
( O
P O
< O
0 O
. O
01 O
) O
. O

The O
same B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
effect B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
occurred O
following O
TRH B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
but O
was O
less O
striking B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
P B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

hCRH O
and O
TRH O
caused O
a O
reduction O
in O
the O
CO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
threshold O
. O

The O
CO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- O
response O
curves O
in O
the O
control O
group O
were O
nearly O
identical O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
indicate O
an O
additive B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effect I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
both O
releasing O
hormones B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
hypercapnic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
ventilatory B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
response B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
in O
humans B_SPECIES[BIO]/B_DISEASE
, O
presumably O
independent B_PERSON/B_DISEASE_ADJECTIVE[DISEASE]
of O
central B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
chemosensitivity I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
. O

Lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
effective O
in O
suppressing O
hepatitis O
B O
virus O
DNA O
in O
Chinese O
hepatitis B_DISEASE
B I_DISEASE
surface I_DISEASE
antigen I_DISEASE
carriers O
: O
a O
placebo O
- O
controlled O
trial O
. O

Lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
a O
novel O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
' I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
dideoxy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
cytosine I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
analogue O
that O
has O
potent O
inhibitory O
effects O
on O
hepatitis O
B O
virus O
replication O
in O
vitro O
and O
in O
vivo O
. O

We O
performed O
a O
single O
- O
blind O
, O
placebo O
- O
controlled O
study O
to O
assess O
its O
effectiveness O
and O
safety O
in O
Chinese O
hepatitis B_DISEASE
B I_DISEASE
surface I_DISEASE
antigen I_DISEASE
( O
HBsAg B_DISEASE/B_GENE
) O
carriers O
. O

Forty O
- O
two O
Chinese O
HBsAg B_DISEASE
carriers O
were O
randomized O
to O
receive O
placebo O
( O
6 O
patients O
) O
or O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
orally O
in O
dosages O
of O
25 O
mg O
, O
100 O
mg O
, O
or O
300 O
mg O
daily O
( O
12 O
patients O
for O
each O
dosage O
) O
. O

The O
drug B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
given O
for O
4 B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
weeks I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

The O
patients B_PERSON/B_BIO
were O
closely O
monitored O
clinically O
, O
biochemically O
, O
and O
serologically O
up O
to O
4 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
after O
drug B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
treatment I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE
. O

All O
36 O
patients O
receiving O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
had O
a O
decrease O
in O
hepatitis O
B O
virus O
( O
HBV O
) O
DNA O
values O
of O
> O
90 O
% O
( O
P O
< O
. O
001 O
compared O
with O
placebo O
) O
. O

Although O
25 O
mg O
of O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
was O
slightly O
less O
effective O
than O
100 O
mg O
( O
P O
= O
. O
011 O
) O
and O
300 O
mg O
( O
P O
= O
. O
005 O
) O
, O
it O
still O
induced O
94 O
% O
suppression O
of O
HBV O
DNA O
after O
the O
fourth O
week O
of O
therapy O
. O

HBV B_PERSON/B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
DNA I_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
values I_PERSON/I_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
returned O
to O
pretreatment B_MEASURE/B_PERSON
levels I_MEASURE/I_PERSON
within O
4 B_TIME[MEASURE]/B_ENT
weeks I_TIME[MEASURE]/I_ENT
of O
cessation B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
therapy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

There O
was O
no O
change B_MEASURE
in O
the O
hepatitis B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
B I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
e I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
antigen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
status I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
or O
in O
aminotransferase B_DISEASE
levels I_DISEASE
. O

No O
serious B_DISEASE_ADJECTIVE[DISEASE]
adverse I_DISEASE_ADJECTIVE[DISEASE]
events I_DISEASE_ADJECTIVE[DISEASE]
were O
observed O
. O

In O
conclusion O
, O
a O
4 O
- O
week O
course O
of O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
safe O
and O
effective O
in O
suppression O
of O
HBV O
DNA O
in O
Chinese O
HBsAg B_DISEASE/B_PERSON
carriers O
. O

The O
suppression B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
> B_DISEASE_ADJECTIVE[DISEASE]
90 I_DISEASE_ADJECTIVE[DISEASE]
% I_DISEASE_ADJECTIVE[DISEASE]
but O
reversible B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
. O

Studies O
with O
long O
- O
term O
lamivudine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
administration O
should O
be O
performed O
to O
determine O
if O
prolonged O
suppression O
of O
HBV O
DNA O
can O
be O
achieved O
. O

Population O
- O
based O
study O
of O
risk O
of O
venous O
thromboembolism O
associated O
with O
various O
oral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contraceptives I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Background O
: O
Four O
studies O
published O
since O
December O
, O
1995 O
, O
reported O
that O
the O
incidence O
of O
venous O
thromboembolism O
( O
VTE O
) O
was O
higher O
in O
women O
who O
used O
oral B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
contraceptives I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
OCs B_LOCATION/B_ORGANIZATION
) O
containing O
the O
third O
- O
generation O
progestagens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
gestodene I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
desogestrel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
than O
in O
users O
of O
OCs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
containing O
second O
- O
generation O
progestagens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

However O
, O
confounding B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
and O
bias B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
design B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
these O
studies B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
may O
have O
affected O
the O
findings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
aim O
of O
our O
study O
was O
to O
re O
- O
examine O
the O
association O
between O
risk O
of O
VTE O
and O
OC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
with O
a O
different O
study O
design O
and O
analysis O
to O
avoid O
some O
of O
the O
bias O
and O
confounding O
of O
the O
earlier O
studies O
. O

METHODS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
used O
computer B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
records I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
patients B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
from O
143 B_LOCATION/B_PERSON
general I_LOCATION/I_PERSON
practices I_LOCATION/I_PERSON
in O
the O
UK B_LOCATION
. O

The O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
based O
on O
the O
medical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
records I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
about O
540 B_MEASURE
, O
000 B_TIME[MEASURE]
women I_TIME[MEASURE]
born O
between O
1941 B_MEASURE
and O
1981 B_MEASURE
. O

All O
women B_PERSON
who O
had O
a O
recorded O
diagnosis B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
deep B_LOCATION/B_DISEASE
- O
vein B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
thrombosis I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
, O
venous B_DISEASE
thrombosis I_DISEASE
not O
otherwise O
specified O
, O
or O
pulmonary B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
embolus I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
during O
the O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_TIME[MEASURE]
period I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_TIME[MEASURE]
, O
and O
who O
had O
been O
treated O
with O
an O
anticoagulant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
were O
identified O
as O
potential B_PERSON/B_DISEASE
cases I_PERSON/I_DISEASE
of O
VTE B_DISEASE
. O

We O
did O
a O
cohort O
analysis O
to O
estimate O
and O
compare O
incidence O
of O
VTE O
in O
users O
of O
the O
main O
OC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparations O
, O
and O
a O
nested O
case O
- O
control O
study O
to O
calculate O
the O
odds O
ratios O
of O
VTE O
associated O
with O
use O
of O
different O
types O
of O
OC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
after O
adjustment O
for O
potential O
confounding O
factors O
. O

In O
the O
case O
- O
control O
study O
, O
we O
matched O
cases O
to O
controls O
by O
exact O
year O
of O
birth O
, O
practice O
, O
and O
current O
use O
of O
OCs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

We O
used O
a O
multiple O
logistic O
regression O
model O
that O
included O
body O
- O
mass O
index O
, O
number O
of O
cycles O
, O
change O
in O
type O
of O
OC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
prescribed O
within O
3 O
months O
of O
the O
event O
, O
previous O
pregnancy O
, O
and O
concurrent O
disease O
. O

findings O
: O
85 O
women O
met O
the O
inclusion O
criteria O
for O
VTE O
, O
two O
of O
whom O
were O
users O
of O
progestagen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
only O
OCs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Of O
the O
83 O
cases O
of O
VTE O
associated O
with O
use O
of O
combined O
OCs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
43 O
were O
recorded O
as O
deep O
- O
vein O
thrombosis O
, O
35 O
as O
pulmonary O
thrombosis O
, O
and O
five O
as O
venous O
thrombosis O
not O
otherwise O
specified O
. O

The O
crude O
rate O
of O
VTE O
per O
10 O
, O
000 O
woman O
- O
years O
was O
4 O
. O
10 O
in O
current O
users O
of O
any O
OC B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
, O
3 O
. O
10 O
in O
users O
of O
second O
- O
generation O
OCs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
4 O
. O
96 O
in O
users O
of O
third O
- O
generation O
preparations O
. O

After O
adjustment O
for O
age O
, O
the O
rate O
ratio O
of O
VTE O
in O
users O
of O
third O
- O
generation O
relative O
to O
second O
- O
generation O
OCs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
1 O
. O
68 O
( O
95 O
% O
CI O
1 O
. O
04 O
- O
2 O
. O
75 O
) O
. O

Logistic O
regression O
showed O
no O
significant O
difference O
in O
the O
risk O
of O
VTE O
between O
users O
of O
third O
- O
generation O
and O
second O
- O
generation O
OCs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Among O
users O
of O
third O
- O
generation O
progestagens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
risk O
of O
VTE O
was O
higher O
in O
users O
of O
desogestrel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
with O
20 O
g O
ethinyloestradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
than O
in O
users O
of O
gestodene B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
desogestrel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
with O
30 O
g O
ethinyloestradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

With O
all O
second O
- O
generation O
OCs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
as O
the O
reference O
, O
the O
odds O
ratios O
for O
VTE O
were O
3 O
. O
49 O
( O
1 O
. O
21 O
- O
10 O
. O
12 O
) O
for O
desogestrel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O
20 O
g O
ethinyloestradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
1 O
. O
18 O
( O
0 O
. O
66 O
- O
2 O
. O
17 O
) O
for O
the O
other O
third O
- O
generation O
progestagens B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

interpretation O
: O
The O
previously O
reported O
increase O
in O
odds O
ratio O
associated O
with O
third O
- O
generation O
OCs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
when O
compared O
with O
second O
- O
generation O
products O
is O
likely O
to O
have O
been O
the O
result O
of O
residual O
confounding O
by O
age O
. O

The O
increased O
odds O
ratio O
associated O
with O
products O
containing O
20 O
micrograms O
ethinyloestradiol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
and O
desogestrel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
compared O
with O
the O
30 O
micrograms O
product O
is O
biologically O
implausible O
, O
and O
is O
likely O
to O
be O
the O
result O
of O
preferential O
prescribing O
and O
, O
thus O
, O
confounding O
. O

MK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
801 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
augments O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
electrographic O
seizure O
but O
protects O
against O
brain O
damage O
in O
rats O
. O

1 B_NUMBER[MEASURE]
. O

The O
authors O
examined O
the O
anticonvulsant O
effects O
of O
MK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
801 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
on O
the O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
seizure O
model O
. O

Intraperitoneal O
injection O
of O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
400 O
mg O
/ O
kg O
) O
induced O
tonic O
and O
clonic O
seizure O
. O

Scopolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
10 O
mg O
/ O
kg O
) O
and O
pentobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 O
mg O
/ O
kg O
) O
prevented O
development O
of O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
behavioral O
seizure O
but O
MK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
801 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 O
. O
5 O
mg O
/ O
kg O
) O
did O
not O
. O

2 B_NUMBER[MEASURE]
. O

An O
electrical O
seizure O
measured O
with O
hippocampal O
EEG O
appeared O
in O
the O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
group O
. O

Scopolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
and O
pentobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
blocked O
the O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
electrographic O
seizure O
, O
MK B_LOCATION
- I_LOCATION
801 I_LOCATION
treatment O
augmented O
the O
electrographic O
seizure O
induced O
by O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

3 B_NUMBER[MEASURE]
. O

Brain B_DISEASE_ADJECTIVE[DISEASE]
damage I_DISEASE_ADJECTIVE[DISEASE]
was O
assessed O
by O
examining O
the O
hippocampus B_BODY_PART_OR_ORGAN_COMPONENT/B_BIO
microscopically O
. O

Pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
produced O
neuronal O
death O
in O
the O
hippocampus O
, O
which O
showed O
pyknotic O
changes O
. O

Pentobarbital B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
scopolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
MK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
801 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
protected O
the O
brain O
damage O
by O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
though O
in O
the O
MK B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
801 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
group O
, O
the O
pyramidal O
cells O
of O
hippocampus O
appeared O
darker O
than O
normal O
. O

In O
all O
treatments B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
, O
granule B_CELL[BODY_PART_OR_ORGAN_COMPONENT]/B_DISEASE_ADJECTIVE[DISEASE]
cells I_CELL[BODY_PART_OR_ORGAN_COMPONENT]/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
dentate B_BODY_PART_OR_ORGAN_COMPONENT/B_GENE
gyrus I_BODY_PART_OR_ORGAN_COMPONENT/I_GENE
were O
not O
affected O
. O

4 B_NUMBER[MEASURE]
. O

These O
results O
indicate O
that O
status O
epilepticus O
induced O
by O
pilocarpine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
is O
initiated O
by O
cholinergic O
overstimulation O
and O
propagated O
by O
glutamatergic O
transmission O
, O
the O
elevation O
of O
which O
may O
cause O
brain O
damage O
through O
an O
excitatory O
NMDA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O
- O
mediated O
mechanism O
. O

Paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
folinic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
metastatic O
breast O
cancer O
: O
BRE O
- O
26 O
, O
a O
phase O
II O
trial O
. O

5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Fluorouracil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
plus O
folinic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
Taxol B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
; O
Bristol O
- O
Myers O
Squibb O
Company O
, O
Princeton O
, O
NJ O
) O
are O
effective O
salvage O
therapies O
for O
metastatic O
breast O
cancer O
patients O
. O

Paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
have O
additive O
cytotoxicity O
in O
MCF O
- O
7 O
cell O
lines O
. O

We O
performed O
a O
phase O
II O
trial O
of O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
175 O
mg O
/ O
m2 O
over O
3 O
hours O
on O
day O
I O
followed O
by O
folinic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
300 O
mg O
over O
1 O
hour O
before O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
fluorouracil I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
350 O
mg O
/ O
m2 O
on O
days O
1 O
to O
3 O
every O
28 O
days O
( O
TFL O
) O
in O
women O
with O
metastatic O
breast O
cancer O
. O

Analysis O
is O
reported O
on O
37 O
patients O
with O
a O
minimum O
of O
6 O
months O
follow O
- O
up O
who O
received O
a O
total O
of O
192 O
cycles O
of O
TFL O
: O
nine O
cycles O
( O
5 O
% O
) O
were O
associated O
with O
grade O
3 O
/ O
4 O
neutropenia O
requiring O
hospitalization O
; O
seven O
( O
4 O
% O
) O
cycles O
in O
two O
patients O
required O
granulocyte B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
colony I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
- I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulating I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
factor I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O
to O
neutropenia O
; O
no O
patient O
required O
platelet O
transfusions O
. O

Grade B_MEASURE/B_PROTEIN[GENE]
3 I_MEASURE/I_PROTEIN[GENE]
/ O
4 B_MEASURE
nonhematologic I_MEASURE
toxicities I_MEASURE
were O
uncommon B_DISEASE_ADJECTIVE[DISEASE]
. O

Among O
the O
34 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
patients I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
evaluable I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
for O
response B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, O
there O
were O
three B_MEASURE
complete I_MEASURE
responses I_MEASURE
( O
9 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
and O
18 B_NUMBER[MEASURE]
partial I_NUMBER[MEASURE]
responses I_NUMBER[MEASURE]
( O
53 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
for O
an O
overall B_MEASURE
response I_MEASURE
rate I_MEASURE
of O
62 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
. O

Of O
the O
19 O
evaluable O
patients O
with O
prior O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
exposure O
, O
11 O
( O
58 O
% O
) O
responded O
compared O
with O
nine O
of O
15 O
( O
60 O
% O
) O
without O
prior O
doxorubicin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

plasma O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentrations O
were O
measured O
at O
the O
completion O
of O
paclitaxel B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
infusion O
and O
at O
24 O
hours O
in O
19 O
patients O
. O

TFL B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
is O
an O
active B_DISEASE_ADJECTIVE[DISEASE]
, O
well O
- O
tolerated O
regimen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
metastatic B_DISEASE/B_BIO
breast I_DISEASE/I_BIO
cancer I_DISEASE/I_BIO
. O

efficacy O
and O
proarrhythmia O
with O
the O
use O
of O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
sotalol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
for O
sustained O
ventricular O
tachyarrhythmias O
. O

This O
study O
prospectively O
evaluated O
the O
clinical O
efficacy O
, O
the O
incidence O
of O
torsades O
de O
pointes O
, O
and O
the O
presumable O
risk O
factors O
for O
torsades O
de O
pointes O
in O
patients O
treated O
with O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
sustained O
ventricular O
tachyarrhythmias O
. O

eighty O
- O
one O
consecutive O
patients O
( O
54 O
with O
coronary O
artery O
disease O
, O
and O
20 O
with O
dilated O
cardiomyopathy O
) O
with O
inducible O
sustained O
ventricular O
tachycardia O
or O
ventricular O
fibrillation O
received O
oral O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
prevent O
induction O
of O
the O
ventricular O
tachyarrhythmia O
. O

During O
oral O
loading O
with O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
continuous O
electrocardiographic O
( O
ECG O
) O
monitoring O
was O
performed O
. O

Those O
patients O
in O
whom O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
prevented O
induction O
of O
ventricular O
tachycardia O
or O
ventricular O
fibrillation O
were O
discharged O
with O
the O
drug O
and O
followed O
up O
on O
an O
outpatient O
basis O
for O
21 O
+ O
/ O
- O
18 O
months O
. O

induction O
of O
the O
ventricular O
tachyarrhythmia O
was O
prevented O
by O
oral O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
35 O
( O
43 O
% O
) O
patients O
; O
the O
ventricular O
tachyarrhythmia O
remained O
inducible O
in O
40 O
( O
49 O
% O
) O
patients O
; O
and O
two O
( O
2 O
. O
5 O
% O
) O
patients O
did O
not O
tolerate O
even O
40 O
mg O
of O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
once O
daily O
. O

Four O
( O
5 O
% O
) O
patients O
had O
from O
torsades O
de O
pointes O
during O
the O
initial O
oral O
treatment O
with O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Neither O
ECG B_DISEASE/B_MEASURE
[ I_DISEASE/I_MEASURE
sinus I_DISEASE/I_MEASURE
- O
cycle B_MEASURE/B_LOCATION
length I_MEASURE/I_LOCATION
( O
SCL B_LOCATION/B_DISEASE
) O
, O
QT B_MEASURE/B_PROTEIN[GENE]
or O
QTc B_LOCATION/B_ORGANIZATION
interval I_LOCATION/I_ORGANIZATION
, O
or O
U B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
wave I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
] I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
nor O
clinical B_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
parameters I_DIAGNOSTIC_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
identified O
patients B_PERSON/B_LOCATION
at O
risk B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
for O
torsades B_DISEASE
de I_DISEASE
pointes I_DISEASE
. O

However O
, O
the O
oral O
dose O
of O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
significantly O
lower O
in O
patients O
with O
torsades O
de O
pointes O
( O
200 O
+ O
/ O
- O
46 O
vs O
. O
328 O
+ O
/ O
- O
53 O
mg O
/ O
day O
; O
p O
= O
0 O
. O
0017 O
) O
. O

Risk B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
factors I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
associated O
with O
the O
development B_DISEASE_ADJECTIVE[DISEASE]
of O
torsades B_DISEASE
de I_DISEASE
pointes I_DISEASE
were O
the O
appearance B_PERSON/B_DISEASE
of O
an O
U B_DISEASE
wave I_DISEASE
( O
p O
= O
0 B_MEASURE
. O
049 B_MEASURE
) O
, O
female B_DISEASE
gender I_DISEASE
( O
p B_PROTEIN[GENE]/B_LOCATION
= O
0 B_MEASURE
. O
015 B_MEASURE
) O
, O
and O
significant B_MEASURE/B_DISEASE
dose I_MEASURE/I_DISEASE
- O
corrected O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
SCL B_MEASURE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
QT B_LOCATION/B_PROTEIN[GENE]
interval I_LOCATION/I_PROTEIN[GENE]
, O
and O
QTc B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
interval B_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
p B_MEASURE/B_PROTEIN[GENE]
< O
0 B_MEASURE
. O
05 B_MEASURE
) O
. O

During O
follow O
- O
up O
, O
seven B_NUMBER[MEASURE]
( O
20 B_NUMBER[MEASURE]/B_LOCATION
% I_NUMBER[MEASURE]/I_LOCATION
) O
patients B_PERSON
had O
a O
nonfatal B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
ventricular I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
tachycardia I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
recurrence I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
and O
two B_NUMBER[MEASURE]
( O
6 B_NUMBER[MEASURE]/B_PERSON
% I_NUMBER[MEASURE]/I_PERSON
) O
patients B_PERSON
died O
suddenly O
. O

One O
female O
patient O
with O
stable O
cardiac O
disease O
had O
recurrent O
torsades O
de O
pointes O
after O
2 O
years O
of O
successful O
treatment O
with O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Torsades O
de O
pointes O
occurred O
early O
during O
treatment O
even O
with O
low O
doses O
of O
oral O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

pronounced O
changes O
in O
the O
surface O
ECG O
( O
cycle O
length O
, O
QT O
, O
and O
QTc O
) O
in O
relation O
to O
the O
dose O
of O
oral O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
might O
identify O
a O
subgroup O
of O
patients O
with O
an O
increased O
risk O
for O
torsades O
de O
pointes O
. O

Other O
ECG O
parameters O
before O
the O
application O
of O
d B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
l I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
sotalol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
did O
not O
identify O
patients O
at O
increased O
risk O
for O
torsades O
de O
pointes O
. O

Recurrence B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
rates I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
ventricular B_DISEASE
tachyarrhythmias I_DISEASE
are O
high B_DISEASE_ADJECTIVE[DISEASE]/B_GENE
despite O
complete B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
suppression I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
the O
arrhythmia B_DISEASE
during O
programmed B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
stimulation I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

Therefore O
programmed O
electrical O
stimulation O
in O
the O
case O
of O
d B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
l I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sotalol I_DISEASE/I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
seems O
to O
be O
of O
limited O
prognostic O
value O
. O

chronic O
hyperprolactinemia O
and O
changes O
in O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
neurons O
. O

The O
tuberoinfundibular B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
dopaminergic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
TIDA B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
system B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
is O
known O
to O
inhibit O
prolactin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
PRL B_PROTEIN[GENE]/B_LOCATION
) O
secretion B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
. O

In O
young B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENT
animals I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_ENT
this O
system B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ENZYME[GENE]
responds O
to O
acute B_DISEASE_ADJECTIVE[DISEASE]
elevations I_DISEASE_ADJECTIVE[DISEASE]
in O
serum B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
PRL I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
by O
increasing O
its O
activity B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
. O

However O
, O
this O
responsiveness B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
is O
lost O
in O
aging O
rats B_BIO/B_PERSON
with O
chronically O
high B_DISEASE
serum I_DISEASE
PRL I_DISEASE
levels I_DISEASE
. O

The O
purpose B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
this O
study B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
to O
induce O
hyperprolactinemia B_DISEASE
in O
rats B_SPECIES[BIO]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
for O
extended B_TIME[MEASURE]/B_LOCATION
periods I_TIME[MEASURE]/I_LOCATION
of O
time B_TIME[MEASURE]
and O
examine O
its O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
dopaminergic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
systems I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

Hyperprolactinemia O
was O
induced O
by O
treatment O
with O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
receptor O
antagonist O
, O
and O
Palkovits O
' O
microdissection O
technique O
in O
combination O
with O
high O
- O
performance O
liquid O
chromatography O
was O
used O
to O
measure O
neurotransmitter O
concentrations O
in O
several O
areas O
of O
the O
brain O
. O

After O
6 O
months O
of O
hyperprolactinemia O
, O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DA B_LOCATION
) O
concentrations O
in O
the O
median O
eminence O
( O
ME O
) O
increased O
by O
84 O
% O
over O
the O
control O
group O
. O

Nine O
months O
of O
hyperprolactinemia O
produced O
a O
50 O
% O
increase O
in O
DA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
concentrations O
in O
the O
ME O
over O
the O
control O
group O
. O

However O
, O
DA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
response O
was O
lost O
if O
a O
9 O
- O
month O
long O
haloperidol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
induced O
hyperprolactinemia O
was O
followed O
by O
a O
1 O
1 O
/ O
2 O
month O
- O
long O
extremely O
high O
increase O
in O
serum O
PRL O
levels O
produced O
by O
implantation O
of O
MMQ O
cells O
under O
the O
kidney O
capsule O
. O

There O
was O
no O
change O
in O
the O
levels O
of O
DA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
, O
norepinephrine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
NE B_LOCATION/B_ORGANIZATION
) O
, O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 B_LOCATION
- I_LOCATION
HT I_LOCATION
) O
, O
or O
their O
metabolites O
in O
the O
arcuate O
nucleus O
( O
AN O
) O
, O
medial O
preoptic O
area O
( O
MPA O
) O
, O
caudate O
putamen O
( O
CP O
) O
, O
substantia O
nigra O
( O
SN O
) O
, O
and O
zona O
incerta O
( O
ZI O
) O
, O
except O
for O
a O
decrease O
in O
5 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
hydroxyindoleacetic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
5 B_LOCATION/B_ORGANIZATION
- I_LOCATION/I_ORGANIZATION
HIAA I_LOCATION/I_ORGANIZATION
) O
in O
the O
AN O
after O
6 O
- O
months O
of O
hyperprolactinemia O
and O
an O
increase O
in O
DA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
concentrations O
in O
the O
AN O
after O
9 O
- O
months O
of O
hyperprolactinemia O
. O

These O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
demonstrate O
that O
hyperprolactinemia B_DISEASE_ADJECTIVE[DISEASE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
specifically O
affects O
TIDA B_DISEASE/B_GENE
neurons B_DISEASE/I_GENE
and O
these O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
vary O
, O
depending O
on O
the O
duration B_MEASURE/B_LOCATION
and O
intensity B_MEASURE/B_LOCATION
of O
hyperprolactinemia B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

The O
age O
- O
related O
decrease O
in O
hypothalamic O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
function O
may O
be O
associated O
with O
increases O
in O
PRL O
secretion O
. O

Treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
- O
related O
disseminated O
necrotizing B_DISEASE
leukoencephalopathy I_DISEASE
with O
characteristic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
contrast I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
enhancement I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
white B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
matter I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

This O
report O
describes O
unique O
contrast O
enhancement O
of O
the O
white O
matter O
on O
T1 O
- O
weighted O
magnetic O
resonance O
images O
of O
two O
patients O
with O
disseminated O
necrotizing O
leukoencephalopathy O
, O
which O
developed O
from O
acute O
lymphoblastic O
leukemia O
treated O
with O
high O
- O
dose O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

In O
both O
patients B_PERSON/B_LOCATION
, O
the O
enhancement B_DISEASE_ADJECTIVE[DISEASE]
was O
more O
pronounced O
near O
the O
base B_LOCATION/B_MEASURE
of O
the O
brain B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
than O
at O
the O
vertex B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
. O

necropsy B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
first B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
case I_BODY_PART_OR_ORGAN_COMPONENT/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
revealed O
loss B_DISEASE_ADJECTIVE[DISEASE]
of O
myelination B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
and O
necrosis B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
the O
white B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
matter I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

Possible B_DISEASE_ADJECTIVE[DISEASE]
mechanisms I_DISEASE_ADJECTIVE[DISEASE]
causing O
such O
a O
leukoencephalopathy B_DISEASE_ADJECTIVE[DISEASE]
are O
discussed O
. O

Thrombotic O
complications O
in O
acute O
promyelocytic O
leukemia O
during O
all B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trans I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
retinoic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
. O

A O
case O
of O
acute O
renal O
failure O
, O
due O
to O
occlusion O
of O
renal O
vessels O
in O
a O
patient O
with O
acute O
promyelocytic O
leukemia O
( O
APL O
) O
treated O
with O
all B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
trans I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
retinoic I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ATRA B_ORGANIZATION/B_LOCATION
) O
and O
tranexamic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
has O
been O
described O
recently O
. O

We O
report O
a O
case O
of O
acute O
renal O
failure O
in O
an O
APL O
patient O
treated O
with O
ATRA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alone O
. O

This O
case O
further O
supports O
the O
concern O
about O
thromboembolic O
complications O
associated O
with O
ATRA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
in O
APL O
patients O
. O

The O
patients O
, O
a O
43 O
- O
year O
- O
old O
man O
, O
presented O
all O
the O
signs O
and O
symptoms O
of O
APL O
and O
was O
included O
in O
a O
treatment O
protocol O
with O
ATRA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

After O
10 B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
of O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
he O
developed O
acute B_DISEASE
renal I_DISEASE
failure I_DISEASE
that O
was O
completely O
reversible B_DISEASE_ADJECTIVE[DISEASE]
after O
complete B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
remission I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
of O
APL B_DISEASE
was O
achieved O
and O
therapy B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
discontinued O
. O

We O
conclude O
that O
ATRA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
a O
valid O
therapeutic O
choice O
for O
patients O
with O
APL O
, O
although O
the O
procoagulant O
tendency O
is O
not O
completely O
corrected O
. O

Thrombotic O
events O
, O
however O
, O
could O
be O
avoided O
by O
using O
low O
- O
dose O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pupillary B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changes B_DISEASE_ADJECTIVE[DISEASE]/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
associated O
with O
the O
development B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
stimulant B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
mania B_DISEASE/B_LOCATION
: O
a O
case B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
report I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
. O

A O
30 O
- O
year O
- O
old O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
dependent O
man O
who O
was O
a O
subject O
in O
a O
study O
evaluating O
the O
anticraving O
efficacy O
of O
the O
stimulant O
medication O
diethylpropion B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
DEP B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
became O
manic O
during O
his O
second O
week O
on O
the O
study O
drug O
. O

Pupillometric O
changes O
while O
on O
DEP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
especially O
changes O
in O
the O
total O
power O
of O
pupillary O
oscillation O
, O
were O
dramatically O
different O
than O
those O
observed O
in O
the O
eight O
other O
study O
subjects O
who O
did O
not O
become O
manic O
. O

The O
large B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
changes I_DISEASE_ADJECTIVE[DISEASE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
total B_MEASURE/B_LOCATION
power I_MEASURE/I_LOCATION
of O
pupillary B_DISEASE/B_PROTEIN[GENE]
oscillation B_DISEASE/I_PROTEIN[GENE]
occurred O
a O
few B_TIME[MEASURE]/B_ENT
days I_TIME[MEASURE]/I_ENT
before O
the O
patient B_PERSON/B_BODY_PART_OR_ORGAN_COMPONENT
became O
fully O
manic B_DISEASE/B_PERSON
. O

Such B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
medication I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
associated O
changes B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
total B_MEASURE
power I_MEASURE
of O
pupillary B_DISEASE/B_PROTEIN[GENE]
oscillation B_DISEASE/I_PROTEIN[GENE]
might O
be O
of O
utility B_LOCATION/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
identifying O
persons B_PERSON/B_LOCATION
at O
risk B_DISEASE_ADJECTIVE[DISEASE]
for O
manic B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
like B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
adverse I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
effects I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
the O
medical B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_ORGANISM_FUNCTION
use I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_ORGANISM_FUNCTION
of O
psychomotor B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stimulants I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
or O
sympathomimetic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
agents I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
. O

Fetal O
risks O
due O
to O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
during O
pregnancy O
. O

Two O
mothers O
with O
heart O
valve O
prosthesis O
were O
treated O
with O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
pregnancy O
. O

In O
the O
first O
case O
a O
caesarean O
section O
was O
done O
one O
week O
after O
replacement O
of O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
with O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
baby B_PERSON
died O
of O
cerebral B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
and O
pulmonary B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
hemorrhage I_DISEASE/I_BODY_PART_OR_ORGAN_COMPONENT
. O

The O
second B_PERSON/B_LOCATION
mother I_PERSON/I_LOCATION
had O
a O
male B_PERSON
infant I_PERSON
by O
caesarean B_TIME[MEASURE]/B_PERSON
section B_TIME[MEASURE]/I_PERSON
. O

The O
baby O
showed O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
induced O
embryopathy O
with O
nasal O
hypoplasia O
and O
stippled O
epiphyses O
( O
chondrodysplasia O
punctata O
) O
. O

nasal O
hypoplasia O
with O
or O
without O
stippled O
epiphyses O
has O
now O
been O
reported O
in O
11 O
infants O
born O
to O
mothers O
treated O
with O
warfarin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
during O
the O
first O
trimester O
, O
and O
a O
causal O
association O
is O
probable O
. O

In O
view B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
risks B_DISEASE_ADJECTIVE[DISEASE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
to O
both O
mother B_PERSON/B_BIO
and O
fetus B_PERSON
in O
women B_PERSON
with O
prosthetic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cardiac I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
valves I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
it O
is O
recommended O
that O
therapeutic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
abortion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
be O
advised O
as O
the O
first B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
alternative I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
negative B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
mucosal I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
potential I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
: O
separating O
central B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
peripheral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
of O
NSAIDs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
man B_PERSON/B_BIO
. O

Objective B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
We O
wanted O
to O
test O
whether O
assessment B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
both O
a O
central B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
pain B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
- O
related O
signal B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
( O
chemo B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
- O
somatosensory B_BODY_PART_OR_ORGAN_COMPONENT/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
evoked O
potential B_LAB_TEST_COMPONENT[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
, O
CSSEP B_LOCATION/B_DISEASE
) O
and O
a O
concomitantly O
recorded O
peripheral B_DISEASE/B_MEASURE
signal I_DISEASE/I_MEASURE
( O
negative B_LOCATION
mucosal I_LOCATION
potential I_LOCATION
, O
NMP B_LOCATION/B_DISEASE
) O
allows O
for O
separation B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
central B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
and O
peripheral B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
of O
NSAIDs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

For O
this O
purpose B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
experimental B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
conditions I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
created O
in O
which O
NSAIDs B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
had O
previously O
been O
observed O
to O
produce O
effects B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
on O
phasic B_DISEASE_ADJECTIVE[DISEASE]
and O
tonic B_DISEASE/B_ORGANISM_FUNCTION
pain I_DISEASE/I_ORGANISM_FUNCTION
by O
either O
central B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
or O
peripheral B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
mechanisms B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
. O

methods O
: O
According O
to O
a O
double O
- O
blind O
, O
randomised O
, O
controlled O
, O
threefold O
cross O
- O
over O
design O
, O
18 O
healthy O
subjects O
( O
11 O
males O
, O
7 O
females O
; O
mean O
age O
26 O
years O
) O
received O
either O
placebo O
, O
400 O
mg O
ibuprofen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
or O
800 O
mg O
ibuprofen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Phasic O
pain O
was O
applied O
by O
means O
of O
short O
pulses O
of O
CO2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
to O
the O
nasal O
mucosa O
( O
stimulus O
duration O
500 O
MS O
, O
interval O
approximately O
60 O
s O
) O
, O
and O
tonic O
pain O
was O
induced O
in O
the O
nasal O
cavity O
by O
means O
of O
dry O
air O
of O
controlled O
temperature O
, O
humidity O
and O
flow O
rate O
( O
22 O
degrees O
C O
, O
0 O
% O
relative O
humidity O
, O
145 O
ml O
. O
s O
- O
1 O
) O
. O

Both O
CSSEPs O
as O
central O
and O
NMPs O
as O
peripheral O
correlates O
of O
pain O
were O
obtained O
in O
response O
to O
the O
CO2 B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stimuli O
. O

Additionally O
, O
the O
subjects B_PERSON/B_ORGANIZATION
rated O
the O
intensity B_MEASURE
of O
both O
phasic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
and O
tonic B_DISEASE
pain I_DISEASE
by O
means B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
of O
visual B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
analogue I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
scales I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
. O

Results O
: O
As O
described O
earlier O
, O
administration O
of O
ibuprofen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
followed O
by O
a O
decrease O
in O
tonic O
pain O
but O
- O
relative O
to O
placebo O
- O
an O
increase O
in O
correlates O
of O
phasic O
pain O
, O
indicating O
a O
specific O
effect O
of O
ibuprofen B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
the O
interaction O
between O
the O
pain O
stimuli O
under O
these O
special O
experimental O
conditions O
. O

Based O
on O
the O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
behaviour I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
CSSEP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
NMP B_DISEASE
, O
it O
was O
concluded O
that O
the O
pharmacological B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
process B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
underlying O
this O
phenomenon B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
was O
localised O
in O
the O
periphery B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
. O

By O
means B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
the O
simultaneous B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
recording I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
interrelated B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
peripheral B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
central B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
electrophysiologic B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
correlates B_DISEASE_ADJECTIVE[DISEASE]/I_LOCATION
of O
nociception B_DISEASE
, O
it O
was O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
separate B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
central B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
and O
peripheral B_LOCATION
effects I_LOCATION
of O
an O
NSAID B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
major B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
advantage I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
of O
this O
pain B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
model I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
is O
the O
possibility B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
of O
obtaining O
peripheral B_DISEASE_ADJECTIVE[DISEASE]
pain I_DISEASE_ADJECTIVE[DISEASE]
- O
related O
activity B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
directly O
using O
a O
non B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
- O
invasive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
technique I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
in O
humans B_PERSON/B_SPECIES[BIO]
. O

Effect O
of O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Glucarates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
basic O
antibiotic O
- O
induced O
renal O
damage O
in O
rats O
. O

Dehydrated O
rats O
regularly O
develop O
acute O
renal O
failure O
following O
single O
injection O
of O
aminoglycoside B_NUMBER[MEASURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibiotics O
combined O
with O
dextran O
or O
of O
antibiotics O
only O
. O

Oral O
administration O
of O
2 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
5 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
di I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
O I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
acetyl I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
D I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
glucaro I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
1 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
4 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
6 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
, I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
3 I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
dilactone I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
protected O
rats O
against O
renal O
failure O
induced O
by O
kanamycin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
- O
dextran O
. O

The O
protective O
effect O
was O
prevalent O
among O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BIO
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
glucarates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BIO
, O
and O
also O
to O
other O
saccharic B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
acid I_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BACTERIUM[BIO]
, O
hexauronic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
acids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
and O
hexaaldonic B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
acids I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
although O
to O
a O
lesser O
degree O
, O
but O
not O
to O
a O
hexaaldose O
, O
sugar B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
alcohols I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
, O
substances O
inthe O
TCA B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
cycle O
and O
other O
acidic O
compounds O
. O

D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
Glucarates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
were O
effective O
against O
renal O
damage O
induced O
by O
peptide O
antibiotics O
as O
well O
as O
various O
aminoglycoside B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
antibitocis O
. O

dose O
- O
responses O
were O
observed O
in O
the O
protective O
effect O
of O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
Glucarates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

With O
a O
D B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
- I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
glucarate I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
of O
a O
fixed O
size O
of O
dose O
, O
approximately O
the O
same O
degree O
of O
protection O
was O
obtained O
against O
renal O
damages O
induced O
by O
different O
basic O
antibiotics O
despite O
large O
disparities O
in O
administration O
doses O
of O
different O
antibiotics O
. O

D B_PERSON
- I_PERSON
Glucarates I_PERSON
had O
the O
ability O
to O
prevent O
renal O
damage O
but O
not O
to O
cure O
it O
. O

rats O
excreted O
acidic O
urine O
when O
they O
were O
spared O
from O
renal O
lesions O
by O
monosaccharides B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BACTERIUM[BIO]
. O

The O
reduction O
effect O
of O
D B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
glucarates I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
against O
nephrotoxicity O
of O
basic O
antibiotics O
was O
discussed O
. O

acute O
severe O
depression O
following O
peri O
- O
operative O
ondansetron B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
. O

A O
41 O
- O
year O
- O
old O
woman O
with O
a O
strong O
history O
of O
postoperative O
nausea O
and O
vomiting O
presented O
for O
abdominal O
hysterectomy O
3 O
months O
after O
a O
previous O
anaesthetic O
where O
ondansetron B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
prophylaxis O
had O
been O
used O
. O

She O
had O
developed O
a O
severe O
acute O
major O
depression O
disorder O
almost O
immediately O
thereafter O
, O
possibly O
related O
to O
the O
use O
of O
a O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonist O
. O

Nine B_TIME[MEASURE]/B_ENT
years I_TIME[MEASURE]/I_ENT
before O
she O
had O
experienced O
a O
self B_PERSON/B_LOCATION
- O
limited O
puerperal B_DISEASE
depressive I_DISEASE
episode I_DISEASE
. O

Anaesthesia O
with O
a O
propofol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
infusion O
and O
avoidance O
of O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
antagonists O
provided O
a O
nausea O
- O
free O
postoperative O
course O
without O
exacerbation O
of O
the O
depression O
disorder O
. O

Hypertensive O
response O
during O
dobutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
stress O
echocardiography O
. O

Among O
3 O
, O
129 O
dobutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
stress O
echocardiographic O
studies O
, O
a O
hypertensive O
response O
, O
defined O
as O
systolic O
blood O
pressure O
( O
BP O
) O
> O
or O
= O
220 O
mm O
Hg O
and O
/ O
or O
diastolic O
BP O
> O
or O
= O
110 O
mm O
Hg O
, O
occurred O
in O
30 O
patients O
( O
1 O
% O
) O
. O

patients O
with O
this O
response O
more O
often O
had O
a O
history O
of O
hypertension O
and O
had O
higher O
resting O
systolic O
and O
diastolic O
BP O
before O
dobutamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
infusion O
. O

continuously O
nebulized O
albuterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
in O
severe O
exacerbations O
of O
asthma O
in O
adults O
: O
a O
case O
- O
controlled O
study O
. O

A O
retrospective O
, O
case O
- O
controlled O
analysis O
comparing O
patients O
admitted O
to O
a O
medical O
intensive O
care O
unit O
with O
severe O
exacerbations O
of O
asthma O
who O
received O
continuously O
nebulized O
albuterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
CNA O
) O
versus O
intermittent O
albuterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
( O
INA O
) O
treatments O
is O
reported O
. O

Forty B_NUMBER[MEASURE]/B_LOCATION
matched O
pairs B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
patients B_PERSON/B_BIO
with O
asthma B_DISEASE/B_LOCATION
are O
compared O
. O

CNA B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
was O
administered O
for O
a O
mean B_MEASURE/B_LOCATION
of O
11 B_MEASURE
+ I_MEASURE
/ O
- O
10 B_TIME[MEASURE]
hr I_TIME[MEASURE]
. O

The O
incidence B_MEASURE
of O
cardiac B_DISEASE
dysrhythmias I_DISEASE
was O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
between O
groups B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANIZATION
. O

Symptomatic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
hypokalemia I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
did O
not O
occur O
. O

CNA B_PERSON
patients I_PERSON
had O
higher B_DISEASE_ADJECTIVE[DISEASE]
heart I_DISEASE_ADJECTIVE[DISEASE]
rates I_DISEASE_ADJECTIVE[DISEASE]
during O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
, O
which O
may O
reflect O
severity B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
of O
illness B_DISEASE
. O

The O
incidence B_MEASURE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
intubation B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
was O
similar B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
. O

We O
conclude O
that O
CNA B_LOCATION/B_ORGANIZATION
and O
INA B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
demonstrated O
similar B_DISEASE_ADJECTIVE[DISEASE]/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
profiles B_DISEASE_ADJECTIVE[DISEASE]/I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
with O
regard B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
safety B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
morbidity B_DISEASE
, O
and O
mortality B_DISEASE
. O

Paraplegia O
following O
intrathecal O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
: O
report O
of O
a O
case O
and O
review O
of O
the O
literature O
. O

A O
patient O
who O
developed O
paraplegia O
following O
the O
intrathecal O
instillation O
of O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
discribed O
. O

The O
ten B_NUMBER[MEASURE]
previously O
reported O
cases B_PERSON/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
this O
unusual B_DISEASE
complication I_DISEASE
are O
reviewed O
. O

The O
following O
factors O
appear O
to O
predispose O
to O
the O
development O
of O
this O
complication O
: O
abnormal O
cerebrospinal O
dynamics O
related O
to O
the O
presence O
of O
central O
nervous O
system O
leukemia O
, O
and O
epidural O
cerebrospinal O
leakage O
; O
elevated O
cerebrospinal O
fluid O
methothexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
concentration O
related O
to O
abnormal O
cerebrospinal O
fluid O
dynamics O
and O
to O
inappropriately O
high O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
doses O
based O
on O
body O
surface O
area O
calculations O
in O
older O
children O
and O
adults O
; O
the O
presence O
of O
neurotoxic O
preservatives O
in O
commercially O
available O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
preparations O
and O
diluents O
; O
and O
the O
use O
of O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
diluents O
of O
unphysiologic O
pH O
, O
ionic O
content O
and O
osmolarity O
. O

The O
role O
of O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
contaminants O
, O
local O
folate O
deficiency O
, O
and O
cranial O
irradiation O
in O
the O
pathogenesis O
of O
intrathecal O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
toxicity O
is O
unclear O
. O

The O
incidence O
of O
neurotoxicity O
may O
be O
reduced O
by O
employing O
lower O
doses O
of O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
the O
presence O
of O
central O
nervous O
system O
leukemia O
, O
in O
older O
children O
and O
adults O
, O
and O
in O
the O
presence O
of O
epidural O
leakage O
. O

Only O
preservative O
- O
free O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
Elliott O
' O
s O
B O
solution O
at O
a O
concentration O
of O
not O
more O
than O
1 O
mg O
/ O
ml O
should O
be O
used O
for O
intrathecal O
administration O
. O

periodic O
monitoring O
of O
cerebruspinal O
fluid O
methotrexate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
levels O
may O
be O
predictive O
of O
the O
development O
of O
serious O
neurotoxicity O
. O

Hyperosmolar O
nonketotic O
coma O
precipitated O
by O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_ORGANISM_FUNCTION
- O
induced O
nephrogenic O
diabetes O
insipidus O
. O

A O
45 O
- O
year O
- O
old O
man O
, O
with O
a O
10 O
- O
year O
history O
of O
manic O
depression O
treated O
with O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
was O
admitted O
with O
hyperosmolar O
, O
nonketotic O
coma O
. O

He O
gave O
a O
five O
- O
year O
history O
of O
polyuria O
and O
polydipsia O
, O
during O
which O
time O
urinalysis O
had O
been O
negative O
for O
glucose B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
. O

After O
recovery O
from O
hyperglycaemia O
, O
he O
remained O
polyuric O
despite O
normal O
blood O
glucose B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
concentrations O
; O
water O
deprivation O
testing O
indicated O
nephrogenic O
diabetes O
insipidus O
, O
likely O
to O
be O
lithium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
. O

We O
hypothesize O
that O
when O
this O
man B_PERSON/B_BIO
developed O
type B_DISEASE
2 I_DISEASE
diabetes I_DISEASE
, O
chronic B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
polyuria I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
due O
to O
nephrogenic B_DISEASE
diabetes I_DISEASE
insipidus I_DISEASE
was O
sufficient B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
to O
precipitate O
hyperosmolar B_DISEASE
dehydration I_DISEASE
. O

Effects O
of O
the O
intracoronary O
infusion O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
on O
left O
ventricular O
systolic O
and O
diastolic O
function O
in O
humans O
. O

Background O
: O
In O
dogs O
, O
a O
large O
amount O
of O
intravenous O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
causes O
a O
profound O
deterioration O
of O
left O
ventricular O
( O
LV O
) O
systolic O
function O
and O
an O
increase O
in O
LV O
end O
- O
diastolic O
pressure O
. O

This O
study O
was O
done O
to O
assess O
the O
influence O
of O
a O
high O
intracoronary O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O
on O
LV O
systolic O
and O
diastolic O
function O
in O
humans O
. O

methods O
AND O
Results O
: O
In O
20 O
patients O
( O
14 O
men O
and O
6 O
women O
aged O
39 O
to O
72 O
years O
) O
referred O
for O
cardiac O
catheterization O
for O
the O
evaluation O
of O
chest O
pain O
, O
we O
measured O
heart O
rate O
, O
systemic O
arterial O
pressure O
, O
LV O
pressure O
and O
its O
first O
derivative O
( O
dP O
/ O
dt O
) O
, O
and O
LV O
volumes O
and O
ejection O
fraction O
before O
and O
during O
the O
final O
2 O
to O
3 O
minutes O
of O
a O
15 O
- O
minute O
intracoronary O
infusion O
of O
saline O
( O
n O
= O
10 O
, O
control O
subjects O
) O
or O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
hydrochloride I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
1 O
mg O
/ O
min O
( O
n O
= O
10 O
) O
. O

No O
variable B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
changed O
with O
saline B_LOCATION/B_MEASURE
. O

With O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
the O
drug O
concentration O
in O
blood O
obtained O
from O
the O
coronary O
sinus O
was O
3 O
. O
0 O
+ O
/ O
- O
0 O
. O
4 O
( O
mean O
+ O
/ O
- O
SD O
) O
mg O
/ O
L O
, O
similar O
in O
magnitude O
to O
the O
blood O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
concentration O
reported O
in O
abusers O
dying O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
intoxication O
. O

Cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
induced O
no O
significant O
change O
in O
heart O
rate O
, O
LV O
dP O
/ O
dt O
( O
positive O
or O
negative O
) O
, O
or O
LV O
end O
- O
diastolic O
volume O
, O
but O
it O
caused O
an O
increase O
in O
systolic O
and O
mean O
arterial O
pressures O
, O
LV O
end O
- O
diastolic O
pressure O
, O
and O
LV O
end O
- O
systolic O
volume O
, O
as O
well O
as O
a O
decrease O
in O
LV O
ejection O
fraction O
. O

conclusions O
: O
In O
humans O
, O
the O
intracoronary O
infusion O
of O
cocaine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sufficient O
in O
amount O
to O
achieve O
a O
high O
drug O
concentration O
in O
coronary O
sinus O
blood O
causes O
a O
deterioration O
of O
LV O
systolic O
and O
diastolic O
performance O
. O

ascending O
dose O
tolerance O
study O
of O
intramuscular O
carbetocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
administered O
after O
normal O
vaginal O
birth O
. O

objective O
: O
To O
determine O
the O
maximum O
tolerated O
dose O
( O
MTD O
) O
of O
carbetocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O
a O
long O
- O
acting O
synthetic O
analogue O
of O
oxytocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
) O
, O
when O
administered O
immediately O
after O
vaginal O
delivery O
at O
term O
. O

Materials O
AND O
methods O
: O
Carbetocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
was O
given O
as O
an O
intramuscular O
injection O
immediately O
after O
the O
birth O
of O
the O
infant O
in O
45 O
healthy O
women O
with O
normal O
singleton O
pregnancies O
who O
delivered O
vaginally O
at O
term O
. O

Dosage O
groups O
of O
15 O
, O
30 O
, O
50 O
, O
75 O
, O
100 O
, O
125 O
, O
150 O
, O
175 O
or O
200 O
microg O
carbetocin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
were O
assigned O
to O
blocks O
of O
three O
women O
according O
to O
the O
continual O
reassessment O
method O
( O
CRM O
) O
. O

RESULTS B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
: O
All O
dosage B_PERSON/B_ORGANIZATION
groups I_PERSON/I_ORGANIZATION
consisted O
of O
three B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_NUMBER[MEASURE]
women I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_NUMBER[MEASURE]
, O
except O
those O
with O
100 B_MEASURE
microg I_MEASURE
( O
n B_OTHER/B_MEASURE
= O
6 B_MEASURE
) O
and O
200 B_MEASURE
microg I_MEASURE
( O
n B_OTHER/B_MEASURE
= O
18 B_MEASURE
) O
. O

Recorded O
were O
dose B_MEASURE/B_DISEASE
- O
limiting O
adverse B_DISEASE_ADJECTIVE[DISEASE]
events I_DISEASE_ADJECTIVE[DISEASE]
: O
hyper B_DISEASE/B_GENE
- O
or O
hypotension B_DISEASE
( O
three B_NUMBER[MEASURE]
) O
, O
severe B_DISEASE
abdominal I_DISEASE
pain I_DISEASE
( O
0 B_NUMBER[MEASURE]
) O
, O
vomiting B_DISEASE
( O
0 B_NUMBER[MEASURE]
) O
and O
retained B_DISEASE
placenta I_DISEASE
( O
four B_NUMBER[MEASURE]
) O
. O

Serious B_DISEASE/B_PERSON
adverse I_DISEASE/I_PERSON
events I_DISEASE/I_PERSON
occurred O
in O
seven B_NUMBER[MEASURE]/B_ENT
women I_NUMBER[MEASURE]/I_ENT
: O
six B_NUMBER[MEASURE]/B_PERSON
cases I_NUMBER[MEASURE]/I_PERSON
with O
blood B_MEASURE
loss I_MEASURE
> I_MEASURE
or O
= O
1000 B_MEASURE
ml I_MEASURE
, O
four B_NUMBER[MEASURE]
cases I_NUMBER[MEASURE]
of O
manual B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
placenta I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
removal I_DISEASE/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
five B_NUMBER[MEASURE]
cases I_NUMBER[MEASURE]
of O
additional B_DISEASE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
oxytocics I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
administration I_DISEASE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
five B_TIME[MEASURE]/B_DISEASE
cases B_TIME[MEASURE]/I_DISEASE
of O
blood B_DISEASE/B_ORGANISM_FUNCTION
transfusion I_DISEASE/I_ORGANISM_FUNCTION
. O

Maximum B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
blood I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
loss I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
was O
greatest B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
at O
the O
upper B_MEASURE
and O
lower B_MEASURE/B_LOCATION
dose B_MEASURE/I_LOCATION
levels B_MEASURE/I_LOCATION
, O
and O
lowest B_MEASURE/B_DISEASE_ADJECTIVE[DISEASE]
in O
the O
70 B_MEASURE
- O
125 B_TIME[MEASURE]/B_LOCATION
microg I_TIME[MEASURE]/I_LOCATION
dose I_TIME[MEASURE]/I_LOCATION
range I_TIME[MEASURE]/I_LOCATION
. O

Four B_NUMBER[MEASURE]
out O
of O
six B_NUMBER[MEASURE]
cases I_NUMBER[MEASURE]
with O
blood B_MEASURE/B_LOCATION
loss I_MEASURE/I_LOCATION
> I_MEASURE/I_LOCATION
or O
= O
1000 B_MEASURE
ml I_MEASURE
occurred O
in O
the O
200 B_LOCATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
microg I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
group I_LOCATION/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

The O
majority B_MEASURE
of O
additional B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
administration I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
of O
oxytocics B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
( O
4 B_MEASURE
/ O
5 B_MEASURE
) O
and O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
transfusion I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
( O
3 B_MEASURE
/ O
5 B_MEASURE
) O
occurred O
in O
the O
dose B_MEASURE/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
groups I_MEASURE/I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
200 B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
microg I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
. O

All O
retained O
placentae B_DISEASE/B_CHEMICAL_CLASS[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
found O
in O
the O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
200 B_NUMBER[MEASURE]/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
microg I_NUMBER[MEASURE]/I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
. O

conclusion O
: O
The O
MTD O
was O
calculated O
to O
be O
at O
200 O
microg O
carbetocin B_LOCATION
. O

Heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
thrombocytopenia O
, O
paradoxical O
thromboembolism O
, O
and O
other O
side O
effects O
of O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
therapy O
. O

Although O
several O
new O
anticoagulant O
drugs O
are O
in O
development O
, O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
remains O
the O
drug O
of O
choice O
for O
most O
anticoagulation O
needs O
. O

The O
clinical O
effects O
of O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
are O
meritorious O
, O
but O
side O
effects O
do O
exist O
. O

Important O
untoward O
effects O
of O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
including O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
induced O
thrombocytopenia O
, O
heparin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
associated O
osteoporosis O
, O
eosinophilia O
, O
skin O
reactions O
, O
allergic O
reactions O
other O
than O
thrombocytopenia O
and O
alopecia O
will O
be O
discussed O
in O
this O
article O
. O

Nonopaque O
crystal O
deposition O
causing O
ureteric O
obstruction O
in O
patients O
with O
HIV O
undergoing O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
therapy O
. O

objective O
: O
We O
describe O
the O
unique O
CT O
features O
of O
ureteric O
calculi O
in O
six O
HIV O
- O
infected O
patients O
receiving O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
the O
most O
commonly O
used O
HIV O
protease O
inhibitor O
, O
which O
is O
associated O
with O
an O
increased O
incidence O
of O
urolithiasis O
. O

conclusion O
: O
Ureteric O
obstruction O
caused O
by O
precipitated O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
crystals O
may O
be O
difficult O
to O
diagnose O
with O
unenhanced O
CT O
. O

The O
calculi B_DISEASE/B_BODY_PART_OR_ORGAN_COMPONENT
are O
not O
opaque B_DISEASE_ADJECTIVE[DISEASE]
, O
and O
secondary B_DISEASE_ADJECTIVE[DISEASE]/B_MEASURE
signs I_DISEASE_ADJECTIVE[DISEASE]/I_MEASURE
of O
obstruction B_DISEASE/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
may O
be O
absent B_DISEASE_ADJECTIVE[DISEASE]/B_CELL[BODY_PART_OR_ORGAN_COMPONENT]
or O
minimal B_DISEASE_ADJECTIVE[DISEASE]
and O
should O
be O
sought O
carefully O
. O

Images O
may O
need O
to O
be O
obtained O
using O
i O
. O
v O
. O
contrast O
material O
to O
enable O
diagnosis O
of O
ureteric O
stones O
or O
obstruction O
in O
patients O
with O
HIV O
infection O
who O
receive O
indinavir B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
therapy O
. O

Ischemic O
colitis O
and O
sumatriptan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
. O

Sumatriptan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
succinate I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
, O
a O
serotonin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
1 O
( O
5 B_PROTEIN[GENE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
hydroxytryptamine I_PROTEIN[GENE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
1 O
) O
receptor O
agonist O
, O
is O
an O
antimigraine O
drug O
that O
is O
reported O
to O
act O
by O
selectively O
constricting O
intracranial O
arteries O
. O

Recently O
, O
vasopressor B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
responses I_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
that O
are O
distinct B_DISEASE_ADJECTIVE[DISEASE]/B_LOCATION
from O
the O
cranial B_DISEASE/B_MEASURE
circulation I_DISEASE/I_MEASURE
have O
been O
demonstrated O
to O
occur O
in O
the O
systemic B_BODY_PART_OR_ORGAN_COMPONENT/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
, O
pulmonary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE
, O
and O
coronary B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
circulations I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
. O

cases O
have O
been O
published O
of O
coronary O
vasospasm O
, O
myocardial O
ischemia O
, O
and O
myocardial O
infarction O
occurring O
after O
sumatriptan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
use O
. O

We O
report O
on O
the O
development O
of O
8 O
serious O
cases O
of O
ischemic O
colitis O
in O
patients O
with O
migraine O
treated O
with O
sumatriptan B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Pallidotomy B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_MEASURE
with O
the O
gamma B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_PERSON
knife I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_PERSON
: O
a O
positive B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
experience I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_DISEASE_ADJECTIVE[DISEASE]
. O

51 O
patients O
with O
medically O
refractory O
Parkinson O
' O
s O
disease O
underwent O
stereotactic O
posteromedial O
pallidotomy O
between O
August O
1993 O
and O
February O
1997 O
for O
treatment O
of O
bradykinesia O
, O
rigidity O
, O
and O
L B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
DOPA I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
induced O
dyskinesias O
. O

In O
29 B_TIME[MEASURE]
patients I_TIME[MEASURE]
, O
the O
pallidotomies B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
were O
performed O
with O
the O
Leksell B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
Gamma I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
knife I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
in O
22 B_MEASURE
they O
were O
performed O
with O
the O
standard B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_BODY_PART_OR_ORGAN_COMPONENT
radiofrequency I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_BODY_PART_OR_ORGAN_COMPONENT
( O
RF B_LOCATION/B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
) O
method B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

Clinical B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
assessment I_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
as O
well O
as O
blinded O
ratings B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
of O
unified B_DISEASE
Parkinson I_DISEASE
' I_DISEASE
s I_DISEASE
Disease I_DISEASE
Rating I_DISEASE
Scale I_DISEASE
( O
UPDRS B_DISEASE
) O
scores B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
were O
carried O
out O
pre B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
and O
postoperatively O
. O

Mean B_MEASURE/B_PERSON
follow O
- O
up O
time B_TIME[MEASURE]
is O
20 B_MEASURE
. O
6 B_TIME[MEASURE]
months I_TIME[MEASURE]
( O
range B_MEASURE/B_LOCATION
6 I_MEASURE/I_LOCATION
- O
48 B_MEASURE
) O
and O
all O
except O
4 B_NUMBER[MEASURE]
patients I_NUMBER[MEASURE]
have O
been O
followed O
more B_TIME[MEASURE]
than O
one B_TIME[MEASURE]/B_LOCATION
year I_TIME[MEASURE]/I_LOCATION
. O

85 B_NUMBER[MEASURE]/B_PERSON
percent I_NUMBER[MEASURE]/I_PERSON
of O
patients B_PERSON
with O
dyskinesias B_DISEASE
were O
relieved O
of O
symptoms B_DISEASE
, O
regardless O
of O
whether O
the O
pallidotomies B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE_ADJECTIVE[DISEASE]
were O
performed O
with O
the O
Gamma B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
knife I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
or O
radiofrequency B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
methods I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
. O

About O
2 B_NUMBER[MEASURE]
/ O
3 B_SEQUENCE[MEASURE]
of O
the O
patients B_PERSON
in O
both O
Gamma B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
knife I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
and O
radiofrequency B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
groups I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
showed O
improvements B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
bradykinesia B_DISEASE/B_MEASURE
and O
rigidity B_DISEASE
, O
although O
when O
considered O
as O
a O
group B_ORGANIZATION/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
neither O
the O
Gamma B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_LOCATION
knife I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/I_LOCATION
nor O
the O
radiofrequency B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
group I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
showed O
statistically O
significant B_DISEASE_ADJECTIVE[DISEASE]
improvements I_DISEASE_ADJECTIVE[DISEASE]
in O
UPDRS B_MEASURE/B_DISEASE
scores I_MEASURE/I_DISEASE
. O

One B_PERSON
patient I_PERSON
in O
the O
Gamma B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
knife I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
group I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
( O
3 B_MEASURE
. O
4 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
developed O
a O
homonymous B_DISEASE
hemianopsia I_DISEASE
9 I_DISEASE
months I_DISEASE
following O
treatment B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE/B_DISEASE
and O
5 B_NUMBER[MEASURE]/B_PERSON
patients I_NUMBER[MEASURE]/I_PERSON
( O
27 B_MEASURE
. O
7 B_MEASURE/B_PERSON
% I_MEASURE/I_PERSON
) O
in O
the O
radiofrequency B_ORGANIZATION/B_MEASURE
group B_ORGANIZATION/I_MEASURE
became O
transiently O
confused O
postoperatively O
. O

No O
other B_DISEASE
complications I_DISEASE
were O
seen O
. O

Gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
knife I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
pallidotomy I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
is O
as O
effective B_DRUG_ADJECTIVE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
as O
radiofrequency B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
pallidotomy I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
controlling O
certain B_DISEASE_ADJECTIVE[DISEASE]/B_NUMBER[MEASURE]
of O
the O
symptoms B_DISEASE/B_LAB_PROCEDURE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
of O
Parkinson B_DISEASE
' I_DISEASE
s I_DISEASE
disease I_DISEASE
. O

It O
may O
be O
the O
only B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
practical I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
technique I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
available I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
in O
certain B_PERSON/B_LOCATION
patients I_PERSON/I_LOCATION
, O
such B_DISEASE_ADJECTIVE[DISEASE]/B_TIME[MEASURE]
as O
those O
who O
take O
anticoagulants B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
have O
bleeding O
diatheses B_DISEASE_ADJECTIVE[DISEASE]
or O
serious B_DISEASE
systemic I_DISEASE
medical I_DISEASE
illnesses I_DISEASE
. O

It O
is O
a O
viable B_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
option I_THERAPEUTIC_OR_PREVENTIVE_PROCEDURE
for O
other B_PERSON
patients I_PERSON
as O
well O
. O

Centrally O
mediated O
cardiovascular O
effects O
of O
intracisternal O
application O
of O
carbachol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
anesthetized O
rats O
. O

The O
pressor O
response O
to O
the O
intracisternal O
( O
i O
. O
c O
. O
) O
injection O
of O
carbachol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 O
mug O
) O
in O
anesthetized O
rats O
was O
analyzed O
. O

This O
response O
was O
significantly O
reduced O
by O
the O
intravenous O
( O
i O
. O
v O
. O
) O
injection O
of O
guanethidine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 O
mg O
) O
, O
hexamethonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O
10 O
mg O
) O
or O
phentolamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
5 O
mg O
) O
, O
and O
Conversely O
, O
potentiated O
by O
i O
. O
v O
. O
desmethylimipramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 O
. O
3 O
mg O
) O
, O
while O
propranolol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
0 O
. O
5 O
mg O
) O
i O
. O
v O
. O
selectively O
inhibited O
the O
enlargement O
of O
pulse O
pressure O
and O
the O
tachycardia O
following O
i O
. O
c O
. O
carbachol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 O
mug O
) O
. O

On O
the O
other O
hand O
, O
the O
pressor O
response O
to O
i O
. O
c O
. O
carbachol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 O
mug O
) O
was O
almost O
completely O
blocked O
by O
i O
. O
c O
. O
atropine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
3 O
mug O
) O
or O
hexamethonium B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BACTERIUM[BIO]
( O
500 O
mug O
) O
, O
and O
significantly O
reduced O
by O
i O
. O
c O
. O
chlorpromazine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
50 O
mug O
) O
but O
significantly O
potentiated O
by O
i O
. O
c O
. O
desmethylimipramine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
30 O
mug O
) O
. O

The O
pressor O
response O
to O
i O
. O
c O
. O
carbachol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
1 O
mug O
) O
remained O
unchanged O
after O
sectioning O
of O
the O
bilateral O
cervical O
vagal O
nerves O
but O
disappeared O
after O
sectioning O
of O
the O
spinal O
cord O
( O
C7 O
- O
C8 O
) O
. O

From O
the O
above O
result O
it O
is O
suggested O
that O
the O
pressor O
response O
to O
i O
. O
c O
. O
carbachol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
ortral O
and O
peripheral O
adrenergic O
mechanisms O
, O
and O
that O
the O
sympathetic O
trunk O
is O
the O
main O
pathway O
. O

Neuroleptic O
malignant O
syndrome O
and O
methylphenidate B_DISEASE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
. O

A O
1 O
- O
year O
- O
old O
female O
presented O
with O
neuroleptic O
malignant O
syndrome O
probably O
caused O
by O
methylphenidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

She O
had O
defects B_DISEASE
in O
the O
supratentorial B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
brain I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
including O
the O
basal B_BODY_PART_OR_ORGAN_COMPONENT/B_DISEASE_ADJECTIVE[DISEASE]
ganglia I_BODY_PART_OR_ORGAN_COMPONENT/I_DISEASE_ADJECTIVE[DISEASE]
and O
the O
striatum B_BODY_PART_OR_ORGAN_COMPONENT
( O
multicystic B_DISEASE_ADJECTIVE[DISEASE]/B_BODY_PART_OR_ORGAN_COMPONENT
encephalomalacia B_DISEASE_ADJECTIVE[DISEASE]/I_BODY_PART_OR_ORGAN_COMPONENT
) O
due O
to O
severe B_DISEASE_ADJECTIVE[DISEASE]
perinatal I_DISEASE_ADJECTIVE[DISEASE]
hypoxic I_DISEASE_ADJECTIVE[DISEASE]
- O
ischemic B_DISEASE
encephalopathy I_DISEASE
, O
which O
was O
considered O
to O
be O
a O
possible B_DISEASE_ADJECTIVE[DISEASE]/B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
predisposing O
factor B_DISEASE
causing O
neuroleptic B_DISEASE
malignant I_DISEASE
syndrome I_DISEASE
. O

A O
dopaminergic B_DISEASE_ADJECTIVE[DISEASE]
blockade I_DISEASE_ADJECTIVE[DISEASE]
mechanism I_DISEASE_ADJECTIVE[DISEASE]
generally O
is O
accepted O
as O
the O
pathogenesis B_DISEASE
of O
this O
syndrome B_DISEASE
. O

However O
, O
methylphenidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
is O
a O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
agonist O
via O
the O
inhibition O
of O
uptake O
of O
dopamine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
and O
therefore O
dopaminergic O
systems O
in O
the O
brainstem O
( O
mainly O
the O
midbrain O
) O
and O
the O
spinal O
cord O
were O
unlikely O
to O
participate O
in O
the O
onset O
of O
this O
syndrome O
. O

A O
relative O
gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminobutyric I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
ergic O
deficiency O
might O
occur O
because O
diazepam B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
a O
gamma B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
aminobutyric I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
- O
mimetic O
agent O
, O
was O
strikingly O
effective O
. O

This O
is O
the O
first O
reported O
patient O
with O
neuroleptic O
malignant O
syndrome O
probably O
caused O
by O
methylphenidate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

differential O
effects O
of O
17alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ethinylestradiol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
on O
the O
neutral O
and O
acidic O
pathways O
of O
bile B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
salt I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
synthesis O
in O
the O
rat O
. O

Effects O
of O
17alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ethinylestradiol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
EE B_LOCATION/B_ORGANIZATION
) O
on O
the O
neutral O
and O
acidic O
biosynthetic O
pathways O
of O
bile B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
salt I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_LOCATION
( O
BS B_LOCATION
) O
synthesis O
were O
evaluated O
in O
rats O
with O
an O
intact O
enterohepatic O
circulation O
and O
in O
rats O
with O
long O
- O
term O
bile O
diversion O
to O
induce O
BS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
synthesis O
. O

For O
this O
purpose O
, O
bile B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_BODY_PART_OR_ORGAN_COMPONENT
salt B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_BODY_PART_OR_ORGAN_COMPONENT
pool O
composition O
, O
synthesis O
of O
individual O
BS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
vivo O
, O
hepatic O
activities O
, O
and O
expression O
levels O
of O
cholesterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
7alpha O
- O
hydroxylase O
( O
CYP7A O
) O
, O
and O
sterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
27 O
- O
hydroxylase O
( O
CYP27 O
) O
, O
as O
well O
as O
of O
other O
enzymes O
involved O
in O
BS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
synthesis O
, O
were O
analyzed O
in O
rats O
treated O
with O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
( O
5 O
mg O
/ O
kg O
, O
3 O
days O
) O
or O
its O
vehicle O
. O

BS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
pool O
size O
was O
decreased O
by O
27 O
% O
but O
total O
BS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
synthesis O
was O
not O
affected O
by O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
intact O
rats O
. O

synthesis O
of O
cholate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
reduced O
by O
68 O
% O
in O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
treated O
rats O
, O
while O
that O
of O
chenodeoxycholate B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
was O
increased O
by O
60 O
% O
. O

The O
recently O
identified O
Delta22 O
- O
isomer O
of O
beta O
- O
muricholate O
contributed O
for O
5 O
. O
4 O
% O
and O
18 O
. O
3 O
% O
( O
P O
< O
0 O
. O
01 O
) O
to O
the O
pool O
in O
control O
and O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
- O
treated O
rats O
, O
respectively O
, O
but O
could O
not O
be O
detected O
in O
bile O
after O
exhaustion O
of O
the O
pool O
. O

A O
clear O
reduction O
of O
BS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
synthesis O
was O
found O
in O
bile O
- O
diverted O
rats O
treated O
with O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
, O
yet O
biliary O
BS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
composition O
was O
only O
minimally O
affected O
. O

activity O
of O
CYP7A O
was O
decreased O
by O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
in O
both O
intact O
and O
bile O
- O
diverted O
rats O
, O
whereas O
the O
activity O
of O
the O
CYP27 O
was O
not O
affected O
. O

Hepatic O
mRNA O
levels O
of O
CYP7A O
were O
significantly O
reduced O
by O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
in O
bile O
- O
diverted O
rats O
only O
; O
CYP27 O
mRNA O
levels O
were O
not O
affected O
by O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
. O

In O
addition O
, O
mRNA O
levels O
of O
sterol B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
12alpha O
- O
hydroxylase O
and O
lithocholate O
6beta O
- O
hydroxylase O
were O
increased O
by O
bile O
diversion O
and O
suppressed O
by O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
. O

This O
study O
shows O
that O
17alpha B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
ethinylestradiol I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
( O
EE B_LOCATION/B_ORGANIZATION
) O
- O
induced O
intrahepatic O
cholestasis O
in O
rats O
is O
associated O
with O
selective O
inhibition O
of O
the O
neutral O
pathway O
of O
bile B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
salt I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
BS B_LOCATION/B_ORGANIZATION
) O
synthesis O
. O

simultaneous O
impairment O
of O
other O
enzymes O
in O
the O
BS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
biosynthetic O
pathways O
may O
contribute O
to O
overall O
effects O
of O
EE B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
on O
BS B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PROTEIN[GENE]
synthesis O
. O

Glibenclamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
- O
sensitive O
hypotension O
produced O
by O
helodermin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
assessed O
in O
the O
rat O
. O

The O
effects O
of O
helodermin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
, O
a O
basic O
35 O
- O
amino B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
acid I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_MEASURE
peptide O
isolated O
from O
the O
venom O
of O
a O
lizard O
salivary O
gland O
, O
on O
arterial O
blood O
pressure O
and O
heart O
rate O
were O
examined O
in O
the O
rat O
, O
focusing O
on O
the O
possibility O
that O
activation O
of O
ATP B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
sensitive O
K B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
+ O
( O
K B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ATP B_PROTEIN[GENE]/B_LOCATION
) O
) O
channels O
is O
involved O
in O
the O
responses O
. O

The O
results B_STUDY[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_MEASURE
were O
also O
compared O
with O
those O
of O
vasoactive B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_PERSON
intestinal I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
polypeptide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_PERSON
( O
VIP B_GENE/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
) O
. O

Helodermin B_GENE/B_DISEASE_ADJECTIVE[DISEASE]
produced O
hypotension O
in O
a O
dose O
- O
dependent O
manner O
with O
approximately O
similar O
potency O
and O
duration O
to O
VIP O
. O

Hypotension O
induced O
by O
both O
peptides O
was O
significantly O
attenuated O
by O
glibenclamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
which O
abolished O
a O
levcromakalim B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
produced O
decrease O
in O
arterial O
blood O
pressure O
. O

Oxyhemoglobin O
did O
not O
affect O
helodermin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
induced O
hypotension O
, O
whereas O
it O
shortened O
the O
duration O
of O
acetylcholine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
( O
ACh B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
) O
- O
produced O
hypotension O
. O

These O
findings O
suggest O
that O
helodermin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
- O
produced O
hypotension O
is O
partly O
attributable O
to O
the O
activation O
of O
glibenclamide B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
- O
sensitive O
K B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_LOCATION
+ O
channels O
( O
K B_PROTEIN[GENE]/B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
( O
ATP B_PROTEIN[GENE]/B_LOCATION
) O
channels O
) O
, O
which O
presumably O
exist O
on O
arterial O
smooth O
muscle O
cells O
. O

EDRF O
( O
endothelium O
- O
derived O
relaxing O
factor O
) O
/ O
nitric B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE_ADJECTIVE[DISEASE]
oxide I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE_ADJECTIVE[DISEASE]
does O
not O
seem O
to O
play O
an O
important O
role O
in O
the O
peptide O
- O
produced O
hypotension O
. O

Long O
- O
term O
efficacy O
and O
adverse O
event O
of O
nifedipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
sustained O
- O
release O
tablets O
for O
cyclosporin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
- O
induced O
hypertension O
in O
patients O
with O
psoriasis O
. O

Thirteen O
psoriatic O
patients O
with O
hypertension O
during O
the O
course O
of O
cyclosporin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
were O
treated O
for O
25 O
months O
with O
a O
calcium B_CHEMICAL_SUBSTANCE[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
channel O
blocker O
, O
sustained O
- O
release O
nifedipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
to O
study O
the O
clinical O
antihypertensive O
effects O
and O
adverse O
events O
during O
treatment O
with O
both O
drugs O
. O

Seven O
of O
the O
13 O
patients O
had O
exhibited O
a O
subclinical O
hypertensive O
state O
before O
cyclosporin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_DISEASE
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_DISEASE
therapy O
. O

Both O
systolic O
and O
diastolic O
blood O
pressures O
of O
these O
13 O
patients O
were O
decreased O
significantly O
after O
4 O
weeks O
of O
nifedipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
therapy O
, O
and O
blood O
pressure O
was O
maintained O
within O
the O
normal O
range O
thereafter O
for O
25 O
months O
. O

The O
adverse O
events O
during O
combined O
therapy O
with O
cyclosporin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
and O
nifedipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
included O
an O
increase O
in O
blood B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/B_GENE
urea I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
nitrogen I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]/I_GENE
levels O
in O
9 O
of O
the O
13 O
patients O
and O
development O
of O
gingival O
hyperplasia O
in O
2 O
of O
the O
13 O
patients O
. O

Our O
findings O
indicate O
that O
sustained O
- O
release O
nifedipine B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
is O
useful O
for O
hypertensive O
psoriatic O
patients O
under O
long O
- O
term O
treatment O
with O
cyclosporin B_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
A I_DRUG[THERAPEUTIC_OR_PREVENTIVE_PROCEDURE]
, O
but O
that O
these O
patients O
should O
be O
monitored O
for O
gingival O
hyperplasia O
. O

